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1042-44 Can a Simple Score Predict Significant and Severe 
Coronary Disease Better Than Physicians and Other 
Scores? 
Michael J. Lipinski, Katerina Shetler, Dat Do, Eddie Atwood, Lars Osterberg, Barry 
Franklin, Jeffrey West, Victor Fro&her. Stanford/PAVAHCS, Palo Alto, CA, William 
Beaumont Hospital, Roya/ Oak, MI 
A variety of treadmill ?.cores are available to aid physicians in determining whether a 
patient has significant or severe angiographic coronary artery disease (CAD). However, 
the incorporation of the scores into practice has been hampered by their complexity. 
There is now a simple score available that can be calculated by adding together a set of 
variables. We compared the simple exercise test scores to physician and scores’ estima- 
tions of disease probability METHODS 682 consecutive male patients with a mean age 
of 59 were considered for the analysis of severe disease and 599 without prior MI were 
considered for significant CAD. With significant CAD defined as any coronary lumen 
occlusion > 50%, 58% had CAD. Severe CAD was defined as > 50% luminal occlusion in 
3 vessels, proximal LAD and another vessel, or left main, with 24% having severe CAD. 
The clinicalitreadmlll test reports were sent to expert cardiologists and to two other 
groups including randomly selected cardiologists and internists who classified them as 
high, low or intermediate probability of CAD I” addition to estimating a numerical proba- 
bility from 0 to 100% for both significant and severe CAD. RESULTS A total of 682 physi- 
cian estimates were returned with the largest group being the expert cardiologist that 
returned 469 reports. When probability estimates were compared, the simple score was 
superior at predicting significant CAD(0.75 area under the curve of an ROC) to ail the 
physician groups (0.70 for the experts, 0.58 for the cardiologists and 0.61 for the inter- 
nists: p< 0.01). The simple score also predicted severe CAD better than all the physician 
groups (.74 AUC of simple, .67 for experts, .60 for cardiologists, and .69 for internists). 
The simple score also placed far fewer patients with significant and severe CAD at low 
probability of disease than the physicians (EC 12% to Simple 3%, RC 15% to 5%, and 
internists 12% to 4%). The simple score performed as well as the Consensus of scores 
and better than the Duke Treadmill Score. (AUC of ROC for simple .75, Consensus .78, 
and the DTS .71). CONCLUSION The Simple Score performs better than the physician 
groups and the Duke Treadmill Score in all areas and performed as well as the Consen- 
sus of scores. 
1042-73 Validation of the Accuracy of Pretest and Exercise Test 
Scores in Women With a Low Prevalence of Coronary 
Disease: The National Heart Lung and Blood Institute- 
Sponsored Women’s lschemia Syndrome Evaluation (WISE) 
Study 
Anthony Morise, Marian B. Olson, C. Noel Bairey Merz, Nathaniel Reichek, William J. 
Rogers, Carl J. Pepine, Steven E. Reis, Barry L. Sharaf, George Sopko, Jannet F. Lewis, 
WVIJ, Morgantown, WV 
Background: Pretest and Exercise Test Scores derived for use I” women without known 
coronary disease have not been tested in women with a low prevalence of coronary dis- 
ease. Methods: We evaluated 434 women undergoing coronary angiography for sus- 
pected myocardial ischemia with an overall low (28%) prevalence of angiographic 
coronary disease, defined as 250% stenosis in 21 epicardial vessel. Overall, 150 under- 
went treadmill exercise testing. Pretest Score incorporated age, symptoms, estrogen 
status, and 6 other coronary risk factors. Exercise Test Score incorporated age, symp- 
toms, estrogen status, diabetes, smoking, and 3 exercise test variables (ST depression, 
Duke angina score, peak heart rate). Using previously defined cutpoints, women were 
placed into low, intermediate, and high probability groups for each of the scores, The 
prevalence of any coronary disease in each subgroup was assessed. Results: The 
prevalence of coronary disease in the Exercise Test Score subgroup was comparable to 
the entire cohort at 27%. Subgroup coronary disease prevalences, expressed as %. are 
shown below (Table). 
LOW Intermediate High 
Pretest 181119(15%) 42/188(22%) 63/l 27(50%) 
Exercise 7/49(14%) 17/68(25%) 17/33(52%) 
P<O.OOl for both rows. When both scores were considered together. the best stratifica- 
tion by Exercise Test Score was in the Intermediate Pretest Score group: low Exercise 
Test Score 119 (ll%), intermediate Exercise Test Score 10143 (23%), high Exercise Test 
score 4/7 (57%) (p=0.09). 
Conclusion: Both Pretest Score and Exercise Test Score perform well in stratifying 
women with a low prevalence of coronary disease. Exercise Test Score appears particu- 
lary useful in women with an intermediate Pretest Score, consistent with American Col- 
lege of Cardiology/American Heart Association guidelines. 
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1042-74 Does ST Depression in Premature Ventricular Contractions 
Predict Ischemia? 
Margaret Leila Rasouli, Myrvin H. El&tad. Long Beach Memorial Medical Center, Long 
Beach, CA, University of California, Irvine, Irvine, CA 
Background: Patients with coronary artery disease frequently have premature ventricular 
contractions (PVC’s) both at rest and during exercise. The voltage and configuration of 
these ectopic beats vary a good deal and, to our knowledge, the ST segment depression 
in these complexes have not been correlated with the presence or absence of ischemia. 
If changes in the ST segment of PVC’s ware a consistent finding during ischemia, this 
would provide one more marker that would be useful when doing exercise testing. Meth- 
ods: We searched our stress testing data base for all patients who had had PVC’s at rest 
or during exercise AND had undergone a coronary anglogram within a few months of the 
stress test: there could be no Intervention between the two procedures. We were able to 
identify 94 patients; 64 had significant coronary artery obstruction more than or equal to 
50% in at least one vessel as detected by angiogram. There were 30 nonischemic sub- 
jects and an additional 6 ambulatory normals were selected to make a sample group of 
100 total subjects. We examned the PVC’s of all 100 patients, at rest and during exercise 
and calculated a ratio: ST depression amplitude divided by the R wave amplitude. Mea- 
surements were performed by an investigator blinded to angiographic results. Compari- 
sons of data between ischemic and nonischemic patients were performed by using the 
ANOVA and the Fisher exact test. Results: We compared 12 lead electrocardiographic 
changes during exercise in 100 patients with PVC’s; 36 were nonischemic and 64 had 
coronary artery disease. ST depression in PVC’s more than 10% of the R wave ampli- 
tude when measured in leads V4-V6 significantly Identified ischemia (Pc.0001). The sen- 
sitlvity of predicting ischemia with this method is 95%, and specificity is 67% It IS most 
reliable with 3 vessel disease (loo%), but does not markedly diminish for 1 or 2 vessel 
disease (94.96%). Conclusion: We believe ST segments observed in PVC’s may be 
another way to identify ischemia. We report a sensitivity of 95%. We predict that when 
present, PVC analysis in conjuction with classic ST depression may considerably dlmin- 
ish the false negative response rate in stress testing. 
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1043-45 Changes in Left Ventricular Shape and Cavity Area After 
Myocardial Splinting in a Cardiomyopathy Dog Model: A 
Real-Time 3-Dimensional Echocardiographic Study 
Jian Xin Qin, Takahiro Shiota, Masami Takagaki, Lisa A. Cardon, Yoshie Ochiai, 
Tomotsugu Tabata, Patrick M. McCarthy, Cyril J. Schweich, Todd J. Mortier, Jr., Richard 
F Schroeder, James D. Thomas. The Cleveland Clinic Foundation, Cleveland, OH, 
Myocor Inc, Plymouth, MN 
Background: The Myocor Myosplint is designed to reduce left ventricular (LV) volume 
and wall stress in dilated cardiomyopathy (DCM), but its impact on 3D LV geometry is 
unknown. 
Methods: Seven dogs with heart failure (ejection fraction < 25%) Induced by rapld ven- 
tricular pacing were studied. Three Myosplint devices were implanted perpendicular to 
the LV long axis at base, mid and apical level and tightened to produce an estimated 20% 
reduction in wall stress. Real-time three-dimensional echocardlography (RTSDE) was 
performed epicardially pre implantation, post tightening and at one month follow-up. The 
LV cavity dnmeters and the area of LV cavity (AC) and myocardium (AM) were measured 
at mid LV, which was recognized by moving the image plane in 3D space with RT3DE. 
The ratlo of LV diameters (septum -lateral I anterior -posterior) was calculated. 
Results: Three Myosplint devices were visualized 
clearly in 3D space (Flgure). The LV shape was con- 
sistently changed from globular to bilobular and the 
ratios of LV cavity diameters ware significantly 
decreased from 0.83 + 0.03 to 0.60 i- 0.10 at end- 
diastole (p = O.OOOZ), from 0.85 r 0.05 to 0.54 i 0.11 
at end-systole (p < 0.0001) and remained during fol- 
low-up (0.54 + 0.06 and 0.55 + 0.09 at end&Hole 
and end-systole, respectively). The AC was signifi- 
cantly decreased after Myosplint implantation and 
remained smaller during follow-up (16 + 2 cm<, 12 + 3 cm’, 13 i 2 cm*, respectively, p < 
0.001) while there was no significant change in AM after Myosplint implantation. 
Conclusion: The Myocor Myosplint device consistently produced unique LV shape 
changes and decreases in LV cavity area, throughout the cardiac cycle, immediately after 
implantation and at pacing one month follow-up. Such a device may allow LV volume 
reduction in DCM without mvocardial resection. 
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1043-46 Improvement of Myocardial Perfusion by Extracorporeal indicator). Pressure-volume loops performed in 10 patients before and 6 months after 
Cardiac Shock Wave Theraov (CSWT) CSD implantation showed improved LV function and no ewdence of constrictive physiol- ._. 
Guido H. Caspari. Katja Brandt-Mainz, Achim Gutersohn. Raimund Erbel. University of 
Essen. Dep. Cardiology Essen, Germany 
WY. 
Valve i CSD (n = 9) CSD Only (n = 5) 
BACKGROUND: Due to the improvement of interVentionelI cardiology and coronary Pre-Implant 6 Months Pre-lmolant 6 Months 
artery bypass grafting techniques the surwal rate of patients is increas& Thus, a need NYHA Class 2.8 f 0.7 2.3 + 0.7 2.2 A 0.5 
for end-stage coronary heart disease (CHD) therapy exists. The clinical benefit of CSWT 
1.6iO.6 
has been reproted before. This studv has been oerformed to test the hvoothesis. that 
LVEDD (mm) 76.0 + 6.2 68.8 + 10.3” 72.8 + 6.4 64.8 + 10.4 ,, ~. ~. 
CSWT results in myocardial revascularisation. METHODS: We used a special R-wave LVESD (mm) 66.7 i- 7.5 58.2 + 7.a* 65.7 -c 4.7 56.7 i 15.8 
triggered shock wave dewce (modified kthotripter) with in-line ultrasound localisation. LVEF% 20.6~104 24.0 i 7.w 18.1 + 3.8 31.0 + 12.8 
This system allows accurate positioning of the therapy focus into the myocardium. We 
have applied 3x1500 impulses with energy flux densities of 0.02 and 0.04mJimm2 into 
the anterior and septal wall in 12 patients (65+/-8years. During and in a period of 6 
months after therapy the medication remainded unchanged. Every patient underwent 
exercise myocardiai perfusion smgle photon emission CT (SPECT) before as well as 6 
months after CSWT. After uniform- processing and display, 2 observers blinded to the 
study protocol reviewed the SPECT images. Using a 24.segment model a semiquantita- 
tive scoring of changes in perfusion before and after CSWT was performed. Subse- 
quently the treated segments (anterior and septal) were compared to the untreated 
segments (inferior and lateral). 
RESULTS: 
SPECT-PERFUSION-CHANGES 
segments n no change 
untreated 144 105 
treated 144 84 
*slgnlrlcant P<“.OO, Ma”” Whitney Hank Urn ,est 
decreased increased 
23 16 
6 54* 
CONCLUSION: Apart from the good cllnical results, these phase 1 data support the con- 
cept that extracorporeal myocardial revascularisation by CSWT improves myocardial per- 
fusion in patients with CHD ineligible for other interventions. 
1043-47 Decreased Plasma Concentration of Brain Natriuretic 
Peptide as a Potential indicator of Cardiac Recovery in 
Patients Supported by Mechanical Circulatory Assist 
Systems 
Ralf Sodian, Matthias Loebe, Christoph Schmitt, Evgenij Potapov, Henryk Siniawski, 
Johannes Miiller, Haraid Hausmann, Heinz R. ZurbrOgg, Yuguo Weng, Roland Hetzer. 
Deufsches Herzzentrum Berlin. Bedin, Germany 
BACKGROUND: It is widely suggested that chronic ventricular unloading in patients with 
end-stage heart failure supported by mechanical circulatory assist systems may lead to 
ventricular recovery. Brain natriuretic peptide (BNP) is produced in the myocardium in 
response to chronic volume overload. The effects of long-term ventricular unloading by 
mechanical circulatory support systems on plasma concentrations of BNP are not pre- 
cisely known. In our current study we investigated the relationship between the plasma 
concentration of BNP, echocardiographic findings and the clinical outcome to determine 
the potential role of BNP as a predictor for cardiac recovery METHODS: Twenty-one 
consecutive patients diagnosed with non-ischemic cardiomyopathy supported by 
mechanical circulatory assist devices were evaluated for preoperative risk factors, 
echocardiographic data and blood chemistry. They were divided into patients who were 
successfully transplanted (Group 1, n = 8). patients who were successfully weaned off 
the assist device who did not require transplantation (Group 2, n = 4) and patients who 
died before transplantation or before weaning (Group 3, n = 9). RESULTS: BNP plasma 
concentrations decreased significantly after initiation of mechanical circulatory support 
(p<O.O17, Wilcoxon’s signed rank test). Furthermore, the changes of BNP plasma con- 
centrations showed a decrease to normal plasma levels within the first week after ImpIan- 
tatlon of the assist device in patients who could be weaned off the system without 
requiring transplantation (Group 2). Additionally. a slower reduction in BNP plasma con- 
centrations was found in patients who finally died (Group 3) or were transplanted (Group 
2) after circulatory support. CONCLUSION: This study shows that ventricular unloading 
with circulatory support systems decr&ses BNP plasma concentrations in patients suf- 
fering from end-stage heart fatlure. Furthermore, we hypothesize that an early decrease 
of BNP plasma concentration may indicate a recovery of ventricular function and predicts 
patients in an early stage of mechanical circulatory support who can potentially be 
weaned off the system wiihout requiring a heart transplantation. 
1043-48 Initial Efficacy Trends With the Acorn Cardiac Support 
Device in Patients With Advanced Heart Failure 
Wolfgang Konertz, Franz X. Kleber. Simon Dushe, Holger Hotz, Katrin Stantke. 
Department of Cardiovascular Surgery, Charit6, Berli,l, Germany, Department of 
Meied,cine, Unfallkrankenhaus, Berlin. Germany 
Background: Chronic therapy with the Acorn Cardiac Support Device &SO), a preformed 
knitted polyester device placed over the cardiac ventricles, has been shown to prevent 
left ventricular (LV) remodeling and improve LV ejection fraction in animal model of 
chronic heart failure (HF). The present study was designed to examine the safety of the 
CSD in patients with advanced HF. Methods: AS of September 1. 2000, the CSD was 
implanted in 29 patients (25 male, 4 female: age 56.9 + 10 years) with HF (NYHA class = 
2.8 + 0.6). 17 patients had concomitant valve repair or replacement (15 mitral), and 12 
received only the CSD. The device was anchored near the AV-grove and tailored anteri- 
orly io fit the ventricles Results: There were no intra-operative complications A 10% rate 
Of  early death (~30 days post-op) occurred in this sews. No adverse events were consid- 
ered device-related during a mean implant duration of 10.5 + 6 months. At E-month fol- 
low-up. patients showed improvement in NYHA class, LV ejection fraction (EF), LV end. 
diastolic dimension (EDD). end-systolic dimension (ESD), and Uniscale (quality of life 
Uniscale 3.3 * 2 1 6.1 i 2.4 4.1 -t 1.8 6.7 i 2.4* 
* = ~~0.05 Pre-Implant vs. 6 Months, paired data, mean i standard deviation. Conclu- 
sion: The results show that the CSD is safe. Furthermore, the trends strongly suggest 
that the CSD improves HF symptoms and LV function. Based on these data, randomized 
clinical trials aimed at evaluating the efficacy of the CSD in patients with HF have been 
initiated 
1043-49 Follow-Up on Passive Cardiomyoplasty In Congestive Heart 
Failure: Influence of the Acorn@ Cardiac Support Device on 
Left Ventricular Function 
Franz X. Kleber, Steffen Sonntag, Heike Krebs, Katrin Stantke, Wolfgang Konertz 
Department of Medicine, Unfallkrankenhaus, Berlin, Germany, Departmenf of 
Cardiovascular Surgery: Chariti, Berlin, Germany 
Background: Heart failure is characterized by deterioration of hemodynamics and pro- 
gressive dilation and reshaping of the ventricles. According to La Place’s law, ventricular 
chamber size contributes to afterload, limiting translation of tewon development into vol- 
ume work. Surgical placement of a passive constraining device over the ventricles could 
halt ventricular dilation or decrease ventricular volumes. However, it might impact dias- 
tolic function by linuting filling or promoting excessive fibrotic response, resultmg in con- 
strictlve physiology. Methods: In 15 patients (all male; age 53.5~11 yr: baseline ejection 
fraction 22.&g%; mean NYHA 2.5i-0.6) we studied left and right ventricular (LV, RV) 
function 3 and 6 months after implantation of an Acorn Cardiac Support Dewe, 10 of 
whom had pre-implantation studies for comparison. Pressure-volume curves were con- 
structed via micromanometer tip LV pressure recordings and biplane ventnculography 
applying Simpson’s rule. Potential constriction was evaluated through assessment of 
end-diastolic LV-RV pressure difference, LV rapid filling wave, RV end diastolic/systolic 
pressure ratio, interventricular dependence, etc. Coronary flow reserve was measured by 
Doppler wire applying 18mcg adenosine. Results: No patient showed clinical signs of 
constriction. End-diastolic LV-RV pressure differences were preserved. Relaxation and 
late diastolic function were unimpaired at operating LV volumes, while systolic function 
was preserved and volumes maintained or decreased. Coronary flow was unimpaired in 
the 11, 7, and 4 patients measured at 3, 6, and 12 months respectively. 
Pre-Implant (tl=lO) Post-Implant (n=lO) 
LVEDVl(mllm2) 163t45 154r56 
LVESVl(ml/mZ) 122247 114&58 
LVEF(%) 27.5 f 14.3 30.3 f 14.2 
Tau(ms) 65rll 58il3 
Chamber stiffness 0.09 t 0.04 0.07 k 0.06 
Conclusions: In patients with dilated cardiomyopathies. the Acorn Cardiac Support 
Device does not have any unfavorable constricting effect on the heart 6 months after 
implantation. Further. results show trends toward reduced ventricular volumes and 
improved systolic and early diastolic left ventricular function, while late diastolic stiffness 
is not increased. 
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1044-51 Improvement of Left Ventricular Remodeling and Function 
by HMG-CoA Reductase Inhibition With Cerivastatin in Rats 
With Heart Failure After Myocardial Infarction 
Johann Bauersachs, Daniela Fraccarollo, Paolo Galuppo, Michael Christ, Georg Erti 
Med,zinische Universitaefsklinik, Wuerzburg. Germany 
Background. Secondary prevention with HMG-CoA-reductase inhibitors (statins) reduces 
cardiovascular events in patrents after myocardial infarction (Ml). The effect of statin 
treatment on left ventricular (LV) remodeling and function in heart failure after Ml is 
unknown. Methods and Results: Rats wth heart failure after extensive MI were treated 
with placebo or with cerivastatin (0.3 mglkgid) as dietary supplement (CER-D) or via gav- 
age (CER-GAV) for 12 weeks starting on the 7th postoperative day. Infarct size and cho- 
lesterol levels were similar among all groups. LV cavity area, an index of LV dilatation, 
was reduced by cerivastatin compared to Ml-rats on placebo. Cenvastatln partially nor- 
malized LV +dPidtmax, an index of myocardial contractility (CER-D: 96255619, CER- 
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GAV: 10266+1633mmHg/s, pqO.05 vs. MI-Placebo), which was significantly reduced in 
Ml-rats on placebo (7956*428mmHg/s “s sham: 11602i152mmHg/s, pcO.001). LV end- 
diastolic pressure was increased in Ml-rats on placebo (24.1k4.1 mmHg vs. sham: 
5.1kO.3 mmHg, p<O.Ol), and significantly reduced by cerivastatin (CER-D: 16.7+2.5 
mmHg, CER-GAV: 13.7k2.7 mmHg, ~~0.05 vs. MI-Placebo). Cerivastatin significantly 
attenuated the increase in LV alpha-myosin heavy chain (MHC) isoenzyme expression in 
Ml-rats. In addition, LV endothelial NO synthase expression which was significantly 
increased in Ml rats was further enhanced by cerivastatin treatment. Conclusions: HMG- 
CoA reductase inhibition with cerivastatin improved LV remodeling and function in rats 
with heart failure independent of cholesterol lowering. This effect was associated with an 
attenuated expression of fetal MHC isoenzymes, and an increased expression of eNOS. 
Statin treatment may retard the progression of heart failure by interference with LV 
remodeling. 
1044-52 Role of Cardiotrophin-1 in Postinfarct Myocyte Hypertrophy: 
Effects of ACE Inhibitors and AT1 Blockers 
Sudhir Gupta, lnder S. Anand. VA Medical Centec Minneapolos, MN, University of 
Minnesota, Minneapolis, MN 
Background: Cardotrophin-1 (CT-I) has been shown to induce hypertrophy in cardiac 
myocytes, characterized by assembly of sacromere in series resulting in eccentric hyper- 
trophy, as seen in post MI hearts. Methods: We investigated the role of the ACE inhibitor 
(ACE-l), enalapril; ATI blocker (ATI-B), candesartan, and their combination on left “en- 
tricular CT-1 expression and myocyte hypertrophy in 6 week Ml and sham operated rats. 
Ml rats were treated with water, ACE-I (lmg/Kg), ATI-B (10mgiKg) or combination in 
drinking water. Treatment was started 24h after MI and continued for 6 weeks, when rats 
were sacrificed. Results: Hemodynamic, echo, and morphometric parameters confirmed 
significant remodeling and LV dysfunction in Ml hearts. All treatments had significant 
effects on these parameters (Table). Myocytes from water treated rats were hypertro- 
phied as compared to sham [length (urn) 185+10 vs 118k5; width (urn) 24k2 Vs 1791; all 
p<O.Ol]. Treatment with candesartan and combination reduced myocyte length [157+10 
and 124~6 respectively] but increased myocyte width [Z&Z and 30+2 respectively; all 
p<O.Ol] as compared to water treated animals. Enalapril treatment tended to reduce 
myocyte hypertrophy [Length 169*9 and width 261t2], but not significantly. As compared 
to sham, water treated Ml rats had a 47% increase in CT-1 mRNA levels. Enalapril 
reduced this to 37%; candesartan to 12% and combination therapy normalized the levels. 
Change in CT-1 levels correlated with change in myocyte length (r2 0.9). Conclusion: 
These data suggests that CT-1 may be involved in the hypertrophic response in post Ml 
ventricular remodeling. 
Sham Ml ACE-I AT-18 ACE-I+AT-IB 
LVDP, mmHg 112*7 5.3AO.03 91i5’V 75*5’\i9 94+4*YO 
LVdp/dt max,mm 26531207 1423*223* 1983+106*\i 175&l O*Yy 2188&l 02’9 
Hg/sec I3 
LVIDd, mm 5.7r0.3 El.5*0.3* c3.5*0.9*‘i 7.4*0.3*Y 7.1+0.8’Y 
LVIDs, mm 2.6k2.2 6.9t0.4* 5+1 *P 5.4+0.7*Y 4.9*:l.1*‘i 
Fractional 55.3~2.2 19.1c2.5’ 27*6.6*‘i 33.7zt7.4”i 36.1+7.8’Yy 
Shortening (%) 
Infarct Size, % LV .__.__. 2&2 28%6 28+3 21*4\i 
Heart Wt /Tibia, 0.39kO.02 0.51+_0.02* 0.48+0.02* 0.41r0.02 0.40*0.02*‘? 
g/cm 
Morphometry LV 5.3kO.03 7.2+0.04 7.0*0.05* 6.3*0.05* 6.6+0.03 
dimension, mm 
P<O.O5 * Vs Sham, Y Vs MI. y Vs ACE-I and 8 Vs AT1 B 
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effects of BH4 treatment on ischemia-repedusion induced global myocardial dysfunction. 
Through augmenting the production and/or availability of NO, BH4 may serve to improve 
coronary endothelial function, decrease lipid peroxidation and restore cardiac function. 
104454 Estrogen Replacement Downregulates Markers of Left 
Ventricular Remodeling After Large Myocardial Infarction in 
the Rat 
Laura J. Collins, Bysani Chandrasekar, Dorothy Martinez-Bonugli, James T. Colston. 
University of Texas Health Science Center. San Antonio, TX 
Background: Left ventricular remodeling is a major cause of morbidity and mortality after 
myocardial infarction (Ml). Previously, we have shown that estrogen replacement 
decreases tissue collagen content in the noninfarcted myocardium and plasma angio- 
tensin converting enzyme levels after large MI. This study chose to determine the relative 
effects of estrogen replacement on myocardial mRNA expression for collagen types I and 
Ill, and angiotensin converting enzyme in the noninfarcted myocardium after large Ml. 
Methods: Ovarlectomized Wistar female rats (n=18) underwent large MIS by ligation of 
the left anterior descending coronary artery. Animals were treated with subcutaneous 
17betaestradiol (E) to achieve plasma estradiol levels of 20-40 pg/ml or sesame oil (con- 
trol). Transthoracic echocardiograms were performed at baseline and 13 weeks after Ml. 
infarct size was calculated from the histologic sections. mRNA expression of collagen 
subtypes (I and Ill) as well as angiotensin converting enzyme was determined by North- 
ern blot analysis followed by densitometry. Results: While vehicle-treated ovariectomized 
animals expressed very high levels of anglotensin converting enzyme, estrogen replace- 
ment significantly inhibited its expression (vs. control; 2.5.fold, p<O.OOOl) in the noninf- 
arcted myocardium. Similarly, estrogen replacement downregulated expression of 
collagen type I (1.3.fold, pcO.005) and type Ill (1.5.fold, p<O.O05) in the noninfarcted 
myocardium. Transthoracic echocardiographic parameters of left ventricular systolic and 
diastolic function were not found to differ between the groups. Mean infarct size was 
40*6% for E treated and 44+4% for the control (p=NS). Conclusions: Estrogen replace- 
ment after Ml favorably downregulates markers of ventricular remodeling. This study has 
demonstrated decreases in both collagen type I (associated with tensile strength) and 
type Ill (associated with elasticity) in the noninfarcted myocardium. This modulation of 
collagen deposition in the noninfarcted myocardium may be regulated through the 
marked inactivation of the local renin angiotensin system. 
1044-55 VEGF cDNA Gene Therapy Postmyocardial Infarction: New 
Strategy to Reduce Adverse Ventricular Remodeling 
Postinjury 
Masoud Sadreddini, Fayez Dawood, Duncan Stewart, Anne Opavsky, Sam Siu, Peter 
Liu. Heart & Stroke/Richard Lewar Centre of ExceNence, Toronto, ON, Canada 
We have demonstrated previously that the coronary microvasculature (MV) is not 
only compromised in the presence of cardiac injury and heart failure, but is also a critical 
determinant of the fate of cardiac remodeling. To determine whether this abnormality is 
potentially reversible, we created a rat model of Ml. through LAD ligation with or without 
microvascular damage using dilute Triton-X (Tri-X) injected in the aortic root (Tri+ or Tri-). 
The animals were then randomized to direct intramyocardial injections of either VEGFIss 
cDNA (VGc, 210 ug/O.Bml) or scrambled control (VG-), leading to 4 experimental 
groups. The animals were followed for 14 days for LV end-diastolic diameter (LVEDD, 
mm), non-infarct wall thickness (WTh, mm), developed pressure (DVP, mmHg) and 
changes in coronary blood resistance on serotonin challenge as an index of endothelial 
function (DCVR, mmHglml/min). The Ml size was the same in all groups. (mew&D, 
*p<O.O5 VG- vs. VG+ groups) 
1044-53 Novel Cardioprotective Effects of Tetrahydrobiopterin in an 
Experimental Model of Global lschemia and Reperfusion 
Subodh Verma, Satish R. Raj, Aaron S. Dumont, Andrew Maitland, Khalid Al-Faraidy, 
Todd J. Anderson. University of Calgary, Ca/gary, AB, Canada 
Background: Tetrahydrobiopterin (BH4) is an absolute cofactor required for the enzyme 
nitric oxide synthase (NOS 3) and the subsequent generation of nitric oxide (NO) from I- 
arginine in the endothelium. In the present study we hypothesized that BH4 may protect 
the myocardium ,against ischemia-reperfusion induced cardiac dysfunction through 
increasing NO production and/or availability. Methods: Male Wistar rats were divided into 
two groups (n=lO per group). Group 1 received BH4 (25mg/kg/day, iv, 7 days) while 
group 2 was injected with saline and served as the control group. Following treatment, 
hearts from both groups were excised and studied using the modified Langendroff proce- 
dure. The hearts were paced and perfused at a constant flow rate of 7 ml/min. LVDP, 
LVSP and LVEDP were determined using a latex balloon inserted into the lefl ventricle. In 
addition, coronary perfusion pressure (CPP) was determined. Following 30 minutes of 
equilibration, the hearts were subjected to 30 minutes of ischemia followed by 30 minutes 
of repedusion. A separate group of saline treated rat hearts were continuously perfused 
for a period of 90 minutes. Following this protocol, the hearts were frozen and malondial- 
dehyde (MDA) levels, an index of myocardial injury, were determined. Data were ana- 
lyzed using ANOVA followed by a Newman Keuls test for post hoc comparisons. Results: 
In the control group, ischemia with subsequent reperfusion resulted in myocardial dys- 
function as evidenced by a decrease in LVDP and an increase in CPP and LVEDP 
(pcO.05). Hearts from the BH4 treated rats exhibited protection against ischemia-reperfu- 
sion induced cardiac dysfunction (LVDP 74+_4 vs. saline 42+5 mmHg, p<O.O02; LVEDP 
IO+3 vs., saline 34~8 mmHg, p<O.O5). A 3 fold increase in MDA levels following 
ischemia-reperfusion was apparent in the saline treated rats which was attenuated in the 
BH4 group (pcO.05). Conclusion: These data uncover, for the first time, novel beneficial 
Tri-VG- Tri-VG+ Tri+VG- Tri+VG+ 
LVEDD 1.011.07 0.99rO.i 1.04r0.06 0.91io.14 
WTh 0.15k.02 0.14*0.005 0.13*0.01 0.15*0.06 
DVP 42*11.22 48.7~10.6 50.8e7.9 56.2r15.9 
DCVR 0.70*..17 0.64+0.17 0.17~0.11 0.35?.24* 
We conclude that VEGF cDNA gene transfer can reduce adverse cardiac remodeling 
post-MI and preserve LV function and microvasculature integrity. This suggested that the 
MV abnormality is potentially reversible and thus may offer a novel way to modulate ven- 
tricular remodeling. 
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1045-56 Prevalence of Left Ventricular Systolic and Diastolic 
Dysfunction in Olmsted County, MN: A Population-Based, 
Cross-Sectional Doppler-Echocardiographic Survey 
Margaret M. Redfield, John C. Burnett, Jr., Steven J. Jacobsen, Douglas W. Mahoney, 
Richard J. Rodeheffer. Mayo Clinic and Foundation, Rochester, MN 
BACKGROUND: Congestive heart failure (CHF) may be associated with combined sys- 
tolic and diastolic left ventricular (LV) dysfunction or an isolated impairment in LV diastolic 
function. LV dysfunction may also be asymptomatic. The prevalence of systolic and dias- 
tolic dysfunction in the community is unknown. The objective of this study was to deter- 
mine the prevalence of systolic and diastolic LV dysfunction using Doppler 
echocardiography (DE) in a random sample of Olmsted County, MN residents > 45 yrs 
old. METHODS: Utilizing the resources of the Rochester Epidemiology Project, 2050 
randomly selected subjects underwent DE performed according to a study protocol and 
reviewed by a single echocardiologist. Quantitative (Biplane Simpsons method; BSEF) 
and semi-quantitative assessment (visual estimate, VEF) of ejection fraction (EF) were 
possible in 79.3% and 99.7% of subjects respectively. The lower limit of normal for BSEF 
(49%) and VEF (52%) was defined in a subset of normal subjects (n=584). Diastolic 
function was classified (normal, mild dysfunction, moderate-severe dysfunction or inde- 
terminate) according to hemodynamically validated criteria which incorportated pulsed- 
wave Doppler of mitral inflow (before and with Valsalva) and pulmonary venous inflow as 
well as Doppler tissue imaging of the mitral annulus. RESULTS: BSEF was < 49% in 
4.1% and VEF was < 52% in 6.3% of the population. BSEF was c 40% in 1 % and VEF 
‘was < 40% in 1.4% of the population. Diastolic function in those with normal or reduced 
BSEF or VEF are below. 
Prevalence of Diastolic Dysfunction 
VEF>=B VEF<5 BSEF>=4 BSEF<4 
2% 2% 9% 9% 
Normal Diastolic Function 66% 15% 66.5% 19.7% 
Mild Diastolic Dysfunction 17% 28% 16.2% 34.3% 
Moderate-Severe Diastolic Dysfunction 5.3% 28% 6% 23% 
Indeterminate (atrial fibrillation, incomplete 11.7% 29% 11 .3% 23% 
assessment, etc) 
Preliminary analysis indicates strong associations between age, gender and cardiovas- 
cular disease for both systolic and diastolic dysfunction. CONCLUSION:These data pro- 
vide an estimate of the prevalence of systolic and diastolic dysfunction in the community. 
Longitudinal studies are needed to determine the association between DE detected LV 
dysfunction and cardiac events. 
1045-57 Acute Aortic Dissection in the Elderly: Clinical 
Characteristics, Management, and Outcomes in the Current 
Era 
Rajendra H. Mehta, PatrickT. O’Gara, Peter G. Hagan, Eduardo Bossone, Alfred0 Llovet, 
Jeanna Cooper, David Bruckman, Kim A. Eagle, Dan Gilon. University of Michigan 
Medical Center, Ann Arbor, ML Hadassah University Hospital, Israel 
Background: Elderly patients with cardiovascular disease differ in clinical manifestation of 
their disease from young pts and often have poor outcomes. Few data exist on the pre- 
sentation, management and outcomes of elderly patients with Acute Aortic Dissection 
(AAD). Methods: We categorized 758 patients with AAD from IRAD into 2 age-based 
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strata < 70 years and > 70 years and compared them with regards to their clinical charac- 
teristics, findings on diagnostic imaging, managem&t and mortality using standard sta- 
tistical methods. Results: 
VARIABLES <70 70 P- VARIABLES < 70 70 P- 
YEA YEARS VALUE YEA YEARS VALUE 
RS OR RS OR 
OLDER OLDER 
DEMO- HISTORY 
GRAPHICS 
Mean age 57.7 
(SD, years) (11) 
Dissection type 67.3 
A (vs. type B) 
Male 74.0 
CLINICAL 
FEATURES 
Chest pain 78.8 
Abrupt onset 88.2 
chest pain 
Syncope 12.8 
Altered 11.3 
conciousness 
Systolic 19.5 
blood pressure 
<l OOmmHg 
Pulse deficits 20.5 
Aortic 35.2 
Insufficiency 
lschemic limb 8.5 
Normal EGG 31.1 
77.0 (5) 
54.3 
52.9 
71.4 0.023 
79.6 0.002 
7.9 0.042 
9.7 
18.8 
13.1 
19.4 
6.0 
22.0 
<O.OOi 
<O.OOl 
0.49 
0.79 
0.012 
<O.OOl 
0.22 
Hypertension 68.1 
Atherosclerosis 22.3 
Diabetes 
Marfans 
syndrome 
Known aortic 
disease 
latrogenic 
dissection 
DIAGNOSTIC 
IMAGING & 
TREATMENTS 
Intramural 
hem&ma 
False 
lumen 
thrombosis 
surgery 
Medical Rx 
Percutaneous 
intervention 
HOSPITAL 
MORTALITY 
2.9 
7.5 
10.6 
2.9 
16.6 29.4 co.oo1 
25.9 46.3 <O.OOl 
61.0 
31.7 
7.3 
22.5 
75.2 0.04 
45.7 <O.OOi 
9.0 4001 
0.0 co.oo1 
19.4 <O.OOl 
7.2 0.006 
37.8 <O.OOl 
57.5 <O.OOl 
4.7 NS 
29.1 0.042 
Conclusions: IRAD provides an opportunity to study elderly with AAD in the current era. 
Our investigation shows significant differences in demographics, comorbidities, clinical 
features, and test findings in elderly patients with AAD as compared to younger cohort. 
Further, our data indicates that elderly patients are more often managed conservatively 
with medical rather than with surgery therapy and have higher in-hospital mortality. 
1045-58 Alcohol Consumption and Risk of Heart Failure in the 
Elderly 
Jerome L. Abramson, Setareh A. Williams, Viola Vaccarino. Yale University School of 
Medicine, Department of Epidemiology and Public Health, New Haven, CZ; AstraZeneca 
Pharmaceuticals, Wayne, PA 
Background: Investigators have shown that moderate alcohol consumption is associ- 
ated with a lower risk of several types of cardiovascular outcomes including myocardial 
infarction, angina pectoris, and sudden cardiac death. However, the association between 
moderate alcohol consumption and risk of heart failure has not been established. 
Methods: The present study examined the association between alcohol consumption 
and risk of heart failure among 2282 persons aged 65 years and older who were enrolled 
in the New Haven, CT. site of the National Institute on Aging’s Established Populations for 
the Epidemiological Study of the Elderly (EPESE) program. Persons with heart failure at 
baseline were excluded from analyses. Alcohol consumption in the month prior to the 
baseline interview was assessed by self-report. The multivariate adjusted relationship 
between alcohol consumption and subsequent risk of heart failure was analyzed using 
Cox proportional hazards regression. 
Results: During an average of 8.6 years of follow-up, 282 persons developed heart 
failure. Among those consuming no alcohol, l-30 ounces of alcohol, and > 30 ounces of 
alcohol in the month prior to baseline, the crude heart failure event rates per 1000 per- 
sons-years of follow-up were 16.3, 11.0, and 6.6 respectively. In multivariate Cox regres- 
sion models that controlled for age, sex, race, education, history of myocardial infarction, 
myocardial infarction during follow-up, history of diabetes, hypertension, pulse pressure, 
body mass index, and smoking, the relative risk (95% confidence interval) of heart failure 
for those consuming no alcohol, l-30 ounces of alcohol, and > 30 ounces of alcohol in 
the prior month was 1.00 (referent), 0.80 (0.57-l .13), and 0.40 (0.20-0.83) (P for trend = 
.OZ). 
Conclusion: Increasing levels of alcohol consumption in the moderate range are associ- 
ated with a decreasing risk of heart failure among the elderly, independent of potential 
confounding factors. This association does not appear to be mediated by the protective 
effect of alcohol against myocardial infarction. 
1045-59 Age as a Confounding Factor on Helicobacter pylori 
Infection and the Risk of Coronary Artery Disease 
Jianhui Zhu, Joseph B. Muhlestein, Julian P. J. Halcox, Javier F. Nieto, Benjamin D. 
Home, Alexandra Zalles-Ganley, Stephen E. Epstein. Washington Hospital Center, 
Washington, DC 
Background: The studies assessing a potential role for H. pylori infection in CAD are con- 
flicting. We investigated the association between H. pylori infection and CAD in two study 
populations: a cross-sectional study (Study #1) to determine risk of having CAD, and a 
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longitudinal study (Study #2) to determine risk of MI or death over a mean follow-up 
period of 3 years in pts with angiographically documented CAD. Methods: Blood samples 
were tested for serum IgG antibodies to H. pylori and C-reactive protein (CRP) levels. 
Results: Study #l: Of 391 pts (62% men, mean age 57) 41% had antibodies to H. pylori. 
CAD prevalence was 70% in H. pylori seropositive and 59% in seronegative pts (P=O.O3). 
Elevated CRP levels (~0.5 mg/dL) were significantly higher in pts with CAD than those 
without CAD (78% vs. 67%. P=O.O2). By univariate analysis CAD prevalence significantly 
increased stepwise depending on H. pylori seropositivity and elevated CRP levels--CAD 
prevalence was 52% in seronegative individuals without elevated CRP levels; 56% in the 
subgroup with H. pylori seropositivity alone and 61% in the subgroup with elevated CRP 
levels alone: and 75% in the subgroup with combined seropositivity and elevated CRP 
levels (Ptrend=O.OOB). However, significance was lost after adjustment for traditional risk 
factors (age, race, male gender, smoking, diabetes, hypercholesterolemia, hypertension). 
Further analyses revealed that age was the critical confounder. Study #2: Of 929 pts 
(77% men, mean age 65 that was older than the NIH patients), 56% had antibodies to H. 
pylori. By univariate analysis the incidence of MI or death was 22% in H. pylori seroposi- 
tive and 18% in seronegative pts (P=O.l). The adjusted hazard ratio of Ml or death for H. 
pylori seropositivity was 1.12 (95%Cl=O.81-1.54). Conclusion: Thus, our data suggest 
that prior infection with H. pylori is not a major factor determining either risk of CAD, or MI 
or death in pts with documented CAD. The results also suggest that previously reported 
positive associations may have been influenced by confounding variables, in particular 
age. 
1045-60 Age Related Differences in Underlying Pathophysiology of 
Suspected Vasovagal Syncope 
Arvinder S. Kurbaan, Nevin Wijesekera, Ann-Christine Franzen, Timothy Bowker, Gita 
Mathur, David Heaven, Richard Sutton, Chef.%% & Westminster Hospital London, United 
Kingdom, London Chest Hospital London, United Kingdom 
Background: In those with suspected vasovagal (neurocardiogenic) syncope (VVS) tilt 
testing demonstrates different haemodynamic responses. These responses may be age 
related, reflecting differing underlying pathophysiology. Methods: Using a 2 stage tilt pro- 
tocol with GTN provocation, 504 consecutive patients were studied. Three age groups 
were defined: ~36, 36-65 and >65 years. Their baseline characteristics and haemody- 
namic responses during both early and tilt-induced collapse were analysed. Haemody- 
namic responses were classified using VASIS criteria: Type 1 mixed-blood pressure (BP) 
and heart rate (HR) fall without significant bradycardia; Type 2A cardioinhibition-BP falls 
before HR: Type 26 severe cardioinhibition-HR falls before or coincident with BP and or 
there is asystole; Type 3 pure vasodepression-BP falls without HR change; Exception 1 
chronotropic incompetence, Exception 2 excessive HR rise, Exception 3 carotid sinus 
syndrome. Results: 32 failed to complete the protocol. Of the remaining 472, those ~36 
were less likely to require GTN provocation (~~0.05) but more likely to have a positive 
result (~~0.05) and one or more of excessive heart rate rise and severe cardioinhibitioni 
asystole. Conversely, those >65 were more likely to have one or more of coronary dis- 
ease, postural hypotension, chronotropic incompetence, carotid sinus syndrome and 
pure vasodepression response. 
Age related baseline characteristics and tilt induced haemodynamic responses 
~36 36-65 >65 
(n=162) (n=154) (1~156) 
Female 56.1 42.2 53.4 
Coronary disease’ 0 7.8 31.4 
Postural hypotension’ 1.9 3.3 18.6 
VASIS Exception I-Chronotropic incornpe- 0 6.5 10.3 
tend 
VASIS Exception 2-Excessive heart rate rise* 25.3 7.1 5.8 
VASIS Exception 3-Carotid sinus syndrome* 0 5.8 15.4 
VASIS Type 2B- Severe cardioinhibition’ 34.0 16.2 5.8 
VASIS Type 3- Vasodepression* 0.6 3.3 23.7 
Numbers in table are percentages, “p<O.OOi 
Conclusion: In VVS baseline characteristics and haemodynamic responses to tilt testing 
differ according to age. In those ~36 VVS is associated with exaggerated autonomic 
responses. However, with increasing age (especially those >65) autonomic responses 
are impaired and cardiac/vascular co-morbidity is often present, This has important ther- 
apeutic implications. 
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1046-61 Performance Characteristics of N Terminal Pro Brain 
Natriuretic Peptide (NT-proBNP) and BNP Assays in the 
Diagnosis of Symptomatic and Asymptomatic Left 
Ventricular Systolic Dysfunction in Primary Care 
Frederick D. R. Hobbs, Russell C. Davis, Andrea K. Roalfe, Joyce E. Kenkre, Juergen 
Trawinski, Michael K. Davies. University of Birmingham, Birmingham, United Kingdom 
Background: Left ventricular systolic dysfunction (LVSD) is the principal and treatable 
cause of heart failure (HF). ACE inhibitors improve symptoms, prognosis and progres- 
sion in all grades LVSD, and b&blockers and spironolactone in some patients. Echocar- 
diography, the most common method of assessment of ventricular function, is not 
routinely accessible to primary care. Assays of natriuretic peptides (particularly BNP) 
may prove useful as screening tests for HF. Previous studies have mainly been in hospi- 
tal, with samples taken under lab condrtions, from unrepresentative populations. Objec- 
tives: To establish the performance characteristics of BNP assays in the diagnosis of 
LVSD in the generalisable population. Methods: 591 patients were randomly selected 
from community populations stratifred for socio-economic status assessed as part of the 
‘ECHOES study of HF prevalence. 33 were diagnosed as having HF on strict criteria, fol- 
lowing clinical assessment, ECG and echocardiography. Blood was taken, kept at room 
temperature for up to 24 hours prior to transfer to a lab for spinning down and freezing. 
Assays of plasma BNP (Shinogi, Japan) were subsequently performed after posting sam- 
ples to a central laboratory, as would occur in routine practice. Assays of plasma BNP 
(Shin@, Japan) and NT-proBNP (Roche Diagnostics) were performed at a central lab. 
Results: Receiver Operator Characteristic (ROC) curves were plotted for diagnosis of 
symptomatic and asymptomatic LVSD for the 2 assays. The area under the curve (AUC) 
for all LVSD was 82% for both NT-proBNP and for BNP (sensitivity of 94% for both and 
specificity of 56% and 63&+% respectively at relevant cut-offs). Both tests had high neg- 
ative predictive values of 99% at cut-off, but low PPVs of 11% and 13% respectively. 
Conclusions: BNP and NT-proBNP have simrlar sensitivity and specificity for the diagno- 
sis of LVSD in a community setting. Their performance is superior to routine screening 
tests such as mammography (AUC 0.85) and PAP smears (AUC 0.70) Despite delays in 
transport, processing and analysis of samples (routine in primary care) NTproBNP and 
BNP remain useful predictors of LVSD. NT-proBNP ELISA may offer technical advan- 
tages. 
1046-62 The Prevalence and Aetiological Associates of Left 
Ventricular Systolic Dysfunction in the Population of North 
Glasgow, Scotland, Aged 55 to 74 Years 
Stephen D. Robb, Theresa A. McDonagh, Caroline E. Morrison, Henry J. Dargie. 
University of Glasgow, Glasgow, United Kingdom 
Background: The epidemiology of heart failure has been previously well described but 
less is known about the epidemiology of its major contributor, left ventricular (L.V.) sys- 
tolic dysfunction. 
Methods: We studied 1009 individuals aged 55 to 74 years randomly selected from the 
urban population of North Glasgow, Scotland. Each person completed questionnaires 
regarding demographics, past medical history, the symptom of breathlessness, and cur- 
rent medication. Their blood pressure was measured and a resting 12 lead E.C.G. was 
recorded and coded according to the Minnesota coding system. A full echocardiogram 
was performed with an L.V. ejection fraction (L.V.E.F.) calculated using a biplane Simp- 
son’s method. 
Results: An L.V.E.F. was able to be calculated in 750 people and the median L.V.E.F. 
was 50.7%. Based on a subgroup considered to be free from evidence of cardiovascular 
disease and Its major risk factors left ventricular (L.V.) systolic dysfunction was taken to 
be represented by an L.V.E.F. of c= 35%. L.V. systolic dysfunction was present in 50 peo- 
ple (6.7%) and its prevalence rose with age; being higher in men than in women (9.4% v 
4.0%, P=O.O04) in each five year age band. The proportion of L.V. systolic dysfunction 
which was considered- to be symptomatic (associated with cardiac-type breathlessness 
or being treated with a loop diuretic) was 46% with no age or gender effect wdent. Only 
16% of individuals with L.V. systolic dysfunction were currently receiving treatment with 
an angiotensin converting enzyme inhibitor. The principle aetiological associate of L.V. 
systolic dysfunction was ischaemic heart disease (based on questionnaire and E.C.G. 
findings) with it accompanying 78% of all cases. Neither isolated hypertension nor diabe- 
tes ‘mellltUS were more prevalent in individuals with L.V. systolic dysfunction than in rndi- 
viduals with normal L.V. function. 
Conclusion: This study found a higher prevalence of L.V. systolic dysfunction than previ- 
ously described in this and other populations. A large proportion of cases were asymp- 
tomatic, and a minority of all cases were receiving adequate treatment. This supports the 
need for screening programmes for L.V. systolic dysfunction in the community. 
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Conclusion: In normal subjects. NT-proE3NP increased markedly with age. In all age 
groups, NT-proBNP was significantly higher in women than in men. In the possible appli- 
cation of NT-proBNP as a marker for CHF, these findmgs need to be taken into account 
when establishing cut-off levels for the dragnosis. 
NT-proBNP geometrical mean concentrations 
Male Female p “due Age me A!% Age lkwend 
btaie Group 1 Group 2 Group 3 Group 4 WerAge 
YWWS (50.59 (60-69 (70.79 (SO Groups 
Female years, years, YWS) years, 
NT- 2&S+- ‘wst- 4’10.6 ,&I+- 27.2+- 51.4+- 108+-8.93 w3.58 
proBNP+-SD 1 79 2.24 1 07 1.58 3 37 (ll=l20, p=8’10- 
(pmo,,,) A,, b7=29@ cn==2 (tl=174, (“S04) (W174, 63 
) 
(n=672) 
NT- ,a+- 21.7+- 0 01 ,2.7+- l&41- 33.2+- C33.1+- r4.50 
p:oBNP+-SD 1.58 1 99 1.28 1 94 4.18 17.5 p=5’10- 
(pmolll) Nor- 
(n=57) (n=;/*j (“S3) (“=45, (n=20) (“dk 10 
1046-65 Performance Characteristics of N Terminal Pro Brain 
Natriuretic Peptide (NT-ProBNP) and BNP Assays in the 
Diagnosis of Heart Failure in Community Settings 
Frederick D. R. Hobbs, Russell C. Davis, Andrea K. Roalfe, Juergen Trawinski. Michael K. 
Davies. University of Birmingham, Birmingham, United Kjngdom 
Background: Heart failure (HF) is a major cause of morbidity and mortality. Treatment 
rmproves prognosis in left ventricular systolic dysfunction (LVSD), the main cause of HF 
Unfortunately diagnosing heart failure on clinical grounds is difficuli and echocardio- 
graphy is not routinely available to primary care in many parts of the world. Assays of 
natriuretic peptides (particularly BNP) may prove useful as screening tests for HF. Previ- 
ous studies have mainly been in hospital, with samples taken under lab conditions, from 
unrepresentative populations. Objectives: To establish the performance characteristrcs of 
BNP assays in the diagnosis of heart failure in the general population. Methods: 591 
patients were randomly selected from community populations stratified for socio-eco- 
nomic status assessed as part of the ‘ECHOES study of HF prevalence. 52 were diag- 
nosed as havrng definite HF on strrct criteria, with a further 15 as probable, following 
clinical assessment> EGG and echocardiography. 33 had LVEF ~40%; other cases ware 
due to valve disease or atrial fibrillation. Blood was taken, kept at room temperature for 
up to 24 hours prior to transfer to a lab for spinning down and freezing. Assays of plasma 
BNP (Shinogr, Japan) were subsequently performed after postrng samples to a central 
laboratory, as would occur in routine practice. Assays of plasma BNP (Shrnogr, Japan) 
and NT-proBNP (Roche Diagnostrcs) were subsequently performed at a central lab. 
Results: Receiver Operator Characteristic (ROC) curves ware plotted for diagnosis of 
heart failure for the 2 assays. The area under the curve (AUC) was 86% for NT-proBNP 
and 83% for BNP (sensitivity of 89% and specificity of 65% at 20 pgiml). Both tests exhib- 
ited very hrgh negative predictive values of 99% at surtable cut-offs. Conclusions: BNP 
and NT-proBNP have similar sensitivity and specificity for the diagnosis of HF in a com- 
munity setting. Despite delays in transport, processing and analysis of samples (routine 
in primary care) NT-proBNP and BNP remain useful predictors of HF. These data suggest 
BNP as a filter to echocardiography may be cost effective and needs formal testing. 
1046-64 The Use of B-Natriuretic Peptide (BNP) in Assessing 
Cardiac Function in Patients With Diabetes Mellitus 
Victoria A. Epshteyn, Katherine Morrison, Padma Krishnaswamy, Radmila Kazanegra, 
Alan S. Maisel, VASDHCS. San Diego, CA 
Background: Diabetic patrents are at significant risk for cardiovascular events. Routrne 
screening of drabetic patients with echocardiography is not feasible, due to its limited 
availability, high cost, as well as the relatively asymptomatic nature of cardiac dysfunction 
in diabetic patients. Brain Natriuretic Peptide (BNP) is secreted predominantly from left 
ventricle (LV) in response to both volume expansion and pressure overload and may be 
elevated early in the course of both systolrc and diasiolic cardiac dysfunction. We there- 
fore asked whether BNP levels can be used to screen diabetic patients for cardiac dys- 
function. 
Methods: The subjects were 111 drabetic patients referred for echocardiography to eval- 
uate the presence or absence of LV dysfunction. Plasma levels of BNP were measured 
by a pomt-of-care immunoassay (Biosite Diagnostics). The results of BNP levels were 
blrnded from cardiologists making the assessment of LV function. 
Results: In 38 patients with normal LV function, BNP = 39 i 8 pg/ml. This is significantly 
less than patients with systolic dysfunction (n = 12) BNP = 379 + 138 pgiml; diastolic dys- 
function (n = 33) BNP = 474 i 106 pgiml; and systolic plus diastolic dysfunction (n = 22) 
BNP = 958 k 169 pg/ml. (PC 0.001). All group comparisons ware made on log trans- 
formed BNP values. BNP levels over 80 pgiml were seen in only 5.3% of patients wrth 
normai LV functron, compared to 94.5% of patients with abnormal ventricular function (P 
c 0.001). A receiver-operating characteristic (ROC) curve showing the sensitivity and 
specificity of BNP against echocardiographic diagnosis revealed the area under the 
curve was 0.953. BNP level of 64 pg/ml was 97% specific and 32% sensitive for detect- 
ing ihe presence or absence of LV dysfunction using echocardiography. 
Conclusion: A simple and rapid assay for BNP can be employed to reliably screen dia- 
bebc patients for presence or absence of LV dysfunction. This test may be especially 
useful for detectrng early LV dysfunction in asymptomatic patients. 
1046-65 N-Terminal Pro Brain Natriuretic Peptide Plasma Level is 
Dependent of Age and Gender: A Survey of a Large Urban 
Population Aged Older Than Fifty Years 
llan Raymond, Bjoern A. Groenning, Frants Pedersen, Jeanett Drmsits, Matthias 
Baumann. Jiirgen Trawinski, Per R. Hildebrandt. Department of Cardiology and 
Endocrinolog& H:S Frederiksberg Hospital, Univers!ty of Copenhagen. Copenhagen. 
Denmark. Integrated Heaith Care Solutions, F: Hoffmann-La Roche Lid, Base/, 
Switzerland 
Background: N-terminal pro brain natriuretic peptide (NT-proBNP) has in several[BGl] 
studies been reported to be a useful marker in the dragnosis of congestive heart failure 
(CHF). The aim of the present study was to examine the influence of age and gender on 
NT-proBNP 
Methods: A total of 683 unselected subjects (mean age 68 years, range 50.90) were 
examined. The participants answered a questionnaire on symptoms, previous heart dis- 
ease and cardiovascular risk factors and ECG and blood samples were obtained. 
Results: We found a significant rncraase with age in the level of NT-proBNP. A srmilar 
pattern was found in “normalli subjects wrthout history of cardiovascular disease or car- 
diovascular medication, normal ECG, blood pressure s140/90, no diabetes or lung dis- 
ease (n=135). The mean concentratran of NT-proBNP in the entire study population was 
higher than in normal subjects (4221.9 (SD) versus 18e1.4 pmolil, ~~2’10~‘~). NT- 
proBNP was significantly higher in females than in males in both study populations. 
mals (n=135) 
1046-66 Variations in Levels of Brain Natriuretic Peptide in Patients 
With Heart Failure: The Effect of Methodology 
Chetan Varma, Nrall Mahon, Salim Fredericks, Sami Firoozi, Manmohan Virdee, William 
Mckenna. st goerges hospital medical school, Iondon, United Kingdom 
Background Serological screening tests for heart failure (HF) are sought. Brain natriuretic 
peptide (BNP) and N-terminal (NT) BNP have been suggested to be useful for screening, 
although which is a more useful marker is not clear-cut. The assay itself should be accu- 
rate, reliable and reproducible but the methodology of BNP measurement is not unified. 
For example in published studies aprotinin, a preservative to prevent the breakdown of 
natriuretic peptides. may or may not be added as part of the serum collection. Compari- 
son between the various available assays and techniques is not readily available. Aims 
We performed a comparison, using the latest commercially available assay kits, between 
samples collected with and without aprotinin to determine whether a difference in results 
occurred and we compared levels of NT BNP and BNP (pg/ml) in the same group of 
patients to assess correlation between these. Methods Patients were recruited from our 
HF clinic. Blood was collected in two tubes, one wrth and one without aprotinin, and spun 
down. Plasma was stored at -80 C. Each collecbon was then assayed simultaneously as 
paired samples in the following manner: (i) pro BNP with aprotinin (A) “s pro BNP without 
aprotinin (B) (manufacturer Biomedica) (ii) BNP with aprotinin (A) “s BNP without aproti- 
nin (B) (Shinaria) (iii) pro BNP with aprotinin (A) (Biomedica) “s BNP with apmtrnin (8) 
(Shinoria) and (iv) pro BNP with aprotinin (A) “s BNP with aprotinin (B) (Peninsula). 
Results 13 patients (mean age 56 * 14, male 10) were enrolled. Severity of HF differed: 
NYHA 3 = 5, NYHA 2 = 4 and NYHA 1 = 4. A total of 42 samples were analysed. Results 
as rn Table. Conclusions Levels of BNP and proBNP are elevated in patients with HF. 
However aprotinin is needed to prevent a significant reduction in BNP Correlation 
between proBNP and BNP was not good. The use of NT BNP needs further evaluation 
before use of this as a screening test for heart failure can be advocated. 
groups mean BNP or proBNP (A) mean BNP (B) R value R 
I 63+29 22i18 0.905 0.002 
ii 75 i 85 48 t 56 0.986 0.008 
iir 63i-29 75+85 0.277 0.12 
iv 51 i-26 73*45 0.314 0.07 
1046-67 Prognostic Value of Amino-Terminal Pro-atria1 Natriuretic 
Peptide Assessed by Sandwich Enzyme-Linked 
lmmunosorbent Assay Compared to Big Endothelin in 
Chronic Heart Failure. 
Rudolf M. Berger, Karin Strecker, Martin Huelsmann, Bernhard Frey, Anja Bojic, Richard 
Pacher, Brigitte Stanek. University of Vienna, Department of Cardiology, Vienna, Austria 
Objectives: To compare the prognostic impact of amino-terminal pro-atria1 natriuretic 
peptide (proANP) assessed by sandwich enzyme-linked immunosorbent assay (ELISA) 
with big endothelin (big ET) in chronic heart failure (CHF). Background: Big ET, an endot- 
helial derived prohormone, as well as natriuretic peptides (including proANP), stress 
induced hormones secreted from the heart, have prognostic importance in patients (pts) 
with CHF Assessment of proANP with ELISA offers a widespread and easy use in con- 
trast to assessment of big ET with radioimmunoassay. Methods: Plasma levels of big ET 
and proANP in addition to 12 clinical and hemodynamic variables, were obtained from 
508 pts with left ventricular ejection fraction (LVEF) < 35% (87% m / 13% f, 36% ischemic 
/ 64% nonischemic dilated cardiomyopathy, 12% NYHA class I, 34% NYHA class 11, 34% 
NYHA class III, 20% NYHA class VI) and were related to mortality within a mean follow- 
up period of 21 2 15 months by a stepwise Cox regression multivariate analysis. Results: 
During the study period 323 pts ware alive (group A), 100 pts died (group B) and 85 pts 
ware transplanted. Brg ET (p < O.OOOl), proANP (p <O.OOOl), NYHA class (p < O.O6f11), 
LVEF (p < O.OOOl), coronary artery disease (p < 0.005), diabetes mellitus (p c 0.005), 
systolic blood pressure (p < 0.01) and R-blocker therapy (p < 0.05) differed significantly 
between groups A and B. In multivariate stepwise regression analysis big ET was the 
strongest independent predictor (p < 0.0001). and proANP did not provide additional 
prognostic information. Excluding big ET from the multivariate model, proANP became 
the strongest independent predictor (p c: O.OOOl), with NYHA class (p < O.GOOl), left “en- 
tricular ejection fraction (p < 0.005), coronary artery disease (p < 0.005) and B-blocker 
therapy (p < 0.05) providing additional prognostic information. Conclusion: In CHF, big ET 
is a strong independent predictor of death without proANP providing additional prognos- 
tic information. Nevertheless, pro ANP is a powerful predictor and more useful in clinical 
prachce as assessed with EL&A. 
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104668 Evaluation of N-terminal Pro-Brain Natriuretic Peptide as 
Marker of Impaired Left Ventricular Function After 
Myocardial infarction 
Andreas Luchner, Christian Hengstenberg, Hannelore Loe&?l, Juergen Trawinski, 
Matthias Baumann, Heribert Schunkert, Guenter A. J. Riegger, Stephan R. Holmer. Klinik 
lnnere Med. II, Regensburg, Germany, Roche integrated Health Care Solutions, Base/, 
Switzerland 
Background: Plasma concentrations of NT-proBNP were found to be increased early 
after acute myocardial infarction (Ml). We tested whether NT-proBNP can ?er”e as pre- 
dictive marker for left ventricular (LV) dysfunction late after MI. 
Methods: In 625 MI patients (MONICA Ml-register, Augsburg; time after MI l-10 years, 
mean 5.6) we assessed the association between NT-pro BNP, LV ejection fraction (EF) 
and mass, and anthropometric, hemodynamic, and metabolic variables. In addition, 465 
of their siblings without MI (no Ml) were studied. NT-proBNP was; measured by non- 
extracted, enzyme-linked, sandwich immunoassay (Roche Diagnostics). 
Results:NT-proBNP was elevated in Ml patients (96.6+13.7 pmol/l vs. noMl 31.2+1.8, 
pcO.001). Particularly elevated NT-proBNP was found in Ml patients with severe LV dys- 
function (LVD, EF<35%, 182.8?;41.9 pmolil, p<O.Ol vs. control and vs. MI without LVD), 
LV hypertrophy (LVH, 214.5161.7 pmolil, ~~0.01 vs. control and vs. MI without LVH), and 
renal dysfunction (ReD, 210.3+51.4 pmol/l, p<O.Ol vs. control and vs. Ml without ReD). 
Multiple regression analyses revealed that NT-proBNP was correlated with EF, LV mass 
index, glomerular filtratron rate, history of Ml, gender, and diastolic blood pressure. Prog- 
nostic parameters are shown in the table. 
JACC February 2001 
with LVEF less than vs. greater than 20%. Baseline and serial levels were compared 
between patients treated with bucindolol and placebo. The Wilcoxon Rank Sum Test was 
utilized for comparisons. Results are expressed as mean +/- SD. Results: Baseline BNP 
and Big-ET levels were greater in NYHA Class IV patients compared to Class Ill patients 
(508 +/- 368 vs. 268 +/- 424, p = 0.001; and 22.4 +/- 18.9 vs. 11.9 +/- 9.0, p = 0.003, 
respectively). BNP and Big-ET levels were also greater in patients with LVEF c 20% com- 
pared to LVEF > 20% (370 +/- 489 vs. 206 +/- 327, and 14.5 +/- 10.0 vs. 11 .l +/- 11 .O, 
both p = 0.003). Baseline neurohormones were not different in the placebo and bucin- 
dolol groups. At 3 months, patients treated wrth bucrndolol had lower Big-ET and NE lev- 
els than patients receiving placebo (10.6 +/- 8.0 vs. 13.9 +/- 11.2, p =0.05; and 420 +/- 
266 vs. 487 +/- 230, p = .03, respectively). These differences were not present at 12 
months. None of the other neurohormones were different between groups at any time 
point. Conclusions: Big-ET and BNP correlate with NYHA Class and LVEF in patients 
w&h advanced heart failure. Bucindolol therapy was associated with an early decline in 
Big-ET and NE, but these changes did not persist at 12 month follow-up. 
1046-71 Effect of Nesiritide on Endothelin-1 Levels in Patients With 
Decompensated Congestive Heart Failure 
Doron Aronson, Andrew J. Burger. Beth lsrael Deaconess Medical Center, Boston, MA, 
Harvard Medical School, Boston, MA 
Background: Endothelin-1 (ET-l) is elevated in congestive heart failure (CHF) and has 
been implicated in mediating elevation of cardiac filling pr&ures, pulmonary hyperten- 
sion, and the progression of circulatory failure. Brain natriuretic peptide (BNP) is pro- 
duced in ventricular myocytes and its levels are substantially augmented in response to 
ventricular overload in CHF, promoting a decrease in cardiac filling pressures. In addition, 
in vitro studies have shown that BNP strongly inhibits ET-1 secretion from endothelial 
cells. We thought to determine whether the administration of nesiritide (human BNP) low- 
ers ET-I levels in patient with CHF. 
Methods: The study population includes a subset of 82 patients with decompensated 
CHF enrolled in the PRECEDENT (Prospective Randomized Evaluation of Cardiac 
Ectopy with Dobutamine or Nesiritide Therapy) study. Patients were randomized to 
receive dobutamine (minimal dose 5uglkglmin n = 27), low-dose (0.015 uglkglmin) 
nesiritide (n = 32), or high-dose (0.03 pgikgimin) nesiritide (n = 23). Plasma levels of 
norepinephrine (NE), ET-l, tumor necrosis factor-a (TNF-a), and interleukin-6 (IL-6) were 
obtained in each patient immediately prior to administration of study drugs and following 
24h of treatment. 
Results: There was no significant change in ET-1 levels with dobutamine therapy (8.5 ? 
0.79 to 8.1 + 0.72 pgiml, p = 0.63). By bontrast, both low-dose (8.6 t 0.69 to 6.9 t 0.58 
pg/ml, p < 0.001) and high-dose (11.7 c 1.3 to 9.0 i- 1 .l pgiml, p = 0.04) nesiritide ther- 
apy resulted in a significant drop in plasma ET-1 levels. In patients receiving nesiritide, 
baseline ET-l predicted the magnitude of the decrease in ET-I at 24h (r= -0.62, p < 
0.0001). No significant change was observed in NE, TNF-u, or IL-6 levels during either 
dobutamine or nesiritide therapy. 
Conclusions: In patients with decompensated CHF, acute BNP infusion induces a rapid 
reduction in plasma ET-l. This effect may account, in part, for the beneficial hemody- 
namic and clinical effects of nesiritide in the setting of heart failure. 
1046-72 Resting Cardiac Production of Natriuretic Peptides 
Determines the Effects of Infusion of Brain Natriuretic 
Peptide in Heart Failure 
Hans P. Brunner-La Rocca, David M. Kaye, Robyn L. Woods, Jacqueline Hastings, 
Fforentina Socratous, Murray D. Esler. Baker Medical Research Institute, Melbourne, 
A&a/ia, Howard Florey Institute, Parkviffe, Australia 
Background: Natriuretic peptides (NP) possess beneficial effects in heart failure (HF). 
Intravenous infusion of brain NP (BNP) and inhibition of degradation of NP have been 
proposed as novel therapies. However, it is unknown whether there are determinants of 
their efficacy. Methods: We assessed plasma levels of atrial NP (ANP) and BNP in arte- 
rial and coronary sinus blood as well as coronary sinus blood flow by thermodilution 
before and after infusion of BNP (15nglkgimin) in 11 patients (pts) with stable heart fail- 
ure (HF; EF 24*2%) and 12 age matched healthy controls. ANP and BNP overflow 
across the heart was used for assessment of NP production. In addition, right heart cath- 
eterisation to measure hemodynamics and determination of cardiac norepinephrine (NE) 
spillover using the tracer drlution method to measure activity of the cardiac sympathetic 
nervous system (SNS) were performed. Results: Arterial concentrations of ANP and 
BNP were correlated with cardiac production in healthy controls but not in HF pts. Addi- 
tionally, elevated filling pressures were related to arterial NP concentrations but not to 
cardiac production of NP in HF pts. As response to BNP infusion, preload reduction was 
present in all subjects, irrespectively of baseline characteristics. However, there was no 
significant reduction in systemic vascular resistance (SVR). Resting cardiac ANP and 
BNP production did not correlate with changes in SVR in healthy controls, but was signif- 
icantly related to SVR reduction as response to BNP infusion in HF pts (correlation with 
change in SVR: ANP r=-0.84, BNP w0.61, p<O.O5). Also, ANP and BNP production 
determined the effects of BNP on the activity of the cardiac SNS (correlation with change 
in cardiac NE spillover: ANP r=-0.68, BNP r=-0.84, p<O.Ol). Conclusion: These findings 
suggest that clearance rate is the major determinant for peripheral plasma concentra- 
tions of ANP and BNP in heart failure, while production is most important in healthy con- 
trols. Nevertheless, a relative insufficiency of NP production seems to be present in 
some, but not all heart failure pts. These pts seem to profit most from BNP infusion lead- 
ing to reduction of both SVR and activity of the cardiac SNS. 
NT-proBNP Sensrtivity Specificity Negative predictive ROC- 
cut-off(pmol/L) W W value (%) area 
LVD 65 67 75 99 0.77 
LVD+LVH 76 83 80 99.8 0.87 
LVD+ReD 162 88 94 99.9 0.94 
Conclusion: Plasma NT-proBNP appears to represent a biochemical diagnostic tool for 
the detection and particularly the exclusion of LV dysfunction with or without concomitant 
LVH or renal dysfunction. 
104669 CHF Severity and Neurohormonal Activation in a Large 
International Population With Chronic Heart Failure Enrolled 
in Val-HeFT 
Roberto Latini, lnder Anand, Serge Masson, Dianne Judd, Monica Salio, Gabriella Baldi, 
Robert Glazer, Dirk P. Spormann, Aldo P. Maggioni, Gianni Tognoni, Jay N. Cohn, on 
behalf of the Val-HeFT Investigators. lstifufo di Ricerche Farmacologiche Mario Negr;, 
Milan, /tag University of Minnesota, Minneapolis, MN 
Background: Chronic heart failure (CHF) is associated with progressive activation of 
various neuroendocrine systems that may relate to the progression of the disease. The 
relation between baseline plasma hormones and CHF severity (NYHA functional class 
and echo LV dysfunction) was assessed in a large (n=5,011 patients; 93% on ACE-I, 
35% on beta-blockers) international clinical trial (V&H&T) which is evaluating the effi- 
cacy of the Ang II receptor antagonist valsartan. Methods: Blood samples were to be 
collected at entry and plasma brain natnuretic peptide (BNP, pg/mL), renin activity (PRA, 
ng/mL/h), aldosterone (Aldo, pg/mL), Big endothelin (Big ET-l, PM), and endothelin-I 
(ET-l, PM) were assayed by specific immunoassays, and norepinephrine (NE, pg/mL) 
with HPLC in core labs. The population was stratified according to NYHA class (II (62%) 
“s III-IV (38%)) median value of LVEF (27%) and LVlDdiBSA (3.57 cm/m2). Results: 
Patients were aged 62.7+11 y (mean *SE), 20.1 % were females. Preliminary results 
indicate that overall median plasma levels of BNR PRA, aldo, NE, ET-l, and Big ET-1 
were 97 pg/mL, 5.3 ngimlih, 101 pg/mL, 393 pg/mL, 2.9 pg/ml and 0.80 pM, respec- 
tively. Relative differences in NH between risk groups were independent of age. Major 
determinant of PRA was baseline therapy with ACEi and diuretics, which did not affect 
BNP. The ratio of hormone levels in the higher “s lower risk (NYHA II, LVEF > 27% and 
LVlDd < 3.57 cm/m*) groups are shown below. 
Risk group BNP PRA Aldo NE ET-1 Big ET-1 
NYHA Ill-IV”s II 1.61 1.62 1.23 1.21 1.05 1.15 
LVEF < “s >27% 1.59 1.51 1.14 1.11 1 .oo 1.08 
LVlDd > “s I- 3.57% 1.94 1.08 1.00 1.12 1 .oo 1.08 
Conclusion: BNP identifies CHF severity as assessed by NYHA class, echo LVEF and 
LV dimensions better than the other NH. Neither ET-1 nor Big ET-1 appear to be strongly 
related to CHF severity. 
1046-70 Baseline and Serial Neurohormones in Patients With 
Congestive Heart Failure Treated With and Without 
Bucindolol: Results of the Neurohumoral Substudy of the 
Beta-Blocker Evaluation of Survival Trial (BEST) 
Robert I? Frantz, Brian Lows, Paul Grayburn, Michel White, Edward M. Gilbert, Heidi 
Krause-Steinrauf, John C. Burnett, for the BEST Investigators. Mayo Clinic and Mayo 
Foundation, Rochester, MN, University of Colorado Medical Center, Denver, CO 
Background: The Beta-Blocker Evaluation of Survival Trial (BEST) examined the effects 
of bucindolol in patients with NYHA Class III-IV heart failure. In order to examine the rela- 
tionship between neurohormones and clinical parameters, and to examine the effect of 
bucindolol on neurohormones, we measured serial norepinephrine (NE), Big-endothelin 
(Big-ET), endothelin-1 (ET-l), N-terminal atrial natriuretic peptide (N-ANP), and brain 
natriuretic peptide (BNP) in 206 patlents randomized to receive bucindofol or placebo. 
Methods: 10 centers participated in the substudy. Neurohormones were measured at 
baseline, 3 and 12 months following initiation of bucindolol or placebo. Baseline levels 
were compared between patients with NYHA Class Ill vs. IV CHF, and between patients 
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1055-43 Assesment of Low Risk Patients Presenting to the 
Emergency Department With Chest Pain: Immediate 
Treadmill Test or Cardiac Stress Imaging? 
Ezra A. Amsterdam, J Douglas Kirk, Deborah B. Diercks, William R. Lewis, Larry Baker, 
Harpreet Johl, Samuel D. Turnipseed. University of California, Davis, Sacramento, CA 
Background: The optimal test for confirming low cardiac risk in patients (pts) presenting 
to the emergency department (ED) with chest pain (CP)has not been clarified. Early 
treadmill exercise testing, myocardial stress scintigraphy (SCINT) and stress echocardio- 
graphy (ECHO) have each been advocated for this purpose. We have utilized immediate 
exercise testing (IET) in this pt. population to identify those requiring admission and 
those who can be directly discharged from the ED. The purpose of this study was to 
determine the appiicability of IET and stress imaging by SCINT or ECHO in the assess- 
ment of these pts. Methods: In 512 consecutwe pts presenting with nontraumatic CP of 
possible cardiac orrgin, we identified those who could be evaluated directly by IET 
(hemodynamic and electrical stability, ECG normal or near normal) and those requiring 
cardiac stress imagrng (SCINT or ECHO) as the initial test (unable to exercise and/or 
secondary repolariration changes on ECG). Results: IET (without prior serial serum 
markers) was applicable in 72% (n=370) of pts (age 53yr,; 51% male) and was negative 
(Neg) in 82% (n=303): positive (Pos) in 9% (n=34), and nondiagnostic in 9% (1x33). 
There were no adverse effects of IET SCINT or ECHO as initial test were required in 
28% (n=l42) of pt.? (age 60 yr,[p&Ob vs. IET], 51% male) and were Neg in 73% (n=104) 
and Pos !n 27% (n=38). Pts with Neg tests were discharged directly from the ED. At 30 
day follow-up there were no infarctions or deaths in either the IET or stress imaging 
groups. Clinical events were limited to the pts with Pos tests in each group and consisted 
of myocardial revascularization in 8 (38%) of the 21 Pos IET pts and 5 (13%) of the 38 
Pos stress imaging pts. Conclusions: IET is safe and accurate for initial assessment and 
short-term prognostic evaluation of a majority of low risk pts presenting with chest pain. 
For the remainder of these pts, who comprise a substantial minority, cardiac stress imag- 
ing is required as the initial test. 
ery and functlonal capacity with mortality Conclusion: Even among very old adults, the 
exercise test is a powerful prognostic tool. Both heart rate recovery and functronal capac- 
ity are mdependent predictors of ail-cause mortality 
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1055-73 Oral Magnesium Supplementation Improves Exercise 
Duration and Quality of Life in Patients With Coronary 
Artery Disease 
Michael Shechter, C. Noel Bairey Mew, Hans S. Stuhlinger, Michael Shark, Shlomi 
Matezki, Othmar Pachinger, Jorg Slany, Babeth Fiabinowitz. The Heart institute, She& 
Medical Center, and Tel Aviv University, Tel Hashomer, Israel, Cedars-Sinai Medical 
Center, Los Angeles, CA 
Background: Coronary artery disease (CAD) patients are often relatively magnesium 
depleted. The impact of magnesium supplementation on exercise duration and quality of 
life in stable CAD patients has not previously been assessed. Methods: In a multi-center, 
randomized, and double-blind trial, 187 stable CAD patients (151 men, 36 women, mean 
age of 63+/-IO years, range: 42.83) were randomized to receive either magnesium oxide 
orally (Magnosolv, 30 mmoliday, Asta Medica, Vienna, Austria) (n=94) or placebo (n=93) 
for 6 months. Entry and after 6 months exit symptom-limited exercise testing (Bruce pro- 
tocol) were performed and quality of life questionnaires were filled out. Results (Table): 
Impact of Magnesium on Exercise Duration at Study Entry and Exit 
Magnesium (r&4) Placebo (n=93) p-value 
Entrv exercise duration (min+//-SD) 6.1+/-2.7 7.8+/-2.9 0.1670 
1055-44 Heart Rate Recovery and Functional Capacity as Predictors 
of Mortality in Very Old People 
Barbara Messinger-Rapport. Eugene Blackstone, Claire Snader, Michael S. Lauer. 
Cleveland Clinic, Cleveiand 
’ Exit exercise duration (min+/-SD) 8.7+1-2.1 7.8+1-2.9 0.0075 p-VdUe 0.0104 0.1624 
Quality of life was significantly improved in the magnesium group by one month and con- 
tinued to be improved compared to no significant improvement obtained in the placebo 
Background: The prognostic value of exercise testing in very old adults has not been 
group (p<O.Ol). Conclusion: Magnesium supplementation significantly improVes func- 
well~defined. Methods: Consecutive adults aaed > 75 wars without a historv of heart fail- 
tional capacity measured by exercise duration and quality of life in stable CAD patients. 
” 
ure, valve disease, or pacemaker implantation underwent symptom-limited exercise test- 
ing and were followed for 4 years. lmparred functional capacity was defined as a peak 1055-74 Improved Exercise Performance on Ranolazine in Patients 
exercise workload < 5 METS in men and < 4 METS in women. An abnormal heart rate With Chronic Angina and a History of Heart Failure: The 
recovery was defined as a failure of the heart rate to fall bv > 12 beats dunnq the first MARISA Trial 
minute after exercise. Results: There were 1108 patients eligible for analyses (mean age 
78, range 75-92, 33% female). Abnormal heart rate recovery was found in 443 (40%) and 
Bernard R. Chaitman, Sandra Skettino, Vincent DeQuattro, Peter C. Ha&y, Petr Jansky, 
impaired functional capacrty in 291 (26%). During follow-up 228 patients (21%) died. In 
J. K. Kuch, John 0. Parker, J. J. Nelson, David Hebert, Andrew A. Wolff. St. Louis 
univariate analyses, death was predrcted by an abnormal heart rate recovery (28% vs. 
University St. Louis, MO, CV Therapeutics, Palo A/to, CA 
16%. hazard ratio [HR] 1.9, 95% Cl 1.5-2.5, P<O.OOOl) and by impaired functional capac- 
ity (36% vs. 15%, HR 2.7, 95% Cl 2.1 to 3.5, P<O.OOOl): see Figure. After adjusting for 
age, gender, standard risk factors, coronary disease history, and use of cardiovascular 
medicatrons, independent predictors of death Included both an abnormal heart rate 
recovery (adjusted HR 1.6. 95% Cl 1.3-2.1, P=O.O003) and impaired functional capacity 
(adjusted HR 2.1, 95% Cl 1.6-2.7, P<O.OOOl). The only other strong (chi-square > 5) pre- 
dictors of risk were age (P<O.OOOi), smoking (P=O.O08), history of myocardial infarction 
(P=O.OZ). and non-use of aspirin (P=O,OOO2). Also of note, the use of beta-blockers 
(n=305, 28% of the cohort) had significant impact on the associations of heart rate recov- 
Background: Ranolazine is a partial fatty acid (pFOX) inhibitor that shifts metabolism 
away from fatty acid oxidation to more oxygen-efficient glucose oxidation. Methods: The 
MARISA (Monotherapy Assessment of Ranolazine In Stable Angina) study randomized 
patients to ranolazine (500 mg, 1000 mg and 1500 mg bid) and placebo in a double- 
blind, 4.period, crossover design study; 29 patients had a history of heart failure (HF) and 
146 did not. All patients performed a modified Bruce exercise test at the time of trough 
(morning) and peak (afternoon) drug levels on each treatment. Results: Exercise dura- 
tion (see graph), time to angina and time to 1 mm ST segment depression were pro- 
longed by ranolazine at peak and trough in both subsets of patients (treatment p- 
values<O.OOl) and increased with dose. On placebo, exercise duration was similar during 
morning (trough) and afternoon (peak) testing in patients without HF, while exercise dura- 
tion in HF patients declined between trough and peak testing. At trough, increases in 
exercise duration on ranolazine were similar in patients with and without HF (treatment by 
HF interaction p-values >O.iO). However, at peak, increases on ranolazine in exercise 
duration and time to 1 mm ST segment depression were greater in HF patients than in 
those wthout HF (treatment by HF interaction p-values 0.01 and 0.007, respectively), 
reversing the fall between trough and peak in exercise performance in HF patients. HF 
patients did not have more adverse events than those without HF. Fianolazine did not 
change rest or exercise heart rate or systolic blood pressure. Conclusion: Patients with 
chronic angina and a history of HF appear to tolerate and to respond to ranolazine, a 
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pFOX inhibitor, at least as well as those without HF. 
*Values are given as least square means. Treatment p-values: trough <O.OOl, 
peakc0.001; treatment by HF interaction p-values: trough=0.939, peak=O.Ol 
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1056-45 Cardiovascular Actions of Chronic Oral Omapatrilat Are 
Superior to ACE Inhibition in Experimental Heart Failure 
Shang-Chiun Lee, John C. Burnett. Mayo Clinic, Rochester, MN 
Background: Omapatrilat (OMA) is a vasopeptidase inhibitor which simultaneously 
inhibits angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) which 
degrades the cardiac peptides ANP and BNP which function via cGMP. Studies report 
that OMA is superior to ACE inhibition (ACE-l) in reducing symptoms of congestive heart 
failure (CHF), yet the cardiovascular actions of chronic OMA versus ACE-I remain poorly 
defined. We investigated the cardiovascular and humoral actions of oral OMA versus 
ACE-I in a canine pacing-induced modal of CHF with a third untreated group as Control. 
Methods: Groups (n = 5, each) received OMA (100 Km&a/kg/d), the ACE-I Fosinopril 
(100 ~moleikgld), or no treatment were studied consciously before and at 10 days of 
CHF. Results: At baseline there were no differences in CO, RAP, PCWP, MAP, SVR, 
plasma ANP, BNP and cGMP, or urinary sodium excretion among groups. In CHF, RAP 
was lower in the OMA group compared to ACE-I and Control groups (0.7 + 0.4 vs 5.2 + 
0.6 vs 4.9 f 1.2 mmHG, P < .Ol). PCWP was lower in the OMA group compared to ACE- 
I, which was lower than Control (7.2 * 0.7 vs 10.6 + 0.9 vs 14.3 * 1.2 mmHG, P < .Oi). 
CO and MAP decreased and SIR increased similarly with CHF (P = NS, among groups). 
Plasma ANP and BNP increased similarly with CHF (ANP: 1654 i- 421 vs 1216 f 475 vs 
1379 f 469, P = NS; BNP: 164 t 30 vs 156 * 46 vs 177 + 56, pgiml, P = NS) despite 
lower stimuli for secretion with OMA as demonstrated by lower atrial pressures. 24 hour 
urinary s&urn excretion decreased similarly with CHF (P = NS, among groups). Impor- 
tantly, plasma cGMP in CHF was higher in the OMA group compared to ACE-I and Con- 
trol groups (26.6 t 3.8 vs 17.1 f 2.9 vs 16.3 + 1.5, pmoliml, P < .05). Conclusion:The 
vasopeptidase inhibitor Omapatrilat uniquely enabled the failing heart to utilize less pre- 
load to ache& a similar cardiac output as compared to ACE-I. Despite lower cardiac fill- 
ing pressures, plasma ANP and BNP with OMA were similar to ACE-I consistent with 
inhibition of peptide degradation. The higher concentration of plasma cGMP with OMA is 
also consistent with potentiation of this cardioprotective second messenger system which 
may explain the favorable cardiovascular actions of OMA which go beyond ACE inhibition 
alone. 
1056-46 Candesartan Restores Impaired Endothelial Dependent 
Vasorelaxation in Heart Failure Animals via Nitric Oxide 
Mediated Effects. 
Hoang Thai, Steven Goldman, Mohamed Gaballa. Southern Arizona VA Health Care 
System, Tucson, AZ, Sawer Heart Center, University of Arizona, Tucson, AZ 
Therapy that improves endothelial function attenuates LV remodeling and enhances sur- 
viva1 in heart failure (HF) patients. This study was designed to determine if angiotensin 
receptor blockade (ARB), using candesartan, will be able to reverse impaired endothelial 
dependent vasorelaxation seen in HF. Myocardial infarcted (Ml) adult Sprague-Dawley 
rats (n=4) in HF were treated with candesartan (10 mgikglday in drinking water) for 8 
weeks. At the end of the treatment period, hemodynamic studies were performed. MI rats 
treated with candesartan had lower (PiO.05) systolic blood pressure (SBP, 128 +- 22 vs 
78 +-8 mmHg), mean arterial pressure (MAP, 111 +- 23 vs 52 +- 8 mmHg), left ventricular 
end diastolic pressure (LVEDP, 16 +- 7 vs 7 +- 4 mmHg), and left ventricular dP/dt (5600 
+- 1889 vs 3525 +- 525 mmHg/sec) than Ml untreated rats. Following the hemodynamic 
studies,.thoracic aortic segments were mounted on a ring apparatus to study vasorelax- 
ation rdsponse to increasing concentrations of acetylcholine (ACh). Sham operated ani- 
mals served as controls. Compared to sham rats, Ml untreated animals had a decreased 
(PcO.05) vasorelaxation response to ACh. Compared to Ml untreated animals cande- 
sartan enhanced (PcO.05) vasorelaxation in Ml rats by 84% and 86% at IO-4 and 10-5 M 
ACh concentrations, respectively. This enhanced vasorelaxation was abolished in the 
presence of the nitric oxide (NO) synthase inhibitor, NG monomethyl L-arginine, (L- 
NAME). To further examine the possible mechanism of action by candesartan, endothe- 
lial cell line was treated with IO and 20 uM of candesartan for 24 hrs. Compared to 
untreated cells, treatment with 20 uM of candesartan increased the endothelial nitric 
oxide synthase (eNOS) protein levels (28.9 +-2.6 vs 16.1 +- 3.7, intensity unitsiug pro- 
tein, 1x4, P<O.O5). These data suggest that candesartan enhances impaired endothelial 
dependent vasorelaxation in HF animals through increased NO bioavailability, possibly 
via up-regulation of eNOS protein in the endothelium. 
1056-47 Elevated Cardiac Tissue Aldehyde Levels in Heart Failure: 
Marker of Increased Oxidative Stress and Amelioration by 
Neurohormonal Blockade 
Gordon W. Moe, Mehrdad Yazdanpanah, Andrea Konig, Marina Romanova, Peter Liu. St 
Michael’s Hospital, Univ of Toronto, Toronto, ON, Canada 
BACKGROUND: Increased oxidative stress has been implicated in the pathogenesis of 
heart failure (CHF). However, studies of oxidative stress in CHF have mainly measured 
selected products of lipid peroxidation. Furthermore, the impact of therapy on oxidative 
stress in CHF has not been assessed. Angiotensin II has been shown to exert its vascu- 
lar effect via an increase in oxidative stress, however whether the same mechanism is 
operational in the failing heart is unclear. 
METHODS: We performed a comprehensive analysis of aldehydes using gas chroma- 
tography mass spectrometry from the LV tissues of 10 normal dogs (N), 8 dogs with 
severe CHF induced by 4 weeks of RV pacing, 8 CHF dogs treated with a type 1 angio- 
tensin receptor (AT,) blocker candesartan (CHF-AT,B) and 6 CHF dogs treated with a 
type A endothelin receptor (ETA) blocker LL. 135252 (CHF- ETAB). 
RESULTS: Data (means*SE) for tissue total aldehyde levels (pmol/lOOmg) and LVEDP 
(mm Hg) are shown in the table (a, pcO.01 vs. N, b, ~~0.05 vs. CHF. c, p<O.O5 vs. CHF- 
AT,B 
N CHF CHF-AT,B CHF- ETAB 
Aldehyde 8398+477 22284-+1 690a 1 1640t1254a,b 15822*964a,b,c 
LVEDP 1 lil 45i2a 35tla,b 331& 
Compared to N, untreated CHF dogs had a 170% increase in total aldehyde levels. 
Marked increases ware also observed in several species of unsaturated aldehydes, 
including 4.OH-alkenals and maiondialdehyde. AT, receptor blockade reduced aldehyde 
levels by a greater amount than ETA receptor blockade, despite similar reductions in 
LVEDP. 
Conclusion: Our study demonstrates for the first time that in canine pacing-induced 
CHF, there is a marked increase in LV tissue aldehyde level, indicative of severe oxidative 
stress in the failing heart. Both AT, and ETA receptor blockade ameliorates oxidative 
stress. The disproportionate reduction in LV aldehyde levels by AT, receptor blockade 
suggest that elevated endogenous angiotensin II induces oxidative stress in the failing 
heart. 
1056-48 Oxidative Damage to Mitochondrial DNA is Attenuated by 
Antioxidant Vitamins in Pacing Induced Heart Failure 
Weike Mao, Chang-seng Liang. University of Rochester Medical Center, Rochester, NY 
Background: Myacyte apoptosis occurs in congestive heart failure (CHF). Recently, we 
showed that cardiac dysfunction and apoptosis could be attenuated by antioxidant vita- 
mins in pacing-induced CHF, suggesting that the deterioration in cardiac function and cell 
death are linked to increased oxidative stress in CHF. However, direct demonstration of 
mitochondrial (mt) DNA damage in CHF is lacking. We carried out the present study to 
determine the mtDNA damage and alleviation by antioxidant vitamins in pacing-induced 
CHF, by measuring mtDNA 8-oxo-7,8-dihydro-2’deoxyguanosine ( 8-oxo-dG ), which is a 
stable oxidized product of deoxyguanosine (dG) by free hydroxyl radicals. 
Methods: Rabbits, receiving rapid ventricular pacing at 360 beatslmin for 8 weeks were 
randomized to receive tocopherol 200 mgi8 weeks,carotene 20 mgi8 weeks,ascorbate 
200 mgi8 weeks or vehicle control, and compared to sham-operated animals without 
rapid pacing. Mitochondria DNA isolated from heart tissue was enzymatically hydrolyzed 
and 8oxodG,dG were measured by a HPLC method using a electrochemical detector 
and YMC 3 micron 4.6mm’15cm Guanine adducts column. 
Results: 
8.oxo-dG (pgiml) 8-oxo-dG/dG ~100,000 
Sham 32.9 i 4.7 3.69 + 0.53 
CHF 69.8 i 12.9* 8.94 k 0.64* 
CHF+VitE 37.9 * f3.7t 4.76 k 0.83t 
CHF+Vits 42.9 + 6.0t 5.69 3~ 1.07t 
n = 7-8 Value are means f SE. ‘PC 0.01 vs Sham.tP< 0.05 vs CHF 
The ratio of 8.oxodG refered to dG in mitochondtial DNA increased 2.42 times after 8 
weeks pacing when compared wth sham group. Both Vitamin E and Vitamin A, C, and E 
attenuate the increase of the ratio during heart failure. 
Conclusion: Oxidative damage to mitochondrial DNA increased in pacing induced heart 
failure.Antioxidant vitamins can protect mitochondria DNA from oxidative damage. 
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1056-49 Effects of Combined Endothelin A Receptor Blockade Plus 
ACE-Inhibition in Rats With Chronic Heart Failure 
Daniela Fraccarolio. Johann Bauersachs, Paoio Galuppo, Markus Kellner, Georg Ertl. 
Llniversitaetskiiniknik Wuetzburg, Wuerzburg, Gerrnan~ Universitaetskl~nik Mannheim, 
Maannheim, Germany 
Background: Right ventricular hypertrophy (RVH) is related to left ventricular (LV) 
remodeling and heart failure. We investigated the effects of the ETA receptor antagonist 
LU 135252 (LU), the ACE-inhibitor Trandoiapril (T), and the combination of LUcT in rats 
wth chronic heart failure (CHF, LV end-diastolic pressure > 15mmHg) on RVH, LVH, car- 
diac ratios of beta-Myosin Heavy Chain (MHC) to alfa-MHC mRNAs and LV dilatation. 
Methods: Seven days after coronary artery ligation, rats were allocated to treatment 
wth LU (47.6mgl100ml), T(0.48mg1100ml) or LU+T in drinking water for 11 weeks. 
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1057-52 Physiological Limits of Left Ventricular Hypertrophy in Elite 
Junior Athletes: Relevance to Differential Diagnosis of 
Athlete’s Heart From Hypertrophic Cardiomyopathy 
Sanjay Sharma, Sami Firoozi, Greg Whyte, Perry M Elliott, William J. McKenna. Si 
George’s Hospital Medical School, London, UnIted Kingdom 
Background: Regular intensive physical traimng in Some sports may cause an increase 
in left ventricular wall thickness (LVWT) creating uncertainty regarding the differential 
diagnosis with hypertrophic cardiomyopathy (HCM). The distinction between physiologic 
hypertrophy in athletes and HCM is crucial since HCM is responsible for about one third 
of all sudden cardiac deaths in young athletes. Available data definrng the athlete’s heart 
are limited to senior athletes. There is a paucity of data in junior athletes (aged 18 or 
less) I” whom sudden death due to HCM is most prevalent. 
Methods: 650 junior elite athletes (74% male), aged 15.6(1.4) yrs (range 14-18 yrs) and 
250 healthy non-athletic controls of similar age, gender and body surface area (BSA) 
underwent 2-D echocardiography. Duration of high-level training amongst athletes 
(regional or national) was 4.3(1.5) yrs. 
Results: Compared with controls, trained athletes had an increased LVWT (9.5(1.6)mm; 
(range 7.14mm) vs. 8.4(1.4)mm; p z 0.0001). The LVWT exceeded predlcted upper limits 
in 33 (5%) athletes. However, in only 1 athlete (0.15%) was the absolute LVWT > 12 mm. 
Each athlete tiith a LVWT exceeding predicted normal limits also had a greater than pre- 
dicted left ventricular cavity size (range 52-60 mm). 
Conclusion: Junior athletes have a greater LVWT compared with non-athletic controls. 
In an important minority (5%) the LVWT exceeds predicted upper limits and is always 
associated with an enlarged left ventricle. A LVWT > 12 mm is exceptionally rare. There- 
fore, a diagnosis of HCM should be considered in any junior elite athlete with a LVWT > 
12 mm and a non-dilated left ventricle. 
1057-53 Efficacy of the Preparticipation Screening for the Detection 
of Cardiovascular Abnormalities at Risk of Sudden Death in 
Competitive Athletes: The Italian Experience 
Pelliccia Antonio, Di Paolo F.M., De Luca R., Buccolieri C., Maron B.J.. Institute of Sport 
Science, Rome, l&/x Minneapolis Heart Institute Foundation, Minneapolis, MN 
Background: There is substantial interest in preparticipation cardiovascular screening in 
athletic populations, and cosVeffective strategies for identification of the potentially lethal 
cardiac diseases are still debated. The 1 Z-lead ECG, in addition to medical history and 
physical examination, is relied upon extensively in the systematic preparticipation 
screening of Italian competitive athletes. The aim of our study was to assess the efficacy 
of this protocol in identifying cardiovascular diseases at risk for sudden death. 
Methods: We examined 5,680 athletes, 72% male, aged 9 to 55 years (median 23), par- 
ticipating in 38 different sports. Of those, 1,211 athletes was referred for evaluation of 
suspected cardiac abnormalities detected at preparticlpation screening protocol (grou. 
A, positive), and 4,469 elite athletes, who had previously been cleared with at screening 
protocol (group 6, negative). All athletes underwent a cardiovascular evaluation at Insti- 
tute of Sports Science with our medical program, that routinely includes echocardio- 
grwhy. 
Results: Cardiac abnormalities were detected in 97 (8%) of the I,21 1 athletes iil group 
A, and in 41 (1%) of the 4,469 elite athletes in group B (p< 0.001). In particular, hyper- 
trophic cardiomyopathy was identified in 10 athletes (0.8%) in group A and none in group 
B (p< 0.001); Marfan syndrome in 5 athletes (0.4%) in group A and in 2 (0.04%) I” group 
B (p< 0.001); dilated cardiomyopathy in 5 (0.4%) in group A and in none from group B (p< 
0.001). Instead, arrhythmogenlc right ventricular cardiomyopathy was detected less fre- 
quently (2 athletes in each group). 
Conclusion: 1) the Italian preparticipation screening protocol, with the 12-lead ECG, 
proved to be efficient in identifying most of the athletes with cardiovascular disease at 
risk of sudden death; only a relatively small proportion (1%) were subsequently identified 
by adding echocardiography to the screening protocol; 2) certain cardiovascular disease 
are more consistently detected, i.e. hypertrophic cardiomyopathy, dilated cardiomyopathy 
and Marfan syndrome. Instead, arrhythmogenic right ventricular cardiomyopathy may not 
uncommonly be missed. 
1057-54 Tissue Factor Expression in Atrial Myocarditis Associated 
With Nonrheumatic Atrial Fibrillation: A Possible Cause of 
Cardiogenic Thromboembolism 
Yoichi Nakamura, Kengo Kusano, Kazufum Nakamura, Tetsuro Emori, Hiroshi Morita, 
Chikao Yutani, Tsutomu Hamuro, Hiromi Matsubara, Tohru Ohe. Okayama University 
Medical School, Okayama, Japan, National Cardiovascular Center. Osaka, Japan 
Background: Recently, atria1 myocarditis has been detected in some patients with so- 
called ‘lone atrial fibrillation.” It was demonstrated that expression of tissue factor, which 
plays a key role in the extrinsic coagulation pathway, is induced by inflammatory cytok- 
ines. To elucidate the mechanism of thrombogenesis in non-rheumatic atrial fibrillation, 
we investigated tissue factor expression on the endothelia of atrium obtained from 
patients with cardiogenic thromboembolism. Methods: Left atrial appendages were 
obtained from 4 patients who had non-rheumatic atrial fibrillation with cardiogenic throm- 
boembolism. Atrial tissue appendages were divided into 7-13 sections and compared 
with control specimens (“~4). The expression of tissue factor was evaluated by immuno- 
histology and scored as follows: O-no staining, l-weak focal staining, 2.multifocal stain- 
ing, 3-diffuse staining. Inflammatory cells infiltrated into the endocardium were also 
identified. Results: All four patients were shown to have borderline or definitive myocardi- 
tis. A number of activated T cells [21.2+-6.2 cells/high power field vs. control 2.2+-4.41 
high power field)(P=0.0025)] and a few macrophages [8.3+-l 0.5 ceils/high power field vs. 
control 2.4+-3.5 cells/high power field (P=N.S.)] were infiltrated into the endocardium. 
Tissue factor was over-expressed on the endothelia, inflammatory cells and denuded 
matrix of endocardlum (mean score;2.39+-0.40) compared to the control group (0.25+- 
Results: 
Sham P CHF LU CHF T CHF LU+T CHF 
Ml Size% 50.5t2 50.213 52.521 53.3+1 
LVEDP(mmHg) 5t0.3 32*5 : 2%*4>- 25~3’ 27+2* 
FlV/BW(mg/g) 0.49eO.03 1.05*0.05* 1.1 l&08-i 0.94rO.l+ 0.82+0.06+8 
RV PMHC:uMHC 0.74+0.06 1.21iO.l~. 0.994 1* 0 81iO.l.:-0 0.47c0.1tn 
LViBW(mglg) 2.0350 05 2.23t0.07= 2.2OfO.07 2.10+0.03$ 2.09r0.04$ 
LV PMHC:aMHC 0.23r0.03 1.09*0.1* 0.96&0.1* 0.65+0.07$ 0.54+0.1t 
Dilatation Index 2022 113+6- 9714*0 89193 E 84i4*# 
x 1000(mm’/g) 
*pcO.O5 vs. Sham; $pcO.O5, tpGO.01, #p<O.OOl vs. P CHF; fi ~~0.05 vs. T CHF. 
Conclusion: LU alone had no effect on cardiac hypertrophy. T and LU+T to a similar 
extent attenuated LV hypertrophy and expression of LV beta-MHC:alfa-MHC mRNAs. 
Combined treatment of LU+T shows a better effect on RVH compared to T alone and 
prevents the increase in RV beta-MHC:alfa-MHC mRNAs. LU and T appear to be com- 
plementary in reduction of LV dilatation. ETA receptor antagonists could be a therapeuti- 
cal option in chronic heart failure in addition to an ACE-inhibitor. 
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1057-51 Peak Oxygen Consumption Measurement Differentiates 
Physiological Left Ventricular Hypertrophy in Junior 
Athletes from Pathological Hypertrophy in Adolescents with 
Hypertrophic Cardiomyopathy 
Sanjay Sharma, Sam Firoozi, Brian Mist, Perry M. Elliott, Greg Whyte, William J. 
McKenna. St George’s Hospita! Medical School, London, United Kingdom 
Background: Hypertrophic cardiomyopathy (HCM) is the commonest cause of sudden 
cardiac death in adolescent (14-18 year old) athletes. A large study of junior elite athletes 
showed 5% to have substantially increased left ventricular wall thickness (LVWT) ranging 
between 12.14mm. Our experience of 95 adolescent patients with HCM suggests that 
8% of patients have a LVWT in the same range. Many patients are highly active but 
remain at high risk of sudden death. Some junior athletes therefore, fall into the “gray 
zone” where distinction between physiological and pathological left ventricular hypertro- 
phy (LVH) is crucial but may be difficult with echocardlography alone. This study evalu- 
ated the role of peak oxygen consumption (pV0,) measurements in differentiating 
physiologic LVH from HCM. 
Methods: Asymptomatic adolescents (off medication) with genetically proven non- 
obstructive HCM and mild LVH (LVWT 12.14mm), male athletes matched for age, LVWT, 
body suriace area (BSA) and healthy non-athletic males without LVH of similar age and 
BSA underwent cardiopulmonary exercise testing on a cycle ergometer. All subjects 
exercised to exhaustion and achieved a maximal heart rate > 90% predicted maximum 
and a respiratory quotient > 1 indicating adequate stress. 
Results: 
Athletes (n=lZ) HCM (n=7) Controls (n=12) p-value 
pVOz (mls/kg/min) 58210 36210 47zt6 <0.0001 
% predicted pVOp 128rll 69rtl4 98tlO <0.0001’ 
* Comparison of athletes with both HCM and controls. 
All athletes achieved a pV02>50 mllkglmin or >llO% of the predicted. No individual with 
HCM had a pV02>45ml/kglmin or >102% of the predicted. 
Conclusion: Peak oxygen consumption clearly drfferentiates physiological LVH from 
HCM in adolescent athletes with a LVWT between 12.14mm (the gray zone). A 
pVOp~50mllkglm~n or >I 10% of the predicted is against the diagnosis of HCM. 
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0.5O)(P=O.O005). There were 1.30+-i .23 thrombi in the presence of inflammation and tis- 
sue factor expression in each section. Conclusion: Atrial myocarditis is a strong risk fac- 
tor for left atrial thrombosis among patients with non-rheumatic atrial fibrillation because 
of the tissue factor expression induced by inflammation. 
1058-57 Coronary Vasomotor Response in Cardiac Transplant 
Recipients. A Detailed Analysis in 286 Investigations 
Michael Weis, Sinan Pehlivanli, Bruno Meiser, Wolfgang von Scheidt. University Hospital 
Grosshadern, Munich, Germany, Stanford University Medical School, Stanford, CA 
1057-55 Cytomegalovirus Hyperimmunoglobulin Treatment in 
Cytomegalovirus Myocarditis and Its Influence on Serum 
Titers of Cardiotropic Viruses 
Bernhard Maisch, Gunther Hufnagel, Sabine Pankuweit. Department of Internal 
Medicine-Cardiology, Philippe University Matburg, Germany 
Background: Treatment of virus-postive myocarditis is a severe problem. We therefore 
carried out a controled trial with 35 cytomegalovirus (CMV) associated myocarditis 
patients having an lymphocytic infiltrate(>l4 leukocytes/mm2) and a positive in situ 
hybridization or PCR for CMV-DNA in the endomyocardral biopsy with CMV hyperimmu- 
noglobulin (CMVhlg) Methods: 10 pts received Pml/kg i.v. for 3 and 1 ml/kg for 2 additional 
2 days alternately. Results: An elimination of cellular infiltrates was seen in 14 out 18 pts 
(P<O,Oi) and of CMV-DNA 13 out of 18 pts (p<O.Oi), which went along with a significant 
improvement of the at least one NYHA class(l5118) and normalized EF(15118) of the 
patients in the treatment group. The control group (n=l7, CMV-DNA positive myocarditis, 
no CMVhlg) demonstrated spontaneous improvement by 1 NYHA class or more (3/17) 
and by EF (7118) a resolution of the infiltrate in 4117 and no more CMV-DNA in 3117. 
Comparing the 2 groups the effect of treatment was still obvious (~~0.05 for elimination of 
CMV and infiltrate and NYHA-class). Because of the potential risk of HIV or hepatitis 
infection with plasma products serum titers of cardiotropic viruses were analysed before 
and after treatment. All treated patients had high CMV-IgG titers before treatment, which 
increased during therapy, IgM antibodies were detectable only in 3 pts inrtially. Only tran- 
siently rising titers for CVB in 2 and for influenza in one case as passive transfer were 
seen. No infection of HIV or hepatitis A,B,C and D were found. Conclusion: CMV-hlg 
treatment eliminates CMV-DNA and inflammatory cells from the myocardium. A transient 
rise of enteroviral antibodbs is possible. CVB, HIV and hepatitis infection could be 
excluded after therapy, however. 
Endothelial activation is an early event in the process leading to cardiac allograft vascul- 
opathy (CAV). Allograft vasomotor dysfunction occurs early after heart transplantation 
(HTx). However, the exact prevalence of this specific entity of CAV over time is not well 
known and, therefore, was investigated in a large patient cohort. 286 investigations were 
performed in 190 HTx patients without angiographic disease. Patients were divided in 3 
groups according to time after HTx; group1 l-6 months after HTx @El); group2 12-26 
months after HTx (n=91); group3 x36 months after HTx (w114). Endothelium-dependent 
(5 and 150ugI5min ic ACh) and -independent (Adenosin;800 ugi5min ic Ado) vasomotor 
function was determined in epicardial (proximal and distal QCA) and microvascular (ic 
Doppler) compartments. Normal epicardial endothelial function (nEEF) was defined as 
diameter dilation to ACh, moderate epicardial endothelial dysfunction (mEED) as O-IO % 
diameter constriction, and severe EED (SEED) as 210% diameter donstriction to ACh, 
respectively. Normal microvascular endothelial function (nMEF) was defined as coronary 
flow velocity increase (CFVI) to ACh > 150% moderate microvascular endothelial dys- 
function (mMED)as CFVI to ACh 100.150%, and severe microvascular endothelial dys- 
function (sMED) as CFVI to ACh <lOO%, respectively. Results: In the total population 
epicardial diameter change to ACh (Ado) amounted to -7215% (12+11’%). Coronary flow 
velocity increase to ACh (Ado) was 159r45% (176r50%) and was independent of basal 
coronary flow. A strong correlation between ACh and Ado response occurred in conduit 
and resistance vessels(r=0.24 and r=0.46; p<O.OOOl), whereas epicardial and rnwovas- 
cular vasomotor responses were unrelated. Table describes prevalence (%) of epicardial 
and microvascular normal and pathological vasomotion. 
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nEEF mEED SEED nMEF mMED sMED 
Group1 50 35 15 26 49 25 
Group2 64 31 5 30 40 30 
Group3 70 23 7 35 40 25 
Conclusion: Allograft MED predominates, owurs early after transplantation, and did not 
chanqe srqnificantly over time EED skghtly decreases over time. The absent association 
between the vasomotor response in both compartments suggests different disease enti- 
ties. 
1058 Allographic Vasculopathy 1058-58 Modulation of Cyclosporin-Induced Coronary Artery Dysfunction by Tetrahydrobiopterin: A Novel Mechanism of 
Protection 
Satish R. Fiaj, Aaron S. Dumont, Khalid Al-Faraidy, Andrew Maitland, Subodh Verma. 
University of Ca/gar)i Calgary, AB, Canada 
Sunday, March 18,2001, 3:00 p.m.-5:OO p.m. 
Orange County Convention Center, Hall A4 
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Hiroshi Tsutsui, Khaled M. Ziada, Paul Schoenhagen, Timothy D. Crows, William A. 
Magyar, Atila lyisoy, Jon Klingensmith, D.Geoffrey Vince, Gustavo Rincon, Steven E. 
105656 
Nissen, E.Murat Tuzcu. The Cleveland Clinic Foundation, Cleveland, OH 
Progression of lntimal Thickening is Greatest Early After 
Cardiac Transplantation and Not Directly Related to 
Changes in Vessel Size (Remodeling): A 4-Year Serial 
Intravascular Ultrasound Study 
1 .  / I I ,  
reactivity via the production of superoxide anions. Since enhanced superoxide produc- 
tion of superoxrde anions. Since enhanced superoxide production may serve to inactivate 
Backaround: Gvclosaorin A f&A) imaairs endothelial function and enhances vascular 
endothelium-derived nitric oxide (NO), we hypothesized that augmenting the production 
of this pathway (with tetrahydrobiopterin) may improve CyA-induced endothelial dysfunc- 
tion. Methods: Experiments were conducted in porcine coronary arteries, In the first 
Background: In native vessel atherosclerosis, remodeling is described as an adaptive 
change in vessel size secondary to plaque accumulation. However in transplant vascul- 
apathy, there is limited data to describe the relationship between intimal thickening and 
coronary remodeling. Methods: In 23 cardiac transplant recipients, serial intravascular 
ultrasound (IVUS) imaging was performed within 8 weeks of transplantation and annually 
for 4 years. In 23 imaged LAD arteries, 54 segments were matched between baseline to 
follow-up. For each patient, 12.5A4.9 mm long matched segments were analyzed using 
still images 1 mm apart., External elastic membrane (EEM) area, lumen area and intimal 
area (IA) were measured and % IA was derived [IA/EEM area x100]. A mean value for 
each segment was calculated. Segments were defined as showing “progression” if mean 
intimal area increased =>lO% of EEM area in one year and “non-progression” if the 
change was ~10%. Positive and negative remodeling of coronary artery were defined as 
=>lO% change in EEM area in one year. Results: During the 1st and 2nd years, intimal 
area increased rapidly from 1.8+1.4 (baseline) to 3.1k2.1 (1st year) to 3.9+2.6 (2nd year) 
mm2 (p<O.OOl for both). Progression was more common in 1st and 2nd years post-trans- 
plant (34/54 segments) than in years 2 to 4 (7/54), p<O.OOOl(Table). However, both posi- 
tive and negative remodeling were observed in progression and non-progression 
segments. Conclusion: In transplant vasculopathy, intimal thickening occurs primarily 
early after transplantation and can be associated with positive or negative remodeling. 
Additionally, change in vessel size was observed in segments without significant intimal 
thickening, indicating that this phenomenon is not solely determined by the degree of dis- 
ease progression. 
Numbers of Segments 
“Progression” 
positive remodeling 
negative remodeling 
“Non-Progression” 
positive remodeling 
negative remodeling 
base-1st vr 
a/33(24%) 
13/33(39%) 
21 (39%) 13 (24%) 3 (6%) 4 (7%) 
7/2 1(33%) 4/l 3(31%) 2/3(67%) O/4(0%) 
5/21(24%) 2/13(15%) i/3(33%) O/4(0%) 
33 (61%) 41 (76%) 51 (94%) 50 (93%) 
1 st- 2nd vr 
12/41(29%) 
8/41(20%) 
2nd- 3rd vr 
17/51(33%) 
1 o/51 (20%) 
3rd. 4th vr 
1 l/50(22%) 
1 +X50(32%) 
study, superoxide anion production in isolated coronary arteries (n=lO) was measured by 
lucigenin-chemiluminescence in the presence and absence of CyA (25uglml) and/or the 
nitric oxide synthase (NOS) cofactor tetrahydrobiopterin (O.lmM). In the second study, 
endothelium-dependent and -independent vasorelaxation to acetylcholine (ACh) and 
sodium nitroprusside (SNP) was assessed in coronary arteries (n=12) incubated with 
CyA and/or tetrahydrobiopterin. Maximum relaxation and agonrst sensitivity were com- 
pared between interventions using a P-way ANOVA followed by a Newman Keul’s test. 
Results: Exposure of coronary arteries to CyA resulted in a marked increase in superox- 
ide anion production (p<O.OOl). In addition, incubation with CyA resulted in impairment in 
endothelium-dependent relaxation to ACh (p<O.O02) without affecting agonist sensitivity. 
Strikingly, co-incubation with tetrahydrobiopterin attenuated the rise in coronary superox- 
ide production and prevented CyA-induced endothelial dysfunction (p<O.O5). CyA did not 
affect endothelium-independent vascular relaxation to SNP. Conclusion: CyA causes cor- 
onary endothelial dysfunction through production of superoxide anions. Exogenous addi- 
tion of tetrahydrobiopterin, the cofactor for endothelial NOS, attenuates CyA-Induced 
superoxide production and improves coronary endothelial function. 
105659 Expression of the Signal Transduction Protein 14-3-3 
Gamma in Injured Arteries and Stimulated Human Vascular 
Smooth Muscle Cells 
Michael V. Autieri, Christopher Carbone, Howard Eisen. Temple University School of 
Medicine, Philadelphia, PA 
Background: Cellular proteins induced by vascular injury which play a role in activation of 
medial vascular smooth muscle cells (VSMC) are potential targets for anti-restenotic 
therapy and therapy for transplant arteriopathy. The 14-3-3 family of proteins are thought 
to act as molecular scaffolds for signal transduction proteins and have been implicated as 
key molecules involved in regulation of cellular growth and proliferation. Our previous 
work has implicated one 14-3-3 isoform, gamma, as involved in activation of cultured 
human VSMC. Therefore, we hypothesized that expression of this protein would also be 
increased in viva models of arterial injury. Methods: In this study we examined 14-3-3 
gamma expression in both immunological and mechanical models of arterial injury by 
northern analysis, and immunohistochemistry. Results: 14-3-3 gamma is acutely 
expressed in aortic medial smooth muscle cells in rat cardiac allografts, with protein 
peaking at 7-10 days post-transplant. 14-3-3 gamma protein is also induced in both 
medial VSMC and neointimal cells in coronary arteries isolated from patients diagnosed 
with severe transplant arteriopathy as compared with coronary arteries isolated from nor- 
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mal and end-stage heart failure patients. 14-3-3 gamma protein is also acutely expressed 
in medial VSMC and neointrmal cells in balloon angioplasty-injured swine coronary arter- 
ies. Expression of this protein in cultured human VSMC is induced by cytokine strmula- 
tion, including FGF, PDGF, TGF-Beta, and T cell conditioned media, but not by 
mechanical manipulation or direct injury of VSMC. This expressron pattern is unique as 
compared with other 14-3-3 family proteins. Conclusions: This data indicates that 14-3-3 
gamma expression is associated with cytokine-induced VSMC activation subsequent to 
arterial injury, rather than direct injury to the VSMC themselves. Taken together, this sug- 
gests that this protein may play a role in vascular proliferative d&eases. 
Results: The mean age of the non-Adventist group was 79.8 +I-2.9 years and the mean 
coronary artery calcium score was 1456.6 +I-1598.6. In the Adventist group, the mean 
age was 82 1 +I62 yrs and the mean coronary artery calcium score was 510.8 +I- 
651.2. Although there was no significant difference in traditional risk factors between the 
groups, the difference in coronary artery calcium score between the groups was statisti- 
cally different (~~0.05). Two Adventist patients and one non-Adventist patient had no cor- 
onary artery calcium (Score 0). 
Conclusion: This prelimmary study suggests that lifestyle measures contribute signifi- 
cantly to the degree of coronary artery calcification (atherosclerosis) and may explain in 
part the increased longevity reported amongst Adventists. 
1058-60 Posttransplant Coronary Artery Disease: Relationship 
Between Atherosclerotic Risk Factors and New 
Vasculopathy Occurring Beyond the First Year After 
Transplant 
1059-62 Endogeneous Nitric Oxide in Patients With Idiopathic 
Dilated Cardiomyopathy Inhibits Positive lnotropic 
Response to Adenylate Cyclase Stimulation 
Edward F. Philbin, Abed Asfour, Adam 8. Greenbaum, Thomas M. McFarland, Debbie 
Rickeard, Gary Franklin, Carrie Nelson, Conrad Drost, Alvise F. Sernabei. Albany 
Medical College, Albany, NY Henry Ford Hospital, Detroit, MI 
Background: The etiology of coronary arterial disease among heart transplant (HT) 
recipients may vary with the time between HT and the onset of vasculopathy (VASC). We 
conducted this study to evaluate the causes of new VASC discovered after the first year 
post-HT. Methods: We reviewed all coronary angiograms (CA) performed on 100 con- 
secutive patients undergolng HT at a single center. VASC was defined as any degree of 
luminal obstruction in 21 of 15 coronary segments by CA. Results: Of 100 patients, 53 
survived 72 years after HT, underwent CA at 1 year post-HT, and had a second CA 
between 2-5 years after HT. Median follow-up among these 53 patients was 5.3 years 
post-HT. Mean age at HT was 50 years; 17% of patients ware women and 9% black. 
VAX was increasingly prevalent after HT (Year 1 prevalence = 15%, Year 2 = 26%, Year 
5 = 36% P=O.Ol). At each interval, subsequent mortality was higher among patients with 
VASC than among those without it. Among 45 patients free of VASC at Year 1, 11 (24%) 
had VASC noted on a subsequent CA. The relationship between risk factors and the 
presence of new, late VASC are shown in the Table. AS shown, the only predictor of new, 
late VASC was absence of treatment with a lipid lowering drug. In addition, the total num- 
ber of risk factors present was not predrctive of new, late VASC. 
Prevalence of Risk Factors Among Patients With and Without New, Late Vasculopathy 
Risk Factors VASC + VASC P 
Treated diabetes meilitus 0% 27 % 0.13 
Treated hypertension 82 % 76 % 0.86 
Treated hyperlipidemia 64 % 94 % 0 04 
Long-term prednisone use 33 % 17% 0.55 
Cytomegalovirus infection 18 % 21 % 0.78 
Treated allograft rejection 67 % 62 % 0.82 
Conclusions: The prevalence of VASC increased over time after HT and was inversely 
related to survivai. VASC was less likely to develop beyond the frrst year after HT if 
patients received lipid lowering drugs, suggesting hyperlipidemia plays a role. Other risk 
factors for new. late VASC were not evident in this series, suggesting that its pauses may 
be different than that of VASC occuring early after HT or native atherosclerosis. The role 
of novel causes of vasculopathy including donor characteristics, HLA matching, cytok- 
ines, other pro-inflammatory molecules deserves further investigation to better under- 
stand this serious and frequently fatal problem 
Sorchiro Ota, Katsuya,Hata, Hiroya Kawai, Hideyuki Takaoka, Toshiro Shinke, Yoichi 
Kijima, Takeomi Muiata, Yoshiaki Ueda, Hidenari Matsumoto, Yoshio Yamanaka, Yoke 
Miyata, Ryohei Yoshikawa, Mitsuhrro Yokoyama. Firsf Department of Infernal Medicine, 
Kobe University School of Medicine, Kobe, Japan 
Background: Recent studies suggest that, in the failmg myocardium, endogeneous nitric 
oxide (NO) attenuates myocardial inatroprc response to p-receptor agonists. However, 
how NO modulates postreceptor P-adrenergic signaling system is still unknown. The aim 
of this study was to examine the effects of cardiac NO synthase (NOS) inhibition on I& 
ventricular (LV) mechano-energetics in response to adenylate cyclase stimulation with 
colforsin damp& (Colt), a water-soluble forskolin derivative, in patients with idiopathic 
dilated cardromyopathy (IDC). Methods: We examined LV contractility (+dP/dt; peak pos- 
itive dP/dt, Emax; the slope of end-systolic pressure-volume relation), external work 
(EW), myocardial oxygen consumption (VOZ) and mechanical efficiency (EWNOP) using 
conductance and Webster catheters before and during intravenous infusion of Colf 
(0.5pg/kg/min), in 8 patrents with IDC (mean LVEF; 35%). Moreover, we examined the 
effects of NOS inhibition with intracoronary infusion of L-NMMA (200 pmol) during Golf 
infusion. Heart rate was kept constant by atrial pacing. In preliminary study, we confirmed 
that intracoronary infusion of L-NMMA alone did not change these variables in five 
patients with IDC (data are not shown). Results: Colf increased +dP/dt, Emax and EW 
(by 21%, 45% and 7% respectwely) without changing V02 or EWN02. L-NMMA potenti- 
ated +dP/dt and Emax response to Golf (by 6% and 16% respectively) without changing 
EW, V02 or EWN02. 
cons?1 
cull 
+dP!at Emax EB’ vo > EBIVQ, 
(nmH&j (mmH$mlhn’l (J I mT) [.rfbeatj WI 
1;385& 274 3.41+1.92 0.23fe.13 332f0.69 17.511;7 5 
1561f372* 445f3.4?* 0.3u*o.li* 3.13zt0.73 1821Q.U 
Cn,f+L-NMMA1654f34a*# 5.75*4.06+, 0.33f0.10+ 3.13f-0.71 19.0+9.7 
W<O.“5 v: Cnnrrol;#P<O.o5 ys calf. 
Conclusion: Inhibition of cardiac NO augments positive inotropic response to adenylate 
cyclase stimulation without changes in energetics in patients with IDC, suggesting that 
NO may influence p-adrenergic postreceptor pathways and participate in pathogenesis of 
human heart failure. 
1059-63 LINCS: L-NMMA in Cardiogenic Shock: Preliminary Results 
From a Prospective Randomized Study 
POSTER SESSION 
1059 Pharmacological and 
Nonpharmacological Treatments for 
Congestive Heart Failure 
Sunday, March 18, 2001, 3:00 p.m.+:00 p.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1059-61 Extent of Coronary Artery Calcification in Elderly Healthy 
Adventist Volunteers Compared to a Healthy Aged Matched 
General Population 
David Grout, Bevan Hokin, Kevin Price, Sudheera Nair, Mark Nidorf Peter L. Thompson, 
Ross G. T Walker. Sydney Heart /mage of Sydney Adventisf Hospitai, Sydnq Ausfraiia, 
West Ausfralian Hearl Research Instifufe, Perfh, Ausfrak 
Background: Whilst it is known that the prevalence of coronary artery calcium in west- 
ern countries mcreases with age, it is incorrect to conclude that coronary artery calcifica- 
tion is Simply an inevitable part of normal ageing. Over the past 10 years, a direct link 
between coronary artery calcium and total atherosclerotic plaque burden has been 
established. It is known that members of the Adventist population who are non-smokers 
and vegetarians have a significantly greater life expectancy than the general population. 
Method: To determine whether lifestyle may be a determrnant of atherosclerotic plaque 
burden, we measured coronary artery calcium in 27 elderly healthy Adventist volunteers 
and 25 age matched healthy controls self-referred from the general population using fast 
gated CT No patients in either group had suffered a cardiac or cerebral event. 
Gad Cotter, Edo K&ski, Olga Milovanov, Alex Blatt Ahmed Salah, Fiikardo Krakover, ZVI 
Vered. Ass&Harofeh Medical Center, Zerifin, Israel 
Background: In a pervious non-randomized feasibility study we have shown that L-NMMA 
is potentially efficient in the treatment of refractory cardiogenic shock. Methods: We have 
enrolled 15 consecutive patients with refractory cardiogenic shock @m-augmented sys- 
tolic blood pressure<100 mmHg during an acute coronary syndrome despite treatment 
with maximal percutaneous revascularization, intraaortic balloon pump (IABP), high-dose 
IV dopamine and IV fluids for at least 1 hour accompanied by signs of peripheral hypop- 
erfusion). All patients continued with conventional treatment and were randomized to no 
further treatment (n=7) or receive L-NMMA 100 mg bolus and 100 mglhour continuous IV 
drip for 5 hours (n=r3). Results: (1) Primary end point: death at one month was 38% in the 
L-NMMA arm vs. 86% in the no-treatment arm (p=O.O4). (2) Secondary end points: 
Death at one week was 25% in the L-NMMA arm vs. 86% in the no-treatment arm 
(p=O.Oi). Unaugmented mean arterial blood pressure (MAP) at 24 hours was 85+/-44 
mmHg in the L-NMMA arm vs. 69+/-10 mmHg in the no-treatment arm (p=O.O4). MAP 
increased by 27+/-13 mmHg vs 5+/-9 mmHg respectively (p=O.OOl). Urine output at 24 
hours was 254+/-48 cc/hour in the L-NMMA arm vs 114+/-l 00 cc/hour in the no-treat- 
ment arm (p=O.O03). Urine out put increased by 160+/-45 cc/hour in the L-NMMA arm vs 
a decrease of 1311-l 10 cc/hour in the no treatment arm (p=O.OOi). Time on IABP was 
61+/-57 hours in the L-NMMA arm vs. 85+/-47 hours in the no treatment arm (p=O.22). 
Time on mechanical ventilation was 77+1-49 hours and 143+/-18 hours respectively 
(p=O.O03). Conclusion: From these preliminary results it seems that L-NMMA is benefi- 
cial in the treatment of patients in refractory cardiogenic shock. 
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105964 lnotropic Effect of Glucose-Insulin-Potassium Infusion: 
Comparison With Low Dose Dobutamine 
Lucas J. Klein, Linda(C) M. C. van Campen, Gertjan T. Sieswerda, Otto Kamp, Cees A. 
Visser, Frans C. Visser. University Hospital VU, Amsterdam, The Netherlands 
Background We previously observed that glucose-insulin-potassium (GIK) infusion 
recruits contractile reserve in dysfunctional segments in patients shortly after acute myo- 
cardial infarction (AMI) to a similar extent as low-dose dobutamine (LDD) infusion. We 
hypothesized that GIK infusion would also result in improved global ventricular function. 
Methods Twenty patients underwent GIK echocardiography 5.2iO.3 days after AMI. The 
GIK protocol consisted of a fixed insulin infusion rate (100 mUikg/hr) and a variable rate 
of glucose/K+, to maintain euglycemia. Four additional patients received an infusion of 
saline instead of GIK. Echocardiograms were made at baseline and after 60 min of infu- 
sion. In all patients LDD echocardiography was performed with echocardiograms at 
baseline and at 15 pg/kg/min infusion. Echocardiograms were analysed off-line and end- 
diastolic (EDV) and end-systolic (ESV) volumes were determined. From these values, 
stroke volume (SV) and ejection fraction (EF) were calculated, as well as cardiac output 
W). 
Results During LDD infusion, both EDV and ESV decreased, with an increase in SV, EF 
and CO (see Table). During GIK infusion, EDV did not decrease whereas ESV did. Also, 
SV and EF increased, without an increase in heart rate (HR) or rate-pressure product 
(RPP). Saline infusion had no effect on EDV, ESV, EF or CO. 
LDD Base LDDiSu p GIK Base GIK60min p 
EDV (ml) 135*36 123~30 .0105 135*30 137224 .7583 
ESV (ml) 63+28 45*19 <.0001 66r26 55*20 .0009 
SV (ml) 72-tZO 78220 .0139 70+16 82k.13 .0130 
EF (%) 54+11 64+9 <.OOOl 52+10 6129 <.OOOl 
CO (I/min) 4.9+1.4 6.5*1 .Q <.OOOi 4.7+1.2 5.7k1.5 .0095 
HR @pm) 68+11 83~13 <.OOOl 68rl2 70+14 .2340 
RPP (^lo-3) 8.7rl.9 10.6k2.5 <.OOOl 8.7rl.9 8.9*1.8 .5674 
Conclusion GIK infusion has a similar inotropic effect as low-dose dobutamine infusion, 
without the concomitant increase in HR and RPP. Because GIK infusion does not 
increase the RPP, in contrast to dobutamine, GIK may be particularly suited to use in the 
setting of (subacute) myocardial infarction in order to improve ventricular function, 
1059-65 Myocardial, Metabolic and Endothelial Effects of 
Trimetazidine in Diabetic Patients With lschemic Dilated 
Cardiomyopathy 
Gabriele Fragasso, Piermarco Piatti, Lucilla Monti, Gianpietro Valsecchi, Riccardo 
Camisasca, Emanuela S&la, Sergio Chierchia. lsfifufo Scienfifico/Universi~~ San 
Fmae/e, Mi/ano, ha/y 
We assessed whether the addition of trimetazidine (TMZ) to standard current therapy, in 
the treatment of diabetic patients (pts) with severe ischemic dilated cardiomyopathy, can 
effectively improve symptoms, exercise tolerance, resting left ventricular function as well 
as skeletal muscle metabolism and release of endothelin-1 (ET-I). Ten such pts (all 
males) on conventional therapy were randomly allocated in a double blind fashion to 
either placebo or TMZ (20 mg tid), each arm lasting 15 days. At the end of each period, 
all pts underwent 2Dechocardiography, exercise testing, hyperinsulinemicleuglycemic 
clamp and forearm indirect calorimetry. Ejection fraction (EF), fractional shortening (FS), 
n?aXimal exercise time (ET), ET-1 levels, M value (index of total body glucose disposal) 
and basal and end-clamp forearm glucose uptake (FGU) were evaluated. Compared to 
placebo, EF (43~6 vs 46i6%, p=O.O3), FS (24t7 vs 27+7%, p=O.O5), ET (426k167 vs 
45Ok.154 set, p=O.O8), M value (3.28+1.51 vs 4.11 +i .63 mgikglmin, p=O.OZ) and FGU 
(2.27k1.43 vs 3.85i2.19 micromol/lOO ml forearm/min, ~~0.05) increased, while basal 
ET1 (13.6t2.7 YS 11.3+2.6 pgiml, ~~0.05) decreased during TMZ. In conclusion, short- 
term TM2 improves left ventricular function and glucose metabolism in pts with diabetes 
and dilated ischemic cardiomyopathy. Additionally, TMZ reduces the release of ET-l, 
These beneficial effects are likely to be dependent on the fact that TMZ inhibits myocar- 
dial oxidative phosphorylation and shifts FFA oxidation to glucose oxidation. These 
effects may be operative in both the heart muscle and the vascular endothelium. 
1059-66 Clinical Determinants of Benefit in Patients With a 
Biventricular Pacemaker for Heart Failure 
Chetan Varma, Peter O’Callaghan, Sami Firoozi, Anne Bradford, Stephen Brecker, 
Edward Rowland, William Mckenna. St Georges Hospital Medical School, London, 
United Kingdom 
Background: Biventricular (BV) pacing has been proposed to manage advanced heart 
failure. The patient subgroup in whom benefit with BV pacing occurs is not clearly 
defined. We aimed to assess which clinical parameters identified patients with improve- 
ment after implantation with a BV pacemaker. Methods: Patients enrolled had advanced 
heart failure on maximal medical therapy with left bundle branch block (QRS > 140 ms). 3 
months after BV pacing patients were classified into two groups - improved or not 
improved - by change in NYHA class and exercise capacity. The parameters of NYHA 
class, ECG (PR interval, axis, QRS duration), echocardrography (left ventricular end 
diastolic dimension, fractional shortening, mitral regurgitant area, aortic time velocity inte- 
gral and diastolic filling time), 6 min walk test and cardiopulmonary exercise test (V02 
max, exercise time ET) were analysed pre implant to determine the differences between 
the two groups. Results: 18 patients ware enrolled of which 14 were successfully 
implanted with a BV pacemaker. 9 were classified as having improved (baseline v paced: 
ET 294 s f 92 v 468 s f 183 (p = 0.05), VO2 12.8 mlikglmin * 1.7 v 16.2 mlikgimin t 1.5 
(p = 0.007), 6 min walk 284 m f 149 Y 371m f 108 (p = 0.036). 5 were classified as not 
improved (no significant difference in any of the parameters ET, V02 or 6 min walk). 
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Baseline differences between the two groups . See table The other measured baseline 
parameters lrsted in the methods section were all non significant (p > 0.05). Conclusions: 
Clinical improvement with biventricular pacing in heart failure is less likely in patients with 
very poor clinical functronal capacity and a markedly prolonged QRS. Caution is needed 
in advocating biventricular pacing for this group of patients. 
Baseline Improved Not improved p (paired Student t test) 
NYHA class 3.2 + 0.4 3.8 f 0.4 0.038 
QRS duration 174+23 220 +_ 38 0.015 
VO2 max 12.6 + 1.6 8.3 k 1 .O 0.010 
1059-67 Comparative Effects of Ventricular Resynchronization 
Therapy in Patients With LV Systolic Dysfunction of 
Idiopathic or lschemic Origin 
Christophe Leclercq, Sr., Christine Alonso, Sr., Dominique Pavin, Sr., Gilles Rouault, Sr., 
Phiirppe Mabo, Sr., Claude Daubert, Sr.. Departement de Cardiologie G/U, Rennes, 
FLWXe 
Biventricular pacing may improve symptoms and exercise tolerance in patients with 
chronic LV systolic dysfunction and intraventricular conduction delay. The aim of this 
study was to compare the long-term effects of Biventricular pacing in patients with dilated 
cardiomyopathy (DCM) of ischemic origin and in patients with idiopathic DCM. This study 
included 90 patients consecutively implanted with a Biventricular pacemaker between 
August 1994 and February 2000. Patients were retrospectively divided into two groups 
(idiopathic and ischemic) according to the results of a recent coronary angiogram. Symp- 
toms and objective data were assessed before PM implant (pre-I) and 6 months (M-6) 
after and compared between the 2 groups. Results are summarized in this table : 
Total (n = 90 Idiopathic (n = 53) lschemic (n = 37) 
Pre-I M-6 p Pre-I M-6 p Pre-I M-6 p 
QRS duration 185*x 158r19 coooo1 184125 159rlB coooo1 186127 15*r21 coooo1 
hs) 
QTSax,s(“) 19i60 153rm <‘moo1 -32r49 +55*75 <00001 -3169 +5oin 0002 
NYHA 3310.5 **m <00001 33r05 2r0.5 c0w0, 3.4a05 2,106 <000D1 
Peak”02(m,/ 1215 16*4 <00001 13r4 17*4 00003 1oi47 15r.l 002 
kglmln) 
L”EF(%) 21a.5 2618 0.0002 2or6 25i8 0007 22-7 27-8 0008 
Conclusion : Permanent Biventricular pacing provides significant and sustarned improve- 
ment in symptoms, exercise tolerance and LVEF in both idiopathic and ischemic DCM 
patients. 
1059-68 Correction of Left Ventricular Dyssynchrony by Left 
Ventricular-Based Pacing in Patients With Severe Heart 
Failure and Left Bundle Branch Block 
Yves Etienne, Philippe Guillo, Jacques Mansourati, Abdelkader Touiza, Martine Gilard, 
Yves Bizais, Jean-Jacques Blanc. University Hospital of Brest, Bresf, France 
Background : Left bundle branch block (LBBB) Induces left ventricular (LV) asynchrony 
which results in deleterious hemodynamic and clinical effects, particularly in patients with 
severe congestive heart failure (CHF). The arm of our study was to evaluate the effects of 
permanent LV-based pacing on LV contraction heterogeneity in such patrents. 
Methods : Twenty-three patients (mean age : 69 * 7 years) with severe CHF (NYHA class 
Ill, n = 8 ; class IV, n = 15) and LBBB (mean QRS duration : 185 f 31 ms) were prospec- 
tively evaluated at baseline and 6 months after implantation of a LV-based permanent 
pacemaker (LV alone, n = 13 ; biventricular, n = 10) by radionuclrde ventriculography in 
the cc best septal ha view with measurement of global LV ejection fraction (EF) and sag- 
mentary EF (segts 1-4 : lateral free wall ; segts 5-8 : septal wall ; segt 9 : valve plane). 
Results : At baseline patients in the study group showed a marked LV dyssynchrony 
between LV free and septal walls. LV-based pacing resulted in a significant improvment in 
NYHA class (from 3.6 + 0.4 to 2.4 A 1 1 p c O.OOOl), increase in LV global EF (from 23.2 
* 7 % to 26.2 + 7 %, baseline vs pacing p c: 0.01) and resynchronization of LV regional 
contraction, mainly due to septal contraction improvement (cf figure) 
- 
*p<.os, -p<.o1, ***p<.ooo1 
In conclusion, LV based permanent pacing reverses LV asynchrony consecutive to LBBB 
in patients with CHF 
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1059-69 Relationship Between Electrical and Hemodynamic 
Parameters Using B&Ventricular and Uni-Ventricular Pacing 
in Heart Failure Patients 
Randy Lieberman. Wisam Martini, Raghava Velagaleti, Suneet Kukreja, Srinavasa 
Madala, Kathryn E. Hiipisch, Michael R. S. Hill. Wayr~s Sfafe UniversifyandHarper 
Hospital, Detroit, MI 
In early clrnical trials implementing bi-ventricular @i-V) pacing for advanced heart farlure 
patients (pts.) with dilated cardiomyopathy and ventricular conduction abnormalities, 
shortening of QRS duration was desired. The relationship of the QRS shortening to 
hemodynamic responses during Bi-V pacing is unclear. The objective of this study was 
to evaluate and compare the changes in QRS duration and QT interval to hemodynamrc 
parameters during various pacing modes. METHODS: Twelve pts. with heart failure 
undergoing elecirophysiological procedure were evaluated following placement of right 
atrial, right (RV) and left (LV) ventricular (via coronary sinus vasculature) pace/sense 
catheters and a pulmonary artery catheter. Twelve lead electrocardiogram cardiac out- 
puts (CO) and pulmonary capillary wedge pressures (PCWP) were obtained in normal 
sinus rhythm (NSR) and during RV, LV and Bi-V pacmg at interventricular (VV) intervals 
of 0, 20, 40 and 80 ms, each with AV and LV first. CO was normalized to cardiac index 
(Cl). Improved systolic and diastolic (CI/PCWP) function was used to determrne the opti- 
mal pacing parameters. Maximum QRS duration and QT rnterval were measured from 
the 12 lead ECG for each pacing mode. RESULTS: NSR CliPCWP was 0.18+0.11, QRS 
duration was 136235 ms and QT interval was 418i58 ms. Bi-V pacing with (VV) interval 
> 0 resulted in improved hembdynamic function (Ct/PCWP=O.lSi-0.11, p=O.O5) and sig- 
mficantly shortened QRS duratron (p=O.OZ) and QT interval (~~0.05) compared to other 
pacing modes (Table). The correlation of the change in CI/PCWP and QRS duration was 
-0.30 and QT interval was -0.04. CONCLUSIONS: Acute Bi-V pacing resulted in hemo- 
dynamic improvements and shortening of QRS duration and QT rnterval compared to 
single site (RV or LV only) pacing; however, the correlation of the electrical and hemody- 
namic changes was moderate. These results suggest that whereas Bi-V pacing may pro- 
vide improvements in hemodynamic function, the change in electrical parameters may 
not adequately reflect those improvements. Additional clinical evaluation is needed. 
A from NSR RV LV Bi-Vvv,o Bi-Vvv,o 
ORS, Ills 6&33 46+56 11137 21136 
QT, ms 70*45 62t58 38+42 291;49 
1059-70 internal Cardioversion of Permanent Atrial Fibrillation in 
Severe Heart Failure is Effective and Leads to Long Term 
Functional Improvement 
Gaetano De Ferrari, Maurizio Landolina, Francesco Cantb, Michela Casella, Barbara 
Petracci, Carlo Campana, Stefano Ghio, Luca Lanzarini SMaffeo Hospifai /WCS, 
Pave, rtajy 
Among patients wrth heart failure (HF), atrial fibrillation (AF) is very common and associ- 
ated wrth increased mortality and morbidity. External cardioversion (CV) is often unsuc- 
cessful, recurrence rate high and an improvement in left ventricular function has never 
been shown. This study assessed the effects of amiodarone treatment and of internal 
cardioversion in 26 pts with advanced HF evaluated for heart transplantation, with perma- 
nent AF and previous failed external CV. Mean age was 57 1 8 yrs, NYHA class 2.5 i 
0.5. All pts had a very dilated LV (mean ED and ES volume were 275 i- 98 and 197 * 80 
ml), and LA (50 ? 6 mm diameter [AE]). Amiodarone 400 mg for 4 weeks before CV and 
200 mg after CV and warfarin were given to all pts. CV was performed via a coronary 
sinus and a high lateral RA 6F coil catheter (Rhythm Technology), delivering a biphasic 
wave beginning at 10 J and increasing by 5 J steps. Successful CV was obtained in all 
patients: with 1 shock in 14 pts (54%), 2 shocks in 6 pts (23 %), 3 shocks in 4 pts (15%) 
and 4 shocks in 2 pts (8%). The mean delivered energy of successful shock was 13.9 i 
5 J. No proarrhythmic event or any other complicatron occurred. 
At 6 months sinus rhythm was maintained in 18/21 pts. (86%); in these pts a significant 
clinical and functional improvement was observed (as shown in the table). Two pts were 
removed from the active heart transplantation list, thanks to the marked improvement. 
No side effect from amiodarone treatment was observed. 
Thus, the combination of internal CV and amiodarone treatment is safe and effective in 
restoring and maintaining sinus rhythm in pts with advanced HF and permanent AF, lead- 
ing to a significant improvement both in symptoms and in cardiac function. 
1059-71 Thermal Vasodilation Therapy Improves Vascular 
Endothelial and Cardiac Function in Patients With Chronic 
Heart Failure 
Takashi Kihara, Sadatoshi Biro, Masakazu Imamura. Shiro Yoshifuku, Kunitsugu 
Takasaki, Yutaka Otuji, Shinichi Minagoe, Yoshifumi Toyama, Chuwa Tel. Firsf 
Department of Infernal Medicine, Kagoshima Universify Kagoshima, Japan. Nanpuh 
hospifal, Kagoshima. Japan 
Background: We previously reported that repeated 60 degrees C sauna, a thermal 
vasodilation therapy, improves hemodynamics and clinical symptoms in patients with 
chronic heart failure (CHF) (Circulation 1995;91,2582-90). But the underlying mecha- 
nisms remain unclear Since vascular endotheliaf function IS impaired in patients with 
CHF we hypothesrzed that sauna restores endothelral function, then rmproves cardiac 
function. Patients and Methods: Twenty patrents (62+/-15 years) with CHF in New York 
Heart Association functional class II or Ill were studied. Their m&cation had not been 
changed for at least 2 weeks before and durmg the study. They had a 60 degrees C far 
infrared-ray dry sauna fcr 15 min and were kept at bed rest with blankets for 30 min once 
a day. The effect of the sauna was evaluated before and at the day after P-week sauna 
therapy. With high-resolution ultrasound, we measured the dram&r of brachial artery at 
rest and during reactive hyperemia (flow mediated dilahon, %FMD) as endothelrum- 
dependent dilation, and after sublingual admrnistrabon of nitroglycerin (%NTG) as endot- 
helium-independent dilation. We also measured plasma levels of brain natriuretic peptide 
(BNP), thiobarbrturic acid-reactive substances and tumor necrosis factor alpha (TNF- 
alpha). Results: All patrents enrolled in the study completed it. No patient experienced 
dyspnea, angina pectoris, or palpitation. Body weight and the values of hematocrit did 
not change after Z-week sauna treatment. After 2-week sauna therapy, %FMD signifi- 
cantly increased from the baseline values (4.4+/-2.5% vs. 5.7+&X%, P<O.Ol). On the 
other hand, %NTG was almost similar (19.2+/-6.5% vs. 18.7+/-6.9%). Plasma levels of 
BNP significantly decreased (from 441+/-444 pg/ml to 293+/-302 pg/ml, P<O.Ol). In addi- 
tion, a significant correlation between delta %FMD and the percent improvement in 
plasma BNP levele was found (r=0.69, P<O.Ol). Plasma levels of thiobarbituric acid-reac- 
tive substances and tumor necrosis factor alpha did not change. Conclusion: Repeated 
sauna therapy improves vascular endothelial function, resulting in the improvement of 
cardiac function in patients wrth chronic heart failure. 
1059-72 Dialysis in Diuretic Resistant Congestive Heart Failure: Pilot 
Experience 
Amar L. Pohwani, Guy A. MacGowan, Dennis M. McNamara, Warren D. Rosenblum, 
Srinivas Murali. University of Pittsburgh, Piffsburgh, PA 
Background: Diuretic resistance is frequently encountered in patients (pm) with chronic 
congestive heart failure (CHF), and is characterized by declining symptoms, progressive 
renal failure, frequent hospitalization and high mortality. Objective: To determine 
whether dialysis reduces hospitalization, and improves NYHA class in diuretic resistant 
CHF patrents. Methods: 9 CHF patients (6 male, 3 female), mean age 66.4 years (range 
51-78 years) with NYHA class IV symptoms on optimal medical therapy were treated with 
dialysis (4 hemo, 5 peritoneal). CHF was due to left ventricular (LV) systolic dysfunction 
(Group A) in 5 patients (4 ischemic, f non-ischemic, mean LVEF 20%) and LV diastolic 
dysfunction (Group B) in 4 patients (1 diabetic, 1 valvular, 2 hypertensive). Results: Data 
at baseline and 7.3 months (range 3-12 months) after dialysis are tabulated. Actuarial 
survival was 88% at 3 months, 85% at 6 months, and 80% at 12 months. Conclusions: 
In patients with diuretic resistant CHF due to LV systolic or diastolic dysfunction, dialysis 
is a) well tolerated, b) improves NYHA class, c) decreases need for inotropic therapy and 
d) reduces hospitalizations. A larger randomized trial is needed to evaluate the role of 
dialysis in diuretic resistant CHF. 
Group A Group 6 
PARAMETERS Baseline After Baseline After 
Dialysis Dialysis 
BUN (mg/dl) 89.9 58.6 64 31.3 
Creatinine (mg/dl) 3.1 3.6 2.8 3.3 
% of Patients on lnotropic Therapy 80% 20% 0% 0% 
NYHA Class II 0% 0% 0% 25% 
NYHA Class Ill 0% 80% 0% 75% 
NYHA Class IV 100% 20% 100% 0% 
#of Hospitalizations within 6 months 2.4 0* 3.2 0.25 
‘P<O.O5 after dialysis vs. baseline 
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1098-43 Forced Vital Capacity in Severe Heart Failure: A Powerful 
Predictor of Adverse Outcome 
Mandeep Ft. Mehra, Patricia A. Uber, Myung H. Park, Robert L. Scott, Carl J. Lavie, 
Richard V. Milani. Ochsner Cardiomyopathy and Heart Transplant Center. New Orleans, 
LA 
Background: Forced Vital Capacity not only reflects pulmonary restrictiOn but also respi- 
ratory muscle dysfunctron. We hypothesized that use of Forced Vital Capacity as a 
marker of peripheral muscle kinetic aberrations might allow better outcome discrimination 
in patient cohorts characterized by a low peak aerobic capacity. 
Methods: In order to investigate this issue, we prospectively analyzed a consecutive 
group of 144 heart failure patients (5&l 1 years, ejection fraction 20*8%, 78% men, 76% 
white, 1-5 years follow-up) listed for heart transplantation (VOa~l4ml/kg/min), and evalu- 
ated baseline Forced Vital Capacity % predicted as a marker for survival. 
Results: Regression analysis for significant correlates of Forced Vital Capacity % identi- 
fied left ventricular ejection fraction ((~0.2, p 0.03), serum sodium (r=O.Z, p O.Oi), bilirubin 
((~0.4, p 0.02) uric acid (r=O.7, p O.OOOZ), Forced Expiratary Volume 1% (r=O.S, 
p<O.OOOl) New York Heart Association class, pulmonary vascular resistance, use of 
amiodarone, peak aerobic capacity, and hemodynamic measurements were not signifi- 
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Methods: We sought to prospectively evaluate the prognostic impact of High Density 
Lipoproteins levels on disease progression in severe heart failure by prospectively exam- 
ining 132 patients listed for heart transplantation between January 1993 and December 
1998 (52+.11 years, 80% men, 79% Caucasian, 60% ischemic etiology, follow-up 
551t264 days). The relationship of High Density Lipoproteins levels (High Density Lipo- 
proteins < 33mgldl (n=47) versus >33mg/dl (n=85)) with the primary composite end point 
of hospitalizations or death was examined. 
Results: Univariate analysis of selected variables is shown in the table. Survival analy- 
sis, using a Cox proportional hazards model, revealed reduced High Density Lipoproteins 
(<33mg/dl) as the most powerful independent predictor of worsening disease progres- 
sion (x219, p=O.OOOl) in concert with black race (x*4, p=O.O4), New York Heart Associa- 
tion class IV (x ‘10, p=O.Ol); conversely, female sex was found to be protective (x ‘5, 
p=O.OZ). No siqnificance was noted with reqard to ventricular geometry or function, 
hemod&ni&peak aerobic capacity, or useif lipid lowering therapy. 
cantly correlated. Survival analysis of patients with a Forced Vital Capacity % ~75% ver- 
sus ~775% usina Kaolan-M&r methods revealed a sianificant discriminant effect 
independent of p&k aerobic capacity (log rank p 0.001). - 
VQ2 Anaerobic Forced Expiratory Forced Vital Capacity 
Alive (n=106) 
Dead (n=38) 
I) value 
Threshold % Vol”me 1% % Predicted 
5&12 4ltl1 75*20 76+19 
54+12 37+10 66*16 68+15 
“S “S 0.01 0.01 
VO, = % predicted for age and gender 
Conclusions: This investigation provides evidence for the incremental prognostic 
impact of Forced Vital Capacity in predicting death after listing for heart transplantation. 
Furthermore, this study alludes to the interrelationship of respiratory mechanics and hor- 
monal-metabolic aberrations that characterize severe chronic heart failure. 
1098-44 Smoking Increases Hospitalization Rate for Heart Failure in 
Patients With Heart Failure and Left Ventricular Dysfunction 
in SOLVD 
Raviprasad G. Subraya, Alan C. Wilson, Clifton R. Lacy, John B. Kostis. UMDNJ-Robert 
Wood Johnson Medical School, New Brunswick, NJ 
Background: The effect of smoking on hospitalization rate due to heart failure in patients 
with heart failure or left ventricular systolic dysfunction has not been well studied, 
Methods: We studied 6797 patients: 2569 in the Treatment Trial (left ventricular dysfunc- 
tion with heart failure) and 4228 in the Prevention Trial (left ventricular dysfunction with- 
out heart failure) of the Studies of Left Ventricular Dysfunction (SOLVD). We evaluated 
hospitalization due to heart failure over an average follow-up of 41.4 months in the Treat- 
ment Trial and 37.4 months in the Prevention Trial, comparing patients who were current 
smokers to non-smokers at baseline. lschemic etiology accounted for 71.3% of heart fail- 
ure patients in the Treatment Trial and 83.2% of left ventricular dysfunction patients in the 
Prevention Trial. Smokers comprised 23.0% of patients in the Combined Trials, 22.1% in 
the Treatment Trial, and 23.5% in the Prevention Trial. 
Results: After adjusting for age, gender, race, ejection fraction, atrial fibrillation, alcohol 
consumption, NYHA class, hypertension, diabetes mellitus, previous myocardial infarc- 
tion, angina, etiology of left ventricular dysfunction, revascularization and medications, 
smokers had significantly higher hospitalization rate in all patients in the Combined Trials 
(RR=l.l7, p=O.O3). The effect was more prominent for patients with ischemic etiology in 
both the Combined Trials (RR=1.27, p=O.O05) and the Prevention Trial (RR=l.44, 
p=O.O02). 
Conclusion: Smoking was associated with increased hospitalization rate for h&art failure 
in SOLVD. This effect was most pronounced in patients with ischemic etiology in the !+e- 
vention Trial. 
1098-64 Serum Total Cholesterol, High-Density Lipoprotein, and 
Prognosis in Patients With Chronic Heart Failure 
Math+ Rauchhaus, Wolfram Doehner, Constantinos H. Davos, Rakesh Sharma, Aidan 
Bolger, Heike Gabriel, Michael Kemp, Andrew J. S. Coats, Stefan D. Anker. NHLI, Clinical 
Cardiofogv London, United Kingdom, Martin-Luther-Universit~t Ha//e-Wittenberg, Klinik 
ftir here Medizin I//, Ha//e/Saa/e, Germany 
Background: We have recently identified low cholesterol to be predictive for increased 
mortality in chronic heart failure (CHF). The aim of this study was to prospectively vali- 
date this finding. Methods: In 114 CHF patients (age 63~1 years, mean+SE, 62% 
ischemic etiology) prospectively enrolled in a derivation study, fasting cholesterol 
(5.2*0.1 mmolll), LDL (3.3+0.1 mmol/l), HDL (1.2+0.04 mmol/l), triglycerides (1.7+0.1 
mmol/l), and tumor necrosis factor receptor 1 (TNFRi, 1495+90 pgiml) were measured, 
Severity of CHF was assessed by NYHA class (l/ll/lllllV:n=l l/34/54/15), MV02 
(17.010.6 ml/kg/min), and ejection fraction (EF, 29+_1%). With the low cholesterol hypoth- 
esis in mind, a second independent CHF population (n=375, age 61r0.7 years) was 
enrolled. Results: During follow-up (40+32 months), 49 patients died (43%) in the deriva- 
tion study. Established CHF prognosticators such as MV02, NYHA class (both pcO.OOi), 
and EF (p<O.Ol) predicted mortality. TNFFil (p<O.OOOl), age (p=O.OOl), and low choles- 
Far01 (p=O.O3) were also predictive. In multivariate analysis, TNFRI (p=O.OOOl), EF 
(p=O.O05), MV02 (p=O.O05), and low cholesterol (p=O.O06) remained related to 
increased mortality, independently of age (p=O.lO), liver and kidney function, and stratifi- 
cation for CHF etiology. Using the best cut-off for survival status at 6 months follow-up, 
MV02 (p=O.O03), TNFRI (p=O.O16), and low cholesterol (p=O.OZi) together predicted 
mortality with high sensitivity (87.5%) and specificity (70.4%). At 12 months, TNFRl 
(p=O.O003), low cholesterol (p=O.OOO$), EF (p=O.OOl), and MV02 (~~0.005) predicted 
mortality more powerfully (sensitivity 80%, specificity 82%). In the validation study, 154 
patients (42%) died and low cholesterol was predictive in both univariate (p=O.OOOZ) and 
multivariate analysis (p=O.O065), independently of serum sodium (pcO.OOOl), kidney 
function (p=O.O003), and age (p=O.O17). Sensitivity and specificity for low cholesterol to 
predict mortality at 6 months was 81% and 61% (12 months: 72% and 63%). HDL was 
not related to mortality in either studies. Conclusion: In CHF, low cholesterol may be 
related to increased mortality. 
1098-65 The Independent Prognostic Impact of Decreased High 
Density Lipoprotein Levels in Severe Heart Failure 
Mandeep R. Mehra, Patricia A. Uber, Myung H. Park, Robert L. Scott, Richard V. Milani. 
Ochsner Cardiomyopathy and Heart Transplant Center, New Orleans, LA 
Background: High Density Lipoproteins are known to interact with cytokine induced 
adhesion cell molecule elucidation and in influencing the generation of prostacyclin via 
cyclooxygenase stimulation, both pathophysiological events that are implicated in the 
natural history of chronic heart failure. 
GtOUD Left Ventricular Bilirubin Sodium Pulmonarv Vascular Event 
Ejection Frac- mg/dl (mEq/dl) Resist&e (woods Free 
tion % units) 
High Density 20+8 1.2+_.9 135*6 2.4+.8 69% 
Lipoprotein 
< 33 mg/dl 
High Density 21*11 0.7+0.4 137+4 1.71.8 83% 
Lipoprotein 
233 mg/dl 
p value “.5 ns 0.01 0.003 0.0006 
Conclusion: This is the first investigation to demonstrate that decreased High Density 
Lipoproteins levels are strongly predictive of clinical worsening in severe heart failure. 
Whether this finding represents a mere risk marker or a potential therapeutic target, 
remains to be elucidated. 
1098-67 Complete Left Bundle-Branch Block (LBBB) Is Associated 
With Increased l-Year Mortality in Patients With Congestive 
Heart Failure (CHF): Data From IN-CHF Registry 
Samuele Baldasseroni, Cristina Opasich, Marco Gorini, Niccolb Marchionni, Carlo 
Campana, Antonella Deorsola, Giulio Masotti, Luigi Tavazzi, Aldo F! Maggioni. ANIXIO 
Research Center, Florence, ttal~ Dept. of Critical Care Medicine and Surgery Section of 
Geriatric Medicine, University of Florence, Florence, /ta/y 
Introduction: prevalence of CHF is increasing over the world. Many clinical features have 
been proposed as prognostic factors in patients with CHF. Among these, the independent 
effect of complete LBBB on mortality is still debated. The aim of this analysis was to 
determine whether LBBB is an independent predictor of mortality in patients with CHF. 
Methods and Results: data for the present analysis were derived from the database of 
the IN-CHF Registry, that was set up by the Italian Association of Hospital Cardiologists 
to analyze the clinical characteristics and trace the follow-up of outpatients with CHF 
diagnosed according to the ESC guidelines. LBBB was diagnosed when a QRS >140 
msec was associated with morphological criteria. Thus, we analyzed the l-year follow-up 
data of 5,517 patients with CHF of different etiologies excluding patients with valvular dis- 
ease or undergoing cardiac transplantation. The underlying cardiac disease was 
ischemic heart disease (45.6%), dilated cardiomyopathy (36%), hypertensive heart dis- 
ease (12.9%), while other etiologies were recognized in 5.5% of cases. LBBB was 
present in 1,391 (25.2%) patients and was associated with an increased l-year mortality 
from any cause (HR: 1.70; 95%CI: 1.41-2.05) and sudden death (HR: 1.58; 95%CI: 1.21- 
2.06). Patients with LBBB had more frequently a dilated cardiomyopathy and a more 
severe clinical status as indicated by worse NYHA class, lower LV ejection fraction, more 
frequent hypotension, 3rd heart sound, increased C/T ratio, atrial fibrillation, and pre- 
scription drugs (p<O.OOl for all comparisons). Multivariate analysis demonstrated that 
LBBB still retained its unfavorable prognostic effect even after adlusting for age, underline 
cardiac disease, all indicators of disease severity and drug prescription (adjusted HR: 
1.36; 95%CI 1.15-l .61). Conclusions: LBBB is a marker of unfavorable prognosis. Such 
association is independent of the severity of CHF and treatment. These data support that 
the hypothesis use of biventricular cardiac pacing might improve survival in patients with 
CHF and LBBB. 
1098-68 Right Ventricular Function Is a Predictor of Outcome in 
Patients With Left Ventricular Dysfunction After Myocardial 
Infarction. The Survival and Ventricular Enlargement Trial 
LeonardoZornoff, Hicham Skali, Martin St. John Sutton, Jean Rouleau, Gervasio Lamas, 
Sandra Lewis, Ted Plappert, Jacques Rouleau, Lemuel Moye, Marc Pfeffer, Scott 
Solomon. Brigham and Women’s Hospital, Boston, MA 
Background: Right ventricular function has betm shown to predict exercise capacity, 
autonomic imbalance, and survival in patients with advanced heart failure. The aim of 
this study was to determine the prognostic value of right ventricle function in patients fol- 
lowing myocardial infarction. Methods: The Survival and Ventricular Enlargement study 
consisted of 2231 patients with acute myocardial infarction and left ventricular dysfunc- 
tion (ejection fraction <40%), who were randomized to treatment with captopril or pla- 
cebo. Two-dimensional echocardiograms were obtained in 416 patients from the echo 
ancillary study (mean 11 .l +I- 3.2 days post-infarction). Right ventricular areas from the 
apical 4-chamber view were digitized at end-diastole and end-systole. Right ventricular 
function was assessed as percent change in cavity area from end-diastole to end-systole 
(fractional area change) and related to outcomes in univariate and multivariate analyses. 
Results: Right ventricular function correlated only weakly with left ventricular ejection 
fraction (rzO.12, p=O.O13). In univariate analyses, right ventricular fractional area change 
was a predictor of mortality, cardiovascular mortality, and congestive heart failure (p < 
O.OOOl), but not recurrent myocardial infarction (p=O.7154). After adjusting for age, gen- 
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der, diabetes meilitus, hypertension, prior myocardial infarction, nuclear and echocardio- 
graphic left ventricular ejection fraction, peak creatine kinase, cigarette use and 
treatment assignment, right ventricular function remained an independent predictor of 
total mortality, cardiovascular mortality and congestive heart failure in a Cox proportional 
hazards model. Each 5% decrease in right ventricular fractional area change was associ- 
ated with a 16% increased odds of cardiovascular mortality (95% Conf&?nce Interval, 
4.3% to 29.2%; p=O.O06). Conclusions: Right ventricular function is a powerful and inde- 
pendent predictor of death and/or the development of heart failure in patients with left 
ventricular dysfunction after myocardial infarction. 
1098-69 A Prediction Model for Mortality and Hospitalizations Based 
on a Cohort of 7274 Patients With Congestive Heart Failure 
tone group and 19 in the placebo group). The table shows the different p values of the 
HRV variables in 3 different categol-ies: death vs. alive and comparison between treat- 
ment groups spironolactone (SP) vs. placebo (PL) at 3 and 6 months. Conclusion: The V 
index measuring the very rapid fluctuations of heart rate was able to distinguish patients 
who died vs. survivors. It increased significantly in patients who received SP compared to 
PL at 3 and 6 months. No difference was observed in any of the 24-hour classical HRV 
parameters either for distinguishing survivors vs. non-survivors or between patients 
receiving SP and PL. In contrast, during the 4.hour night period, non-survivors had a 
lower parasympathetic activity, as assessed~by pm150 and InHE SDNN increased signifi- 
cantly in patients treated with spironolactone at 3 months, but not in those receiving pla- 
cebo. The reduction of mortality observed in RALES study with spironolactone may be in 
part related to enhanced parasympathetic activity. 
James Brophy, Gil& R. Dagenais, Frances McSherry, William Williford, Salim Yusef. 
Centre hospitaiier de Wniversit~ de Mont&l, Montreal, PQ, Canada 
24 hour V index 
4 hour SDNN 
Death versus alive SP vs. PL 3 months SP vs. PL 6 months 
0.02 0.007 <O.OOl 
NS 0.04 NS 
Background: Congestive heart failure (CHF) is a leading cause of ,patient morbidity and 
mortality but reliable models to predict patient outcomes in the angiotensin converting 
enzyme (ACE) inhibition era are lacking. Methods: Multivariate statistical modelling of the 
7274 patients who were taking ACE inhibitors on entry into the DIG cllnical trial and sub- 
sequently followed for a mean time of 3 years. The outcome measures were total mortal- 
sty and hospitalization due to CHF. Results: The total mortality of this cohort was 419 
(5.8%), 788 (10.8%) and 2067 (28.4%) at 6, 12, and 36 months respectively. Long-term 
mortality was statistically associated with male gender (Hazard ration (HR) 1.24, 99% Cl 
1.07.1.43), older age (HR 1.14 (I.07 - 1.23). cardiomegaly (HR 1.45 (1.28 - 1.66)), wors- 
ening NYHA class (HR 1.36 (1.23 - 1.50)), and diabetes (HR 1.27 (1.13 - 1.45)). A low 
ejection fraction (HR 1.26 (1.16 - 1.36)) and impaired renal function (HR 1.74 (1.50 - 
2.02)) were sustained predictors of both increased mortality and of the combined end- 
point. Race, etiology and most clinical signs and symptoms of CHF were not independent 
predictors of outcomes. Conclusions: This study reveals Ihe contemporary,natural history 
of the largest cohort of patients with established CHF yet studied. The main clinical pre- 
dictors of adverse patient outcomes have been identified. 
1098-72 Obesity Does Not Impact Survival of Patients With 
Advanced Heart Failure: Analysis of 1021 Patients 
Tamara 9. Horwich, Gregg 6. Fonarow, Michele A. Hamilton, Mary A. Woo. UCLA 
Medical Center, Los Angeles, CA 
Background: Previous reports link obesity to the development of heart failure (HF). 
However, the effect of obesity on mortality in patients with established HF has not been 
studied. 
1098-70 Increasing Pulse Pressure Contributes to Lifetime Risk of 
Congestive Heart Failure 
Donald M. Lloyd-Jones, Martin G. Larson, Alexa Beiser, Ralph 9. D’Agostino, 
Ramachandran S. Vasan, Emelia J. Benjamin, Daniel Levy. NHLWs Framingham Heart 
Stud% Framingham, MA, Massachusetts General Hospital, Boston, MA 
Background: Lifetime risk calculation allows estimation of the absolute risk of developing 
a given disease before dying of another cause With the aging of the population, conges- 
tive heart failure (CHF) is becoming a major public health concern, and pulse pressure 
(PP) appears to be a risk factor for CHF. However, there have been no estimates of the 
lifetime risk of CHF based on PP levels. Methods: We included all subjects in the 
Framingham Heart Study who were examined from 1971.1996 and were free of CHF at 
baseline. Each subject was classified according to the average of all PP measurements 
in the 6 years prior to index ages of 50, 60, and 70 years, disregarding treatment status. 
Subjects were classified into groups based on PP as follows: Group 1 (PP ~45 mmHg); 
Group 2 (PP 45-64 mmHg): and Group 3 (PP >65 mmHg). Lifetime risk of CHF was cal- 
culated for each group, with death free of CHF as a competing event. Results: We fol- 
lowed 3303 men and 3919 women; 618 developed CHF and 2035 died free of CHF. The 
remaining lifetime risk of CHF at each index age is shown in the Table, by sex and base- 
line PP group. There was a stepwise increase in lifetime risk of CHF with increasing PP 
at all ages, resulting in approximately P-fold risk for subjects in the highest verssus lowest 
PP groups. At age 60, subjects in the highest PP group had a remaining lifetime risk of 
nearly 1 in 3 for the development of CHF. Conclusions: Lifetime risk of CHF increases 
with increasing PP for men and women at each age. Thus, elevated PP may identify 
patients at high risk for CHF in the long term, who may benefit from aggressive therapy 
aimed at blood pressure reduction. 
Methods: We analyzed a cohort of 1021 patients with advanced HF referred to a single 
center for transplant evaluation and followed in a comprehensive heart failure manage- 
ment program. The cohort was 76.4% men, with mean LVEF 23%. Body mass index 
(BMI) calculations used weight after Swan Ganz catheter guided unloading therapy. 
Patients were subdivided into BMI categories defined as underweight BMI =< 20.7, rec- 
ommended BMI 20.7-27.7, overweight BMI 27.8. 31 .O and obese BMI >= 31 .I. 
Results: Mean BMI was 28.6, and 14.7% of patients fell into obese BMI category. The 
four BMI groups had similar profiles in terms of ejection fraction, serum sodium, albumin, 
urea nitrogen and creatinine levels, smoking history, and history of sudden death. The 
obese group had a significantly younger mean age than the full study cohort (48.5 vs. 
52.1) and the obese and overweight groups had significantly higher rates of hypertension 
and diabetes, higher levels of cholesterol, triglycerides, and LDL, and larger LVEDD. 
Univariate analyses showed no association between BMI and survival, and the four BMI 
subgroups had similar 1, 2, and 5 year survival. Percent ideal body weight was also not 
predictive. In multivariate analysis, ACEI use, CAD, PCW pressure, and serum sodium 
level predicted survival, but BMI did not. 
Conclusions: In a large cohort of patients with advanced HF of multiple etiologies, obe- 
sity is not associated with increased mortality. Further studies need to delineate whether 
weight loss promotion in medically-optimized heart failure patients is a worthwhile thera- 
peutic goal. 
Lifetime risk through age go(*); through age 94(A). 
Lifetime Risk of CHF by PP: Men Lifetime Risk of CHF by PP: Women 
Index Age Group 1 Group 2 Group3 Group1 Group 2 Group 3 
50’ 15.2% 25.0% 29.9% 13.4% 19.0% 24.6% 
6w 15.6% 19.7% 32.7% 9.3% 19.7% 29.7% 
7w 17.0% 19.1% 25.1% 14.1% 15.7% 24.9% 
1098-73 Novel Effect of Long-Term Digoxin Therapy on Heart Rate 
Variability in Patient With Chronic Atrial Fibrillation: A 
Prospective Study 
Anselma Intini, Naab Al-Saady, Yee Guan Yap, Johan Waktare, Mandy Graham, Bryan 
Mist, Marek Malik, A. John Camm. St. George’s Hospital Medical School, London, United 
Kingdom 
1098-71 The Beneficial Effect of Spironolactone on Heart Rate 
Variability in Severe Congestive Heart Failure 
Ali R. Bilge, Badreddine Ahmadoun, Pierre Block, Daniel Duprez, Agnessa Babloyantz, 
Luc A. Pierard. University hospital cardiology department, Liege, Belgium, Brussels 
University Soivay Institute, Brussels, Beigium 
Background : Improvement of parasympathetic activity is one of the potential mecha- 
nisms explaining the results of RALES study. Classical and non-linear analysis of heart 
rate variability was pertormed in the Belgian RALES population. Methods : 24-hour Halter 
recordings were obtained before randomization and after 3 and 6 months. We performed 
temporal, spectral and non-linear analysis. The latter evaluates successive RR intervals 
and 2 measures were defined: 1. The regularity index R, the percentage of RR intervals 
not exceeding 16 msec of difference between 3 consecutive beats 2. The variability index 
V, which is the ratio of the systematic increase and decrease of three consecutive RR 
intervals over the remaining beats. Temporal and spectral parameters were assessed 
during both 24 hours and a 4 hour night period (from’0 to 4 h a.m.) where hourly prema- 
ture beats rate was reduced. Results: 66 patients were studied at baseline and 18 died 
during the study period. The 3 Halters were obtained in 42 patients (23 in the spironolac- 
Background: It is well known that reduced heart rate variability (HRV) during sinus 
rhythm is associated with an adverse prognosis in a variety of clinical settings. Pharma- 
cological interventions that augment HRV, in particular the vagal component, can be ben- 
eficial and may be protective against arrhythmic cardiac mortality. Recent data suggest 
that HRV appears to be a measure of vagal tone in patients with atrial fibrillation (AF). 
However, a paucity of data exists regarding the effect of pharmacological treatment on 
HRV in these patients. The aim of this study was to investigate the effect of long-term 
digoxin administration on the circadian fluctuations of HRV during AF. Methods: The 
study population consisted of 10 patients (3 men and 7 woman: range 66-74 yr) with par- 
sistent AF. HRV (SDNN: standard deviation of RR intervals- a measure of sympathovagal 
modulation; and RMSSD: root-mean-square of successive difference- a measure of 
vagal tone) was analyzed prospectively from 24-h Halter recordings while on digoxin for a 
minimum of 6 months and after wash-out. Results: 24-hour HRV parameters showed a 
significant increment during the evening to early morning period (18:OO - 1O:OO hr for 
RMSSD: p=O.O5 to p<O.OOl; 1800 - 07:OO hr for SDNN: ~~0.05 to p=O.O04) while on 
digoxin compared with wash-out state but not during the daytime period (figure). The dif- 
ference is more pronounced for RMSSD, which is a more accurate measure of vagal 
tone. Conclusion: This study showed for the first time that long-term therapy with digoxin 
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enhances cardiac vagal tone in the setting of AF. Digoxin treatment may have a novel 
protective effect in the prevention of arrhythmic death, particularly in the early morning 
period when sudden death is likely to occur. 
ia-issd 
WE (hours) 
1098-74 Heart Failure in a Veteran Cohort: Predictors of Outcome 
Maria N. Ansari, Aii Tutar, Jean Bullard, John R. Teerlink, Barry M. Massie. San 
Francisco VAMCAJCSF; San Francisco, CA 
Background: Survival estimates in CHF patients are highly variable depending upon the 
population studied and methodology used. Most data are derived from epidemiology 
studies, in which limited information is available about patient characteristics, or clinical 
trials thai have highly selective entry criteria. Therefore, we examined survival rates in a 
well-characterized unselected outpatient cohort. 
Methods: Charts of consecutive VA outpatients (n=417) with a CHF diagnosis from 71 
98-12198 were reviewed and survival was examined through 512000. 42 were excluded 
because of lack of CHF by Framingham criteria or lack of follow-up within the VA system. 
Determinants of survival were assessed by proportional hazards models lhat included 5 
clinical and treatment variables. 
Results: In 375 patients (mean age 72, 96% men), EF was reduced (~45%) in 66%, pre- 
served (~45%) in 27%, and unknown in 7%. Survival in the total cohort was 79.5% after 
a mea” of 20 months, and was not significantly different in the low and preserved EF 
subgroups (79.8% and 80.2% respectively). Significant predictors of mortality and the 
associated hazard ratios are shown in the table. 
Conclusions: Mortality in this cohort was similar to class II-IV trial patients with low EF, 
and surprisingly was similar in low and preserved EF groups. Severe renal dysfunction 
was the most significant adverse predictor. Interestingly, low SBP was a” adverse predic- 
tor in low EF patients, whereas high SBP was associated with higher mortality in pre- 
served EF patients. Treatment by a cardiologist was associated with improved survival. 
ACE inhibitor therapy, but not beta-blocker treatment was associated with better survival 
in low EF natfents. 
Significant Predictors of Survival and Hazard Ratios with 95% Confidence 
intervals 
Total Cohort EF <1x=45% EF >45% 
n=375 n=248 WI01 
Cn2.5mgidl 3.0 (Cl 1.7-5.3) 3.2 (Cl 1.5-6.8) 3.+ 1.4-9.5) 
Age (per decade increment) 1.4(CI 1.1-1.9) 1.5 (Cl 1.1-2.0) 
SBP (per IOmmHg increment) 1.04 (Cl 1.0-l .I) 0.87 (Cl X9-.95) 1.07 (Cl 1.0-l .I) 
ACE I use 0.47 (Cl .26-.84) 
Cardiology Provider 0.54 (Cl .31-.95) 0.48 (Cl .25-.93) 0.39 (Cl .12-1.39) 
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1099-45 Implications of Symptomatic, Hemodynamic, and EKG 
Changes During Exercise Stress Testing in Patients With 
Aortic Stenosis: Relationship to Coronary Artery Disease 
Luc M. Beauchesne, Kwan L. Ghan, Kathy J. Ascah, Ian G. Bum/ash. University of 
Oftawa Heart Institute, Ottawa, Canada 
Background: Recently, exercise stress testing (EST) has been increasingly utilized in the 
assessment of patients with aortic stenosis (AS). However in AS patients, the relation- 
ship of the EST responses to CAD is unclear. Methods: In 47 consecutive pts with mod- 
erate isolated AS (AVA < or =1.2 cm2, Al < or =I+) undergoing treadmill EST and 
coronary angiography, we investigated whether any symptomatic, hemodynamic or EKG 
response during treadmill EST predicts obstructive CAD (> or =70% stenosis in > or =l 
large or medium-sized epicardial artery). Results: One pt was excluded because of rest- 
ing LBBB. Of ihe remaining 46 pts, 21 pts (46%) had obstructive CAD and 25 pts (54%) 
were free of obstructive CAD (non-CAD). CAD and non-CAD groups were similar for age 
(70+9 vs 66~1 lyrs, p=NS), valve area (0.79iO.28 vs 0.78?0.20 cm2, p=NS), history of 
angina (86 vs 68%, p=NS) and use of negative chronatropic meds (57 vs 44%, p=NS). 
The CAD group tended to have a lower maximum achieved workload compared to the 
non-CAD group (3.4a2.4 vs 4.6r2.8 mets, p=O.13), however functional impairment was 
similar (59r41 vs 66r39% of predicted workload, p=NS). Angina during EST developed 
I” 38% of the CAD group and 28% of the non-CAD group (p=NS). Maximum ST segment 
depression from baseline was similar in the CAD and non-CAD groups (1.0*0.9 vs 
0.9+1.3mm, p=NS) despite correcting for exercise workload achieved (2.1i2.3 vs 1.5&2.0 
mm/lOO% predicted workload, p=NS). EST were positive for ischemia (> or =lmm ST 
depression) in 42% of the CAD group and 32% of the non-CAD group (p=NS). CAD and 
non-CAD groups were similar for the development of > or =2 mm ST depression (19% vs 
20%. p=NS), total “umber of positive leads (1.722.5 vs 1.4+2.4 lead, p=NS) and time io 
ST segment normalization during the recovery period (484i53 vs 45it.98 sew, p=NS). 
The development of systolic hypotension during exercise (BP fall zlOmmHg) dtd not pre- 
dict coronary status (26% CAD vs 16% non-CAD, p=NS). No adverse events occurred 
with treadmill EST. Conclusions: Treadmill EST can be safely performed in patients with 
moderate or severe AS. However, symptomatic, hemodynamic and ECG responses dur- 
ing EST provide no information on the presence or absence of concomitant obstructive 
CAD. 
1099-46‘ Effects of Atrial Flutter on Exercise Tolerance in Adult 
Congenital Heart Patients 
Wei Li, Michael Y. Hen&, Jane Somerville. Royal Brompfon Hospital, London, United 
Kingdom 
Background: Atrial flutter (AFL) is a frequent complication in adult congenital heart 
patients and leads to deterioration of patients’ effort tolerance and Ability Indices. Meth- 
ods: Exercise tests using modified Bruce protocol were performed in 20 consecutive 
such patients during AFL and again 24-48 hours after DC conversion to sws rhythm 
(SR). Basic abnormalities of the patients were one ventricle 9 (5 with Fontan type sur- 
gery), transposition of great arteries 4 (3 had Mustard and 1 arterial switch), hypertrophic 
cardiomyopaihy (HCM) 3, closed atrial septal defect 2 and others 2. Age at study was 21 
to 62 years, 11 female. AFL presented for 2-21 (mean 7) days; first attack in 4 and subse- 
quent in 16 who were on antiarrhythmics. Results: 
Exercise test AFL SR P value 
Duration (min) 6.4+1-4.1 Ii +/-3.7 <O.OOi 
Heart rate at rest (bpm) 106+/-21 110+/-14 <O.OOi 
Heart rate at peak (bpm) 157+/-31 129+/-24 40.01 
Delta systolic BP (mmHg) 51-1-24 23+/-l 6 <O.Ol 
Oxygen saturation at rest (%) 91+/-10 91+/-7 NS 
Oxygen saturation at peak (%) 79+/-22 81+/-14 NS 
During AFL, delta systolic BP (mean&D = -16*5.5 mmHg) of patients with Fontan repair 
was significantly lower than the rest patients (13*11 mmHg), P<O.OOl. Exercise test was 
limited by pre-syncope in 415 Fontan and 1 arterial switch patients. Heart rate was over 
200 beat/minute within 0.5 to 12 minutes (mea” 6) in 5 patients (415 without antiarrhyth- 
mics). With SR exercise was stopped due to fatigue in 19/20 patients and target rate in 1/ 
20. Conclusion: Atrial flutter causes significant reduction in exercise tolerance in adult 
congenital heart patients and results in syncope from hypotension and high heart rate in 
those with Fontan. Marked improvement in effort tolerance occurred after regaining SR. 
Thus, it is important to return and maintain SR in these patients. 
1099-47 Safety of Cardiac Rehabilitation for Defibrillator Recipients 
Bradley P. Knight, Al McAuley, Melvyn Rubenfire, Radmira Greenstein, Chi-Wo Ghan, 
Kristina Wasmer, Christian Sticherling, Robert L. Baker, Steven P Chough, Hakan Oral, 
Frank Pelosi, Jr., Fred Morady, Adam Strickberger. University of Michigan, Ann Arbor, MI, 
Oakwood Hospitals, Dearborn, MI 
Background: Cardiac rehabilitation (CR) has been shown to be beneficial for pts with 
heart disease. However, there are little dais regarding the safety of a” exercise training 
program for pts with an implantable defibrillator. 
Methods: Seventeen pts with a” implantable defibrillator were enrolled in a g-month CR 
program as part of a prospective study designed to determine the safety of exercise train- 
ing in defibrillator recipients. Pts with exercise-induced ventricular arrhythmias, hyper- 
trophic obstructive cardiomyopathy, and severe aortic stenosis were not included. The 
mea” age of the pts was 54ili years,,94% were male, and 59% had coronary artery dis- 
ease. The mea” ejection fraction was 0.28+0.12, and 53% of pts had congestive heart 
failure. Fifty-nine percent were being treated with beta-blocking drugs, and 35% were 
being treated with amiodarone. The mea” time from defibrillator implantation to initiation 
of CR was 8.2A9.5 months. The mea” difference between the age-predicted, maximum 
HR and the defibrillator cut-off rate was 7?13 bpm (the cut-off rate was below the age- 
predicted, maximum HR in 5 pts). A symptom-limited exercise treadmill test was per- 
formed in each pt before enrollment in CR with the maximum HR limited to 10 beats less 
than the defibrillator cut-off rate. Exercise prescriptions were based upon the Karvonen 
equation. Pts were scheduled to undergo ECG-monitored exercise for 60 minutes, 3 
times per week for 2 weeks, followed by unmonitored, supervised exercise for 90 min- 
utes, 2 times per week for 22 weeks. 
Results: The mean MET capacity during treadmill testing was 7.3i4.2 METS and the 
peak HR was 125?29 bpm. Pts underwent 2.3*1.8 months of CR (92 participant-hours of 
monitored exercise and 118 participant-hours of unmonitored exercise). No cardiac com- 
plications occurred during or within 24 hours of exercise. The mea” number of defibrilla- 
tor therapies/month during the 6 months prior to enrollment in CR was 0.5fl.7 compared 
to 0 therapies/month following enrollment (p=O.24). 
Conclusion: Cardiac rehabilitation appears to be safe in pts with a” implantable defibril- 
lator. Further study is needed to determine if exercise training reduces the frequency of 
defibrillator therapies. 
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1099-48 A Randomised and Controlled Trial of Beta Blockers for the 1100-50 The Effects of Beta Blockade on the Cardiac Ryanodine 
Treatment of Recurrent Syncope in Patients With a Positive Calcium Release Channel in an Animal Model of Heart 
or Negative Response to Head-Up Tilting Test Failure 
Rodoifo Ventura, Renke Maas, Daniel &idler, Andreas Schuchert. Thomas Meinertz. 
Department of Cardiology, University Hospital Eppendorf, Hamburg, Germany 
Background: The efficacy of betablockers in preventing syncope is controversial. Previ- 
ous trials with betablockers only assessed patients (pts)with a positive result of head-up 
tilting test (HUT). Thus, the value of HUT in predicting the efficacy of therapy has not 
bee” assessd yet. Methods: 56 pts (36 female, 44t18 years) with recurrent syncope (> 1 
event in the last 6 months) of suspected neurocardiogenic origin were included in the 
study. Independently from the response to HUT pts were randomised to metoproloi or 
propanolol (28 pts, group A) at the maximal tolerated dose (86-+23 and 98+29 mgid, 
respectively) or to no pharmacological therapy (28 pts, group B). Pts of group 6 were 
requested to drink sufficiently, to weal. elastic stockings, and in case of prodromal symp- 
toms to assume supine position with the feet elevated. Primary end-point was the first 
recurrence of syncope. Results: During 1 year of follow-up 20 pts of the group A had no 
recurrence while 8 experienced further syncopal events. Conversely, in the group B 20 
pts had recurrences and 8 remained free of symptoms. In the group A, of 8 pts with 
recurrences 5 had a positwe and 3 had a negative response to HUT while of 20 pts with- 
out recurrences of syncope 12 had a positive and 8 a negative HUT result. In the group 6 
of 20 pts with recuwnces 10 had a positwe and 10 a negatwe HUT result while of 8 rjts 
without recurrences 4 had a positive and 4 a negative response to HUT. Conclusions: 
B&blockers are efficacious in preventing recurrent syncope of suspected neurocardio- 
genie origin. The efficacy of therapy seems to be not predicted by HUT. 
Alfonso F. J. Prieto, Steve Reiken, Steve 0 Marx, Marta Gaburjakova, Jana Gaburjakova, 
Jie Wang, Kun Lun He, Geng Hua Yi, Daniel Burkhofi, Andrew R Marks. Columbia 
Universify College of Physicians & Surgeons, New York, NY 
Background: Limited data is 
available on how beta blockers 
exert their beneficial clinical 
effect in heart failure (HF) at the 
cellular level. The cardiac intrac- 4 - :: 
ellular calcium release channel 
(ryanodine receptor, RyR2) has %I : 
been recently reported to be $5 : 
hyperphosphorylated and dys- 
functional in HF, leading to 
abnormal &kium handling. We 
g o 
propose that beta-blockade can 
reverse the hyperphosphory- 
lated dysfunctional state of 
RyRP. Methods: Normal, HF (rapid cardiac pacing-induced), HF with beta-blocker admin- 
istration mongrel dogs were compared. Severe HF was documented with a -43% reduc- 
tion in LV dP/dt max (to -1800 mg Hg/s), -18% reductions in peak LVP (to -112 mm Hg), 
-22% drop in mean aortic pressure (to -87 mm Hg) , -27% increase in resting heart rate 
(to -115 beatslmin), and a rise in end-diastolic pressure to > 18 mm Hg. Beta blocker 
administration, hemodynamics, cardiac homogenates, immunoprecipitation, back-phos- 
phorylation, single channel recordings of RyR2, and immunoblots were performed as 
previously described. Results: Figure 1 demonstrates the relative PKA phosphorylation 
of RyR2 in normal (n=2), heart failure (n=6), and heart failure with beta blocker (n=4) 
dogs. There was a” approximately four-fold increase in RyR2 phosphorylation in the HF 
dogs, and beta blocker treatment in HF dogs normalized RyRZ phosphorylation. Single 
channel recordings of RyR2 demonstrate a significantly increased open probability and 
subconductance states in the HF dogs. RyR2 single channel properties were normalized 
I” the beta blocker treated dogs. Conclusions: We conclude that in HF, RyR2 is hyper- 
phosphorylated and dysfunctional. Administration of beta blockers in HF dogs restores 
normal RyR2 phosphorylation and function. This data helps to elucidate the molecular 
mechanisms to explain the clinical benefits of beta-blockers in HF, and may lead to navel 
approaches for the treatment of HF and arrhythmias. 
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1100-49 Preserved Efficacy of Metoprolol in Patients With Heart 
Failure Homozygous for the Hypofunctional Gly389 Variant 
of the Betal-Adrenergic Receptor. A Substudy of the 
MERIT-HF 
Rudolf A. De Boer. Yigal M. Pinto, Corine Volkers, Robert H. Henning, Edith Olthof, 
Alistair S. Hall, Wiek H. Van Gilst, Reinhold Kreutz, Dirk J. Van Veldhuisen. University 
Hospitai, Thoraxcenter, Department of Cardiology Groningen, The Netherlands, 
University of Groningen. Department of Clinical Pharmacology, Groningen, The 
Netherlands 
Background-A Giycine for Arginine substitution in codon 389 (G>C) has been associ- 
ated with decreased sensitivity of the betal-adrenergic receptor (BARl) in in-vitro stud- 
ies. Since beta-blockade is useful in chronic heart failure (CHF), we hypothesized that 
homozygosity for this hypofunctional variant might modulate the effects of selective beta- 
blockers in CHF. Methods --We studied 287 CHF patients enrolled in the MERIT-HF trial. 
DNA was isolated from blood cells. We analyzed the relation between BAR1 genotype 
and ciinlcal characteristics and response to beta-blockade. Results -- There were 156 
patients with the CC, 110 with the GC, and 21 with the GG genotype. We compared 
patients with the CC and the GG genotype. At baseline, heart rate (HR) was higher in 
patients with the GG genotype (87-cl4 bpm) than in those with the CC genotype (82~11 
bpm, p=O.O5). When assessing the response to metoprolol, GG patients showed a more 
pronounced decrease in HR than CC patients (-19110 vs.-15+11 bpm, p<O.O5), they 
were generally titrated to higher dose (162t73 vs. 145i63 mg. p&33) and they seemed 
to reach the target dose of 200 mg more often (75% vs. 54%, p=O.17), resp. Event free 
survival was improved by metoprolol in all genotypes Conclusions - In this exploratory 
study in patients with CHF, the GG genotype of the BAR1 was found to be associated 
with an increased HR, while it showed a different response to beta-blockade. We specu- 
late that this genetic variant of the BAR1 may be of influence in CHF and that patients 
homorygous for the hypofunctional Gly389 type BAR1 may particularly benefit from beta- 
blockade 
1100-51 Influence of Long Term Treatment With Carvedilol and 
Metoprolol on &Adrenergic Signal Transduction and 
Intracellular Calcium Handling in Cardiomyopathic 
Hamsters 
Karsten Filzmaier, Ulrich Schotten, Carsten Hoeper, Eckard Picht, Mireille Van Helden, 
Bemd Koenigs, Miriam Vogel, Ruediger Blindt, Peter Hanrath. University Hospital 
Aachen, Aachen, Germany 
Background: The evidence for the beneficial role of B-adrenoceptor antagonists in the 
management of chronic heart failure is now substantial. However, underlylng mecha- 
nwns are not well understood. We investigated the influetice of long term oral application 
of the O-adrenoceptor antagonists Carvedilol (CD) and Metoprolol (MP) on O-adrenerglc 
signal transduction and intracellular calwm transients in 810 14.6 cardlomyopathic ham- 
sters and FIB normal control hamsters. Methods: Cardiomyopathic hamsters were 
treated with CD, MP or Placebo (PL) for 50 days. 1 baseline-group of CMH (BL) and the 
normal hamsters were not treated. BL hamsters were sacrificed when treatment started 
in the other groups. Force (FC; mNlmm2) and time of contraction (TC, set) was mea- 
sured in left ventricular Isolated papillary muscles. Stimulation with lsoprenaline (ISO; lo- 
lo-105 mM), Calcium (CA: 1.8-12.6 mM) and a force frequency (FF; 0.5-3 Hz) was per- 
formed. In isolated cells calcium transients were measured by FURA II during FF. Protein 
levels of inhibitory and stimulating G-Protein (Gi,Gs), Calsequestrln (CQ), Phospholam- 
ban (PL) and Calcium-ATPase of the sarcoplasmatic reticulum (SERCA) were deter- 
mined by Western blot analysis. Results: All groups showed maximum FC at 10-6 mM 
ISO, 0.5 Hz or 9 mM CA. There was no difference in diastolic or systolic FC and TC 
behwen the groups (e.g. increase in FC at 10-5 mM IS0 in %: CD 225+/-22; MP 204+1- 
22; PL 228+/- 31; BL 204+/-20; control Hamsters 196+/-38 (p>O,O5). Also no difference 
between diastolic and systolic intracellular calcium concentration and 75% decay time 
was seen on single cell level. The protein expression of Gi, Gs, CQ, PL and SERCA was 
not altered by the different treatments. Conclusion: Favourable effects I” treating chronic 
heart failure with B-adrenoceptor antagonists are presumably not due to changes in intra- 
cellular O-receptor signal transduction or calcium handling. These results challenge both 
the role of changes in O-adrenirgic sIgnaIling in failing myocardium and the importance 
of R-blocking properties of O-adrenoceptor antagonlsts as an explanation of their benefi- 
cial properties. 
1100-52 Chronic Therapy With Carvedilol Attenuates Cardiomyocyte 
Apoptosis in Dogs With Heart Failure 
Hani N. Sabbah, Ramesh C. Gupta, Suhdish Mishra, Victor G. Sharov, Anastassia Todor, 
Takayuki Mishima, George Suzuki, Sidney Goldstein. Henry Ford Health System, D&oil, 
MI 
Background: Chronic therapy with beta-blockers has been shown to improve LV ejection 
fraction, attenuate progressive LV remodeling and reduce mortality in patients with 
chronic heart failure (HF). In this study, we examined the effects of chronic therapy with 
carvediloi (GARV) on cardiomyocyte apoptosis in dogs with HF produced by intracoro- 
nary microembolizations. 
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Methods: Twenty four dogs with HF (LV ejection fraction 30%.40%), were randomized to demographic characteristics, medical history and AMI presentation. Results: Significant 
3 months therapy with low dose (LD) CARV (0.3 mg/kg Bid, 1x8) high dose (HD) CARV differences by age were observed. (p value of the Cochran-Armitage test for trend for all 
diomyocyte apoptosis was quantified as TUNEL positive cardromyocytes per 1000. LV 
homogenate was also used to examine the expression of the apoptosis-associated pro- 
teins B&Z, Bax, procaspase-3 (CPP32) and the active form of caspase-3, ~17. Bands 
from Western blots were quantified in densitometric units. 
Results: The results are in the table. 
PL LD-CARV HD-CARV 
(1.0 mg/kg Bid, n=8) or to placebo (PL, n=8). The incidence of cardiomyocyte apoptosis variables = 0.001 except prior AMI and hypertension for which p = ns). 
was assessed at the end of the study in LV frozen section using the TUNEL method. Car- Characteristics 65-69 yrs 70-74 yrs 75-79 yrs 80-84 yrs 85 yrs or 
older 
15.9 
35.0, 
48.0 
34.6 
% of Cohort 20.6 23.7 21.4 18.3 
Male Sex(%) 62.5 57.3 51.3 44.2 
Functional limitations(%) 11.3 15.3 23.0 32.1 
Prior heart failure(%) 13.0 16.2 20.7 26.3 
TUNELc per 1000 0.36* 0.04 0.20 f 0.02’ 0.09 i- 0.02’* 
B&2 0.9 s 0.2 1.9 f 0.4” 2.3 2 0.2’ 
Bax 0.7 f 0.1 0.9* 0.1 0.6 f 0.1 
CPP32 0.9 f 0.2 0.6* 0.1 0.4 s 0.1* 
Pf7 3.8 f 1.5 0.5 i 0.3’ 0.4io.1* 
Compared to PL, CARV reduced the number of TUNEL positive cardiomyocytes in a 
dose-dependent manner (*=Pr0.05 vs. PL; **= P<O.O5 vs. LD-CARV). Both doses of 
CARV were associated with increased 6~1-2, no change in Bax, and a decrease in 
CPP32 and ~17. 
Conclusions: In dogs with HF, chronic therapy with CARV attenuates cardiomyocyte 
apoptosis, a finding consistent with increased expression of Bcl-2, an anti-apoptosis pro- 
tein, and decreased expression of ~17, a pro-apoptosis protein. 
1100-53 Protein Kinase CE Modulates Apoptosis Induced by p- 
Adrenergic Stimulation in Adult Cardiac Myocytes: Role of 
!&-Adrenergic Receptor Dependent ERK Activation 
Yukitaka Shizukuda, Taihei Naya, Tuan A. Pham, Peter M. Buttrick. University of ttlinois at 
Chicago, Chicago, IL 
Prior disease(%) coronary 41.6 44.6 47.1 48.6 51.4 
Prior renal insufficiency(%) 6.6 8.5 10.5 12.8 15.9 
Diabetes mellitus(%) 32.8 33.6 32.9 29.3 21.8 
Prior AMl(%) 28.2 29.4 29.5 29.6 28.5 
Hypertension(%) 59.6 61.8 63.2 63.5 60.3 
Present with chest pain(%) 89.2 87.0 84.4 81.2 73.9 
Arrive<6 hours after 58.4 56.1 53.4 49.7 43.4 
onset(%) 
ST segment elevation(%) 31.9 30.6 28.7 27.5 26.0 
Normal LV function(%) 48.8 46.7 44.1 39.3 32.2 
Hear rate>1 00 beats/min(%) 21.5 23.7 26.4 28.0 30.2 
Conclusions: Traditionally defined ‘“elderly” AMI patients are not a homogeneous popula- 
tion, but demonstrate significant differences by age. Future research should not treat this 
population as homogenous, but instead explore the therapeutic and prognostic implica- 
tions of its heterogeneity. 
lssei Shiotani, Hiroshi Sate, Hideyuki Sate, Eiji Hishida, Kunihiro Kingjoe, Daisaku 
Nakatani, Noritake Hoki, Tsunehiko Kuzuya, Masatsugu Hori, Yozo Ohnishi. Osaka 
University Graduafe Schoo(, deparfmenf of infernal Medicine and Therapeufics, Suifa, 
Japan, Osaka prefectural general hospital, Osaka, Japan 
1101-55 Depression Predicts 12-month Prognosis in Elderly Patients 
With Acute Myocardial infarction 
rats and maintained in culture for 48 h before pharmacological intervention for 24 h. The 
Background$-adrenergic induced apoptosis (APO) of cardiai: myocytes may play a sig- 
activation of individual PKC isoforms was assessed with translocation and the role of 
nificant role in the progression of heart failure, where adrenergic tone is elevated. How- 
individual PKC isoforms was confirmed using isoform specific translocation inhibitors. 
The extent of apoptosis was measured both by TUNEL and DNA gel electrophoresis. 
ever, a role for protein kinase C (PKC) in 5.adrenergic induced Apo is not well described. 
Results$-adrenergic stimulation by isoproterenol (Iso, 1OpM) significantly enhanced the 
Thus, we describe the signaling pathways by which PKC is involved in this study, Meth- 
specific activity of PKCe. Iso induced Apo (49.0+1.0% vs. 14.7+0.8% in controls, PcO.05) 
that was blocked by a PKCE specific banslocation inhibitor (PKC&-I, 18.2?1.6%, P<O.O5), 
but not by a PKCG inhibitor (39.3r3.2%) or a cPKC inhibitor (41.9+0.8%). The suppres- 
ods:Adult rat ventricular myocvtes (ARVM) were harvested from 6-8 week male Wistar 
sion of PKCs activity by PKCE-I resulted in activation of ERK and ERK inhibition by PD 
98059 50pM (38.1+1.6%, PcO.05) reduced the anti-apoptotic effect of PKCE-I. suggest- 
ing that enhanced ERK activation is critical for the anti-apoptotic affect of PKCE suppres- 
sion. Furthermore, ERK was not activated by PKCE suppression in the presence of a 8s. 
adrenergic specific blocker ICI 118551 (0.1 uM), suggesting that p,-adrenergic stimula- 
tion is required for ERK activation, Conclusion:The activation of PKCE by 8-adrenergic 
stimulation suppresses an anti-apoptotic signal related to f3,-adrenergic dependent ERK 
activation. Therefore, PKC isoform targeted therapy may be useful to suppress apoptosis 
in heart failure patients with elevated catecholamines. 
Backgrounds: Several studies have found that depression is associated with an 
increased risk for cardiac events after the onset of acute myocardial infarction (AMI). 
However, few studies have examined this relationship in the elderly. The aim of the 
present study is to assess the impact of depression on prognosis of elderly patients hos- 
pitalized for AMI. Methods: Consecutive patients with AMI were registered from April 
1998 through June 1999 and all patients who survived to be discharged were enrolled in 
this study (n=618; 510 men; mean age 63+10 y.0.). Depression was assessed using the 
20.item self-report Zung Self-Rating Depression Scale (SDS). Patient with a score of 40 
or higher was diagnosed as depression. The patients were followed for 12 months. Car- 
diac events (cardiac death, re-MI, revascularization, heart failure) were examined and 
compared between elderly (265 y.o., 283 patients) and young patients (~85 y.o., 335 
patients). Results: The SDS score identified depression in 264 patients (42.7%). Preva- 
lence of depression was not dependent of age (p=O.485) and gender (p=O.409). The car- 
diac event rate at 1 -year was 31.2% (88 events) in the elderly patients and 26.0% (87 
events) in the young patients For depressed populations, the rate of cardiac events was 
33.3% in contrast to 24.6% of the nondepressed. Multiple logistic regression analyses 
showed that depression was significantly associated with l-year cardiac events (odds 
ratio 1.54, 95% Cl 1.04 to 2.29, P=O.O32) after controlling for severity of myocardial inf- 
arction, risk factors, e.g., hypertension, diabetes mellitus, hypercholesteloremia, smoking 
and obesity. Depression was a significant risk factor for cardiac events (odds ratio 1.82, 
95% Cl 1.09 to 3.02, p=O.O22) in the elderly patients, However, there was no association 
between depression and cardiac events in the vounq patients (odds ratio 1.31, 95% Cl 
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1101-54 Heterogeneity in Older Acute Myocardial Infarction Patients: 
The Importance of Age 
Rajendra H. Mehta, Saif S. Rathore, Martha J. Radford, Alan K. Berger, Yongfei Wang 
Harlan Krumholz. Yale University School of Medicine, New Haven, GE Qualidigm, 
Middletown, CT 
Background: Patients aged 65 years or older with acute myocardial infarction (AMI) have 
often been perceived as a homogeneous group - ‘The elderly”. However, the association 
of age with clinical characteristics among the traditionally labeled “elderly” is not well 
described. Methods: We evaluated 163,140 Medicare beneficiaries aged 65 years or 
older hospitalized with AMI at non-governmental acute care hospitals in 1994.95. 
Patients were divided into 5 age-based strata (see table) and evaluated for age trends in 
1101-56 How is the Outcome of Coronary Stenting in the Elderly 
Compared to Younger Patients? 
Daniela Trabattoni, Piero Montorsi, Alessandro Loaldi, France Fabbiocchl, Stefano Galli, 
Luca Grancini, Paolo Ravagnani, Sergio Cozzi, Antonio L. Bartorelli. Centro Cardiologico 
Monzino, IRCCS, Institute of Cardiology, University of Milan, Milan, /t&y 
Purpose: To assess clinical outcomes following coronary stenting in pts >75 years and to 
compare them to those obtained in younger pts. Methods: New generation stents were 
implanted in 130 old (0)pts (mean age78t4 yrs: range 76-96), 200 middle-aged (M) pts 
(mean age:6227 yrs; range 51-75) and 150 young (Y) pts (mean age:48+4 yrs; range 31- 
50). 0 pts were more hypertensive (0’:51%, M:43%,Y*:21%; p’<O.OOi), diabetic 
(0*:14%, M:ll%,Y’:4%; p*<O.O04) and presented more severe coronary artery disease 
(213 VD: 51%0*,42% M, 34% Y*; p*=O.O4). No significative difference in lesion length 
and morphology, reference vessel diameter and percent diameter stenosis was present. 
Stable angina (55% 0, 64% M, 67% Y; ns), unstable angina (31% O*, 22% M, 13% Y*; 
p”<O.OOl) and acute Ml (13% 0, 10% M, 12% Y; ns) were the indications for stenting. 
Coronary revascularization required cardiopulmonary supportlintra-aortic balloon pump 
in 3% of 0 and 0.5% of M and Y pts (ns). High and similar technical 
(0:95%,M:96%,Y:97%;ns) and clinical success (0:91%, M:95%, V:96%; ns) were 
achieved in all groups. MACE were: death (3.8% O,l% M, 0% Y; ns), urgent CABG (0.7% 
0, 0% M, 0% Y: ns), SAT (0.7% 0, 0.5% M, 0% Y; ns) and major bleeding (5.3% 0, 4.5% 
M, 1.2% Y; ns). Table shows six-month clinical and angiographic results. Conclusions: 
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POSTER SESSION Coronary stenting in the elderly is safe and effective. Desprte more unfavorable clinical 
oresentation. coronarv arterv disease extension and risk factors. elderlv oatients showed _ _ ,
acute and long-term outcomes similar to those observed in younger pts. 
Old (130 pts) Middle-Aged (200 pts) Young (150 pts) p 
Death (%) OS 0 0 ns 
Angina (%) 15 8.8 11 “S 
Q-MI (%) 2.2 0 0 “S 
Re-PTCA (%) 12.2 15.4 23.2 ns 
CABG (%) 2.2 3.7 1 ns 
Restenosis (%) 347 27.2 27 ns 
1101-57 Coronary Stenting Is Safe and Effective in a High Risk 
Octogenarian Patient Cohort 
Dmitri V. Baklanov, Constantin B. Manx, Marek C. Chawarski, Deanna F. Juhasz, 
Eugene A. Caracciolo, Thomas J. Donahue. Hospifal of Saint Raphael, New Haven, CT 
Background: Despite the widespread use of coronary stenting, little is known about the 
acute and long term results in octogenarians who represent an inherently high risk popu- 
lation as well as an increasing percentage of treated patients with coronary heart dis- 
ease. Methods: One hundred ninety seven consecutive patients (57% female) older then 
80 years old (84 +/- 3 years) who underwent 214 coronary stent procedures were stud- 
ied. Each patient had post procedural serial cardiac enzymes and EC& collected, and 
was iollowed for a minimum of six months (range 6-24 months) after the procedure. Pro- 
cedural success was defined as less than 20% residual stenosis, TIMI 3 flow, and 
absence of major complications (death, non-fatal myocardial infarction, coronary artery 
bypass graft surgery, mator bleeding, and stroke). Srxty-five percent of patients presented 
with an acute MI or unstable angina, and 93% were functionally NYHA Class Ill or IV. 
Fifty three percent of stenoses were classified as B2 or C. Glycoprotein llbllla receptor 
inhibitors were used in 13% of the procedures. Twenty percent of patients had prior coro- 
nary bypass graft surgery, 66% had prior myocardial infarction, and 48% had three ves- 
sel coronary heart disease. Results: Procedural success was 93%. Stenosis seventy was 
reduced from 73 +I- 16% to IO +/- 11% after the stenting procedure. Death during the 
index hospitalizatron occurred rn 2.5% of patients, and 2% of patients suffered a stroke. 
Late death occurred in 4.1% of patients. Target lesion revascularization rate during the 
follow up period was 8.6%. Multivariate analysis of selected angiographic and clinical 
variables did not reveal any predictors of major cardiac events. Conclusions: Despite a 
high risk clinical and angiographic profile. coronary stenting can be safely performed in 
octogenarians with a high procedural success rate, low complication rate, and excellent 
long term outcome. 
1101-58 Right Ventricular Involvement Increases Mortality Only in 
the Acute Phase of Inferior Myocardial infarction and Only 
in Elderly Patients 
Hector Buena, Ramon Lopez-Palop, Esther Perez-Dawd, Manuel Martinez-S&s, Ana 
Herranz. Hospital General Universitario “Gregorio Maranon’: Madrid, Spain 
Right ventricular involvement (RVI) increases mortality in patients with inferior myocardial 
infarction (IMI), particularly in those of advanced age. The duration of the interaction 
between age and RVI on the increase in mortality in patrents with IMI is unknown. Meth- 
ods. The short- and long-term mortality of 798 consecutive patients admitted to our CCU 
with an IMI of less 48 hours of evolution was studred. We performed an stratified analysis 
according to the patients age (>65 years old versus < 65 years) and to the presence of 
RVI (defined by echocardiographic and/or electrocardiographic criteria). A complete fol- 
low-up was obtained in 98% of patients. Results. In the whole group, the mean age was 
64 years, 78% were men and 54% received reperfusion therapy. The median follow-up 
time was 45 months. Survival curves by each stratum are shown in the graph. 
Conclusions: In IMI, RVI is associated with a lower long-term survival only in elderly 
patients. However, this drfference in survival is a consequence of the increase in mortality 
produced in the early phase. 
1102 Cardiomyopathy: Specific Types 
Monday, March 19, 2001, 9:00 a.m.-l 1:OO a.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 9:00 a.m.-i 0:OO a.m. 
1102-59 The Aetiology of Heart Failure in Iron Overload 
Lisa Anderson, Sally Hoiden, Bernard Davis, Emma Prescott, Glare Charrier, David 
Firmin, Beatrix Wonke, John Porter, J Malcolm Walker, Dudley Pennell. Cardiac Magnetic 
Resonance Unit, Royal Brompton Hospital, London, United Kingdom, University Cotkge 
Hospital, London 
Background: Heart farlure in the setting of iron overload can occur in both hereditary 
hemochromatosis and the hemoglobinopathies. The most striking model is found in 
patients with thalassemia major, where cardiomyopathy remains the major cause of 
death. As these patients often present suddenly and cardiac involvement correlates 
poorly to liver iron and serum ferritin, the role of iron in thalassemic heart failure has 
recently been questioned, and myocarditis has been suggested as an alternative cause. 
Furthermore, separate aetiologies for left (LV) and right (RV) ventricular dysfunction have 
been proposed. Methods: We investigated this issue in 151 patients with thalassemia 
major using cardiac magnetic resonance (mean age 27.8years). Myocardial iron concen- 
trations were measured using T? values, which are inversely proportional to tissue iron 
concentration. Results: Despite long-term iron-chelation in all patients, 58% were found 
to have excess myocardial iron deposrtion (T2* <20ms). In these patients, there was a 
progressive linear decline in left and right ventricular ejection fraction [LVEF and RVEF] 
(r=O.62, pcO.0001 for LVEF and r=O.53, p<O.OOOl for RVEF) and a progressive rise in LV 
mass (r=O.44, p< 0.0001) and LV end systolic volume (r=O.50, p<O.OOOl) with increasing 
myocardial iron. LVEF correlated linearly with RVEF (r=O.69, p<O.OOOi). When the 
patients were grouped by 5-year age intervals, the highest mean myocardial iron and 
lowest mean EFs were found in the late teens and early 20s when compliance to chela- 
tion regimes is most difficult. This corresponds to the steep fall in the survival curve in 
this age group. Mild myocardial iron deposition was detected as early as 7 years and 
severe deposition as early as 12 years of age. Conclusion: These data suggest a com- 
mon aetiology, namely iron deposition for left and right ventricular failure in thalassaemia 
major. Currently available iron-chelation regimes are ineffective in preventing myocardial 
iron deposition in the majority of these patients. Increased efforts need to be directed 
towards early detection in high-risk populations in order to prevent the unnecessary 
death of young patients from this treatable cardiomyopathy. 
1102-60 Paradoxical Echocardiographic Findings in Senile Cardiac 
Amyloidosis Versus Primary Amyloidosis: An Insight Into 
the Mechanism of Cardiomyopathy 
Belinda Ng, Ravin Davidoff, Martha Skinner, Rodney H. Falk. Boston University Medical 
Center Boston, MA 
Background: Senile cardiac amyloidosis (SCA) is characterized by the deposition of 
wild-type transthyretin in the heart. This contrasts with primary (AL) amyloidosis in which 
light chain fragments produce the cardiomyopathy. The aim of this study was to deter- 
mine whether these two diseases can be distinguished echocardiographically. 
Methods:We blindly compared the echocardiograms of all 10 patients ‘wth SCA seen 
over 4 years with 20 randomly selected patrents with AL amyloid of the heart. The clinical 
and demographic features of both sets of patients were also reviewed. 
Results: SCA patients were significantly older (75 i 5.1 yrs versus 56 + 11.2 yrs) and 
were predominantly male (g/IO). Left ventricular internal dimensions were similar in both 
groups, but SCA patients had thicker walls and were more likely to have a reduced left 
ventricular ejection fraction (EF). All SCA patients had congestive heart failure (CHF) 
compared to 18120 patients with AL amyloid. 
SCA (N=l 0) AL (N=20) P 
IVS 17.2Lt2.9mm 14.6*2.9mm 0.031 
LVPW 17c4.2mm 15.3i3.3mm 0.23 
RV wall 9.5+1.4mm 9.3c1.4mm 0.74 
EF<40% 5 (50%) 2 (10%) 0.026 
Afib 4 (40%) 1 (5%) 0.031 
All SCA patients sun/ived at least one year from the onset of CHF symptoms with 2 sub- 
sequent deaths at 2 and 2.5 years after onset. Only 6120 patients with AL amyloid are 
alive at a mean follow-up of 14 months. 
Conclusion: Despite older age, thicker ventricles, and worse systolic function, patients 
with SCA have a longer survival than those with AL amyloid with cardiac involvement. 
These apparently paradoxical findings support the hypothesis that a toxic component of 
the light chains exist in AL cardiomyopathy and is absent in SCA. This underscores the 
diagnostic imperatwe of distinguishing these two entities with similar echo appearances 
but vary different clinical outcomes. 
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1102-61 Systolic Myocardial Velocities by Pulsed Doppler Tissue 
Imaging Are Preserved Before the Onset of Heart Failure 
Symptoms in Patients With Primary Cardiac Amyloidosis 
Jun Koyama, Patricia A. Ray, Ravin Davidoff, Rodney H. Falk. Boston Medical Center, 
Boston, MA 
Background: Pulsed Doppler tissue imaging (DTI) is a well-established method to esti- 
mate the regional myocardial velocities, but there are few data concerning the clinical 
value of TDI in primary cardiac amyloidosis. 
Methods: Seventy-nine consecutive biopsy-proven patients with primary amyloidosis 
were examined by TDI. Fifty-seven had evidence of heart involvement, of whom 25 had 
clinical CHF. Twenty-two patients had non-cardiac amyloidosis. Sample volumes were 
placed on the basal and mid-posterior walls in the parasternal long-axls view, and on the 
basal interventricular septum, basal lateral, basal inferior, and basal anterior walls in api- 
cal two and four chamber views. Peak systolic wall motion velocities (S-vel), peak early 
diastolic wall motion velocities (E-vel), and peak atrial systolic wall motion velocities (A- 
vel) were measured. 
Results: The fractional shortening was within normal range, although it was significantly 
higher in the control and no-CHF groups (0.41+0.1 and 0.38*0.1) than in the CHF 
patients (0.32+0.1. P<O.O5). The values of E-vel in no-CHF were significantly lower than 
those in control (PcO.01) and the values in CHF were also significantly lower than those 
in no-CHF (P=O.Oi) at all sites. On the other hand, the values of S-vel in CHF were lower 
than those in no-CHF (P<O.Ol), but there were no significant difference between control 
and no-CHF in S-vel values at any site (P=O.86). The values of A-vel in CHF were also 
lower than those in no-CHF (P<O.OOl), but there was no difference between control and 
non-CHF in A-vel values at any site (P=O.lO). 
Conclusion: Cardiac amyloidosis is characterized by an early impairment in early car- 
diac relaxation whereas S-vel impairment occurs only after CHF onset. Thus systolic 
dysfunction can be detected by pulsed tissue Doppler even when fractional shortening 
remains in the normal range. 
JACC February 2001 
1102-63 Increase of Natriuresis by Low-Dose Spironolactone in 
Congestive Heart Failure Only in Combination With ACE- 
Inhibition 
Michael Christ, Daniela Fraccarollo, Georg Ertl, Norbert Gretz, Martin Wehling, Johann 
Bauersachs. Institute of C/in. Pharmacology, Mannheim, Germany. Med. 
Universrtatsklinik, Wuerzburg, Germany 
Overall mortality IS markedly reduced by addition of the mineralocorticoid receptor antag- 
onist spironolactone on ACE-inhibition in patients with severe congestive heart failure 
(CHF). The aim of the present study was to investigate a hypothesised interaction of 
spironolactone and ACE-inhibitors on renal electrolyte and volume regulation. Methods: 
Wistar rats with extensive myocardial infarction or sham-operation were treated either 
with placebo, with the ACE-inhibitor trandolapril, with low-dose spironolactone or with a 
combination of both. Twelve weeks after MI, rats were housed in metabolx cages for 24 
hours. Results: Urinary volume and sodium excretion was significantly increased in CHF 
rats on a combined treatment with spironolactone and trandolapril (21.2+2.6 mud, 
2489i320 mmolid; mean&D, p<O.O5 vs. other experimental groups) vs. placebo-treated 
rats (16.7+5.6 mud, 1431%458 mmolld), while these parameters were neither affected in 
rats on spironolactone (16.lk6.6 mlid, 1153r273 mmolid) nor trandolapril alone 
(15.9t4.2 mL/d, 1392~294 mmol/d). Effects on natriuresis coincided with a significant 
reduction of LV enddiastolic pressure (LVEDP) in rats on trandolapril and spironolactone 
(10.8?8.2 mmHg; ~~0.05 vs. CHF placebo: 23.3i-7.2 mmHg; sham-operated rats: 
5.1t0.9 mmHg), while LVEDP remained elevated in rats treated with either compound 
alone (trandolapril: 19.6t9.09; spironolactane: 18.0r6.9 mmHg). The fractional sodium 
excretion (fNa) did not differ between CHF and sham-operated rats (0.26?0.02 % vs 
0.30+0.04 %). fNa was significantly increased in CHF rats on a combination of TR and 
SP (0.46+0.04 %; p&O5 vs all other groups), while treatment with TR or SP alone did 
not change FSE (TR: 0.32+0.03 %; SP: 0.28+0.06 %). In summary, we found an unex- 
pected tnteraction of low-dose spironolactone and the ACE-inhibitor trandolapril in exper- 
imental CHF leading to marked effects on renal electrolyte and volume excretion, which 
was not apparent by treatment with either drug alone. These findings may explain at least 
in part the beneficial effects of adding spironolactone on ACE-Inhibition in CHF patients 
as demonstrated in the RALES-study. 
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1102-62 Analysis of Myocardial Sympathetic Innervation in Patients 
With Cardiac Amyloidosis Using l-123 MIBG Imaging 
Minor” Hongo, Hiroki Kasai, Kazuhisa Urushibata, Hiroshi Imamura, Mafumi Owa, 
Tadashige Fujii, K&hi Kubo. Shinshu University School of Medicine, Matsumoto, Japan 
Backround: Although a high incidence of myocardial adrenergic denervation has been 
reported in patients with familial amyloid polyneuropathy (FAP), assessment of cardiac 
sympathetic nerve function has not been available in patients with AL (primary) amyloido- 
sis. Methods: To assess myocardial adrenergic nerve activity in AL amyloidosis, we 
examined 15 patients using l-123 MIBG scintigraphy. We also compared the findings with 
those of 16 patients with FAP. Results: The heart/media$tinal (H/M) activity ratios (1.66 + 
0.10vs1.39~0.11at30min,p~0.001and1.54r0.06vs1.32~0.12at3h,p~0.001) 
and myocardial washout (41.1 * 4.7 vs 25.1 + 3.7 %, P < 0.001) were significantly 
increased in 11 of the 15 patients with AL amyloidosis who showed no autonomic symp- 
toms compared with patients with FAP. These values were similar between 4 patients 
with AL amyloidosis and autonomic neuropathy and those with FAP. Of the 11 patients 
with AL amyloidosis and no autonomic symptoms, 6 patients with congestive heart failure 
had siginificantly decreased H/M ratios (1.50 + 0.03 vs 1.59 t 0.04, p c 0.01 in the 
delayed images) and increased washout (44.2 + 2.3 vs 37.4 + 4.0 %, p < 0.01) compared 
with the other 5 patients without heart failure. In patients with AL amyloidosis, the wash- 
out ratio was inversely correlated with the low frequency component of heart rate variabil- 
ity (I = -0.69, p c 0.05) alone. Conclusions: Patients with AL amyloidosis and no 
autonomic dysfunction showed enhanced cardiac adrenergic neuronal activity with mild 
sympathetic dysfunction in parallel with the presence of congestive heart failure. In con- 
trast, patients with AL amyloidosis and autonomic neuropathy and those with FAP exhib- 
ited prominent myocardial adrenergic denervation with normal sympathetic neural 
function. Thus, there are great differences in myocardial uptake and turnover of MIBG in 
patients with cardiac amyloidosis, which is dependent on the presence or absence of car- 
diac autonomic dysfunction. 
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Atrio-Biventricular Pacing Improves Cardiopulmonary 
Exercise in Heart Failure Patients With Stable Sinus Ryhthm 
Chetan Varma, Sr., Sam Firoosi, Sr., Sanjay Sharma, Sr., William J. McKenna, Sr., 
Claude Daubert, Sr.. Dpt de Cardiologie CHU, Rennes, France 
Background : Multisite pacing offers a novel approach for the treatment of advanced 
heart failure (HF). Objective evidence of benefit is needed and cardiopulmonary exercise 
testing (CPX) provides a reliable assessment of change in functional capacity in HF. We 
assessed the effect of atrio-biventricular pacing compared to no pacing upon CPX 
parameters of patients enrolled in the multicentre MUSTIC (Multisite Stimulation in Cardi- 
omyopathies) trial -a prospective, randomised, single blinded crossover study. Methods 
: Patients enrolled (NYHA class Ill HF on maximal medical therapy, stable sinus ryhthm, 
left bundle branch block, QRS > 150 ms and 6.minute walk < 450 m) were implanted and 
randomised to active (atrio-biventricular, VDD-) and inactive (VVI 40) pacing with 3 
months in each pacing mode. Detailed 15 second data and plots of ventilation, inspired 
oxygen, expired carbon dioxide and heart rate were recorded at the end of each period (n 
= 35) and maximal exercise indices analysed in patients with a respiratory quotient (RQ) 
> 1 (n = 30). Anaerobic threshold (AT) was also calculated from all interpretable exercise 
plots (n = 12) Results : 
Baseline Inactive (I) Active (A) A vs I % p value (A vs I) 
pVO2 (mlikglmin) 13.9 + 3.5 14.3 r 4 8 15.8 r 4.4 + 10.5 0.02 
ET (seconds) 393+ 186 437 zk 233 501 A 223 + 14.6 c 0.001 
VEIVCOP 44.8 r 13.5 45.4 + 10.9 41.4 t 8.1 -? 0.02 
AT (%) 38 k 9 39+11 44+13 + 13 0.2 
RQ 1.12r0.13 l.l6i-0.13 1.21 +0.22 +3 0.2 
PHR (bpm) 120+22 122r21 123+21 + 0.8 0.7 
pVO2 = peak oxygen uptake ; ET = exercise time ; VE/VCOP = ratio of ventilation to CO2 
expiration at peak exercise ; pHR = heart rate at peak axerc~se Conclusion : Atrio-Biven- 
tricular pacing in patients with HF and sinus ryhthm: (1) Improves exercise time (2) 
Increases pVO2, with no change in pHR, implying augmentation of cardiac function (3) 
Leads to a beneficial effect in VEN02 suggesting normalisation of the increased ventila- 
tory drive seen in patients with HF. 
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Elevated Levels of Inflammatory Cytokines and 
Overexpression of iNOS in Skeletal Muscle of Patients With 
Chronic Heart Failure: Effects of Regular Aerobic 
Endurance Training 
Voiker Adams, Axe1 Link+ Paul C. Schulze, Stephan Gielen, Sven Moebius-Wink& 
Gerhard Schuler, Rainer Hambrecht. Univefssify Leipzig, Heart Center; Leipzig, Germany 
Background: In patients (pts) with chronic heart faliure (CHF) functional work capacity IS 
inversely correlated with the expression of inducible nitric oxide synthase (iNOS) in skei- 
etal muscle (SM). in vitro studies suggest that inflammatory cytokines regulate INOS 
expression. The present study was designed to analyze the effect of exercise training 
(ET) on the amount of inflammatory cytokines in SM and its relation to tNOS expression 
in pts with stable CHF. 
Methods: Twenty pts were prospectively randomized either to a training group (T) or an 
inactive control group (C). At baseline and after 6 months, pts underwent a needle biopsy 
of the vastus lateralis muscle. Expression of INOS was quantified by immunohistochem- 
istry (%iNOS positive stalned tissue area) and confirmed by semiquantltative RT-PCR. To 
quantify the specific tissue concentration of IL-16 and TNF-a in SM quantitative immuno- 
histochemistry was performed. 
Results: ET leads to a significant reduction of either IL-10 by 27% (from 1 .Ol rtO.09 to 
0.78 r0.08 % positive stained tissue area; ~~0.05 versus C) and TNF-a by 28% (1.53 
to.14 to 1.13 iO.ll % positive stained tissue area: ~~0.05 versus C). Simultaneously 
iNOS exprewon decreased by 32% (2.20 + 0.46 ver.sus 1.51 i 0 38 % positive stained 
tissue area; p=O.Oi versus C) after 6 month of ET. There was a trend to an increase in 
iNOS expression in C (2.03 t 0.59 versus 2.78 + 0.83 % pos. tissue area). Changes in IL- 
16 were significantly correlated to changes in INOS expression (w0.51, p=O.O2). 
Conclusion: These results suggest, that in pts with CHF physical exercise training 
reduces the local concentration of inflammatory cytokines in the skeletal muscle. These 
beneficial training effects may contribute to reduced iNOS expression in SM of these 
patients. 
levels, resting plasma norepinephrine levels, left ventricular ejection fraction, peak exer- 
cise heart rate, peak exercise systolic blood pressure, age and cardiothoracic ratio. At 
multivariate analysis, the independent predictors for cardiac death veere: 1) peak exercise 
heart rate; 2) left ventricular ejection fraction; 3) peak exercise plasma norepinephrine 
levels; and 4) plasma norepinephrine levels at rest (all p<O.O5). In addition, elevated exar- 
cise plasma norepinephrine level (-amp;#8224; 640 pg/ml) was a prognosttc predictor by 
Kaplan-M&r analysis (pcO.01). Conclusions: The present study showed that the exer- 
cise plasma norepinephrine levels can provide prognostic information in patients with 
mild heart failure, in addition to the degree of left ventricular systolic dysfunction, chrono- 
tropic incompetence, and resting levels of plasma norepinephrine. The determination of 
plasma norepinephrine levels during exercise is useful to predict cardiac death m patients 
with mild heart failure. 
812-5 
IO:15 a.m. 
Beneficial Effects of a Phosphodiesterase Type 5 Inhibitor 
(Sildenafil) on Exercise, Neurohormonal Activation, and 
Erectile Dysfunction in Patients With Congestive Heart 
Failure-d Double-Blind Placebo-Controlled Cross-Over 
Ramdomized Study 
Edimar A. Bocchi, Guilherme GuimarPes, Giovanni Bellottl, Jose A. F. F&mires. Heart 
Institute of Slo Paula University Medical School, Sk Paula, Brazil 
812-3 ._ 
9:45 a.m. 
The Endotoxin, Cytokine, and Metabolic Response to Acute 
Exercise in Patients With Chronic Heart Failure and Healthy 
Controls 
Mathias Rauchhaus, Hendrik B. Schmidt. Wolfram Doehner, Aidan Boiger, Rakesh 
Sharma, Michael Kemp, Stefan D. Anker, Ursula Muller-Werdan, Karl Werdan. Klinikfijr 
lnnere Me&in 111, Martin-Luther-Univerisit~t Ha//e- Wittenberg, Ha/le/Saa/e, Germany 
Clinica/ Card;o/ogx NHLI, London, United Kingdom 
Background: Acute exercise is a potent stimulus for the hypothalamo-pituitary-adrenal 
axis. It has been postulated that the increase in tumor necrosis factor-alpha (TNF) during 
exercise s?rves anaboltc function to decrease glucose and increase fat oxidation which IS 
required to achieve maximal exercise capacity In severe chronic heart failure (CHF), 
endotoxin and cytokines are elevated and catabolic/ anaboiic imbalance has been 
reported. Methods: Treadmill exercise tasting (respiratory quotient at peak VO2>1.0) was 
used to investigate the kinetics of plasma cortisol, dehydroepiandrosterone (DHEA), 
endotoxin, TNF, and soluble TNF receptors 1 and 2 (TNFRlI7NFR2) in 25 untrained 
patients with CHF(age 61rlO years, NYHA 3.110.8, mean&D) and 18 untwned healthy 
controls (age 36220 years, p<O 01). Results: Patients had higher endotoxin (0.6kO.2 vs 
0.4+0.1 EUlml, p&01), TNFRI (3.4el.5 “s 1.8*0.6 ngiml), TNFR2 (8.0i3.7 “s 3.5+1.2 
rig/ml, both p<O.OOl), but lower DHEA (16.1+10.3 vs 33.7k22.8 nmo!/l, p=O.OOl) at base- 
line (vs controls), the latter resulting in a higher cortisol/DHEA ratio in patients (33217 vs 
16*13, p=O.OOl). At peak exercise (peak V02 41.&14.4 vs 14.2r3.9 ml/kg/min, 
p<O.OOOl), endotoxin had increased by 18% in controis and by 23% in patients (both 
p<O.OOOi vs baseline) which represents an 80% higher increase in patients than in con- 
trols (p=O.O16). In controls, the rise in endotoxin was paralleled by an increase in TNF 
(+24%, p=O.O4), TNFRl (+35%), TNFRZ (+79%), and DHEA (+30%, all p<O.OOl), the lat- 
ter causing the cortisol/DHEA ratio to fall (-24%, p=O.Ol vs baseline). By contrast, none 
of these parameters changed significantly in patients (all p>O.ZO). Conclusion: In 
untrained healthy controls, acute exercise rises the release of endotoxin and cytokines 
which is paralleled by an increase in DHEA. This is suggestive for a physiological hor- 
monal and cytokine response m order to achieve maximum exercise capacity. In CHF, 
however, chronically elevated endotoxin and cytokine concentrations may result in catab- 
olism over anabolism and, subsequently, in a diminished anabolic response to exercise. 
Backgroud: Sildenafil (S) use is potentially hazardous in CHF. The influence of phos- 
phodiesterase type 5 (PDES) inhibition on exercise, and newhormonal activation in 
CHF is unknown. Methods: We studied 18 pts with CHF in NYHA class II (16) and in III 
(2), with erectile dysfunction (ED) > 6 months, LVEF 23 + 7%, and EDLV diameter 75 f 9 
mm. On the 1st day, the pts were submitted to a cardiopulmonary(CP) self-control tread- 
mill 6’ walk test (6’), and after to an ECG monitored CP treadmill maximal exercise test 
(Ex) 60, and 90 min after (randomly) oral S (50mg) or placebo (P). We determined at: 
basal positjon (b), last min of 6’ and in the peak Ex: heart rate (HR), SAP (mmhg), DAP, 
peak Vo2 ( mllKg/min), Slope VEiVco2, exercise time (ET, in min), distance (D, miles), 
and the neurohormonal activation (win in ng/nl/h, norepinephrine in pglml).lt was 
repeated on the 2nd day with cross-over. The efficacy of S was assessed by the Interna- 
tional Index of Erectile Function (IIEF) (question 3 and 4). Results:(P and S respectively). 
S reduced: b-HR (75114, 72~15, p:.OOl); b-SAP(l17*16, 110*19, p=.OO5); b-DAP 
(70~6, 5r10, p=O.O3); 6’.HR (107i23, 99i-22, p=O.OOZ); B’-slope (33,7, 31+6, p=.OO7), 
Ex-slope (33+8, 31+5, p=.O4). S increased the ET (12~3, 14+3, p=.Ol); Ex-V02 
(17+3,18+3, pz.02). S did not change (p=ns) the D (0.2 r.03, 0.25 0.03); 6’-Vo2 (11~2, 
llt2): 6’.SAP(l26+21, 12lt22); Ex-SAP (135518, 133r29); 6’.DAP(70il3.70~12): Ex- 
DAP (76+12, 72+14); and Ex-HR- (122&2, 123_t Bl).The IIEF improved (pc.001) (ques- 
tion 3 from 0.9+0.4 to 4.2t.8; 4 from 0.9LO.4 to 4.2+0.5). No pt presented non tolerated 
side effects. b, 6’ and Ex norepinephrine levels did not change: b-P 620.+448, b-S 
6242268; 6’.P 1604 + 1922, 6’-S 1758t1501 Ex-P 2890 + 3198, Ex-S 2557r2554. S 
reduced b renin activity from 14*15 to 8.9+9.7. Conclusion in addition to efficacy in the 
treatment of ED in CHF, PDE5 inhibitors may have beneficial effects increasing the exer- 
cise capacity, reducing the slope VENcoP, and renin activity. Exercise mechanisms 
including the high norepinephrine levels may counterbalance effects of PDE5 inhibitors 
on heart rate and systemic blood pressure. Our results would be considered in Guide- 
lines for Sildenafil use in CHF 
ORAL CONTRIBUTIONS 
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812-4 
IO:00 a.m. 
Exercise Plasma Norepinephrine Levels as a Prognostic 
Marker for Cardiac Death in Patients With Mild Heart Failure 
822-I Transforming Growth Factor Beta-l Inhibition Exacerbates 
Ventricular Remodeling Early Following Myocardial 
Infarction 
Toru Kinugawa, Kazuhide Ogino, Shulchi Osaki, Masahiko Kate, Akihiro Endo, Osamu 
Igawa, lchiro Hisatome, Chiaki Shigemasa, Masatoshi Fujita. Tottori University, Yonago, 
Japan, Kyoto University, Kyoto, Japan 
Fiona See, Henry Krum, Paul Martin, Alex Tzanidis. Monash University, Prahran, 
Australia 
Background. High plasma norepinephrine levels are associated with a poor prognosis in 
patients with heart failure. Patients with heart failure have altered plasma norepinephrine 
response to exercise, but the value of exercise plasma norepinephrine for determining 
prognosis has not been well defined. This study determined whether exercise plasma 
norepinephrine levels could predict cardiac death in patients with mild heart failure. Meth- 
ods: During 1987 - 1992, 148 patients with mild heart failure (mean age: 59?11 years) 
and 27 control subjects performed submaximal treadmill exercise test with serial mea- 
surements of plasma norepinephrine levels. Clinical, echocardlographic, exercise and 
catecholaminergic variables considered relevant to the cardiac death were examined by 
Cox regression model. Results: During a median follow-up of 9.9 years, 30 cardiac (17 
heart failure deaths and 13 sudden deaths) occurred among patients. Significant predic- 
tors for cardiac death by univariate analysis were peak exercise plasma norepinaphrlne 
Background: The profibrogenic peptide, transforming growth factor pt (TGFPt) has been 
implicated in early cardiac remodeling following left ventricular (LV) myocardial infarction 
(MI). To char&wise this, we examined the effects of blockade of TGFP, activity in rat 
heart early post-Ml. 
Methods: LVMI was induced in female Sprague Dawley rats by ligation of the LAD. On 
day 1 following operation, LVMI animals began a B-day treatment with either anti-TGFP, 
antibody (o;TGF& Ab) (lmgikglday; ip; n = 4) or control immunoglobulin (IgG) (lmglkgl 
day; ip; n = 4). Sham animals received IgG (n = 4). LV dimensions and function were 
assessed by echocardiography on days 1 and 13. Animals were sacrificed on day 14 and 
cardiac tissue was processed for immunohistochemical and molecular analyses. 
Results: Infarct sizes in the LVMI groups were similar on day 1 (IgG: 3l.O~t0.8%;aTGFfi, 
Ab: 30.9+0.5%; p = NS). However, aTGF& Ab treatment exacerbated infarct expansion 
over the study period resulting in a larger infarct compared to IgG-treated animals on day 
13 (IgG: 36.2+0.9%; nTGF& Ab: 40.9*1.3%: p c 0.05). This exacerbation was associ- 
ated with a thinner anterior wall at the site of infarct (IgG: 1.6rO.lmm; uTGF& Ab: 
164A ABSTRACTS - Cardiac Function and Heart Failure JACC February 2001 
1.2~0.lmm: p < 0.05) and greater compensatory hypertrophy, as suggested by a thicker 
posterior wall (IgG: 2.9+0.2mm; oiTGF6, Ab: 3.7fO.l mm; p < 0.05) and greater heart 
weight to body weight ratio (IgG: 0.42iO.01; aTGF6, Ab: 0.47+0.01; p < 0.05). At day 14, 
TGFP, gene expression was elevated above sham in both the infarct zone (IZ) (142%; p 
< 0.05) and in the border and non-infarct zones combined (BZ+NIZ) (30%; p c 0.05) and 
this was associated with marked increases in collagen type I deposition throughout the 
myocardium (IZ: 186%; BZcNIZ: 152%; p < 0.05). aTGF6, Ab treatment resulted in 
attenuation of this increase in collagen type I deposition in the border zone by 25% com- 
pared to IgG-treated animals (p < 0.05). 
Conclusions: Treatment with an aTGF6, Ab early post Ml appeared to have detrimental 
effects on cardiac remodeling, suggesting that TGF6, may play an important role in the 
reparative process in the acute phase post-MI. 
\ 
11:45 a.m. 
822-4 Regional Variation and Dynamic Turnover of Cardiac 
Collagen Matrix in Canine Experimental Heart Failure 
Gordon W. Moe, Nafiseh Nili, Effat Rezaei, Andrea Konig, Marina Romanova, Bradley H. 
Strauss. St Michael’s Hospital, Univ of Toronto, Toronto, ON, Canada 
822-2 
11:15 a.m. 
Effect of ACE Inhibitors and AT1 Blockers on Myocardial 
Expression of Matrix Metalloproteinases in Post MI 
Ventricular Remodeling. 
BACKGROUND: Remodeling of the cardiac collagen matrix may be an important mech- 
anism for the progression of heart failure (CHF). Although previous studies using models 
of cardiomyopathy often revealed little change in collagen content, detailed assessment 
of regional variations and the turnover of cardiac collagen as well as the impact of ther- 
apy on these parameters have not been conducted. 
METHODS: We measured collagen content (hydroxyproline), collagen synthesis (14C- 
hydroxyproline) and gelatinase (matrix metalloproteinase, MMP) activity (by zymography) 
from the LV endocardium, LA, RA, RV and interventricular septum (IVS) in 8 normal dogs 
(N), 8 dogs with CHF induced by RV pacing (CHF) and 5 dogs with CHF treated with a 
type 1 angiotensin (AT,) receptor blocker candesartan (CHF-ATfrB). 
RESULTS: Data (means?SE) for collagen synthesis (cpmimg) of various intracardiac 
anatomic sites are shown in the table. * ~0.05 vs. N 
Sudhir Gupta, lnder S. Anand. VA Medical Center, Minneapolis, MN, Unwersity of 
Minnesota, Minneapolis, MN 
Background: Matrix metalloproteinases (MMP’s) have been demonstrated to play a sig- 
nificant role in post myocardial infarct (Ml) ventricular remodeling. Methods: We studied 
the effects of the ACE inhibitor (ACE-l), Enalapril: AT1 blocker (AT1 -B), Candesartan, and 
their combination on the tissue levels of MMP-2, MMP-9 and MMP-13 in the remote non- 
infarcted myocardium (RNM) of 6 week post Ml rats and corresponding areas of sham 
operated rats by RT-PCR. Infarcted rats were treated with water, ACE-I (lmg/Kg), ATl-B 
(lOmg/Kg) or combination in the drinking water. Treatment was started 24h after Ml and 
continued for 6 weeks, when rats were sacrificed. Results: Hemodynamics and Echocar- 
diographic data showed that the Ml hearts were significantly remodeled and dysfunc- 
tional as compared to sham (LV Developed Pressure (LVDP), 56+9 vs 1 l&7 mm Hg; LV 
Fractional Shortening (%) 19.1?2 vs 55.3~2; pcO.01). Treatment with ACE-I, ATl-B and 
combination therapy improved LV function (LVDP, 91+5, 75~5 and 94?4 mmHg; LV Frac- 
tional Shortening (%) 27r6, 34t7 and 3627 respectively for ACE-I, AT1 -6 and combina- 
tion). As compared to sham, in water treated Ml rats, there was a 92% increase in MMP- 
2, 31% increase in MMP-9, and 41% increase in MMP-13 mRNA in the RNM. There was 
no effect of ACE-I on MMP. ATl-B treatment reduced the expression of MMPP (38%) 
and MMP-13 (20%). In contrast, the combination decreased the expression of all MMP’s 
to normal level?, (fig). Conclusion: These data suggests that whereas, AT-18 decrease 
MMP mFiNA, ACE-I did not. However, in presence of ATlB. ACE-I had a synergistic 
effect in reducing MMP expression. 
822-3 
11:30 a.m. 
Altered Atrial Matrix Metalloproteinase Activity and Calcium 
Homeostasis in Chronic Rapid Pacing-Induced Atrial Failure 
Brian D. Hoit, Yasuchika Takeishi, Marjorie Gabel, Michael J. Cox, Darryl Kirkpatrick, 
Richard A. Walsh, Suresh C. Tyagi. University Hospitals of Clevelandand Case Western 
Reserve University Cleveland, OH, University of Mississippi, Jackson, MS 
Background: We previously demonstrated that six weeks of rapid atrial pacing produces 
atrial systolic failure characterized by absent atrial booster pump function, ‘increased 
atrial chamber stiffness, enhanced atrial conduit function, atrial enlargement, and normal 
ventricular systolic function. However, the mechanisms responsible for these abnormali- 
ties are poorly understood. Therefore, we examined left atrial myocardium from dogs with 
rapid pacing-induced (400 bpm for 6 weeks) atrial failure (AF) and from control dogs 
(Con). Methods: Western blotting was used to determine the levels of proteins involved in 
calcium homeostasis (SERCA 2A, phospholamban, Na+-Ca2+ exchanger). Activation of 
matrix metalloproteinases (MMP)were measured using gelatin and casein zymography, 
and levels of tissue inhibitor of metalloproteinase-4 (TIMP-4) and the TIMP-WMMP-2 
complex (CTIMP-4) were measured with Western blot analysis. Results: There were no 
differences in SERCA 2A or Na+-CaZ+ exhanger protein levels, but phospholamban level 
was significantly decreased in atrial samples from rapidly paced dogs (51.2+_7.8 vs 
77.0+10.0, p<O.Oi). The activity of MMP-9 was selectively and significantly increased by 
-5O%, and the level of complexed TIMP-4 protein was significantly decreased by -50% 
in samples from dogs with atrial failure: 
TIMP-4 CTIMP-4 MMP-9 MMP-2 MMPB MMP-i 
LV LA RA RV IVS 
N 4.2+0.5 5.9lkO.8 4.9il.l 5.110.9 3.5kO.4 
CHF 5.9il.2 9.5&l .5’ 9.0*1.4* 7.OM.Q 4.1f0.8 
CHF-AT, rB 4.4fl.3 7.412.1 6.8zb2.9 5.6f2.9 3.3+0.7 
Collagen content was similar for the 3 groups in all intracardiac sites (data not shown in 
the table). However, there was significant inter-site variation (p<O.OOOOl, ANOVA) in all 
groups with higher values observed in the LA and RA. When compared to N, collagen 
synthesis was increased in the LA and RA in the CHF group and unchanged in the 
treated group. Inter-site variation was observed only in the CHF group (p=O.O34), with 
highest values observed in the LA and RA. Compared to N, activity of 72.kDa gelatinase 
(MMP-2) was increased by 250% in the LV endocardium, 300% in the RA and 650% in 
the RV in the CHF group, with a modest reduction observed in the candesartan-treated 
dogs. 
CONCLUSION: Our data therefore suggest that in canine pacing-induced CHF, there is 
dynamic collagen turnover with an increase in both synthesis and breakdown resulting in 
net unaltered collagen content. The increased collagen turnover is attenuated by AT, 
receptor blockade and this attenuation may contribute to an anti-remodeling effect. 
822-5 
Noon 
Urotensin II Stimulates Collagen.Synthesis by Cardiac 
Fibroblasts and Hypertrophic Signalling in Cardiomyocytes 
via G(alpha)q- and Ras-Dependent Pathways 
Alex Tzanidis, Ross D. Hannan, Walter G. Thomas, Done Onan, Fiona See, Henry Krum. 
Monash University Medical School, Alfred Hospital, Melboure, Australia, Baker Medical 
Research Institute, Melbourne, Australia 
Urotensin II (U-II) is a somatostatin-like peptide recently identified as the most potent 
vasoconstrictor known. In this study, we examined whether U-II promotes adverse car- 
diac remodeling through non-haemodynamic effects on the myocardium. In a rat model 
of heart failure post-myocardial infarction, increased U-II peptide expression was 
observed in both infarct and non-infarct regions, particularly in areas of fibrosis. In iso- 
lated neonatal cardiac myocytes and fibroblasts, constitutive expression of both prepro- 
U-II and the U-II receptor, GPR14 (hereafter referred to as the urotensin receptor, UTR) 
was detected, suggesting the presence of local production and effects of U-II. In vitro, U- 
II (lo-7mol/L, 24 hours) stimulation of cardiac ftbroblasts increased al(l) and al(lll) pro- 
collagen gene expression by 150% and 60%, respectively, in comparison to controls 
(PiO.01). In isolated cardiac myocytes, sttmulation by IO-7mol/L ET-1 and lo-4mol/L 
phenylephrine caused significant cellular hypertrophy, as determrned by changes in total 
protein content (ET-I: +31%, P<O.OOl; PE: +29%; PcO.05) or activation of fetal gene pro- 
grams associated with the hypertrophic phenotype, while U-II (lo-7mollL to IO-1lmoWL) 
had no effect. In contrast, expression of a recombinant rat UTR in neonatal cardiomyo- 
cytes resulted in significant U-h-dependent activation of hypertrophic signalling as dem- 
onstrated by increased activity of co-transfected reporter constructs for the hypertrophic 
phenotype, including atrial natriuretic peptide, myosin light chain-2 and a-skeletal actin. 
This effect was found to be mediated through Gaq- and Ras-dependent pathways. These 
results indicate that, in addition to potent haemodynamic effects, U-II is implicated in 
myocardial fibrogenesis through increased collagen synthesis by cardiac fibroblasts, and 
may also be an important determinant of pathological cardiac hypertrophy in conditions 
characterised by U-II receptor upregulation. 
Con (n=6) .22+/-.05 .08+/-.Ol .22+/-.07 .64+/-.03 .26+/-.03 .13+/-.08 
AF (n=6) .22+/-.06 .04+/-.Ol’ .35+/-.07* .55+/-.13 .18+/b.05 .19+/-.06 
(‘=pcO.OOl). Conclusions: Thus, rapid pacing-induced atrial failure with normal ventricu- 
lar function is associated with differential changes in MMP activity, an unchanged number 
of calcium pumps, and compensatory changes in the level of phospholamban. 
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I 132-47 Left Ventricular Response To Chronic Mitral Regurgitation: 
Is Ventricular Enlargement Uniformly Present? 
Roshan Mathew, Nwle Guilmette, Nihad Al-Assaad, Sherif B. Labib, Edgar C. Schick, 
William H. Gaasch. Lahey Clinic, Burlington, MA 
Background: Left ventricular enlargement (LVE) is generally held to be an important com- 
ponent of the LV response to chronic, severe mitral regurgitation (MR). Indeed, it has 
been suggested that the diagnoses of chronic, severe MR should be questioned if LVE is 
not oresent. Methods: in an attemot to refine our understandino of the LV resoonse to 
1132-45 Effects of Ramipril on Left Ventricular Mass and Function in 
chronic severe MR, we identrfied 51 patients (pts) known to have chronic MR and color 
Doppler evidence of severe MR (data base calendar years: 1997.99). We then assessed 
Normotensive, High-Risk Patients With Normal Ejection the prevelance of LVE in this group. LVE was defined as end diastolrc diameter >55mm at 
Fraction. A Substudy of HOPE 
Eva M. Lonn, Roya Shaishkoleslami, Qilong Yi, Jacqueline Bosch, Alison Magi, Salim 
Yusuf. McMaster University: Hamilton, ON, Canada 
Background: The effects of long-term ACE-inhibition on left ventricular (LV) mass and 
functlon in high-risk cardiovascular patients without overt hypertension and without heart 
failure (HF) or LV systolic dysfunction are not well studied. 
Methods: We compared echocardiographic changes in LV mass and function (LV mass 
Index [LVMI], thickness of the interventricular septum and posterior walls of the LV 
[IVS+PW], LV ejection fraction [LVEF), LV end-diastolic volume (LVEDV), LV end-systolic 
volume (LVESV) and wall motion score [WMS]) in 446 high-risk patients, randomized to 
Placebo, Ramipri12.5 mgiday (Ram 2.5) or Ramipril 10 mgfday (Ram 10) and followed for 
4 years. Patients enrolled in the study had cardiovascular disease or diabetes with addi- 
tional risk factors, but no hypertension or well-controlled blood pressure, and no heart 
failure or depressed LV systolic function. 
Results: Mean patients’ age was 65 years and mean baseline blood pressure and ejec- 
tion fraction were similar in all study groups, 131/75 mmHg and 58% respectively. 
Changes rn the echocardiographrc measurements (study/end-baseline) are summarized 
in the table: 
Placebo (n=l51) Ram 2.5 (n=149) Ram 10 (n=l46) p 
4 LVMI (g/me) +3.9 F 25 +4.2 A 22 -2.0+27 0.02 
n(lVS+PW)(mm) +0.10+3 -0.16+3 -0.70 t 3 0.10 
a LVEF (%) -2.0 i- 9 -1.5i-9 -0.1 c 9 0.06 
a LVEDV (ml) +4.2 i 31 -0.4 i 33 -5.9 * 35 0.01 
A LVESV (ml) 15.3 + 20 +2.9 i 18 -1.9* 19 0.01 
4 WMS +0.05 i 0.1 +0028*0.1 ~0.018 A 0.1 0.06 
Adjustment for blood pressure changes durrng the study and multivariate adjustment did 
not alter the study results. 
Conclusions: Ramipril significantly reduced LVM and LV volumes with trends towards 
improved LVEF and WMS. These effects were dose-dependent and could not be 
explained by blood pressure changes alone. Long-term ACE-inhibitor therapy has a ben- 
eficial, dose-dependent effect on LV remodeling and function in high-risk patients with 
cardiovascular disease without hypertension or with well-controlled blood pressure and 
without HF or LV dysfunction. 
mid-chordal level (echocardiography). Pts with acute MR, other valvular drsease, or coro- 
nary heart disease were excluded. Results: The average age of pts was 66+1 lyears. 
Transmitral E velocity(CW Doppler) was 155-t3Ocm/s supporting the color Doppler diag- 
nosis of severe MR. Mean LV end drastolic diameter was 59+13mm, range 46-70mm; 
systolic diameter 38&9mm; ejection fraction 60%r12. Mean left atrial size was 56+4mm. 
Eleven of the 51 pts (21%) drd not exhibit LVE; transmitral E velocity was >130cm/s in 9 
of the 11. The body surface area was not significantly different between those with LVE 
and those without (1.9r0.3 vs 1.7r0.3m2). Results were similar in the 17 pts with chronic 
atrial fibrillation (21% did not have LVE)vs the 34 with sinus rhythm (23% did not have 
LVE). There was no significant relation between age, gender,or ejection fraction, and LV 
size. Conclusion: Data indicate that LVE is not present in 21% of patients with chronic, 
severe MR. While the mechanism unclerfying lack of LVE remains unclear, the presence 
of normal LV size should not necessarily be used as evidence against the presence of 
chronic, severe MR. 
1132-48 Prevalence and Pathophysiologic Consequences of Mitral 
Regurgitation in Patients With Mild-to-Moderate Heart 
Failure 
Prakash C. Deedwania for the Zofenopril/FosinopriI CHF Group. VA Central California 
Heaith Care System, fresno, CA, UCSF School of Medicine, San Francisco, CA 
Although patients with severe CHF are known to have mitral regurgitation (MR), the prev- 
alence and functional consequences of MR in patients with mild-to-moderate CHF have 
not been established. Accordingly, we evaluated the frequency and severity of MR in 91 
patients with CHF (NYHA II-III) by echo-Doppler studies performed in uniform style in a 
multicenter CHF study. The echo-Doppler data were analyzed at the core laboratory. 
Sixty-six patients (73%) had adequate color Doppler studies. The LVEF, LV end diastolic 
and LV end systolic volumes (LVEDV, LVESV) and LA volume were calculated. The MR 
jet area was measured and averaged in 2 views and graded mild if ~4cms, moderate if >4 
to &xr?. and severe if >8cms. Fifteen patients without CHF or mitral valve disease 
served as controls. MR was present in the majority (49/66, 74%) of CHF patients versus 
305 (20%) in controls (p<.OOl). Sixteen CHF patients had mild MR and 33 had moder- 
ate-to-severe MR. LV volumes, LA size, and exercise duration (ExDUR,min) in CHF 
patients with MR and without MR are shown in the table. Conclusion: These results 
showed that, even in mild-to-moderate CHF, a majority of patients had significant MR. 
Although the presence of MR did not seem to have an adverse impact on exercise capac- 
1132-46 Effect of Spironolactone on Plasma Brain Natriuretic 
ity, it was associated with larger LVESV and LVEDV, identifying a subgroup in which for- 
Peptide and Left Ventricular Remodeling in Patients With 
ward stroke volume would improve significantly with therapy directed to reduce mitral 
Congestive Heart Failure 
regurgitation. 
LVEDV LVESV LAV ExDur,min 
Takayoshi Tsutamoto, Atsuyuki Wada, Keiko Maeda, Naoka Mabuchi, Masaru Hayashi, CHF with MR 136+44cc 96+37cc 67~23~~ lOt3.2 
Takashi Tsutsui, Masato Ohnishi, Masahide Sawaki, Masanori Fujii, Takehrro Matsumoto. CHF without MR 96t37cc 69c23cc 56?2Occ lOk3.2 
Takashi Yamamoto. Toshiki Matsui, Masahrko Kinoshita. Shiga University ofMedica/ 
Science, Otsu, Japan 
p-value ,003 .Ol .I0 0.87 
Background: Aldosterone (ALD) promotes collagen synthesis and structural remodeling 
of target organs such as the heart. Spironoiactone, an ALD receptor antagonist, has 
been recently reported to improve the mortakty of patients with congestive heart failure 
(CHF). However, the effects of sprronolactone on left ventricular volume and left ventrrcu- 
lar mass (LVM) and plasma brain natriuretrc peptide(BNP) have not been fully elucidated. 
Method. Thirty-seven patients with mid to moderate symptomatic leff ventrrcular dys- 
function who received standard therapy. were randomly divided into two groups: treat- 
ment with spironolactone (n=20) and placebo (n=l7). To evaluate the effects of 
spironolactone on neurohumorai factors and left ventricular remodeling, we measured 
plasma neurohumoral factors and performed echocardiography after 4 months of therapy 
of spironoiactone or placebo. Results: The left ventricular end-diastolic volume index 
(LVEDVI) and LV mass index (LVMI) were significantly decreased(LVEDVI: 192kll vs. 
1781-10 mUm2. p=O.Ol: LVML158r7.8 vs. 14&7.5 g/m2, p=O.O02) The ejection fractron 
(EF) was significantly increased rn the spironolactone group (32.2k2.2 vs. 3521.9%. 
~~0.05) but did not change in the placebo group. Plasma levels of BNP and procollagen 
type Ill aminoterminal peptide (PIIINP) srgnificantly decreased after the treatment of 
spironolactone (BNP:ZOOt66 vs90+27pg/mL, p<O.O1; PIIINP: 0.64+0.04 vs. 
0.48iO.04UimL. p<O.OOi), but did not change in the placebo group. There was a signifi- 
cant positive correlation between the changes of PIIINP and changes of the LVEDVI 
(rsO.45, p=O.O45) as well as the LVMI (rzO.65, p=O.O019) with spironolactone treatment. 
Conclusion: These findings indicate that 4 months of treatment with spironolactone 
improve left ventricular volume, LVMI and EF and decrease plasma levels of BNP and 
PIIINP, suggesting that endogenous aldosterone has an important role in the left ventric- 
ular remodeling of patients with CHF 
1132-49 Echocardiographic Predictors of Mortality in Nonischemic 
Cardiomyopathy: Report From the PRAISE-2 
Echocardiographic Substudy 
Christopher H. Cabell, Eric J. Velazquez, Jean G. Dumesnil, Douglas A. Criger, Robert 
N. Belkin, Allen B. Miller, Anne 6. Cropp, James G. Jollis, Thomas Ryan. Duke Clinical 
Research Institute, Durham, NC, Pfizer Central Research, Groton, CT 
Background: Prognosis among patients with congestive heart failure is generally poor. 
While echo predictors of outcome have been identified in several large trials, the majority 
of these patients had coronary disease. PRAISE 2 offered the unique opportunity to 
study patients with severe heart failure of non-ischemic etiology. The echocardiographic 
substudy was designed to understand the relationships between baseline echo parame- 
ters and outcome in those with non-ischemic cardiomyopathy. Methods: Recruited 
patients had NYHA class > Illb, ejection fraction < 30%, non-ischemic etiology, and were 
randomized to amlodipine or placebo. The primary outcome was all cause mortality. 
Baseline ethos were analyzed blindly at a core lab. Mitral regurgitation was graded semi- 
quantitatively as none through severe. Regression analyses were used to determine 
which characterrstics predicted mortality. Results: The study recruited 93 patients with 
interpretable ethos. There were 28 (30%) deaths overall of which 79% were cardiac in 
origin. There were no significant differences between treatment groups in clinical charac- 
teristics, echo findings, or death. Therefore, the patrents were combined Into a srngle 
analysis group. In univariate analyses, a lower ejection fraction, larger left ventricular 
dimensions, increasing mitral regurgitation, and velocities of mitral inflow and pulmonary 
venous flow were ail predictive of mortakty (pc.05). Ejection fraction < 25% (p=.OOl) and 
E/A > 1.6 (p=.024)were most predictive of mortality. In multivariate analyses, only mitral 
regurgitation was independently predictive of mortality. With each increased grade of 
mitral regurgitation the adjusted odds of death was 2.07 (95% Cl 1.20, 3.55). Conclusion: 
In this study, echocardiographic findings were strongly predictive of mortality Both sys- 
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tolic and diastolic parameters contribute to this prognostic power. Mitral regurgitation 
severity was the only echocardiographic parameter independently predictive of mortality 
in these patients. The baseline echocardiogram provides important prognostic informa- 
tion to clinicians caring for patients with severe heart failure of non-ischemic etiology. 
1132-50 Sensitivity, Specificity, and Prognostic Value of Serum 
Markers of Cardiac Extra-Cellular Matrix Turn-Over in Heart 
Failure 
Faiez Zannad, FranFois Alla, Anna Kearney-Schwartz, Brigitte Dousset. lNSERM- 
University Hospital, Nancy, France 
Background: Serum procollagen type I and type III provide a useful tool for monitoring “at 
a distance” cardiac extra-cellular matrix and fibrosis. Collagen type I is predominant in 
the myocardium and collagen III most specific to the cardiovascular system. Our objec- 
tive was to evaluate the sensitivity, specificity, determinants and prognostic value of 
serum procollagen type I and type Ill in patients with heart failure (CHF). Methods: Using 
RIA, we measured serum procollagen C and N-terminal type I and III propeptides (PICP, 
PINP, PIIINP) in 261 patients with CHF, before randomization into the RALES trial (NYHA 
Ill/IV, aged 33.90, mean LVEF=26%, ischemic heart d1sease=46%) and in 95 healthy 
adults (aged 44-72, 50% men). Statistical analysis used logistic regression and Cox 
model. Results : Tested markers were not affected by age nor gender. Mean PIIINP was 
higher in patients with CHF than in controls (5.0+/-2.5 v.s 3.4+1-l .2 ug/L, p<O.OOOl). Val- 
ues of PICP and PINP were not different between the two sample populations. In CHF 
patients, PIIINP levels wen? positively associated to lschemic etiology (5.3 vs. 4.7 ug/L, 
p=O.OZ) and negatively to digoxin therapy (4.7 vs. 5.4 pg/L, p=O.OOi), and were corre- 
lated to serum ANP (r=0.177, p=O.O05) but not to NYHA class nor to LVEF Sensitivity 
and specificity ranges for the diagnosis of heart failure were respectively 70% and 63% 
with 3.5uggiL PIIINP level as a cut point and 56% and 83% with 4.1 ug/L as a cut point. In 
CHF patients, baseline PIIINP >3.85 pg/L was associated with an increased risk of death 
(RR=236 [1.34-4.181, p=O.O03) and of death + hospitalization (R&1.83 [1.18-2.831 ; 
p=O.O07). Baseline PINP and PICP were not associated with outcome. Conclusion: As 
opposed to procollagen type I, serum procollagen type Ill discriminates heart failure 
patients from healthy subjects and was associated with poor outcome in CHF. It should 
be further investigated as a tool for the diagnosis and risk stratification of CHF patrents. 
1132-51 Circulating Matrix Metalloproteinase May Relate to 
Proinflammatory Cytokine in Patients With Dilated 
Cardiomyopathy 
Taketoshi Yamazaki, Jong-Dae Lee, Hiromasa Shimizu, Hiroyasu UZUI, Yasuhiko 
Mitsuke, Takanori Ueda. Fukui Medical University, Fukui, Japan 
Background: It has been reported that MMP protein content and activity were upregu- 
lated in the failing human heart , suggesting that these proteins may contribute to myo- 
cardial remodeling, and that proinflammatory cytokines regulated tissue inhibitors of 
MMP (TIMP) and disintegrin MMP in cardiac cells. However, there are few reports to 
describe the relation between circulating MMPs and proinflammatory cytokines in chronic 
heart failure(CHF). Methods: We measured circulating MMP to examine whether the cir- 
culating MMPs were related to proinflammatory cytokines or cardiac event in patients 
with CHF.Circulating levels of MMP-9, its inhibitor TIMP-I, and proinflammatory cytok- 
ines (IL-l beta, TNF-alpha, and IL-6 ) were measured by enzyme-linked immunosorbent 
assay methods in 39 patients with CHF(left ventricular ejection fraction(LVEF)<50%, 18 
men, 66*12 years old, 17 patients with idiopathic dilated cardiomyopathy(DCM) and 22 
with old myocardial infarction(OMI) ). Fifteen age-matched subjects having normal coro- 
,naty arteries and normal ejection fraction were used as controls(CTL). Results: The level 
of MMP-9 was significantly greater in DCM (77r22 “g/ml) compared to OMI (24~5 “g/ml, 
p<O.Ol) and CTL(17?1 “g/ml, p<O.O5). TIMP-l(DCM:152+14 ngiml, OMl:143+14 “g/ml, 
CTL:124r9 “g/ml) was identical in each group A significant positive correlation was 
found between the levels of MMP-9 and IL-6 in DCM patients(r=0.58, ~~0.05) but not in 
OMI (r=O.O3, pzO.91). We also tested the clinical importance of MMP-9 as a marker for 
cardiovascular prognosis in CHF. When the patients with CHF were divided into two 
groups on the basis of median of MMP-S(group H>22.5ng/ml, group Lc22Sng/ml), Car- 
diac events( rehospitalization or cardiac death) occurred frequently in group H (5/19= 
26.3%) than in group L (l/20 = 5.0%) during the follow-up(lZO-720 days). Conclusion: 
Our data indicated that circulating MMP-9 content was increased in DCM patients, sug- 
gesting a close relation between this enzyme activity and the degrdation of cardiac inter- 
stitial tissue, and that the high levels of circulating MMP-9 may predict higher incidence of 
cardiac event in patients with CHF. 
1132-52 Transforming Growth Factor-P 1 Gene Expression is 
Increased in Mononuclear Cells of Patients With Chronic 
Heart Failure: Implications for Cardiac Remodeling 
Henry Krum, Rachel Denver, Alex Tzanidis. Mmash University A/red Hospital, 
Melbourne, Australia 
Background: Pathological cardiac remodeling is characteristic of chronic heart failure 
(CHF) and associated with infiltration of activated mononuclear cells. Recent studies sug- 
gest that profibrogenic transforming growth factor beta-f (TGFbl) may be a partial medi- 
ator of this process. We therefore sought to determine whether peripheral blood 
mononuclear cells (PBMC) display activation of TGFbl in patients (pts) with CHF com- 
pared with normal subjects (N), and whether neuroharmonal factors increased in CHF 
such as endothelin-1 (ET) may contribute to this activation. Furthermore, as monocytes 
are the predominant mononuclear cell type found in injured myocardium, we additionally 
examined these cells in isolation. Methods: PBMC wen? isolated from venous blood by 
gradient centrifugation and total RNA extracted. Competitive RT-PCR was used to mea- 
sure TGFbl mRNA in: i) PBMC from 16 CHF pts (mean EF 32+15%, NYHA Class II/Ill/IV 
47/33/20%) and 9 N; Ii) PBMC N cultured serum free and stimulated with either PHA/LPS 
as positive control or ET-I (IO-7M) for 4, 24 or 48 hrs (unstimulated cells=negative con- 
trol); and iii) in monocytes isolated from N PBMC by adherence, then stimulated for 24 
hrs, as above. Results: TGFbl mRNA in PBMC was significantly increased by 55% in 
CHF pts c.f. N (68.1k6.3 vs 44.0+.5 copies TGFbl per ng RNA, p<O.Ol), and correlated 
modestly with EF (R=-0.369). In PBMC culture studies, PHAfLPS caused an increase in 
TGFbl mRNA, maxmal at 48 hours (210%; pcO.005). ET-1 stimulated cells,demon- 
strated a 60% increase in TGFbl mRNA at 4 hours compared with controls (p<O.O05), 
returning to control levels by 48 hours. Moreover, we observed a 110% increase in 
TGFbl protein from ET-1 stimulated PBMC in the first 24 hours of culture, suggesting 
translation into peptide synthesis (24.5+0.1 vs 51.7k2.4 pgiml, p<O.O05). Both PHA/LPS 
and ET-1 stimulated TGFbl gene expression in monocyte-enriched cultures at 24 hrs 
similar to that observed in PBMC. Conclusion: These results demonstrate that TGFbi 
gene expression is increased in PBMC in CHF ps, and may contribute to TGFbl-depen- 
dent cardiac remodelling via mononuclear cell infiltration. Activakon of the ET system 
may be an important mediator of this process. 
1132-53 Elevation of Pericardial Fluid Matrix Metalloproteinase-2 
(MMP-2) Level Is Closely Associated With Left Ventricular 
Dilation and Myocardial Remodeling 
Shoichi Miyamoto, Noritoshi Nagaya, Keiichi Tambara, Tomoyuki Iwase, Kinro Ueda, Ario 
Yamazato, Shun-ichi Tamaki, Masashl Komeda, Masatoshi Fujita. Take& Hospifal, 
Kyoto, Japan, Kyoto University: Kyoto, Japan 
Objectives: The purpose of this study was to investigate whether matrix metalloprotein- 
ases (MMPs) and tissue inhibitors of MMPs (TIMPs) represent autocrineiparacrine fac- 
tors and are accumulated in pericardial fluid. Background The development of 
congestive heart failure (CHF) is associated with left ventricular (LV) dilation and myocar- 
dial remodeling. However, fundamental mechanisms that contribute to this remodeling 
process remain unclear. The MMPs and TlMPs have been demonstrated to play a signif- 
Icant role in tissue remodeling through a number of pathological processes. Methods: We 
measured the concentrations of these enzymes (MMP-I,2, and TIMP-1,2) simulta- 
neously in plasma and pericardial fluid in 20 patients during coronary artery bypass graft 
surgery. Results: MMP-2 levels were significanyly higher in pericardial fluid than in 
plasma (93t_32 vs.68+34ng/ml,p<0.05). Interestingly,the pericardial fluid levels of MMP-2 
were significantly higher in patients with impaired LV function than in those with normal 
LV function (lOlk33 vs,68+34ng/ml, p<O.O5). Peticardial fluid MMP-2 levels had closer 
relations with LVEDVI (r=0.609, p=O.O122) and LVESVI (r=0.693, p=O.O020) than did 
plasma MMP-2 levels (LVEDVI: wO.532, p=O.O423; LVESVI: r=0.482, p=NS). MMP-2 lev- 
els in pericardial fluid but not in plasma inversely correlated with LV ejection fraction (I=- 
0.593, p=O.O130). In contrast, none of hemodynamic variables correlated with MMP-1 
and TIMP-1,2 levels in plasma or pericardial fluid. Conclusion: MMP-2 levels in pericar- 
dial fluid served as more sensitive and accurate indicators of LV dilation and myocardial 
remodeling than did MMP-2 levels in plasma. Thus, MMP-2 may be secreted from the 
heart into the pericardial space with the progression of CHF, and it may have a patho- 
physiologic role in LV remodeling process as an autocrine/paracrine factor. 
1132-54 Lack of Compensatory Activity of Brain Natriuretic Peptide 
(BNP) in Patients With Left Ventricular Remodeling 
Atsushi Hirayama, Tomohito Otani, Kazunori Kashiwase, Yuya Mizuno. Hiroyoshi 
Yamamoto, Kazuhisa Kodama. Osaka Police Hospital, Osaka, Japan 
Background: Plasma levels of endogenous atrial (ANP) and brain (BNP) natriuretic pep- 
tides increase with the seventy of chronic heart failure. The biological receptors of both 
peptides are down regulated, and their compensatory activity attenuated. As these pep- 
tides also increased in patients with left ventricular (LV) remodeling after myocardial inf- 
arction (Ml), the compensatory activity may attenuated. To elucidate the hypothesis, the 
relations of plasma level of cardiac natriuretic peptide levels (ANP and BNP) and their 
biological marker, cyclic GMP (cGMP), were studied in patients with or without LV remod- 
eling after Ml. Methods: Plasma ANP, BNP and cGMP level were measured by the radio- 
immunoassay in 47 pakents with first anterior Ml. LV volumes and functions were 
calculated with the area-length method using LV grams at 1 M and 6M. Significant dilata- 
tion of end-diastolic volume index defined as more than 10% increase during the study 
period was observed in 16 patients (group D) and not in 31 patients (group N). Results: 
There were no significant differences in LV function and hemodynamic variables at 1M 
between two groups. Although BNP level was significantly higher in group D (321~52 pg./ 
ml) than in group N (85k.28 pg./ml), there were no differences in ANP (group D vs. N; 
108+21 pg./ml vs. 71+10 pg./ml) and cGMP level (group D vs. N; 5.8r2.1 pmollml vs. 
4.9+2.1 pmoliml). There were significant positive correlation between ANP and cGMP in 
both groups (p=O.Ol). There was a positive correlation between BNP and cGMP in group 
N (p=O.Ol), but there was no significant correlation between BNP and cGMP in group D. 
Conclusion: The compensatory activity of BNP but not ANP is attenuated in patients with 
LV remodeling after Ml. Thus, the increased levels of BNP predict the clinical worse out- 
come through the progressive LV dilatation. 
1132-55 Time Course of Cardiac Structural, Functional, and 
Electrical Changes in Asymptomatic Patients 
Postmyocardial Infarction, Their Interrelation and 
Prognostic Impact 
Peter Gaudron, lngrid Kugler, Kai Hu, Wolfgang Bauer, Christoph Eilles, Georg Ertl. 
University of Heidelberg, Department of Medicine 2, Mannheim, Germany, Medizinische 
Universitaetsktinik, Wuerzburg, Germany 
Background: Mechanisms linking left ventricular (LV) dysfunction and sudden death in 
patients post myocardial infarction (MI) remain controversial. 
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Methods: We prospectively studied 134 asymptomatic p&en& after MI. LV volume was 
measured by gated single photon emission computerized tomography (End-diastolic vol- 
ume index, EDVI, ml/m”, dilation=EDVI t two standard deviations of mean). hemodynam- 
its by Swan-GanzB catheter (stroke volume index, SVI, ml rn-‘), Duration and dispersion 
of QT interval (difference of longest and shortest QT interval. 12.lead-electrocardio- 
gram), severity of ventricular arrhythmias (LOWN-grade) and heart rate variability 
(SDNN, ms, standard deviation of intervals of sinus depolarisations, Xhour Halter) were 
analysed. 
Results: Of 134 patients 37 (28%) showed LV dilatation. During Follow-Up (mean 87 
months, visits: 4days, 4weeks, 0.5, 1.5, 3 and 5.7years) 16 (12’io) of 134 patients died. 
Death was cardiac in 14 (88%) and sudden in 12 (75%). Of 37 (28%) patients with dila- 
tion, 12 died (32%); 4 (5.8%) without dilation died. EDVI in survivors at 3.7years (9013) 
was increased Versus /Idays, lweeks and 0.5year (75&?, 77+2, 7923, ~~0.05). EDVI in 
nOnsurViVOrS increased (84+6, 94+9#, liOiQ#“, 115*7#‘, 148+16#*) and were beyond 
0.5 years significantly higher. 
4 clays 4 weeks 0.5 year 1.5 year 3 years 5-7 years 
SDNN No”s”r”l”ois 53i10 109t30 147*39# 126r20 101+8- 
Survivors 83*5 1 m3*5+ 127*6+* x37=6+* 12**4+* 127*6+* 
LOYwgrade Nons”r”i”ors 2.8*0 5 3.oio 7 5.44 5s 5&0.4# 5&0.3# 
S”‘“l”‘xS 2.5io 4 2.&0.6 2 710.3 2 810.4 31*03 
S”, NOnS”r’ll”OiS BOiP’# 42+3 34+4 344 31~5 
S”i”l”OlS 3a+, 44il.e 441,# 42316 422,# 
lnitlally low SVI in n~n~urvw~rs normalized after 4 weeks but fell again thereafter. LOWN- 
score in nonsurvivors increased (beginning O.Byears after Ml). EDVI and LOWN-score 
correlated (r=O.Q8, p<O.OOOl), respectivly EDVI and QTc duration (rzO.998, p<O.Ol). 
*pcO.O5 Versus survivors, tpxO.01 Versus 4days, $p<O.O5 Versus 4weeks, $p<O.OOl 
Versus 4weaks. #p<O.O5 Versus 4days. 
topic HTX model In this reproducible acute rejection model, mild histologic rejection was 
observed ai post-operation-day (POD) 2 and exacerbated until the heartbeat stopped at 
POD 6. A signlflcant decrease in the maximum upstroke velocity (Vmax) of MAP in the 
allografts with mild rejection was observed as early as POD 2. At POD 6, Vmax and the 
amplitude of MAP were greatly reduced in the allografts (1 IQ*16 V/see and 69+12 mV, 
respectively) compared with that in the isografts (192~21 V/xc and 122?16 mV, respec- 
tively, n=15, p<O.Ol). The 90 percent of action potential duration (APDSO ) was signifi- 
cantly increased in the allografts with severe rejection from 191+25 ms immediate after 
HTX to 278+27 ms at POD 6. A significant increase (38&7%) in the dispersion of APDQO 
(the difference between the maximal and minlmal APDQO among 16 mapping array 
points recorded simultaneously in the right atrium or ventricle) was observed prior to the 
histologic change and hemodynamic alteratlan. All of these altered parameters were sig- 
nificantly correlated with the rejection grades and the hemodynamic alterations (p<O.Ol). 
These results demonstrate that EP abnormalities assessed by MAP-Mapping, especially 
the heterogeneity of APDQO, representing the functional alteration of the cardiac myo- 
cytes occurred earlier than the destruction of myocyte integrity observed histologically, 
and could be used as indictors for identifying the onset and severity of CAR. 
113348 Tacrolimus Monotherapy: 8 Year Experience in Cardiac 
Transplantation 
David A. Baran, Ira Galin, Lea1 Segura, Rhodora Correa, Mary Courtney, Steven 
Lansman. Alan Gass The Cardiovascular Institute, Mount Sinai School of Medicme., 
New York City, NY 
Conclusion: Progressive remodeling may link LV dysfunction, electrical instability and 
sudden death after Ml. 
BACKGROUND: Tacrolimus (TAC) is increasmgly used III cardiac transplantation 
because it is felt to be more potent, with fewer side effects than cyclosporine. We 
reviewed our 8.year experience with TAC as monotherapy (1.e. steroids and TAC, weaned 
to TAC alone, without the use of an anti-lymphocyte drug). Patients on primary TAC (P) 
and steroids after transplant and patients converted (C) from a cyclosporine-based regi- 
me” were studied. 
1132-56 Progressive Increase in Tissue Inhibitors of Matrix 
Metalloproteinase After Long Term Treatment With Beta- 
Blockers in Patients With Heart Failure 
METHODS: Between April 1992 and March 2000, 174 adult patients had heart trans- 
plants: 52 P and 39 C patients respectively. 44 of the P patients (85 %) and 26 of the C 
patients (67 %) were weaned to monotherapy. 
RESULTS: 
Johnny Lee, Marrick Kukin, Calvin Eng. Cardiovascular Institute, Mount Sinai School of 
Medicine, New York, NL: Bronx VA Medical Center. New York, NY 
Background: The matrix metalloproteinases (MMPs) are a group of enzymes that con- 
tribute to extracellular remodeling. Additionally, a class of inhibitors called tissue inhibi- 
tors of MMPs (TIMPs) has been shown to tightly regulate MMP activity. We examined 
the activity of plasma MMP-3 (stramelysin) and TIMP-1 m patients with congestive heart 
failure before and after beta-blocker treatment. 
Methods: Forty-four patients (mean age 58 i 19 years) with NYHA Class II-IV, were on 
standard therapy prior to initiation of a beta-blocker The beta-blocker (either metoprolol 
[n-19] or carvedllol [n=25]) was titrated up to 25 mg BID over a 4 week period and main- 
tained at that dose for a year. Measurement of MMP-3 and TIMP-1 (by ELISA) were par- 
formed at baseline (prior to beta-blocker) and at 6 months and 1 year of beta-blocker 
therapy. 
Results: There was a progressive increase in TIMP-1 from: 352 “g/ml (baseline, pre 
beta-blocker), 376 rig/ml (6 months of therapy), 453 “g/ml (1 year of therapy), p<.OOOl. 
ANOVA. There was no significant change in MMP-3 with treatment: 34 “g/ml (baseline), 
33 rig/ml (6 month), 37 ngiml (1 year), p=NS There was no significant difference 
between carvedilol and metoprolol in either MMP-3 or TIMP-1, 
P Group- Steroids were weaned 245+140 days post-transplant. The frequency of high- 
grade rejection (r ISHLT grade 3A) was 0.64 per patient during steroid weaning, and 0.27 
thereafter (p=O.O2). Freedom from rejection prior to monotherapy was 61 %, and 80% 
afterward. Two patients (4.5%) developed significant transplant arteriopathy (250 % focal 
or moderate diffuse stenosis). There was 1 death in this cohort at 6 months from rejec- 
tion (98 % survival). Mean follow-up was 2.1 f 1.14 years (range 0.5 -4.7 years). 
C Group- TAC conversion occurred at 391 i 499 days post-transplant. Anti-lymphocyte 
drugs were discontinued rapidly, and steroid weaning occurred 253 i 356 days. The 
(election frequency (>3A) was 0.88 per patient during steroid weamng, and 0.08 on 
monotherapy (p<O.Ol). Freedom from rejectlon on cyclosporine was 54 %, rising to 92 % 
on monotherapy. 3 (11 %) patients developed significant arteriopathy. There were 2 late 
deaths (5.5, and 6.4 years) from non-cardiac causes. Mean follow-up was 4.2 * 2.3 years 
(range 0.6 -8.3 years). 
CONCLUSION. Patients on a single immunosuppressant showed a low Incidence of 
rejection and transplant arteriopathy, with excellent intermediate-term survival Long term 
follow-up is awaited to confirm these promising initial results. 
Condition #Biopsies #23A 2 3A Rejections Freedom from 
Conclusion: Beta-blocker therapy results in a progressive increase in TIMP-1 over a 
year of therapy with no change in MMP3 activity. Thus, an addltional beneficial effect of 
beta-blockers in heart faliure may be a shift towards conditions that favor less extracellu- 
lar matrix degradation. The results of the present study suggest the possibility that the 
use of beta-blockers in heart failure lead to a progressive mcrease in TIMP-1 over time 
which alters the balance of MMPs and TIMPs. to one that favors less remodeling. 
TAC Conversion 
Pre-monotherapy 
TAC Conversion 
Post-monotherapy 
E?rlowy TAC: Pre- 
monotherapy 
309 
190 
654 
Rejections per patient 2 3A Rejection 
11 (3.6%) 0.42 54 % 
2 (1.1%) 0.08 92 % 
28 (4.3%) 0.64 61 % 
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1133-57 Alterations in the Endomyocardium Monophasic Action 
Potential as an indicator of Cardiac Allograft Rejection at 
Early Stage 
Luyl Sen, Noel Boyle, Hillel Laks, Guanggen GUI. UCLA Medical Center/UCLA School of 
Medicine, Los Angeies, CA 
Cardiac allograft rejection (CAR) remains a major complication of heart transplantation 
(HTX) and diagnosis is reliant on the histological examination of endomyocardial biopsy 
(EMB) specimens. Recent reports suggest that the electrophysiology (EP) alteration, 
such as atrial conduction disturbance and prolonged ventricular evoked response, could 
be used as the early warning sign of myocardium injury in CAR. Recently, we developed 
an EP catheter, which enables us to 3-dlmentionally map the endomyocardlum 
monophasic action potential (MAP). To determine the significance of MAP-Mapplng in 
CAR, we evaluated the correlation of the alterations of each MAP-Mapping parameter 
with the rejection grades and hemodynamic parameters using a rabbit functional hetero- 
Priomy TAC: Post- 
monotherapy 
337 12 (3.6%) 0.27 a0 % 
1133-59 Elevated Levels of Plasma C-Reactive Protein and Tissue 
Plasminogen Activator Antigen are Associated With 
Increased Frequency of Grade 3 Rejection in Cardiac 
Transplant Recipients 
Marc S. Eisenberg, Robert R. Sciacca, Hong Jun Chen, Mark K. Warshofsky, Allan 
Schwartz, LeRoy E Rabbanl. Columb!a University Coiiege of Physicians and Surgeons, 
New York, NY 
Inflammatory and hemostatic factors may be involved in the pathogenesis of allograft 
rejection in cardiac transplant patients. We hypothesized that plasma levels of C-reactive 
protein (CRP) and tissue plasminogen activator (t-PA) would correlate with the frequency 
of severe rejection in cardiac transplant recipients. We studied 89 cardiac transplant 
patients who were referred for routine endomyocardial biopsy and/or surveillance coro- 
nary angiography. Plasma levels of CRP and t-PA were measured by their respective ELI- 
SAs. Patients were followed for episodes of allograft rejection. During the follow-up 
period of 3.7 +/- 2 1 years (range .2-9.8 years) post-transplant, grade 3 rejections aver- 
aged .35 +I- .50 episodes/year (range O-2.9). Rejection frequency correlated significantly 
with I-PA (p<.Ol), CRP (p<.O2), donor age (p<.O2), and gender mismatch of donor and 
recipient (pc.02). Multiple regression analysis demonstrated a significant independent 
effect of t-PA, CRP, and gender mismatch (all pc.05). Subjects who were simultaneously 
in the lowest tertial for t-PA and CRP had a rejection frequency of .09 +/- .14 episodes/ 
year while those in the highest tertial for t-PA and CRP had a reiection frequency of .58 +/ 
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- .79 episodes/year. Taken together, these flndings suggest that elevated plasma levels of 
CRP and t-PA are associated with increased frequency of grade 3 rejection in cardiac 
transplant recipients. 
1133-60 Withdrawing Prednisone After Heart Transplantation Is 
Associated With More Rejection but Equivalent Side Effects 
Edward F. Philbin, Debbie Rickeard, Gary Franklin, Carrie Nelson, Conrad Drost, Abed 
Asfour, Alvise F. Bernabei. Albany Medical Cokge, Albany, N): Henry Ford Hospital, 
Detroit, MI 
Backgrouncl: Withdrawing prednisone (PRED) after’heart transplantation (HT) is contro- 
versial because increased allograft rejection (REJ) and fewer drug side effects are both 
potential outcomes of corticosteroid withdrawal. We report our experience with selecting 
patients for PRED withdrawal based their having a favorable early post-HT REJ history. 
Methods: We reviewed medical records and heart biopsies from 100 consecutive 
patients who underwent HT at a single center, excluding 12 who died and 2 who were 
lost to follow-up during the first year after HT. Results: Median follow-up among the 66 
evaluable patients was 4.2 years. Mean age at HT was 51 years; 22% were women and 
10% were black. PRED was withdrawn in 57% of the 66 patients. The median time of 
PRED withdrawal was 27 months after HT; accordingly, this was chosen as the cut-point 
for “early” versus “late” REJ among patients continued on PRED. By intent, patients who 
had PRED withdrawn were less likely to have had 1 or more episodes of treated REJ 
prior to PRED withdrawal (35% vs. 65%, PsO.05) than those in whom PRED was contin- 
ued. They also had fewer early REJ episodes per patient (0.5 vs. 1 .I, P<O.O5). During the 
late period (227 months after HT), patients continued on PRED had fewer episodes of 
REJ than those who had PRED initially withdrawn (14% versus 29% with >l episode, 
P=O.15; 0.2 vs. 0.4 episodes/patient, P=O.O5). Of 13 patients initially withdrawn from 
PRED who rewired restartina it, acute REJ was the reason in 11. The prevalence of con- 
ditions considered possible or definite side effects of PRED use are shown in the Table. 
Potential Drug Side Effects PRED Withdrawn Pred Continued P 
JACC February 2001 
Diabetes mellitus 25 % 26 % 0.90 
Treated hypertension 77 % 75 % 0.69 
Treated hyperlipidemia 90 % 83 % 0.59 
Coronary artery disease 31 % 42 % 0.53 
Osteoporosis 4% 14 % 0.23 
Conclusions: In our experience, selecting patients with fewer early episodes of REJ as 
the ones for PRED withdrawal results in their having a greater incidence of late REJ and 
insignificant reductions in major PRED-related side effects. These data do not suggest 
that routine PRED withdrawal after HT is a convincingly superior strategy, even among 
patients at lower risk for allograft REJ. 
1133-61 Blood Level of Cyclosporine A Is Not Related to the Risk of 
Acute Cardiac Allograft Rejection 
Edward F. Philbin, Tamara Z. Kamash, Gary Franklin, Debbie Rickeard, Carrie Nelson, 
Conrad Drost, Alvise F. Bernabei. Albany Medical College, Albany, NI: Henry Ford 
Hospital, Detroit, MI 
Background: Practices regarding the dosing of cyclosporine A (CSA) vary significantly 
among heart transplant centers perhaps because of limited information about the rela- 
tionship between CSA blood level and the risk of acute cardiac allograft rejection (REJ). 
Methods: We reviewed medical records coincident with 2,452 BX performed on 177 
heart transplant recipients at a single center over 12 years. For all BX, patients were 
being treated with CSA, had GSA whole blood levels measured coincident with the BX 
using fluorescent polarization immunoassay and there was available documentation 
regarding whether or not the BX necessitated treatment for acute REJ. By protocol, all 
patients were treated with standard triple-drug immunosuppression. Prednisone was 
always used during the first year after transplant but withdrawn in 57% of patients at a 
median of 27 months after transplant. Acute REJ was usually treated when BX showed 
International grade 2 2. Results: Mean CSA blood levels were similar for 2,314 BX not 
treated for acute REJ and 136 BX treated for acute REJ (266+147 versus 301rl61, 
P=O.35). Among 1,171 BX performed during the first year after transplant, CSA levels 
were again similar among 1,093 BX not treated for acute REJ and 76 BX so treated 
(369+149 versus 361il60, P=O.59). The Table shows the rate of treated acute REJ strat- 
ified by quartile of CSA blood level for all BX (columns 2&3, P=O.71) and only BX per- 
formed during the first year after transplant (columns 4&5, P=O.56). Even after 
adjustment for other factors including the use of azathioprine, mycophenolate and pred- 
nisone, there was still no relationship between CSA level and the occurrence of treated 
acute REJ. 
Quartile CSA Blood REJ Rate CSA Blood REJ Rate 
Level Range Level Range 
1 26-181 36/613 (5.9%) 42-264 22/293 (7.5%) 
2 161-256 35/613 (5.7%) 265.350 171293 (5.6%) 
3 256.364 29/613 (4.7%) 350.456 16/293 (5.5%) 
4 364-992 361613 (6.2%) 456-992 23/292 (7.9%) 
Conclusion: Within the range of concentrations commonly observed in a single center, 
CSA blood level alone is a poor predictor of the risk of treated acute cardiac REJ. Thus, 
dosing of CSA should not be arbitrary but rather tailored to an individual patient’s risk of 
REJ, including past episodes. 
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1134-62 T Wave Alternans is Prevalent and Correlates With NYHA 
Functional Class, LV Function, and Size in Patients With 
Idiopathic Dilated Cardiomyopathy 
Yee Guan Yap, Kudret Aytemir, Niall Mohan, Mark Gallagher, William McKenna, A. John 
Camm. St George’s Hospital Medical School, London, United Kingdom 
Background: Microvolt T wave alternans (TWA) is a measure of transmural dispersion & 
marker of ventricular tachyarrhythmias. We hypothesised that TWA is influenced by LV 
function & size in DCM patients. Method: We performed TWA on 69 DCM patients (41 
M, age: 47.9 + 14.5) & 54 controls (26M, 42.1 + 16.1) using controlled bicycle exercise 
(CH2000, Cambridge Heart). Echocardiogram, VO,max, Halter recording &late potential 
were also performed. x2 test, student’s t-test & Pearson’s correlation were used. Results: 
10 DCM patients & 5 controls had indeterminate results. There was a significant higher 
prevelence of TWA+ in DCM than controls (table). TWA+ patients had wow.? NYHA 
class, LV function & size. No association between TWA & history of VFisustained VT, 
NSVT, VPBs frequency, QT dispersion & late potential (p=NS). Conclusions: In DCM 
patients, TWA+ is prevalent & associated with worse NYHA class, LV size & function, 
suggesting a marked degree of transmural dispersion in these patients & carries a prog- 
nostic significance. 
DCM patients TWA+ (n=36) TWA- (n=21) p-value 
Age (vr.9 50.7*14.0 42.2+13.3 p=O.O26 
LVEF (%) 36.9216.0 46.3kl3.9 ~~0.026 
LVEDD (mm) 65.5ilO.Q 56.6+6.3 p=o.o04 
LVESD (mm) 53.6?13.7 44.938.3 p=o.o03 
VOpmax (mlikgimin) 52.9*21.4 67.93z16.4 p=O.O06 
NYHA: class I ,I=10 n=13 
Class II n=l6 n=8 p=o.o03 
Class Ill n=6 fl=O 
History of VFlsus- 4 4 p=NS 
tained VT 
Documented NSVT 
VPBs >lO/hr 
QT dispersion 
Positive SAECG 
DCM 
Controls 
10 7 
10 5 
27.6tl6.5 27.6kl6.9 
14 6 
TWA+ TWA- 
36 21 
2 47 
p=NS 
p=NS 
p=NS 
p=NS 
p<0.0001 
1134-63 Quantitative Assessment of Global and Regional 
Myocardial Function in Patient With Thalassemia Major With 
and Without Myocardial Iron Overload 
Michael F. Vogel, Lisa Anderson, Sally Holden, John E. Deanfield, Malcom Walker. 
Middlesex HospW London, Unifed Kingdom, Roya/ Brompton Hospital, London, United 
Kingdom 
Background:Development of congestive heart failure is a late complication of myocardlal 
iron overload in patients with thalassemia major. As ventricular function and exercise 
capacity may remain normal unit1 late in the disease process, early recognition of myo- 
cardial dysfunction due to iron loading is dewable to guide interventions such as chela- 
tion therapy. Methods:lron load of the myocardium was studied with magnetic resonance 
imaging (MRI) by measuring t2*, which is inversely proportional to tissue iron. Within 30 
days of MRI tissue Doppler imaging (TDI) of the RV and LV free wall and the septum was 
performed in an apical four-chamber view. 46 patients with thalassaemia were examined 
at age 29.2 (17.5-39.6) years and compared to 114 controls with normal hearts.40/46 
patients were asymptomatic, and 44146 had normal LV shortening fraction on m-mode 
echocardiogram. Results: Compared to normals all thalassemia patients had reduced 
global LV and RV longitudinal function and impaired diastolic function with a prolonged 
isovolumic relaxation time. 36146 had excess myocardial iron deposition (t2*<20ms).Of 
these, 33 had reglonal wall motion abnormalities in the septum (n=28), LV (n=3), RV 
(n=l) and septum and LV (n=l)dete&d by TDI. By contrast only 3112 patients with nor- 
mal t2* and thus normal myocardial iron concentration had regional wall motion abnor- 
malities, located in the septum in all 3(p<O.O5). Conclusion: Asymptomatic thalassemic 
patients with abnormal myocardial iron load and normal LV fractional ShOrteninQ have 
impaired longitudinal function, and a high incidence of regional wall motion abnormalities, 
which may both be early signs of myocardial dysfunction not detectable by conventional 
indices of functional assessment 
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1134-64 Severely Decreased Cardiac 123 I-Metaiodobenzylguanidine 
Uptake Predicts Future Deterioration of Heart Failure in 
Patients with Idiopathic Dilated Cardiomyopathy 
Shinichiro Yamada, Kenji Kaihotsu, Akira Takarada, Takatoshi Hayashi, Yasuhiro 
Tsumura, Akihiro Yoshida, Kohei Yamashiro, Teishi Kajiya. Himeji cardiovascular center, 
Himeji. Japan 
Background: Cardiac sympathetic nerve dysfunction plays an important role in the patho- 
genesis and development of heart failure. The purpose of the study is to evaluate the 
prognostic significance of 1231.metaiodobenzylguanidine imaging (MIBG) in patients with 
idiopathic dilated cardiomyopathy (DCM). Methods: Diagnostic catheterization, echocar- 
dlography and MIBG were performed at initial diagnosis of DCM in 166 patients (116 
male, 56.1+12.9 years). For MIBG imaging, heart to mediastinum uptake ratio at initial 
(HIMi) and delayed (HIMd) were obtained. These patients were followed prospectively for 
2.8+1.2 years. Result: Eight patients with sudden death (unknown reason) were excluded 
from analysis. During the follow-up period, 37 patients developed heart failure resulted in 
emergent admission and 7 died subsequently. Echocardiographic indlces at initial diag- 
nosis did not differ between the patients with and without the developement of heart fail- 
ure or death. However, HiMi and HiMd at initial diagnosis were significantly lower in 
death or heart failure group. Multiple logistic regression analysis showed that HiMd was a 
strongest predictor of the deterioration of heart failure (chi square=1 2.6, p=O.O004). Con- 
clusion: This study demonstrates that MIBG Imaging is a good predictor for deterioration 
of heart failure and indicates the importance of sympathetic nerve function in DCM. 
Heart failure Stable (N=121) Deterioration/death (N=37) P value 
Age 54.5+-13.1 60.9+-10.6 0.007 
LVDd 62.6+-8.2 64.3+-8.2 0.28 
EF 31.6+-9.8 31.9+-8.7 0.87 
HIM i 2.041.0.27 1.87+-0.29 0.001* 
H/M d 1.90+-0.34 1.66+-0.28 0.0002* 
* statistically sigmflcant 
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cardiac death (CD), sustained ventricular tachycardialventricular fibrillation (SVT/VF), or 
congestive heart failure (CHF). Forty-six patients showed TWA positive and were divided 
into the following two groups according to the median value of OHR : Group A (n=24; 
23%) with OHR less than 100 bpm and Group B (n=22; 21%) with OHR less than 110 
bpm and more than 100 bpm. TWA was negative in 37 pts (36% Group C) and indetermi- 
nate in 21 patients (20%). During a follow-up duration of 21+14 months, there were 14 
total cardiac events (4CD, SSVTNF, ICHF), 11 cardiac events (4CD, GSVT/VF, ICHF) 
including 3SCD in Group A, 2 (PSVTiVF) in Group B, IJISVTAIF) in group C. Univariate 
analysis showed that lWA with OHR less than 100 bpm (TWA+OHFi), TWA, EF, and 
NYHA were identified as univariate predictors of cardiac event. MultivarIate Cox hazard 
analysis revealed that T!AIA+OHR was the only independent predictor in stratifying the 
high risk patients in DCM. (chi-square,7.5; % Risk Reduction, 90 % ; 95% C.1, 47 to 98: 
p=O.O06). Conclwon: The OHR of TWA is a powerful risk stratifier and provides an addi- 
tional prognostic value in patients with DCM. 
1134-65 Has the Prognosis of Idiopathic Dilated Cardiomyopathy 
Improved in the Community? The Heart Muscle Disease 
Registry of Trieste 
Andrea Di Lenarda, Gastone Sabbadini, Roberto Gortan, Ellsa Carniel, Mauro Driussi, 
Cristiana Zanchi, Cinzia Di Chiara, Mlila Davanro, Giulio Scheri, Gianfranco Sinagra. 
Department of Cardioiogfi Tries&, /B/y 
Objectives: Although large clinical trials have demonstrated that new effectwe treat- 
ments for heart failure (HF) can reduce patient morbidity and mortality there is no clear 
evidence that these results have been translated into an improved prognosis of the dis- 
ease in the community. 
Methods: From 1978 to 1997, 429 HF patients affected by idiopathic dilated cardiomyop- 
athy (IDC) were consecutively studied in the Department of Cardiology of Trieste and pro- 
spectively enrolled in our Heart Muscle Disease Registry. Ninety-five patients (group 1) 
were scheduled between 1978 and 1987, whereas 334 (group 2) between 1988 and 
1997. Baseline clinical profile was similar in the 2 groups. Compared to patients of group 
1, those of group 2 were: a) sistematically followed up in our HF Clinic; b) more frequently 
treated with ACE-inhibitors (89 vs 19%, p<O.OOOl), b&-blockers (66 vs 4%, p<O.OOOi), 
digitalis (84 vs 71%, p=O.OOS) and less frequently with diuretics (60 vs 73%, p=O.O2) and 
amiodarone (22 vs 34%, p=O.Oi) Automatic defibrillator was inplanted in 3 patients of 
group 2 (2,7%). 
Results: Two, 5 and 10 year hospitalization-free survival was respectively 75, 55 and 
38% in group 2 vs 61, 42 and 21% in group 1 (p=O.O02 after stratification for HF severity). 
Two, 5 and 10 year risk of major adverse events (death. heart transplant, hospitalization) 
due to worsening HF was respectively 11, 22 and 39% in group 2 vs 31, 45 and 63% m 
group 1 (p<O.OOOl), while the risk of arrhythmias-related events was respectively 6, 20 
and 50% in group 2 vs 19, 36 and 59% in group 1 (p=NS). Hospitalizations for worsening 
HF were 8.8/100pts/yr in group 2 vs 18.3ilOOptsiyr in group 1 (p<O.OOOl), while hospital- 
izations for arrhythmias were 6.8/100pts/yr in group 2 vs 9.411 OOptsiyr in group 1 (p=NS). 
Conclusions: The analysis of our Registry shows that the employment of new effective 
treatments and the planning of a close clinical follow up are associated with a significant 
benefit on morbidity and mortality in IDC patients, mainly due to a reduction in pump fail- 
ure related events. 
1134-66 Onset Heart Rate Criteria of Microvolt-Level T-Wave 
Alternans Provides an Additional Prognostic Value in 
Nonischemic Dilated Cardiomyopathy 
Hidetsuna Kitamura, Yoshio Ohnishi, Kazumasa Adachi, Katsunori Okajima, Akihiko 
Ishida, Erdulfo J. Galealw F, Akihiro Yoshida, Mitsuhiro Yokoyama. Kobe University 
School of Medicine , Firsf Department of Internal Medicine, Kobe, Japan 
To prevent sudden cardiac death (SCD) is one of the major current issues in non- 
ischemic dilated cardiomyopathy (DCM). Recently, the analysis of microvolt-level T-wave 
alternans (TWA) has been proposed as a powerful non-invasive tool to identify the high 
risk patients. The importance of onset heart rate (OHR) in TWA has been well recog- 
nized in previous study by Smith et al. The goal of the present study is to clarify whether 
the OHR in TWA provides an additional prognostic value or not in pts with DCM. Methods 
and Results: We prospectively investigated 104 patients (84 men; 52215 years) with 
DCM undergoing TWA during exercise testing usw?g a CH2000 system (Cambridge 
Heart, Inc.), as well as determination of left ventricular end diastolic diameter, left ventric- 
ular ejection fraction (EF), signal averaged ECG, the presence of non-sustained ventricu- 
lar tachycardia and NYHA classification. The end point of this study was defined as 
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1135-68 Increased Expression of Mitochondrial Cytochrome c and 
Caspases 2,3 and 7 in Myocardium of Dogs With Chronic 
Heart Failure 
Sudhish Mishra, Ramesh C. Gupta, Victor G. Sham”, Takayuki Mishima, Anastassia 
Todor, George Suzuki, Sidney Goldstein, Hani N. Sabbah. Henry Ford Health System, 
Defroft, Ml 
Background: Cardiomyocyte apoptosis or programmed cell death occurs in heart failure 
(HF) and may play an important role in the progression of the disease. One signal trans- 
duction pathway considered important in mediating this process of cell death is increased 
cytosolic levels of mitochondrial cytochrome c. Cytochrome c can activate a series of 
caspases, members of a family of cyst& proteases, that trigger apoptosis. Caspases 2, 
8, 9, and 11 initiate the apoptotic process while caspases 3, 6, and 7 execute apoptosis. 
Methods: To explore whether this signaling pathway is activated in the failing heart, we 
examined the expression of cytosolic cytochrome c and tissue levels of caspase 2, 3, and 
7 in LV myocardium of 6 dogs with chronic HF (LV ejectIon fraction 22 + 1%) produced by 
intracoronary microembolizations. LV tissue from 6 normal (NL) dogs was used for 
comparison. Expression of cytochrome c was determined from Western blots using 
100,OOOg LV cytosolic fraction prepared from homogenate. Tissue levels of caspase 2, 
3, and 7 were determined in LV homogenate using Western blots. In all Instances, den- 
sity of bands was expressed as densitometric units/IO ug protein. 
Results: Cvtosolic levels of cvtochrome c and tissue levels of caspases 2, 3, and 7 were 
significantly-higher in HF dogscompared to NL (Table). 
NL HF P-value 
Cytochrome c 2.9 f 0.1 6.0 f 0.3 P=O.OOl 
Caspase 2 2.1 t 0.2 5.2 f 0.8 P=O.O04 
Caspase 3 0.3 t 0.02 2.5 i 0.2 P=O.OOl 
Caspase 7 2.5 f 0.2 6.7 + 0.6 P=O.OOl 
Conclusions: Cytosolic cytochrome c is increased in LV myocardium of dogs with 
chronic HF. This is accompanied by an increase in the expression of caspase 2, an initl- 
ator of apoptosis, and by an increase in caspases 3 and 7, executioners of apoptosis. 
The results are consistent with the observations of cardiomyocyte apoptosis in HF and 
point to the cytochrome c caspase signal transduction pathway as a potentially ~mpor- 
tant element of the programmed cell death machinery in the failing heart. 
1135-69 Hypertensive End Organ Damage and Premature Mortality 
Are p38 MAPK Dependent in a Rat Model of Cardiac 
Hypertrophy and Failure 
Thomas M. Behr, Sandhya S. Nerurkar, Allen H. Nelson, Tina Woods, Anthony Sulpizio, 
&deep Chandra, David Brooks, John C. Lee, Robert W. Coatney, Christiane E. 
Angermann, Jonathan D. Sackner-Bernstein, Joseph Sisko, Jerry Adams, Eliot H. 
Ohlstein, Robert N. Will&e. SmithKline Beecham, King of Prussia, PA 
Background: lsoforms of p38-Mitogen Activated Protein Kinase (MAPK) in perfused 
hearts and/or cultured cardiac myocytes are activated by neurohormones, cytokines, wall 
stress, ischemia and repeifusion. The aim of the present study was to investigate (1) acti- 
vation of cardiac ~38 during the development of HF and (2) the chronic effects of a spe- 
cific ~38 inhibitor (58239063) in a model of cardiac hypertrophy and failure (spontaneous 
hypertensive rats-stroke prone (SHR-SP)). 
Methods: In the time course study (I), SHR-SP were divided into two groups and fed 
either standard rat chow (SRC-SP) (n=l5), or a high salt/fat diet (SFD-SP)(n=35) to 
accelerate HF. Animals were sacrificed at regular intervals for p38 analysis (phospho- 
specific antibody). A time-course of Sprague-Dawley (SD) rats was also assessed as 
control. In the treatment study (Z), SHR-SP were divided into four groups (n=20 each) 
and fed either SRC, SFD or SFD plus 58239063 (1200 or 2000ppm). 
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Results: In the time course study (l), activated ~38 was elevated significantly at 3, 6 and 
9 weeks in the myocardium of the SFD-SP rats (n=3 for each time point). In this group, 
activated ~38 levels were decreased in end stage failure when compared to baseline. No 
change in total ~38 protein was noted. SD rats showed no age related ~38 activation, nor 
did the SRC-SP. The chronic treatment (2) with SB239063 resulted in 100% survival for 
both dosages aHer 20 weeks compared to 50% survival in the untreated SFD group and 
90% survival in SHR-SP on SRC (p<O.O5). Echocardiography showed prevention of LV 
hypertrophy and failure in the treatment groups. Additional end-organ protection 
observed in the treatment group included: preservation of endothelium dependent 
vasorelaxation, inhibition of proteinuria, and decreased incidence of stroke diagnosed by 
MRI. 
Conclusion: These results demonstrate a crucial role for p38MAPK in the premature 
morbidity/mortality and end-organ damage in hypertensive cardiac hypertrophy and fail- 
ure. The robust efficacy observed with chronic ~38 MAPK inhibltlon represents a com- 
mon pathway approach to the treatment of heart failure which differs fundamentally from 
the traditional concept of blocking specific neurohormonal receptors. 
1135-70 Increased Expression of Cardiotrophin-1 and gp130 During 
Transition From Hypertrophy to Ventricular Dilatation in 
Hypertensive Rats 
active in IDC while the ~38 MAPK cascade prevails in ICM. These differenses may be 
important determinants in the future development of etiology specific treatments for heart 
failure. 
FaS Fas-L c-Jurl ~38 MAPK 
NL 3.5 * 0.2 4.1 r 0.2 6.1 + 0.3 ~12~0.1 
IDC 3.6 im 0.3 1.8 f 0.2’ 7.2 k O.l* 0.2 f 0.03’ 
ICM 1.8 i 0.2*” 7.3 r 0.3”” 4.1 * 0.2*” 3.5 -c 0.2’” 
*=p<O.O5 NL vs. IDC and ICM; “=P<O.O5 IDC vs. ICM 
1135-72 Angiotensin II Antagonism Blunts Cardiac MCP-1 
Expression and Macrophage Infiltration in an Animal Model 
of Evolving Heart Failure 
Thomas M. Behr, Sandhya S. Nerurkar, Frank C. Barone, Robert N. Willette, Allen H. 
Nelson, Christiane E. Angermann, Karin M. Anderson, Robert W. Coatney, Eliot H. 
Ohlstein, Jonathan D. Sackner-Bernstein. SmifhKline Beecham Pharmacology King of 
Prussia, PA, St. Luke’s Roosevelt Hospital, New York, NY 
Neurohormonal and cytokine activation occur early in the development of heart failure 
(HF), yet the potential for these two systems to interact is incompletely defined. Prior 
studies have shown that in vascular tissues angiotensin II (All) can upregulate expres- 
sion of MCP-1, a potent chemoattractant for monocytes, macrophages and 
lymphocytes. The aim of this study was to establish whether All antagonism influences 
MCP-1 expression in myocardium of an animal model of HF (spontaneous hypertensive 
rats-stroke prone - SHR-SP) 
Methods. SHR-SP were randomly assigned to either standard rat chow (SRC), high salti 
fat diet (SFD) or SFD with eprosartan (SFD-E), an All type1 receptor antagonist, via 
osmotic minipump (25mgikgiday) for 28 weeks. MCP-1 levels were determined by quan- 
titative TaqMan real-time PCR, ELISA and immunohistochemistry. Macrophage infiltra- 
tion into myocardium was quantified immunohistochemically as the total area and 
number (no) of macrophages per eyefield at 100x magnification. 
Results. 
Background Cardiotrophin-1 (CT-i) is a potent cytokine that stimulates the assembly of 
sarcomeric units in series in cardiomyocytes through gpl30 signaling, resulting in longi- 
tudinal myocardial cell hypertrophy. However, the role of CT-I and the gpl30-signaling 
pathway during transition from IeH ventricular hypertrophy (LVH) to left ventricular dilata- 
tion (LVD) remains to be determined. Methods We examined the expression of CT-I, leu- 
kemia inhibitory factor and gp130 by competitive RT-PCR and I or Western blotting in 
Dahl salt-sensitive (DS) rats with a high-salt diet, which showed a distinct transition from 
LVH to LVD. Results The expression level of CT-1 mRNA was significantly increased at 
LVD stage (10.0+0.7x106 copies*) compared with that of LVH stage (3.3+0.8x106 cop- 
ies) and age-matched controls (1.3+0.3 and 2.1+0.5x106 copies at LVH and LVD stage, 
respectively, n=6 for each group, ‘p<O.Oi). mRNA expression of leukemia inhibitory fac- 
tor was not detected in the left ventricle at any stages by RT-PCR. The protein level of CT- 
1 in the left ventricle was increased by 1.17+0.19- and 1.56+0.12*-fold compared to that 
from control rats at the LVH and LVD stages, respectively. The protein level of gp130 was 
significantly increased by 2.57+0.43’- and 2.41+0.73’-fold compared with that of control 
rats at each stage. Isolated myocyte length (p) was 162+3# vs.152+3 (DS rats vs. age- 
matched controls) and 175+3# vs.163~2, and width was 35+1# vs.29+1 and 32+1 
vs.32+1 at the LVH and LVD stages (n=130, #p<O.O5), respectively. The ratio of the left 
ventricle to body weight was 3.06cO.09’ vs.l.98+0.05 at LVH stage and 4.03+0.21* 
vs.1.99+0.09 at LVD stages. Left ventricular end-diastolic dimension (LVDD), determined 
by echocardiography, was decreased (6.70+0.13* vs.7.27+0.10) at the LVH stage and 
was significantly increased (9.13+0.18’ vs.7.96+0.18) at the LVD stage. Wall stress (g/ 
cm2) was increased only at the LVD stage (207+9* vs.59+ 3). Conclusion Thus, the 
increased CT-1 expression seems to be related to increased wall stress, LVDD and myo- 
cyte length. CT-1 may play a central role in ventricular dilatation by increasing the myo- 
cyte length during transition from LVH to LVD in the rat hypertensive model. 
Yoshihito Takimoto, Takeshi Aoyama, Yoshitaka Iwanaga, Toshiaki Izumi, Yasuki Kihara, 
Shigetake Sasayama. Kyoto University Kyoto, Japan 
SRC SFD SFD-E 
Mortality at 28 weeks 0% 90% 0% 
MCP-I mRNA (copies of mRNA/ng total 994+140 4169+739’ 2696+51 It 
RNA) 
MCP-I protein (nglmg total protein) 76m3 163+33*’ 71+5 
Macrophage area (mm’/eyefield) 2637k243 5387*700*** 13631t331tt 
Macrophage no 4424 9li12 23+6 
Cardiac output (ml/min) 149k1.2 1os.9*9.9** 162.8i5.6 
(tp<0.05 vs. SRC), (*p<O.Ol vs. SRC), (‘*p<O.O5 vs. SRC and SFD-E), (ttp<O.O5 com- 
pared to SRC and p<O.OOl compared to SFD), (‘**p<O.Ol compared to SRC). 
Conclusions:MCP-l was significantly upregulated in this model of HF, and was associ- 
ated with immune cell infiltration, ventricular dysfunction and disease progression. All 
antagonism blunted MCP-1 expression, macrophage infiltration and significantly reduced 
mortality suggesting a key role for MCP-1 in the mechanism of action of eprosartan. 
MCP-1 appears to be an important therapeutic target in HF. 
1135-71 Discordant Regulation of Apoptosis Associated Proteins in 
Cardiomyocytes Isolated From Patients With lschemic POSTER SESSION 
Versus Idiopathic Dilated Cardiomyopathy 
Anastassia Todar, Victor G. Sham”, Norman Silverman, Sidney Goldstein, Hani N. 
Sabbah. Henry Ford Health System, Detroit, MI 
1136 Cardiac Rehabilitation 
Background: Cardiomyocyte (CM) apoptosis has been shown to occur in myocardium of Monday, March 19, 2001, Noon-2:00 p.m. 
patients with ischemic (ICM) and diopathic drlated cardiomyopathy (IDC). The mecha- Orange County Convention Center, Hall A4 
nisms responsible for activation of a this cell suicide gene program are not fully under- 
stood. Fas is a member of the tumor necrosis factor receptor family. Activation of Fas by 
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its ligand can cause apoptosis of Fas bearing cells by activating members of the caspase 
family. The stress-activated protein kinase (SAPK) cascade and p38 mitogen activated 1136-43 The Challenge of Enhancing Exercise Compliance 
protein kinase (~38 MAPK) cascade have also been implicated in the activation of CM 
apoptosis. In the present study, we examined the possible involvement of FasiFas-L inter- 
Barry A. Franklin, Jason M. Conviser, Bob Stewart, Judie Lasch, Gerald C. Timmis 
action, SAPK and ~38 MAPK in CM apoptosis in ICM versus IDC. 
William Beaumont f-kxpital, Royal Oak, MI 
Methods: CM isolated from the LV df i explanted ICM hearts and 7 IDC hearts were Background: Recent public health recommendations have emphasized the importance 
used in this study. CM isolated from the LV of 5 normal (NL) donor hearts were used for of moderate-intensity exercise on most, and preferably all days of the week. Although 
comparison. Polyclonal rabbit anti Fas, Fas-L, c-Jun, p38 MAPK antibodies were used health club memberships have escalated in recent years, there has been a paradoxical 
for Western blots and the bands quantified in densitometric units. increase in the prevalence of modern chronic diseases, especially obesity. 
Results: The results are shown in the table. Compared to NL, Fas was significantly 
downregulated in ICM but was unchanged in IDC. Fas-L, on the other hand, was down- 
regulated in IDC but significantly upregulated in ICM. C-Jun, a protein downstream of the 
SAPK cascade, was upregulated in IDC and downregulated in ICM while ~38 MAPK was 
downregulated in IDC and upregulated in ICM. Fas, Fas-L, c-Jun and ~38 MAPK were 
significantly altered in ICM compared to IDC. 
Conclusion: The downregulation of Fas-L in the face of unchanged Fas in IDC makes 
Fas-mediated CM apoptosis not likely in this disease etiology. On the other hand, the 
marked upregulation of Fas-L in ICM, while does not ensure Fas-mediated CM apopto- 
sis, it makes such a possibility more likely. The SAPK pathway appears to be more 
Methods: To evaluate the exercise habits of persons who voluntarily joined recreational 
fitness facilities, we conducted a retrospective review of member utilization records in 
one of the largest commercial fitness/health clubs (n = 325) in the U.S. 
Results: Over a one year period (1999), 831,041 new members (mean i SD age = 31.4 
+ 10.8 years: 50.4% male) joined an existing member database of 3,694,999. Workouts 
for new members were verified and tabulated using a computerized card swipe tracking 
system, with specific reference to January joiners (i.e., New Year’s resolutions). Club uti- 
lization among 1999 joiners varied from 2.9 i 4.3 swipes per month in March to a low of 
1.3 f 3.2 swipes per month in December. Average monthly usage was 1.9 f 2.9 card 
swipes. Of the 831,041 new members, 89,071 (10.7%) joined in January. The latter 
demonstrated higher average card swipes in February and March than those joining in 
later months, but lower average utilization in every month thereafter. Moreover, January 
joiners were more likely to use the clubs on average 5 1 x/month. 
Conclusion: These findings, from the largest database reported to date, are the first to 
document compliance rates among new members in commercial fitness facilities. 
Accordingly, strategies should be developed to perpetuate compliance to exercise 
programs. 
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1136-44 Assessment of Cardiac Rehabilitation Training in 
Cardiology Fellowship Programs 
Jeffrey S. Mandak, Marjorie L. King, Dalynn T. Badenhop, John M. Costello. James W. 
Ziccardi, Robert E. MartIn, Frederic D. Seifer. American Assonafion of Cardiovascular 
and Pulmonary Rehabilitation, Middleton, WI 
(mean age: 57.7k9.4, 62.9% men). ED was observed in 134 pts (49.8%). Pts with ED 
had a median stay in the prog of 57 d. vs. 303 d. for those without ED, (p<O.OOl). Univari- 
ate predictors for ED were: 
ED (+I ED (-) P value OR 
Background: Despite the clear benefits of cardiac rehabilitation in the prevention and 
treatment of cardiovascular disease, less than 25% of patients who potentially could ben- 
efit are referred to such programs. Cardiac rehab training during cardiology fellowship 
may be inadequate and this deficit may contribute to the underutiliraiion of cardiac 
rehab. The purpose of the present study is to evaluate the state of cardiac rehab educa- 
tion in cardiology fellowship programs. 
Methods: Directors of 153 adult cardiology training programs were contacted regarding 
ihe extent of cardiac rekab education provided for their fellows. Tabulated program data 
was divided according to whether they provided > or 5 1 hour of cardiac rehab training 
during a 3 year fellowship. 
Results: Response rate was 39% (59) despite 3 attempts to contact non-responders. 
On site cardiac rehab programs are available in 56% of the fellowship programs, 32% 
have programs at an affiliate hospital, 8% have no associated rehab facility. Directors 
reported that 56% of cardiologists in their programs routinely refer patients to rehab. 
Lectures pertaining to cardiac rehab are provided in 66% of programs for an average of 
2.9 hrs (SD 2.6, median 1 hr). Electwes are offered by 24% though only 18% of their fel- 
lows participate. Flehab rotations are mandatory in only 29% of programs. Nine pro- 
grams (15%) offer no cardiac rehab training. Training in exercise prescription, smoking 
cessat!on, and nutrition is not offered in 22% 22% and 30% of programs respectively. 
On site cardtac rehab facility and a cardiac rehab “expert” on faculty were assoclaied with 
more extensive training. (p<O.OS for each) Physicians involved in fellowship programs 
offering > 1 hr of cardiac rehab training were more likely to refer paiients to cardiac rehab. 
(62% referring vs. 40% for those in programs with i 1 hr of training; p<O.O5) 
Conclusions: Despite the requirement for cardiac rehab training, 15% of cardiology fel- 
lowship programs offer no training at all and a majority of those that do provide a median 
of only 1 hour of cardiac rehab education during an entire 3 year fellowship. This lack of 
training correlates with the underutilization of cardiac rehabilitation. 
Mare than 55 years old 54.5% 69.5% 0.014 0.52 (0.31-0.89) 
Less time awlability 37.9% 22.2% 0.007 2.13 (1.2-3.81) 
WC signed by r&dive 22% 37.8% 0.007 0.46 (0X-0.83) 
Not signing de WC (pts) 23.1% 13.3% 0.051 0.51 (0.26-I) 
Previous CABG 14.9% 28% 0.012 0.45 (0.23-0.86) 
Last year’s smoking 29.8% 17.03% 0.02 2.07 (1.11-3.89) 
Smoking on entry 17.9% 6.7% 0.008 3.05 (1.28-7.49) 
Adherence 1 st month > 70% 49 3% 76.3% 0.0001 0.3 (0.17-0.53) 
After using multiple logistic regresston analysis, the independent predictors of ED were 
the lack of available time for exercising (~~0.03; ORzl.9 IC 95% 1.06-3.6), the fact of 
being a smoker on entry to the prog (p=O.O2; O&3.5 IC 95% 1.18.10.46), and the lack of 
adherence to the prog during the first month (p<O.OOOl; OR=0.29 IC 95% 0.16-0.52). 
Conclusions: Variables related to personal commitment such as having time availability, 
good initial compliance with the sessions and not being a current smoker at entry, were 
the major predictors of permanence in the rehabilitation prog. These simple variables 
could be useful to identify patients at risk of early drop out in the first month of the prog, in 
whom to apply special adherence strategies. 
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830 Novel Approaches to the Treatment of 
Heart Failure 
1136-73 Physical Activity Promotes a Healthy Cardiovascular Risk 
Factor Profile but Is Unrelated to the Presence or Extent of 
Subclinical Atherosclerosis 
Monday, March 19, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Room 230B 
Allen J. Taylor, Tammy Watkins, Debbie Bell, Jon Carrow, Jody Bindeman, Irwin M. 
Feuerstein, Henry Wang, Saroj Bhatlarai, Patrick G. O’Malley. Walter ReedArmy Medical 
Center, Washington. DC 
830-I 
2:oo pm. 
Effects of Long-Term Selective ETA Receptor Blockade on 
Neurohumoral Activation In Congestive Heart Failure 
Background: Regular physical activity leads to a more favorable cardiovascular risk fac- 
tor profile and a lower risk of developing incident coronary heart disease It is unknown 
whether this effect is mediated by effeds on the presence and extent of atherosclerosis 
or other factors such as promotion of plaque stability. 
Methods: Physical activity was measured using the Baecke Physical Activity Index in 
630 asymptomatic men and women ages 40-45 without known heart disease. The 
degree of physical activity was compared to the cardiovascular risk factor profile and the 
presence and extent of subclinical atherosclerosis. 
Results: Sports-related physical activity was associated with lower body mass index (r = 
-.I 1; P = .OOl), higher HDL cholesterol (r = .13, P = ,003) and less glucose resistance as 
assessed by fasiing serum insulin levels (I = -.16; P=.OOl). Leisure-time and work-related 
physical activity were unrelated to any coronary risk variables. Subclinical atherosclero- 
sis measured using coronary calcium quantitation with EBCT was unrelated to all physi- 
cal activity dimensions. Comparing the most sedentary (lowest quartile) and most active 
(highest quartile) patients, the prevalence of coronary calcium (17.0% vs. 18.5%; P=.92) 
and mean coronary calcium scores (8+31 vs. 5?15; P=.87) were similar. In a multivariate 
model controlling for standard cardiovascular risk factors and physical activity level, only 
LDL cholesterol was associated with the presence of coronary calcium. 
Conclusion: Physical activity, particularly high-intensity exercise in sports-related activi- 
ties, promotes a healthy cardiovascular risk profile including lower body mass index and 
insulin resistance but is unrelated to the presence and extent of calcified coronary ath- 
erosclerosis. This suggests that the risk reduction associated with physical activity is 
mediated by factors other than retarding the development of calcified atherosclerosis. 
Frank Ruschitzka, Frank Ens&it, David Hurlimann, Richard Pacher, Veselin Mitrovic, 
Matthias R. Schulze, Wolfgang Kiowski, Georg Nell, Thomas F. Luscher. University 
Hoospifal, Zurich, Switzerland 
Background: The aim of this study was to investigate the neurohumoral activation during 
long-term treatment with different doses of the selective ETA receptor antagonist 
darusentan on top of standard therapy in patients with congestive heart .failure (CHF). 
Methods: Plasma-levels of endothelin-1, big-endothelin-1, Adrenalin, Noradrenalin, ANP, 
BNP and cGMP where measured before and during chronic treatment with the orally 
available selective ETA receptor antagonist darusentan (30, 100, or 300 mg) in a double- 
blind placebo controlled randomized multicenter clinical trial in 157 patients with CHF 
(present or recent hlstory of NYHA Ill) on top of standard medication. Results: Long-term 
treatment with darusentan significantly improved cardiac index. Baseline ET-1 positively 
correlated with pulmonary vascular resistance (PVR; r=0.64946, pcO.OOOl), pulmonary 
capillary wedge pressure (PCWP; wO.41334, p<O.OOOl), mean pulmonary artery pres- 
sure (MPAP; r=O.5684, pcO.0001) and right atrial pressure (RAP; r=0.58313, p<O.OOOl), 
but was inversely related to cardiac index (r=-0.52305, p<O.OOOl). Three weeks after 
treatment with darusentan, plasma ET-1 dose-dependently increased by 20% after 
administration of 30 mg of the ETA antagonist (p=O.O031), by 20% after 100 mg 
(p=O.O204), by 60% after 300 mg (p<O.OOOl), respectively. Plasma catechoiamines, 
natrluretic peptides and cGMP levels remained unchanged. 
1136-74 Variables Associated With Personal Commitment Are the 
Major Predictors for Early Dropouts to a Cardiac 
Rehabilitation Program 
Guldo Bergman, Balkis Rolong, Ruth Henquin, Luis Guzman, Rosa Zilberberg, Carina 
Gambarte, Jorge Schneider, Aldo Negn, Melina Huerin. lnstituto Cardiovascularde 
6uenos A1re.5, Buenos Aires, Argentina 
Early dropout (ED) represents an important limiting factor for the efficacy of Cardiac 
Rehabilitation (CR). The present study was developed to identify on admission and on 
the initial phase of the program (prog), variables related to those patients (pts) at risk for 
ED, defined as dropout prior to complete the first six months of the prog. In addition to 
clinlcal variables, a patlentb and/or relative’s signature of a written compromise (WC) and 
a simple questionnaire (Q) Inquiring about smoking and economic status, time availability 
for exercising, family support and their usual compliance with medical indications was 
evaluated at admission. Adherence during the first month was also considered, defined 
as assistance to > 70% of the sessions. The study included 269 consecutive patients 
Elasellne Placebo 30mg 1 oomg 300mg 
Cardiac mdex 2.16*0 35 2.38CO 43 2.55*0.47*- 2.71*0.46*’ 2.75*0.43” 
ET-I (pgiml) 3.18*1.31 3.15*1.47 3 7&l 30 4.20~1.41’ 4.66i1.52”’ 
BIS-ET-I (fmo,irnl) 3.753.5 3 .l+2.1 3.7a.9 ‘uk2.6 3.7+2 2 
AdrenalIn (pgirnl) 41+27 24-r15 28122 8&X 43*23 
Naradrenalin (pghi, ,!38*173 ,37&3 173*91 309*194 252*118 
ANP (“g/m,, m3*1*5 ,99+132 1911151 x7+172 224_1148 
BNP (“g/ml, 58&83.3 43.9+x.4 51.0*89.0 35.0*2lX 35.3+33.5 
cGMP (nghq 9.Ok5.9 7.6-t3 8 7.fZt3.4 8 w3.2 9.0+4.4 
*p=0.05,**p<0.001,*** piO.0001. Conclusions: This study for the first time demonstrates 
that long-term ETA -receptor blockade improves hemodynamics without neurohumoral 
activation in CHF. Thus, ETA-receplot-blockade may advance as a new therapeutical 
approach in CHF 
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830-2 
2:15 p.m. 
Improved cGMP Generation Correlates to Hemodynamic 
Improvement in Heart Failure Patients After 21 Days 
Treatment With the ET-A Receptor Antagonist LU135252 
Jan Monti, Sebastian Philipp, Michaela Scheuermann-Freestone, Thomas Langenickel, 
Thomas Netter, Rainer Diet& Thomas Luescher, Roland Willenbrock. Franz-Volhard- 
Clinic, Char&, Humboldt-Universifx Berlin, Berlin Germane Knoll-BASF Pharma, 
Germany 
Background: The ratio of the second messenger cGMP to plasma concentrations of ANP 
or BNP correlated to the effectiveness of the natriuretic peptides. The present study was 
designed to analyse whether a 3 week treatment of heart failure patients with the specific 
ET-A’receptor antagonist LU135252 influences the cGMP/BNP ratio and whether this 
ratio correlates to hemodynamic changes. Methods: Patients with an ejection fraction 
=35% (n=l57, mean age 57 years) received LU135252 (double-blind, either 30, 100, 300 
mgld or placebo) over a period of 21 days. Plasma concentrations of ANP, BNP and 
cGMP were determined before randomisation and after 21 days of treatment. Invasive 
hemodynamic evaluation was performed before and after the first application of 
LU135252 and after chronic treatment and revealed significant changes in cardiac index 
and pulmonary vascular resistance. Results: Plasma BNP concentrations decreased with 
100 mg (56+10 at baseline to 34+3 pmol/l, p<O.OOl) and 300 mg (46+8 to 33+6, 
p<O.OOl). The cGMPIBNP ratio increased in all treatment groups to 0.30+0.03 (30 mg), 
0.32+0.03 (100 mg) and 0.39-cO.04 (300 mg), indicating improved second messenger/ 
hormone coupling after 21 days of treatment. The cGMP/BNP ratio was significantly cor- 
related (p<O.OOl) to the decrease in pulmonary vascular resistance, while no such corre- 
lation existed between cGMP/BNP ratio and systemic vascular resistance. Conclusions: 
These data indicate that the increased cGMP/BNP ratio specifically reflects the decrease 
in pulmonary vascular resistance. The improved cGMPiBNP ratio might either be a direct 
effect of chronic ET-A receptor blockade on the efficacy of natriuretic peptides or might be 
a marker of improvement of heart failure. 
830-3 
2:30 p.m. 
BG9719 (CVT-124), an Al -Adenosine Receptor Antagonist, 
Protects Against the Decline in Renal Function Observed 
With Standard Congestive Heart Failure Therapy 
Stephen Gottlieb, D. Craig Brater, lgnatius Thomas, Edward Havranek, Robert Bourge, 
Steven Goldman, Farere Dyer, Miquel Gomez, Evan Beckman, William Abraham. 
Supported by Bogen, Inc., Cambridge, MA 
Background: Decreases in renal function are common and associated with adverse clin- 
ical outcomes in congestive heart failure (CHF) patients. Antagonism of Al-Adenosine 
receptors may improve renal function due to selective renal afferent arteriolar vasodilata- 
tion and increase sodium excretion via effects on the proximal and distal tubules. Meth- 
ods: BG9719, a selective Al-Adenosine receptor antagonist, was given to 79 stable 
NYHA Class ll.or Ill CHF patients with edema despite treatment with ACE inhibitors and 
diuretics. Patients were equilibrated on a 30 mEq Nat / 60 mEq K+ diet, on ACE Inhibi- 
tors, but diuretics were discontinued. On 2 separate dosing days, single infusions of 
BG9719 were administered +/- furosemide (60 mg), in a randomized, double-blind, pla- 
cebo controlled, crossover study to assess renal function and output. Results: A statisti- 
cally significant dose response for renal output (urine volume, sodium excretion) was 
observed across three dose levels of BG9719. No significant increase in potassium 
excretion was observed. Renal function (% change from baseline in creatinine clearance) 
improved after BG9719 compared to placebo (+ 13.5% vs 3.1%). In contrast, the 
increased renal output seen with furosemide was associated with a significant decline in 
renal function. BG9719, when given in association with furosemide, produced an additive 
effect on renal output and protected renal function when compared to furosemide alone 
(+I% “S -17%). 
Change From Baseline in Excretion (O-6 hrs) 
Excretion Placebo BG 9719 ( 0.75 ug/mL) 
Na+ (mEq)** 8.7 43.0 
Urine Volume (mL)‘* 180.9 606.8’ 
K+ Wq) 9.3 14.2 
Na+ (mEq) (+Furosemide) 187.8 270.0* 
Urine Volume (mL) (+Furosemide) 1,565.3 2,131.: 
*Statistically significant difference (~~0.05) or ** dose response 
Conclusions: On a background of ACE inhibition, single dose treatment with BG9719 
alone induced a potassium neutral natriuresis associated with improved creatinine clear- 
ance. In contrast, creatinine clearance declined with furosemide. The addition of BG9719 
to standard therapy further improved renal output while protecting renal function. Treat- 
ment with an Al -Adenosine receptor antagonist may be useful in the therapy of CHF. 
830-4 
2:45 p.m. 
Preliminary Studies on the Use of 3,5-Diiodothyropropionic 
Acid, a Thyroid Hormone Analog, in the Treatment of 
Congestive Heart Failure 
Eugene Morkin, Jr., Gregory Pennock, Peter H. Spooner, Joseph J. Bahl, Katherine 
Underhill Fox, Steven Goldman. Southern Arizona Veterans Administration Health Care 
Sysfem, Department of Cardiology, Tucson, AZ, University of Arizona, Sawer Heart 
Center, Tucson, AZ 
Background: Thyroid hormone has unique actions that make it a novel and possibly 
useful agent for treatment of congestive heart failure. Because of potential adverse 
effects of thyroid hormone, however, there has been interest in developing analogs with 
fewer undesirable side effects. We report the first clinical use of a thyroid hormone ana- 
log, 3$diiodothyropropionic acid (DITPA), for the treatment of heart failure. 
Methods: A dose-ranging study was performed in 7 normal volunteers. A double-blind 
comparison then was made of the drug vs. placebo in a group of 19 patients with NYHA 
Class ll/lll congestive failure. Patients were randomly assigned to receive either 1.875 
mglkg of DITPA or placebo daily. After two weeks the drug was increased to 3.75 mglkg 
daily for an additional two weeks. Clinical assessment, exercise capacity,echocardio- 
graphic measurements, radionuclide ejection fraction and right heart catheterization were 
obtained before and after therapy. 
Results: DITPA was well tolerated in normal volunteers. In heart failure patients receiv- 
ing the drug, no arrhythmias or other adverse effects were noted. Systolic function was 
unchanged by echocardiographic parameters but isovolumetric relaxation time was 
decreased significantly after two weeks (P = 0.05) and four weeks of treatment (P = 
0.02), suggesting improvement in the active phase of LV relaxation. Cardiac index was 
increased (P = 0.06) and peripheral vascular resistance was decreased (P = 0.03) for 
the group treated with drug for four weeks. Serum thyrotropin values were decreased and 
reverse T3 levels were increased significantly. Total serum cholesterol (P = 0.005) and 
triglycerides (P = O.OOB)were decreased significantly. 
Conclusions: The results indicate that DITPA is well tolerated in both normal volun- 
teers and patients with heart failure. In heart failure patients, treatment with the drug 
resulted in improved diastolic function, increased cardiac index and lower peripheral vas- 
cular resistance. Serum cholesterol and triglyceride levels also were reduced. DITPA 
could represent a useful new agent for treatment of congestive heart failure. 
830-5 
3:oo p.m. 
Conivaptan (Cl-1025, YM087), a Combined Vasopressin V,,/ 
V, Receptor Antagonist, Reduces Pulmonary Capillary 
Wedge Pressure Independent of Baseline Serum Sodium or 
Vasopressin Levels in Heart Failure Patients 
William B. Smith, Stuart Russell, Jalal K. Ghali, Christopher A. Painchaud, Paulina 
Selaru, Maha M. Ghazzi, Marvin A. Konstam, James E. Udelson. New Orleans Center for 
Clinical Research, New Orleans, LA, Duke University: Durham, NC 
Background: Arginine vasopressin (AVP) may contribute to progression of heart failure 
(HF) through actions on VIA and V, receptors. Conivaptan is a combined vasopressin 
V,,N, receptor antagonist. We characterized the effects of single IV doses of conivaptan 
on pulmonary capillary wedge pressure (PCWP) and urine output (UO) and assessed 
these effects’ correlation with baseline serum sodium (Na) or plasma AVP levels. Meth- 
ods: A randomized, double-blind, placebo-controlled trial enrolled patients (N=142) with 
NYHA Class Ill (89%) or IV (11%) HF who were on background medications. Hemody- 
namics were measured before administration of conivaptan IO, 20, or 40 mg or placebo 
and for 12 hours after. Results: Mean baseline PCWP for the conivaptan-treated groups 
was 24.6 -i- 0.6 mmHg. Mean baseline Na (137.5 t 0.4 mEq/L) and median baseline AVP 
(2.3 pg/mL) were within normal ranges. Conivaptan resulted in a significant decrease in 
PCWP and increase in UO versus placebo (mean peak reductions in PCWP 3-6 hours 
post treatment: -10.4% f 2.9 mmHg, -16.1% i- 3.0 mmHg, -21.5%‘+ 3.2 mmHg, -20.8%* 
* 3.0 mmHg, and mean increase in average hourly UO O-4 hours post treatment: -14.8 + 
15.1 mL, 66.2* * 15.0 mL, 119.7* f 16.3 mL, 169.3* * 15.4 mL for the placebo, 10, 20, 
and 40 mg groups, respectively,*p<0.05). In the conivaptan-treated groups, there was no 
evidence of a significant correlation between changes in PCWP or UO and baseline Na 
or AVP (correlation coefficients rpcwP, Na = -0.17 [Figure], ruO, Na = -0.013, rPcwp, AVP = 
0.06, rue, AvP = -0.2, respectively). Conclusions: In most compensated patients with 
advanced HF on background therapy, AVP and serum Na levels are normal. However, 
the PCWP reductions and increased UO seen with conivaptan in this stable patient pop- 
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ulation suggest that AVP remains important and that Gonlvaptan may have applicability in 
a more general population of HF patients, not just those with severe HF and hyponatre- 
mia. 
830-6 
3:15 p.m 
Ranolazine improves Left Ventricular Mechanical Efficiency 
in Dogs With Heart Failure: Comparison with Dobutamine 
Hani N. Sabbah, Margaret P Chandler, George Suzuki, Hideaki Morita, Omar Nass, 
Brent Blackburn, Andrew Wolff, William C Stanley. Henry Ford Health System, Detroit, 
MI, Case Western Reserve Univewty, Cleveland, OH 
Background: Ranolazine, a partial fatly acid oxidation (pFOX) Inhibitor was shown to 
acutely improve LV function in dogs with chronic heart failure (HF). In the present study, 
we tested the hypothesis that partial switching of the substrate use of the heart away 
from fatty acids towards carbohydrates with ranolazine improves LV function by improving 
mechanical efficiency without the need for an increase in myocardial oxygen consump- 
tion (MVO,) and/or coronary blood flow. 
MethQds: Chronic LV dysfunction and failure was produced in 6 dogs by multiple 
sequential intracoronary microembolizations. LV ejection fraction (EF). stroke volume 
(SV), total LV coronary blood flow (CBF), MVOp and myocardlal efficiency were mea- 
sured before (PRE) and after (POST) intravenous administration of dobutamine (2 to 4 
pgikglmin for 30 min) or ranoiaz~ne (0.5 mglkg bolus + 1.0 mglkgihr for 30 min). LV 
mechanical efficiency was determined as the ratio of LV power to LV energy expenditure, 
calculated from the LV systolic pressure, cardiac output, and the MVO,. 
Results: The results are shown in the Bble. Both dobutamine and ranolazine signifi- 
cantly increased EF and SV to the same extent and without having any effects on heart 
rate or systemic pressure. The improvements in LV function see” with dobutamine were 
associated with increased CBF and MVO, and no change in LV efficiency. In contrast, 
ranolazine improved LV function without increasing CBF or MVO:! along with a significant 
improvement in LV efficiency from 24 + 3% to 33 f 4% (P<O.O5). 
Dobutamine Dobutamine Ranolazine Ranolazlne 
PRE POST PRE POST 
EF (%) 29i4 39 i 5’ 28i3 37+3 
SV (ml) 2053 26f4 19+3 25+3* 
CBF (mlimin) 69213 95+19* 5oi13 46i-10 
MV02 (umol/ 218 i 31 306 i 66” 223 i 55 210f45 
min) 
*=P<O.O5 PRE vs. POST, “=P=O 07 PRE vs. POST 
Conclusions: Unlike dobutamine, acute intravenous infusion of the pFOX inhibitor rana- 
lazine significantly improved LV function through a marked increase in LV mechanical 
efficiency. This points to a novel approach for the treatment of HF based on a class of 
drugs that optimizes myocardial efficiency. Additional studies, however, are needed to 
determine whether the benefits of ranolazine in HF can be maintained with chronic 
therapy. 
ORAL CONTRIBUTIONS 
832 Cardiomyopathy: The Genetic Puzzle 
Unfolds I 
Monday, March 19, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Room 231A 
832-l 
200 pm. 
Mutations in the Gene for Troponin I (TNNl3) in Familial 
Hypertrophic Cardiomyopathy 
Jens Mogensen, Perry M. Elliott, lb C. Klausen, Ole Havndrup, Henrik Egeblad, Ulrik 
Baandrup, Paal S. Andersen, Michael Christiansen. Henning Bundgaard, William J. 
McKenna, Anders D. Borglum. Skejby Univers/ty Hospital, Department of Cardiology 
Aarhus, Denmark 
Background: Familial hypertrophic cardiomyopathy (FHC) is a prevalent hereditary heart 
disease. Disease associated mutations have been identified in 9 different sarcomeric 
genes. Aim: To Investigate the frequency of TNN13 mutations and the associated phano- 
type in a consecutive referral FHC population. Methods: We studied 120 unrelated FHC 
probands with unexplained hypertrophy of the myocardlum (>15mm) and their family 
members. Genetic analysis was performed by linkage analysis of all know” FHC loci, 
direct sequencing of the 8 exons of TNNl3, and restriction enzyme cleavage assays. 
Results: Two novel and 2 previously reported missense mutations were identified in 6 
unrelated families (frequency: 5%). Mutations were absent in 140 control chromosomes. 
The echocardiographic findings varied considerably. Eight individuals had mainly septal 
hypertrophy, 4 had apical hypertrophy, 1 had the obstructive form of FHC, 1 had severe 
biventricular hypertrophy accompanied by heart failure, and 1 had concentric hypertro- 
phy. Five individuals had abnormal ECGs despite normal echocardiograms, 3 had epi- 
sodes of non sustained ventricular tachycardia, and 3 died suddenly all in their fiRies. The 
penetrance was 68% and non-penetrant disease carriers were all below the age of 33. 
Conclusion: TNN13 mutations appear to be associated with a heterogeneous phenotype 
and often a severe prognosis. 
Phenotype characteristics of TNN13 mutations 
Mutation No. of gene- No. of pheno- No. of No. of sud- 
type positive type positive symptomatic den deaths 
individuals individuals individuals 
Argl62Trp, identified in 7 5 5 1 
2 unrelated families 
AsplSOGly 3 2 2 
Asp1 96As” 5 3 1 
Serl99As”, identified 14 11 11 2 
I” 2 unrelated farmlies 
Total 29 21 19 3 
832-2 
2:15 p.m. 
Association Between a Calcineurin B Gene Variant and 
Idiopathic Dilated Cardiomyopathy in Black South Africans 
Richard Brooksbank, A J. Woodiwiss, D Skudicky, K Sliwa, GP Candy, D Defterios, P 
Sareli, GR Norton. University of the Witwatersrand, Johannesburg, South Africa, Chris- 
Hani Baragwanath Hospital, Johannesburg, South Africa 
Background. There is evidence to indicate that idiopathic cardiomyopathy (IDG) has a 
genetic basis. Recent data suggests that calcineurin, a phosphatase that influences 
basal transcription of a number of growth factors, is associated with the development of 
ventricular hypertrophy and dilatation in cardiac disease. We evaluated whether a genetic 
variant of the caicineuri” B gene is associated with IDC in black South Africans. Meth- 
ods. Using direct sequencing genotyping, for a T to C substitution at the third base of 
codon 32 of axon 1 of the calcineunn B gene, was performed on deoxyribonucleic acid 
obtained from both 149 black South Africans with left ventricular (LV) dilatation and an LV 
ejection fraction ~40% and without a” established cause of heart failure, as well as in 96 
normal control subjects. Results. The CC genotype was found in excess in patients with 
IDC as compared to control subjects (pcO.004; Table). Conclusions. These data sug- 
gest that the calcineurin gene locus may be associated with the development of IDC in 
black South Africans. 
Table. Genotype and allele frequency of the calcineurin gene polymorphism (II; 
(frequency)) 
Genotype Allele 
cc CT TT c T 
Patients (“=149) 28 (0.19) 61 (0.41) 60 (0.40) 117 (0.61) 181 (0.39) 
Controls (n=96) 7 (0.07) 48 (0.50) 41 (0.43) 62 (0.67) 117 (0.33) 
832-3 
2:30 p.m. 
The Prognosis of Familial Hypertrophic Cardiomyopathy 
Caused by Myosin Binding Protein-C Glu451Gln Mutation is 
More Unfavorable Than That of lnsG791 Mutation 
Hideshi Niimura, Ryuichiro Anan, Linda L. Bachinski, Barry J. Maron, Shinichi Minagoe, 
Robert Roberts, J G. Seidman, Christine E. Seidman, Chuwa Tei. Kagoshima University 
Kagoshima, Japan, Harvard Medical School, Boston, MA 
Background: We have reported that the mutation in the cardiac myosin binding protein- 
C gene cause a familial hypertrophic cardiomyopathy with a notable feature; later onset 
and better prognosis than familial hypertrophic cardiomyopathy caused by the mutations 
in beta cardiac myosl” heavy chain gene and cardiac troponln T gene. In these two 
genes, it has been reported that each mutation cause different clinical features such as 
age of onset, left ventricular wall thickness and prognosis. But in the cardiac myosin bind- 
ing protein-C gene, clinical features in each mutation have not been analyzed sufficiently 
Methods: We have analyzed and compared the prognosis of eight familial hypertrophic 
cardiomyopathy families who have three different mutations; 20 individuals in one family 
have cardiac myosin binding p&x-C gene Glu451Gln mutation (missense mutation, 
predicted to produce a truncated protem and full length one amino acid substituted pro- 
tein), 106 individuals in three families have cardiac myos~” binding protein-C gene 
lnsG791 mutation (one base insertion mutation, predicted to produce a truncated pro- 
tein), 60 individuals I” four families have beta cardiac myosin heavy chain gene 
Arg719Trp mutation (missense mutation, predicted to produce a full length one amino 
acid substituted protein). Results: Eight disease-related deaths out of 20 affected indi- 
\iiduals were observed in cardiac myosin binding protein-C gene Glu451Gln mutation. 
eight disease-related deaths out of 106 were observed in cardiac myosi” binding protein- 
C gene lnsG791 mutation and 36 dis&se-related deaths out of 60 ware observed I” beta 
cardiac myosin heavy chain gene Arg719Trp mutation. The prognosis of cardiac myosin 
binding protein-C gene Glu451Gln mutation is significantly better than that of beta car- 
diac myosin heavy chain gene Arg719Trp mutation (pcO.O5), but is more unfavorable 
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than cardiac myosin binding protein-C gene lnsG791 mutation (p<O.Oi). Conclusion: 
Even in the familial hypertrophic cardiomyopathy caused by cardiac myosin binding pro- 
tein-C gene mutation, which is reported to have relatively favorable prognosis, have 
diverse clinical outcomes in different mutations. 
832-6 
3:15 p.m. 
Sudden Death Among Patients with a Hereditary 
Cardiomyopathy Due to a Missense Mutation in the Rod 
Domain of the Lamin AIC Gene 
832-4 
2:45 p.m. 
Differentially Expressed Genes in Human Hearts with 
Hypertrophic Cardiomyopathy 
Saroja Bharati, Takeshi Sasaki, Christine Siedman, Humberto Vldaillet. Hope Children’s 
Hospital, Oak Lawn, IL, Marshfield Clinic, Marshfield, WI 
Do-Sun Lim, Silvia Lutucuta, Robert Roberts, Ali J. Marian. Bay/or College of Medicine, 
Houston, TX 
Hypertrophic cardiomyopathy (HCM)), a single gene disorder, is caused by mutations in 
sarcomeric proteins. Patients with HCM, a paradigm of cardiac hypertrophic response, 
exhibit diverse clinical and pathological phenotypes. While the molecular genetic basis of 
HCM is well defined, the pathogenesis of its diverse phenotypes is unknown, but is 
expected to involve activation of diverse pathways. To identify molecules involved in the 
pathogenesis of cardiac phenotypes in HCM, we performed mRNA subtraction between 
normal and HCM human hearts. We screened 288 independent clones and found that 66 
were differentially expressed. Sequence analyses identified an array of 20 functionally 
known genes, of which 14 were analyzed by Northern blonings. Expression of 12/14 
genes was increased by >2 fold in the HCM heart. To determine whether differentially 
expressed genes were also upregulated in other HCM hearts, Northern blotting was 
repeated for 6 genes in 5 additional hearts. Expression of myosin light chain 2 (MLCP) 
was increased in 3, skeletal muscle LIM protein in 4, voltage-dependent anion channel 1 
in 1, a-subunit of G protein in 3, heart-shock protein 70 in 2, and NADH dehydrogenase 
in 2 hearts, at least by 2 fold. These findings suggest ihat an array of genes wiih diverse 
functions is upregulated in the myocardium of human patients with HCM to a variable 
degree. The diversity of the differentially expressed gen& and differences in the pattern 
of myocardial gene expression between different HCM hearts may contribute to ihe diver- 
sity of clinical and pathological phenotypes of HCM. Identification and characterization of 
differentially expressed genes could provide for new therapeutic and preventive 
approaches in HCM. 
List of Differentiialy expressed genes 
Background: Missense mutations in the rod domain of the lamin AIC (LMNA) gene are a 
genetic cause for adult-onset dilated cardiomyopathy (DCM). Although the variant of 
DCM is associated with progression of conduction system (CS) disease and heart failure 
(HF), thus far there is no clinical, pathological and genetic correlation for sudden death 
(SO) that occurs frequently in this entity. Methods: We undertook a prospective study of 
a kindred with the variant of DCM and SD. Subjects were consIdered to be genettcally 
predisposed if they were heterozygous for LMNA or obligate carriers. Clinical work up 
included an entire cardiovascular evaluation. Paihological evaluation was completed in 5 
hearts including gross and detailed serial section examinations of entire conduction sys- 
tem (CS) in 4 with SD. Results: Among 22 family members, 13 (59%) were genetically 
affected. Disease seventy progressed with advancing age. In Stage 1, cases were 
asymptomatic and dlsplayed no sign of overt disease. Stage II was heralded by first- 
degree AV block and occurred by agB 50 in all genetically predisposed. In Stage Ill, defi- 
nite progression of disease and symptoms were present in all cases. Clinical manifesta- 
tions of Stage Ill included: a) sinus node and atria dysfunction such as atrial flutter, 
fibrillation and SSS; b) gradual prolongation of AH and HV intervals with LBBB; and c) left 
ventricular dysfunction and heart failure (HF). About 50% had stroke or TIA and all 
required heart transplantation or permanent pacing (PM)..AII those who died suddenly 
had PM. Pathological evaluation in SD cases demonstrated distinct degenerative 
changes and marked fatty infiltration throughout the CS, the atria and ventricles. Con- 
clussions: 1)Patients with the variant of familial DCM exhibit a pattern of disease pro- 
gression far more predictable than that observed in individuals with “idiopathic” DCM. 
2)The clinical stages of the disease will be useful in counseling the unaffected relatives 
and in deciding the optimal timing of anticoagulation and/or ICD placement. S)Finally, the 
significant lack of myocardium in the atria may explain the patients’ excessive risk for 
SSS, stroke and SD. 
832-5 
3:oo p.m. 
Genetic Screening in Hypertrophic Cardiomyopathy: Most 
Beta-Myosin Mutations That Are Identified Are Novel With 
Undefined Clinical Outcomes 
Said1 A. Mohiddin, Judith Wink@ Elisha MClam, David A. Begley, Lameh Fananapazir. 
NHLBI, National lnsfitutes of Health, Bethesda, MD 
Background: Hypertrophic cardiomyopathy (HCM) may be caused by one of several 
mutations in 9 sarcomeric genes, commonly, by mutations in the beta-myosin heavy 
chain gene (MYH7): >60 r&t&ions, mostly missense in the head or head-rod junction of 
beta-myosin have been described. Some of these mutations have been associated with 
marked cardiac hypertrophy and a high incidence of sudden death, and others with mild 
disease and a benign prognosis. Hence, we evaluated the yield of Single Strand Confor- 
mation Polymorphism (SSCP) as a screening method for detecting MYH7mutations and 
its utility for genotype-phenotype correlations in HCM patients. 
Methods: Genomic DNA from 100 consecutive unrelated HCM patients was screened 
with SSCP for mutations in the first 23 exons of MYH7(coding head and head-rod region 
of beta-myosin). Anomalous conformers were sequenced. Whenever possible, restric- 
tion endonu@eases confirmed abnormal sequence. 
Results: 17 distinct MYH7 mutations resulting in single amino acid substitutions in con- 
served regions of beta-myosin were found in 19 of the 100 patients: 13 of the mutations 
or 76% have not been reported previously. All novel mutations were in or near important 
functional domains of beta-myosin, and 2 resulted in novel amino acid substitutions 
(Arg’43Gly and lle736Thr) at residues previously associated with HCM (novel hot spots). 
A family history of HCM was present or probable in 10119 (53%) patients. There was no 
difference in the frequency of a family history of HCM between patients with novel and 
known mutations [6/13 (46 %) versus 417 (57%); p=ns]. 
Conclusions (1) MYH7mutations associated with HCM are more common than we have 
previously recognized; (2) most MYH7mutations are novel with as yet undefined natural 
histories; (3) occurrence of private mutations in most patients renders genotype-pheno- 
type correlations even more challenging; and (4) any methods selected for genetic analy- 
ses must be able io identify novel mutations. Further studies are necessary to define 
clinical outcomes of the novel molecular causes of HCM. It should also now be possible 
to determine whether mutations in the same functional domain of beta-myosin have simi- 
lar natural histories. 
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1165-45 Elevated Levels of Hemostatic Markers in Elderly Patients 
With Atrial Fibrillation Who Received Adjusted Dose 
Warfarin 
Keiko Nakagawa, Tadakazu Hirai, Yoshiko Uchiyama, Tomaki Kameyama, Noriko 
Shinokawa, Syutaro Takashima, Takashi Nozawa, Hidetsugu Asanoi, Hiroshi Inoue. 
Toyama Medical and Pharmaceutical University Toyama, Japan 
Background: Elderly patients with chronic atrial fibrillation (AF) are at high risk for throm- 
boembolism. But it is unclear whether the optimal intensity of oral anticoagulation with 
warfarin is similarly effective in both elderly and younger patients with AF. We investi- 
gated relation between the intensity of anticoagulation and hemostatic activities in 
younger and elderly patients with chronic AF. Methods: Hemostatic markers for abnor- 
malities of hypercoagulability were evaluated III 55 patients (33 males, 22 females, mean 
age 66 years) with chronic AF who had received oral anticoagulation treatment with war- 
farin. Plasma levels of markers for platelet activity (platelet factor 4 and P-thromboglobu- 
[in), thrombotic status (thrombin-antithrombin Ill complex (TAT)) and fibrinolytic status (D- 
dlmer and plasmin-a-plasmin inhibitor complex (PIG)), as well as Prothrombin-lnterna- 
tional Normalized Ratio (PT.INR), were measured. Transesophageai echocardiography 
(TEE) was performed to evaluate risk of cardiogenic embolism and aortic atherosclero- 
sis. Results: Younger patients with thrombo test (TT) ~25% (mean PT-INR; 2.3) showed 
significant decrease in levels of TAT, D-dimer and PIC when compared with those with 
TT>25% (mean PT-INR; 1.6). Similarly, elderly patients with TT<25% (mean PT-INR; 2.2) 
showed significant decrease in levels of D-dimer and PIG levels as compared with those 
with TT>25% (mean PT-INR; 1.5). However, elderly patients with nr<25% showed higher 
levels of TAT and D-dimer than younger patients with TT<25% did (TAT; 8.14+2.08 vs 
2.61+0.62 ngiml, ~~0.05: D-dimer; 137.8r29.0 vs 59.6 $9.6 rig/ml, p<O.O5). In TEE vari- 
ables of elderly patients, severity of aortic atherosclerosis, but not left atrial findings, was 
significantly related to abnormalities of hemostatic markers even in those treated with 
adequate dose of warfarin. Conclusion: Despite treatment with oral anticoagulation in 
AF, elderly patients with severe aortic atherosclerosis still have an increased risk of 
thromboembolism. 
1165-46 Predictors of Recurrent Stroke Among Patients With Acute 
lschemic Stroke: The VA Experience 
Gilbert J. L’ltalien, Linda S. Williams, Morris Weinberger. Roudebush Veterans Affairs 
Medical Center, Indianapolis. IN, Bristol-Myers Squibb Pharmaceutical Research 
Institute, Wallingford, CT 
Background: We sought to determine whether clinical, demographlc factors or both pre- 
dict recurrent stroke among VA patients admltted to VA hospitals for acute ischemic 
stroke. Methods: All VA patients were identified with a first-listed discharge diagnosis of 
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acute ischemic stroke between 1991 and 1997. Measured demographic and clinical vari- 
ables included, age, ethnicity, US region, chronic cadiovascular conditions, number of 
discharge diagnoses, hospital length of stay, &-charge destination, and Charlson index. 
Clinical outcome was, defined as hospital admlssion for recurrent stroke. Cox regression 
Hazard Ratios (HR) were calculated to identify the main determinants of outcome. 
Results: A total of 55,094 patients were identified. Mean age of the predominantly male 
(98.2%) cohort was 67.8 years and 72.5% were Caucasian. There were an average of 6 
discharge diagnoses per patient and the mean length of admission was 21.6 days. Most 
patients were discharged to home (69%), and the mean Charlson Index was 3.0. The 
rate of recurrent stroke was 8.2%. Clinical variables such as diabetes (Hfl~1.2, p=.OOOl) 
and atria fibrillation (AF) (HR=1.2, p=.Ol), were the strongest predictors of recurrent 
stroke followed by the Charlson Index (H&.1, p=.Ol), ethnicity (H&1.1. p=.OZ), age 
(HR=0.99, p=.OZ), number of discharge diagnoses (HRz0.97, p=.OOl), and US region 
(HR=O.89, p=.OZ) Conclusions: Cardiovascular risk factors such as diabetes and AF 
tend to predominate over demographic factors contributing to recurrent stroke in the VA 
population. Post-stroke theraples should be more aggressively targeted to treat these 
iactors. 
1165-47 Interests of Radiofrequency Ablation of Paroxysmal 
Supraventricular Tachycardia in Elderly Patients 
B&rice Brembilla-Perrot. Daniel Beurrier, Pierre Hounez. CHU of Brabois. Vandoeuvre, 
France 
Background: Paroxysmal supraventricular tachycardia are often not tolerated in old 
patients. The purpose of the study was to evaluate the risks and benefits of radlofre- 
quency catheter ablarion of paroxysmal supraventncular tachycardla in patients older 
than 70 years compared to those obtained in patients younger than 70 years. Methods: 
Study population consisted of 209 p&en&, 18 to 86 years old (mean 56*19) with refrac- 
tory paroxysmal supraventricular tachycardla and normal sinus rhythm ECG: 157 are 
younger than 70 years (group l), ana 52 older than 70 years (group 2). Clinical presenta- 
tion was similar for the sex : female sex was the most frequent (72, 60 %); groups differed 
by a higher incidence of dilated cardiomyopathy in group 2 (21 %) than in group 1 (4% 
)(p<O.Ol). Electrophysiologic data were similar m groups 1, and 2 : airioventricular nodal 
reentrant tachycardia was more frequent (82, 85 %) than accessory pathway reentrant 
tachycardia (18, 15%) Incidence of immediate complications related to the procedure 
were similar, 11% in group 1 (1 definitive complete AV block),and 12 % in group 2 (1 
death).The follow-up (3tl years) indxxted a similar Incidence of late recurrences of 
tachycardia (7, 11.5%), a regression of cardiomyopathy in all patients but one, the 
occurence oi 2 deaths unrelated to a cardiac cause in group 2 (NS), and the deveiop- 
merit of chronic atria1 fibrillation in 2.5 % in group 1, 6 % in group 2 (NS). Conclusion: 
The benefits of radiofrequency treatment of paroxysmal supraventricular tachycardia in 
elderly patients are higher than in younger patients in term of regression of dilated cardi- 
omyopathy which is frequent in this range of age. The incidence of complications is not 
increased, but are often more severe 
1165-48 Is the Electrophysiological Mechanism of Paroxysmal 
Supraventricular Tachycardias Modified by the Age of the 
Patient ? 
@atrice Brembilla-Perrot. Pierre Houriez, Daniel Beurrier, Christine Suty-Selton, Olivier 
Claudon. CHlJ of Brabois, Vandoeuvre, France 
Background The purpose of the study was to evaluate the influence of age on the 
mechanism of paroxysmal supraventricular tachycardia III patients without known Wolff- 
Parkinson-White syndrome. Methods: 494 patients aged 9 to 86 years, with paroxysmal 
supraventricular tachycardia and normal sinus rhythm were studied. Electrophysiological 
study used a standardized protocol (atrial pacing and programmed atria stimulation 
using up to 2 extrastimuli, in control state and if necessary after infusion of isoproterenol). 
Results: 20 patients (group 1) 10 males. 10 females were younger than 20 years ; 48 
patlents (group 2), 21 males, 27 females were aged from 20 to 29 years ; 55 patients 
(group 3), 24 males, 31 females. were aged from 30 to 39 years ; 85 patients (group 4), 
38 males, 47 females. were aged from 40 to 49 years ; 125 patrents (group 5), 59 males. 
66 females,were aged from 50 to 59 years ; 83 patients (group 6). 34 males, 49 females 
ware aged from 60 to 63 years ; 57 patients (group 7), 26 males, 31 females, were aged 
from 70 to 79 years ; 21 pattents (group 8), 9 males, 12 females, were older than 80 
years The ratio male/female was not different in each group. The incidence of atrioven- 
tricuiar nodal reentrant tachycardia, accessory pathway reentrant tachycardia, induction 
of associated atrial fibrillation were similar in each group and respectively 75, 25, and 
10% in group 1, 65, 35, and 8% in group 2, 65, 35, and 14% in group 3, 61, 39, and 13% 
in group 4, 74, 26, and 15% in group 5, 63, 27, and 13% in group 6, 70, 30, and 12% in 
group 7, 62. 38, and 5% in group 8. Conclusion: Age of the patient does not influence 
the mechanism of the tachycardia or other electrophysiologic data. Atrioventricular nodal 
reentrant tachycardia IS the most frequent cause for paroxysmal tachycardias in patients 
with normal s!nus rhythm ECG from childhood to old age 
1165-49 Study of the Behavior of Autonomic Nervous System in 
Patients With Vasovagal Syncope: Is There Any Difference 
Between Young and Elderly Patients? 
George E. Kochiadakis, Nikos E. Igoumenidis, Maria E. Marketou, Emmanuel M. 
Kanoupakis, Emmanuel N. Slmantlrakis, Stavros I. Chrysostomakis, Michael I. Hamilos, 
Panes E. Vardas. Cardiology Dept., Heraklion University Hospital, Herakiion. Greece 
Background: Spectral analysis of heart rate variability was used to compare the 
changes in autonomic function during tilting in young and elderly patients with vasovagal 
syncope. 
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Methods: Twenty-one young (24 + 6 years) and 15 elderly (72 + 7 years) patients with 
unexplained syncope and a positive tilt test ware included in the study. Frequency 
domain measurements (expressed as In(ms’/Hz) of the low (0.06-0.10 Hz) and high 
(0.15-0.40 Hz) frequency bands (indexes of sympathetic and parasympathetic tone. 
respectively) and the ratio low / high frequency were computed from Halter recordings for 
4 minute intervals before and after tilting in both groups. 
Results: The mean values of low and high frequency were significantly higher in the 
young than in the elderly patients before tilt (low frequency: 5.36 versus 4.64 and high 
frequency 5.32 versus 4.49, p <O.Ol), while the low I high frequency ratio did not d&r 
(1.02 versus 1.05). In response to tilt, low frequency decreased in both groups, but in the 
elderly patients the decrease was greater (A low frequency: 0.64 & 0.47 versus 0.30 k 
0.22, p ~0.01). High frequency decreased to the same extent in both groups (A high fre- 
quency: 0.31 * 0.20 in young, 0.29 + 0.24 in elderly patients). The low / high frequency 
ratio remained constant in the young patients but decreased significantly in the elderly 
(from 1.05 to 0.97. p < 0.02). Of the 21 young patlents, 10 had a cardioinhibitory 
response to tilt, 4 had a vasodepressor and 7 a mixed type response. Of the 15 elderly 
patients, 1 had a cardioinhibitory, 9 a vasodepressor and 5 a mixed type response. 
Conclusions: Elderly patients have a more marked withdrawal of sympathetic tone in 
response to tilt than do young patients. This greater degree of sympathetic inhibition 
could explain the higher incidence of vasodepressor syncope in these patients. 
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1166-51 A New Method to Assess Left Ventricular Recovery on 
Chronic Circulatory Support Using Automated 
Echocardiography 
John Gorcsan, Ill, Donald Severyn, Bartley F! Griffith, Robert L. Kormos. Universifyof 
Pittsburgh, Pittsburgh, PA 
Background: Identification of patlents who may have recovery of left ventricular function 
on chronic mechanical assist devices for severe heart failure is difficult. 
Methods: To test the hypothesis that automated quantitative echocardiography can 
assess cardiac recovery, 13 patients aged 45 * 15 yrs on 267 + 192 days of left ventricu- 
lar assist device support for severe heart failure were studied. Devices were Thor&c in 
7 and Novacor in 6. Echo automated border detection and noninvasive arterial pressure 
were used to measure stroke area, fractional area change, and estimate preload- 
adjusted maximal power, a load-independent index of ventricular function. On-line data 
were collected during full mechanical support at 6.0 + 1.3 Umin and during a transient 
decrease to partial support at 3.0 f 0.6 Umin. 
Resuks: With partial mechanical support. 9 patients demonstrated a failing left ventricle 
pattern: stroke area decreased from 5.6t1.4 to 4.4t1.3 cm’, fractional area change 
decreased from 39+22 to 21 +I 7 % and preload adjusted maximal power was 1.6fl.4 
mWicm4. All 9 01 these patients remained device dependent; 7 were transplanted, 1 died 
on the device and one is awaiting transplant. In contrast, 4 patients demonstrated a 
recovered left ventricle pattern with partial mechanical support: stroke area increased 
from 5.0il.3 to 5.9*l.5cm2 *, fractional area change was > 30%*, and preload-adjusted 
power (figure) was 5.5+1 6 mW/cm”*, (*p<O.O5 versus device-dependent patients). All 4 
of these patients with this pattern were weaned to successful device removal and sur- 
vived to hospital discharge. 
Conclusion: Noninvasive assessment using echo automated border detection during 
partial mechanical support has potential to determine ventricular recovery and predict 
successful device removal in patients on chronic left ventricular assist devices 
1166-52 Does Standby Cardiopulmonary Bypass Support Improve 
Survival in Patients Who Sustain a Cardiac Arrest During 
Elective Percutaneous Coronary Interventions? 
Fayaz Shawl, Syed Mahmood, John Hakim, Cathy Pollock, Elizabeth Humphreys 
Washington Adventist Hosp~iai, Takoma Park, MD 
Background: Since 1988, a policy of “standby Cardiopulmonary Bypass Support (CPS)” 
and “next available operating room” is used for all elective coronary intervention (Cl). 
Standby CPS IS defined as a perfuslonist physically present along with the CPS system 
at and dedicated to the catheterization laboratory. Method/Results: A total of 23,472 Cl 
ware undertaken using this policy and 39 (0.2%) required emergency institution of CPS 
due to refractory cardiac arrest. Cardiac arrest occurred following abrupt vessel closure 
in 28 patients, ieft main dissection in 5 patients, vessel perforationlembolus in 5 patients. 
and refractory pulmonary edema in 1 patient. All patients were intubated receiving CPR 
while CPS was instituted. Mean time to CPS was 18 i 9 minutes. Ten patients were sus- 
tained on CPS for 134 ? 22 minutes until a surgical suite became available Four of 39 
176A ABSTRACTS - Cardiac Function and Heart Failure 
(10.3%) remained in refractory ventricular fibrillation until revascularization was com- 
pleted. Two patients required percutaneous LV venting. Twenty-nine patients (74%) went 
on to complete their Cl and 24 survived to be discharged from the hospital. Those who 
had Cl had their CPS cannulas removed percutaneously. Two of these developed femoral 
artery pseudoaneurysm. Of the 10 patlents who went to surgery, 7 survived. Conclu- 
sions: “Standby CPS” along with ‘first available operating room” appears to decrease 
mortality in patients who sustain a cardiac arrest during elective Cl. Also, this policy may 
make Cl safe in hospitals without immediate surgical back up. 
1166-53 lntraaortic Balloon Pumping Improves Left Ventricular 
Function but Not Prevents Remodeling in Patients With 
Microvascular Reperfusion Injury After Anterior Wall Acute 
Myocardial Infarction 
Satoshi Ku&u, Hikaru Sate, Takuji Kawagoe, Masaharu Ishihara, Yuji Shimatani, Kenji 
Nishioka, Yasuyuki Kono, Suji Nakamura, Takashi Umemura. Hiroshima City Hospital, 
Hiroshima, Japan 
Background: Although microvascular repetfusion injury as evidenced by persistent ST 
segment elevation after successful revascularization is associated with worse recovery of 
left ventricular function, the effect of IABP under these conditions remains unclear. Meth- 
ods: The purpose of this study was to assess whether intraaortic balloon pumping 
(IABP) could improve left ventricular function in patients with microvascular reperfusion 
injury after coronary angioplasty for acute myocardial infarction (AMI). We studied 76 
patients with a first anterior AMI who underwent coronary angioplasty within 6 hours after 
the onset. Microvascular reperiusion injury was defined as persistent ST segment eleva- 
tion (>50% of the initial value) after revascularization. Results: Thirty-nine patients were 
assigned to conventional therapy (control group) and 37 were assigned to IABP (IABP 
group). lncidences of in-hospital death, congestive heart failure and reinfarction were 
similar between the two groups. There was no significant difference in pretreatment left 
ventricular ejection fraction (LVEF) between the two groups (46.4+9.6% “s 48.7+7.9%, 
p=O.90). Predischarge LVEF was significantly higher in IABP group (50.9~11.5% “s 
58.2+15.2%, p=O.O4). This higher LVEF in IABP group was sustained during the follow- 
up (51.2~15.1% “s 61.3+13.7%, p=O.OZ). In contrast, left ventricular end-diastolic volume 
index was similar between the two groups at predischarge (80.lr26.0ml/m2 “s 
8l.li13.4ml/m2, p=O.86) and at follow-up (85.8r7.7mllmZ “s 83.8+18.5ml/mZ, p=O.77). 
Conclusions: IABP enhances improvement of left ventricular function independent of 
remodeling in AMI patients with microvasc+r reperfusion injury after successful revas- 
cularization. 
1166-54 Predictors of In-Hospital Mortality and Complications in 
1,009 Patients Treated With Intra-Aortic Balloon Pumping at 
the Texas Heart Institute 
Theodore K. La”, William K. Vaughn, James Ferguson. Texas Heart Insrifute, Houston, 
TX 
Background: We sought to describe the clinical predictors of in-hospital mortality and 
complications from our recent clinical experience with intra-aortic balloon pumping 
(IABP) at the Texas Heart Institute. 
Methods: We extracted clinical variables from an ongoing registry of balloon pump 
usage (BENCHMARK). All patients treated with IABP at the Texas Heart Institute 
between February 1997 and May 1999 were included (n=1,009). Variables associated 
with in-hospital mortality, lower extremity ischemia, and IABP-related bleeding were iden- 
tified and examined with a stepwise linear logistic regression model for each of the 
respective outcomes. 
Results: The mean age of the population was 62 years; 73.6% were male. The average 
ejection fraction was 29%. IABP was most frequently utilized to wean from cardiopulmo- 
nary bypass (30.5%) and in patients with cardiogenic shock (26.1%). Independent out- 
come predictors are summarized below. 
Outcome Variable Odds Ratio Significance 
(p value) 
In-Hospital Mortality Left ventricular assist device 4.04 0.0001 
(36.7 %) 
Lower Extremity 
lschemia (4.3 %) 
IABP-Related Bleed- 
Ing (1 .o %) 
Female sex 
Insertion location (operating room, 
catheterization lab, units, or emer- 
gency center) 
Low molecular weight dextran 
Coronary bypass surgery 
coronary stent 
Transmyocardial laser revascular- 
ization procedure 
Female sex 
History of peripheral vascular dis- 
ease 
t-PA “se 
Atherectomy 
1.47 0.021 
0.65 0.0001 
0.59 0.004 
0.52 0.0001 
0.44 0.002 
5.38 0.037 
2.18 0.02 
12.0 0.036 
11 .a 0.029 
6.63 0.006 
Conclusions: Specific variables can be identified that independently predict in-hospital 
mortality and complications. Female gender continues to be associated with both 
increased in-hospital mortality and a greater risk of lower extremity ischemia. 
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1166-55 Clinical Experience of an Automatically Primable 
Percutaneous Cardiopulmonary Support (PCPS) on 
Patients With Severe Cardiogenic Shock 
Takeshi Shimamoto, Mitsuhiko Matsuda, Takeshi Soeda, Sadatoshi Yuasa, Shinji 
Masuyama. Matsue Red Cross Hospital, Matsue, Japan 
Backgrounds: Circulatory support is crucial to manage severe shock. We have applied 
PCPS(TERUM0 EBS) with automatic priming function, which can start within 5 minutes. 
This article reports its efficacy. Methods: Between 10195 and 3100, 41 patients with car- 
diogenic shock received PCPS. Seven patients were not indicated for resuscitation, but 
support was Initiated due tq family’s request. Those are excluded from this study. Other 
34 patients (25 men) are studied. Their mean age was 66.3(range: 40 to 87). The type of 
shock was cardiac arrest in 5(14.7%), hypotension in 15(44.1%) and ventricular fibrilla- 
tion in 14(41.1%). Their diseased coronary artery was no organic legion in 2(5.8%), one 
in 10(29.4%), two in 7(20.6%), three in 10(29.4%) and three vessel plus left main trunk 
disease in 5(14.7%). The PCPS was indicated because of vasospastic angina in 
1(2.9%), pure AMI in 15(44.1%), papillary muscle rupture in 2(5.6%), free wall rupture in 
2(5.8%), ventricular septal perforation in 1(2.9%), abrupt closure in 7(20.6%), coronary 
dissection in 2(5.8%), coronary rupture in 3(8.8%) and pulmonary embolism in 1(2.9%). 
Fourteen patients(41.2%) fell into shock due to failure of intervention. The site where 
their shock occurred was out of hospital in 2(5.8%), on ward in 17(50.0%) and in cathe- 
terization laboratory in 15(44.1%). Conventional cardiopulmonary resuscitation was per- 
formed in 19(55.9%). Neurological deficit on insertion of PCPS was observed in 
5(14.7%). Results: The mean PCPS duration was 905.8 min(range: 52 to 10080). Fif- 
teen(44.1%) underwent catheter intervention and 12(35.3%) received emergency opera- 
tion(CABG in 10 and MVR in 2). Twenty seven patients (79.4%) were weaned from PCPS 
and discharged. This includes 10 p&(29.4%) who underwent operation. Neurological def- 
icit on discharge was observed in 6(17.6%). Conclusion: An automatically primable 
PCPS is useful to quickly initiate the circulatory support and to protect brain from further 
ischemic damage. Prompt cardiac operation or intervention, quick application of PCPS, 
which is achieved with automatic priming function, and intact neurological function might 
be key factors for successful recovery. 
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1167-56 The Effect of Biventricular Pacing on Ejection and Filling 
Hemodynamics in Dilated Cardiomyopathy Patients With 
Activation Disturbances: The MUSTIC study 
Alison M. Duncan, Sr., Tom D. Wait, Sr., Derek G. Gibson, Sr., Claude Daubert, Sr.. Dpt 
de Cardiologie CHU, Rennes. France 
Aim : To assess the effect of biventricular pacing on ejection and filling times within the 
cardiac cycle in patients with dilated cardiomyopathy (DCM) and impaired activation. 
Methods : 34 patients (pts) aged 65 + 9 years, with DCM and left bundle branch block 
(DCM-LBBB), mean intrinsic QRS duration : 176 f 19 ms, were studied before and after 
atrio-biventricular pacing. Doppler echocardiography was used to assess relative left 
ventricular (LV) ejection and filling patterns (expressed in secimin). Results were corn-’ 
pared with 17 normal subjects, aged 63 + 10 years, mean QRS duration : 91 + 9 ms, and 
with 16 pts aged 63 r 9 years with dilated cardiomyopathy but normal activation (DCM- 
NA). Results : In normal subjects relative ejection time occupied 20 * 3 seclmin, and rel- 
ative filling time was 28 f 4 sec/min. In pts with DCM-NA (end diastolic dimension (EDD) 
7.1 + 0.7 cm and end systolic dimansion (ESD) 5.9 f 0.7 cm), these times did not differ 
from normal. LV cavity dimensions were similar in pts with DCM-LBBB (EDD 7.4 f 0.9 cm 
and ESD 6.2 i 0.9 cm), but relative ejection time (17 r 3 secimin) and filling time (23 * 5 
secimin) were both shorter compared with controls and with patients with DCM-NA. 
Thus, in pts with DCM-LBBB before pacing, the ventricle was neither ejecting nor filling 
for 20 f 4 secimin compared with 12 f 2 sec/min in controls (all p < 0.001). In pts with 
DCM-LBBB after biventricular pacing, relative ejection time increased (to 20 + 3 xc/ 
min), and relative filling time increased (to 30 + 4 secimin, both p < 0.001). Thus, in pts 
with DCM-LBBB subsequent to biventricular pacing, the total time in the cardiac cycle 
spent neither ejecting nor filling fell, to 10 r 5 seclmin, which was not significantly differ- 
ent from either subjects or patients with DCM-NA. Conclusion : In patients with dilated 
cardiomyopathy, superadded LBBB greatly reduces the time available for left ventricular 
ejection and filling, with considerable prolongation of the two isovolumic periods. Atrio- 
biventricular pacing effectively normalizes this deleterious effect of abnormal activation. 
1167-57 Diagnostic Impact of Prominent Left Ventricular 
Trabeculation: Echocardiographic Differentiation of 
Secondary Hypertrophy vs. Dilated Cardiomyopathy vs. 
Isolated Ventricular Non-Compaction 
Philipp A. Kaufmann, Christine Attenhofer-Jest, Erwin Oechslin, Rolf Jenni. 
Echocardiographl Universily Hospital, Zurich, Switzerland 
Background: Trabecular meshwork with deep endomyocardial spaces surrounded by 
exaggerated hypertrophy of the trabeculae is a leading feature of isolated ventricular 
noncompaction (IVNC). As prominent trabeculation is also found in left ventricular hyper- 
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trophy (LVH) secondary to hypertension or in dilated cardiomyopathy (DCM) this finding 
alone may be mesleading. We aimed at determining unambiguous echocardiographic 
criteria allowing a differentiation of these disorders. Methods: In seven out of a series of 
34 patients with IVNC we established echocardiographic patterns characteristics for 
IVNC by validation against the anatomic examination due to death (n=4) and heart trans- 
plantation (n=3). These criteria where then applied to LVH (n=9) and DCM (n=lO) 
patients to test their discriminating validity. Results: After excluding any coexisting car- 
diac abnormality (by definition) the following criteria were found to allow the diagnosis of 
IVNC: i)Two-layer structure of thickened wall consisting of a) a compacted (C) thin epi- 
cardial band of uniform tissue b) a much thicker noncompacted (N) endocardial layer 
oftrabecular meshwork with deep endomyocardial spaces. The endsystolic ratio of N/C 
was 3.510.8 in IVNC. In LVH and DCM there was no two-layered structure but the ratio of 
trabeculated to untrabecuiated wall was 1 .I 10.5 and 0.810.4 (both p<O.Ol vs. IVNC) 2) 
Direct blood flow from the ventricular cavity into deep intertrabecular recesses documen- 
teed by color Doppler 3) The predominant iocalisation of IVNC was mid-lateral (7x), api- 
cal (6x) and mid-inferior (6x) Conclusions: The above criteria including a ratio of N/C >2 
are diagnostic for IVNC allowing unambiguous differentiation from LVH and DCM. 
1167-58 Consistent Effects of Growth Hormone on LV Function in 
Early and Advanced Stage of Heart Failure in 
Cardiomyopathic Hamsters 
Takao Nishizawa, Mitsunori lwase, Hiroaki Kanazawa, Tetsuro Nagasaka, Takaaki 
Hasegawa, Ryoji Ishiki, Fuji Somura, Hideo Izawa, Yoshihiro Ishikawa, Mitsuhiro Yokota. 
Nagoya University, Nagoya, Japan 
Background: TO-2 cardiomyopathic hamsters progressively developed LV dysfunction, 
resulting in a picture of human dilated cardiomyopathy. Clinical usefulness of growth hor- 
mone (GH) therapy is yet controversial and its efficacy may depend on the extent of LV 
functional deterioration. Accordingly, we compared the effects of GH on LV function in 
young (V: 8-12 weeks old) and adult (A: 18-22 weeks old) TO-2 hamsters. Methods and 
Results: LV function was assessed by echocardiography (13MHz). TO-2 hamsters were 
treated with human recombinant GH (2 IU/kg, s.c., daily, Y: n=8, A: n=9) or saline (V: n=8, 
A: n=9) for 4 weeks. Plasma GH levels in young TO-2 hamsters ware significantly less 
than those of age-matched control Fib hamsters (1.43rO.i 6 vs. 3.33k0.89 rig/ml). In 
adult hamsters, there was no difference between 2 groups (TO-2: 1.31+0.69 vs. Fl b: 
1.84+0.72 nglml). Body weight gain in young GH-treated group was greater than in 
young untreated group (+37.7+1.2 vs. +19.5+1.4 g). Body weight gain in adult GH- 
treated group was also greater than in adult untreated group (+22.0+0.8 vs. +5.8+0.9 g). 
LV function was progressively depressed in young untreated TO-2 hamsters, i.e. LV frac- 
tional shortening (FS) decreased from 46.3+2.2 to 24.9t1.4% and LV end-diastolic 
dimensions (Dd) increased from 4.OkO.l to 5.0+0.lmm. In young GH-treated group, 
LVFS (31.9+2.2%) at 1’2 week was significantly (p<O.OOi) greater than in untreated 
group, however, LVDd (5.3iO.lmm) was similar to that in the untreated group. Further- 
more, LV function was gradually depressed in adult untreated hamsters, i.e. LVFS 
decreased from 21.5k2.5 to 12.6+0.9% and LVDd increased from 6.0t0.2mm to 
6.8i0.3mm. In adult GH-treated group, LVFS (19.0&i%) at 22 week was significantly 
(pcO.001) greater than in untreated group and preserved the value of pretreatment 
(18.6+0.3%), again, LVDd (6.8*O.lmm) was similar to that in the untreated group. Con- 
clusion: GH induced cardiac protective effects in concert with systemic growth, irrespec- 
tive of age and the severity of LV dysfunction. 
1167-59 Long Acting Calcium Channel Blocker, Benidipine, Inhibits 
Cardiac Capillary Angiogenesis and Remodeling at an Early 
Stage of Type II Diabetes Mellitus 
lchiro Sakuma, Subrina Jesmin, Satoshi Fujii, Akira Kitabatake. Hokkaido University 
Graduate School of Medicine, Sapporo, Japan 
Background: We had observed that, in Otsuka Long-Evans Tokushima Fatty (OLETF) 
rats, a model of type II diabetes mellitus (NIDDM), reactive capillary (CAP) angiogenesis 
and concomitant fibrosis are promoted, which may result in decrease in myocardial com- 
pliance Thus, we studied whether benidipine (BN) reverses the cardiac remodeling. 
Methods: Male OLETF rats (8 weeks) were treated for 12 weeks with BN (3 mglkgl 
day)(DMTx, n=lO) or vehicle (DM, n=10), Long-Evans Tokushima Otsuka rats as control 
(Con, n=lO). Results: Body, heart and left ventricular (LV) weights, plasma glucose and 
insulin were significantly higher in DM than Con. BN lowered blood pressure. Morpho- 
metric analysis of LV CAP network and myocyte were done by double staining of CAP 
endothelial cells. CAP density (imm2) was higher in DM compared with Con (2404+//-200 
vs 1817+/-184, pc.Ol), but unchanged in DMTx (2140+/-173), and the larger CAP myo- 
cyte ratio in DM (2.0+/-.l vs 1.3+/-Z) was reversed in DMTx (1.7+/-.i, p<.Ol). CAP pro- 
portion(%) of Con, DM and DMTx (venular:intermediate:arteriolar) was 58+/-l 1:22+/- 
6:21+/-6, 18+/-4:50+/-3:31+/-4 and 16+/-3:37+/-4:45+/-6 (p<.Oi). Percent ratio of col- 
lagen and non-collagen protein was higher in DM (7.1+/-1.2, pc.01) compared with Con 
(4.8-c/-.2), and reversed to 5.0+/-.3 in DMTx. Myocyte Area (MA, mm2), myocyte number 
(NM, imm2) and CAP domain area (CDA, mm2) were also significantly changed in DM 
and reversed in DMTx. Increased molecular expressions of VEGF, TGF-beta and basic 
FGF were found in DM by immunohistochemistry, but remained unchanged in DMTx (all 
p<.Oi, lower number means deeper immunostaining). Conclusion: Thus, BN given at an 
early stage of NIDDM suppressed cardiac CAP angiogenesis and concomitant fibrosis, 
which otherwise would lead to diabetic cardiomyopathy. 
MA MN CDA TGF-beta VEGF bFGF 
Con 53911.47 1350+/-77 555+/-56 x4+/-.Ol .64+/-.03 .58+/-.05 
DM 636+/-23 120511-76 419+/-38 .49+/-.06 .47ci-.05 .49+/-.07 
DMTx 563+/-52 1274+/-113 470+/-36 .60+/-.02 .56+/-.05 .56+/-.04 
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1167-60 Bundle Branch Reentry Remains a Common and Easily 
Treatable Cause of Sustained Ventricular Tachycardia in 
Cardiomyopathy Patients 
James Coromifas, John Kassotis, Constantinos A. Costeas, Mark L. Blitzer. Columbia 
University New York, NY 
Background: Bundle branch reentry (BBR) Is cited as the mechanism of up to 6% of all 
sustained monomorphic VT (SMVT) and up to 50% of SMVT in patients with idopathlc 
dlfated (ID) cardiomyopathy (CM). The purpose of this study was to assess the incidence 
and clinical characteristics of BBR. Methods: Twenty five consecutive patients with 
inducible SMVT including 14 with ischemic CM, 8 with IDCM and 3 with valvular heart 
disease (VHD). Results: Nine patients had BBR as a mechanism of the SMVT (3/14 
ischemic CM, 5/S IDCM, and 113 VHD). The presentation was VT in 5 patients (4 inces- 
sant), syncope in 4 patients (one with VT) and cardiac arrest in 1 patient. The cycle 
length of the induced BBR VT was 270 + 40 msec (range 208-330 msec) and 819 VT had 
a typical LBBB morphology. BBR VT was induced with long-short pacing cycles in 4 
patients and standard stimulation protocols in 5 patients. In all patients, initiation was 
dependent on an achieving a critical conduction delay in the His Purkinje system (HPS) 
and there was a His or right bundle (RB) potential preceding each ventricular depolariza- 
tion. In 819, spontaneous variations in V-V intervals was preceded by similar changes in 
H-H intervals and spontaneous termination of BBR VT occurred following block in the 
HPS in 3/9 patients. Atypical features included an unusual BBE morphology in one 
patient with typical BBR using the RB for anterograde conduction, 2 to 1 block to the His 
I” one patient and an HV during the BBR VT shorter than the baseline HV in one patient. 
Radiofrequency (RF) catheter ablation of the RB was performed in 7 patients and in all 
BBR VT was no longer inducible. In 5 patients, other VT were inducible after ablation and 
ICD were placed in 2 patients. The other 3 patients already had ICD and had presented 
with incessant VT, which ceased after the ablation. Conclusions: BBR should be consid- 
ered in all patients with CM especially IDCM presenting with VT or syncope. BBR VT is 
rapid, often incessant and may not satisfy all classic criteria for BBR. Radiofrequency 
ablation can be a useful adjunct to ICD therapy in these patients. 
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1168-61 The Extent of Coronary Artery Disease and Long-Term 
Survival in Patients With Symptomatic Left Ventricular 
Systolic Dysfunction 
G. Michael Felker, Linda K. Shaw, Christopher M. O’Connor. Duke Clinical Research 
Institute, Durham, NC 
Background: An ischemic etiology of heart failure (HF) is known to be a predictor of 
adverse outcome. Many previous studies have used a clinical (rather than angiographic) 
definition of ischemic HF, resulting in potential misclassification of patients and providing 
little information about the prognostic importance of the extent of coronary artery dis- 
ease. Methods: We assessed the coronary anatomy and long-term survival of patients 
with symptomatic HF (NYHA class II or greater) and ejection fraction ~40% undergoing 
diagnostic coronary angiography between 1986 and 1999. Patients with recent MI, 
severe valvular disease, or congential heart disease were excluded. Results: 1921 
patients met entry criteria for the study. Patients with >75% stenosis of at least one epi- 
cardial vessel, history of MI, or history of revascufarization were classified as having 
ischemic HF (n=1304). All other patients were considered to have non-ischemic HF 
(11~617). Baseline clinical characteristics ware substantially different between the two 
groups, with ischemic patients more likely to be older, male, and white, and diabetic. 
Using a Cox proportional hazards model, ischemic heart failure was associated with a 
significantly worse survival than non-ischemic HF (univariate hazard ratio 1.7, p<O.OOOl). 
This finding persisted using more detailed descriptions of the extent of coronary artery 
disease such as the number of diseased vessels (hazard ratio 1.3 per vessel, p<O.OOOl) 
When assessed in a multivariate model, the number of diseased vessels provided more 
prognostic information than the binary classification (ischemic vs. non-ischemic). Con- 
clusions: Angiographically diagnosed symptomatic ischemic HF is associated with a 
worse survival than non-ischemic HF. The extent of CAD is also a powerful predictor of 
survival, and the number of diseased vessels provides additional prognostic data beyond 
the determination of ischemic etiology alone. Coronary angiography is a crucial part of 
the evaluation of symptomatic heart failure with substantial prognostic and therapeutic 
implications. 
1168-62 Predictors of Sudden Death and Death Due to Progressive 
Heart Failure in Patients in MERIT-HF 
Sidney Goldstein, Hans Wedel. Henry FordHealth System, Detroit, ML MERIT-Hf Study 
Group, Sahlgrenska Hospital, Gothenburg, Sweden 
Background: Predictors of the mode of death are important in making decisions with 
regard to the appropriate drug or device therapy for heart failure. 
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Methods: The mode death and demographic characteristics of the 2001 placebo 
patients in the MERIT-HF trial with NYHA Class II-IV heart failure and EF<40% were 
studied. 
Results: There were 217 deaths (11%) during the one year of follow-up, 132 (60%) were 
sudden (SD) and 58 (27%) due to progressive heart failure and 29 (13%) due to other 
causes. A special mortality events committee established the mode of death in all 
patients. Analysis of dichotomized baseline characteristics, which reached multivariate 
significance, is listed below. Analysis of continuous variables indicate that individuals in 
NYHA III/IV, >65 yr. age and with systolrc blood pressures (Sys BP)<130 are more likely 
to die of progressive heart failure rather than SD. Ejection Fraction (EF) was not predic- 
tive of the mode of death. 
Conclusion: Advanced age, low systolic blood pressure and NYHA Class tend to predict 
the heart failure patients who are most likely to die of progressive heart failure and there- 
fore are less like to benefit from device therapy. 
SD HF 
Risk Variable RR P-value RR P-VaiUa 
Male Sex 1.85 ,015 1.41 .32 
Age ~35 1.32 .12 3.88 .OOOl 
NYHA III-IV 1.52 ,031 3.17 .0027 
Heart Rate >80 1.24 .25 1.84 ,038 
Sys BP ~130 1.30 .15 5.99 .OOOl 
EF ~30% 1.67 .006 2.04 .022 
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1168-65 Alterations in Circulating Plasma Adenosine in Dilated 
Cardiomyopathy: A Baseline and Dipyridamole Stress Study 
Christina Petersen, Francesca Guideri, Alessandro Pingitore, Lorenza Pratali, Emifio 
Pasanisi, Eugemo Picano, France Laghi Pasini. CA/R, lnsfifute of Clinical fhysiologfi 
Piss, /tag Department of Internal Medicine, Section of Clinical Immunology S&a, /ta/y 
Background: Plasma adenosrne levels are abnormally elevated rn heart failure. Dipy- 
ridamole stress increases plasma adenosine levels in normal subjects. Aim of the study 
was to assess the plasma adenosine response curve to dipyridamole rn patients with 
depressed global left ventricular function. Methods: Two groups of patients were studied: 
I (n=26, mean age 67k-5 years), with ejection fraction 59 r 4% and known or suspected 
coronary artery disease; and II (n=l3, mean age 63ki 1 years) with idiopathic cardiomy- 
opathy, dyspnea NYHA class 2-3, e]ection fraction 32~ 5%. Adenosine was serially 
assessed by HPLC method in blood samples from peripheral vein at baseline, 2, 6, and 
12 minutes during dipyridamole infusion corresponding to no dose (baseline), low dose 
(0.28 mg/kg), standard dose (0.56 mglkg), and high dose (0.84 mgikg) respectively. 
Results: Dipyridamole - induced increase in plasma adenosinewas higher in Group I 
(1=259+90% vs II= 39 +49%, p<O.OOi). In Group I, adenosine increased progressively 
from baseline (210~42 nM/L) to “low” (63lt210 nM/L), “standard” (647+176 nM/L) and 
“high” dose (742 f 202 nM/L, p< 0.0001 vs baseline). In Group II baseline plasma ade- 
nosine levels (281+24 nM/L) were higher than rn Group I (p<O.OOl) and showed a 
blunted response to dipyridamole infusion after “low”(391 f 123 nM/L, p<O.OOl vs base- 
line), “standard” (375 t 53 nM/L, p=ns vs “low”), and “high” dose (327 f 64 nM/L p=ns vs 
“standard” ). Conclusion: When compared to patients with normal baseline function, 
patients with severe leff ventricular dysfunction have higher baseline adenosine plasma 
levels and a blunted peak adenosine increase. 
1168-66 Mode of Death in Non - lshcemic Heart Failure 
Alan B. Miller, Robert N. Belkin, Victoria Bernstein, David Frid, Jacques Lenis, Emile 
Mohler, Gerald Neuberg, Sherryn Roth, Bruce Sussex, Michael Zile, Anne Cropp, Mrlton 
Packer. University of Florida Jacksonville, Jacksonville, FL 
Introduction: In chronic congestive heart failure, mortality is generally equally divided 
between pump failure (PFD) and sudden death (SD). Methods: The PRAISE 2 trial ran- 
domized 1656 patients with non-ischemic heart farlure, NYHA class IIIB-IV symptoms, to 
receive amlodipine vs placebo. All patients received standard triple therapy and were fol- 
lowed for a mean of 30 months. Results: There ware a total of 597 deaths (36.1%) adju- 
dicated using prospective definitions. The majority of these deaths were attributed, by a 
blinded adjudication committee, to cardiovascular causes (517/697-66.6%). Of these, 
272 (52.6%)were SD and 146 (28.2%) were PFD. The non-ischemrc subset in PRAISE 1 
(421 Patients, 119 deaths;1 06 cardiovasc”lar)is a cohort with nearly identical baseline 
characteristics and followed for a mean of 14 months. In this study, mortality was also 
higher for SD (73 patients,68,9%)than PFD (36 patients, 34%). Combrning the two trials 
for a total of 2077 patients and 623 cardiovascular deaths (30.0%),the incidence of SD is 
55.4%(3451623)and PFD is 30.0%(185/623)P=c0.001. The ratio of SD to PFD is virtually 
the same rn both trials (2.0 PRAISE 1 ,I.9 PRAISE 2). Conclusions: 1)SD is the most 
common mode of death in patients with non-ischemic heart failure, occurring almost 
twrce as frequently as PFD. 2) Cause-specific mortality appears to be related to the etiol- 
ogy of heart failure. 
1168-67 Low Incidence of Myocardial Infarction in the BEST Heart 
Failure Study 
Stephen S. Gottlieb, Christopher O’Connor, Peter E. Carson, Jonathan F. Plehn, Michel 
White, lnder Anand, Marc Silver, Jeffrey L. Anderson. Heidi Krause-Steinrauf, for the 
BEST Investigators. University of Maryland, Baltimore, MD 
Although ischemic heart disease is the cause of the cardiomyopathy in a majority of 
American patients with congestive heart failure, the importance of myocardial infarction 
in the subsequent course of patients with severe heart failure is uncertain. BEST, an NIH 
and VA sponsored placebo-controlled clinical trial of bucindolol in patients with class Ill 
and IV heart failure, enrolled 2708 patients with an average follow-up of 2 years. An end- 
points committee evaluated the cause of death, including MI, sudden death, progressive 
heart failure, other cardiovascular and non-cardiovascular death. The committee also 
assessed the incidence of myocardial infarction, based upon meeting predetermined cri- 
tena of 2 of the following: clinical, EKG and enzyme charcateristics. Events with evidence 
of an ischemic cause, but not meeting MI criteria, were classified as acute coronary syn- 
drome (ACS). Although Ml was reported by investigators in 131 patients (pts), this was 
verified by the endpoints committee in only 65 pts (2.4%). An additional 40 pts (1.5%) 
had a verified acute coronary syndrome. Thus, only 3.9% of patients had a documented 
ischemic event. Sudden death (SD) occurred in 385 patients (14.2%). The table shows 
the incidence of MI, ACS and SD in patients with ischemic cardiomyopathy (CAD) and 
presumed non-ischemic etiology (non-CAD) of the heart failure by treatment group, 
where * = p < 0.05 vs placebo: 
1168-63 Digoxin Withdrawal in Dilated Cardiomyopathy Patients 
Following Normalization of Ejection Fraction With Beta 
Blockers 
Nicolas W. Shammas, Melodee L. Harris, Dawn McKincey, William J. Hauber. 
Cardiovascular Medicine, PC., Davenport, /A 
The effect of withdrawal of digoxin on left ventricular function in patients with history of 
idiopathic dilated cardiomyopathy (IDCM) following normalization of their left ventricular 
ejection fraction (LVEF) with beta blockers (BB) remains unknown. 8 consecutive IDCM 
patients (male=5, female=3) who had normalization of their LVEF following BB treatment 
had their digoxin withdrawn as part of an office protocol and their LVEF was followed. 
‘Baseline EF’ prior to BB initiation (carvedilol=6, atenolol=l, metoprolol=l) was measured 
with isotope ventriculography (IVG), echocardiography or left ventriculopgraphy. ‘Post BB 
EF’ was measured in all patients with IVG at a mean of 17.25 + 5.38 month. ‘Follow up 
EF’ was measured “sing IVG after digoxin withdrawal at a mean of 6.99 + 4.34 month. An 
experienced blinded reader interpreted the IVG scans. Below is a table summarizing the 
findings: 
Baseline EF Post BB EF Follow up EF 
28.5 * 8.26 56.1 c 4.65 51 .o * 7.35 
p<O.OOOl (Baseline EF vs Post BB EF); ~~0.05 (Post BB EF vs Follow Up EF); p&O01 
(Baseline EF vs Follow Up EF). Conclusion: this data provides potential evidence that 
digoxin withdrawal can significantly reduce LVEF in IDCM patients who had normalization 
of their LVEF after BB treatment. BB continues to have a significant positive impact on 
LVEF despite digoxin withdrawal. Large controlled trials are needed to confirm these find- 
ings. 
1168-64 Repeated Episodes of Myocardial Stunning Are Cumulative 
in Man 
Edward Barnes, David i? Dutka, Masood Khan, Roger J. C. Hall, Paolo G. Camici. MRC 
Clinical Sciences Centre, NHLl at Hammersmith Hospita/, London, United Kingdom, 
Division of Cardiology, NHLI at Hammersmith Hospital, London, United Kingdom 
Background: In patients with coronary artery disease (CAD), we have shown that a sin- 
gle episode of dobutamine-induced ischemia is followed by myocardial stunning. To 
determine whether repeated episodes of ischemia are cumulative and induce more 
severe stunning, we studied 9 patients with angiographically proven CAD and normal LV 
function. 
Methods: Patients underwent dobutamine-induced ischemia on two occasions, 75 min- 
utes apart. Absolute myocardial blood flow (MBF, ml/min/g) was measured with positron 
emission tomography and Hs ‘so at baseline, peak stress and after stress for each 
ischemic episode. Quantitative echocardiographic assessment of global (EF) and 
regional systolic function (shortening fraction [SF]), was performed at rest and regular 
intervals affer dobutamine. SF was assessed for regions subtended by a coronary artery 
with a > 70% diameter stenosis. 
Results: There was reversible global and regional dysfunction after each ischemic epi- 
sode (table). Regional MBF at baseline was 1.02+0.35. Both EF and SF were more 
severely impaired 45 minutes after the second episode of stress compared with 45 min- 
utes after the first (both pcO.Ol), despite no differences in the duration of the 2 bouts of 
dobutamine or MBF at peak stress (1.72 vs 1.69). After the 1st and 2nd episode of 
ischemia, when LV function was impaired MBF was 1.15+0.39 and 1.20a0.43 respec- 
tively, confirming stunning. 
Conclusions: Repeated episodes of dobutamine-induced ischaemia lead to cumulative 
myocardial stunning and could play a role in the pathophysiology of chronic LV dysfunc- 
tion in patients with CAD. 
Time in parenthesesare after second dobutamine. (%p<O.Ol, t=p<O.OOl vs 
baseline). 
Time Baseline 30 45 60 30(2) W2) W3 
(mins) 
EF 58.1+2 53.5*2 55.5?2 56.8+2 51.8+2t 52.3+2t 55.6+3 
SF 3.26*1 2.69klT 2.98+1 3.05+1 2.63rlT 2.65+1t 3.06~1 
CAD Non-CAD 
Placebo Bucindolol Placebo Bucindolol 
Ml 9.0% 5.2% 25% 0.9% 
ACS 2.8% 1 .5% 1.1% 0% 
SD 16.4% 17.0% 13.0% 8.4% * 
As expected Ml and ACS occurred predominantly in CAD patients, confirming the classi- 
fication. Overall, bucindolol decreased Ml and ACS (p < 0.05). Although sudden death 
was more likely in CAD pts, the excess rate was only 5.9%. With bucindolol, SD 
decreased only in pts classified as non-CAD at trial entry. We conclude that SD occurs in 
both CAD and non-CAD pts. While CAD may be the cause of some SD, most SD 
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appears unrelated to CAD. Similarly. the incidence of subsequent MI and ACS is low in 
patients with severe CHF. Nevertheless, in BEST beta-blockade decreased the frequency 
of ischemic event?.. 
1168-68 Myocardial Viability by Dobutamine Stress 
Echocardiography Predicts Improvement in Ejection 
Fraction with S-Blockade in Patients with Heart Failure: The 
BEST Trial. 
Eric J. Eichhorn, Paul A. Grayburn, Susan Mayer, Martin St John Sutton, Christopher 
Appleton, Jonathan Plehn, Jae Oh, Barry Greenberg, Anthony DeMaria, Heidi Krause- 
Steinrauf, For The BEST investigators. UTSourhwesfern Medica/ Center, Da//as, TX 
Background: O-blockers (BB) improve survival and reduce hospitaliraiion in chronic 
heart failure (Cl-IF) by brologically improving left ventricular (LV) ejection fraction (EF) 
over 2-3 months of therapy However, BB acutely reduce EF by pharmacologic with- 
drawal of adrenergic support to the failing heart. A good predictor of those individuals 
who will improve with this therapy has not been identified. This substudy of the Beta- 
Blocker Evalualion of Survival Trial (BEST) examines whether myocardial viability, as 
determined by dobutamine stress echocardiography (NE) will predict EF improvement. 
Methods: 79 patients with Class Ill/IV CHF were studied with DSE prior to receiving 
treatment with bucindolol (n=41) or placebo (n=38). Regional wall motion was assessed 
by a bllnded central reader using tine 16 segment model and a regional wall motion score 
index (WMSI) was calculated as ihe sum of the scores in each segment divided by the 
iota number of segments visualized. Contractrle reserve was defined as a change in 
WMSI < -0.2. WMSI was compared to change in LVEF by MUGA after 3 months of ther- 
apy. Death or CHF hospitalization (events) in the bucindolol patients with and without 
reserve were compared to placebo patients using the log-t-ank test to compare time-to- 
event distributions. The average duration of follow-up was 24 months. 
Results: Change in WMSI correlated inversely with change in LVEF at 3 months in the 
buclndolol patients (r=-.72, p=O.OOOl). While this substudy was not powered for events, 
bucindolol patients with contractile reserve had a trend toward fewer evenis (p=O.146) 
and those without reserve had no benefit of therapy (p=O.8). 
Conclusions: Presence of contractile reserve predicts improvement in EF with O-blocker 
therapy in patients with CHF and suggests that reverse remodeling is related to myocar- 
dial viability. 
rized as NYHA IV at least once since onset of CHF were eligible. The primary endpoint 
was the absolute change from baseline to latest available LV ejection fraction (EF) mea- 
surement determined by radionucllde ventriculography between Carvedilol and placebo. 
Results: The trial prospectively randomized 118 patients with CHF of ischemic (n=44) or 
non-ischemic (n=74) etiology, a mean i-SD [median] age of 53.3k9.8 [55.5] years, and a 
mean LVEF at baseline of 19.91t6.6 [20.1]%. Mean *SD [median] absolute change of 
LVEF from baseline was +6.0&9.3 [+3.9]% in the Carvedilol group versus +0.7*7.1 
[O.O]% in the placebo treated patients (p<O.OOB [<0.006, Wilcoxon, Z-sided]) in the inten- 
tion-to-treat population (n=74) and +8.2ilO.3 [+6.0]% in Carvedilol versus +1.417.9 
[O.O]% on placebo (p<O.Oll [<0.013, Wilcoxon, 2.sided]) in the per-protocol population 
(n=52). Serious adverse events were experienced by 33/60 patients (13 deaths) on pla- 
cebo and 29158 patients (9 deaths) on Carvedilal. 
Conclusion: Even I” patients with endstage CHF accepted for TX pharmacological ther- 
apy may significantly improve cardiac function over a prolonged period of time. Carvedilol 
appears to be an appropriate and safe drug also in this severely 111 patient population. 
1168-71 The Prognostic Value of Peak Exercise Oxygen 
Consumption (VOp) Testing in Heart Failure Patients on 
Beta-Blockers 
Linda R. Peterson, Allison Barrett, Pilar Herrero, Timothy Meyers, Ali A. Ehsam, Edward 
M. Geltman, Gregory A. Ewald, Michael W. Rich, Joseph G. Rogers. Washington 
University, St. Louis 
7 168-69 Echo-Doppler Mitral Flow Monitoring: an Operative Tool to 
Evaluate Day-to-Day Tolerance and Effectiveness of Beta 
Blockers Therapy in Patients With Chronic Heart Failure. 
Background: In the early 1990’s, studies showed that testing of peak oxygen consump- 
tion (VO,) in patients with heart failure (CHF) predicted outcome and arded in the timing 
of cardiac transplantation. However. these studies were performed before beta-adwner- 
gic blockers were shown to decrease mortality in the CHF patients and, hence, before 
these drugs became widely used in this population. Moreover, since beta-blockers are 
known to affect heart rate and blood pressure and may cause fatigue, their affect on VO, 
peak measurements and their prognostic value is not clear. Thus, the purpose of this 
study was to determine the prognostic value of VO, peak in predictmg mortality in 
patients with CHF Methods: Patients from the heart failure/transplant clinic (N=279) who 
underwent VO, peak testing from 5/l l/93 to 9/l/00 were studied. A patient’s VO, peak 
test date was either his/her first test ever (if never on beta-blockers) or the first test date 
after being started on beta-blockers. Patients were excluded if actuarial survival was 
unknown or if patients were taking a beta-blocker other than carvedilol or metoprolol. 
Results: Of the 279 patients studied (age range 19-73 years), 39 died and 38 were 
transplanted. Forty-three percent (N=lZO) were on beta-blockers at the time of their VO, 
lest. The mean VO-, oeak of the oatients who were still alive at the end of the follow-up 
period was significaiily higher than in those who were not (p=O.OOl): 
Soccorso Capomolla, Oreste Febo, Giampaolo Guazzotti, Angelo Caporotondi, Maria 
Teresa La Revere. Marco Gnemmi, Andrea Mortara, Giandomenico Pinna, Margherita 
Vona, Franca Cobelli. Fondazione S. Maugeri, Clinica de/ Lavoro e de//a Riabilitazione, 
IRCCS, kbt. Scient ~%ntescano, Moniescano(Pavia), k/y 
Beta-Blocker Patients Non-Beta-Blocker Patients 
Background: predictors of effectiveness and tolerance of treatment with beta-blockers in 
patrenis with chronic heart failure (CHF) have not been still identified. Recent data shown 
that baselIne mitral flow and its variations after loading manipulations are a powerful 
prognostic marker in this population. Aims: to evaluate if diastolic reserve could foretell 
ihe tolerance and the effectiveness of a chronic treatment with carvedilol in patients with 
CHEMethods: the mitral flow pattern (MFP) has been recorded by methodic echo-Dop- 
pier at baseline, after infusion of nitroprusside of sodium (1.2r.8 microgramslkgimin) and 
after passive leg lifting I” 118 consecutive patients (52k9 yrs) with CHF(EF25%+7). The 
clinical management of titration dosage, therapeutic variations, Interruption treatment, 
additional examinations and the hard cardiac events (cardiac death and transplantation 
in [status onej) were considered. According to deceleration time(DT) of early diastolic fili- 
ing of mitral flow after loading manipulations we identified the following MFP:Gl- restric- 
tive irreversible(DT<l30 msec);GZ- restrictive reversible(DT xl30 msec);G8 non- 
restrictive stable(DTx130 msec);G4-non-restrictive instable(DTcl30msec).Results:G1- 
G4vsG2-G3 (‘p<.O5).& table: MFP and NYHA functional class were significantly corre- 
lated to the complexity of the clinical managemeni((f+.46 p<.OO4). The patients that had, 
or acquired a restrictive MFP afbr loading manipulations suf!ered a better number of car- 
diac events than those that had or acquired a non-restrictive MFP(19/29(65%) vs. 9189 
(lo%), pc.00001). Conclusions: In patients with CHF and similar degree of systolic dys- 
function, those who showed a reduced diastolic reserve are more frequently intolerants 
and manifest a small clinical benefit after beta-blockers therapy. 
VO, peak of patients alive 
(mlikglmin) 
VO, peak of patients dead 
or transplanted (ml/kg/ 
min) 
17.1 * 5.6 15.8 * 4.8 
13.3 * 3.4 13.8 +z 6.1 
Analysis with a Z-way ANOVA showed that there was no significant effect of beta-blocker 
status on a patients’ outcome as predicted by his/her VO;?. Conclusion: Beta-blocker 
use in patlen& with CHF does not detrimentally affect the prognostic value of VO, peak 
testing. 
1168-72 Is There a Difference in Patient Comprehension of Acute 
and Chronic Clinical Cardiovascular Trials? 
Rita Yuval, Klari Uziel, Nomi Gordon, Amnon Merdler, Nader Khader, Bashaer Karkabi, 
David A. Halon, Basil S. Lewis. Lady Davis Carmel Medical Center, Haifa, lsrael 
Background: Despite attention to GCP guIdelines and concern for pt rights, little atten- 
tion has been paid io pts’ point of wew regarding participation in randomized clinical tri- 
als. Pt comprehension may be different if recruited in an acute vs chronic medical 
situation. 
MFP(pts) Dcm(nxJ) therapeutic Treatment AddltiO”ai 
“arlatlom p&s(%) hterr”pti0” pts(%) eXamlnatio”S pts(%, 
Gi (17) 33*30 14(82%)* 10(59%)’ 15(88%)* 
G2 (42) 46132 10(24%) 1(2%) 12(28%) 
G3 (47) 57i-32 2(4%) l(S) 4(8%) 
G4 (12) 24*14* 6(50)* 5(41%) 7(58%)’ 
1168-70 Efficacy and Safety of Carvedilol in Severe Heart Failure 
Patients Accepted for Heart Transplantation 
Methods: We studied 70 consecutive pts participating in 6 clinical heart failure (CHF) 
trials. After end (3-6 mth later) of follow-up period, anonymous self-completed question- 
naire was administered and analyzed. Findlngs were compared with those of 150 acute 
infarction (Ml) pts who answered similar questionnaire after participating in the ISIS-4 
study. 
Results: Twelve (18%) of CHF trial pts reported little or no comprehension of the trial, 
while 38 (56%) believed they had partial and 18 (27%) full understanding of the trial. 
Findings were almost identical in Ml trial pts (18%, 50%, 32%, NS). In both CHF and Ml 
pts, perceived comprehension was greater in those with a longer recollected duration of 
explanation (CHF p=O.O03, Ml p<O.OOl). In CHF pts comprehension was greater in pts 
who had participated in a positive study (p=O.O02). In neither group was comprehension 
related to recollected type of explanation (oral, written, both) or by whom explanation 
given (physician, nurse, both). 
Relation between recollected duration of explanation and perceived 
comprehension 
Christiane E. Angermann, Arigelika Costard-Jaeckle, Mario C. Deng, for the EFICAT-Trial 
study group. Me&x/ Clinic (lnnenstadf) of the University, Munich. Germany, 
Cardnthoracic Clinics of the Univers~bes Kiel, Muens?er, Germany 
Background: Carvedilol has shown beneficial effects on mortality in NYHA class II-IV 
patients with congestive heart failure (CtiF). This study was performed to determine 
effects of Carvedilol in patients with end stage CHF accepted for transplanlation (TX). 
Methods: The study was designed as a double-blind, randomized, placebo-controlled 
trial and conducted in 3 German transplant centers. Study duration was 12 months. 
Patients accepted for TX with advanced left ventricular (LV) systolic dysfunction catego- 
Little/no Partial Full 
comprehension comprehension comprehension 
Recollected duration CHFpts Ml pts CHF pts Ml pts CHF pts MI pts 
of explanation 
Short 6 (60%) 10 4 (40%) 4 (29%) 0 (0%) 0 (0%) 
(71%) 
Medium-length 5 (12%) 12 24 (59%) 38 (60%) 12 (29%) 13 (21%) 
(19%) 
Long 1 (6%) 1 (2%) 10 (59%) 21 (43%) 6 (35%) 27 (55%) 
ISOA ABSTRACTS - Cardiac Function and Heart Failure JACC February 2001 
Conclusions: 1. Despite the major difference between recruiting pts to a clinical trial in 
chronic elective outpatient setting (CHF) vs acute emergency situation (acute Ml), per- 
ceived comprehension of the trial was almost identical in the 2 pt cohorts. 2. In both 
groups, almost 20% of pts reported little or no understanding of the trial. 3. Much 
progress needs to be made to achieve goal of true informed consent in clinical research 
trials. 
botic and profibrinolytic response to exercise, and second, to determine whether 
differences in response occurred between subjects who developed ischemia and those 
who did not. Methods: We studied 218 subjects (158 male) aged 58+/- 12years who 
underwent a diagnostic exercise stress test. 31% had known coronary artery disease. All 
studies were performed in ihe morning. The Bruce protocol was used, and the majority of 
patients had adjunct Tc99m sestamibi scanning. Samples were obtained with subjects 
seated immediately before and after maximal exercise from a” intravenous cannula or 
separate venipuncture, after initial discard of 3ml blood. Von Willebrand factor (vWF) was 
measured using Immune- turbidometric Assay, fibrinogen using the Claws method; tis- 
sue plasminogen activator (TPA) antigen, plasminogen activator inhibitor (PAI-1) antigen 
and C-reactive protein was measured using an ELISA assay. ’ = p<O.OOl for exercise 
versus rest values. Changes were compared between ischemic and nonischemic groups. 
Results: 
Comparison of % Increase with Exercise 
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1169-43 Maximal Exercise Testing Without Direct Physician 
Supervision 
Keith Ende, Mark Goodwin, Vincent Bufalino, Debra Doud, Marybeth Antone. Edward 
Cardiovascular Institute, NapewiNe, IL, Midwest Heart Specialists, Naperville, IL 
Maximal Exercise Testing (MET) has been used extensively over 50 years to diagnose 
various cardiac conditions, particularly coronary artery disease. This procedure has 
proven safe with 0.8 major complications per 10,000 tests when done under direct physi- 
cian supervision. As better-trained personnel became available, we sought to determine 
the safety of utilizing non-physician practitioners to supervise exercise studies in a car- 
diovascular center. Physicians screened and referred all patients to the lab but were not 
present for the study. Cardiologists were avaiiable within the car$ovascular institute. 
From July 1, 1996 to August 17, 1999, 10,003 patients were tested at the Edward Cardio- 
vascular Institute, a” outpatient diagnostic center on the hospital campus. All referred 
patients presented with various reasons for stress testing, some of which included chest 
pain, arrhythmias, congestive heart failure, and risk factor evaluations. All test supervi- 
sors were either Master-Prepared Exercise Physiologists or Bachelor-Prepared Nurses. 
All of them were ACLS certified and had completed an exercise course along with 500 
directly supervised METS. The test supervisors performed 12-lead interpretations, symp- 
tom analysis, and determined proper end-points. All tests were interpreted by cardiolo- 
gists. 
The 10,003 METS included exercise and pharmacologic studies. Only two patients had 
major complications with one sustained ventricular tachycardia and one ventricular fibril- 
lation, requiring full resuscitation. There were no deaths or myocardial infarctions. Both of 
the patients were stabilized and revascularized. Only six patients had testing deferred at 
ihe discretion of the supervisor for new onset ischemia, uncontrolled hypertension, or 
arrhythmias. Therefore, maximal exercise testing is a safe procedure when performed by 
well-trained non-physician personnel in an appropriate cardiovascular center-type set- 
ting. 
lschemia No lschemia Unadi ~-value Adi we sender 
(“=62) (n4 56) 
TPA 70%* 1 1 1 %* 0.03 0.04 
vWF 9%* 14%” 0.03 0.18 
Fibrinogen 2%* 4%’ 0.36 NS 
Heart rate 107%* 1 1 1 %* 0.10 NS 
Systolic BP 32%’ 34%’ 0.36 NS 
PAI- and C-reactive protein did not change significantly with exercise. Conclusions: 
Exercise produced significant increases in vWF, TPA and fibrinogen both in sub@& who 
did and did not develop ischemia. These prothrombotic(vWFand fibrinogen) and profi- 
brinolytic (TPA) changes may provide a balance and explain why exercise rarely leads to 
thrombosis. However, the percent increase for TPA versus vWF was greater among sub- 
jects without ischemia than those with ischemia. Further prospective study is needed to 
determine whether an imbalance in the hemostatic response to exercise stress is predic- 
tive of AMI. 
1169-74 Exercise Capacity Precisely Reflects Arteriogenic 
Adaptation to Femoral Artery Occlusion in Mice 
Swen Wolfram, Tibor Ziegelhoeffer, Dim&i Scholz, Borja Fernandez, Wolfgang Schaper. 
Max-Pfanck-institute, Dept. Experimental Cardiology, Bad Nauheim, Germany 
Background: A large number of methods is used for evaluation of capillary (angiogene- 
sis) or arterial (arteriogenesis) growth in experimental animals. Although these methods 
can predict relatively well the increase or decrease in perfusion of targeted areas, they do 
not reflect the physiological performance itself so important in human medicine. 
Methods: Six male wildtype mice svl29 underwent a bilateral femoral artery ligation. Six 
non-ligated littermates served as a control. Seven days after ligation, all mice had to per- 
form a standard exercise test on a rodent treadmill until the point of fatigue was reached. 
At the end of the exercise test the performed work for each animal was calcul&d and 
expressed in Joule (J). Exercise tests were repeated every seven days until day 28 post- 
ligation. Color Laser Doppler Perfusion Imaging (LDI) of the feet were performed before, 
on day 3, 7, 14 and 21 after surgery in a climatized chamber at 37OC. 
1169-44 Assessment of Tolerance of Acute Exercise and Bicycle 
Results: Exercise capacity was significantly decreased at each time point tested 
Training in Moderate Heart Failure Patients With Cardiac 
(P<O.Ol) when compared to control. It increased from 21.20 f 1.58 J at day 7, to 37.03 f 
Troponin I? 
4.44 J at day 14, and to 48.20 + 4.64 J at day 21, representing the 29.1%, 50.8% and 
66.1% of control, respectively. After 28 days exercise capacity remained unchanged 
Olaf Schulz, Ariane Kramer. Heinrich-Mann-Hospital for Cardiac Rehabilitation, Bad 
Liebenstein, Germany, Cooperative Interventional Cardiology Spandau, Berlin, Germany 
Cardiac troponin I (cTnl), indicating myocardial damage, has bee” reported to be ele- 
vated in decompensated heart failure (HF). We tested, whether a release of cTnl can be 
observed in moderate HF after acute and endurance physical activity. Methods: 28 HF 
patients (NYHA 11-111, ejection fraction 31+8%) without signs of myocarditis or myocardial 
ischemia were investigated at a symptom-limited exercise test (E) (68237 Watt) and a 
bicycle training session (T) (48130 Watt over 20.30min; at >80% of max heart rate). cTnl 
was measured at red and hourly over 5 hours after E as well as 4 and IO hours after T 
with a new dendrimer technology (Stratus CS, Dade Behring, Marburg, Germany; cutoff 
value for minor myocardial damage 80 pgiml). The results were compared with data from 
IO subjects without HF (control group; ejection fraction 260%). Results: (1 index for 
~~0.05, 2 for pc0.001: “between rest and max post-exercise level, # between E and T, 
§between patients and control): 
cTnl [pgiml] at baseline max after E max after T 
no HF (“=lO) l&10 40+14 31+16# 
moderate HF (n=28) 42t54§ 77i61**,§ 5&56’,##,§ 
In moderate HF, cTnl exceeded 100 pg/ml at rest in 2, after E in 6 patients. After T, cTnl 
was increased only in this 2 patients who showed elevated cTnl already at rest. Conclu- 
sion: In contrast to subjects without heart failure, some moderate heart failure patients 
showed a slight cTnl-release after symptom-limited exercise. Bicycle training at submaxi- 
mal heart rate appears to be safe in terms of a cTnl-release. 
1169-73 Hemostatic Response to Exercise Stress: Potential 
Mechanism of Increased Cardiovascular Risk 
Anne Binasis, Stephanie Pratley, Paul Roach, Elizabeth Bernard, Margaret Duguid, 
Marie-Christine Kopp, Mark Woodward, Geoffrey H. Tofler. Roya/ North Shore Hospital, 
Sydnel: Australia 
Background: Traditional risk factors fail to fully predict acute myocardial infarction (AMI). 
While ischemia during exercise testing is a prognostic marker, AMI frequently occurs at 
sites that had no prior severe stenosis. Since heavy exertion can trigger AMI, and hemo- 
static factors predict risk, the purpose of the study was first, to determine the prothrom- 
when compared to day 21 (66.8% of control; 46.67 i 4.67 J). Exercise capacity of “on- 
ligated control animals did not change during the four weeks of exercise t&i”g indicating 
ihat no training effect was produced by the weekly exercise tests. The data obtained by 
LDI show a” increase in foot perfusion from 29.9% at day 3, to 46% at day 7, to 50.1% at 
dayl4, and to 56.4% of control at day 21 with no increase thereafter. 
Conclusion: The results of exercise tests are in good agreement with perfusion mea- 
surements obtained by LDI. This indicates, that exercise capacity as a physiological 
marker provides a useful tool to evaluate success of a” arterio and/or angiogenic ther- 
apy. Moreover, exercise testing can examine the accuracy of other methods used for 
evaluation of capillary and collateral artery growth. 
ORAL CONTRIBUTIONS 
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804-2 
4:15 p.m. 
The Use of N-Terminal Atrial Natriuretic Peptide and Brain 
Natriuretic Peptide to Detect the Presence of Left 
Ventricular Systolic Dysfunction: A Population Based Study 
Stephen 0. Robb, Theresa A. McDonagh, Caroline E. Morrison, Henry J. Dargie 
University of Glasgow, Glasgow United Kingdom 
Background: Circulating levels of both N-terminal atrial natriuretic peptide (N-ANP) and 
brain “atriuretic peptide (BNP) have been shown to be elevated in left ventricular systolic 
dysfunction (L.V.S.D.) and may be potential screening tests for the condition. 
JACC February 2001 ABSTRACTS - Cardiac Function and Heart Failure 18lA 
Methods: 1009 individuals agecl55 to 74 years were randomly selected from the popula- 
tion of North Glasgow. Each completed questionnatres regarding medical history, breath- 
jessness, and medication. A 12 lead E.C.G. was recorded and Minnesota coded. An 
echocardiogram was performed and N-ANP and BNP were measured in a blood sample 
by indirect radioimmunoassay. An L.V. ejection fractron (L.V.E.F.) was calculated usrng a 
biplane Simpsons method in 750 people; whose results were considered further. 
Results: The median L.V.E.F. was 50.7% Based on a subgroup considered free from 
evidence of cardiovascular disease L.V.S.D. was defined as an L.V.E.F. of ~~35%. This 
was found in 50 individuals (6.7%). Peptide concentrations were higher in individuals with 
L.V. systolic dysfunctron than in individuals with normal L.V. function: N-ANP: 3.89 v 
2.24ng/ml*‘. BNP: 39.35 v 13.30pg/ml**(** PcO.001). Receiver operator curves showed 
that N-ANP at a concentration (cont.) of 1.73ng/ml had a sensitivity (sens.) of 80% and a 
specificity (spec.) of 31.8% for detecting L.V.S.D.. BNP at a cont. of 15.20pglml per- 
formed better: sens. 82.0% spec. 57.6%. The negative predictive values (N.P.V.) were 
high: N-ANP 95.6% BNP 97.8%. A group of 301 individuals with evidence of ischaemic 
heart disease on E.C.G. and questionnaires had a prevalence of L.V.S.D. of 13.0%. The 
N.P.V. of peptide measurements was high in thus group: N-ANP at 1,45ng/ml 95.6%. BNP 
at 8.30pgiml 98.2%. The prevalence of L.V.S.D. in 204 individuals who reported breath- 
lessness was 12.4%. BNP was superior to N-ANP as a screening test in this group: sens. 
88.0%, spec. 56.9%, and N.P.V. 97.1% at a cont. of 160pg/ml. The corresponding val- 
ues for N-ANP at a cont. of 1.84ngiml were sens. 64.0%, spec. 38.3%, and N.PV. 
94.5%. 
Conclusion: The role of N-ANP or BNP in screening IS likely to be to exclude L.V.S.D.. 
so avoiding the need for echocardiography in some individuals. 
804-3 
4:30 p.m. 
N-Terminal Pro Brain Natriuretic Peptide Reduces the Need 
for Echocardiography in the Diagnosis of Heart Failure in 
the General Population 
Bjoern A. Groenning, llan Raymond, Fran& Pedersen, Jens C. Nilsson, Matthias 
Baumann, Jijrgen Trawinski, Per R. Hildebrandt. Department of Cardiology and 
Endocrinoiogy, H:S Frederiksberg Hospital, University of Copenhagen, Copenhagen, 
Denmark, Integrated Health Care Solutions. F Hoffmann-La Roche Ltd., Base/, 
Swifzerland 
Background: The purpose of the study was to evaluate N-terminal pro brain natriuretic 
peptide (NT-proBNP) as a marker for heart failure and/or impaired left ventricular ejection 
fraction (LVEF) in a large age-controlled sample of the general population. 
Methods: Randomly selected subjects (385 women & 298 men) in 4 age groups (50-59 
(n=177); 60-69 (n=207); 70-79 (n=177); >80 years (n=122)) filled in a heart failure ques- 
tionnaire, were examined clinically, had an electrocardiogram (ECG) and an echocardio- 
graphy performed and plasma levels of NT-proBNP and creatinine (CREA) were 
measured. 
Results: Left ventricular dysfunction (LVD) was present in 11% of the subjects, defined 
as LVEFc0.55. EGG’s were classified as normal (NECG) (72%) or abnormal (28%) from 
predefined criteria. From data on previous heart disease, symptoms, medic&on and clin- 
ical examrnation, subjects were classified according to the Gothenburg Heart Failure Cri- 
teria (GHFC) as normals (53%) Stage 1 (21%), Stage 2 (20%) or Stage 3 (6%). Markers 
for LVD were evaluated in a multiple regression analysrs, where NT-proBNP, sex, systolic 
blood pressure, CREA and NECG came out as independent predictors of LVD. A high 
level of NT-proBNP was associated with a low LVEF (r=-0.33, p=3*10-‘*). NT-proBNP and 
NECG were the only variables to remain independent markers for LVD across all gender- 
and age groups. Markers for the clinical diagnosis of heart failure (GHFC 1.3) were eval- 
uated in multiple logistic regression analyses. Across ail GHFC stages, NTproBNP came 
out as the most powerful independent marker, eliminating LVEF from the logistic model in 
all GHFC stages, except Stage 1. In GHFC stages 2 & 3 taken together (manifest heart 
failure), NT-proBNP (standardized parameter estimate (SPE) =-0.25), age (SPE=-0.23) 
heart rate (SPE=-0.19) and NECG (SPE=0.13) came out as independent markers. 
Conclusion: in this large sample of the general population, NT-proBNP came out as the 
single most powerful marker for LVD as well as for the clinical diagnosis of heart failure, 
The results point towards an increased role for NT-proBNP in the pre-hospital diagnosis 
of heart failure and may reduce the need for echocardiography at this diagnostic level. 
804-4 
4145 p.m. 
B-Type Natriuretic Peptide (BNP) Predicts Future Cardiac 
Events in Patients Presenting to the Emergency Department 
With Dyspnea 
Alex T. Harrison, Padma Krrshnaswamy, Radmila Kazanegra, Quyen Dao, Alan Maisel. 
San Dkgo VA Health Care System, San Diego, CA. University of California San Diego 
(UCSD), San Diego, CA 
Background: BNP is a neurohormone secreted irom the cardiac ventricles in response 
to volume expansion and pressure overload. We have recently demonstrated that BNP 
can differentiate congestive heart failure (CHF) from other causes of dyspnea in patients 
presenting to the emergency department (ED). The purpose of this study was to assess 
whether BNP levels drawn in patients presenting to the ED with dyspnea was a predictor 
of future cardiac events. 
Methods: In 325 patients presenting to the ED with dyspnea, BNP levels were 
determined. Patients were then followed for 6 months lookmg for the following endpoints: 
death (cardrac and non-cardiac). hospital admissions (cardiac), and repeat ED visits for 
CHF 
Results: 95 patients (29%) developed a cardiac endpoint withrn 6 months of the Initial 
ED visit. Initial BNP level was 804 ci- 105 pg/mL in patients with a CHF endpoint versus 
211 +/- 27 pg/mL in patients without a CHF endpoint (p < 0.0001). A receiver operator 
curve (AOC) analysis yielded: 
flOC (Area Under the Curve = 0.859 +/- 0.023) 
The above BNP cut-points displayed the following: 
BNP W Accuracy Sensitivity Specificity Positive Negative 
mL) (%) w (“4 Predictive Predictive 
Value (%) Value (%) 
480 85.5 57.9 91.4 58.9 91.1 
210 76.6 84.2 75.0 41.7 95.7 
58 59.4 96.5 51.5 29.7 98.6 
BNP also distinguished cardiac from non-cardiac mortality. Patients who died from car- 
diac causes (N=26) within 6 months of the initial ED visit had significantly higher BNP val- 
ues (1096 -I-/- 194 pg/mL) than those patients (N=16) who died of non-cardiac causes 
(127 +/- 31 pg/mL; p < 0.0001). 
Conclusion: Thus, BNP levels measured in patients presenting with dyspnea to the ED 
are highly predictive of future cardiac events. Utilization of BNP levels in patients pre- 
senting with symptoms of GHF should prove to be a cost-effective solution in decreasing 
subsequent repeat ED visits, hospitalizations, as well as overall cardiac mortality. 
804-5 
5:OO p.m. 
Sequential Measurement of Natriuretic Peptides to Monitor 
Progression of Heart Failure 
G Tjeerdsma, Yigal M. Pinto, Frans Boomsma, Dirk Jan van Veldhuisen. University 
Hospital, Groningen, The Netherlands 
Background: Early identification of chronic heart failure (CHF) patients at high risk for 
progression of CHF may allow for a change in strategy before symptoms ensue. Although 
it is known that elevated levels of N-terminal natriuretic peptides (N-ANP) are found in 
patients with CHF, it is unknown whether sequential N-ANP measurement can identify 
patients at risk for progression of heart failure. Methods: We studied 280 patients with 
advanced CHF (NYHA functional class IIIIV, mean left ventricular ejection fraction 0.22 
(+/-0.07). N-ANP (pmol/l) was determined at baseline and after 1 and 3 months. Patients 
were stratified into 4 groups; 1) baseline N-ANP>iOOO and subsequently increasing, 2) 
baseline N-ANP>lOOO and subsequently decreasing, 3) baseline N-ANP <IO00 and sub- 
sequently increasing, 4) baseline N-ANP<lOOO and subsequently decreasing. 
Results:The highest risk ratio for progressron of CHF (pcO.002, risk ratio 5.56 [1.88- 
16.471) was found in patients with a high baseline N-ANF, who increased further, accord- 
ing to the Cox proportional-hazards model. This was independent of other baseline char- 
acteristics. Of all cases of worsening HF 49% occurred in these patients. No significant 
increases of risk were observed in any of the other subgroups. Finally, patients in this 
group had the poorest survival outcome (figure, piO.001, compared to the other groups). 
Conclusion: A high and further increasrng N-ANP powerfully predicts worsening of CHF, 
and predicts a poor outcome. Therefore, sequential N-ANP measurement could be of 
value to monitor CHF and to direct treatment. 
804-6 
535 p.m. 
Superiority of Plasma BNP to Echocardiography in 
Assessing the Impact of Therapy Upon NYHA Class in a 
Heart Failure Clinic 
Shang-Chiun Lee, Sharon M. Sandberg, Denise M. Heublein, Susan M. Nelson, 
Margaret M. Redfield, John C. Burnett. Mayo Clinic, Rochester 
Background: BNP has recently been reported to serve as a guide for CHF therapy. It 
remains however unknown if changes in plasma BNP correlate with symptoms following 
the therapy. We compared the utility of plasma ENP to echocardiographic measurement 
of ejection fraction (EF) in assessing the impact of therapy upon NYHA classification. 
Methods: Ninety-eight subjects with known heart failure (HF) were evaluated (CHF: 
NYHA I = 17; NYHA II = 38; NYHA Ill = 29; NYHA IV = 14). Baseline EF measured with 
2-D and M mode echocardiography and plasma BNP measured with radioimmunoassay 
(Shionogi) were obtained. NYHA class was determined independently by attending HF 
specialists, who were blinded to the study. Forty-one subjects were (e-studied during a 6. 
12 month follow-up period during which drug therapy was optimized by the attending HF 
specialists. Results: At baseline, both plasma BNP and EF correlated positively with 
NYHA (P < 0.0001 vs P = 0.05, respectively). Plasma BNP was a more sensitive and 
specific marker for NYHA class when compared to EF by ROC analysis (area under ROC 
curve: 0.90 vs 0.73, respectively). At follow-up, only changes of BNP correlated to 
changes of NYHA class after optimizing therapy (P = 0.02) while changes in EF did not 
correlate (P = 0.78). When comparing the two visits, BNP decreased (-45% +/- 12%, N = 
14, P = 0.002) in subjects whose NYHA class improved while BNP remained unchanged 
(-1% +/- IO%, N = 25, P = 0.95) in those whose NYHA class remained stable. In two 
patients whose NYHA class deteriorated, BNP tended to increase (+58% +/- 5% N = 2, 
P = 0.06). There was no change in EF in those whose NYHA class improved or remained 
unchanged (+40% +/- 22%, P = 0.09 and +14% +/- IO%, P = 0.20, respectively). With 
further analysis, the absolute change in BNP in those who improved NYHA class was 
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also greater than in patients whose NYHA class remained unchanged (-92.0 +/- 28 vs -6 
+/- 22 pgiml, P = 0.02). Conclusion: This investrgation demonstrates the superiority of 
plasma BNP compared to EF by echocardrography in assessing the impact of therapy 
upon NYHA class. This study supports BNP as a non-invasne test that may enhance the 
medical management of HF therapy in the outpatient setting. 
JACC February 2001 
4:30 p.m. 
837-3 Vitamin C and E Retard the Progression of Transplant 
Associated Coronary Arteriosclerosis-Impact of Baseline 
Endothelial Function 
Dominik Behrendt, Marco Wainstein, Peter Ganz, Scott Kinlay, James C. Fang. Bugham 
and Women’s Hospital, Boston, MA, Linus Pauling Institute, CorvaNis, OR 
Background: In heart transplant patients, excessive vascular oxidant stress may predis- 
pose to transplant associated arteriopathy (TxAA). Endothelial dysfunction is associated 
with more rapid development of TxAA. We have shown recently that treatment with anti- 
oxidant vitamins C and E retards progression of TxAA. Whether coronary endothelial 
dysfunction soon after transplantation determines the response to antioxidant vitamin 
therapy is unknown. Methods: In a double blind prospective study, 35 patients (O-2 years 
post cardiac transplantation) were randomized to combined treatment with vitamin C 500 
mg bid and E 400 IU bid (n=15) or placebo (n=20) for 1 year. Coronary vasomotor 
response to acetylcholine (ACh) (10-S to 10-6 M) was assessed at baseline to identify 
patients with normal (dilation to ACh) versus abnormal (constriction to ACh) endothelial 
function. The average intimal index obtained from 10 random sites during IVUS pullback 
was the primary endpoint to evaluate the progression of TxAA. Results: Over 1 year, inti- 
mal index increased 9t10 % (me.an~SD) in the placebo group, but remained unchanged 
(Or4 %) in the vitamin group (p=O.O03). in the placebo group, patients with abnormal 
endothelial function at baseline (n=S) demonstrated a greater increase in intimal index 
than patients with normal endothelial function (n=lZ) (1 I+12 % vs 5+4 % ~~0.05). In the 
vitamin group, intimal index remained unchanged in patients with both normal (n=6) and 
abnormal (n=9) endotheiial function (1+3 % and -1 + 5 % respectively). Conclusion: Sup- 
plementation with antioxidant vitamins C and E retards the progression of transplant cor- 
onary arteriopathy In the placebo group, endothelial dysfunction identifies patients, who 
are at increased risk for TxAA. Antioxidant vitamins prevent progression of TxAA espe- 
cially in patients at high risk with endothelial dysfunction at baseline. 
837-4 
4:45 p.m. 
lntimal Thickness One Year After Cardiac Transplantation Is 
a Strong Predictor of Long Term Clinical Outcome: A Serial 
Intravascular Ultrasound Study 
Ravish Sachar, Samir Ft. Kapadia, Khaled M. Ziada, Navdeep Boparai, Luba Platt, 
Timothy D. Crow?, Robert E. Hobbs, Steven E. Nissen, E. Murat Turcu. The Cleveland 
Clinic Foundation, Cleveland, OH 
ORAL CONTRIBUTIONS 
837 Cardiac Transplantation, Rejection, and 
Graft Vasculopathy 
Monday, March 19, 2001, 4:00 p.m.-530 p.m. 
Orange County Convention Center, Room 230B 
837-i 
4:00 p.m. 
Enhanced Vascular Smooth Muscle Cell Expression of Early 
Growth Response Factor-l as a Result of Acute Cellular 
Rejection and Graft Vasculopathy in Cardiac Transplant 
Recipients 
Howard J. Eisen, Sheri E. K&man, Michael Autieri. Temple University School of 
Medicine, Philadelphia, PA 
Acute cellular rejection (R) and graft vasculopathy (GV) are significant causes of morbid- 
ity and mortality in patients after cardiac transplantation (TxP). Though R has been impli- 
cated in the epidemiology of GV development and may be related to GV pathogenesis, 
the exact relationship of these on a molecular level is not well understood. Early growth 
factor-l (Egr-1) is a transcription factor which is induced by vascular injury and regulates 
the expression of other genes which result in activation and remodeling of vascular 
smooth muscle cells (VSMCs). Previous work in animals has shown that Egr-1 expres- 
sion is enhanced in the early stages of GV but the expression of this gene in TxP patients 
as a result of R or GV is unknown. To understand the role of Egr-1 in the development of 
R or GV and to explore its potential as a surrogate marker for both, we obtained endomy- 
ocardial biopsy specimens from TxP patients and coronary artery specimens from TxP 
patients with GV who were retransplanted and from normal controls who died of non-car- 
diac causes. The samples were fixed in formalin, embedded in paraffin and analyied 
immunohistochemically with antibodies specific for Egr-1. Extensive expression localized 
to the nucleus of VSMCs of arterioles was noted in biopsies from patients with ISHLT 
Grade 3A (moderate) R with no expression in biopsies from patients with ISHLT Grade 0 
(no) R. Nuclear expression of Egr-1 was also noted in cardiac myocytes and lymphocytes 
of patients with 3A R but this was not seen in patients with Grade 0. Even more extensive 
nuclear expression of Egr-1 was noted in VSMCs in the intima and media of arteries 
obtained from patients with GV compared to a complete absence of expression observed 
in coronary arteries from non-transplant patients without coronary artery disease. We 
conclude that Egr-I expression is enhanced in the nuclei of VSMCs of endomyocardia I 
biopsies from patients with 3A R and from coronary arteries of patients with GV. Egr-1 
expression in VSMCs may thus play a role in the development of GV in TxP patients with 
R as the Egr-I expression observed in R can result in VSMC remodeling. 
4:15 p.m. 
837-2 Thl Differentiation of Circulating T Lymphocytes Predicts 
Coronary Endothelial Dysfunction in Cardiac Transplant 
Recipients 
Jiirg Koglin, Heiko Methe, Daniela Wiegand, Bruno Meiser, Wolfgang von Scheidt. 
Medizinische Kiinik 1, Universiltsklinikum Grosshadern, Munich, Germany 
Background: The development of transplant vasculopathy remains to be the major 
impediment to long-term graft survival. In animal models, Thl differentiation of activated 
lymphocytes has been suggested to promote this form of chronic rejection. 
Methods: To test this hypothesis in the human setting, we evaluated 34 transplant recip- 
ients 1 to 3 years after transplantation. To detect early signs of transplant vascuiopathy, 
coronary microvascular endothelial function was assessed as vasomotor response to 
acetylcholine (30 ~gimin ix. for 5 min) measured with an intracoronary Dopplerwire. A 
coronary flow reserve c2 was considered abnormal. To compare T cell differentiation in 
recipients with and without endothelial dysfunction, we measured intracellular interferon- 
y and interleukin-4 expression in circulating CD3 cells using flow cytometry. To assess 
transcriptional activation of the Thl or Th2 program in these cells, we measured relative 
gene transcript levels (RT-PCR) of Thl and Th2 signature cytokines and transcription fac- 
tors. 
Results: Endothelial dysfunction was detected in 8 out of 34 transplant recipients. The 
presence of endothelial dysfunction was strongly associated with an increased expan- 
sion of interferon-y-producing CD3 lymphocytes (25.1*3.9% versus 8.7*5.6%; pcO.0001) 
indicative of a Thl response. Transcript levels for the Thl cytokines interferon-y 
(p=O.OOOi) and interleukin-2 (p<O.Oi), and the Thl transcription factor Stat4 (~~0.05) 
were significantly increased in recipients with endothelial dysfunction. In marked con- 
trast, lymphocytes expressing interleukin-4 or transcript levels of Th2 markers (interleu- 
kin-4 and -10, Stat6) did not differ between recipients with and without endothelial 
dysfunction. 
Conclusion: The development of endothelial dysfunction as an early marker of trans- 
plant vasculopathy is associated with the emergence of interferon-y-producing Thl lym- 
phocytes This indicates that Thl mechanisms might contribute to the development of 
transplant vasculopathy. Clinically, cytokine profiling of circulating lymphocytes from 
transplant recipients might be a useful to evaluate the arteriosclerotic risk after transplan- 
tation. 
Background:. Intravascular ultrasound (IV&S) is a sensitive method for evaluating 
allograft vasculopathy after transplantation, but the ability of h/US to predict long term 
clinical outcome remains undefined. 
Methods: From 1992 to 1997, IVUS was performed after transplantation in 297 vessels 
in 143 patients (2.1t0.7 arteries/patient). lntimal thickness was measured at 2 time 
points, baseline (1.0?0.5 months) and 1 year (12.0+0.5 months). For each coronary seg- 
ment, the sates with the minimum and maximum thickness were identified. Abnormal 
thickness was defined as 20.5.mm. Paired analysis of 1069 matched sites at 1 year mea- 
sured the change in intimal thickness. Two cohorts were identified, patients wth “rapidly 
progressive” vasculopathy, defined as an increase in thickness >0.5mm at 1 year at any 
site, and patients with “minimal progression,” no site increasing 20.6 mm. Donor trans- 
mitted atherosclerosis was also assessed at baseline. Patients were followed for a com- 
posite endpoint of all cause mortality, new segmental left ventricular dysfunction, new Q- 
waves, and/or a fall in ejection fraction <35%. 
Results: Ultrasound at 1 year demonstrated rapidly progressive vasculopathy at one or 
more sites in 54/143 (37%). At a mean follow-up of 59?18 months (range 30-90) com- 
posite adverse outcomes occurred more frequently in the rapidly progressive group than 
the minimal disease group (35% vs 17%, p=O.O3). Although mortality was not different 
(17% vs ll%,p=O.45), actuarial Kaplan-Meier 5 year event free survival was worse 
among patients with rapidly progressive disease, (67% vs 86% p=O.O05). There was no 
significant difference in outcome in patients with donor transmitted lesions (25% vs 21%, 
p=O.57) 
Conclusions: Rapidly progressive transplant vasculopathy, defined as >0.5mm increase 
in intimal thickness within the first year after transplantation, is a powerful predictor of 
event-free survival. 
837-5 
5:00 p.m. 
Regulation and Induction of Growth and Transcription 
Factors During Cardiogenesis and Bone Marrow Cell 
Transdifferentiation 
Erin Lewis, Caryn Fellows, Karin Haseroth, Xiaoqin Qu, Jennifer Cho, Stephen Pan, Hal 
A. Skopicki. Co//ege of Physicians and Surgeons, New York, NY 
The use of adult bone marrow stromal cells as a reservoir for transplantation into dam- 
aged myocardium suggests that both growth and transcription factors specific for meso- 
dermal cell determination and differentiation are transiently expressed in bone marrow in 
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vitro. To understand the in viva reievance of the expression of these factors, we per- 
formed lmmunofluorescent analysis of the transcription factors GATA4 and GATAG and 
the growth factors BMP4 and BMP2 during murine cardiogenesis to ascertain which fac- 
tors may be inductive and which were induced. GATA4 was detected first at day 6.0 p.c. 
and was, surprisingly, localized within decidual cells. BMP4 protein was expressed by 
day 7.0 in the cells surrounding the developing heart followed by GATA4 (cardiomyo- 
cytes) and GATAG (endocardium) at day 7.5. By day 9.5, BMP4 protein was readily 
detected in the embryo, but restricted to the body wall immediately anterior to the devel- 
oping heart and in the pharyngeal endoderm. BMP4 and BMPP proteins were present in 
cardiomyocytes by day 10.5 but by day 15.5, neither BMPZ nor BMP4 could be detected 
within the cardiomyocytes, although BMPZ was present in developing nerves, cartilage 
and tongue. To elucidate the expression pattern of these proteins in stem cells from the 
murine bone marrow, specimens were passaged for up to 30 days (n=3 cultures each) in 
the presence or absence of 5.azacytidine. lmmunofluorescent analysis of the isolated 
cells confirmed their pluripotentia nature. While both BMP4 and BMPP were expressed 
!n these mesenchymal cells, at no time was GATA4 or GATAG expressed. RT-PCR from 
both treated and untreated marrow cell cultures confirmed the upregulation of BMPP but 
at no time could Nkd.5 be detected. We conclude that the formation of cardiomyocytes 
tequires the ordered expression and induction of both growth factors and transcription 
factors, highlighted by the markers BMPL, BMP4, GATA4 and GATAG that are carefully 
regulated both temporally and according to cell type during cardiac development. The 
expression of these proteins by bone marrow cells must be carefully considered if they 
are to to render the cardiac phenotype via myogenic transformation after transplantation 
in damaged myocardium. 
837-6 
515 p.m. 
Successful Satellite Cells Grafting Following Myocardial 
Infarction in Rabbits 
Alex Blatt, Dror Robinson, Zvi Nevo, Gad Cotter, Edo K&ski, ZVI Vered. AssafHarofeh 
Medical Center, Jzrifn Israe!. Tel-Aviv Universify. Tel-Aviv, Israe) 
Background: Cell grafting by mature skeletal myofiber, known as satellite cells, is a 
promising approach to prevent heart failure post myocadial infarction. We suggest a new 
experimental rabbit model employing a more physiologic insult: sudden and persistent 
total main artery occlusion. Materials & Methods: l- 14 Rabbits Cardiac Injury Model: 
New Zealand whrtes rabbits, weighing 3.0 to 4.0 Kg were anesthetized with IV Pentobar- 
bital. The heart was exposed via mid thoracotomy, and the marginalis sinistra artery was 
ligated 1 to 1.5 cm above the apex. 2. Skeletal Myoblast Isolation and Culture: Muscle 
biopsies were collected under sterile condition. The tissue explants were dissected into 
small pieces, which were left dry for attachment to vertical standing culture dish. After a 
few days, single cells began to migrate out of the explants forming a monolayer. Within 2. 
3 weeks the cells were expanded by 2-3 orders of magnitude. Cell’s phenotype was 
assessed by immunohistochemistry for myogenin. 3. Satellite Cell Labeling: Two days 
prior to cell collection and implantation, by direct injection, the cells in the monolayers 
underwent fluorescent labeling. The cultures were incubated for the terminal 48 hours 
with a red fluorescent dye. .4- Cell Transplantation: Single cell pellets for resuspension at 
106 I1 ml, directly injected to the proper areas of the infarcted heart in 7 rabbits. In the 
other 7 rabbits, 1 ml saline was injected without cells (control). Animals were evaluated 
by ECG and echocardiography before and after each procedure and on a weekly basis 
until the animals were sacrificed. Results: ECG and echocardiography documented the 
presence of myocardial Infarction. After sacrifice, in histological section macro and micro- 
scopic transmurzl areas with the typically changes of acute myocardial infarction were 
seen. Histochemicai staining identified viable grafted cells in high density 6 weeks post- 
transplantation in 6 of the 7 transplanted hearts. Autofluorecence was eliminated by con- 
trol group preparation calibration. Conclusion: Satellite cells, can be successfully grafted 
into rabbit hearts following myocardial infarction. 
ORAL CONTRIBUTIONS 
845 Beta-Blocker Therapy for Heart Failure: 
New Results 
Tuesday, March 20, 2001, 8:30 a.m.-lo:00 a.m. 
Orange County Convention Center, Room 230B 
8:30 a.m. 
845-i Baseline and Three Month Change in Systemic Venous 
Norepinephrine as Predictors of Clinical Outcomes in the 
BEST Trial Investigators. 
Michael Ft. Bristow, R Zelis. VA Cooperafive Clinica/ Trials Center, Palo Alto, CA, NHLBI, 
Bethesda, MD 
The BEST (P-blocker Evaluation of Survival fial) trial compared the third generation, 
nonselectlve P-blocker bucindolol to placebo for the primary endpoint of all-cause mortal- 
ity. In BEST 2118 of the 2708 randomized subjects also had baseline systemic norepi- 
nephrine (NE) measurements performed by HPLC, and 1674 of these subjects had 
follow-up measurements after three months of treatment. Compared to placebo, bucin- 
dolol lowered NE by 19 % (p< ,001) at 3 months. In agreement with previous studies, 
baseline NE was a strong predictor of mortality, with the low and high tertile groups hav- 
ing hazard ratios (HRs) plus 95 % confidence intervals (Cls) compared to the intermedi- 
ate group of 0.56 (0.48, 0.66) and 2.66 (1.70, 4.15), respectively. For change in NE, 
which in a large heart failure clinical trial has not been previously evaluated as a predictor 
of outcome, a surprisrng nonlinear effect was observed. Compared to the intermediate or 
‘“no change” group (NE change of IV758 to + 358 pgiml) both the decrease (change of > 
-758 pgiml) and the increase (change > + 358 pglml) NE groups had a higher mortality 
(respective HRs (Cls) of 2.58 (1.56, 4.25) and 2.03 (1.48, 2.77). These data indicate that 
in subjects with NYHA Class Ill or IV heart failure with LVEF ,,T .35 treated with placebo 
or bucindolol, marked decreases or increases in NE predict increased mortality. The NE 
lowering effect of bucindolol therefore may have negatively impacted clinical outcomes in 
BEST. 
845-2 
8:45 a.m. 
The Effect of Metoprolol CR/XL in Patients With Severe 
Heart Failure in MERIFHF 
Sidney Goldstein, Finn Waagstein, Ake Hjalmarson. Henry ford Health System. Defroif, 
Ml, MERIT-HF Sfudy Group, Sahlgre’nska University, Gofhenberg, Sweden 
Background: In the MERIT-HF study metoprolol CR/XL (meto CR/XL) was shown to 
decrease total mortality by 34% in a broad spectrum of patients with heart failure in 
NYHA Class II-IV with EF c 40%. The specific benefit of beta blockers (BB) in severe 
high-risk patients is still uncertain. Hence a post-hoc analysis was performed in order to 
examine the effects of meto CR/XL in such patients. 
Methods: 795 of the 3991 patients enrolled in the MERIT-HF in NYHA class III/IV and 
who had EF < 25% (mean age 65 years; mean EF 19%) were included in this sub-group 
analysis. 
Results: The annual mortality in the placebo group wasl9.1% vs 11.7% in the meto CR/ 
XL group, a reduction of 39% (95%Cl 0.42 to 0.89) nominal p=O.O086. Death due to 
worsening heart failure decreased by 55% and sudden death decreased by 45% in the 
meto CR/XL treated patients. The combination of total mortality and any hospitalization 
decreased by 29% (p=O.O012), total number of hospitalizations for worsening heart fail- 
ure by 44% (p<O.OOOl).A significant improvement in NYHA class (p=O.O032) was also 
observed. The mean dose of meto CR/XL was 148 mg and tolerability was excellent: 
there were 31% more total withdrawals (p=O.O27), and 49% more withdrawals due to 
worsening heart failure (p=O.O12) in the placebo group compared to the meto CR/XL 
group. 
Conclusions: The observed mortality and morbidity benefits in this post-hoc sub-group 
analysis is similar to that observed in the total MERIT-HF study and together with the 
results from the Copernicus study support the benefit associated with BB therapy in high- 
risk heart failure patients. 
845-3 
9:00 a.m. 
Plasma N-Terminal Pro-Brain Natriuretic Peptide and 
Adrenomedullin: Prognostic Utility and Prediction of 
Benefit From Carvedilol in Chronic lschemic Left Ventricular 
Dysfunction 
A. Mark Richards, Robert Doughty, M.Gary Nicholls, Stephen MacMahon, Norman 
Sharpe, Judy Murphy, Eric A. Espiner, Christopher Frampton, Tim G. Yandle. 
Christchurch School of Medicine, Christchurch, New Zealand. Universify of Auckland, 
Auckland, New Zealand 
Background: Plasma concentrations of the amino terminal portion of pro-brain natri- 
uretic peptide (N-BNP) and adrenomedullin (ADM) were analysed for prediction of 
adverse outcomes and response to treatment in 297 patients with ischemic left ventricu- 
lar dysfunction randomly assigned to receive carvedilol or placebo. Methods and 
ResuI%: N-BNP and ADM levels above the group median were associated with signifi- 
cantly (all P<O.OOl) increased risks of mortality (risk ratios with 95% confidence intervals 
4.67 [2-10.91 and 3.92 [1.76-8.71 respectively) and admission with heart failure (4.7 [2.2- 
IO.31 and 2.4 [1.3-4.51 respectively). On multivariate analysis both N-BNP and ADM inter- 
acted with treatment to predict death or admission with heart failure independent of age, 
NYHA class, left ventricular ejection fraction, history of previous myocardial infarction or 
previous admission with heart failure. Carvedilol reduced risk of death or admission to 
hospital with heart failure in those patients with above-median levels of N-BNP and/or 
ADM to rates not significantly different from those observed in patients with levels below 
the group median. Conclusions: In established ischemic left ventricular dysfunction 
plasma N-BNP and ADM are independent predictors of mortality and heart failure. 
Carvedilol added to converting enzyme inhibitor and loop diuretic (t digoxin) reduced 
mortality and admission to hospital with heart failure I” those patients with higher pre- 
treatment olasma N-BNP and ADM levels. 
845-4 
9:15 a.m. 
Prospective Randomized Double-Blind Comparison of the 
Effects of Carvedilol Versus Metoprolol on Endothelial 
Dysfunction and Hemodynamic Parameters in Chronic 
Heart Failure 
Nina Schoene, Christina Keicher, Sandra Erbs, Stephan Gielen, Claudia Walther, Axel 
Link+ Gerhard Schuler, Rainer Hambrecht. University of Leipzig - Heart Center, Leipzig. 
Germany 
Backgmund: Recent clinical trials have shown similar beneficial effects of metoprolol 
(M), a selective beta blocker, and carvedilol (C), a non-selective beta blocker with alpha-i 
antagonistic and antioxidative properties, on cardiac performance and mortality of 
patients with chronic heart failure (CHF). Aim of this study was to assess differences in 
endothelium-dependent vasodilation between M and C. Methods: 36 male patients with 
stable CHF were randomly assigned to receive either M (n=12, 100 mg bid), C (n=lZ, 25 
mg bid), or placebo (S n=l2) in addition to standard medical therapy. At the beginning (B) 
and after six months (6 mo) left ventricular ejection fraction (LVEF) was assessed by 
echocardiography and peak oxygen uptake was determined by ergospirometry. Stepwise 
intraarterial infusion of acetylcholine (Ach) was performed to assess agonist-mediated 
endothelium-dependent vasodilation of the radial artery. Changes in internal diameter 
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(ID) ware determined using a high-resolution ultrasound system (NIUS-02) with a 10 
MHz probe. Results: LVEF improved significantly from 28+3% at B to 34&i% after 6 mo 
in C (~~0.05 versus B and P) and from 29+2% to 33+2% in M (~~0.05 versus B and P). 
There was a comparable improvement of peak oxygen uptake by 1152% in C and by 
13i3% in M. After 6 mo of therapy there were no significant affects on endothelium- 
dependent vasodilation neither in M, C, or P (C: 125c40pm at B and 120+50pm after 6 
mo, M: 120%30pm at B and 120t70ym after 6 mo, P: 130t30pm at 6 and 140+30wm 
after 6 mo, p=NS). Conclusion: In patients with CHF carvedilol and metoprolol show 
similar beneficial effects on LVEF and peak oxygen uptake. In contrast, neither M nor C 
could substantially correct endothelial dysfunction in this CHF population. 
ORAL CONTRIBUTIONS 
847 Prognosis From Exercise Testing 
Tuesday, March 20, 2001, 8:30 a.m.-i 0:OO a.m. 
Orange County Convention Center, Room 231 A 
845-5 
9:30 a.m. 
Comparative Effects of Metoprolol and Carvedilol on Lefl 
Ventricular Function in Heart Failure 
847-l 
8:30 a.m. 
Predictors of Mortality Among Patients With an Excellent 
Exercise Capacity 
Sorin Brener, Eugene Blackstone, Michael S. Lauer. Cleveland C/ink, Cleveland 
James E. Udelson, George V. Antonopoulos, Jesse A. ‘Berlin, Jesse Chittams, Marvin A. 
Konstam, Milton Packer. Tufts-New England Medical Center, Boston, MA 
Background: Clinical trials have shown that beta-blockers can predictably improve left 
ventricular ejection fraction (LVEF) in pts with heart failure (CHF). However, it is not 
known whether available agents differ in their effects. Methods: We performed a meta- 
analysis of two types of trials that evaluated the effects of beta-blockers on LVEF in CHF: 
1) randomized controlled studies that compared placebo to either metoprolol (734 pts 
studied in 6 trials) or carvedilol (1208 pts studied in 9 trials) and 2) randomized controlled 
trials that directly compared metoprolol with carvedilol (248 pts in 4 trials). The duration 
of treatment between the two LVEF measurements varied from 3 to 15 mos, and was 
similar acorss treatments: (metoprolol: 7.7 mos, carvedilol: 8.2 mos, and direct compari- 
sons: 9.6 mos). Data were independently extracted by 2 observers, and discordances 
resolved by consensus review of primary data. Results: Table=Change in LVEF (%, 
mean r SE) Conclusion: Based upon published placebo-controlled and active controlled 
randomized trials, carvedilol has more favorable effects on LVEF than metoprolol. 
Whether these differences in EF translate into differences in major outcomes is now 
being evaluated in a large-scale double-blind comparator trial (COMET). 
Change in LVEF (%, mean + SE) 
Placebo (-P) Drug Placebo (P) Difference (Drug -P) 
-Controlled 
Metoprolol 
Carvedilol 
Active- 
Controlled 
+6.3 + 0.2 +2.5 + 0.1 +3.8 + 0.5’ 
+7.9 f 0.3 t1.2 * 0.1 +6.5 -+. 0.5’,+ 
Metoprolol+5.5 + 0.2 Carvedilol+8.9 ? 0.2 Difference 2.9 + 1 .l** 
Background: Patients with an exercise capacity of at least 10 METS are believed to be at 
low risk irrespective of history and other exercise test findings. Predictors of outcome in 
this group have not been well defined. Methods: Consecutive adults referred for symp- 
iom-limited exercise testing between 1990 and 1997 who had an exercise capacity of at 
least 10 METS were followed for 4.5 years. Patients with valve disease, and pacemakers 
were excluded. Chronotropic incompetence was defined as failure to tise > 80% of heart 
rate reserve at peak exercise. An abnormal heart rate recovery was present if the differ- 
ent between peak heart rate and heart rate 1 minute was i= 12 beats/minute. Results: 
There were 9926 patients eligible for analyses (mean age 50+/-g, range 30-82, 7% were 
65 or older, 11% female). Chronotropic incompetence was present in 833 (8%), an 
abnormal heart rate recovery in 922 (9%), and an abnormal SFsegment response in 
1303 (14%). During follow-up 159 patients died (2%). Univariate predictors of death 
included age z 65 (5% vs. I%, hazard ratio [HR] 3.9, 95% Cl 2.7-5.7, PcO.OOOl), known 
coronary disease (3.6% vs. l.l%, HR 3.6, 95% Cl 2.6-4.9, P<O.OOOl), exercise capacity 
(for each 2.5 MET decrease HR 2.3, 95% Cl 1.6-3.2, P<O.OOOi), chronotropic incompe- 
tence (3% vs. 1.5%, HR 2.1, 95% Cl 1.3-3.2, P=O.OOl), abnormal heart rate re’covery 
(2.5% vs. 1.5%, HR 1.6, 95% Cl 1 .O-2.5, P=O.O4), and an abnormal ST-segment 
response (2.2% vs. 1.4%, HR 1.6, 95% Cl 1 .I-2.5, P=O.OZ), as well as diabetes (P=O.O3) 
and hypertension (P=O.O002). In a multivariable Cox regression analyses only 4 variables 
predicted death: Age > 65 (adjusted HR 3.0, 95% Cl 2.0-4.6, P<O.OOOl), known coronary 
disease (HR 2.2, 95% Cl 1.5-3.1, P<O.OOOl), decreased chronotropic response (for each 
20% decline in proportion of heart rate reserve used HR 1.3, 95% Cl 1.1-1.6, P=O.Oi), 
and decreased exercise capacity (for each 2.5 MET decrease HR 1.6, 95% Cl 1 .l-2.3, 
P=O.O3). Conclusions: Mortality rates among patients with an exercise capacity of at 
least 10 METS are very low, even among those of age > 65 and those with krrwn coro- 
nary disease. Still, even in fhis very low risk cohort, exercise capacity and chronotropic 
response provide some prognostic information 
*p <O.OOl vs placebo, +pcO.OOl carvedilol vs metoprolol **p<O.Ol carvedilol vs meto- 
prokl 
345-6 
9:45 a.m. 
Prior Inhaled Beta Agonist Use Does Not Preclude Beta 
Blocker Therapy for Heart Failure 
847-2 
8~45 a.m. 
Heart Rate Recovery After Exercise Testing and Risk of 
Coronary Disease in the Framingham Heart Study 
John S. Golden, Catherine C. Fallick, Susan J. Morikawa, Donna J. Mateski, Sharon R. 
Josephson, Mary C. Langford, Pamela P Barnett. Kaiser Permanents Mid-Atlantic 
States, Fairfax, VA 
Ali MorshedCMeibodi, Martin G. Larson, Daniel Levy, Christopher J. O’Donnell, 
Ramachandran S. Vasan. NHLBlk Framingham Heart Study, framingham, MA, Boston 
University School Of Medicine, Boston, MA 
Background: The benefits of beta blockers in heart failure (HF) have been well estab- 
lished. Their more widespread use, however, has been been limited by perceived can- 
traindications to beh blockade in certain patient subsets. Studies evaluating beta 
blockers in HF have routinely excluded patients (pts) treated with inhaled bronchodila- 
tars. However, bronchospasm may reflect persistent volume overload rather than primary 
airway disease in HF pts. We hypothesized that many HF pts could be withdrawn from 
inhaled bronchodilators and successfully treated with beta blockers after treatment for 
volume overload. 
Background: A delayed recovery of heart rate (HRR) after graded exercise has been 
associated with increased all-cause mortality in high risk cohorts. The impact of HRR 
after exercise on cardiovascular and coronary morbidity and mortality in the general pop- 
ulation is not known. 
Methods: We retrospectively evaluated 139 pts referred to our HF Treatment Program 
with systolic dysfunction (LVEF ~35%) and NYHA Class 11-111 HF. All were treated with 
diuretics and ACE inhibitors or AFiBs. Inhaled beta agonists were discontinued and beta 
blockade initiated in all pts without an absolute contraindication (refusal, symptomatic 
hypotension, or PFT evidence of reversible airway disease). 
Results: Beta blockade with Carvedilol (C) or Metoprolol (M) was attempted in 56/63 
(89%) of pts with a history of beta agonist use (BA+) and 66176 (87%) of pts without a 
history of beta agonist use (BA-). Mean baseline NYHA functional class was 2.7+0.6 in 
both groups. Pts were followed for a mean of 18+7 months. 49% were treated with C and 
51% with M. There were no instances of treatment-induced bronchospasm. The mean 
daily beta blocker dose achieved (expressed in C equivalents: 1 mg C = 2 mg M) was 
42~22 mg in the BA+ group and 41 rl8 mg in the BA- group. At follow-up, 52 (93%) of the 
BA+ and 62 (94%) of the BA- pts remained on beta blockers. All cause hospitalization 
rates were 14% and 21% in the BA+ and BA- groups, respectively. At follow-up, 53/56 
(95%) of BA+ pts and 62/66 (94%) of BA- pts were alive (p=NS for all comparisons, with 
either C or M). 
Conclusion: Most HF pis with a history of inhaled beta agonist use tolerate beta blocker 
treatment. Outcomes in this group are similar to those seen in pts without a history of 
bronchodilator use. Prior beta agonist therapy without PFT evidence of reversible airway 
disease should not be a contraindication to beta blocker use in HF pts. 
Methods: We evaluated 2967 subjects (1400 men, 1567 women, mean age 43 years) 
from Framingham Offspring cohort, free of cardiovascular disease (CVD), who under- 
went a multistage treadmill exercise test at examination cycle 2. We used Cox propor- 
tional hazards regression (adjusting for standard CVD risk factors) to examine the 
relations of HRR measures (fall m HR from peak exercise at 1, 2, 3, 4 minutes of recov- 
ery) - assessed as continuous variables and as quintiles - and the incidence of coronary 
heart disease (CHD), CVD (CHD, stroke, heart failure and intermittent claudication) and 
all-cause mortality. 
Results: During follow up (mean of 15 years), 214 subjects developed CHD (156 male, 
58 female), 411 developed CVD (259 male, 152 female), and 167 died (105 male, 62 
female). In multivariable models, none of the continuous HRR indices was associated 
with the incidence of CVD, CHD, or with all-cause mortality. In threshold models with 
quintile-based cut points, the top quiniile of HRR (with the greatest decline in HR: 39-85 
bats/min) at one minute post-exercise was associated with a lower risk of CHD [Hazards 
ratio 0.53, 95% Cl, 0.31-0.90, p=O.O2] and of CVD [Hazards ratio 0.71, 95% Cl, 0.51. 
0.99, p=O.O4], but was unrelated to all-cause mortality (p=O.65). 
Conclusions: A rapid decline in heart rate in the early recovery period following exercise 
is associated with a reduced risk of CHD and CVD, but not all-cause mortality. Our find- 
ings should be confirmed in other population-based samples. 
847-3 
9:00 am. 
Use of the Logical Data Analysis Method for Assessing 
Long-Term Mortality Risk After Exercise 
Electrocardiography 
Michael S. Lauer, Sorin Alexe, Eugene Blackstone, Hemant Ishwaran, Peter L. Hammer. 
Cleveland C/inic, C/eve/and, Rutgers University, Piscataway 
Background: “Logical Data Analysis” (LDA) is a logic and optimization based mathemat- 
ical methodology used for analyzing d&sets in various areas, but not yet applied in 
medicine. The key ingredient is the systematic identification of syndromes. Methods: 
Using a cohort of 9454 patients referred for exercise testing, LDA was applied to identify 
high risk and low risk syndromes based on 20 clinical & exercise covariates. The high risk 
syndromes were associated with z 4 fold increased risk of death compared to the mean 
death rate, while low risk syndromes were associated with > 3.5 fold decrease. An axam- 
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pie of a high risk syndrome: age a 54, resting heart rate z 88, heart rate recovery < 8. An 
example of a low risk syndrome: age < 58, no resting ST-T abnormalities. Syndromes 
were derived on a training set of 4727 patients and validated on 4727 different patients 
There were 26 high risk and 18 low risk syndromes selected in the training set. Results: 
In the validation data set (mean age 53, 78% male), 156 patients died over 6 years. At 
least one high-risk syndrome was present in 991 patients (21%); > 1 low risk syndrome in 
3756 (80%). On this basis a risk score was developed, a score value > 0 (meaning a 
greater proportion of high risk syndromes was present) was noted in 1090 (23%), and it 
was associated with a markedly increased death risk (10% vs. I%, hazard ratio 7.1, 95% 
Cl 5.1 to 9.9, P<O.OOOi: Figure). After adjusting for age, gender, risk factors, and exercise 
findings, the risk score remained independently predictwe (adjusted high risk 1.6, 95% Cl 
1.0 to 2.6, P=O.O3). Conclusion: Using the LDA method, we can easily identify a subset 
of patients who not only had an increased risk of death but also accounted for the major- 
ity of deaths. Moreover, the method provides a comprehensible explanation of reasons 
for which a patient is classified es high risk or low risk. Future research is needed to 
determine how best to use IDA for risk stratification. 
exercise and 1 minute later Based on maximization of the log-rank chi square statistic, a 
heart rate recovery <= 18 beats per minute was considered abnormal. Results: The 
median heart rate recovery was 30 beats per minute (Zth-75th percentiles 22 to 37). An 
abnormal heart rate recovery was noted in 805 patients (15%). There were 190 deaths 
(3.5%). An abnormal heart rate recovery was strongly predictive of death (9% vs. 3%, 
hazard ratio [HR] 3.9, 95% Cl 2.9-5.2, P<O.OOOl); see Figure. After adjusting for age, 
gender, ejection fraction, evidence of ischemia, resting heart rate, exercise capacity, and 
standard risk factors an abnormal heart rate recovery remained strongly predictive of 
death (adjusted HR 1.9, 95% Cl 1.4-2.6, P<O.OOOl). Conclusion: Even in the absence of 
a cool down period and even after accounting for ejection fraction, heart rate recovery is 
a powerful and independent predlctor of death. 
847-4 
9:15 a.m. 
Should 50% or 75% Luminal Occlusion Be Used to 
Diagnose Significant Coronary Disease? 
Michael J. Lipinski, Dat Do, Vinod K. Raxwai. Victor F. Froelicher. Stanford/PAVAHCS, 
Palo A/to: CA 
There has been controversy over what is the best angiographic luminal dimension crite- 
rion associated with &hernia for using a stress test to diagnose significant coronary 
artery disease. if one assumes ST segment depression or scores are indicators of 
ischemia, then whatever angiographic criteria best discriminates those with ischemic and 
non-ischemic responses would be the best angiographic marker for ischemia. To study 
this, we calculated the Area Under the Curve using ROC curves of ST depression and 
scores for different angiographic cut-points in order to determine the best angiographic 
cut-point for defining coronary disease. Methods Five hundred and ninety nine consecu- 
tive males without prior MI with a mean age of 59ill years were analyzed in this study. 
This study calculated the number of patients of this population that would be considered 
to have coronary artery disease at different cut-points for angiographic luminal occlusion. 
Cut-points were calculated between 40 to 95% coronary lumen occlusion. ROC analysis 
was then performed comparing ST depression and scores at each of these cut-points. 
Results The cut-point for coronary lumen occlusion that returned the highest AUC for ST 
depression and scores was 75% coronary luminal occlusion. The figure below illustrates 
the differences with AUC peaking at 75% and then subsequently declining. Conclusion It 
appears that the best cut-point for defining significant angiographic disease based on 
ischemic versus non-ischemic individuals is 75% or greater coronary luminal occlusion. 
Scores and ST segment depression best discriminate those with significant coronary dis- 
ease when a luminal occlusion cut-point of 75% is utilized. 
,: 
847-5 
9:30 a.m. 
Heart Rate Recovery in the Absence of a Cool Down Period 
as a Predictor of Mortality: The Case of Stress 
Echocardiography 
Junko Watanabe, Marx Thamilarasan, Eugene Blackstone, James D. Thomas, Michael 
S. Lauer. Cleveland Clinic, Cleveland 
Background: When measured in the setting of a cool-down period, heart rate recovery 
has been shown to be an independent predictor of death. Stress echocardiography 
necessitates immediate rest and assumption of a supine position, which would be 
expected to enhance heart rate recovery. It is not known if heart rate recovery followng 
Stress echocardiography predicts mortality. Methods: Consecutive patients (N=5785, 
meen age 58+/-12, 37% female) who underwent stress echocardiography and who did 
not have heart failure, valve disease, atrial fibrillation or pacemakers, were followed for 
3years. Heart rate recovery was defined as the difference between heart rate et peak 
847.6 
9:45 a.m. 
The Prognostic Impact of the Chronotropic Index on the 
Prediction of Cardiac Death in Patients Undergoing 
Exercise Treadmill Testing. 
Howard C. Lewin, Babak Azarbal, Enrique F. Schlsterman. Sean W. Hayes, John D. 
Friedman, lshac Cohen. Xing-Ping Kang, Daniel S. Berman. Cedars-Sinai Medical 
Center, Los Angeles, CA 
Background: The Duke Treadmill Score (DTS) is a well-established prognostic marker of 
cardiac death (CD). Recent publications suggest that the chronotropic index (Cl), a mea- 
sure of heart rate (HR) response to exercise that accounts for age, physical fitness, and 
resting HR, is an independent predlctor of mortality. To date, these 2 markers have not 
been studied in the same pt population. We therefore sought to determine whether Cl 
adds incremental value to the DTS in the prediction (pop) of CD. Methods: We exam- 
ined 5558 consecutive pts undergoing exercise stress testing with no history of angiogra- 
phy, coronary revascularization (revasc), heart failure, or valvular heart dlsease and not 
taking beta-blockers who performed symptom-limited exercise stress as part of a myo- 
cardial perfusion study. The mean follow-up was 20.8k4.5 months (96% complete) for 
CD, all follow-ups>1 year. 329 pts underwent early revasc and were censored from the 
prognostic analysis. Cl was defined as %HR reserve/% metabolic reserve. A low Cl, or 
chronotropic incompetence, was defined as Cl&8 as previously reported. Pts were cat- 
egorized based on the DTS (low risk DTS>B and mod-high risk&). Cox-regression mod- 
els were performed. Results: The pt pop was 59% male, 61.1+12 years old. 5% of pts 
had history of MI. 1337 pts (27%) had a low Cl and 3043 (61%) had mod-high DTS. 27 
pts died during the follow-up. After adjusting for the univariate predictors of CD (age, pre- 
test likelihood of ischemia, family history of CAD, and Ml), both the DTS and the Cl were 
predictive of CD (p=O.O15 and p=O.O2, respectively). Pts who had both a mod-high DTS 
and a low Cl were at significantly higher risk for CD compared to pts with mod-high DTS 
and normal Cl (1.0% vs. 0.3%, respectively p<O.Ol). Conclusions: Thus. Cl is an 
important predictor of CD, adding incremental value to the DTS. 
N=1521 516 2133 812 
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POSTER SESSION streptozotocin-induced diabetic cardiomyopathy. Methods: Experiments were conducted 
on left ventricular papillary muscles from male diabetic Wistar (n=16) and age-matched 
1197 Cellular and Molecular Mechanisms 
control rats (n=15). The following mechanical indices were determined: the maximum 
unloaded shortening velocity (Vmax, in Lmax. s-l), the total isometric tension normalized 
Causing Heart Failure I 
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Orange County Convention Center, Hall A4 
per cross-sectional area (TF, in mN.mm-2). Using A. Huxley’s equations, we calculated 
the CB number per mm2 at peak isometric tension (m, in 109 per mm2), the CB single 
force in isometric condition (pi, in pN), the maximum value of the rate constant for CB 
attachment (fl, in s-1) and detachment (gl and 92, in s-l), and the maximum turnover 
rate of mvos~n ATPase per site in isometric conditions (kc@. in s-l). Data are exaressed 
as means * SEM. Comparisons between controls and diabetics were performed using 
Student’s unpaired t-test (see table). Results: The contractile impairment observed in 
diabetic rats, attested by the decrease in TF and Vmax, was associated wth a significant 
reduction in total CB number without change in CB single force. Diabetics exhibited lower 
values of rate constants for CB attachment and detachment, and a decreased tuwwer 
rate of myosin ATPase as compared to controls. Conclusion: Cur results suggest that the 
mechanical impairment observed in streptozotocin-induced diabetic rat cardiomyopathy 
is associated with a decrease in CB total number and CB kinetics alteration without 
change in CB single force. 
Peter Liu, Fayez Dawood, Wen-Hu Wen, Michael J. Sole, Jean L. Rouleau, Duncan J. 
Stewart. Heart & Stroke/Richard Lewar Centre of Excellence, Toronto‘, ON, Canada 
Presentation Hour: 9:00 a.m.-10:OO a.m. 
1197-43 Microvascular Integrity Contributes to the Myocardial 
Remodeling in Pressure Overload LV Hypertrophy 
Following Aortic Banding 
We have previously demonstrated the presence of mrcrovascular angiopathy (MVA) in 
cardiomyopathies, and its impact in LV remodeling post myocardial infarction in the rat 
model. To understanding why patients with microvascular disease such as diabetes or 
hypertension are prone to heart failure, and to determine how microvascular angiopathy 
may contribute to the remodeling process in pressure overload hypertrophy, we studied a 
rat model of aortic banding (AoBd) with or without microvascular angiopathy. Rats 
(n=91) were randomized to coronary endothelial denudation with intra-aortic ultra low 
dose Triton-x (0.01%) and temporary aortic occlusion or placebo, and were subjected to 
individually calibrated aortic banding or sham controls. At 35 days post banding, the ani- 
mals underwent determinations of in viva Millar LV systolic and end-diastolic pressures 
(LVSP and LVEDP, mmHg) and perfusion fixed analysis of LV wall thickness (WTh, 
mm)and cavity area (Ar, mm”). The results showed (M&D, *p<O.O5 vs. Sham and 
#pcO.O5 “s AoEd alone): 
LVSP LVEDP WTh LVAr 
Sham 12w3.9 6411.7 1.2iO.l 48.1+1.8 
AoBd 214?50.4* 11.8M.8* 2.1?0.3* 45.0+4.0 
TritoncAoBd 188f31.1* 21.618.2^# 1.6?0.2”# 54.8?0.9*# 
The triton treated hearts were more drlated, wrth thin walls, and showed severe MVA with 
complete absence of “on Willebrand staining, and also had a significantly higher 35 day 
mortality (67%) vs. those without triton treatment (50%). 
We conclude that microvascular dysfunction contributes to adverse remodeling in pres- 
sure overload hypertrophy by inducing LV diastolic dysfunction, decreased wall thick- 
ness, increased LV dilatation and mortality. Thus, microvascular angiopathy may 
contribute to the adverse cardiac remodeling and rapid progression to heart failure follow- 
ing pressure induced hypertrophy. 
1197-44 A Polymorphism of the Endothelial Nitric Oxide Synthase 
Gene is Associated with Increased Sympathetic Drive in 
Patients With Congestive Heart Failure 
Phrlip F. Binkley, Ywen Liu-Stratton, Patty S. Hatton, Glen Cooke. The Ohio State 
University, Columbus, OH 
Background: Dysregulation of nitric oxide (NO) synthesis is thought to be a determinant 
of the altered vasoreactivity of patients with congestive heart failure (CHF) and may con- 
tribute to the autonomic imbalance typical in CHF. A thymidine (T) to cytosine (C) transi- 
tion in the promoter region of the endothelial NO synthase (eNOS) gene is associated 
with decreased NO production and increased risk of coronaryvasospasm in patients with 
normal ventricular function. We tested whether patients having CHF with this polymor- 
phism were characterized by a greater magnitude of the autonomic imbalance typical for 
patients with CHF as reflected by analysis of heart rate variability (HRV). 
Methods: 31 patients having CHF underwent genotyping for the C or T allele of the 
eNOS promoter polymorphism. Supine electrocardiographic recordings obtained in each 
subject were submitted to spectral analysis of HRV. 
Results: No differences in HRV were noted between patients homozygous for the T 
allele (N=lZ) or heterozygous for the T and C alleles (N=13). These patients were 
grouped together (TTTTC) and compared to the CC homozygous patients (N=6). CC 
patients were found to have signrficantly greater sympathetic drive as reflected by an 
increase in low frequency HRV (2.6 +.8 x iv3 beats/minute’ vs 1.8 +.9 x lo6 beats/ 
minute2; p=.O3). The ratio of parasympathetically mediated high frequency to total HRV 
tended to decrease in CC patients (CC: .19+.09 vs TT/TC: .37+.X; p=.l). Left ventricu- 
lar ejection fraction was significantly (p=.OOZ) greater in CC patients (34+12%) than in 
TT/TC patients (21+8%). 
Conclusion: Despite a relative preservation of ventricular function, CC patients with 
CHF have a significant activation of sympathetic drive and relative reduction of parasym- 
pathetic activity. The reduction in NO production in C homozygotes may predispose 
these patients to an acceleration of the autonomic imbalance typical for patients with 
CHF and may contribute to an acceleration of disease progression. 
1197-45 Alteration of Cross-Bridge Properties in Diabetic Rat 
Cardiomyopathy 
Joseph Thierry, Coirault Catherine, Chemla Denis, Dubourg Olivier, Lecarpentier Yves. 
H6pitai Ambroise Par& Boulogne, France, INSERM U451, Palaiseau, France 
Background: Human diabetes mellitus is associated with a high risk for developping a 
cardiomyopathy, independent of coronary atherosclerosis, which results in cardiac con- 
tractile dysfunction. As crossbridge (CB) represents the molecular motor of force genera- 
tion in heart, we investigated the number, single force and kinetics of CB in a rat model of 
TF Vmax m Pi fl 92 kcat 
1197-73 Functional-Related Distribution of P,-Adrenergic Receptor 
in Cardiac Chambers 
Heng-Jie Cheng, Zhu-Shan Zhang, Tomohiko Ukai, Hideo Tachibana, Akihiko Igawa, 
David Sane, Che-Ping Cheng. Wake Forest University School of Medicine, Winston- 
Salem, NC 
Background: The cardiac P3-adrenergic receptor &-AR) is a Gi protein-coupled recep- 
tor, which mediates a negative inotropic effect in response to endogenous catecholamine 
stimulation. b,-AR may play an important role in cardiac performance. However, the dis- 
tribution of P,-AR in chambers of the normal and failing myocardium has not been stud- 
ied. Methods: We developed a technique for harvesting viable myocytes from each 
canine cardiac chamber. A fragment of canine P3-AR gene was isolated and sequenced. 
We designed specific primers as well as synthesized a &-AR cDNA probe to assess pa- 
AR mRNA levels of each cardiac chamber. We further examined the effect of &-AR stim- 
ulation on contractile performance and [Ca2+]i transient in 5 dogs before and after pac- 
ing-induced heart failure (CHF). Results: Viable myocytes were isolated from each 
chamber of the heart with a yield of 80.85%. Cardiomyocyte !&-AR mRNA was detected 
from each chamber using the designed primers rn RT-PCR. A fragment of canine &AR 
gene was cloned and was an exact match of published canine Pa-AR sequence. Using 
the cloned canine S3-AR cDNA probe, a single band of &-AR mRNA, about 3.4 Kb, was 
detected from each chamber of the heart. The expressron of P3-AR mRNA in the normal 
left ventricle (LV) myocytes was significantly less than that in other chambers. In CHF LV 
myocytes, P3-AR mRNA level was increased significantly by 73% when compared with 
that in normal LV myocytes. Consistent with these findings, &-AR stimulation induced a 
direct inhibition on myocyte contraction and relaxation, and decreased the peak systolic 
[Caa+l transient. These negative inotropic effects were amplified in CHF myocytes. Con- 
clusion: P,-AR was detected in all chambers of both normal and CHF canine myocar- 
dium. The reduced expression of &-AR in the LV may be functional-related and 
explained by a survival strategy as to the LV has to overcome the high blood pressure to 
pump enough blood for circulation. Moreover, &-AR is up-regulated in the failing myocar- 
dium, which may be one of several different maladaptive mechanisms responsible for the 
progression of CHF. 
1197-74 Increased DNA Content and Transcriptional Activity in 
Myocytes From Pressure Overloaded Human Myocardium 
Eyal Amon, Stefan Hein, Sawa Kostin, Manfred Richter, Erwin P. Bauer, Wolf P 
Klovekorn, Jutta Schaper. Max-Planck-lnstituts, Bad Nauheim, Germany, Kerckhoff- 
Clinik, Bad Nauheim, Germany 
Background: The hypothesis was tested that not only structural degeneration combined 
with the development of fibrosis contributes to the progression of heart failure but that 
nuclear changes are involved as well. 
Methods: We studied this problem in 44 patients with longstanding hypertrophy due to 
aortic valve stenosis who showed varying degrees of reduction of left ventricular function 
(EF, 20-70%) and in controls. Biopsies were removed during valve replacement opera- 
tion. Cellular degeneration was determined by electron microscopy, the degree of fibro- 
sis, presence of macrophages (CD 68) and Ki 67 positive myocyte nuclei by 
immunohistochemical morphometry and apoptosis by the TUNEL method (% of total 
myocytes). Quantitative confocal microscopy was used to measure fluorescence intensity 
(AU) of TGF-b 1, DNA content (Feulgen stain) and the non-snRNP splicing factor SC-35 
indicating active transcription. This method has the advantage to analyse individual myo- 
cyte nuclei. Values were obtained as AU/pixel and calculated with respect to nuclear size. 
Results: Myocyte hypertrophy and cellular degeneration increased with decreasing EF. 
With declining left ventricular function nuclei showed enlargement and polyploidy indi- 
cated by KI 67 staining resulting in an increased content of DNA. SC-35 was upregulated 
suggesting increased transcriptional activity. This data indicates a counterregulation to 
disturbed transciption and translation as shown by deranged protein expression. Fibrosis 
and TGF-PI expression might further damage cardiomyocytes.Results see table. 
Conclusion: It is concluded that progression of functional deterioration in overload 
hypertrophy is caused by continuous remodeling of all components of the myocardium 
and that it also involves changes in the transcription/translation machinery. 
Patients Control Group I Group II Group Ill 
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Conclusion: Assessment of LAVPD during dobutamine echocardiography offers a sim- 
ple. rapid and accurate non-invasive method for differentiation between ischemic and 
non-ischemic DCM. 
1198-48 Regional Myocardial Flow-Metabolism Relationship in 
Patients With Idiopathic Dilated Cardiomyopathy 
Danilo Neglia, Cecilia Marini, Elena Toschi, Oreste Sorace, Piero Salvadori, Gianmario 
Sambuceti. Oberdan Parodi, Antonio L’Abbate. CNR Institute of Clinical Physiology: Piss, 
/ta/y 
Background: In patients with idiopathic dilated cardiomyopathy a depressed myocardial 
blood flow (MBF) either at rest and during pharmacologic vasodilatation has been dem- 
onstrated.The relationship between regional MBF and glucose,metabolism has not yet 
been extensively evaluated. Methods: We studied 40 patients (30 males, mean age 5%+- 
10 years, LV EF 29+-7%) using positron emission tomography with nitrogen-13 ammonia 
to quantitate regional MBF at rest and after i.v. dipyridamole (0.56 mg/Kg in 4’). Regional 
myocardial glucose uptake was semiquantitatively evaluated by fluorine-18 deoxyglucose 
(FDG) injected, after a glucose meal, within 30’ from i.v. dipyridamole. This protocol was 
chosen to enance regional differences in flow and metabolism. Two patients did not show 
significant myocardial FDG activity and were excluded from analysis. Regional percent- 
age profiles of dipyridamole MBF and of FDG activity were obtained for 6 left ventricular 
regions, taking the region with the maximal MBF value as reference. The comparison of 
percentage profiles allowed to recognize mismatch (MBF%c%O% and FDG% 
>MBF%+SO%) or match regions (MBF%<%O% and FDG%c%O%). Results: Out of the 
22% segments analysed, a mismatch was present in 64 (2%%), a match in 3% (17%) and 
a normal pattern in 126 (55%). As compared with normal regions, mismatch segments 
showed a similar resting MBF (0.60+-0.20 vs 0.62~.0.23 mllminlg, ns) and a more 
depressed dipyridamole MBF (1.03+-0.44 vs 1.39+-0.64 mliminlg, ~~0.01) while match 
segments showed a more depressed MBF at rest (0.51+-0.1% mliminig, ~~0.05) and 
after dipyridamole (1.01 t-O.50 mliminlg, p<O.Oi). At least one mismatch or match region 
was present respectively in 25 patients (66%) and in 16 patients (42%), 6 showing also 
mismatch. During dipyridamole, typical chest pain and/or ST segment ischemic changes 
occurred in IO patients, 8 showing mismatch patterns. Conclusion: Regional myocardial 
flow-metabolism mismatch or match patterns are frequent in patients with idiopathic 
dilated cadiomyopathy. These results suggest the coexistence of regional myocardial 
ischemia and depressed viability in these patients. 
1198-49 Isolated Ventricular Non - Compaction is Associated With 
Coronary Microvascular Dysfunction 
Philipp A. Kaufmann, Christophe A. Wyss, Erwin Oechslin, Rolf Jenni. Cardiovascular 
Center, University Hospits/, Zurich, Switzerland 
Background: Although in isolated ventricular non-compaction (IVNC) the characteristic 
features (two-layered structure with uniform tissue and a much thicker endocardial layer 
of trabecular meshwork) are predominantly found in the apical and the midventricular 
segments, hypokinesia may not entirely be confined to these segments resulting in a 
decreased global ejection fraction (EF). We studied whether a global microcirculatory 
dysfunction underlying the IVNC could contribute to explain these discrepancies. Meth- 
ods: Myocardial blood flow (MBF, mllminlg) was measured in IO patients with IVNC and 
in 11 volunteers at rest and after adenosine (Ado, 0.14mglkglmin over 7 minutes) using 
ammonia-PET. Coronary flow reserve (CFR) was calculated as Ado/resting for the apex 
as well as for 4 (septal, anterior, lateral and inferior) midventricular and basal segments 
each. The CFR values and the static perfusion scans where compared to the echocardio- 
graphic findings (wall motion abnormality, trabeculation) in each segment. Results: In 
none of the volunteers a defect of the static ammonia-PET scan was found, CFR aver- 
aged 3.9*0.9. In patients with IVNC a perfusion scan defect was found in 12 of 14 seg- 
ments with trabeculation (sensitivity %6%), while a normal perfusion was found in 70 
segments of 76 without trabeculation (specifiaty 96). In 36 of the 39 segments with wall 
motion abnormalities the flow reserve was decreased (agreement 92%). By contrast, 
CFR was only reduced in 7 of the 24 segments with normal wall motion. All patient with 
IVNC had at least 2 segments with severely depressed CFR. Conclusions: In IVNC a 
depressed CFR is not only confined to segments with excessive trabeculation but 
extends to almost all segments with wall motion abnormality. Thus, coronary microcircu- 
latory dysfunction seams to be an important characteristic of IVNC. 
1198-50 Abnormal Coronary Blood Flow Reserve in Idiopathic 
Dilated Cardiomyopathy is Due to Impairment of Both 
Endothelium-Dependent and Independent Microcirculatory 
Vasodilation 
Menahem Can&t, Amir Lerman, llyas S. Karaalp, Waseem M. Akhter, Anilkumar Mehra, 
Uri Elkayam. LA County/University of Southern California MedIcal Center, LOS Angeles, 
CA, Mayo Clinic, Rochester, MN 
Background: Studies in a limited number of patients with new onset nonischemic cardi- 
omyopathy have demonstrated impaired endothelium-dependent coronary vasodilation 
but suggested preserved endothelium-independent vasodilation. The purpose of this 
study was to evaluate mechanisms of impaired coronary vasodilatory capacity in a large 
number of patients with chronic advanced heart failure due to nonischemic 
cardiomyopathy. 
Methods: We studied endothelium-dependent (during intracoronary infusion of 10-a to 
1u4 M of acetylcholine) and endothelium-independent (after administration of 18-36 mcg 
of adenosine) coronary blood flow reserve and calculated changes in coronary vascular 
resistance in 25 patients with nonischemic, dilated cardiomyopathy and 25 patients with 
normal cardiac function, nonobstructive coronary artery disease who were studied for 
chest pain and were matched by age, gender and serum cholesterol level. 
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1198-46 Renin-Angiotensin-Aldosterone System Gene 
Polymorphisms as Predictors of Improvement in Systolic 
Performance in Dilated Cardiomyopathy 
A Tiago, D Skudicky, AJ Woodiwiss, GP Candy, R Brooksbank, K Sliwa, P Sareli, GR 
Norton. Dept Physiology University of the Witwatersrand, Johannesburg, South Africa, 
Dept Cardiology: Baragwanath Hospital, PO Bertsham, Johannesburg 2013, South Afrfca 
Introduction. Reproducible markers are required to predict the variable improvement in 
cardiac function that occurs in patients in heart failure on medical therapy. We evaluated 
whether genetic polymorphisms of the renin-angiotensin-aldosterone (RAA) system pre- 
dict improvement in left ventricular (LV)systolic function subsequent to medical therapy in 
patients with idiopathic dilated cardiomyopathy. Materials and Methods. 107 Black 
patients with IDC had LV ejection fraction (EF) determined using radionuclide ventricu- 
lography prior to, and subsequent to initiating furosemide, digoxin and angiotensin-con- 
verting enzyme inhibitor (ACEI) therapy. The patients were genotyped for the ACE gene 
insertion/deletion (l/D) polymorphism, the M235T variant of the angiotensinogen (AGT) 
gene and the C-344T polymorphism of the aldosterone synthetase (GYP1 182). Results. 
Prior to initiating medical therapy, the I/D polymorphism of the ACE gene was associated 
with LV EF (p<O.O4). Moreover, the 344T allele of the CYPllB2 gene was associated 
with a smaller increase in LV EF approximately 6 months (n=83; p<O.O4), 2 years (n=50, 
p<O.O2), 2.5 years (n=50; p<O.O005), and when considering the final LV EF in all patients 
evaluated (n=107, p<O.O0005), subsequent to initiating medical therapy. Neither the ACE, 
nor AGT gene variants examined were associated with change in LV EF. Conclusions. 
The CYPllB2 gene variant is strong predictor of improvement in systolic performance 
following medical therapy in patients with IDC. 
1198-47 Differentiation Between lschemic and Non - lschemic 
Dilated Cardiomyopathy Based on Left Atrioventricular 
Plane Displacement During Dobutamine Echocardiography 
Konstadina P. Bouki, Theodoros Kakavas, Konstadinos Kostopoulos, Georgios Tsamis, 
Loukianos Rallidis, Kyriakos Poulopoulos, Takis Xydas, Thomas Apostolou, Evaggelos 
Papasteriadis. Nikaia General Hospital, Pireaus, Greece 
Background. Previous reports have shown that recording of left atrioventricular plane 
displacement (LAVPD) during stress echocardiography accurately identifies coronary 
artery disease in patients without dilated cardiomyopathy (DCM). In the present study we 
estimated the response of LAVPD during dobutamine echocardiography in patients with 
DCM and we evaluated the ability of this parameter to identify the ischemic or non- 
ischemic origin of the disease. 
Methods. Forty-seven patients with at least moderate left ventricular dysfunction of 
unknown origin and 10 aged-matched healthy volunteers (HV) underwent dobutamine 
echocardiography. The LAVPD was measured at baseline and at low (L) (5-10 pgr/Kg/ 
min) and peak doses (PD) (20-40 @gr/Kg/min) of dobutamine. All the 47 patients under- 
went coronary angiography and according to the results they were divided into two 
groups (ICM group; 25 patients with ischemic cardiomyopathy, NI-DCM group; 22 
patients with non-ischemic DCM). 
Results. The two groups of patients had similar baseline characteristics. The LAVPD 
showed significant increase at PD of dobutamine, in NI-DCM group (2.3k0.8mm) and in 
HV (3.611.3mm), but not in ICM group (0.7 +l.Omm ) 
ICM NI-DCM HV 
LAVPD, Baseline (mm) 7.8f1.4 8.4k2.0 13.%+1.5 
LAVPD, LD Dobutamine (mm) 8.li1.5 9.5~2.5 16.li2.1’* 
LAVPD, PD Dobutamine (mm) 8.6?1.3 10.7ti.l’ 17.6?2.7** 
“p=0,01 “p=O.O02 ANOVA compared to baseline 
Use of a LAVPD increase<l.5mm at PD of dobutamine resulted in a sensitivity of 80% 
and a specificity of 95% for detection of coronary artery disease in patients with DCM. 
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Results: Coronary blood flow response to both adenosine and acetylcholine was signifi- 
cantly larger in control patients Versus patients with cardiomyopathy (330*20% Versus 
220r20%, p<O.OOOl and 153f27% Versus 88 +19%, p=O.O5 respectively). Similarly, con- 
trol patients had a larger reduction in coronary vascular resistance with acetylcholine (- 
55*3% Versus -27+8%, p=O.O05). More patients with cardiomyopathy (18/25:72% Ver- 
sus 4125:16%, ~~0.02) showed abnormal endothelium-independent coronary flow 
reserve (~250% increase in coronary blood flow with adenosine). 
Conclusions: Abnormal coronary blood flow reserve in patients with chronic heart fail- 
ure due to nonischemic cardiomyopathy is not limited to endothelium-dependent vasodl- 
lation. Impairment of endothelium-independent coronary vasodilation is common (>70% 
of patients) and indicates that structural changes of the coronary microcirculation in addi- 
tion to endothelial dysfunction are responsible for decreased coronary vasodilatory 
capacity in patients with nonischemic cardiomyopathy. 
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1199-52 Peak V02 Does Not Predict Survival in Heart Failure 
Patients Treated Chronically With S-Blockers 
Marc A. Simon, Eugene E: Wolfel, Brian D. Lowe?., Michael R. Bristow, Simon F. Shakar. 
Unfversity of Colorado Heart Center, Denver, CO 
Previous studies have shown that peak VO, is predictive of survival in patients with heart 
failure. Chronic P-blockade improves survival and ejection fraction in these patients but 
does not improve functional capacity. We sought to evaluate the predictive value of peak 
VO, for patients treated with P-blockade. We performed a retrospective review of all 
charts available on site at the University of Colorado Heart Failure Clinic. Inclusion crite- 
ria included treatment with P-blockade of at least 3 months duration with a documented 
peak VO, measured prior to the initiation of treatment. Primary endpoints were cardiac 
transplantation and death. We identified 135 patients meeting the inclusion criteria 
(LVEF = 21% f 9%, Age 53 + 12, 75% male) who were initiated on P-blockade between 
May 1992 and November 1999. Of these, 13 died and 13 were transplanted. Average 
follow up was 2.4 years. There were 115 patients with peak VOp > 14 cc/Kg/min and 20 
patients with a peak VOs < 14 cc/Kg/min. Kaplan-Meier curves were not significantly dif- 
ferent between groups. Predicted 5 year survival without transplant was 66% for patients 
with peak VO, < 14, and 69% in patients with peak VOp > 14 (~~0.72). 
Conclusion: Peak VO, is not as predictive of survival in heart failure patients treated 
chronically with P-blockade. Further studies involving more patients are needed to evalu- 
ate the role of metabolic testing in prognosis. 
1199-53 Baroreflex Sensitivity Is a Powerful Tool to Monitor Cardiac 
Reinnervation After Orthotopic Cardiac Transplantation in 
Man 
G Tjeerdsma, Joop D. Lefrandt, Johan Brugemann, Dirk Jan van Veldhuisen. University 
Hospital, Groningen, The Netherlands 
Background: Baroreflex sensitivity (BRS) measures modulations of heart rate in 
response to variations in blood pressure. After cardiac transplantation (HTX) the heart is 
completely denervated and@ a result,BRS is absent. Whether or not reinnervation 
occurs remains a matter of debate. We hypothesized that increased BRS reflects auto- 
nomic reinnervation after HTX. Methods: Six patients (age 54+4 years) were studied in 
the first year (mean 5*4 months) and second year (mean 20r4 months) after HTX. The 
transfer function technique is a well accepted technique for measuring baroreflexes. By 
using this technique, BRS and phase shift can be calculated. This phase shift indicates 
whether blood pressure variation is followed by a subsequent change in heart rate and is 
normally negative. Phase shift was calculated in both periods for all patients. Results: No 
graft rejections were detected in the present study group. After HTX, BRS increased from 
0.9kO.9 (first year) to 2.4+1.3 (second year), pcO.O3,(figure). Phase was positive in 4/6 
patients in the first year, however became negative in 5/6 patients 2 years after HTX, indi- 
cating a response of heart rate after a change in blood pressure. Conclusions: Our 
results provide new evidence for the occurrence of reinnervation after HTX as demon- 
JACC February 2001 
strated by enhanced BRS and a change in phase shift. This change in phase shift indi- 
cates that. 2 years after HTX, variations in blood pressure can induce a baroreflex 
mediated heart rate response. 
BRS change after HTX 
0 1 2 
O=HTX 
1 = first year after HTX 
2 = second year after HTX 
1199-54 Survival of Patients Waiting for Heart Transplant: The 
Information Brought by Usual Statistical Techniques May Be 
Misleading 
Christine Mestre, Francois Delahaye, Guy de Gevigney, Muriel Rabilloud, Rene 
Ecochard, Corinne Ducreux, Georges Dureau, Hugues Milon. HOPlTAL 
CARDIOLOGIQUE, LYON, France 
Background: With Y~sual statistical techniques (Kaplan-Meier) comparing survival in 
operated and non-operated patients, patients are categorized either in the operated 
group or in the non-operated group. This leads to a selection bias, in favor of the oper- 
ated group, as the most severe patients, who die rapidly, were not given the opportunity 
to be o$erated on. Methods: We analyzed data from a large cohort of patients (389) put 
on one of the heart transplant waiting lists in our hospital between 1st January 1988 and 
31st December 1996, using the Kaplan-M&r method and the Mantel-Byar method, in 
which an operated patient is first considered as a non-operated patient up to the time of 
surgery, then as an operated patient. Results: By 25 October 1997, 98 patients (25%) 
were not transplanted; 70% of them died while waiting for transplant. One- and two-year 
survival rate (95% confidence interval), with the 2 techniques, were as follows: 1 year: 
Kaplan-M&r: Transplanted: 80 (75-85); Non transplanted: 31 (22-40): Mantel-Byac 
Transplanted: 54 (42-65); Non transplanted: 71 (64-78): 2 years: Kaplan-Meier: Trans- 
planted: 72 (67-77); Non transplanted: 18 (10.26); ManteCByac Transplanted: 48 (38. 
58); Non transplanted: 51 (40-63). In multivariate analysis, treatment with ACE-inhibitors 
(relative risk [RR] = 0.60), natremia (RR = 0.83 for a 9 mmol/l increase), and transplant 
(RR = 0.13) predicted a better survival; hospitalization in intensive care unit predicted a 
lower survival (RR = 2.90). Compared with non transplanted patients, during the postop- 
erative period, RR of death was >> 1 during the first weeks, it was < 1 after the 83rd post- 
operative day. Conclusion: The ManteCByar statistical method, which is more “correct” 
than the Kaplan-M&r method, gives very different results. Survival is initially better in 
non transplanted patients; it is better in transplanted patients when they have survived 3 
months after the surgery. 
1199-55 Left Ventricular Function and Exercise Tolerance After Heart 
Transplantation 
Michael Dandel, Ralf Ewert, Manfred Hummel, Johannes Miiller, Rudolf Meyer, Roland 
Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany 
Background: The contribution of left ventricular (LV) dysfunction to the reduced exercise 
tolerance of heart recipients, with and without transplant coronary disease (TxCAD), is 
barely known. To obtain more information, we assessed LV function and exercise toler- 
ance in non-rejecting heart recipients in connection with post-transplant time, amount of 
interstitial fibrosis and presence of TxCAD. Methods: Echocardiographic assessment of 
LV function (M-mode-, 2D-, flow Doppler and tissue Doppler imaging recordings), exer- 
cise testing (cycle ergometer), cardiac catheterization and biopsies were performed in 
130 adult patients of both sexes with post-transplant times of 6 weeks to 13 years. 
Results: In both sexes and all age groups peak oxygen consumption and workload, sig- 
nificantly lower during accelerated TxCAD, were suboptimal even without TxCAD and 
appeared to be closely related to diastolic dysfunction. Beyond the first post-transplant 
year we fou?d progressive alteration in LV diastolic function that predominantly involved 
distensibility/stiffness. Impaired diastolic function appeared to be connected to the 
amount of interstitial fibrosis. The invasively measured LV end-diastolic pressures, higher 
during TxCAD (p = 0.0002), were elevated even without T&AD (il.8 +6.1 mmHg). The 
LV ejection fraction (LVEF) was significantly lower during accelerated TxCAD (p = 
0.0002), but the mean value was not below the normal range (60 ~5.4%) and there was 
no significant correlation between LVEF and peak oxygen consumption. Although 94.5% 
of all tested patients had normal LVEF, only 18.5% showed peak oxygen consumption 
values above 20 ml/min/kg. During exercise, the heart rate increased only by 30.5% and 
although significant, the correlation between the peak oxygen consumption and heart 
rate increase was poor (I = 0.50 : p < 0.01). Conclusion: In heart recipients, with or with- 
out TxCAD, the LV diastolic dysfunction, closely related to the amount of interstitial fibro- 
sis, is a major cause of reduced exercise tolerance and should be considered in the 
therapeutic management. In the majority of patients T&AD aggravates an already pre- 
existent diastolic dysfunction rather than primarily causing it. 
JACC February 2001 
1199-56 Etiology of Atrioventricular Conduction Block in Patient 
Following Heart Transplantation 
Guanggen Cui, Jon Kobashigawa, Luyi Sen. UCLA Medical Center/UCLA School of 
Medicine, Los Angeles, CA 
Various atriaventricular conduction blocks (AVB) following heart transplantation (HXT) 
have been reported, however, their incidence and etiology have not been clarified. In 
order to determine the etiology of AVB following HXT, 892 consecutive patients undergo- 
ing arthotopic HXT at UCLA MedIcal Center between 1984 to 1998 were included in the 
study. Total of 78 patients had AVB, and the incidence was 8.7%. Sixty-one patlents had 
first degree AVE. Thirty of them had persistent atrial fibrillation (Af) or flutter (AF) and 21 
patients (70%) associated with cellular rejection. Among those, 12 associated with 
severe rejection (grade IIIA and IIIB), 7 with mild rejection (IB) and 2 with humoral rejec- 
tion. Seven patients (26%) had transplant coronary artery disease (TCAD). In 2 patients 
with rejection grade 0, AVB occurred immediately after HXT and only persisted 2 days. 
Another 31 patients had only first degree AVB, but no Af or AF. The incidence of cellular 
rejection (45%) occurred in these patients was significantly lower (pcO.Ol), and the rejec- 
tion was also less severe (IIIA and IllB was 6114, IA and IB was 6114). Eight patients had 
TCAD, 2 had humoral rejection. However, 7 occurred perioperativelly without rejection, 
other 4 occurred during catheter intervention. Second degree AVB Mobitz I was occurred 
in 6 patients, only2 associated with cellular rejection, 4 with TCAD, in 2 of them AVB was 
occurred during PTCA. One patient had Mobitz II during coronary artery stenting. Com- 
plete AVB was occurred in IO pattents, 2 of them associated with cellular rejection, 4 with 
TCAD. In other 4 patients AVB was occurred perioperatively or during catheter interven- 
tion. Significant inter-atnal conduction disturbance manifested by increased of the termi- 
nal force of the P wave in Lead VI was observed in 92% first-degree AVB patients with 
and 80% without Af or AF (~~0.05). There was no difference in the prevalence of AVB 
between different surgical procedures. These results suggest that the first-degree AVB 
was etialogically related with the cellular and humoral rejection and TCAD Induced atrial 
conduction disturbance, while second and third-degree AVB were mainly the conse- 
quences of surgical and catheter intervention injury. 
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1201-62 Troponin I Release Pattern and Myocardial Dysfunction 
After High-Dose Chemotherapy 
Daniela Cardlnale, Maria Teresa Sandri, Alessandro Martinoni, Alessio Tricca, Elena 
Borghini, Maurizio Civelli, Giuseppina Lamantia, Giovanni Martinelli, Cesare Fiorentinl, 
Carlo M. Cipolla. lstituio Ewopeo di Oncologia, Milan, Italy 
Background. We previously demonstrated that, in patients with aggressive maiignan- 
ties, even minimal elevation of troponin I (Tnl) after high-dose chemotherapy (HDC), is 
associated with long-term left ventricular systolic dysfunction. However, the time cour.se 
of the subclinical myocardial damage, as well as the ability of Tnl to differentiate high- 
and low-risk groups for development of investigation-driven therapeutic and management 
pathways, have not been fully elucidated. Methods. In 125 cancer patients (29 men, 96 
women; mean age 46~11 years) undergoing HDC, we measured Tnl serum concentra- 
tion by using an immunoenzymometric assay (Stratus II, Dade). Tnl positivity (+) was 
considered when values exceeded the r0.4 nglml threshold. Samples were obtained 
soon after HDC treatment (early Tnl) and 3 months later (late Tnl). Left ventricular ejec- 
tion fraction (EF) was evaluated by echocardlography before (b) and 3 (3m) and 7 (7m) 
after HDC. Patients were grouped according to Tnl result?.: Group 1: both early and late 
Tnl negatiwty (-),n=85; Group 2: early Tnl+ and late Tnl-,n=24; Group 3: both early and 
late Tnl+,n=16. Results are shown in the table. ‘=p<O.Oi vs. b; #=p<O.Ol vs. 3m; 
§=p<O.Ol vs. Group 1; O=pcO.Ol vs. Group 2. ConclusionsTreatment with HDC was 
associated with early Tnl increase and long-term lower EF in 32% of cases. In many of 
them (40%), in which late ventricular dysfunction was even greater, Tnl positivity was 
also detectable 3 months ‘after treatment. This suaaests a oossible continuous Tnl 
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1201-61 Cardiac Troponin Tfor Risk Stratification in Decompensated 
Heart Failure 
Carlos H. Del Carlo, Antonio C. P. Barr&o, Christopher M. O’Connor, Wendy A. Gattis, 
C&a Cassaro-Strunz, Maria R. D.‘O. Latorre, Jo& A. F. Ramires. Heart /nsfih& (/nCor). 
University of Sri0 Paula Medical School, Seiko Paula, Brazil. Duke University Medical 
Center, Durham, NC 
Background: Previous studies have detected elevated cardiac troponin T (cTnT) levels 
in pts with advanced heart failure (HF). However, the clinical significance of this marker in 
HF pts needs better evaluation. This study assessed the association of clinical character- 
istics and laboratory findings (cTnT, CK-MB mass, sodium, creatinine) with prognosis in 
pts with decompensated HF. Methods: From January 1999 to September 1999, we pro- 
spectively studied 70 pts (aged 21-80 years; LVEFc=50%; male: 48 pts) with decompen- 
sated HF (NYHA class Ill: 11 pts, IV: 59 pts). We excluded those pts which 
decompensation was related to infection, acute arrhythmia, and with recent history (~30 
days) of cardiac or non-cardiac surgery, unstable angina and myocardial infarction. cTnT 
was analyzed with a third generation immunoassay (Roche Diagnostics). All pts were 
monitored during a median follow-up period of 6 months. Results: There were 15 in-hos- 
pital deaths, the total mortality was 47.1% (33 pts) and 28 pts needed hospital readmis- 
sion because of new episode of HF decompensation. cTnT levels >0.05 “g/ml were 
associated with an increased risk of mortality at 6 months compared with pts with lower 
levels, 64.0% versus 37.8% (RR=1.69,95%CI=i .05-2.73, p=O.O47). In a multivariate Cox 
proportional hazard analysis, independent predictors for 6 months mortality were cTnT 
>0.05 ngIml (HR=2.1, p=O.O3) and mean arterial pressure (MAP) <=QO mmHg (H&2.3, 
p=O.O4). Based on cTnT and MAP, the pts were divided into three subgroups at high, 
intermediate and low-risk for in-hospital death, total mortality and cardiac event (death 
and/or rehospitalization because a new episode of HF decompensation). 
Risk group (n) LOW (“=I a) Intermediate High (n=14) P-Value 
(w38) 
Characteristic cTnT<=O.O5 cTnT>0.05 or cTnT>O.OB and (Chi-square) 
and MAP>90 MAP<=90 MAP<=90 
In-hospital 1 (5.6%) 10 (26.3%) 4 (28.6%) 0.161 
death 
Total mortality 3 (16.7%) 20 (52.6%) 10 (71.4%) 0.005 
Cardiac event 7 (38.9%) 28 (73.7%) 12 (85.7%) 0.009 
Conclusion: cTnT and MAP provide independent and complementary prognostic infor- 
mation in pts with decompensated HF. The combination of cTnT and MAP are useful 
parameters for risk stratification in HF pts. 
-- 
release or a biphasic myocardial cells damage. 
early/late Tnl b EF(%) 3m EF(%) 7m EF(%) 
Group 1 -/- 63.9+6 59.&4 63.2+4# 
Group 2 +I- 64.7+6 54.4+3*5 54.4+3?j 
Group 3 +I+ 64.5~5 50.4+9’?j@ 45.6~10’#§@ 
1201-63 Decreased IL-6 Concentrations as a Marker of Successful 
Treatment in Patients with Chronic Heart Failure 
Bjoern Mayer, Stephan R. Holmer, Christian Hengstenberg, Guenter A. J. Riegger, 
Heribert Schunkert. University of Regensburg, K/in/k lnnere Med. /I, Regensburg, 
Germany 
Background: Chronic heart failure is characterized by persistent immune activation. It 
has been demonstrated that interleukin-6 (IL-6) is induced via activation of the renln 
angiotensin system and that ACE inhibitors may result I” a significant reduction of IL-6 
concentrations. However, the effect of an additional beta-adrenergic blockade (BB) on IL- 
6 levels in chronic heart failure remains unknown. 
Methods: Twentyone patients with stable chronic heart failure (NYHA class 11-111, ejection 
fraction<40%, mean age 57.6k12.4 years) with a standardized therapy of the ACE- inhib- 
itor captopril (100.150mg/d), and furosemid (40.lZOmg/d), f digoxin (O,l-0,2mgid), 
ispironolactone (25.50mg/d) received additional metoprolol (six week uptitration phase 
according to the MERIT protocol) IL-6 and active renin were assessed prior to BB and 
after three month. 
Results: BB resulted in a significant heart rate reduction (68.3?13.0/min vs. 84.5+13.9/ 
min; p<O.Ol). Active renin was significantly reduced after BB (64*59 vs. 1941207 @ml; 
p=O.Ol), suggesting an inhibition of the renin angiotensin system. In chronic heart failure 
prior to BB, IL-6 levels were markedly elevated (8.7r9.7 pgiml; for comparison 2.1*1.5 
pgiml in healty volunteers, n=461). Treatment with BB resulted in a marked reduction of 
IL-6 concentrations 4.48t3.1 pgiml (p=O.O38 vs. before BB). Moreover, a highly signifi- 
cant correlation was found between the change of IL-6 levels and the change of the LV 
endsystolic diameter (LVESD; see graph; r2=0.439, p=O.O03). 
Change of IL6 levels (pg/tnL) 
Conclusion: In patients with chronic heart failure addition of a bet&receptor blocker 
causes supression of the renin system as well as a reduction of IL-6 concentrations. The 
change of IL-6 during BB treatment may be useful as a predictor of an improvement or 
worsening of LV dimension. 
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1201-64 Relationship Between Interleukin-6 Spillover in the Lungs 
and Pulmonary Vascular Resistance in Patients With 
Congestive Heart Failure 
Naoko Mabuchi, Takayoshi Tsutamoto, Atsuyuki Wada, Keiko Maeda, Masar” Hayashi, 
Takashi Tsutsui, Masato Ohnishi, Masahide Sawaki, Masanori Fujii, Takehiro Matsumoto, 
Takashi Yamomoto. Shiga University of Medical Science, Otsu, Japan 
Background: Although plasma interleukin (IL)-6 has been reported to increase in 
patients wtth congestive heart failure (CHF) especially in pulmonary hypertension, 
whether IL-6 is produced in pulmonary circulation and the relationship between the IL-6 
spillover and the pulmonary vascular resistance (PVR) in patients with CHF remain 
unknown. Method: We measured plasma levels of IL-6 and cyclic guanosine monophos- 
phate (cGMP), a second messenger of nitric oxide which stimulate soluble guanylate 
cyclase, in the main pulmonary artery (PA) and pulmonary capillary wedge region (PC) in 
consecutive 50 CHF patients and 9 age-matched normal sub)ects. Results: Plasma IL-6 
concentrations increased significantly from the PA to PC both in normal subjects and 
patients with CHF [ Normal: PA, i.O+O.i; PC, l.ZkO.2 pg/mL. mild CHF (NYHA II): PA, 
2.21-0.3; PC, 2.7-t0.3 pg/mL, severe CHF (NYHAIII-IV): PA, 4.6rl .O; PC, 5.7rl.2 pg/mL 1. 
IL-6 spillover in the lung [ (PC-PA) IL-6*cardiac output*(l-hematocrit/lOO) 1 increased in 
patients with severe CHF compared with normal subjects and mild CHF patients (Nor- 
mal: 0.5kO.2, mild CHF: 1.2*0.2, severe CHF: 2.3r0.6 ng/min). There was a significant 
positive correlation between the IL-6 spillover in the lung and PVR (w0.430, p=O.OOl), 
and cGMP production in the lung (r=O.432, p=O.O009). Among the hemodynamic vari- 
ables, neurohumoral factors, and medications, plasma norepinephrine level (p<O.OOOl) 
showed independent and significant positive, and treatment with beta-blockers (p=O.O04) 
showed independent and significant negative relations with IL-6 spillover in the lung. 
Conclusion: The IL-6 spillover in the pulmonary circulation increases with the severity of 
CHF and manly associates with activation of the sympathetic nervous system. The local 
production of IL-6 in the lung may modify the PVR in autocrine or paracrine manner in 
patients with CHF. 
1201-65 Endotoxin and Severity of Chronic Heart Failure 
Mathias Fiauchhaus, Wolfram Doehner, Aidan Bolger, Rakesh Sharma, Hendrik Schmidt, 
Constantinos Davos, Michael Kemp, Andrew J. S. Coats, Stefan D. Anker. NHLI, Clinical 
Cardiology London, United Kingdom, Martin-Luther-Universit~t Hal/e- Wittenberg, Klinik 
fiir lnnere Medizin /I/, Ha//e&a/e, Germany 
Background: Bacterial lipopolysaccharide (LPS, endotoxin), via bacterial translocation 
across the intestinum, has been suggested to trigger inflammatory immune activation 
that is present in a large number of patients with chronic heart failure (CHF). Elevated 
LPS plasma concentrations have been found in acutely decompensated CHF patients 
and in children with congenital heart daease. Methods: In order to validate previous find- 
ings on increased LPS concentratrons in CHF, we consecutively enrolled 120 patients 
(age 65*11 years, mean&D; 102 males) and 90 healthy controls (age 63k.18 years, 
p=O.47; 64 males) in a cross-sectional study. Etiology of CHF was ischemic in 73 patients 
(61%). CHF severity was assessed clinically by NYHA class (l/ll/lll/lV:n=10/47/41/22, 
respectively). In control subjects, the mean LPS plasma concentration was 0.42+0.12 
EUiml (range 0.25-l .02 EUlml, median 0.41 EUlml) and was not different from 0.40r0.16 
Elf/ml found in patients with NYHA class I (range 0.03-0.61 EU/ml, median 0.43 EUlml, 
p&78). An increase in LPS concentration was observed in patients with NYHA class II 
(0.47~0.17 EUlml, range 0.2-1.3 EU/ml, median 0.44 ELI/ml) which was significantly dif- 
ferent from control values (p&03). Patients with NYHA class III showed a similar LPS 
concentration (0.46*0.19 ElJ/ml, range 0.18-l .12 EU/ml, median 0.45 EUlml, ~~0.01 vs 
controls; p>O.20 vs NYHA class I and II). The highest LPS plasma concentration was 
found in patients with NYHA class IV (0.60+0.24 EU/ml, range 0.28-l .li EUlml, median 
0.52 EUlml) which was markedly increased compared to controls (pcO.0001) and 
patients in NYHA class I, II, and Ill (all p<O.Ol, all ANOVA). Whereas only 4 of the 90 con- 
trol subjects (4%) exhibited LPS concentratrons above the mean+2SD’s of controls, 20 of 
120 CHF patients showed LPS plasma concentrations above this cut-off (p=O.O07, chi- 
square test). Conclusion: There is a rise in LPS plasma concentration from patients in 
NYHA class I to those in class IV who are in fact not only acutely decompensated. This 
finding adds new evidence to the suggested pathophysiological role of circulating LPS in 
CHF and may be of importance to a broader spectrum of CHF patients than previously 
thought. 
1201-66 Evidence of Endotoxin Exposure in Patients With Severe 
Chronic Heart Failure by Determination of Antiendotoxin 
Core Antibody Levels 
Aidan P. Bolger, Mohammed Rashid, Rakesh Sharma, Mathias Rauchhaus, Wolfram 
Doehner, Robert Stephens, Robin Barclay, Andrew J. S. Coats, Esq., Stephan D. Anker. 
National Heart and Lung Institute, London, United Kingdom 
Background: Cardiopulmonary bypass (CPB) is associated with bacterial endotoxin 
(lipopolysaccharide or LPS) exposure, pro-Inflammatory cytokine release and a con- 
sumption of antibodies directed against LPS core antigen (EndoCAb). Low preoperative 
EndoCAb levels predict a worse outcome in patients undergoing CPB. Circulating endot- 
oxin levels are also elevated in edematous chronic heart farlure (CHF) patients and fall 
following diurekc therapy. It has been proposed that LPS triggers the pro-inflammatory 
cytokine production wan in these patients by Ita action on peripheral monocytes. The 
effect of endotoxin exposure on EndoCAb levels in CHF patients is unknown. Methods: 
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF) andEndoCAb IgG and 
IgM levels were determined in 57 CHF patients (age 65t2y, NYHA 2.7eO.1, peak VOe 
18.0+0.9, LVEF 35.0+_2.5. mean&EM) and 31 healthy controls of similar age by 
enzyme-linked immunosorbent assay. Results: TNF levels were elevated in CHF 
patients of NYHA class II-IV versus controls (ANOVA pcO.01). There were no differences 
between levels of EndoCAb IgG (expressed in mean EndoCAb median unitdMUiSEM), 
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in any heart failure group (II 237.4227.0, Ill 236.7k36.5, IV 187.4k24.6) versus the con- 
trol group (214.43-26.6) or between CHF groups. EndoCAb IgM levels, however, were sig- 
nificantly lower in NYHA class IV patrents (54.4212.6) versus all other groups (controls 
112.lil6.5. p<O.OOl, II 156.5127.0: p<O.OOl, Ill 97.2t17.3: p<O.Ol). Conclusion: In 
patients with severe CHF low levels of EndoCAb IgM antibody may reflect consumption 
of these antibodies due to chronic exposure to circulating endotoxin. This phenomenon 
may in part explain the exaggerated inflammatory immune actwation seen in these 
patients. The predictive power of EndoCAb IgM levels on morbidity and mortality in CHF 
patients warrants further investigation. 
1201-67 High Tumor Necrosis Factor Levels Are Associated With 
Exercise Intolerance and Neurohormonal Activation in 
Chronic Heart Failure Patients 
Mariantonietta Cicoira, Aidan Bolger, Wolfram’Doehner, Mathias Rauchhaus, 
Constantinos Davos, Rakesh Sharma, Faisal Al-Nasser, Andrew J. S. Coats, S&fan D. 
Anker. National Heart & Lung Institute, London, United Kingdom 
Background. Immune activation plays an important role in the progression of chronic 
heart failure (CHF). Recent pilot studies reported beneficial effects of anti-cytokine treat- 
ment in CHF patients. Except in patients with cardiac cachexia, the impact of various 
degrees of immune activation on disease severity and muscle function has never been 
reported. Such analyses may also provide information about the target population for 
therapeutic TNF antagonism. Aim. We sought to investigate whether different degrees of 
TNF activation are associated with exercise intolerance, neurohormonal activation and 
alterations rn muscle mass and function in CHF patients without a history of weight loss 
in the previous two years. Methods. Patients were divided into quartiles according to 
their TNF levels (frrst quartile: 0.98-4.90 pglml, second quartile: 5.00-6.60 pglml; third 
quartile 6.80.9.00pg!ml; fourth quartile 9.80-32.00pgiml). Every patient underwent a car- 
diopulmonary exercise testing, quadriceps muscle strength test, quadriceps fatigue test 
and assessment of thigh muscle and fat cross-sectional area (CSA, by CT scanning). 
Results. Patients in the highest TNF quartile had the lowest peak oxygen consumption 
(t3.1r4.1 miiminikg vs. 18.lt5.3, 18.8k4.8 and 18.7i5.6, pcO.Ol), the highest VEiVCOP 
slope (~~0.05) and catecholamine levels (~~0.05) compared with patients in the first 
three quartiles. Patients with the lowest TNF levels had preserved thigh muscle size and 
quadriceps strength. StrengthiCSA was similar in the four groups. Muscle strength during 
fatigue test was significantly lower in the fourth quartile (p=O.Ol) compared with the other 
three groups. Conclusions. In CHF patients only the highest TNF levels are associated 
with a poor functional status and neurohormonal activation. This group of patients may 
represent the target population for TNF antagonism. 
1201-68 Elevated Plasma Levels of Pentraxin 3 in Patients With 
Chronic Heart Failure 
Marco Metra, Massimo Locati, Giuseppe Peri, Savina Nodari, Federica Vigliani, A. Doni, 
Albert0 Mantovani, Livio Dei Cas. Chair of Cardio/ogL: Brescia, Italy, Department of 
Biotechnology, Section of General Pathology: Brescia, /taly 
Background. Pentraxin 3 (PTXB) is a member of the pentraxin family, together with C 
reactive protein and serum amyloid P component. It was originally identified as an IL-l/ 
TNFa inducible gene, produced and released by endothelial and muscle cells during 
inflammation. 
Methods. To assess the role of PTX3 in heart farlure, we measured its plasma levels and 
those of the pro-inflammatory cytokines monocyte chemotactic protein-l (MCP-1) and 
TNFa in 22 subjects with normal LV function and 35 patients with heart failure (left ven- 
trrcular ejection fraction c 40%) and correlated them with clinical and hemodynamic 
parameters. 
Results. PTXS, MCP-1 and TNFu plasma levels were significantly increased in the 
patients with heart failure compared with control subjects (1.67 f 1 .O vs. 0.80 i 0.61 ngi 
ml, 0.29 i 0.09 vs. 0.21 f 0.05 ngiml, and 8.9 + 4.8 vs. 3.1 f 1.8 pglml, respectively; all 
p<O.OOl). PTX3 plasma levels were not correlated with MCP-1 and slightly related to 
TNFa (r=O.29; p<O.O5), while MCP-1 and TNFu correlated each other (r=0.53; p<O.Ol). 
PTX3 correlated with the severity of heart failure, as shown by its significant relations 
with the New York Heart Association functional class, serum sodium, cardiac index, 
stroke volume index, systemic vascular resistance and left ventricular ejection fraction (I 
= 0.57, - 0.60, - 0.39, - 0.27, 0.32, - 0.28, respectively; all p ~0.05). In contrast, nocorre- 
lation was found with age, sex, and cause of HF. One year mortality was of 3113 patients 
with plasma PTX3 above the median value of 1.6 rig/ml (23%) versus none in the 22 
patients with lower values. 
Conclusions. Patients with heart failure present increased PTX3 plasma levels which 
are slightly related to those of other pro-inflammatory cytokines and correlated with 
indexes of the severity of heart failure. These data are consistent with the hypothesis that 
inflammatory mechanisms may contribute to heart failure progression and candrdate 
PTX3 as an independent marker of heart failure severity. 
1201-69 Immune-Genetic Control of Hyperprolactinemia in Patients 
with Heart Failure and Correlation with Ventricular Function 
Dennis Cokkinos, Constantinos Limas, Christos Kroupis, Antigoni Haidaroglou. On?.& 
Cardiac Surgery Centeer, Athens, Greece 
Background: Prolactin represents a stimulatory link between the neuroendocrine and 
immune systems, but its involvement in the neurohumoral adaptations to heart failure 
(HF) has not been explored. Methods: We prospectively studied 55 patlents (45 males, 
10 femalies, age 48+7 years) with NYHA Class II/Ill HF due either to dilated cardiomyop- 
athy (CMP) (n=33) or ischemic heart disease (IHD) (n=22). Serum prolactin levels were 
determined by radioimmunoassay, soluble interleukin-2 receptor (slL-2R) levels by 
enzyme-linked immunoassay and HLA-DQ genotyping with PCR. Left ventricular ejection 
fraction (LVEF) and end-diastolic diameter (LVEDd) were assessed echocardiographi- 
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caily. Results: Hyperprolactinemia (17.324 nglml [Group I] vs 4,6&2ng/mi, [Group II], 
p<O.Ol) was found in 14 patients (8 with IHD, 6 with CMP). The distribution of HLA-DQBI 
alleles was compared in the two groups and showed a significant increase in the fre- 
quency of *0301 (86% in Group I vs 45% in Group II, p<O.O5). Histidine at posltion 30 of 
the HLA-DQBI gene was found in 22% of Group II but in none of Group I patients. Fur- 
thermore, there was an inverse correlation between the presence of histidine at positron 
30 and the levels of serum pro&tin. Both sii-2R levels, a marker of T-cell activation, and 
concanavalin A- stimulated lymphocyte proliferation were lower in Group I patients 
(561t106 vs 804t109 pgiml and 20.8i4 vs 37.3i5 cpmXlO3 [3H] thymidine, respec- 
tively). LVEF was sigtxficantly higher (32t5%) and LVEDd smaller (6Z.OiBmm) in Group I 
compared to Group II (25*4% and 68.0+5mm, respectively, p<O.Ol) patients. Conclu- 
sion: Hyperprolactinemia presents in 25% of patients with HF and may reflect decreased 
activation of T-lymphocytes associated with relatively preserved LV systolic function is 
under immune-genetic control at the HLA-DQ locus. 
1201-70 increased Serum Concentration of Leptin in Patients With 
Severely Impaired Exercise Intolerance in Chronic Heart 
Failure 
Paul Christian Schulz+ Axel Link@ Sven Moebius-Winkler, Sandra Erbs, Volker Adams, 
Juergen Kratzsch, Nina Schoene, Stephan Gielen, Gerhard Schuler, Rainer Hambrecht. 
University of Lefpzig, Heart Cenfe~, Deparfment of Cardiology, Leipzig, Germany 
University of Leipzig, Department of Clinical Chemistry, Leipzig, Germany 
Background: Patients (pts) with chronic heart farlure (CHF) show a progressive exercise 
intolerance in addition to metabolic alterations finally leading to a catabolic state in 
advanced CHF. The association of intrinsic skeletal muscle abnormalities with the pro- 
gression of impaired muscle function in CHF has been described. Leptln, the product of 
the obesity gene, is related to energy expenditure and weight loss. The aim of this study 
was to assess leptin concentrations in relation to exercise intolerance in pts with CHF 
Methods: The study group consisted of 53 pts with CHF (LVEF 25.1&.4%, age 56.6+9.2 
years, BMI 26.8e3.6 kgim2, V02ma.x 16.3e4.2 mlikglmin) and 12 healthy controls (LVEF 
71t6.0, age 59.5213.0 years, BMI 29.823.9 kg/mZ, VOPmax 26.7r5 2 mllkgimin). Peak 
oxygen consumption was assessed by ergospirometry. Serum samples were obtalned 
from all individuals and leptin was measured by radioimmunoassay. TNFa was quantified 
by ELISA. Pts with CHF were subclassified in regard to VOPmax of more or less than 14 
miikgimin. Results: 
Controls CHF 
V02max>14 ml/ V02max<14 ml/ 
kgimin kglmin 
Leptin @g/ml) 7.8 i- 6.6 5.7 t 3.6 10.8 t 8.8’ 
TNFa (pg/ml) 1.7i 1.1 2.6 i 1.2 3.7 + 1.6’ 
BMI (kg/mZ) 29.8 5 3.9 27 4 + 3.8 26.4 t 4.1 
(*p<O.Ol vs. V02ms.x > 14 mlikglmin) Conclusion: These results suggest, that severely 
impaired exercise intolerance, a key symptom in pts with advanced CHF is accompanied 
by significantly increased serum levels of leptin. This finding indicates that hyperlepti- 
naemia might be involved in catabolic alterations and the progressive exercise intoler- 
ance in pts with severe left ventricular dysfunction. 
1201-71 Augmented Peripheral Chemosensitivity and Periodic 
Breathing Pattern Are Related to Elevated Levels of the Ob 
Gen Product Leptin in Patients With Chronic Heart Failure 
Wolfram Doehner. Mathias Rauchhaus, Karl Egerer, Waldemar Banasiak, Andrew J. S. 
Coats, Stefan D. Anker, Massimo F. Piepoli, Piotr Ponikowski. NHLI, London. l/n&d 
Kingdom. Cardiac Dept. Mi/i@ry Hospital, Wroclaw, PO/and 
Background: Augmented peripheral and central chemosensitivity (CS) are features of 
abnormal cardiorespiratory control in chronic heart failure (CHF). It may contribute to 
autonomic imbalance and to the ongin of periodic breathing (PB). The underlying mecha- 
nisms for upregulated CS remain uncertain. Experimental studies have shown that leptin, 
the adipocyte spectfic ob gene product may act to potentiate CS. We have demonstrated 
that leptin levels, even after correction for total body fat mass, are elevated in CHF. We 
investigated whether leptin level is related to altered CS and PB in CHF. 
Methods: In 16 stable CHF patients (6Ot2 years, NYHA-class II/Ill/IV: 6/9/l, peak V02 
15.9k1.6 mlikglmin, LVEF 23_t3%) peripheral CS (transient hypoxic method) and central 
CS (CO, rebreathing method) were assessed. PB was defined as the presence of a slow 
rhythm in respiration (a discrete peak in day-time resting respirogram within the fre- 
quency range 0.003.0.04Hz). Plasma leptin levels were measured by radioimmunoassay. 
Results: We confirmed overactive CS in CHF (peripheral CS: 0.71~0.38L/minl%Sa02, 
central CS: 3.5il.2Umin/mmHg, both p<O.Ol vs reference control values in our lab). 
Leptin levels were not-significantly higher in CHF compared the control values I” our lab 
(6.4*1.1 vs 4.4+0.6 nglml, p=O.l). After correction for total body fat mass, leptin levels 
were higher in CHF than in controls (38.4k4.6 vs 23.9+2.1ng/ml/lOOg, p=O.O03). Leptln 
levels correlated with peripheral chemosensitivity (r=O.54, p&05). This correlation 
improved after correction of leptin for fat mass (i-=0.65, pcO.01). No correlation was found 
between leptin levels and central chemosensitivity. The presence of PB was associated 
with no difference in cardiorespiratory function, but with elevated leptin level (8.5t1.6 I/S 
3.710.6 pcO.05). After correction for body fat mass this difference in leptin levels 
remained significant (46.326.6 vs26.5t3.8, p<O.OS). 
Conclusion: Peripheral but not central CS IS strongly related to plasma leptin levels in 
CHF. Abnormal elevated leptin levels in CHF could mediate a metabolic signal resulting 
in augmented chemosensitivity and abnormal breathing pattern. 
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1201-72 Plasma Oxidized Low-Density Lipoprotein Concentration as 
a Useful Marker of Oxidative Stress in Patients With 
Congestive Heart Failure 
Takashi Tsutsui, Takayoshi Tsutamoto, Keiko Maeda, Naoko Mabuchl, Masaru Hayashl. 
Atsuyuki Wada, Masato Ohnishi, Masahide Sawaki. Masanori FU~II, Takehiro Matsumoto, 
Takashi Yamamoto. First Department of lnternai Medicine Shiga University of Medical 
science, otsu, Japan 
Background: Oxidative stress appears to increase in congestive heart failure(CHF). 
However, it is difficult to measure oxygen-derived free radicals in viva. Recently, a high 
sensitive and specific assay system of plasma oxidized low-density lipoprotein (oxLDL) 
was dlscovered. Method: We measured plasma oxLDL by the sandwich ELISA using a 
specific monoclonai anribody against oxLDL (Clinical Biochemistry 2000;33:243) in age- 
matched normal subjects(n=7) and in patients with CHF(n=75, mean ejection frac- 
tion(EF)=35%, NYHA functional class:l-IV) and monitored them prospectively for a fol- 
low-up period of 486 days. Results: Plasma oxLDL was significantly higher in the 
patients with CHF than m the normal subjects (7.2r2.1 vs.l3.2+7.1 unit/ml, p=O.O217). 
There was a significant correlation between plasma OXLDL and NYHA functional class 
(r=O.443,p<O.O001). There was a significant negative correlation between plasma oxLDL 
and EF(r=-0.367, p=O.O019). To evaluate the relation between plasma oxLDL and prog- 
nosis of patients with CHF. 75 patients were monitored for a mean follow-up period of 486 
days. The frequency of the mortality and morbidity was significantly higher in a high 
oxLDL group (oxLDL>ll 8 unit/ml, n=38) than in a low oxLDL group (oxLDLc11.8 unit/ 
mL, n=37). Plasma oxLDL was significantly decreased after administratlon of carvedilol 
(20.0+6.8 vs. 12.5+4.4 uniVmL, n=6, p=O.O142). Conclusion: These results indicate that 
plasma oxLDL level is a useful marker of oxidative stress in patrents with CHF and 
patients with a high plasma oxLDL level had poor prognosis, suggesting that oxidative 
stress has an important role in the pathophysiology in the progressIon of CHF 
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854-l Chronic P-Adrenergic Stimulation Induces Dose-Dependent 
Myocardial Proinflammatory Cytokine Expression and 
Hypertrophy Independent of End-Systolic Wall Stress 
David R. Murray, Sumanth D. Prabhu, Bysani Chandrasekac University of Texas Heaffh 
Science Center, San Antonio, TX, University of Louisviile, Louisville, KY 
Increase in wall stress, either via pressure or volume overload, has been shown to pro- 
mote myocardial expression of tumor necrosis factor (TNF).alpha, a cytoklne implicated 
in heart failure. Whether catecholamines stimulate myocardial and systemic cytokine 
elaboration Independent of increased wall stress is not known. Accordingly, rats received 
either isoproterenoi (high dose, HD, 100 uglkgihr; low dose, LD, 25 uglkgihr, n=4igroup) 
or saline (control, n=4) via miniosmotic pumps for 7 days. Myocardial cytokine expression 
was analyzed by both Northern and Western blotting, and localized by immunohis- 
tochemistry (IHC). Circulating levels of cytoklnes were measured by ELISA. Ventricular 
size, performance, and end-systolic wall stress were evaluated by echocardiography. In 
control myocardlum. neither TNF-alpha nor lnterleukin (IL)-1 beta were detected, 
whereas IL-6 was present at very low levels. lsoproterenol led to a dose-dependent 
increase in “RNA expression (HD vs. LD: IL-1 beta, 2.13.fold; IL-6, 1.44-fold; TNF-alpha, 
1.79-fold; all p ~0.05) and protein levels (HD vs. LD: IL-i beta, p=NS; IL-6, 1.56.fold, p 
~0.01; TNF-alpha, 2.16.fold, p ~0.01) of all three cytokines. All three cytokines were 
detected by IHC throughout the myocardium, localized to resident cells and vessels, in 
animals treated with Isoproterenol. Neither treatment group had detectable levels of 
cytokmes in the serum. lsoproterenol led to significant increases (vs. baseline, p ~0.05) 
in heart rate, LV mass, wail thickness (LD, 1.54.fold; HD, 1.57.fold) and fractional short- 
ening (LD, 1.49.fold; HD, 1.22.fold) without affecting systemic pressure or end-diastolic 
dimension. However, end-systolic dimension (LD, 1.86-fold; HD, 1.59.fold) and end-sys- 
tolic wall stress (LD, 2.81.fold; HD, 2.29.fold) were reduced (p ~0.05). We conclude that 
chronic b-adrenerglc stimulation induces myocardiat, but not systemic, elaboration of 
TNF-alpha, IL-1 beta, and IL-6 despite reductions in LV end-systolic wall siress. Thus, in 
pathologic states characterized by increased sympathetic tone such as heart failure, adr- 
energz activation may serve as a stimulus for myocardial cytokine expression. 
854-2 
10:45 a.m. 
Circulating Cytokine Levels in Hypertensive Patients With 
Left Ventricular Diastolic Dysfunction Without Failure 
Timothy J. Regan, Albert Y Sun, Charles Laham, Anita Raghuwanshi, Malthi R. 
Masurekar, Garikiparthy N. Jyothirmayi, Jing Liu. UMDNJ-New Jersey Medical School, 
Newark. NJ 
Background:Cytokines in the circulation of patients with heart failure due to myocardial 
disease are significantly increased. Whether a secondary phenomenon or one that may 
contribute to pathogenesis is unknown. Methods:To assess cytokine levels before the 
onset of heart failure, we have studied hypertensive patients without other known disease 
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(N=31). There was no significant coronary disease, dilation or hypertrophy of the left ven- 
tricle (LV) on angiography. These subjects had normal ejection fraction but increased 
diastolic chamber stiffness. Circulating levels of tumor necrosis factor alpha (TNF-a), sol- 
uble TNF receptors (sTNF-RI and sTNF-RII), as well as interleukin-6 (IL-6) and IL-6 
receptor (IL-6 sR), were measured from EDTA treated plasma samples by ELISA, for 
comparison with 9 non-cardiac subjects. 
Results: Cytokine Levels (pg/ml) 
854-5 
1 I:30 a.m. 
Exposure of Cardiomyocytes From Failing Explanted 
Human Heart to Hypoxia and/or Angiotensin-II Leads to 
Activation of Caspase-3 and to Cleavage of DNA 
Fragmentation Factor (DFF45ACAD) 
TNF-a STNF-RI sTNF-RI, IL-6 11-s SR 
Normals 0.32 + 0.79 768 + 193 2374 + 320 0.96 + 0.93 50,000 + 13,oocl 
tiypertensives 1.29+1.27 1534 + 505 3120 + 597 3 55 + 2.52 45,000 + 1 *,ooo 
P co.01 <O.OC, co.001 <IlOO, NS 
Conclusions:The findings were apparently unrelated to age, gender or obesity. While 
the basis for early LV dysfunction prior to heart failure is presumably multifactorial, ele- 
vatecl levels of circulatimg proinflammatory cytokines may contribute to the pathogenesis 
of LV dysfunction. Enhanced TNF-a receptor levels in hypertensives may be sufficient to 
limit activity of the cytokine. Conversely since IL-6 increments occur without an increase 
of circulating recptors activity of this cytokine may predominate. IL-6 can downregulate 
sarcoplasmic reticulum calcium ATPase (SERCAP) gene expression and protein levels 
(Villegas S. at al., Basic Res Cardiol., 95:47-54, 2000). The cytokine may thus contribute 
to enhanced diastolic stiffness. 
Victor G. Sharov, Anastassia Todor, Norman Silverman, Sidney Goldstein, Hani N. 
Sabbah. Henry Ford Health System, Detroit, MI 
854-3 
1l:OO a.m. 
Endomyocardial Cytokine Gene Expression and LV- 
Massindex in Patients With Idiopathic Dilated 
Cardiomyopathy 
Background: ACE inhibitors and beta-blockers have been shown to attenuate cardiomy- 
ocyte (CM) apoptosis in heart failure (HF). This benefit may be due, in part, to alleviation 
of hypoxia with beta-blockers and inhibition of angiotensin-II (A-II) with ACE inhibitors. 
Methods: In this study, we examined the effects of hypoxia and A-II on the activation of 
caspase-3 (Gas-3) and on cleavage of DFF45/lCAD, the former a key effector of apopto- 
sis, in CM isolated from left ventricular myocardium of 7 explanted hearts of patients with 
ischemic cardiomyopathy (ICM). Comparisons were made using CM isolated from left 
ventricular myocardium of 5 normal (NL) human donor hearts. CM were incubated for 3 
hours under normoxia (NX, 5% CO, + 95% N,), hypoxia (HX, 5%COe + 95%N,), NX + 
0.5 mM A-II and HX + 0.5 FM A-II. A polyclonal rabbit antibody that recognizes both the 
pro form (CPP32) and the active form (~17) of Cas-3 and rabbit polyclonal antibody that 
recognizes both intact DFF45/ICAD and cleaved cDFF45/lCAD were used for Western 
blots and the bands quantified in densitometric units. 
Results: The results are shown in the table. Hypoxia, A-II and their combination pro- 
duced a graded increase in the expression of CPP32, ~17, DFF45/lCAD and cDFF45/ 
ICAD. 
Marc Vanderheyden, Georg Baumgarten, Douglas Mann, Walter J. Paulus. 
Cardiovascular Center, OLV ziekenhuis, A&f, Belgium, Baylor CoNege of Medicine, 
Houston, TX 
The in viva functional significance of pro-inflammatory cytokines for the failing human left 
ventricle(LV) remains und.etermined. The present study investigated the relation between 
endomyocardial gene expression of TNFa, IL-6 and IL-1 b and LV function parameters in 
patients with non-ischemic idiopathic dilated cardiomyopathy(DCMP) and variable 
degrees of LV dysfunction. LV microtip pressures, angiographic volumes, echocardio- 
graphic wall thickness and snap-frozen LV endomyocardial biopsies were obtained in 10 
patients referred for diagnostic left-right heart catheterization. Intensity of LV endomyo- 
cardial TNFa, IL-6 and IL-lb gene expression was determined using quantitative RT- 
PCR. IL-lb and TNFa were closely linked (r= 0.845;p=.OO2). TNFa correlated with LV 
massindex and LV wall thickening(Wth). This correlation improved when TNFa was nor- 
malized for LVEDP TNFaILVEDP also significantly correlated with LV systoltc wall 
stress(SysWS). Similar correlations were noted for IL-t b not for IL-6. 
NL ICM ICM ICM ICM 
NX NX HX NX + A-II HX + A-II 
CPP32 4.5 + 0.2 4.1 + 0.2 10 * 0.3’A 9.5 f 0.01’” 12 + 0.3*” 
P17 0 0 15 i 0.5’” 15 f 0.6*” 24 f 0.5- 
DFF45 6.4 + 0.2 11 * 0.4” 17 + 0.2- 19*0.1*” 19 + 0.8’” 
cDFF45 0 0 2.3 f 0.5”” 4.4 r 0.1’” 7.3 f 0.5”” 
*=P<O.O5 vs. NL-NX: “=P<O.O5 vs. ICM-NX 
Conclusion: Hypoxia and enhanced levels of A-II, well recognized features of HF, are 
potent triggers of Cas-3-mediated CM apoptosis. Therapies that limit these triggers of 
CM apoptosis are likely to attenuate ongoing CM loss in HF and, consequently, help limit 
the progressive deterioration of global cardiac performance that is characteristic of the 
HF state. 
Lvmassindex Wth sysws 
TNFa R=-0.786/p=.017 R=-0.831/p=.Oll ns 
TNFa/EDP R=-0819/p=.007 R=-0.841/p=.009 R=O.E12/p=.012 
Conclusion: DCMP patients with high TNFa expression have lower LV massindex, more 
depressed LV wall thickening and higher LV SysWS. The inverse relation between LV 
massindex and TNFa suggests pro-apoptotic effects of TNFa in the failing human heart. 
854-6 
I?:45 a.m. 
Magnitude of Procaspase-8 Overexpression Determines 
Severity of Myocyte Apoptosis-Induced Cardiomyopathy in 
Transgenic Mice: An Echo-Doppler Cardiographic Study 
Madhulika Chandra, Detlef Wencker, Richard N. Kitsis, Jamshid Shirani. Albert Einstein 
College of Medicine, Bronx, NY 
854-4 
ii:15 a.m. 
Induction of Tumor Necrosis Factor-Alpha and Left 
Ventricular Dysfunction in the Recipient Heart Following 
Myocardial infarction in the Remote Donor Heart in a 
Heterotopic Syngenic Transplant Model: Evidence of a 
Novel Unique Cytokine lntranet Signaling Pathway 
Hiroshi Nakamura, Gordon Moe, George Naik, Josef Penninger, Fayez Dawood, Jianxin 
Ren, Peter Liu. Heart & Stroke/Richard Lewar Centre of ExceNence, Univ of Toronto, 
Toronto, ON, Canada 
Background: A transgenic murine model of dilated cardiomyopathy with impaired left 
ventricular (LV) systolic and diastolic function secondary to spontaneous myocyte apop- 
tosis has been developed, through overexpression of an autoactivatable mutant pro- 
caspase8 protein in the myocytes. Objective: In order to evaluate the relation of the 
level of expression of procaspase-8 protein to the severity of cardiomyopathy, and sur- 
vival, we performed transthoracic echo-Doppler cardiography (TTE) in 23 awake mice: 9 
nontransgenic (NTG), 9 high expressing (L7), and 5 low expressing (L169) mice. TTE 
parameters included: LV end-diastolic and end-systolic diameters (EDD and ESD), mean 
LV diastolic wall thickness [(WTD), averaged from septal and posterior wall thicknesses], 
LV relative wall thickness (RWT), LV fractional shortening (FS), ejection time [(ET) aortic 
Doppler], LV rate corrected velocity of circumferential shortening (Vcfc), E and A veloci- 
ties (mitral pulsed Doppler), left atrial diameter (LA) and degree of RV dilation [graded 0 
(none) - 3 (severe)]. Results: Table (mean+SEE). 
Activation of neurohormones and cytokines contribute to cardiac remodeling after myo- 
cardial infarction (Ml). To examine the crosstalk between these stress response systems 
and the host, and confirm whether each factor is intrinsic or extrinsic, we performed syn- 
genie heterotopic cardiac transplantation and simultaneously induced Ml in the the donor 
heart with coronary ligation. Both recipient and donor hearts were evaluated histologi- 
cally at 1 or 3 weeks after the transplantation. Tumor necrosis factor-a (TNF-a), angio- 
tensin II (ANG II), and adrenomedullin (ADM) were also measured in both recipient and 
donor hearts by tissue ELISA and RIA Cardiac function of both recipient and donor 
hearts were evaluated hemodynamically and echocardiographically. At 3 weeks post-op, 
the Ml group when compared to shams showed %MI= 49.4*6.6%, reduced %FS 
(15.1t7.2 vs 23.1+7.8%, mean* SD, p<.O5), and increased LV end-diastolic pressure 
(LVEDP, 23.5k21.9 vs 5.9&2.9 mmHg, pc.05). Surprisingly, the cardiac function of recipi- 
ent unintervened hearts in the ligation group showed also reduced %FS when compared 
to the sham group (41.3i1.6 vs 47.8r5.5%, pc.05) increased LVEDP (16.1125 vs 
6.8k1.3 mmHg, pc.O5), and depressed +dP/dt (5393+2583 vs 8645+1412 mmHg/sec, 
pc.05) at 1 week after the operation. TNF-a was not only present in the donor myocar- 
dium in the ligation group but was also significantly elevated in the recipient myocardium. 
In contrast, ANG II and adrenomedullin were upregulated only in the infarct region of the 
donor heart. This unique transient cardiac dysfunction of the recipient hearts was signifi- 
cantly reversed by treatment of the MI animals with chimeric TNF-a soluble receptor 
(TNFR:Fc). Therefore, our data suggest that post myocardial infarction, there is a gener- 
alized activation of cytokine network (intranet) which may exert adverse effects in similar 
target tissues remote from the original site of activation. In contrast, the actions of ANG II 
and adrenomedulkn are much more localized. Systemic administration of TNF-a inhibitor 
may provide a novel strategy to reduce cardiac remodeling after accute myocardial infarc- 
tion. 
HR (bpm) EDD (mm) WTD (mm) RWT FS (%) Vcfc (circ/ 
s) 
NTG 613*14 2.29kO.i 1 0.77r0.02 0.69kO.04 69+3 4.9r0.2 
L189 495+35 2.93*0.17’ 0.61iO.O4* 0.42*0.01* 45*4* 3.8+0.5 
L7 506*17’ 3.32*0.07*# 0.58~0.03’ 0.35r0.02* 3052.’ 2.4i;O.2*# 
’ pcO.01 v NTG. # p<O.Oi v L169. Compared with NTG, L7 showed severe LV (Table), LA 
(2.20 * 0.12 v 0.74 + 0.10 rnm)r#] and RV (1.9 + 0.4 v 0 r 0 grade)[“#] dilation with 
reduced FS and Vcfc (Table). An intermediate degree of these abnormalities were seen 
in L169 [LA 1.51 + 0.02 mm(*), RV 0.8 r 0.21. Abnormal mitral E/A were noted rn all L7, 
80% (4/5) of L169, and in no NTG. 5 month survival was lowest for L7 (44%) intermedi- 
ate for L169 (73%) and normal for NTG (EE%)[p<O.OOl]. Procaspase-8 protein expres- 
sion was approximately 20 times higher in L7 v L169. Conclusions: The severity of 
cardiomyopathy in this transgenic murine model correlates with the degree of expression 
of procaspase8 protein. 
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856 Cardiovascular Therapy in the Elderly: 
Safety, Efficacy, Outcomes, and Eligibility 
Tuesday, March 20, 2001, lo:30 a.m.-Noon 
Orange County Convention Center, Room 231 A 
856-l 
10:30 a.m. 
Initiation and rapid in-hospital titration of ACE lnhbitor is 
safe in an Elderly population with Class IV Heart Failure 
John M. Cahtll, Peter Quigley, Brian Maurer, Ken MC Donald, Bronagh Travers, Mary 
Ryder, Mark Ledwidge. SI VINCENT’S CARDIOMYOPATHY RESEARCH CENJRE, 
DUBLIN, Ireland, LABORAJOIRES SERVIER (IRELAND) LTD., DUBLIN, Ireland 
ACE inhibitors at clinlcal trial dose (CTD) continue to be underused in heart failure due to 
left ventricular systolic dysfunction (LVSD). Possible reasons include concern about 
hypotension and renal dysfunction. Manufacturers recommend to titrate doses at mter- 
vals of two weeks. This prevents achievement of CTD before discharge from hospital and 
may contribute to underdosmg in the community. Aims: To examine the impact of rnitia- 
tion and rapid titration of ACE inhibitor to at least CTD before discharge on systolic blood 
pressure and renal function. Methods: 65 patients (mean age 71 ? 11 years) admitted 
with class IV heart failure and LVSD not previously treated with ACE inhibitor therapy 
were initiated on perindoprif and titrated to either maximally tolerated doses or 8mg. Indi- 
ces of renal function (creatinine, urea, potassium) and systolic blood pressure were 
observed at baseline and discharge. Length of stay and titration intervals to maximally 
tolerated ACEI dose were recorded. Results: The mean length of stay was 12.2 t 7.7 
days and 96% of patients achieved at least CTD (perindopril 4mg) before discharge. The 
mean final dose of perindopril was 5.7 f 1.9 mg with half of patients achieving high dose 
therapy (> 4mg). The average time to titration to final dose was 5.5 + 4.2 days. Mean 
baseltne urea, creatinine and potassium did not change from admission to discharge 
(urea 8.4 * 2.5 to 9.2 i- 3.9 mmol/L, p = 0.15; creatinine 122.7 i 30.3 to 122.4 k 35.4 
mmol/L, p = 0.93; potassium 4.0 * 0.5 to 4.0 i 0.3 mEq/L, p = 0.86). There was no signif- 
icant treatment related increase in mean creatinine (148.8 t 19.9 to 148.6 t 30.7 mmol/L, 
p = 0.97) in those (48% of total population) with evidence of chronic renal impairment 
(creatinine z-120 mmol/L). SBP decreased from 132 r 28 mmHg on admission to 117 i: 
18 mmHg on discharge (p = 0.03) with no recorded incidence of symptomatic hypoten- 
sion. Patients titrated to high dose therapy were more likely to have SBP )i 140 mmHg on 
admission (p = 0.03). Conclusions: Initiation and rapid in-hospital titration of ACE inhibi- 
tor to at least CTD is feasible and safe even in a high risk, elderly heart failure population. 
Routine application of this approach may help avoid underdosing of ACE inhibitors in the 
community. 
856-2 
10:45 a.m. 
Age and Quality of Care Provided to Elderly Patients With 
Acute Myocardial Infarction 
Saif S. Rathore, Rajendra H. Mehta, Yongfei Wang, Alan K. Berger, Martha J. Radford, 
Harlan M. Krumholr. Yale University School of Medicine, New Haven, CT Qualidigm, 
Middletown, CT 
Background: Variation in quality of acute myocardial infarction (AMI) care among older 
elderly sub-groups is unexplored. 
Methods: We evaluated 151,297 patients 65 years and older hospitalized with AMI in 
1994-95. Patients were divided into 5 age-based strata (table) and evaluated for use of 6 
ACCiAHA guideline-recommended AMI therapies: aspirin at admission (ASA-A) and dis- 
charge (ASA-D), beta blocker at admission (66-A) and discharge (BB-D), repedusion 
within 6 hours (REP), and ACE inhibitors (ACEI) for low LVEF Multivariable logistic 
regression models evaluated therapy use in ideal (no contraindications) patients adjust- 
ing for demographics, clinical characteristics, physician, and hospital factors, 
Results: Few elderly patients were Ideal for therapy, with smaller proportions in older 
sub-groups. Therapy use was lower among older efderiy patients in unadjusted and 
adjusted comparisons. 
65-69 70-74 75-79 80-84 a5 
Proportion of patients classified as ideal(%) 
ASA-A’ 55.8 53.1 50.7 49.9 51.0 
BB-A* 31.7 30.6 28.5 26.6 22.5 
REP’ 33.4 20.2 17.3 3.6 N/A 
ASA-D 48.6 47.2 46.3 48.2 51 .Q 
BE-D* 10.1 9.2 8.3 ’ 7.3 6.0 
ACEI 14.6 14.9 14.8 14.3 12.6 
Therapy use among Ideal patients(%) 
ASA-A 89.9 88.2 85.2 83.1 78.5 
BB-A’ 65.4 64.4 60.8 58.1 50.2 
REP* 70.0 63.3 56.0 43.8 N/A 
ASA-D’ 82.2 79.6 75.9 74.6 69.8 
BB-D’ 56.4 55.6 49.9 47.5 41.2 
ACEI 58.3 60.2 60.8 59.6 58.8 
Multivariable adjusted odds ratios (95% Cl) of therapy use 
ASA-A 1 .oo 0.92 (0.86,0.99) 0.86 (0.80.0.92) 0.88 (0.82,0.94) 0.90 (O.WO.97) 
BB-A 1 .oo 0 99 (0.94,1.05) 0.92 (0.87.0 98) 0.90 (0.85.0.97) 0 78 (0 72.0.84) 
REP 1 .oo 0.76 (II 71,0.82) 0.60 lO.56,O.S5) 0.38 (0 34.0.44) NIA 
ASA-D 1 .oo 0.90 (0.840 9s) 0.82 (0.75.0.87) 0.86 (o.sw.92) 0.81 (0.75,O 871 
BB-D 1 .oo 0.97 (0.86,1 09) 0 81 (0 72,O.W) 0.77 (0 67.0.89) 0.68 (0.59,o.ao: 
ACEI 1.00 1.06 (WV,, ,171 1.04(*.94.1.15) 0.94 (0.85,1.05) 0 85 (0.76.0 96) 
‘p=“.“uI to1 trend 
Conclusions: Older elderly patients receive fewer indicated AMI therapies and are less 
likely to be classified as ideal for these therapies. The large number of elderly patients 
who fall outside of guideline-based therapies emphasizes the need for evidence of effica- 
cious treatments in this population. 
856-3 
11 :oo a.m. 
Efficacy of External Cardioversion of Atrial Fibrillation in 
Aged Patients: Immediate and Long-Term Results 
Stefano Fumagalli, Lorenzo Boncinelli, Ernesta Bondi, Veronica Caleri, Silvia Gatto, 
Giorgio Baldereschi, Paolo Valoti, Mauro Di Bari, Giufio Masotti, Nrccolo’ Marchionni. 
Dep. of Critical Care Medicine and Surgery Section of Gerontology and Geriafrics, 
University Florence, f&/y 
Background. The influence of age on long-term results of direct-current external cardio- 
version (ECV) of atrial fibrillation (AF) has never been investigated, though this arrhyth- 
mia is highly prevalent and associated with increased morbtdity and mortality in older 
patients. This study was aimed at identifying the effect of age on immedrate and long- 
term results of ECV of AF. Methods. We prospectively analyzed 250 consecutive 
patients with AF, divided into three age-groups (<=65 yrs, n=77, age=57+6; 66-74 yrs, 
n=92; age=70*3; ~75 yrs, n=81, age 81+5, age range 34-100) who underwent a stan- 
dardized procedure of ECV. Results. At univariate analysis, immediate efficacy of ECV 
(overall, 91.2%) was lower in older patients and in those with chronic obstructive putmo- 
nary disease, higher for a 3-90 than lor a <2 or a 290 days duration of AF and indepen- 
dent of underlying cardiac disease, hypertension, diabetes, previous AF, and left atrial 
dimensions. However, duration of AF was the only multivariate predictor of ECV immedi- 
ate success. Major complications occurred in only three patients. Of 220 patients dis- 
charged in sinus rhythm, 211 were followed-up for 34i25 months. AF relapsed in 45.5% 
of them. The relapse rate was lower in coronary heart disease (CHD) than in vaivular 
heart disease, congestive heart failure or lone AF, and also lower in patients without a 
previous AF Age, comorbidity, duration of AF, left atrial dimensions and post-ECV treat- 
ment were not associated with the relapse rate. Underlying cardiac disease was the only 
multivariate predictor of the relapse rate, with CHD showing a significantly lower risk. 
Conclusion. Both immediate and long-term results of ECV of AF an effective and safe 
procedure, are unaffected by age. 
856-4 
II:15 a.m. 
Eligibility for New Therapies in Elderly Heart Failure 
Patients: Results From the National Heart Failure Project 
Edward P. Havranek, Frederick A. Masoudi, Pam Wolfe, Kelly A. Westfall, Richard J. 
Delaney, Christine L. Mulgrew, Harlan M. Krumholz, Diana L. Ordin. Colorado 
Foundation for Medical Care, Aurora, CO, Health Care Financing Adminstration, Boston, 
MA 
Background: The majority of heart failure (HF) patients are elderly. The clinical charac- 
teristics of this population might limit eligibility for and therefore the Impact of new HF 
therapies. Patients with creatinine >2.5 mg/dl or potassium >5.0 mmolil were excluded 
from a spironalactone trial, with obstructive lung disease from beta blocker trrals, and with 
diastolic dysfunction- ejection fraction (EF) > 40%. from both. Methods: As part of a 
national effort by the Health Care Financing Administration to improve care for Medicare 
patients, abstracted data from the medical records of 37,500 Medicare patients hospital- 
ized for HF between 4/98 and 3199 were analyzed. Results: Patients were of median age 
78 and were 57.1% female; age and gender distribution are shown in the table. Creati- 
nine 22.5 mgidl was present in 13.6% and increased with age (pcO.001). Potassium >5.0 
mmolll was present in 20.4%. Chronic obstructive pulmonary disease was present in 
33.5%. Among those in whom EF was recorded in the chart, it was340% in 49.0%. Con- 
clusions: Many elderly heart failure patients are ineligible for or have contraindrcations to 
proven heart failure treatments. Data on the safety and efficacy of emerging therapies I” 
this population are needed. 
Age: ~65 65-69 70-74 75-79 80-84 85 
7.8% 10.8% 18.1% 19.9% 20.1% 25.3% 
% Female: 41.6% 49.7% 50.3 54.5% 59.3% 69.7% 
% EF c 40 58.7% 55.9% 53.9% 52.4% 50.3% 42.6% 
856-5 
II:30 a.m. 
Aggressive Treatment of Endothelial Dysfunction in 
Geriatric Patients: The Simvastatin, Ascorbate, and Vitamin 
E in Seniors (SAVES) Study 
James H. Stein, Cynthia M. Carlsson, Kristi Papcke-Benson, Susan E. Aeschlimann, 
Molly L. Games, Patrick E. McBride. University of Wkxonsin Medical School, Madison, 
WI 
Background: Geriatric patients with hypercholesterolemia have severe endothelial dys- 
function. Because cholesterol-lowering therapy and antioxidant vitamins improve endot- 
helium-dependent vasodilation in young and middle-aged adults, we evaluated the 
effects of simvastatin (20 mg nightly) and combined antioxidant vitamin therapy (vitamins 
C+E, ascorbic acid 1000 mg c alpha-tocopheryl 400 IU daily) on endothelial function in 
older adults with hypercholesterolemia. 
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Methods: In a double blind, placebo-controlled, sequential-design study, 17 subjects 2 
70 years old (mean+SD age, 7524 years) received simvastatin for 6 months, followed by 
simvastatin and vitamins C+E for 6 more months. Endothelial function was measured by 
flow-mediated vasodilation of the brachial artery using high-resolution ultrasound (7.5 
mHz, Hewlett-Packard). Images were stored digitally and analyzed in triplicate by two 
readers using MedArchive Viewer 2.1 (Secure Archive). 
Results: At baseline, subjects were hypercholesterolemic (total cholesterol 249+23, 
LDL-C 169+22, HDL-C 55+14, triglycerides 13of48 mg/dL) and had savers endothelial 
dysfunction (flow-mediated vasodilation = 3.2i-3.1%). Simvastatin reduced TC (-24%, 
p<O.OOl) and LDL-C (-26.3%, p<O.OOl) levels, but did not improve flow-mediated vasadi- 
lation (mean A=O.3%, 95%CI -1.9.2.5%, p=O.801). After adding vitamins C+E, lipid lev- 
els remained stable but flow-medlated vasodilation did not change (mean A =O.O%, 
95%CI -2.l-2.0%. p=O.974). After controlling for brachial artery diameter, only age corre- 
lated significantly with flow-mediated vasodilation (r=-0.48, p=O.O41). At baseline, nitro- 
glycerin-mediated vasodilation also was impaired (10.&4.8%) and did not change with 
either therapy (p=O.494). 
Conclusion: Older patients with hypercholesterolemia have severe endothelial dysfunc- 
tion that does not improve with aggressive lipid-lowering therapy, alone or in combination 
with vitamins C and E. Reduced nitroglycerin-mediated vasadilation may reflect 
impaired vasodilator reserve in older patients. 
lar dystrophy (Emery-Dreifuss or limb-girdle type in 6 cases). Four patients had elevated 
creatine kinases and all 3 probands had abnormal muscle biopsies. Cardiac involvement 
included conduction abnormalities (6 cases) and atrial and/or ventricular arrhythmia in all 
patients. LMNA mutations were found in 2 families; linkage to the LMNA locus was 
excluded in the third family. The 2 LMNA mutations were confined to exon 6: 1) a nt 959 
deletion, previously reported, which is predicted to shift the reading frame, and encode 
an aberrant carboxyl terminal of the LMNA protein; 2) a novel missense mutation leading 
to an Arg377His substitution. This residue is highly conserved across differing species 
and substitution at this locus may impair appropriate protein dimerization. Conclusion: 
These results suggest that LMNA mutations can cause Familial Dilated Cardiomyopathy 
in a relevant proportion of cases. The results also highlight the variability in skeletal mus- 
cle disease phenotype that characterizes LMNA mutations. Furthermore, the 2 mutations 
described suggest that different pathogenetic mechanisms could be involved: such as 
haploinsufficiency and dominant negative effects. Future studies will extend the LMNA 
screening to other affected families. 
1231-44 Angiotensin-Converting Enzyme Gene Polymorphism 
Predicts Aldosterone Escape in Chronic Heart Failure 
Patients 
856-6 
ii:45 a.m. 
Long-Term Outcome of Revascularization or Medical 
Therapy in a Cohort of Elderly Patients 
Mariantonietta Cicoira, Luisa Zanolla, Andrea Rossi, Lorenzo Franceschini, Giorgio 
G&s., Giulio Cabrini, Alberta Bonizzato, Maristella Graziani, Piero Zardini. Divisione 
Cliniciuata di Cardiologia, Verona, /k/y 
Michelle M. Graham, Peter D. Faris, William A. Ghali, Merril L. Knudtson, on behalf of the 
APPROACH Investigators. Foofhills Hospital, Calgary, AB, Canada 
Background: An increasing number of elderly patients with ischemic heart disease are 
referred for coronary artery bypass graft surgery (CABG) or percutaneous coronary inter- 
vention (PCI). However, the benefits of aggressive revascularization strategies in this 
population have been questioned due to reports of poor outcomes. We sought to 
describe the crude and-risk-adjusted survival by prescribed treatment (CABG, PCI or 
medical therapy) for patients in 3 age categories: i 70 years, 70-79 years and > 80 years 
Of age. 
Methods: Using APPROACH, a clinical data collection initiative capturing all patients 
undergoing cardiac catheterization and revascularization in the province of Alberta, the 
characteristics and long-term outcomes of a cohort of over 6000 elderly patients with 
ischemic heart disease treated with CABG, PCI, or medical therapy were determined. 
Results: Elderly patients wars more likely to have comorbidities such as peripheral vas- 
cular disease, cerebrovascular disease, hypertension, and diabetes then their younger 
counterparts (p< 0.001). There was also a greater incidence of unstable angina, and 
ssvare coronary artery disease in this group (p< 0.001). Adjusted actuarial survival rates 
at four years, and absolute risk reduction (ARR) associated with revascularization are 
shown in the table below. 
Adjusted Survival (% ARR (%) (Versus Medical Therapy) 
Age Medical PCI CABG PCI CABG 
< 70 (n=15,392) 90.8 93.8 95.0 3.0 4.3 
70-80 (n=5198) 79.1 83.9 87.3 4.9 8.3 
>= 80 (rk983) 60.3 71.6 77.4 11.3 17.0 
Conclusions: Elderly patients may have greater absolute benefit with surgical or percu- 
taneous revascularization compared to younger patients. Age alone should not be a 
contraindication to these procedures. 
Background: A relevant number of chronic heart failure (CHF) patients has elevated 
serum levels of aldosterone despite chronic administration of angiotensin-converting 
enzyme (ACE) -inhibitors, but the mechanisms of this ‘escape’ have never been investi- 
gated. We hypothesized that ACE gene l/D polymorphism, which accounts for half of the 
variance of ACE levels in individuals, might also determine ACE-inhibitors response in 
CHF patients. Methods: We prospectively studied 134 CHF patients (left ventricular 
ejection fraction ~45%) in treatment with ACE-inhibitors >6 months presenting at our 
Heart Failure Clinic. Patients with angiotensin receptor antagonists or aldosterone antag- 
onists wars excluded from the study. Serum aldosterone levels wars determined in a fast- 
ing state and after 30 minutes in supine position. Aldosterone ‘escape’ was defined as 
serum aldosterone levels above the normal range of our laboratory (>42 /I). Patients were 
then divided into two subgroups according to the presence (group 1) or absence (group 2 
) of ‘escape’. Genotype analysis was performed by polimerase chain reaction (PCR) with 
a three-primer system. Results: The prevalence of ‘escape’ in our population was 10%. 
The two groups did not differ concerning duration of treatment and dose of ACE-inhibitor, 
beta-blockers, diuretics and renal function. The distribution of the three genotypes in 
group 1 and 2 is shown in table. There was a statistically significant different distribution 
of genotypes in the two groups, with a higher proportion of DD genotype in group 1 com- 
pared with group 2 (p=O.Ol). Conclusions: CHF patients with aldosterone ‘escape’ have 
a higher prevalence of DD genotype. ACE gene polymorphism might therefore guide to 
optimize medical therapy in CHF patients. 
Group 1 n(%) 
Group 2 n(%) 
Total n(%) 
DD ID II 
8 (60%) 5 (40%) 0 (0%) 
29 (24%) 69 (57%) 23 (19%) 
37 (28%) 74 (55%) 23 (17%) 
1231-45 Reduced Vascular Endothelial Growth Factor Receptor But 
Not VEGF Production Distinguishes lschemic From 
Nonischemic Cardiomyopathy 
1231 
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Orange County Convention Center, Hall A4 
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1231-43 Lamin A/C Gene Mutations in Families With Dilated 
Cardiomyopathy, Conduction System Defects, and Skeletal 
Muscle Disease 
Matthew R. G. Taylor, Gary L. Brodsky, Francesco Muntoni, Gianfranco Sinagra, Andrea 
Di Lenarda, Misi Robinson, Pamela Fain, Luisa Mestroni. University of Colorado Health 
Sciences Center: Cardiovascular Institute, Denver, CO, Imperial Colege School of 
Medicine, London, United Kingdom 
Background: Familial Dilated Cardiomyopathy is a cardiac muscle disease character- 
ized by systolic dysfunction and ventricular dilation; in many cases it results from genetic 
mutations. Recently, lamin A/C gene (LMNA) mutations have been implicated in this dis- 
ease. The overall spectrum, the frequency, and the genotype/phenotype correlation of 
LMNA mutations in this condition are unknown. Methods: We are studying 37 pedigrees 
with autosomal dominant or recessive transmission of Familial Dilated Cardiomypathy. 
We selected 3 of these families with an illness complicated by skeletal muscle abnormal- 
ities and/or cardiac conduction defects, suggestive of LMNA mutations. Mutation scraen- 
ing was performed by means of sequence analysis. Linkage to the LMNA locus was 
analyzed using polymorphic CA repeats. b: There was significant inter- and intra-familial 
phenotypic variability, ranging from complete absence (3 cases) to overt signs of nluscu- 
Shoukang Zhu, Manisha H. Shah, Christine S. Moravec, Rene Alvarez, Pascal 
Goldscmidt-Clermont, Philip F. Binkley. The Ohio State University, Columbus, OH, 
Cleveland Clinic Foundation, Cleveland, OH 
Background: Increased VEGF expression has been proposed to be a compensatory 
response to myocardial ischemia. It is unknown whether there is an increased expression 
of VEGF in ischemic cardiomyopathy (ICM) which distinguishes it from nonischemic car- 
diomyopathy (NICM). We therefore tested whether the myocardial expression of VEGF, 
its positive transcription factor HIF-1, and two VEGF receptors differed in ICM, NICM and 
normal myocardium. 
Methods: Left ventricular tlssueobtained from the explanted hearts of 45 transplant 
recipients (35 ICM, 10 NICM) and from 5 normal hearts which could not be used for 
transplantation was harvested for RNA extraction, reverse transcription, and Real-Time 
PCR quantitation of VEGF, HIF-1, and the VEGF receptors Flt-1 and KDR. The final 
quantitation of target was analyzed by using a comparative C, method where amount of 
gene expression of target is normalized to an internal control (185 ribosomal RNA) and is 
reported as n-fold difference relative to calibrator (normal myocardium). 
Resulb: Neither VEGF expression (ICM:l.27?1.52 vs NICM: 1.02+.73:~=.6) nor HIF-1 
expression (ICM:l.00+1.7 vs NICM: .87+.93;p=.8j differed between ICM and NICM. 
The constitutively active VEGF receptor KDR was not different (ICM: .64+.40 vs DCM: 
.90+.88;p=.20), but a significant reduction (p=.O3) in the inducible receptor Flt-1 was 
seen in ICM (ICM: .85+.6Ovs NICM: 1.50+1.3). 
Conclusion: ICM and NICM are not different in gene expression of VEGF, the transcrip- 
tion factor HIF-I or KDR. However, a significant reduction in the hypoxia induced Fit-1 
receptor is seen in ICM indicating that a deficiency in the capacity to produce this recep- 
tor distinguishes ICM and NICM. This decreased receptor expression may limit the myo- 
cardial response to VEGF in ICM and suggests that receptor rather than VEGF 
expression comprises a novel therapeutic target for the treatment of ICM. 
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1231-46 Isolated Diastolic Dysfunction Is Coupled to Reduced 
Phosphotransfer Enzyme Activity in Experimental Renal 
Hypertension 
Chari Y. T Hart, Petras P. Dzeja, Andre Terzic, Margaret M. Redfield. Mayo Clinic, 
Rochester, MN 
Background: Hypertensrve heart disease is associated wiih diastolic dysfunction prior to 
any impairment in systolic performance. The energetic basis for this functional abnormal- 
ity is not fully understood. Inefficient handling of mtracellular ADP induced by pharmaco- 
logic inhibition of creatine kinase (CK) has been demonstrated to impair relaxation 
without effects on systolic function in vitro. Another phosphotransfer enzyme adenylate 
krnase (AK) has also been shown to facilitate myofibrillar relaxation. We hypothesized 
that diastolic dysfunction assocrated with hypertensive heart disease may be associated 
with reduced activity of ADP-handling phosphotransfer enzymes CK and AK. Methods: 
Renal HTN was produced by bilateral renal wrapping. Dogs with systemic hypertension 
(HTN) for Swks (Grp 1, n=7) or 12 wks (Grp 2, n=5) and sham operated dogs (SHAM, 
n=6) underwent invasive hemodynamic evaluation to characterize systolic (End systolic 
elastance, Ees) and diastolic (Tau, LV end diastolic pressure (LVEDP)) function followed 
by analysis oi CK and AK activity. and CK isoform profile in LV myocardium. Results: 
‘~~0.05 vs. SHAM. 
SHAM Grp 1 Grp 2 
MAP (mmHg) 124~4 166~6 181k12 
Ees (mmHg/ml) 521 7*1 10*4 
Tau (msec) 4122 5023’ 62&l 0’ 
LVEDP (mmHg) 7i-0.3 7*1 10tl’ 
LV “ass (g/kg body wt) 4.9t0.3 6.OtO.2 6.&0.3’ 
Renal HTN dogs were characterized by hypertrophy and drastoiic abnormalities with pre- 
served contractile function. Total CK activity in LV myocardium was reduced in Grp 1 (- 
24%, p=O 008) as compared to SHAM (3138*127 nmol ATP/min/mg protein) without 
changes in the CK isoform profile. In contrast, Grp 2 demonstrated CK isoform shift from 
MM to MB (4%MB in SHAM vs. 18%MB in Grp2, p=O.O57). The initral rate of CK activity 
in Grp2 was reduced (-41% vs. SHAM) without a significant change in total CK activity. 
AK activity tended to be reduced in Grp l(-lS%, p=O.O6) and Grp 2 (-14%, p=O.O8) as 
compared to SHAM (5071-16 nmol ATPiminimg protein). Conclusion: These data sug- 
gest that phosphotransfer enzyme activity is reduced in hypertensive heart disease and 
may compromise intracellular ADP-handling and energy-dependent processes responsr- 
ble for optimal myofrbrillar relaxation. 
1231-47 Adenoviral-Mediated Gene Transfer of the Cardiac 
Transcription Factor Nkx2.5 into Adult Cardiomyocytes 
Angela M. Brown, Mary S. Rackley, Robert S. Ross, Terrence X. O’Brien. lVledica/ 
University of South Carolina, Gazes Institute, RHJ-VAMC, Charleston, SC, UCLA School 
of Medicine, Los Angeles, CA 
Background: The cardiac-specific transcription factor Nkx2 5 (or CSX) is required for 
early cardiogenesis, maintains expression in the adult heart, and is associated with 
human cardiac malformations. Previously. we showed Nkx2.5 is upregulated in an ani- 
mal model of ventricular pressure-overload. Nkx2.5 has also been shown in other cell 
types to have regulatory interactions with Serum Response Factor (SRF). Methods: To 
address the role of Nkx2.5 in the adult cardiomyocyte, adult feline cardiomyocytes were 
isolated and infected with adenovrruses constructed to overexpress Nkx2.5 or SRF. We 
also constructed an adenovirus containing 638 bp of the cardiac Atrial Natriuretic Factor 
(ANF) promoter fused to a luciferase transgene. This served as a marker of Nkx2.5 tran- 
scriptional activation since this promoter contains two Nkx2.5 and two SRF DNA binding 
elements. This dicistronic ANF638/luctferase vector also contained a CMV-driven green 
fluorescent protein reporter which was used to normalize transfection efficiency, Results: 
Infection wrth Nkx2.5 activated ANF638iLuciferase over 4.fold in adult cardiomyocytes. 
This is the first demonstration of Nkx2.5 cardiac regulation beyond cardiogenesis. SRF 
activated ANF638ilucrferase over S-fold in the adult cardiomyocytes and co-infection of 
both Nkx2.5 and SRF vectors further increased reporter expression by 50%. Co-Infection 
of these two factors did not further augment alpha-adrenergic stimulation of the ANF6381 
Luciferase transgene. Conclusion: An adenoviral-mediated approach allows Nkx2.5 to 
be overexpressed in adult cardiomyocytes. Exogenous Nkx2.5 activates an ANF pro- 
moter known to respond to cardiac hypertrophic growth stimuli. Additionally, the combina- 
torial effect of SRF on this promoter provides a model of Nkx2.5 transcriptional 
regulation. 
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123352 Depression and Risk of Heart Failure Among Older Persons 
Jerome L. Abramson, Alan Berger, I-larlan M. Krumholz, Viola Vaccarmo. Yale Universify 
School of Medicine, New Haven, CT; University of Minnesota Medml School. 
Minneapolis, MN 
Background: Investigators have shown that depression is associated wrth an increased 
risk of coronary heart drsease. However, it is unknown whether depression is a risk fac- 
tor for heart failure, independent of Its association with myocardial infarction. 
Methods: This study examined whether depression was a predictor of incident heart fail- 
ure among 4538 persons age 60 years and older enrolled in the Systolic Hypertension 
and the Elderly Program (SHEP). Depression was defined as a score of 16 or more at 
baseline on the Center for Epidemiologic Studies Depression (CESD) scale. The rela- 
tionship between depression and heart failure was assessed using Cox proportional haz- 
ards regression. 
Results: The average follow-up time was 4.5 years. Heart failure developed in 138 
(3.2%) of 4317 non-depressed persons and in 18 (8.1%) of 221 depressed persons. 
After controiling for age, sex, race, history of myocardial infarction, diabetes, angina, 
blood pressure, cholesterol levels, electrocardiographic abnormalities, smoking, disabil- 
ity, and SHEP treatment group. depressed persons had more than a twofold higher risk of 
developing heart failure compared to non-depressed persons (hazard ratio 2.59; 95% 
confidence interval 1.57-4.27: p c ,001). Upon additional adjustment for the occurrence 
of myocardial infarction during follow-up, depressed persons remarmed at elevated risk of 
heart failure (hazard ratio 2.82; 95% confidence interval 1.71-4.67; p < .OOl). 
Conclusion: Depression is associated with a substanttal increase in the risk of heart fail- 
ure among older persons, independent of potential confounding factors. 
1233-53 Assessment of 30-Day Pre-Hospital Medication Adherence 
in Elderly Patients With Congestive Heart Failure 
Gwen W. Oldenqurst, Peter Vaitkevicius, John Quinn, Susan McCaughan, Carol Brown, 
Matthew Tayback, Sheldon H. Gottlieb. Johns Hopkins University, Baltimore, MD 
Background: Non-adherence (NA) with medication (MED) prescribed for CHF is often 
noted as a precipitant of hospital admission in elderly (age260 years) patients (PTS) but 
NA has seldom been documented in an objective and verifiable way rn the period just 
prior to hospital admission. The purpose of this study was to determine the frequency of 
NA with MED by subjective and objective criteria among elderly PTS hospitalized for 
CHF. 
Methods: NA was defined as refills of prescriptions providing ~85% of the prescribed 
CHF MED during the 30 days prior to CHF admission, as documented by pharmacy 
record review, or missrng 21 day of CHF MED in the week before CHF hospitalization, as 
reported durrng structured interview. PTS 3-month outpatrent pharmacy record provided 
information about MED, refill dates, and quantity of pills dispensed for the 30 day period 
prior to CHF hospitalization. Self-report was compared to pharmacy record review. 
Results: In the first 6 months of a 12.month study, 53 CHF PTS with complete pharmacy 
records admitted to a community teaching hospital were reviewed. The mean age was 
7228 years (range 60.89 years); 57% (30153) were women, and 85% were Caucasian. 
PTS were taking 3.18 + 0.3 CHF MED (range O-7 MED) by both self-report and phar- 
macy record review. By self-report, only 5153 (9%) of PTS missed any MED in the 1 week 
before CHF hospitalizatton. By pharmacy record review, 34/53 (64%) were NA wrth 1 or 
more MED in the 30 days prior to admission (pcO.001); 7% (4/53) were NA with ai/MED. 
Sixty-four percent (34153) of PTS had a prior history of CHF and 58% (31153) had been 
previously hospitalized for CHF; the remaining 36% (19/53) were newly diagnosed CHF. 
Sixty-eight percent (23/34) of PTS with a prior history of CHF were NA with 1 or more 
MED in the 30 days prior to hospitalization; 52%(12/23) of PTS with newly dragnosed 
CHF who were on medication were NA with MED (NS). 
Conclusion: Elderly CHF PTS under-report NA to CHF MED. Efforts to obfectively docu- 
ment and to reduce NA by utrlizing centralized pharmacy records may play a major role in 
reducing CHF hospitalizations among elderly PTS. 
123354 Low-Dose g-Blocker Therapy Improves Left Ventricular 
Function During Exercise in Elderly Patients With 
Myocardial lschemia and Preserved Left Ventricular 
Function 
Joao B. Serro-Azul, Mauricio Wajngarten, Maria C. Giorgi, Jose C. Meneghetti, Creuza 
Dal 50, Humberto Pier& Amit Nussbacher, Otavio Gebara, Ligia 8. Pinto, Nubia W. 
Vieira. HEART INSTITUTE (InCor) UMIVERSITY OFSAO PAULO, MEDICAL SCHOOL, 
SAO PAULO, Brazil 
Background. Although S-blocker therapy has recognized benefits, it is less often pra- 
scribed to older individuals due to fear of causing heart failure. Furthermore, the ideal 
dose for elderly patients IS not well established. Recently, it has been shown that higher 
doses of B-blockers were associated with greater risk of heart failure. We aimed to evalu- 
ate a titration strategy for prescribing an effective dose of propranolol (PROP) wrthout 
depressing left ventricular (LV) performance in elderly patients with myocardrai rschemia 
and preserved LV function. Methods.14 male patients (73.6+5.3 years) with myocardial 
196A ABSTRACTS - Cardiac Function and Heart Failure JACC February 2001 
ischemia and preserved LV function received oral PROP in an initial daily dose of 30mg. POSTER SESSION 
The dose was increased according to heart rate (HR) verified at a weekly stress test in a 
work load that corresponded to daily life activity of most elderly people (50 W). A 15% HR 
reduction was considered an effective response. Patients underwent gated blood pool 1234 Heart Failure Practices and Management 
scans at rest and during exercise before (6) and after (A) receiving PROP. Results. 1) 
HR reduction at 50 Wand at rest were similar (21%; 24%: P=O.2886): 2) The mean dose 
Programs 
of PROP was 73.6t27.6mg; 3) PROP improved exercise duration (6: 12.2+2.0min; A: 
13.lt1.7min; P=O.O313) and abolished ST depression in 8 patients; 4) At rest, ejection 
Tuesday, March 20, 2001, Noon-2:00 p.m. 
fraction was unchanged (B: 57.816.4%; A: 58.4+7.3%; P=O.4395) by PROP; 5) During Orange County Convention Center, Hall A4 
maximal exercise, PROP reduced end-systolic volume index (B: 37.61-10.6mlim2; A: 
34.5+8.8ml/mZ; P=O.O224) and increased ejection fraction (6: 56.2&5%; A: 60.2+7.2%; 
Presentation Hour: Noon-l :00 p.m. ~ 
P=O.O033). Conclusion. In elderly patients wtth myocardial ischemia and preserved LV ~ 
function, a 15% HR reduction at rest, that was achieved by a low-dose of PROP, seems 
1234-57 A Prospective Randomized Study Comparing Outcomes 
- 
to be a good strategy. This dose reduced ischemia without compromising LV petfor- and Outpatient Care Delivery Methods for Chronic Heart 
mance at rest and actually improve it during maximal exercise. Failure 
1233-55 Beta Blockade is Tolerated and Improves Cardiac Function 
Mary D. Bondmass, J. Daniel Ben&r, Gerard Castro, Boar Avitall. University of ///inok at 
Chicago, Chicago, IL 
in Elderly Heart Failure Patients 
Background: Outcomes related to chronic heart failure (HF) remain relatively poor 
Guiliermo B. Cintron, Juan M. Aranda, Barry H. Greenberg, Ming Heng, Dale G. despite advances in pharmacological therapy and medical and nursing can?. Experts 
Renlund, Surai Thaneemit-Chen, Heidi Krause-Steinrauf, for the BEST Investigators. VA agree that outpatient care may be among the factors affecting HF outcomes. We hypoth- 
Medica/ Center, Tampa, FL, University of South Florida, Tampa, FL esized that the method by which outpatient care is delivered may also affect outcomes in 
Background: Congestive heart failure (CHF) prevalence increases with age. Although 
this patient population. 
beneficial effects of adrenergic beta blockers (BB) in CHF patients (pts) has been dem- 
Methods: A prospective, randomized design was used to compare HF outcomes from 
onstrated, there is little information regarding how the elderly with CHF tolerate and 
two home care delivery methods. At our academic medical center, HF patients were ran- 
respond to BB. 
domized to receive home follow-up care for three months post discharge. Care was deliv- 
Methods: The Beta-Blocker Evaluation of Survival Trial (BEST) database was analyzed 
wed by either the nurse-visits or the nurse-telemanagement method. In the latter, 
to determine whether the BB bucindalol can be safely and effectively administered to eld- 
patients used trans.telephonic home monitoring devices to measure their weight, blood 
erly CHF pts. All BEST pts had Class III-IV CHF with left ventricular ejection fraction 
pressure, heart rate, and oxygen saturation. These data were transmitted daily to a 
(LVEF) ~0.35, N=2708. To parallel Medicare, we selected age p 65 years (yrs) as a 
secured Internet site and an advanced practice nurse, working collaboratively with a car- 
cutoff. Pts randomized to receive BB (n=1354) were divided into 2 age subgroups (~65 
diologist, subsequently managed patients via the telephone. Both delivery methods ud- 
“S 265 yrs). 
lized the same HF.specific clinical guidelines to direct care. Outcomes included HF 
Results: The older subgroup (72 + 5 yrs, n=533) had more males, longer CHF duration, 
readmissions and length of stay (LOS), anxiety, depression, self-efficacy, and quality of 
mm Class IV CHF, more coronary disease and coronary bypass, (~~0.05) than the 
life (QOL). Data were tested utilizing general linear-analysis of variance (ANOVA) and 
younger subgroup (52 i 9 yrs, n=821). A lower number of the older pts reached the ini- 
repeated-measures ANOVA. 
tial target titration BB dose (364, 68% vs 632, 77%, old vs young; p<O.OOl). Of older pts 
Results: No significant baseline differences were found. Patients in the nurse-teleman- 
87% were taking BB at 3 months (mos), 81% at 12 mos and 78% at 24 mos as compared 
agement group (“~85, 62.2 & 12.1 yrs.,55.3% African American[AA], 42.4% female [F]) 
to 90% 86% and 78% of younger pts (p=NS). Even though baseline heart rate was 
had fewer HF re-admissions (0.9 + 0.4 vs. 2.1 + 1.3, p 5 0.001) and LOS(4.7 r 2.4 vs. 9.7 
lower (78 i 12 vs 84 + 14 beats/minute [bpm] in older pts, pcO.OOl), when given BB older 
t 4.3,~ < 0.001) compared to the nurse-visits group (n=79, 60.6 + 14.8 yrs.,70.9% AA, 
pts had a similar decrease in heart rate at 3 mos (-9.3 + 13 vs -9.4 + 13 bpm, p=NS). At 
34.2% F). P&post assessment indicated lower post anxiety scores (p 5 O.OOi), greater 
3 mos LVEF increased significantly in both subgroups on BB (p=<O.OOi), but less so in 
improvement in post QOL scores (p=O.O2),and increased self-efficacy for medication, 
the elderly (4.9 + 7 vs 5.9 ? 8 LVEF units, p=O.O29). For the whole BEST randomized 
activity, and symptom control (p < 0.001) for the nurse-t&management group. 
cohort, mortality was higher in the elderly a?. compared to younger pts (37% vs 26%, 
Conclusion: Considering baseline similarities and the use of the same HF clinical &de- 
p<O.OOi). There was no statistical difference in survival between placebo vs BB in either 
lines to direct care, we believe these data suggest that the care delivery method (nurse- 
subgroup. 
visits vs. nurse-telemanagement) may have affected the HF outcomes in this patient 
Conclusions: When compared to younger pts, the elderly with CHF can tolerate BB 
sample. 
with similar physiologic effects. In this study the BB, bucindolol, did not adversely affect 
survival in elderly pts with CHF. 1234-58 A Controlled Trial of Heart Failure Management Programs 
1233-56 Prevalence of Isolated Left Ventricular Diastolic 
Dysfunction in 139 Consecutive Patients Admitted to 
Gospital With Heart Failure 
Luigi P. Badano, Maria 6. Albanese, Claudia Fresco, Daniela Miani,.Paola De Biaggio, 
Elena Gremese, Marco Ghidina, Dario Gregori, Paolo M. Fioretti. Cardio/ogy Unit, A.O. S 
Maria de//a Misericordia, and IRCAB Foundation, Udine, /t&y 
Background. There is a paucity of data about the prevalence of isolated diastolic heart 
failure (DHF) in unselected pts admitted to hospital for congestive HF. Methods. We pro- 
spectively obtained echo in 139 consecutive pts (54% males, age -72+/-g years, range 
48-85 years) in sinus rhythm, and without significant valvulopathy (except heart valve 
prosthesis), admitted to our hospital with HF. HF was defined as either the presence of 2 
of the following major signs and symptoms: pulmonary oedema, paroxysmal nocturnal 
dyspnoea, orthopnea, r&s, third heart sound; or 1 of the major and 2 of minor criteria: 
cardiac dyspnoea, ankle oedema, less than 400 m walk without dyspnoea. Results. 
Average LVEF was 42+/-16%, LV end-diastolic volume was 76+/-31 mlim2, E/A ratio was 
1.5+/-1.0, E wave deceleration time was 2011-1-82 ms. 92 pts (66%) showed LV systolic 
dysfunction (LVEF< 45%). 44 of the 47 remaining pts (50% males, age 71+/-Q years, 34 
pts in NYHA II, and 10 pts in NYHA Ill) with LVEF>= 45% fulfilled diagnostic criteria for 
isolated DHF (Eur Heart J 1998; 19:990). In these pts, LVEF was 59+/-15%, end-diastolic 
volume was 55+/-31 mlim2, E/A was 0.46+/-0.01, E wave deceleration time was 263+/- 
102 ms, isovolumic relaxation time was 118+/-32 ms, pulmonary A wave velocity was 
37+/-g cm/s, and the difference between pulmonary A wave and mitral A wave duration 
was 64+/-8 ms. In addition, we found that limiting Doppler analysis to LV filling indexes 
alone, prevalence of DHF was 9%. Adding LV relaxation time, prevalence of DHF 
increased to 18%. Finally, adding LV distensibility indexes (i.e. pulmonary vein flow anal- 
ysis) prevalence of DHF was 32%. ConclusionsOur data represent the first prospective 
application of standardized diagnostic criteria for detection of DHF among unselected pts 
admitted to hospital with HF Using these criteria, prevalence of DHF was as high as l/3. 
Analysis limited to LV transmitral filling indexes alone leads to severe underestimation of 
prevalence of DHF in pts hospitalized with HF. 
Barry M. Massie, Jeffrey West, Denise Van Ostaeyen, Alice Salbalvaro, Ralph 
Moskowitz, Sheila Ford, Sharon Zhou, Min.Hui Wang, Sierra Pacific VA Heart Failure 
Group. VA Medical Center, San Francisco, CA, lschemia Research and Education 
Foundation, San Francisco, CA 
Background: CHF is a frequent cause of hospitalization, with a large attendant cost. 
Many approaches have been proposed to reduce this burden, but few have been evalu- 
ated in prospective controlled studies and most of these are not generalizable because 
they have involved patients (Pts) from a single center; none have compared different 
interventions. 
Methods: Therefore, we performed a randomized, parallel comparative group study 
involving 5 VA facilities. 147 Pts with symptomatic CHF with either a low EF or objective 
PE or X-ray evidence of CHF were assigned to either: 1) Usual Care (UC, n=50), con- 
sisting of an educational session and follow-up by their primary provider: 2) Nurse Man- 
ager (NM, n=41), who through regular telephone contact promoted dietary and 
medication compliance, adjusted medications and informed primary providers about sta- 
tus changes; 3) Home Monitoring (HM, n=44), consisting of daily weight, vital signs, and 
symptoms transmitted to a core facility plus weekly nurse telephone calls, with primary 
providers notified by fax for prespecified vital sign or symptom changes. In 2 sites, Pts 
were also randomized to a specialist-run Heart Failure Clinic (HFC, n=12) as a pilot 
study. Follow-up was for 3-13 mos (mean 7.7), with a primary endpoint of time to death 
or cardiovascular hospitalization. 
Results: The mean age was 69; 99% ware male; 75% had CAD; mean EF was 42.2%; 
and 37, 49, 37, and 22 Pts were in NYHA II, IIIA, 1118, and IV, respectively. No significant 
intergroup baseline differences were present. 18 Pts died (15 of cardiac causes) and 35 
Pts were hospitalized for a cardiovascular cause. Endpoint-free survival was 66% with 
UC, 68% with NM, 54% with HM, and 90% in the HFC. There were no significant differ- 
ences between either NM or HM and the UC control group, but a trend toward improved 
outcome with HFC compared to the two other interventions (p=O.O9) was observed. 
Conclusion: These results raise doubt about the efficacy of HM and NM interventions 
when applied to Pts from multiple institutions with providers who are not closely involved 
with the programs. In contrast, HFC management may improve outcomes, but additional 
studies are required because of the small size of this pilot group. 
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1234-59 integration of Best Practice into Multidisciplinary Care for 
Heart Failure in the Elderly: New Benefits Realised 
John M. Cahill, Ken McDonald, Mark Ledwidge, Peter Quigley, Brian Maurer, Mary 
Ryder, Bronagh Travers. 57: VINCENT’S CARDIOMYOPATHY RESEARCH CENTRE, 
DUBLIN, Ireland, Laboratoires Servier (Ireland) Ltd., DUBLIN, Ireland 
Background: Despite a growing body of data demonstrating the benefits of multidiscr- 
piinary care in heart failure, persistently high rates of readmission, especially within the 
first month of discharge, continue to be documented. Aims/methods: As part of an 
ongoing, randomised study on the value of multtdiscipfinary care in a high risk, elderly 
(mean age 69 years) heart failure population, we examined the effects of incorporation of 
three best practice issues on previously high (20%) one month readmission rates. Unlike 
previous studies of this approach, both multidisciplinary (MC) and routine care (RC) pop- 
ulations ware cared for by the cardiology service. Additionally, all were required to adhere 
to predefined stability criteria prior to discharge (clinically stable with no changes in body 
weight or medication for 48 hours) and (in systolic dysfunction) to receive maximum toler- 
ated ACE inhrbitor dose prior to discharge. We analysed death and unplanned heart fail- 
ure related admissions at one month following discharge. Results: This is an early report 
from the first 100 patients (67% male, 71% systolic dysfunction with a mean ejection frac- 
tion of 31.0%). During index hospitalisation (mean length of stay 10.5 * 5.0 days), 100% 
of patients were cared for by the cardiology service and complied with discharge stability 
criteria. 94% of this elderly population with systolic dysfunction achieved target or high 
dose therapy with ACE inhibitors. Complete elimination of one month hospital readmis- 
sion was observed in both RC and MC groups. This unexpected result represents a dra- 
matic improvement both for this patient cohort and in comparison with available data from 
multidisciplinary care programmes. Conclusions Critical contributors to this improve- 
ment appear to be systematic application of the components of best practice described 
above. More widespread application of this approach may have a dramatic improvement 
on early readmission for CHF in addition to the proven benefits of multidisciplinary care. 
1234-60 Can the External Peer Review Process Provide Adequate 
Feedback to Sustain the implementation of the Heart Failure 
‘Guidelines by Primary Care Providers? 
Judy D. Wiles, Jaspal S. Samra, Ruyayya Gill, Prakash C. Deedwania. VA Central 
California Health Care System, Fresno, CA, UC.9 School of Medicine, San Francisco, 
CA 
In a previous study, we have shown that academic detailing and aggressive provider 
feedback improved the implementation of practice guidelines in the management of 
patients with HF by primary care providers (PCPs). Data showed a 54% improvement in 
LV function evaluation and a 38% increase in the use of ACE inhibitors in the treatment of 
HF However, the PCP performance tracking and feedback loop created during the study 
was too labor intensive and could not be sustained. External peer review process 
(EPRP) has been frequently utrlized to evaluate the performance of PCPs in adhering to 
practice guidelines. Based on mstitutional guidelines, it was decided to perform monthly 
documentation audits by EPRP on random HF patients seen in the Primary Care Clinics 
(PCC). The number of patients reviewed and the PCP targeted varied each month. In 
order to evaluate the efficiency and accuracy of EPRP, we reviewed the adherence to HF 
practice gurdelines by PCP and compared it to the EPRP data over a six-month time 
period. We reviewed the guidekne criteria in 346 patients via direct chart audit and/or 
computerized database information retrieval. The EPRP results (n=36) showed LV func- 
tion documentation in 97% (n=35) and ACE inhibitor use rn 96% (n=21). In comparison, 
the direct chart audit showed that the LV function measurement was documented in 65% 
@x225) of the patients. Of these, 87% (n=196) were on ACE inhrbitors. Conclusion: 
Based on direct comparison with chart audits, our data showed that the EPRP data do 
not accurately reflect the adherence to the practice guidelines by PCPs. Provrder feed- 
back mechanisms used in the EPRP did not successfully encourage the PCP to consis- 
tently use practice guideline criteria, Therefore, continued academic detailing and 
provider feedback by the HF team might be essential to maintain adherence to practice 
guidelines by PCPs. 
1234-61 Current National Rates of ACE Inhibitor Dosing for Medicare 
Beneficiaries With Heart Failure: Results From The National 
Heart Failure Project 
Frederick A. Masoudi, Edward f? Havranek, Harlan M Krumholz, Kelly A. Westfall, Pam 
Wolfe, Diana L. Ordin. Colorado Foundation for Medical Care. Aurora, CO, Health Care 
Financing Adminsitration, Boston, MA 
Background: Recent studies suggest that ACE inhibitors are more effective when pre- 
scribed in higher doses and are prescribed in suboptimal doses for the elderly. We 
sought to characterize current national patterns of dosing of ACE inhibitors for elderly 
patients with chronic HF admitted for hospital treatment. Methods: As part of the 
National Heart Failure (NHF) project, up to 800 Medicare heart failure discharges from 41 
98-3199 were sampled systematically for each state, the District of Columbia, and Puerto 
Rico. We assessed the preadmission ACE inhibitor dosing among patients admitted with 
HF who had a documented history of HF and LVSD by determining what proportion of 
those patients were taking less than 50% of the lowest dose targeted in the clinical triais. 
Results: Of the 37,500 charts in the analysts, 4,326 (12%) met criteria for inclusion in 
this analysrs. The median state rate of ACE inhibitor dosing that was 2 50% of the lowest 
dose from the trials beta-blocker use was 56.1% (range 21.2% to 71.4%). Dosing to the 
50% level or higher was significantly and independently associated with black race, high 
admission blood pressure and hypertension, but not LVEF; older patients were signifi- 
cantly less likely to be dosed at the 50% level. Conclusion: Among patients with chronic 
HF who have a clinical decompensation requiring hospitalization, the preadmrssion dos- 
ing of ACE inhibitors is commonly not t 50% the lowest dose that was targeted in the trr- 
als. Thus pattern may reduce the effectiveness of ACE inhibitor therapy and represent an 
opportunity to improve the care of older patients wrth HF. 
1234-62 Changes in Heart Failure Drug Utilization During 1999: The 
Canadian CHF Clinics Network Experience 
J. Malcolm 0. Arnold, John D. Parker, Jonathan G. Howl&t, Andrew P Ignaszewski, 
Stuart J. Smith, Wlodzimierr Czamocki, Marie-Helene Leblanc, Peter Liu, A. Reuben J. 
Rajakumar, Israel Belenkie, Dante Manyari. London Health Sciences Centre, London, 
ON, Canada 
Background: The Canadian CHF Clinics Network was established to improve the cur- 
rent management of CHF, to implement new proven strategies in a trmely manner, and to 
monitor treatment trends in 11 initial centres across Canada. The first formal meeting of 
the Network members was in July 1998 when, through consensus, a manual of CHF 
management for physicians, nurses, and patients was developed. 
Methods: A computerized database was designed and implemented in Jan 1999 and 
883 patients were seen and had their data entered in the first 12 months. These patients 
represent both new patients to the clinic and some previously seen in the clinic but who 
were being entered into the longitudinal database for the first time. 
Results: Selected mean baseline characteristics of these patients were: age 64 years, 
male 72%; ischemic aetiology 62%; NYHA Class I 13.0% II 34.8%. Ill 40.8%, IV 11.4%; 
LVEF 24%. Drug utilization changed from the first to the last quarter of 1999 with an 
increase in ramipril (27.1 vs 10.3%, p<O.OOOl) while all ACE-I use remained constant 
(70.3%), and spironolactone (31.8 vs 5.0%, p<O.OOOi). Beta blocker use was 39.9% but 
showed a nonsignificant increase to 44.7% (carvedilol 22.4%, metoprolol 20.6%). Furo- 
semide and digoxin use remained unchanged at 69.4 vs 73.4% and 50.0 vs 50.5% 
respectively. The physician-patient interaction resulted in a change of drug treatment in 
46% of encounters and education regarding medication in 46%, CHF 42%, fluid/salt 
42% home weight monitoring 42%, and exercise 27% respectively. 
Conclusion: Several important major clinical trials were presented or published in 1998/ 
99 including HOPE, RALES, CIBIS-2, MERIT-HF, and BEST. The impact of these trials 
was rapidly assimilated into clinical practrce. The clinics emphasized the importance of 
patient education of their disease, their medications and early warning signs of worsen- 
ing heart failure. Assessment of clinical outcomes is being prospectively captured within 
the Network database. While national utilization of the same medications in general med- 
ical practice over the same time penod is not avarIable at this time, the data support the 
role of such clinics in translating clinical trials into clinical practice. 
1234-63 Elderly Heart Failure Patients Receive Less Intense Medical 
Management 
Stephanie H. Dunlap, Rrcardo I. Vicuna, Jun Chiong, Benjamin J. Rhee, Andrew J. 
Krainik. University of ///iflois at Chicago, Chfcago, /L 
Background: It has been demonstrated in previous studies that elderly patients (pts) are 
less likely to receive standard therapies for cardiovascular disorders such as myocardial 
infarction and unstable angina. Reports also describe an association between younger pt 
age and higher frequency of ACEI therapy (tx) in HF pts. The purposs of this study was to 
investigate the association of the overall quality of care (QOC) in elderly hospitalized HF 
pts and to compare their QOC to that of younger HF pts. Methods: All medical records 
(MR) from our institution with the primary discharge diagnoses of HF during fiscal year 
1996 were retrospectively examined and assessed for the presence of 9 clinical quality 
care indicators. The 9 clinical indicators, based on previously published guidelines, were 
assessment of LV function; ACEI tx; target dose of ACEI tx; multiple weight measure- 
ments; hydralazine-nitrate tx if ACEI contraindicated; increased diuretic tx from admis- 
sion; digoxin tx; aspirin tx in ischemrc pts; sodium/fluid restrrction and/or dietary consult. 
Drug tx was not scored if there ware contraindications to the drug being evaluated. Pts 
were divided into 2 age groups: ~70 yrs. vs. 3 70 yrs. of age. Results: The study included 
223 pts (53% female, 65% black, 19% Hispanic, 14% white) with mean age of 60~15.3 
yrs. (SD). 30% of pts included were older than 69yrs. The elderly pts were less likely to 
receive ACEI tx compared wrth younger pts (68% vs 94% p=O.Oi). The target dose of 
ACEI was less frequently reached in elderly pts despite no contraindications for ACEI 
(40% vs 56%, p=O.Ol). Digoxin therapy (70.4% vs 88% p=O.O2) and salt and/or fluid 
restriction (48% vs 60.4%, p =0.05) was also less commonly prescribed in older pts. No 
difference in the frequency of systolic dysfunction (74% vs 67% p=NS), chronic renal 
insufficiency (23% vs 32%, p=NS), and atrial fibrillation (17% vs. 12% p=NS) was found 
between groups. Conclusions: Elderly pts less frequently receive optimal care based on 
these 9 clinical QOC indicators especially as regards use of ACEI therapy. This study 
underscores the need for continued attention to QOC measures, especially rn those with 
the highest risk for HF. 
1234-64 Diagnosis of Heart Failure in Europe: A Survey of 
Perceptions and Practice From Over 1,300 Physicians and 
Over 11,000 of Their Patients 
John G. F. Cleland, Karl Swedberg, Ferenc Follath, Alain Cohen-S&l, Richard Hobbs, 
on behalf of the IMPROVEMENT of Heart Failure Survey. University of Hull, Kingston 
upon Hull, United Kingdom 
The IMPROVEMENT of Heart Failure Survey, an rnitiative of the Study Group on Diagno- 
sis of the European Society of Cardiology (ESC), was conducted between September 
1999 and May 2000. The primary objective was to determine whether ESC guidelines on 
the diagnosis and treatment of heart failure were being applied in practice rn a sample of 
the 47 ESC member nations and possible reasons for any failure of their application. 
Over 1,363 randomly selected primary care physicians (PCP) from 14 ESC Nations were 
involved. Each PCP kept a record of all patients with heart failure or prior myocardiai inf- 
arction for 6-8 weeks. A random selection of patients from this list was obtained to deter- 
198A ABSTRACTS - Cardiac Function and Heart Failure JACC February 2001 
tlons. Over 90% of ECG’s were abnormal. Only 45% of PCP’s rkported that they wouid 
usually request an echo in patients with suspected heart failure, range 10% in Nether- 
lands to 73% in France. 46% reported that they differentiated between left ventricular 
systolic and diastolic dysfunction in their practice, range 26% in UK to 84% in Hungary. In 
practice >80% had an echocardiogram with little international variation. Most echo’s were 
abnormal and 53% of echocardiograms showed a dilated or poorly contracting ventricle. 
Of 2,579 patients in whom left ventricular ejection fraction was reported it was ~40% in 
only 33% of those ~75 years and 30% of those >75 years (31% overall). This large sur- 
vey suggests that there are deficiencies in PCP’s knowledge about appropriate diagnos- 
tic steps in patients with heart failure and that important international differences exist. 
Other elements within the health care system may compensate for these deficiencies. 
mine whether the PCP’s perception of how heart failure was managed concurred with ,1234-67 The Rate of Re-Admission is Similar for Congestive Heart 
their actual practice. 11,062 patients were surveyed, of whom 3,561 ~75 years and 4,800 
>75 years were symptomatic and receiving diuretics and constitute the focus of this anal- 
Failure Patients With Normal and Abnormal Systolic 
ysis. PCP’s stated that they recognised heart failure predominantly by exertional breath- 
Function 
lessness and ankle swelling and these, together with fatigue, were the most prevalent Thomas D. Stamos, Smitha Thomas, James T. Thomas, Khaled Albasha, James E. 
symptoms in practice. Over 90% of PCP’s believed that they usually requested an ECG Calvin, Russell E. Kely. Rush-PresbyTerian-St. Luke’s Medical Center, Chicago, IL, Cook 
and almost 80% a chest X-ray. Actual practice patterns qenerallv followed PCP percep- County Hospital, Chicago, IL 
Background: Congestive heart failure (CHF) with abnormal systolic function is associ- 
ated with a high rate of hospital readmission. Whether patients with CHF and normal 
systolic function have a similar rate of re-admission remams poorly studied. We com- 
pared the re-admission rate in heart failure patients with normal and abnormal systolic 
function (Fxn). Methods: Detailed clinical data was prospectively collected on 144 con- 
secutive patients admltted with a clinical history and physlcal findings compatible with a 
diagnosis of CHF and in whom the primary admission diagnosis was CHF. Re-hospital- 
ization was examined over an B-month follow-up period. Patients with a non-cardiac 
cause for volume overload or significant valvular heart disease were excluded. Left ven- 
tricular function was determined by echocardiography; normal ejection fraction defmed 
as > 50%. Results: 88 of the 144 oatients (61%) had abnormal svstolic function and 56 
1234-65 Czirdiology Specialist Care of Heart Failure Patients 
patients (39%) had normal systolic function. Differences in baseline characteristics are 
shown in the table. There were no significant differences in HTN, diabetes, smoking or 
Improves Survival lipids. The rate of re-hospitalization over an B-month follow-up period was similar for the 
Maria N. Ansari, Ali Tutar, Jean Bullard, Barry M. Massie, John R. Teerlink. San 
two groups (30.4% for normal systolic function vs. 30.7% for abnormal systolic function). 
Francisco VAMC/UCSF; San Francisco, CA 
Conclusion: CHF with normal systolic function results in a high rate of re-hospitalization, 
which is similar to the rate seen in CHF patients with abnormal systolic function. 
Background: Both generalists and cardiologists frequently manage patients with chronic Abnormal Fun- Normal Function p-value 
heart failure and since practice patterns differ between these groups, we sought to com- 
pare outcomes of patients with an outpatient diagnosis of CHF based on provider type. 
Methods: Outpatients at San Francisco VAMC with an encounter form diagnosis of CHF 
from 7/98-12/98 were eligible (“~417); 42 patients were excluded for absence of CHF by 
Framingham criteria or lack of primary care within the VA. Clinical progress notes, phar- 
macy profiles and patient status records were reviewed and survival was assessed from 
7/l/98 to 5/l/00. Patients with any visit to a cardiologist were assigned to the Cardiology 
group , and all others as the primary care provider (PCP) group. Characteristics of 
patients in the 2 provider groups were compared and multlvariate survival analysis was 
performed for the total cohort, the reduced LV function group (EFs45%) and the pre- 
served LV function group (EF>45%). 
Results: Most CHF patients were cared for by PCP (62%). Cardiology patients were 
younger (age 69 vs 73; p<.OOl), with a lower EF (34% vs 40%; p<.OOl), lower SBP (121 
vs 134: p=.O3), and lower HR (75.0 vs 79.7; p=.OO3). Cardiology patients were also more 
likely to have had an assessment of EF (pc.01). Cardiology CHF patients had a higher 
prevalence of hyperlipidemia, DM, and CAD than the PCP group. In the absence of con- 
traindications, cardiologists used more beta blockers (59% vs 37%; p<.OOl) and ACE I 
(93% vs 82%; pc.Oi) compared to the PCP group. One year and 22 month survival was 
10.8% and 20.5% overall, 13% and 24.4% in the PCP group, and 7.3% and 14.2% in the 
cardiology group. Cardiology care was a strong independent predictor of survival in the 
overall group (HR 52, 95%CI .31-.87; p=.O3) and reduced EF group (HR .48, Cl .25-.93; 
p=.O3), but not in the preserved LV function group (HR .39, Cl .12-1.39; p=.l5). 
Conclusions: Cardiology care of outpatients with CHF in our sample was associated 
with improved survival in the reduced EF and overall groups. The improved survival may 
be related to higher rates of appropriate guideline compliance in managing these 
patients. 
1234-66 International Variability of the Characteristics of Heart 
Failure Managed in Primary Care: The IMPROVEMENT of 
Heart Failure Survey 
John G. F. Cleland, Karl Swedberg, Ferenc Follath, Jiri Widimsky, Universiry &Hull, 
Kingston upon Hull, United Kingdom 
Patients managed in clinical practice may differ substantially from patients in clinical trials 
and this may apply especially to heart failure. The IMPROVEMENT of Heart Failure Sur- 
vey, an initiative of the Study Group on Diagnosis of the European Society of Cardiology 
@SC), was conducted between September 1999 and May 2000. The survey was 
designed to provide unique international comparative data. Over 1,363 randomly 
selected primary care physicians (PCP) from 14 European countries were involved. Each 
PCP kept a record of ail patients with heart failure or prior myocardial infarction for 6-8 
weeks. A random selection of patients from this list was obtained to investigate their clin- 
ical characteristics. 11,062 patients were surveyed, of whom 3,561 ~75 years and 4,800 
>75 years were symptomatic and receiving diuretics and constitute the focus of this anal- 
ysis. Myocardial infarction was reported as a contributing factor to heart failure in 33.5% 
of cases, ranging from 45% in the Czech Republic to 20% in Turkey. lschaemic heart dis- 
ease without myocardial infarction contributed to an ADDITIONAL 31 .l%. 15.1% had had 
either a CABG or PTCA with large international variation. Hypertension, diabetes and 
atrial fibrillation were reported in 53.0%, 19.9% and 24.3% respectively. Idiopathic dilated 
cardiomyopathy was reported in only 6.7%, ranging from 15% in Hungary to 1% in Tur- 
key, and 48.3% of these were reported to have at least one other contributing factor 
(other than age or genetic condition). 52.8% of echocardiograms showed a dilated or 
poorly contracting ventricle. Of 2,579 patients in whom left ventricular ejection fraction 
was reported it was ~40% in only 33% of those ~75 years and 30% of those >75 years 
(31% overall). Patients with a diagnosis of heart failure managed in primary care differ 
substantially from those in clinical trials. Substantial international variation exists. 
Age 
tion (n=88) 
54 years 
(n=56) 
60 years 0.005 
Male Gender 68% 40% 0.001 
History CAD 35% 16% 0.02 
ETOH Use 39% 21% <0.05 
# Patients Re-admitted 27 (30.7%) 17 (30.4%) 0.92 
1234-68 Effect of Normal Hematocrit on Left Ventricular Mass in 
Patients With Cardiac Disease and LVH on Dialysis 
Toniya Singh, Ramon Castello, Frederick A. Dressier, Dennis A. Anthonis, Arthur J. 
Labovitz. St. Louis University St, Louis 
Cardiac disease is the most common cause of death in dialysis patients. Anemia poses a 
significant threat to cardiovascular mortality by contributing to the development of LVH. 
Current guidelines recommend correction of anemia to a hematocrit (hct) of 30% using 
erythropoetin alfa. We conducted a randomized controlled trial with 98 patients on dialy- 
sis with cardiac disease and LVH to see whether correction of hct to 42% was more effec- 
tive in reversing LVH in this sub group of patients. These patients were randomly 
assigned to Group A (hct 42%)and Group B (hct 30%) and echocardiograms were per- 
formed at baseline, 9 months and 18 months. Both groups were similar at baseline 
regarding left ventricular mass index (LVMI), left ventricular end diastolic dimension 
(LVEDD), left ventricular end systolic dimension (LVESD), ejection fraction (EF) and 
mean arterial pressure (MAP) measurements. 
LVMI (gmlm2) LVf+l (gmfm2) 18 p value 
Baseline months 
Gp A( hct 42%) (n=43) 179.34 163.23 0.005 
Gp B( hct 30%) (n=55) 183.39 180.90 0.41 
In patients with a higher hct, there was a significant left ventricular mass regression from 
baseline to 18months, such a difference was not seen in patents with a subnormal hct. 
There was no significant difference in cardiovascular mortality between the 2 groups 
(p=O.3), there was also no significant difference in overall mortality in both groups 
(p=O.3). As expected higher LVMI, Larger LVEDD and LVESD and lower EF served as 
markers of mortality in both groups (pcO.5). 
Thus while a higher hct did lead to LVMI regression it did not have a significant impact on 
mortality. Further studies are needed to identify a subgroup of patients who might have a 
survival benefit from a higher hematocrit 
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1235-70 Ventricular Rapid Filling Wave Duration: A New 
Hemodynamic Index Distinguishing Differing 
Pathophysiology in Constrictive Pericarditis 
Sunao Kojima, Yoichi Goto. National Cardiovascular Center, Suita, Osaka, Japan 
Post-operative left heart-dominant constrictive pericarditis (CP) has been reported not to 
necessarily fulfill the classic criteria for diffuse CR We hypothesized that the duration 
and/or depth of “a dip and plateau pattern” may distinguish the differing pathophysiology 
of CP from various etiology. Methods: To test this hypothesis, we measured the duration 
of a ventricular rapid filling wave (RFWD), i.e., time from the nadir of the “dip” to the “pla- 
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teau”, and related it to hemodynamic, echocardiographic, computed tomographic (CT), 
and pathologic findings in 20 patients (pts) with CP from various ettoiogy. in all 20 pts, dip 
and plateau patterns were recorded at catheterization in both left (LV) and right ventricu- 
lar (RV) pressure waves, and the diagnosis of CP was confirmed at surgery or by tagged 
tine magnetic resonance imaging. Pts were divided into two group?.: LVCIOO msec (S) 
group (n=i 1) and LV<lOO msec (L) group (n=9). Results: There were no signrficant differ- 
ences in demographic factors bebveen S and L groups. The classic criteria of CP 
(LVEDPRVEDP<5 mm Hg, pulmonary artery systolic presswe( mm Hg, and 
RVEDPIRVSP>l/3) were fulfilled in 10 of the 11 pts (91%) in S group, but in only 4 of the 
9 pts (44%) in L group (p<O.O5). In contrast, left heart-dominant pericardial adhesion was 
observed in only 1 pt (9%) rn S group, but in 5 pts (56%) in L group (pcO.05). Although 
the pericardial thickness or the incidence of calcification did not differ between the two 
groups, localized pericardiat lesions such as intrapericardial hematoma or clot were 
observed in none of S group but in 3 pts in L group (p=O.O7). Stepwise multiple regres- 
sion analysis indicated that LV RFWD was determined by the extent of pericardial adhe- 
ston (p=O.Ol) and the presence of localized lesions (p&05). A separate analysis 
revealed that the depth of RFW does not distinguish the pathophysiology of CP. Conctu- 
sion: LV RFWD is a new hemodynamic index which distinguishes differing pathophystol- 
ogy in CP: A short LV RFWD (<lo0 msec) indicates diffuse pericardial adhesion, 
whereas a long LV RFWD indicates left-dominant or localized pericardial lesions. 
1235-71 Detection of the Infectious Etiology of Pericardial Effusion: 
impact of Pericardial Effusion and PericardiaUEpicardiaI 
Biopsy Analyses 
Bernhard Maisch, Sabine Pankuweit, Awn D. Ristic. Department of Internal Medicine- 
Cardiology, Philipps Universftx Marburg, Germany 
Background: The identification of viral and bacterial etiology of pericarditis has obvious 
implications for the treatment selection: Only patients with virus- and bacteria-negative 
effusions should be considered for corticord or immunosuppressive therapy. The aim of 
the present study was to investigate impact of pericardiaf effusion and pericardial/epicar- 
dial biopsy analyses on identification of infectious agents causing pericarditis. Methods: 
Patient population included 260 consecutive patients undergoing pericardiocentesis, 
pericardioscopy and pericardial/epicardial biopsy (57.3% males, mean age 58.6113.9 
years). In all patients pericardial effusion analyses for neoplastic and inflammatory cells, 
cytokines, conventronal lab analyses and epicardiallpericardial biopsy histology, immuno- 
histochemistry and PCR analyses of microbial agents were performed. The presence of 
the following infectrous agents was specifically considered: RNA of enteroviruses (EV), 
the DNA of adeno- (ADV), cytomegaio- (CMV), Ebstein Barr-(EBV), herpes simplex 
(HSV), influenza virus (IV), borrelia burgdotferi (BD), chlamydia pneumontae (CP), myco- 
bacterium tuberculosis (TBC) in addition to bacterial and vtral cultures from the effusion 
and serological assessment for HIV, hepatitis 6, B, A. Results: 65% of investigated 
patients had non-malignant pericardial effusion. The following etiologies could be 
assessed: ADV 201260 (7.7%); EV 1 i/260 (4.2%) CMV lo/260 (3.8%) IV 5/260 (1.9%), 
hepatitis B 5/260 (1.9%) HSV 5/260 (1.9%) Parve B19 21260 (0.8%) TBC 9M60 (3.5%) 
BD 21260 (0.8%) other bacteria 15/260 (5.7%), uremia 16/260 (6.2%). No etiological 
agents were identified in 651260 patients with pericardial effusion (25%). These were 
terned autoreactive when lymphocytes and/or anticardiac antibodies were detected 60/ 
260 (23.1%) and idiopathic if only serous fluid was isolated 5/260 (1.9%). Conclusions: 
Etiological differentiation of infectious pericardrtis using pericardial effusion and pericar- 
dial/epicardial biopsy analyses is posstble in the large majority of patients. Contribution of 
PCR tnolecular techniques is crucial in revealing the specific etiology of the disease. 
123572 Relationship Between Pericardial Friction Rub and Effusion 
in Pericarditis 
Shlomc Natan, Bart Jan Mewing, Evert J. P. Lamfers, Anton J. M, Oude Ophuis, Freek 
W. A. Verheugt. Heartcenter. University Medical Center, Nijmegen, The Netherlands, 
Canisius Wilheimina HospitaI, Nijmegen, The Netherlands 
Background:tn clinical pericarditis often a pericardiaf friction rub is heard and pericardial 
effusion (PE) is seen on echocardiography. However, sometimes a rub is heard without 
PE and sometimes the other way around. The relationship between the presence of a rub 
and the amount of PE, if any, has hardly been studied in non-surgical pericarditis. 
Methods: In 134 non-surgical patients (pts) a cltnical diagnosis of pericarditis was made 
using history, fever, lab tests and ECG. The presence of a pericardial friction rub was 
scored and PE was quantitatively assessed by echocardiography: small (cl mm), moder- 
ate (l-10 mm) or large (>iO mm). 
Results: In the 71 pts with no or a small PE a rub was heard in 38 (54%) in those with 
moderate PE (n=29) in 16 (55%) and in those with a large PE in 16138 (42%, p=ns). 
When the suspected etiology was taken into account, there was no relation with the 
amount of PE, but there was a relation with the presence of a rub. 
Suspected etiology total pts with rub P 
auto-immune 9 l,(li%) 0.008 
neoplastic 11 2 (18%) 
idiopathic 54 29 (54%) 
infectious (viral/bacterial) 44 24 (56%) 
post-infarct 20 14 (70%) 
Given the fact that many cases of idiopathic pericarditis are infectious in origin, inflamma- 
tory responses in the pericardium are more often correlated wrth a rub than the non- 
inflammatory causes of pericarditis. 
Conclusion: Although often suggested by clinicians, we could not identify a correlation 
between a pericardial friction rub and the amount of PE in this large study. However, 
inflammatory pericarditis is more often associated with a rub suggesting that rather than 
the rough pericardial surfaces fibrin strings cause the rub, where they may serve as 
snares. 
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1235-73 Sensitivity and Specificity of Two-Dimensional 
Echocardiographic Signs of Cardiac Tamponade 
Arsen D. Ristic, Petar M. Seferovic, Biljana Obrenovic-Krrcanski, Ruzica Maksimovic, 
Gorica Ristic, Radica Pesic, Gordana Draganic, Dejan Simeunovic, Danijela Zamaklar- 
Trifunovic, Miodrag C. Ostojlc. University institute for Cardiovascular Dfseases, Be/grade, 
Vugos/avia 
Background: Echocardiographic prediction of cardiac tamponade is controversial. The 
aim of the present study was to evaluate ssnsrtivity and specificity of two-dimensional 
(2D) echocardiographic signs of cardiac tamponade in comparison to the invasively 
assessed hemodynamics. Methods: In 50 pts with large pericardial effusions (PE) (58% 
males, mean age 54.2t9.6 yrs, PE> 2 cm anteriorly) echocardiography was performed 
immediately before cardiac catheterization and pericardiocentesis. Diagnosis of cardiac 
tamponade was established only if both clinical (jugular venous distention, tachycardia, 
hypotension, pulsus paradoxus) and hemodynamic signs were present (elevation and 
equilibration of intrapericardial and right atrial (RA) pressures). Results: According to the 
clinical and hemodynamic criteria 8/50 pts (16%) undergoing pericardiocentesis for large 
symptomatic PE had cardiac tamponade. Average volume of PE evacuated by pericardr- 
ocentesis in pts with tamponade was larger but not significantly different in comparison to 
pts without tamponade (725r344 ml vs. 6495421 ml; p=O.317). Sensitivity vs. specrficity 
vs. positive predictive value of the PD-echocardiographic signs of cardiac tamponade 
was respectivelly: RA diastolic collapse - 45 pts (100% vs. 11.9% vs. 17.8%) left atrial 
(LA) diastolic collapse - 4 pts (37.5% vs. 90.5% vs. 42.9%) right ventricular (RV) dras- 
tolic collapse - 38 pts (75% vs. 23.8% vs. 15.8%), “swinging heart” - 29 pts (75% vs. 
45.2% vs. 20.7%), sudden leftward motion of interventricular septum.(lVS) during rnspira- 
tion - 10 pts (100% vs. 95.2% vs. DO%), and sustained inferior vena cava congestion 
(>2.5 cm) not influenced by inspiration - 29 pts (100% vs. 50% vs. 27.4%). Among the 
investigated echocardiographic parameters RA collapse and VCI congestion had high 
sensitivity but low specificity. Leftward IVS motion in inspirum was the only parameter 
with both high sensitivity and specificity, but it occurred in only 20% of pts. Conclusion: 
All investigated parameters had tow posrtive predictive value for cardiac tamponade, 
except sudden leftward IVS motion (80%) in inspirum and LA collapse which could be 
demonstrated in only 20% and 8% of pts respectively. 
1235-74 Long-Term Survival After Pericardiectomy for Constrictive 
Pericarditis is Determined Mainly by the Underlying 
Etiology: A Large Surgical Center Study From 1977 to 2000 
Stefan C. Bertog, Paul Schoenhagen, Eugene H. Blackstone, Bruce W. Lytle, Allan L. 
Klein. Cleveland Clinic Foundation, Cleveland, OH 
Background: Constrictive pericarditis (CP) is the result of a spectrum of primary cardiac 
and noncardiac conditions. Little data exists on the cause-specific survival after per,- 
cardiectomy in the modern era. Methods: We analyzed the records of 150 patients who 
underwent pericardiectomy for CP over a 23.year period at a single surgical center. The 
dragnosis of CP was established by surgical report and clinical findings. Vital status was 
obtained by chart review and search of the Social Security Administration Death Master 
File. The Kaplan-M&r method was used to estimate overall survival and survival by eti- 
ology group. Cox proportional hazards regression analysis was performed to assess the 
effect of various causes for CP on long-term survive. while adjusting for age. Results: 
The etiology of CP was idiopathic in 62 patients (41%, medran age 59) prior cardiac sur- 
gery in 54 (36%, median age 65) radiation treatment rn 15 (lo%, median age 53) a 
combination of prior surgery and radiation in 5 (3.4%, median age 55) and miscella- 
neou~ in 14 patients (9%, m&an age 53). Vital status was obtained on 142 patients 
(95%). Median follow-up was 6.75 years. Perioperative (30 day) mortality for all patients 
was 3.5%. Actuarial survival at 1, 5 and 10 years was 87.3%, 77.8% and 63% respec- 
tively. Kaplan-Meier curves for the subgroups are shown in Figure 1. ldropathic CP had 
the best prognosis (10 year survival: 82% versus age matched control: 85%). Age, risk 
ratio (RR) 1.04, 95% confidence interval (Cl) 1.01-I .06; prior cardiac surgery, RR 2.2, Cl 
1.3-3.9, and mediastinal radiation, RR 6.3, Cl 3.2-l 2.2, were predictors of poor surwal 
Conclusion: Survival after pericardiectomy for CP is determined mainly by the etiology 
of constriction and may reflect the prognosis of the underlying condition. The almost nor- 
mal survival in the group with idiopathic CP emphasizes the long-term safety of surgical 
pericardiectomy in this group. 
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861 Percutaneous Septal Ablation for 
Hypertrophic Obstructive 
Cardiomyopathy: The Latest Data 
Tuesday, March 20, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Hall F5 
861-I Septal Ablation for Hypertrophic Obstructive 
Cardiomyopathy: An Analysis of the Patients With 
Dissatisfactory Reduction of the Outflow Gradient 
861-3 
2:30 pm. 
Regression of Left Ventricular Hypertrophy After Non- 
Surgical Septal Reduction Therapy for Hypertrophic 
Obstructive Cardiomyopathy 
Wojciech Mazur, Sherif F. Nagueh, Nasser M. Lakkis, Katherine J. Middleton, Donna 
Killip, William H. Spencer, III. Baylor Colkge of Medicine, Houston, TX, The Methodist 
Hospital, Houston, TX 
Background: The long-term effects of non-surgical septal reduction therapy (NSRT) with 
intracoronary ethanol on LV hypertrophy are unknown. 
Methods: Twenty-six patients (53+15 years) with hypertrophic cardiomyopathy (HCM) 
2:oo p.m. scheduled for NSRT also underwent echocardiography at baseline and 1 and 2 years 
after the procedure with LV size, function and outflow tract gradient assessed by tran- 
sthoracic echocardiography. Wall thickness of individual myocardial segments, planime- 
tered myocardial area and mass calculation were used to assess LV hypertrophy. 
Results: Patients experienced symptomatic improvement and increase in exercise toler- 
Lothar Faber, Bemd Werlemann, Leon Krater, Hubert Seggewiss, Dieter Horstkotte. ante (pc.05). 
Heart Center North Rhine- Westphalia, Bad Oeynhausen, Germanl: Leopoldina Hospital, Variable Baseline 1 Year 2 Years 
Schweinfurf, Germany Outflow gradient (mmHg) 3&6 3rl2* 0+3* 
Background and introduction: In 90% of the patients (pts). with symptomatic hyper- LV ejection fraction (%) 72.5*6 70.3*10 68r9’ 
trophic obstructive cardiomyopathy (HOCM) the outflow gradient (LVOTG) can signifi- 
cantly be reduced or removed by interventional septal ablation (PTSMA). Pts. with a 
Wall thickness score mitral level (mm) 72.4+10.5 57.&l 1’ 51.5+9*t 
dissatrsfactory LVOTG response are not characterized sufficiently. 
Wall thickness ?&ore papillary muscle level (mm) 73ill 59+8.8 53ta.7*t 
Results: From 241 ots. m-evaluated 3 months after PTSMA. 32 (13%) had PTSMA fail- LV mass (gm) 301178 223*51* 
190&3*t 
ure (PF) defined as a less than 50% LVOTG reduction. On average, these pts. were 
younger (45?18 vs. 53214 years; p<O.Oi) and had a slightly thicker septum (21.7e3.2 vs. 
20.&3.6 mm; p=O.l). 
The leading cause for PF was an insufficient PTSMA scar on 2Dechocardiography 
(n=i6: successful re-PTSMA in 6 pt.?., spontaneous LVOTG reduction in 3 pts. after 12 
months). Suboptimal scar localization, observed in 7 pts. treated before introduction of 
routine echocardiographic guidance (MCE) for PTSMA and requiring a re-PTSMA in 4 
pts. and surgery in 1 pt., was not seen with MCE-guided interventions any more. 
Another group of pts. with PF included cases with persisting SAM and LVOTG despite a 
correctly placed and sufficiently large PTSMA scar due to excessive elongation of the 
mitral leaflets (n=5; spontaneous LVOTG elimination in one of them after 12 months). 
One pt. had coexistent fibromuscular subaortic stenosis and underwent successful sur- 
gery for this problem. 
Conclusions: After exclusion of scar mrsplacement by MCE, pts. still remain who seem 
to be less suitable for PTSMA. Furthermore, LVOTG elimination may need up to 1 year. 
Pm-interventional pt. selection, echocardiographic assessment, and pt. information 
should take these findings into consideration. 
861-2 
215 p.m. 
Evaluation of Left Ventricular Oufflow Tract Area After 
Septal Reduction in Hypertrophic Obstructive 
Cardiomyopathy: A Real-Time Three-Dimensional 
Echocardiographic Study 
Marta Sitges, Takahiro Shiota, Harry M. Lever, Jian Xin Qin, Fabrice Bauer, Hiroyuki 
Tsujino, Yong Jin Kim, Jeannie K. Drinko, Deborah A. Agler, Samir Ft. Kapadia, E. Murat 
Tuzcu, Nicholas G. Smedira, Bruce W. Lytle, James D. Thomas. The Cleveland Clinic 
Foundation, Cleveland, OH 
Background:The comparative impact of percutaneous septal alcohol ablation (PTSMA) 
and surgical myectomy (MYO) on left ventricular outflow tract (LVOT) area in patients with 
hypertrophic obstructive cardiomyopathy (HOCM) is not well defined. Real-time three- 
dimensional echocardiography (RTSDE) provides accurate information about the LVOT 
geometry and shape. We aimed to analyze the change in LVOT area after septal reduc- 
tion interventions in patients with HOCM using RT3DE. 
Methods: 21 patients (mean age 55~17) with HOCM undergoing PTSMA (n=iZ) or MY0 
(n=9) were studied at baseline and during follow-up with RTSDE. LVOT area was mea- 
sured after observing the LVOT in the 3-dimensional space as the smallest area during 
mid-systole. LVOT pressure gradients (PG) were obtained by conventional CW Doppler. 
Results: LVOT area increased from 0.96iO.15 to 2.5+0.9 cm2 (p<O.O5) and LVOT pres- 
sure gradient (PG) decreased from 69+45 toi8fl2 mm Hg (~~0.05) after a mean follow- 
up of 4 months after intervention. Results of PTSMA and MY0 groups are shown in the 
following table: 
Background: Both percutaneous transcoronary alcohol ablation (PTSMA) and surgical 
myectomy (MYO) are effective treatments to relieve left ventricular outflow tract (LVOT) 
obstruction in hypertrophic obstructive cardiomyopathy (HOCM). Our aim was to analyze 
the impact of septal reduction treatment on left venticular (LV) diastolic function. 
Methods: Echocardiography was performed in 53 HOCM patients at baseline and after 
PTSMA (n=33) or MY0 (n=ZO) (mean follow-up 4.8M months). LV diastolic function was 
analyzed using PW-Doppler of the mitral inflow (E, A) and pulmonary veins flow (S, D), 
mitral annulus tissue Doppler imaging (Ea) and color M-Mode flow propagation velocity 
(VP) of the mitral inflow. LVOT pressure gradient (PG) and mitral regurgitant volume 
(MRV) were calculated. Left atrium (LA) area and M-Mode LV dimensions were also 
obtained. 
Results: LVOT PG decreased from 63i42 to 23222 mmHg (p<O.Ol). MRV also 
decreased after both procedures from 26*22 to 12+15 ml ( p< 0.01). Significant reduc- 
tions were seen both in the septum and posterior wall thickness after treatment (2.4f 0.4 
to 1.8f0.5 mm and 1.5iO.3 to 1.3kO.2 mm, respectively, ~~0.01 for both). Diastolic 
parameters and LA area are shown in Table. 
E/A S/D VD (cm/& E/Vu Ea (cm/se) E/Err LA (cm”) 
Pm 1.7?1.8 1.2fO.8 66+24 1.5+0.6 6.5e 15f8 29+_ 
PTSMA MY0 
Pm- Post- Pm- Post- 
LVOT area (cm2) 0.96kO.2 2.0r0.9* 0.97t0.2 3.0+0.73** 
Rest PG (mmHg) 66+46 22*14* 73+47 14+6’ 
*p<O.O5 versus Pre-;Ap<O.Ol versus PTSMA. 
Increase in LVOT area along with PG decrease were seen both in the MY0 and in the 
PTSMA groups, being the increase in LVOT area greater in the MY0 than in the PTSMA 
group (P<O.Ol). 
Conclusions: RT3DE demonstrated an effective increase in LVOT area after both 
PTSMA and MYO. This technique may be useful for assessing the results of sepia1 
reduction in oatients with HOCM. 
Post 110.7 * 1.31to.5 74i36: 1.410.8 7f2 tlf;6* 25+6’ 
‘~~0.05 versus Pre- 
No correlation was found between the decrease in MRV or in LVOT PG and E/A changes. 
When comparing PTSMA with MY0 patients, no difference was found in the degree of 
change in any parameter of diastolic function. 
Conclusion: Diastolic function changes after septal reduction interventions in HOCM 
patients, the change being similar after both MY0 and PTSMA. The increase in Vp and 
Ea together with the reduction in LA size suggest improvement in LV relaxation and 
decrease in LA pressure. Thus improvement in diastolic function may be related to regres- 
sion of secondary hypertrophy in response to the relief of the LVOT obstruction produced 
by PTSMA or MYO. 
861-S 
3:oo pm 
Comparison of Ethanol Septal Reduction Therapy with 
Surgical Myectomy for the Treatment of Hypertrophic 
Obstructive Cardiomyopathy 
Sherif F. Nagueh, Steve R. Ommen, Nasser M. Lakkis, Rick A. Nishimura, Donna Killip, 
William A. Zoghbi, Hartzell V. Schaff, Gordon K. Danielson, Miguel A. Quifiones, A J. 
Tajik, William H. Spencer, Ill. Baylor College of Medicine, Houston, TX, Mayo C/irk, 
Rochester, MN 
Mass index (gm/m*) 
‘p<O.O5 vs baseline, tp.xO.05 vs 1 year 
151*32 112t21’ 95+24*t 
All parameters of LV hypertrophy showed evidence of regression. LV end-diastolic and 
end-systolic dimensions increased significantly at both the 1 and 2 year time points 
(pc.001). The total reduction in mass at 2 years was related to peak CK (r=.48; p=.O19) 
and the acute reduction in outflow tract gradient (r=.63, p<.Ol). 
Conclusions: LV hypertrophy in HCM patients regresses and myocardial mass may nor- 
malize following relief of obstruction. NSRT results in LV remodeling characterized by 
increase in LV size, decrease in extent of hypertrophy, and preserved ejection fraction. 
861-4 
2:45 p.m. 
Improved Diastolic Function After Septal Reduction in 
Obstructive Hypertrophic Cardiomyopathy. 
Marta Sitges, Takahiro Shiota, Harry M. Lever, Jian Xin Qin, Fabrice Bauer, Jeannie K. 
Drinko, Deborah A. Agler, Maureen G. Martin, Nicholas G. Smedira, Bruce W. Lytle, 
Samir R. Kapadia, E. Murat Tuzcu, Mario J. Garcia, James D. Thomas. The Cleveland 
Clinic Foundation, Cleveland, OH 
Background: Non-surgical septal reduction therapy by intracoronary ethanol (NSRT) 
gained interest as a new treatment for drug-refractory symptoms in hypertrophic obstruc- 
tive cardiomyopathy (HOCM). However its role in comparison to surgical myectomy is 
unknown. 
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follow-up, 39 pts had a a benign course (Gr.A) while a symptomatic deterioration was 
seen in the remaining 15 pts (Gr.6). Comparison of findmgs at the first and last echocar- 
diagram in Gr.A did not reveal any significant change. In Gr.B, conversely, there were 
over time significant decreases in both LVEF (from 70112 to 54+12%, p<O.OOl) and 
RVEF (from 50+11 to 33+12%, pcO.001) and a significant increase in RV ED area (from 
15+4 to 2514 cm3, p<O.OOl). At last echocardiogram, a LV/RV area<2 was found in 5139 
Gr.A pts and lo/15 Gr.B pts (piO.Ol), and a RVEFc40% was detected in 11139 Gr.A pts 
and 7115 Gr.B pts (~~0.05). Conclusion: (1) A progressive mcrease in RV cavity and 
decrease in RV contractility can occur in a subset of HC pts: (2) such a phenomenon is 
associated with clinical deterioration and should be regarded as a marker of a more 
severe disease. 
3:12 p.m. 
1009-202 Effect of Left Ventricular Outflow Tract Obstruction on 
Hemodynamic Adaptation to Exercise in Hypertrophic 
Cardiomyopathy 
Quirino Ciampi, Sandra Betocchi, Anna Violante, Fiore Manganelli, Maria A. Losi, Giulia 
Sica, Carlo G. Tocchetli, Raffaella Lombardi, Elpidlo Pezrella, Filippo Finizio, Albert0 
Cuocolo, Massimo Chiariello. Fedetico // University of Naples, Naples, My 
Background. Exercise is considered harmful in patients with obstructive hypertrophic 
cardtomyopathy (HOCM), despite little evidence in literature. Aim of our study is to 
assess hemodynamlc adaptation to isotonic and isometric exercise by ambulatory radio- 
nuciide monitoring of left ventricular function (VEST) in HOCM, in non obstructive hyper- 
trophic cardiomyopathy (HNOCM), and in controls. Methods. We studied 15 HOCM (age 
37~14 years, 14 men), 23 HNOCM (age mean 39i15 years, 15 men), e 9 healthy sub- 
jects (age 36214 years. 7 men). During VEST monitoring, they underwent isotonic exer- 
cise by treadmill (Bruce protocol), and isometric exercise by a dynamometer gripped at 
75% of maximal voluntary contraction for up to 5 min. VEST data were analyzed at base- 
line, at 1, 3, 6, min and at peak exercise (Pex) during isotonic exercise, and at baseline, at 
1 min, and at Pex during isometric exercise. Stroke volume, cardiac output , and systemic 
vascular resistance were normalized to baseline value and expressed as a %. Results. 
Isotonic exercise: HOCM and HNOCM showed a significant decrease in stroke volume 
(figure, left) (p<.OOl by ANOVA, pc.01 controls “s HNOCM & HOCM,), cardiac output 
(p<.OOl by ANOVA, pc.01 controls vs HNOCM & HOCM), and ejection fraction (p<.OOl 
by ANOVA); there were no changes in systemic vascular resistance. Isometric exercise: 
controls showed a significant increase in SV (figure, right) (p=.OO8) and in ejection frac- 
tion (p=.OO3), but neither did HOCM nor HNOCM. Systemic vascular resistance 
increased significantly in HOCM (pz.003) and HNOCM (p=.OOl), but did not change in 
controls.Conclusion. Patients with hypertrophic cardiomyopathy had a similar hemody- 
namic adaptation to isotonic and isometric exercise, regardless of the presence of left 
ventricular outilow tract obstruction, compared to controls. Hence. Isotonic and isometric 
exercise poses no greater harm to HOCM than to HNOCM. 
Methods: 41 consecutive NSRT patients (BCM) with I-year follow-up were compared 
with age and gradient matched septal myectomy patients (Mayo). All patients had left 
ventricular outflow obstruction with a resting gradient greater than or equal to 40 mmHg 
and none had concomitant procedures. Endpoints included hemodynamics, exercise toi- 
erance, and symptom class. 
Results: In addition to the matching variables, there were no baseline differences in 
NYHA class, severity of mitral regurgitation, use of cardiac medications, or exercise 
capacity One death occurred during NSRT (LAD dissection). The incidence of pace- 
maker implantation for complete heart block was higher after NSRT (22% vs 2% in sur- 
gery; p=O.OP). Seven of 9 pacemakers in the NSRT occurred in the in&al experience 
prior to the use of contrast echocardiography and a modified ethanol injection technique. 
At 1 year, all improvements were similar between the 2 modalities. 
Baseline Follow-up Baseline Follow-up 
Gradient (mmHg) 
NYHA class I-II (%) 
NYHA class Ill-IV (%) 
METS 
% predicted peak 02 
‘pcO.001 vs baseline 
surgery surgery NSRT NSRT 
78-33 4*7 76&23 8i15’ 
22 98 10 100 
78 2* 90 
5.31-l .7 6.5tl.5’ 5.921.4 7.5t1.9’ 
55t15 69*17 57+11.5 72.5118 
Conclusions: NSRT guided with contrast echocardiography is an effective procedure for 
treating HOCM patients. The hemodynamic and functional improvement at l-year follow- 
up is similar to surgical myectomy. 
861-6 
3:15 p.m. 
Long-Term Clinical and Hemodynamic Outcome after 
Percutaneous Septal Ablation for Hypertrophic Obstructive 
Cardiomyopathy 
Leon Krater, Hubert Seggewiss, Axel Meissner, Lothar Faber, Dieter Horstkotte. Heart 
Cenler Norih Rhine-Westphalia, Bad Oeynhausen, Germane Leopoldina Hospitai, 
Schweinfurt, Germany 
Background and Introduction: Septal ablation (PTSMA) by alcohol injection into septal 
branches ot the left coronary artery is a promising treatment for symptomatic patients 
(pts.) with hypertrophic obstructive cardiomyopathy (HOCM), leading to reduction of left 
ventricular outflow gradients (LVOTG) and climcal improvement during short-term tollow- 
up. We now analyze clinical and non-invasive results in 107 consecutive pts. with a fol- 
low-up after PTSMA > 24 months. 
Methods and results: Two out of 107 pts. died during in-hospital stay (VF and pulmo- 
nary embolism 1 pt. each). Mean CK rise was 659i33 U/I. A permanent DDD-pacemaker 
(DDD-PM) had to be implanted in 10 pts. Mean follow up duration was 27+4 months. 
There was one asymptomatic AV-block (2nd degree) 22 months after PTSMA in a 60. 
year old female pt., who received a DDD-PM. In another 23.year old female pt. an ICD 
was implanted after CPR for unknown reason. One 86-year-old women with chronic AF 
died from stroke 23 months after PTSMA. No documented ventricular tachyarrhythmias 
or ventricular septal defects were observed. Further clinical and echocardiographic data 
are shown in the table: 
Baseline Last Follow up p-value 
NYHA class 2.8 i 0.5 1.2 +0.9 <0.0001 
LV enddiastolic diameter (mm) 46.8 M.9 48.5 f 5.2 n.5. 
LVOTG at rest (mm Hg) 62538 8i16 <0.0001 
LVOTG at Valsalva (mm Hg) 147i56 23+24 <0.0001 
Maximum workload (Watts) 88?57 122+43 <0.0001 
Conclusions: PTSMA leads to significant and persistent LVOTG reduction and improve- 
ment without global left ventricular dilatation or fatal brady-/tachyarrhythmic events during 
long-term follow up. Spontaneous degeneration of the AV conduction system together 
with the PTSMA-Induced damage may lead to conduction problems in individual patients 
late after the procedure. 
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3:oo p.m. 
1009-201 Long-Term Changes in Right Ventricular Geometry and 
Function in Patients With Hypertrophic Cardiomyopathy 
Francesco Pelliccia, Cinzia Cianfrocca, Giuseppe Mararzl, Mario Pagliei, Vincenzo 
Venturini, Marcello Mariani. Colleferro Hospital Rome, /k-~/y 
Background: Little information is available on the long term impact of HC on the right 
ventricle (RV). Methods: Over a IO-year period, serial echocardiograms could be 
obtained in 54 HC pts (35 males, age: 45+19 yrs) who had normal LV and RV size and 
function at diagnosis. Time interval between the first and the last echocardiogram was 
4+3 yrs (range: 2-10 y(s). In both LV or RV, the following measures ware derived (apical 
I-chamber view): long-axis length (L) and transverse midcavitary diameter(T), end-dias- 
tolic (ED) and end-systolic (ES) areas as well as election fraction (EF). Results: During 
3:24 p.m. 
1009-203 Favourable Outcome of Pregnancy in a Non-Referral Based 
Population With Hypertrophic Cardiomyopathy 
lacopo Olivotto, Carolina Becattini, Daniela Vargiu, France Cecchi. Azienda Ospedaliera 
Caregg!, Firenze, lfaly 
The prevalence of complications during pregnancy in patients with hypertrophic cardi- 
omyopathy (HCM) is still uncertain. Aim of this study was to analyse the outcome and 
complications of pregnancy in a large unselected population with HCM.Among an unse- 
lected population of 202 patients followed for lo*5 years, the climcal history of all female 
patients (n=63) was reviewed. All women with pregnancies were interviewed regarding 
using a questionnaire; medical records were analysed with regard to pregnancy and 
labour (including deceased patients). Of 63 women, 44 (70%) went through at least one 
complete gestation (range up to 10, mode 2). The total number of pregnancies was 93 
Mean age at the time of the first and last pregnancy was 26*4 and 32+5 years, respec- 
tively. Age at first dlagnosls of HCM was 42i-12 years: only 6 of the 44 patients (14%) 
was diagnosed before or during fertile life (only 3 of which received medical treatment 
during pregnancy). Most women had spontaneous vaginal deliveries (n=40, 91%); only in 
4 patients one or more caesarian sections were performed. Eleven women (25%) suf- 
fered >l abortions (up to 3), between week 6 and 25. Only in one case this attributed to 
HCM, in a 33-year old women receiving beta-blocking agents. No life-threatening cardiac 
complications occurred, and in most women (n=35 79%) ail gestations were completely 
uneventful. In the remaining 9 women the following problems were encountered: risk 01 
abortion (1x5), premature delivery (n=l), fetal distress requiring urgent caesarean sec- 
tion (n=2, in one case due to Rh isoimmunization) and neonatal death of unclear cause 
(n=l). In 33 of the 44 patients (75%) there were no cardiac symptoms during pregnancy. 
The remaining 11 women complained of palpitations (n=6), mild to moderate dyspnea 
(n=4), atypical chest pain (n=l). In conclusion, pregnancy was well tolerated and assorx 
ated with favourable outcome in a non-referral population with HCM. Thus, pregnancy 
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should not be discouraged per se in women with HCM, although caution is mandatory in 
patients with specific risk factors, and adequate genetic counselling is required in all 
cases. 
3:36 pm. 
1009-204 Septal Ablation for Hypertrophic Obstructive 
Cardiomyopathy: Normalization of an Abnormal Blood 
Pressure Response 
Lothar Faber, Bernd Werlemann, Peer Ziemssen, Hubert Seggewiss, Dieter Horstkotte. 
Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germanl: Leopoldina Hospital, 
Schweinfurt, Germany 
Background and introduction: In patients with hypertrophic obstructive cardiomyopa- 
thy (HOCM), an abnormal blood pressure response (BPR) with exercise seems to be a 
marker for an increased risk of sudden death. Percutaneous septal ablation (PTSMA) is a 
new symptomatic treatment option for HOCM with so far unknown prognostic effects. We 
therefore analyzed the exercise BPR before and 12 months after PTSMA. 
Methods and results: In 197 pts. studied, mean resting outflow gradient (LVOTG) was 
reduced from 6Oi34 to 9+15, provoked LVOTG from 126+48 to 28+34 mm Hg (p<O.OOOl 
each). At baseline, 54 pts. (27%; group 1) had an abnormal exercise BPR defined as a 
rise of ~20 mm Hg or a blood pressure fall with submaximal upright bicycle exercise. BPR 
was normal in 106 pts (54%; group 2). The remaining 37 pts. (19%) did not undergo 
baseline exercise testing due to symptoms of congestion or extracardiac limitations, and 
were excluded. Group 1 pts. were younger (47~15 vs. 53*15 years; p<O.Oi), and had 
smaller (LV enddiastolic diameter 44-t6 vs. 47*6 mm; p<O.O05) and more vigorously con- 
tracting ventricles (LV fractional shortening 46&7 vs. 43*9%; ~~0.05). 12 months after 
PTSMA, in 45 pts. of group 1 (83%) the initially abnormal BPR was normalized with a 
systolic exercise blood pressure rise from 115+15 to 151-t28 mm Hg (p<O.Ol), while it 
remained abnormal in 9 pts. of group 1. Lack of BPR normalization was not associated 
with a higher residual LVOTG. 
Conclusions: In symptomatic HOCM, an abnormal BPR seems to be associated with 
younger age and a smaller, hypercontractile LV. LVOTG elimination by PTSMA results in 
normalization of an abnormal BPR in the majority of pts.. Whether this effect of PTSMA 
leads to a prognostic benefit, and why BPR remains abnormal in some pts. despite suc- 
cessful septal ablation, remains to be assessed by further investigation. 
3:48 p.m. 
1009-205 The Short-Term Effect of Cibenzoline on Left Ventricular 
Diastolic Function in Hypertrophic Obstructive 
Cardiomyopathy as Compared With Bisoprolol 
Isa0 Kondo, Katsufumi Mizushige, Shim Nozaki, Yasuyoshi Iwado, Masakazu Kohno. The 
Second Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan 
Background: Cibenzoline (CBZ) can improve left ventricular (LV) diastolic function as 
well as LV outflow obstruction in hypertrophic obstructive cardiomyopathy (HOCM). How- 
ever, whether the improvement of LV diastolic function by CBZ is due to LV afterload 
reduction or primary lusitropic effect of CBZ on LV, has not been clarified. 
Purpose: The aim of this study is to investigate the effect of CBZ on LV diastolic function 
in HOCM as compared with bisoprolol. 
Methods: Twenty-three patients with HCM (11 pts; HOCM, j2 pts; non-obstructive HCM; 
HNCM) were examined. To assess LV filling pressure, pulsed-wave Doppler, color M- 
mode and tissue Doppler echocardiography were performed before and 90 min after oral 
administration of CBZ (300 mg), and after treatment of bisoprolol (5 mg/day, 10 days) 
Early (E) and late (A) diastolic LV inflow velocity (E) and flow’propagation velocity (FPV) 
and early diastolic mitral annulus velocity (Ea) were measured. E/FPV and EiEa were 
calculated as indices of LV filling pressure. 
Results: In HOCM, pressure gradients at LV outflow tract were markedly decreased after 
oral admi&tration of CBZ (from 83 t 42 to 40 * 33 mmHg, p c 0.005). Bisoprolol also 
decreased LV outflow obstruction (from 83 + 42 to 44 + 40 mmHg, p < 0.005). After 
administration of CBZ, EiFPV and EiEa were significantly decreased in both HOCM 
(from1.75r0.53to1.32~0.28,p~0.05,from18.9~6.2to14.8i5.0,p~0.05,respec- 
tively) and HNCM (from 1.75 * 0.58 to 1.41 r 0.73, p < 0.05, 13.0 f 4.3 to 9.7 + 3.6, p < 
0.01, respectively). However, E/FPV and E/Es were not changed by bisoprolol in HNCM. 
The effects of CBZ and bisoprolol on LV diastolic function were different in patients with 
HCM. 
Conclusions: CBZ improved LV diastolic function in HCM, whereas bisoprolol did not 
affect it. It is concluded that the primary lusitropic effect of CBZ rather than after load 
reduction on LV might have contributed to the improvement of diastolic function in 
HOCM. 
4:oo p.m. 
1009-206 Impairment of Coronary Vasodilator Capacity Is Predictive 
of Unfavorable Outcome in Patients With Hypertrophic 
Cardiomyopathy 
France Cecchi, Roberto Gistri, lacopo Olivotto, Roberto Lorenzoni, Giampaolo Chiriatti, 
Francesco Mazzuoli, Albe,rto Dolara, Paolo G. Camici. Card!ologia San Luca Ospedale 
careggi’ FIrem?, My 
Background. Coronary vasodilator capacity (CVR) is impaired in patients with hyper- 
trophic cardiomyopathy (HCM), especially in the presence of systolic dysfunction. How- 
ever, the prognostic value of coronary flow reserve in the long term is unknown. We 
evaluated the outcome of a consecutive group of HCM patients who underwent measure- 
ment of myocardial blood flow (MBF) between 1989 and 1993. Methods. Fifty-five 
patients (M/F 40115, age 44*16 years) were followed for over 7 years following assess- 
ment of regional MBF by by positron emission tomography using 13N-ammonia at base- 
line (Bas) and after dipyridamole administration (Dip). Results. Seventeen of the 55 
patients (25%) had an unfavorable outcome, including 11 with heart failure (with 4 
deaths) and 6 with sustained ventricular arrhythmias, (with 1 cardiac arrest and 3 sudden 
deaths). Compared with the uncomplicated patients, those wtth adverse outcome 
showed a significant reduction of CVR and absolute septum-free wall difference [S-FW]in 
Bas- and Dip-MBF (table). A CVRc2 had a 41% positive and a 94% negative predictive 
value for an unfavorable outcome (total accuracy 56%) These values became 60% and 
85%, respectively (total accuracy 76%), when CVR<P was combined with Bas-[S- 
FW]<O.Z mllmglg): at multivariate analysis, such association had a 7.6 odds ratio for a 
negative outcome (95%CI, 2.5-23.3; p<O.O05), independent of age and NYHA class. 
Conclusions. Impairment of coronary vasodilator capacity is associated with adverse 
long-term outcome in HCM patients, especially in the presence of a homogeneously 
blunted perfusion. Conversely, non-homogeneous segmental myocardial blood flow is 
associated with a benign prognosis, possibly reflecting areas of maintained perfusion. 
Uncomplicated Unfavorable P value 
COtme tl=38 outcome N=17 
Mean CVR 1.9+0.7 1.6+0.4 <0.05 
Bas[S-FW] (mliminlg) 0.32+0.24 0.13i;o.10 <0.02 
Dip[S-FW] (ml/min/g) 0.49+_0.46 0.19*0.15 <0.02 
With CVR<2 and Bas [S-FW] co,2 8 (21%) 12 (71%) co.005 
4:12 p.m. 
1009-207 An Abbreviated 2-Step Dobutamine Provacation to Aid in 
Guidance of Alcohol Septal Ablation for Hypertrophic 
Obstructive Cardiomyopathy 
John B. Patterson, Kevin M. Rankin, Sanjay K. Gandhi, Dalane W. Kitzman, Gregory A. 
Braden. Wake Forest University School of Medicine, Winston-Salem, NC 
Background: Selective ETOH Septal Ablation (SA) is rapidly becoming the treatment of 
choice for symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). 
However, because uncertainty remains about the dosage of ETOH administered and the 
number of septal perlorators which need to be treated, a significant number of patients 
need repeat procedures. As resting outflow track gradients in HOCM are load depen- 
dent, and therefore variable at the time of ETOH SA, another assessment of efficacy is 
needed. 
Methods: We report our initial experience at Wake Forest University utilizing resting and 
provoked Doppler gradients from an abbreviated P-step Dobutamine infusion at 5 and 20 
mcglkgimin in the cath lab to assess the adequacy of treatment during ETOH SA. 
Results: 8 patients were treated between 10199 and Q/00; 7 had intra-cath lab Dob- 
&mine provocation. All patients had either rest or provoked gradients exceeding 100 
mmHg and mean septal wall thickness was 21 mm. Initially, the most proximal reason- 
able sized septal perforator was cannulated. The territory supplied was confirmed by 
optison localization in the septum. 1.5-2.5~~ of ETOH was infused and Doppler gradi- 
ents reassessed. Additional ETOH was infused (1 patient) or another septal treated (3 
patients) if either rest or Dobutamine provoked substantial gradients remained. Late fol- 
low-up rest and provoked gradients were available in 4 patients. Resting and Dob- 
utamine provoked gradients were markedly reduced with ETOH SA and these gradient 
reductions were sustained at follow-up. 
Pre-Treatment Post-ETOH Follow-Up 
Rest 75 31* 20+ 
Dob. 185 50 54+ 
P coo1 .08 .40 
* P < 0.1 pre vs. ETOH MmHg) 
+ p ns ETOH vs. follow-up 
Conclusion: An abbreviated Dobutamine provocation protocol is a useful adjunct in 
performing ETOH SA and altered treatment strategy in over 50% of patients. The reduc- 
tion in provoked gradients in the cath lab may predict durable long-term results. 
4124 p.m. 
1009-208 Systolic Outward Movememt of Left Ventricular Apical Wall 
as Seen by Tagging MR Images in Patients With Apical 
Hypertrophic Cardiomyopathy 
Masaki Tsukamoto, Satoshi Hirasaki, Kazuto Yamamoto, Akiko Matsuo, Hiroyuki Matsui. 
Takashi Nakamura, Akihiro Azuma, Hiroki Sugihara, Toshiro Kuribayashi, Masao 
Nakagawa. Kyoto Prefectural Yosanoumi Hospital, kyoto, Japan, Kyoto Prefectural 
University of Medicine, Kyoto, Japan 
Background: Tagging MR image is used to evaluate regional wall motion of the left ven- 
tricle. Our aim was to evaluate the apical wall motion of the left ventricle using tagging 
MR images in patients with apical hypertrophic cardiomyopathy (APH). Methods: We 
studied 31 patients with APH. The tagging image of the left ventricle (LV) was obtained 
from the four-chamber view. We recorded displacement of myocardial tags from end 
diastole to end systole perpendicular to the long axis of the LV. Wall thickness of the api- 
cal portion was determined as the total of the septum and lateral wall at end diastole in 
MR image. All the patients were examined echocardiographically to detect the paradoxic 
jet flow (diastolic jet flow away from the apex). We scored the defect of beta-methyl-p- 
iodophenyl-pentadecanoic acid (BMIPP) from normal, 0 to absent, 3. Results: Ins 14 
patients, apical tags moved inward throughout the systolic phase but in the remaining 17, 
the tags moved outward away from the long axis during late systole. In these17 patients, 
apical hypertrophy was more severe (3.53*0.68cm vs 2.85+0.64cm, p<O.O5), paradoxic 
jet flow was more frequent (64% vs 14%, p-x0.05) and defect score of BMIPP was higher 
(2.1+0.6 vs 1.3+0.7, p&01) than in those without outward movement. Cardiac events 
occurred in 4 patients: sudden death in one, ventricular tachycardia in one and angina1 
attack in another 2 patients. In all the 4 patients, the apical tags moved outward. This sys- 
tolic outward movement may be related to the obliteration of the apical lumen as sug- 
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gested by the paradoxic jet flow, which will cause high mural pressure and may lead to 
the myocardrat ischemia or damage. Conclusion: Myocardial tagging is useful in detect- 
rng the outward movement in APH and rn predichng the occurrence of cardiac events. 
4:36 p.m. 
1009-209 Effect Of The Degree Of Left Ventricular Hypertrophy On 
Hemodynamic Adaptation To Exercise In Hypertrophic 
Cardiomiopathy 
* p<o.o5, ** p<O.O05, compared wrth group 1; *** p<O.O05 compared with controls 
Conclusions: These results indicate that LA size is an important predictor of exercise 
performance, a findrng that may be related to impaired atriai transport mechanism and 
associated LV diastolic function during exercise LA size should be considered in studies 
that rely on MVO, for determination of success of therapies in patients with HCM. 
POSTER SESSION 
Quirino Ciampi, Sandra Betocchi, Anna Violanie, Fiore Manganelli, Maria A. Losi, Giulia 
Sica, Carlo G. Tocchetti, Raffaella Lombardi, Teresa Pellegrino, Esther Campopiano, 
Mariano Aversa, Atberto Cuocolo, Massimo Chiariello. Fed&co /I University school of 
Medicine, Naples, b/y 
1264 Mechanical and Neurohormonal 
Mechanism Effecting Myocardial Function 
Background Massive LV hypertrophy (LVH) rn hypertrophic cardiomyopathy (HCM) car- 
ries high risk of sudden death. Our study assesses hemodynamic adaptation to exercise 
by ambulatory radionuclide monitoring of LV function (VEST) in HCM with different 
degrees of LVH and in controls. Methods. We studied 10 controls and 44 HCM patients; 
these ware divided into 3 groups according to the number of hypertrophied LV segments: 
6 with 1 segment (mild LVH), 26 with 2 segments (moderate LVH), 12 with >=3 LV seg- 
ments (severe LVH). During VEST, they exercised on a treadmill (Bruce protocol). VEST 
data were analyzed at baseline, at 3 min and at peak exercise (Pex). Stroke volume (SV) 
and peripheral resistance (PR) were expressed as a % of basekne, for ejection fraction 
raw date are supplied. Results. There were no basal differences in age, NYHA functional 
class, incidence of angina, presence of LV tract obstruction among 3 HCM groups. In 
comparison to HCM with moderate and severe LVH, those with mild LVH had a lower 
ejection fraction (74t6, 76t6, 65k9, p=.Oi) and a better left atrial fractional shortening, 
an estimate of LV end-diastolic pressure (22+7, 16r6, 25+9, p=.O3). During exercise, 
ejection fraction and SV increased in controls, did not change in HCM with mild and fell in 
HCM with moderate and savare LVH (p<.OOl and p=.OOl by ANOVA, respectively, fig- 
ure). Pressure-rate product and PR were similar among 3 HCM groups. Conclusion. 
High degree of LVH reduces wall stress and leads to supernormal systolic function at 
basekne, while it causes a drop in SV and ejection fraction during exercise, probably 
related to exercise-Induced ischemia. This might be the background for reported high risk 
of sudden death in HCM with severe LVH. 
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1264-43 Body Mass Index, Obesity, and Cachexia vs Survival in 
Chronic Heart Failure: Results From the ELITE 2 Study 
S&fan D. Anker, Constantinos H. Davos, Darrel Francis, Robert Segal, Emanuela 
Santoro, Philip A. Poole-Wilson, Bertram Pitt, Andrew J. S. Coats. National Heart & Lung 
Institute, London, United Kingdom, Franz-Volhard-Klinik,in;k, Char26 Campus Berlin-Buch, 
Berlin, Germany 
Background: The relationship between survival and body weight and body weight 
changes has not been studied in a contemporary large scale population of chronic heart 
failure (CHF) patients. Whether obesity is frequent in CHF and how it relates to survival 
patients is not known. Methods: We included in the analysis 3084 patients of the ELITE 
II study (31% female, age 71t7y, median folfow-up 18 months, 513 deaths) in whom 
body weight and height data were available for assessment of body mass index at base- 
line (BMI: 26.2e4.44 kg/m2, weightlheight2) and at predetermined intervals during the 
study. Results: Higher BMI was strongly related to improved survival (risk ratio [RR] 
0.94, 95% confidence interval [Cl] 0.92-0.96). Patients in the 4th BMI-quintrle (Q, BMI 
26.81-29.40 kg/m2) had the lowest mortality (7.2% at iy, 12.8% at 2~). Compared to 
patients in the 4th BMI-Q, mortality was similar in obese patients (5th BMI-Q: 729.40 kg/ 
m2, RR 1.29, p=O.l3), but higher in the 3rd (RR 1.60, p=O.O03), 2nd (RR 1.80, 
p=O.O002), and 1st BMI-Q (mortality 17.2% at ly, 29.7% at 2y, BMic22.73, RR 2.50, 
p<O.OOOi). The cumulative frequency of weight loss >7.5% was 5.4, 10.2, 16.6 and 
24.2% at 6, 12, 18 and 24 months, respectively. Survival after the development of 
cachexia was reduced compared to that in patients without weight loss (pcO.0001). 
Female sex (RR 1.54) age (RR 1.028, both pcO.OOOl), higher baseline serum uric acid 
levels (RR 1.127 per 100 umol/L, p=O.O02) and higher baseline BMI (RR 1.02 par kglm2, 
~~0.05) independently predicted future development of weight loss. Conclusion: Low 
body weight and weight loss are important prognostic indicators of survival in patients 
with CHF. Mildly obese patients show the best survival. In CHF, a higher BMI may indi- 
cate preserved metabolic efficiency and/or energetic reserves, and should not be consid- 
ered an adverse risk factor. 
1009-210 
4:48 p.m. 
Left Atrial Dimension Predicts Impaired Exercise 
Performance in Non Obstructive Hypertrophic 
Cardiomyopathy: Relation to Impaired Left Ventricular 
Systolic and Diastolic Function but Not to Severity of Left 
Ventricular Hypertrophy 
David A. Begley, Saidi Mohiddin, Lameh Fananapazir. National Institutes of He&h, 
Bethesda, MD 
Background: Patients with hypertrophic cardiomyopathy (HCM) often have exercise lim- 
itation. We studied the relatron of cardiac chamber dimensrons, left ventricular (LV) mass, 
LV systolic and diastolic function and myocardiat perfusion to exercise performance in 
patients wtth non-obstructive HCM. 
Methods: Two age- and gender-matched groups of patients with LV gradients ~30 mm 
Hg ware selected based on maximum oxygen consumption (MVOe) during symptom-lim- 
ited upright bicycle exercise testing with breath-by-breath gas analysis: group1 (n=29), 
MVO, < 2.0 mlO&$min; and group 2 (r&9), MVO, > 20 mlOz/kg/min. Controls were 21 
normal subjects. All patients had echocardiograms and magnetic resonance imaging. 
Rest and exercise radionuclide angiography was performed on 35 patients and exercise 
thallium scintigraphy rn 37 patients. 
Results: There was a significant negative correlation between MVO, and left atrial (LA) 
diastolic dimension (p<O.Ol), and exercise ejection fraction (EF, ~~0.05) in the HCM 
patrents. Multiple regression analysis including age, gender, and LV mass index (LVMI) 
demonstrated that LA dimension was an independent predictor of MV02 and exercise EF 
(p<O.OOl, and ~~0.005, respectively). Exercise EF also con&tad with MVO, (r=O.43, 
p<O.O5). Patients in group 1 had reduced peak filling rate (PFR) and tended to have lower 
t&me to peak filling rate (TPFR) compared with group 2. There was no correlation 
between LVMI and MVO.,, PFR or TPFR. Myocardral perfusion abnormalities were 
present in 16/20 patients in group 1 and 13115 patients in group 2 (p>O.O5). 
LAmm LVMI MVOe Rest EF Exercise PFR TPFR 
tim” mlOe/ (96) EF (%) mlisec ms 
kglmin 
Group 1 41+9 88t36*** 15+4 68+13 7l_t13 2.811.0 514t97 
1264-44 Valvular-Ventricular Remodeling and Mitral Leaflet 
Geometry in Dilated Cardiomyopathy 
David T. M. Lai, Paul Dagum, Tomasz A. Timek, Frederick A. Tibayan, David Liang, 
George T Daughters, II, Neil 6. Ingels, Jr., D. C. Miller. Stanford Universify Schoolof 
Medicine, Stanford, CA, Research Institute of the Palo Alto Med,cai Foundation, Palo 
Alto, CA 
Background: The effect of valvular-ventrrcular remodeling on mitral leaflet 3-D geometry 
in dilated cardiomyopathy (DCM) is unknown. 
Methods: In 8 sheep, radiopaque markers were implanted in the mitral annulus, midline 
anterior and posterior mitral leaf@ papillary tips, and left ventricle (LV). Following 
recovery, 3-D marker coordinates were obtarned by biplane videofluoroscopy and rapid 
pacing was initiated. At onset of DCM with mild-moderate mitral regurgitation, marker 
coordinates were compared with control values at end-systole. Tethering distance from 
papillary tips to mid-anterior mitral annulus, major and minor annular axes, chordal 
“length” from papillary tips to leaflet edges and mrdline leaflet length were measured. 
Leaflet geometry was measured relative to a best-fit annular plane. 
Results: 
Control (*SD) Cardiomyopathy (*SD) p value 
LV volume (ml) 124i45 159 +57 c.001 
Anterior papillary tip tethering (mm) 40 i 5 41 *4 ,003 
Posterior papillary tip tethering (mm) 43 * 6 45 i 6 .Oi 
Minor annular axis (mm) 28?3 35i3, <.OOl 
Major annular axis (mm) 38 f 4 43*3 c.001 
Anterior leaflet length (mm) 21.2tl.8 24.3 i- 2.7 .02 
Posterior leaflet length (mm) 11.7e2.4 13.3 + 2.6 <.OOl 
Anterior papillary to posterior leaflet 25.0 t 4.0 26.7 + 3.5 <.OOl 
chordae tendinae (mm) 
Posterior papillary to anterior leaflet 28.9 f 6.6 30.5 + 6.0 .08 
chordae tendinae (mm) 
Group 2 
Controls 
35i8” a5i45*** 29r6** 76+14 83~14 3.9-tl .o* 462?55 
31*5** 53*12 31*12*’ 
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Figure depicts direction and magnitude of leaflet displacement (mm, ~~0.05). 
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Conclusion: Dilated cardiomyopathy perturbed mitral leaflet geometry, with the basal 
portion of both leaflets being restricted. Most interestingly, despite LV and annular dilata- 
tion and increased papillary tip tethering, lengthening of the chordae tendinae and/or 
leaflets prevented similar restriction of the leading edges of the leaflets. Such chordal/ 
leaflet remodeling is surprising and needs to be taken into account during valve repair. 
1264-45 In-Vitro Delivery of Non-Stimulatory Cardiac Contractility 
Modulating Electric Signals Improve Intrinsic Contractile 
Function of Cardiomyocytes Isolated From Dogs With 
Chronic Heart Failure 
Victor A. Maltsev, Bella F&on, Yuval Mika, Nissim Darvish, Sidney Goldstein, Shlomo 
Ben-Haim, Hani N. Sabbah. Henry FordHealth System, Detroit, MI 
Background: We previously showed that global LV function improves acutely in dogs 
with heart failure (HF) during regional delivery of a non-stimulatory electrical cardiac con- 
tractility modulating (CCM) signal (/mpu/se Dynamics, Inc., Israel) from epicardially 
placed myocardial transvenous electrodes. In the present study we examined whether 
the beneficial effects of CCM signals on global LV function in dogs with HF result from 
improved intrinsic contractile function of cardiomyocytes and whether delivery of the 
CCM signals is associated with enhancement of Ca2+ transients. 
Methods: Cardiomyocytes were isolated from 5 dogs with HF (LV ejection fraction 
~30%) produced by multiple intracoronary microembolizations. Extent of cardiomyocyte 
shortening (S), peak velocity of shortening (dS/dt) and peak velocity of relengthening 
(dR/dt) were measured by edge detection method. Peak (Fmax) and integral (IF) of Ca” 
transients were assessed from Flue-3 fluorescence measurements. Data were collected 
at baseline and during CCM signal delivery. For each parameter, the percent change 
from baseline was calculated. 
Resulk: The results are shown in the table. Application of the CCM signal to isolated 
cardiomyocytes significantly increased S, dS/dt and dR/dt as well as Fmax and (IF) 
Baseline CCM Signal % Change 
s we 4.9 A 0.5 6.0 -f: 0.6* 27 f 5 
dS/dt (pm/set) 72 A 8 831: 10* 19*5 
dR/dt (pm/sac) 72+9 89 r 10’ 32 t 7 
Fmax (mV) 119i32 135*35* 19+5 
IF (mV.sec) 34r9 40~10' 19*5 
*=P<O.O5 Baseline vs. CCM Signal 
Conclusions: Delivery of CCM signals to isolated tailing cardiomyocytes improves intrin- 
sic contraction and relaxation and enhances Ca2+ transients. These observations pro- 
vide an explanation for the observed improvement of global LV function in dogs with HF 
during CCM signal delivery and reinforces the potential usefulness of this approach as an 
adjunct to the treatment of chronic HF. 
1264-46 Cardiac Sympathetic Nerve.Terminal Dysfunction in Pacing- 
Induced Heart Failure is Associated With the Reduction of 
Nerve Growth Factor 
Fuzhong Qin, Suzanne Y. Stevens, Chang-seng’Liang. University of Rochester Medical 
Center, Rochester, NY 
Background: Recent studies suggest that norepinephrine (NE) decreases myocyte pro- 
duction of nerve growth factor (NGF) and that this may lead to reduction of cardiac adren- 
ergic nerve fibers. In this study, we proposed to measure whether NGF is reduced in the 
failing myocardium where NE storage is known to be reduced. 
Methods: Adult mongrel dogs with rapid pacing-induced heart failure (HF, 225 beatslmin, 
8 weeks) or control were used. We measured that 1) plasma NE (radioenzymatic assay), 
2) NGF and NGF receptor t&A protein expression (Western blot and immunohistochem- 
istry), 3) neuronal catecholamine (CA) profiles (glyoxylic acid-induced histofluorescence) 
and 4) neuronal tyrosine hydroxylase (TH) profiles (immunohistochemistry). 
Results: Table shows plasma NE (@ml) was increased in HF. This was associated with 
decreased myocardial NGF and trkA protein (optical density), neuronal CA profiles 
(counts/field) and TH profiles (counts/field). A decrease in tissue NGF or trkA in HF was 
confirmed by immunohistochemistry. 
Conclusion: Myocardial NGF and NGF receptor trkA were decreased in HF. These 
changes were associated with elevated plasma NE, and decreased neuronal CA and TH 
profiles. The results suggest that in HF, excess NE reduces tissue NGF production, which 
is probably responsible for the decreases of CA and TH in the heart. 
Group Plasma NE NGF protein TrkA protein CA profiles TH profiles 
Control 02610.08 11.7*0.5 4.1r0.3 498+34 823i72 
HF 1.40+0.33* 8.9+0.8* 3.2+0.8' 193r25* 321+48* 
n=6. Values are mean&E, ‘PiO.05 vs control. 
1264-47 Antioxidants Prevent the Alterations in Cardiac Sympathetic 
Nerve Terminal Function and P-Adrenergic Receptor 
Density in Heart Failure 
Fuzhong Qin, Junya Shite, Robin Stuart, Suzanne Y. Stevens, Chang-seng Liang. 
University of Rochester Medical Center; Rochester, NY 
Background: We have shown previously that norepinephrine (NE) administration pro- 
duces sympathetic denervation and P-adrenergic receptor (PAR) downregulation, and 
that these changes are prevented by antioxidant vitamins. In the present study, we pro- 
posed to determine whether antioxidant vitamins also prevent sympathetic nerve terminal 
abnormalities and PAR downregulation in chronic heart failure (CHF). 
Methods: Antioxidant vitamins (A: 20 mg, C: 200 mg, and E: 200 mg, 8 weeks) were 
administered to rabbits with pacing-induced CHF and sham-operated control animals. 
We measured cardiac function (echocardiography), plasma [NE] (HPLC), cardiac oxida- 
tive reserve ([GSHl/[GSSG] ratio), cardiac CA profiles (histofluorescence, counts/field), 
and NE uptake-l site density and DAR density (radioligand assay, fmolimg). 
Results: Rapid cardiac pacing produced CHF as evidenced by cardiac dilation, 
decreased LV systolic shortening, and increased plasma [NE] (data not show). These 
changes were associated with decreased cardiac [GSH]/[GSSG] ratio, CA profiles, NE 
uptake site density and DAR density. Antioxidant vitamins had no effects in control ani- 
mals. In contrast, vitamins administration in CHF not only reduced the cardiac dilation 
and systolic dysfunction, but also abolished the decreases of [GSH]/[GSSG], CA profiles, 
NE uptake site density and PAR density in CHF (Table). 
Conclusion: Oxidative stress plays an important role in the reduction of neuronal CA, 
cardiac NE uptake, and DAR density in CHF. Antioxidant therapy may be beneficial in the 
treatment of CHF. 
Group [GSH]/[GSSG] CA profiles NE uptake PAR 
Control 152+24 194*9 347239 100+8 
CHF 24i6* 125~10' 200~~17 681-8* 
CHFcvitamins 71*15# 214+18# 3liLt15# 97?5# 
n=6-9. Values are mean&E. *P<O.O5 vs Sham. #PcO.O5 vs CHF. 
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1265-48 Poly-ADP-Ribose Synthetase (PARS)-Inhibition Protects 
Against Myocardial and Endothelial Repetfusion Injury 
After Heart Transplantation 
Gabor Szabo, Csaba Szabo, Susanne BLhrle, Siegfried Hagl. University of Heidelberg, 
Heidelberg, Germany, /no&k Corporation, Beverly, MA 
Free radical production and related cytotoxicity during ischemia/reperfusion may lead to 
DNA strand-breakage which activates the nuclear enzyme p&y-ADP-ribose synthetase 
(PARS) and initiates an energy consuming, inefficient repair cycle, with transfer of the 
ADP-ribosyl moiety of NADc to protein acceptors. The aim of the present study was to 
investigate the effects of the inibition of PARS on myocardial and endothelial function dur- 
ing reperfusion after reversible hypothermic ischemia in a rat heart transplantation model. 
lntraabdominal heterotopic transplantation was performed in Lewis rats. After one hour of 
ischemic preservation, reperfusion was started after application of either saline vehicle 
(control, n = 12), or PJ34 (3 mgikg) a selective PARS-inhibitor (n=12). Coronary blood 
flow (CBF), left ventricular pressure (LVP), its first derivative (dP/dt), end-diastolic pres- 
sure (LVEDP), isovolumic relaxation constant (TE) were measured after 60 minutes and 
24 hours of reperfusion. Endothelium-dependent vasodilatation to acetylcholine (ACH) 
and endothelium-independent vasodilatation to sodium nitroprusside (SNP) were also 
determined. After one hour, CBF was significantly higher in PJ34 group in comparison to 
control (3.84kO.39 and 2.88*0.35, mliminlg, ~~0.05). The PJ34 group showed a better 
recovery of systolic function and myocardial relaxation (maximal LVP: 114+3 vs. 83+4 
mmHg, ~~0.05, maximal dP/dt: 4103*237 vs. 174Oki 16 mmHg/s, ~~0.05, TE: 11.3+1 .l 
vs. 18.2+1.6 ms, ~~0.05, intraventricular volume=80 ~1). While the vasodilatatory 
response to SNP was similar in both groups, ACH resulted in a significantly higher 
increase in CBF in the PJ34 group (98+15% vs. 51+15%, p<O.O5). LVEDP was similar in 
both groups. After 24 hours, there was no difference between the groups in basal CBF, 
LVP, dP/dt, TE, LVEDP and the response of CBF to SNP However, ACH led to a still sig- 
nificantly higher increase in CBF in the PJ34 group (134+38% vs. 88*14%, ~~0.05). 
Thus, PARS inhibition improves myocardial and endothelial function during early rep&u- 
sion after heart transplantation and have a persisting beneficial effect against reperfusion 
induced graft coronary endothelial dysfunction. 
1265-49 The Heparan Sulfate Proteoglycan-Antithrombin Pathway in 
Postischemic Hearts 
Carlos A. Labarrere, David R. Nelson, Slava Titov, Jeanne C. Helmreich, Steven J. Miller. 
Methodist Research Instituie, Indianapolis, IN 
Background: The deposition of fibrin and subsequent ischemia within the heart is mainly 
prevented by the presence of antithrombin in blood vessels and cardiomyocytes. We 
asked if changes in myocardial antithroinbin were directly associated with the outcome of 
heart transplant recipients and studied whether the antithrombin binding was mediated 
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by heparan sulfate proteoglycan molecules. Methods: Human and rat myocardlal tis- 
hues were used. Endomyocardial biopsies (n=7755) from 141 cardiac transplant recipi- 
ents were studied immunohistochemically for antithrombin and the heparan sulfate 
proteoglycan (HSPG) molecules perlecan, syndecan-I, and syndecan-4. Coronary 
artery disease was evaluated angiographically (3.8 i 0.2 angiogramsipatient). A left 
anterior descending ligation rat model of ischemia/infarction was used to assess postis- 
chemic changes in myocardial antithrombln and perlecan mRNA (n=45). Results: Anti- 
thrombin was identified in the microvasculature and in cardiomyocytes. The loss of 
cardiac antithrombin was associated with significantly increased risk [RR(95% Cl)] of cor- 
onary artery disease [7.5(3.5-l&l)] and graft failure [10.3(2.9-36.5)]. The recovery of 
cardiac antithrombin following an initial loss significantly reduced the risk of CAD 
(p=O.O2) and graft failure (p=O.O4). Interestingly. although syndecan-I and -4 were not 
consistently identified, perlecan protein in all heart transplant biopsies colocallzed with 
vascular antithrombin reactivity. However, perlecan mRNA was detected in all rat hearts 
irrespective of the presence or absence of anbthrombin binding. Conclusions: The data 
suggest that the bmding of antithrombin in ischemic hearts, which is directly associated 
with outcome, is mediated mainly by the HSPG perlecan, and the loss of antithrombin 
binding is associated most probably with post-translational changes. 
caval vein 21.2 cm and its collapse index < 40% were considered as signs of RAP> 5 
mmHg. See table 1. * pc.005 Conclusions: In patients with CHF failure physical exams- 
nation has a limited reliability to identifying hemodynamic alterations. Echo-Doppler indi- 
ces can greatly improve the evaluation of hemodynamic abnormalities which could have 
an important role in maneglng unloading therapy in these patients. 
Clc2.2 L/minim2 PWP>18 mmHg RAP>5 mmHg 
Physical signs 
Echo-Doppler 
SfSlS 
25% 
99%’ 
spec Sens Spec Sells spec 
72% 17% 88% 50% 76% 
98%* 91%* 82% 80%’ 98%* 
1267-59 Noninvasive Differentiation of Pseudonormal From Normal 
Transmitral Flow by Doppler Total Ejection lsovolume (TEI) 
Index: A Simultaneous Echocardiography-Catheterization 
Study in Patients With Anteroseptal Acute Myocardial 
Infarction 
1265-50 Assessment of Eotaxin Chemokine Levels and Mast Cell 
Counts in Posttransplant Rat Hearts 
Alaa ElDin Abdelrheim, Yutaka Orsuji, Kunitsugu Takasaki, Toshinori Yuasa, Eiji 
Kuwahara, Hui Zhang, Keiko Matsukida, Akira Kisanuki, Shinichl Minagoe, Chuwa Tei 
Kagoshima University, Kagoshima, Japan 
Martin Zweifel, Kathanna PI&, Thomas Schaffner. Paul Mohacsi. Division of Cardiology, 
University Hospita/, Bern, Switzerland, lnsfifufe of Pathology. Univewty Hospitai, Bern, 
Switzeriaand 
Background: Increase in mast cell counts in human posttransplant hearts, and its possi- 
ble impiicatlon in myocardial fibrosis has been described. The chemokine eotaxin has 
been shown to attract mast cells in human skin via the receptor CCRB. Since eotaxin 
mANA was shown to be present in the human heart, but no data on eotaxin protein 
expression in posttransplant hearts are available so far, we hypothesized, that eotaxin 
levels might be Increased in posttransplant hearts, thus leading to an increase of mast 
cell counts. Methods: An allogeneic (Brown Norway to Lewis) and an isogeneic (Lewis to 
Lewis) model were used, in which eotaxln levels were measured by ELISA of homoge- 
nates from heterotopically transplanted hearts and from recipient hearts five days after 
transplantation. Hearts from anesthetized and hepann infused animals served as con- 
trols for the donor hearts, and hearts from animals which underwent laparatomy (sham 
operation) served as controls for the recipient hearts. Plasma samples were collected 
before the operation and at the time of organ harvest. Mast cells were counted on histo- 
logic sections stained with Giemsa stain or naphthol chloroacetate I new fuchsin. 
Results: Eotaxin levels were significantly increased only in posttransplant hearts com- 
pared to control hearts, irrespective of the presence (allogeneic group [n = 41: 0.53 +I- 
0.21 vs 0.16 +/- 0.03 pg / mg protein [mean +/- SD], p < 0.05) or !he absence (isogeneic 
group [n = 41: 0.65 +I- 0.22 vs 0.28 +/- 0.11 pg i mg protein, p < 0.05) of gross leucocyte 
infiltration. However, mast cell counts did not change significantly within the five day 
observabon penod, although a tendency towards decrease was observed in hearts which 
underwent an acute rejection reaction (0.72 +I- 0.46 vs 2.49 +I- 2.85 per mm2). Plasma 
eotaxin levels did not differ significantly between before, and five days after operation. 
Conclusions: Although eotaxin levels were increased in posttransplant hearts, mast cell 
counts did not change significantly. These findings should lead to further investigations of 
function. and particular localization of eotaxin protein and mRNA in the posttransplant 
heart, and the behaviour of cardiac mast cells over the time. 
Background: Differentiation of pseudonormal from normal transmitral flow is important 
in patients with potential congestive heart failure. Patients with pseudonormal mitral flow 
usually have left ventricular dysfunction as well, which can be estimated by recently pro- 
posed combined systolic and diastolic Doppler index - total ejection isovolume (TEI) 
index. The purpose of this study was to Investigate whether differentiation of pseudonor- 
mal from normal transmitral flow by TEI index is feasible or not. Methods: Subjects con- 
sisted of consecutive 26 patients with anteroseptal acute myocardial infarction (AMI) and 
transmitral Doppler flow E/A 2 1. Based on pulmonary capillary wedge pressure (PCWP), 
patients were divided into pseudonormal group (PCWP 2 18 mmHg, n = 12) and normal 
group (PCWP < 18 mmHg, n = 14). TEI index was measured as (a b)/b where a is the 
interval between the cessation and onset of mitral flow and b is the aortic flow ejection 
time. Results: 1) TEI index was significantly higher in pseudonormal group compared to 
normal group (0.75 + 0.13 vs 0.49 f 0.08, P c 0.001). 2) There was a close correlation 
between TEI index and PCWP (r’ = 0.82, P< 0.0001). 3) By setting TEI index ~0.6 as 
diagnostic criteria of pseudonormal mitral flow, the index differentiated pseudonormal 
from normal mitral flow with sensitivity, specificity, and over all accuracy of lOO%, 93%, 
and 97%, respectively. Conclusion: TEI index allows simple and nonInvasive differentia- 
tion of pseudonormal from normal mitral flow in patients with anteroseptal AMI. 
Pseudonormal Mitral Flow 
TEI index 
TEI index > 0.6 
12 
TEI index < 0.6 
0 
Normal Mitral Flow 1 13 
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1267-58 In Patients With Chronic Heart Failure Echo-Doppler 
Monitoring is More Accurate Than Physical Examination to 
Detect Severe Hemodynamic Alterations 
Soccorso Capomolla, Oreste Febo, Giampaolo Guazzotti, Angelo Caporotondi, Marco 
Gnemmi, Andrea Mortara, France Cobelli, Giandomenico Pinna, Roberto Maestri. 
Fondazione S. Maugeri, IRCCS, F’avia, Montescano(Pawa), /t&y 
Background: In patients with chronic heart failure(CHF) the diagnostic power of physical 
signs for estimating hemodynamic profile is uncertain. Aims: to compare the relative reli- 
ability of clinical signs and echo-Doppler for Identifying severe hemodynamic alterations 
in patients with CHF. Methods: 268 consecutive patients with CHF (EF 25t7%) and 
sinus rhythm, evaluated for cardiac transplantations, were studied. Physical examnation 
were obtained by four experienced cardiologists before rigth-sides cardiac catheteriza- 
t!ons and simultaneous Echo-Doppler studies. The end-points were: the identification of 
low output( cardiac index < 2.2 I/min/m2 SSA); the high pulmonary wedge pres- 
sure(mean PWP>18 mmHg); the high right atrial pressure( mean RAP>5 mmHg). Signs 
of peripheral hypoperfusion and/or a proportional atierial pressure(systolic-diastolic pres- 
sure/systolic pressure’lOO)c25% were constdered as physlcal signs of low output; audl- 
ble third heart sound pulmonary r&s and/or orthopnea as sign of high PWP and 
distension of external jugular veins or the presence of epatojugular reflux at 45” and or 
epatomegaly( liver margin felt >3 cm below the costal margin& sign of high RAP Cl was 
measured by PW-Doppler using aortlc method: an DT of early diastolic transmitral flow 
<130 msec was considered as an index of high PWP End-inspiratory diameter of inferior 
1267-60 Doppler Tissue imaging for Assessment of Impaired Left 
Ventricular Relaxation in Patients With Left Ventricular 
Systolic Dysfunction 
Alan Waggoner, Giridhar Vedala, Benico Barzilai, Victor G. Davila-Roman. Washington 
University School of Medicine, St LOUIS, MO. 
Invasive studies have demonstrated progressive impairment of myocardial relaxation with 
worsening left ventricular systolic dysfunction (LVD). However, patients with LVD often 
have variable findings of diastolic function when assessed by pulsed Doppler echocardio- 
graphic measurements of LV relaxation and filling. Doppler tissue imaging (DTI) has 
been reported to be a more reliable non-invasive method to identify impaired LV relax- 
ation due to its relative load-independence. We evaluated 37 patients with LVD (17 
ischemic etiology, 20 idiopathic) and 14 normal controls of similar age (55+12 vs 47 i 19 
years, p=ns). Patients with LVD were divided into two groups based on LV ejection frac- 
tion: <30% (SEV LVD, n=Zl), 31-50% (MILD LVD, n=16). The early diastolic myocardial 
velocity (Em) was obtained by DTI at the LV basal lateral segment from the apical 4 
chamber view. Pulsed Doppler measurements included mitral E and A velocities (vel), Ei 
A ratio, and deceleration (DecT) and isovolumic relaxation times (IVRT). RESULTS 
(Table): Em was significantly lower in patients with mild LVD compared to normal controls 
and was further reduced in patients with severe LVD. Doppler mitral E vel and E/A were 
not significantly different among patients and normal controls. DecT was significantly 
shorter in patients with Severe LVD compared to those with mild LVD and normals. IVRT 
was longer in patients with mild LVD compared to other groups, but was similar in 
patients with severe LVD and normals. 
Em (cm/s) E vel (cm/s) E/A DecT (ms) IVRT (ms) 
NORMAL 16x5 80+30 1.5+.6 198121 97212 
MILD LVD 12*3# so*30 1.3t.8 244?106 122?35# 
SEV LVD 9+3n# 9oi30 2.0i1.4 153i47# 90+26* 
# p < 0.01 vs. NORMAL p < 0.03 vs. MILD LVD * p c 0.01 vs. MILD LVD 
CONCLUSIONS: DTI measurements of early diastolic myocardial velocities (Em) provide 
a more useful, non-invasive method to Identify abnormal LV relaxation in patients with 
LVD than pulsed Doppler mitral flow velocity Indices. There is progressive impairment of 
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LV relaxation with increasing severity of LV systolic dysfunction that is best identified with 
DTI Em. Further studk?.s are needed to correlate the significance of DTI measurements of 
diastolic function with clinical outcomes. 
1267-61 Parallel Systolic and Diastolic Function Abnormalities in 
Hypertensive Left Ventricular Hypertrophy With Normal 
Doppler Mitral Inflow: Insights From Doppler Tissue 
Imaging 
Craig S. Vinch, Jeffrey C. Hill, Theo E. Meyer, William H. Gaasch, Gerard P. Aurigemma 
University of Massadhusetfs Medical School, Worcester, MA, Lahey Ciinic, Burlington, 
MA 
Background: Hypertensive LV hypertrophy (LVH) is strongly associated with CHF even 
when ejection fraction (EF) and standard Doppler mitral inflow velocities (E, A, E/A ratio) 
are normal. Mitral annulus Doppler tissue imaging (DTI) has been proposed as a rela- 
tively load-independent method of assessing LV diastolic function. Accordingly, we inves- 
tigated whether DTI provided incremental information concerning diastolic dysfunction in 
pts with LVH, normal EF, and normal E/A. Methods: Data from 18 pts (age 57+14) with a 
history of hypertension, LVH by echo, normal EF (66+7%), and E/A >l were compared 
with 26 normal controls (C)(age 43+16). No subject had focal wall motion abnormalities 
or significant valvular disease. In addition to E, A, E/A ratio, deceleration time (TIT), and 
pulmonary vein flow velocities (S, D, S/D ratio), we obtained DTI early (EpTI ), late (AD71 ), 
and EoTl /AoTt ratio. Fractional shortening at the midwall (FSmw,%) was used as a sys- 
tolic function parameter which accounts for LV geometry (relative wall thickness) 
Results: LVH did not differ from C with regard to DT and pulmonary vein S/D ratio. Of the 
diastolic parameters, only E oTI discriminated LVH from 6; FSmw was lower in LVH, 
despite normal EF. 
Grow LV LA E:A DT S/D EnTl t EIEnTl t FSmw( 
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Methods: AF was induced by atrial stimulation in 26 open chest dogs. The maximum 
value of the first derivative of LV pressure curve (max dP/dt) was obtained by a Millar 
catheter for 100 consecutive cardiac cycles.lnitially, data were correlated to the RR,/RRe 
ratio using all cardiac cycles. Another regression line (simpkfied regression line) was sub- 
sequently generated using 8 data points at both extremely large and small RRtIRRa. 
Results:ln each dog, 1) The average max dP/dt for all cardiac cycles was closely 
approximated by the value determined from the regresslo” line at RRtIRRe = 1 (I = 
0.715) (left panel). 2) Similarly, close approximation was observed when estimated from 
the value at RRfIRR, = 1 in the simplified regression line (right panel). 3) The average 
max dP/dt in all animals was 2552 c 1043 mm Hgisec, while the estimated max dP/dt 
using the simplified approach was 2134 t 1043 mm Hglsec with a correlation coefficient 
of I = 0.977. 
Conclusion: LV systolic function can be clinically estimated simply and accurately by 
obtaining only a few selected values with extremely large and small RRf/RR2 ratio. 
-.. I.. 
Masst Sizet (msec) (cm/ %)t 
(9) (cm) SX) 
Controls 124+27 3.3kO.5 1.4&0.5 236+53 1.3kO.4 16+5 5.3k1.6 22+3 
LVH 189r67 3.9i0.5 1.2+0.2 270t49 1.4+0.3 11+4 8.4~~3.6 17+2 
tdifference p.zO.05 by unpaired t-test. The E/E,, ratio, previously shown to correlate 
with pulmonary capillary wedge pressures, was signficantly greater in LVH than C, sug- 
gesting elevated LV filling pressures; this was supported by greater LA size in LVH. Con- 
clusion: LVH pts with normal EF were not readily distinguishable from C by standard of 
refined mitral or pulmonary vein flow velocity measurements. Mitral annular DTI, by con- 
trast, may indicate a diastolic abnormality not apparent from these measurements and 
was paralleled by lower FSmw. Thus in hypertensive heart disease, DTI findings and 
FSmw may potentially be used to define a “transition state” between normal diastolic 
function and heart failure with normal EF 
1267-62 Usefulness of Myocardial Intravenous Contrast 
Echocardiography in Idiopathic Dilated Cardiomyopathy 
Yoke Miyata, Hiroya Kawai, Katsuya Hata, Toshiro Shinke, Yoshiaki Ueda, Hidenari 
Matsumoto, Soichiro Ota, Yoshio Yamanaka, Ryohei Yoshikawa, Osamu Iseki, Mitsuhiro 
Yokoyama. The lsf department of internal medicine Kobe University school of medicine, 
Kobe, Japan 
Background: It has been shown that intrinsic microvascular dysfunction is present in 
idiopathic dilated cardiomyopathy (IDC). Recently, myocardial intravenous contrast 
echocardiography (MCE) has been introduced to examine myocardial micro circulation 
noninvasively. The aim of this study was to evaluate whether intravenous MCE can be 
used to assess myocardial micro circulation in IDC and prognostic significance of this 
method. Methods: We performed standard echocardiographic examination and MCE by 
intravenous injection of Levovist (Schering, Germany) at baseline and during hyperemia 
with ATP (150 kgikglmin) in 14 patients with IDC (group D; LV end-diastolic dimension 
(LVDd) 61+1.6mm and LV fractional shortening (FS) 15.1+1.7% ) and 6 normal volun- 
teers (group N). We analyzed the time-intensity curve from the area of the anteroseptal 
region and measured the change in peak contrast intensity (API) from baseline to ATP 
infusion. Moreover in group D, we reperformed standard echocardiographic examination 
after 3 months of intensive medical therapy, and responder to the therapy was defined as 
decrease in LVDd > 5mm to a final LVDd < 55mm and increase in FS > 5% to a final FS > 
25%. Results: API was lower in group D than in group N ( 3.2 +1.2 dB vs 12.1k3.4 dB, 
p<O.OOl). Six patients in IDC were responders and 8 were nonresponders. API was 
higher in the responders than in the nonresponders ( 9.1tl.6 dB vs 2.&0.5 dB, p < 
0.001). Conclusion: The data suggests that myocardial micro circulation in IDC is 
impaired and clinical outcome may be predicted by magnitude of its impairment. Intrave- 
nous MCE with ATP may be a new modality in the management of patients with IDC. 
1267-64 Myocardial Metabolism and Nitric Oxide Production in 
Human Failing Heart Using l-123 BMIPP Scintigraphy. 
Nishio May”, Sinsuke Nanto, Tomoki Ohara, Junichi Kotani, Tetuya Watanabe, Masashi 
Fujita, Masaki Awata, Syuichiroh Higo, Setki Nag& kansai rosai hospifai, amagasaki, 
Japan 
Background: The production of nitric oxide (NO) in the failing heart is reported to 
increase, but the endothelial cellular function in the systemic vessels are thought to be 
deteriorated in the failing hearts. Therefore, NO levels in the systemic blood may be bal- 
anced according to the severity and duration of chronic heart failure. However, the patho- 
physiological role of NO in chronic heart failure is not clearly elucidated. Purpose: This 
study was undertaken to assess the relationship among the systemic blood levels of NO, 
left ventricular ejection fraction, the levels of brain natriuretic peptide (BNP), and the free 
fatty acid (FFA) utilization in patients with chronic heart failure. Method: Twelve patients 
with chronic heart failure (the NYHA class I or II, mean age; 6ti7year.s old) underwent 
the I-123.iodophenyl .3-methyl-pentadecanoic acid (BMIPP) scintigraphy. Myocardial FFA 
utilization was estimated with the ratio of cardiac uptake of BMIPP to an injected dose 
corrected for heart size (corrected %DU) in an anterior planar image obtained 20 minutes 
after the injection of BMIPP (111 MBq). One week after the estimation of myocardial FFA 
utilization, they underwent cardiac catheterizaion to estimate ventricular ejection fraction 
(EF) and to sample the blood from the aorta to estimate levels of the end-product of NO 
(nitratecnitrite) and BNP. Result: The plasma nitrateinitrite level in the aorta (ranging 
from 7.4 to 22.7pmoliL) was correlated with BNP (ranging from 2 to 420pg/ml, (r=-0.707, 
~~0.05)) and EF (ranging from 25 to 70%, (r=0.770, p<O.O5)). On the other hand, the 
plasma NO level was correlated with corrected %DU(r=0.607, p<O.O5). Conclusion: In 
the chronic heart failure, the reduction of NO levels in the aorta may contribute to the pro- 
gression of the severity of chronic heart failure, and the metabokc shift in substrate utili- 
zation of the failing myocardium. The endothelial cellular function in the systemic vessels 
may modify the pathophysiology of chronic heart failure. 
1267-65 Contractile Reserve By Echocardiography is a Better 
Predictor of Cardiovascular Mortality Than Nuclear Viability 
by SPECT Perfusion Imaging 
Binoy K. Singh, J. Mahenthtran, Varinder P. Singh, lgor Izrailtyan, Ehtasham Qureshi, 
Elmo ACIO, Farooq A. Chaudhry. Columbia University St. Luke3 Roosevelt Hospital 
Center, New York, NY 
Background: We have previously demonstrated that assessment of myocardial viability 
(MV) in patients with severe left ventricular dysfunction (LVD) and coronary artery dis- 
ease (CAD) is important in risk stratification and prognosis. The ability of dobutamine 
stress echocardiography (DSE) to detect viable myocardium by the presence of contrac- 
tile reserve (CR) and SPECT perfusion imaging (NPI) to detect nuclear viability (NV) is 
known. However, a comparison between the prognostic implications of CR versus NV in 
the same group of patients has not been evaluated. 
Methods: We studied 46 patients (37 males, mean age 62 yrs +/- 10) wtth severe LVD 
1267-63 Left Ventricular Systolic Function During Atrial Fibrillation (mean left ventricular ejection fraction 18% +/-a) and angiographically significant CAD. 
Can Be Accurately Determined Using Only a Minimal 
The mean follow up time was 20 months +/- 7. Each patient underwent both DSE and 
Number of Cardiac Cycles 
NPI, within 24 hours of each other, for the assessment of MV. DSE and NPI images were 
evaluated using the standard 16 and 20 segment models, respectively. %CR and %NV 
Tomotsugu Tabata, Richard A. Grimm, Neil L. Greenberg, Junko Watanabe, Deborah A 
Agler, Don W. Wallick, ShaoWei Zhuang, YouHua Zhang, Kent A. Mowrey, Todor N. 
Mazgalev, James D Thorns. The Cleveland Clinic Foundation, Cleveland, OH 
Background: The clinical assessment of left ventricular (LV) systolic function during 
atrial fibrillation (AF) is problematic due to beat to beat variability. Preliminary studies 
have shown that the systolic parameters during AF closely correlated with the ratio of the 
preceding and prepreceding RR intervals (RRtIRRe), and the parameters estimated at 
RRtIRR, = lin the linear regression line accurately evaluated LV contractile function. 
Purpose: To estimate LV systolic function during AF using only a few selected cycles 
with extremely large and small RR,/RR, ratio. 
were calculated for each patient by dividing the number of segments demonstrating MV 
by the total number of segments for each technique, respectively. Survival analysis was 
completed using the Cox proportional hazard regression model. 
Results: 13% patients had cardiac death. 30% patients had other cardiac events (i.e., 
cardiac hospital admisston, revascularization, and transplant). Univariate analysis of 
demographic, clinical, and imaging data revealed that lower %CR (p=O.O38) was a signif- 
icant predictor of cardiovascular mortality. Multivariate analysis showed lower %CR (risk 
ratio 2.0 per segment; 95%CI=l.l to 3.7) to be an independent predictor of cardiovascu- 
lar mortality %NV did not reveal any discriminatory value in predicting cardiovascular 
mortality. 
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Method: We prospectively evaluated the NOGA TM findings in 12 consecutive pts with 
NIDC (defined as pts with history of heart failure, no prior MI, no ~30% lesion on angio- 
gram and global hypokinesis with LVEFc35%). 
Results: All 12 pts had hypertension with mean age of 54.2i12.3 years, 33% were 
smokers, 25% had diabetes and 59% had hypercholesterolemia. The mean LEVF by 
ventriculogram was 25.lf7.3%. The mean UV and LS in each of the 12 standard 
NOGA’* myocardial segments are: 
uv (mv) Septal Anterior Lateral Posterior 
Apex 12.8k44.8 12.0i5.1 12.3+4.9 12.515.6 
Mid 13.3k3.8 12.4+5.4 11.6k5.5 11.8*4.8 
Basal 7.6k3.5 8.7+3.9 9.734.7 7.1?2.7 
LS (%) Septal Anterior Lateral Posterior 
Apex 5.513.9 8.8+5.3 2.819.8 6.8?3.7 
Mid 2.6ti2.7 4.9+5.1 4.lf6.1 3.1f5.4 
Basal 3.2ti.4 3.6+4.4 1.815.3 4.1t3.2 
As expected, both UV and LS are smaller in amplitude towards basal segments due to 
the presence of mitral valve annulus. 
Conclusions: 1) Despite poor LVEF, pts with NIDC have preserved UV similar to pts with 
normal myocardium. 2) Pts with NIDC have markedly diminished mechanical function 
with LS comparable to non-viable myocardial segments. 3) Thus mark discordance in the 
electromechanical findings, with “normal” UV and “non-viable” LS defines a unique 
NOGATM map for pts with NIDC. 
1267-69 Does Impedance Cardiography Accurately Determine 
Cardiac Hemodynamics in Patients With Heart Failure? 
Mark H. Drazner, Brenda S. Thompson, Paul B. Rosenberg, Daniel L. Dries, Clyde W. 
Yancy. University of Texas Southwestern Medical Centeer, Dallas, TX, St. Paul Medical 
Center, Dallas, TX 
Conlusion: %CR by DSE is a significant predictor of cardiovascular mortality in patients 
&ith severe LVD and GAD. DSE CR IS superior to NPI NV in predicting cardiovascular 
mortality. 
1267-66 Left Ventricular Structure and Function in Morbid Obesity: A 
Transesophageal Echo Study 
Tat W. Koh, Louise Bowles, Peter G. Mills, Martin T Rothman, Peter Kopelman, Adam D. 
Timmis. London Chef Hospital, London, Unifed Kingdom, Royal London Hospital, 
London, United Kingdom 
Background: In subjects with morbid obesity (body mass index (BMI) >40) data on 
adaptive changes in cardiac structure and function from transthoracic echo (TTE) is often 
limited by poor visualization. Methods: 23 asymptomatic obese subjects (OBS) (aged 
43*7 yrs, 10 male) without hypertension were studied using transesophageal echocar- 
diography (TEE) as part of the baseline investigations of a clinical trial of gastroplasty for 
treatment of morbid obesity. We compared the findings to a control group (CTL) of 10 
subjects of Similar age (40+11 yrs) referred for TEE to exclude cardiac source of embo- 
Ius, who had structurally normal hearts. We recorded transesophageal M-mode echocar- 
diagrams of the LV cavity at the level of the papillary muscle and transmrtral Doppler. 
Body weight and BMI for OBS were significantly higher than CTL (150r32 vs 76~8 kg, 
52t10 vs 25+3 kgim2, P&01). Results: M mode ethos and Doppler were successfully 
recorded in all OBS subjects on TEE. TIE was only possible in 78% and 88% of OBS 
subjects for recording LV M-modes and mitral Doppler respectively. On TEE, LV cavity 
size (end diastole and end systoie) was greater in OBS than CTL (5.320.6 vs 4.3 iO.5 
cm, 3.5t0.5 vs Z.&O.4 cm) as was wall thickness (anterior wail, 1.3?0.1 vs 1.0~0.1, 
P<O.OOl for all) LV ma.ss was greater in OBS compared to CTL even after correction for 
body surface area (149+34 vs 75*4 gim2, P<O.Ol). LV mass correlated significantly with 
with BMI ((~0.46 P<O.O5). Diastolic indices were abnormal in OBS with increased A 
wave velocrty (0.7iO.2 vs 0.4+0.1 cm/s), reduced E/A ratio (1.2&0.5 vs 2.1-r0.9) and pro- 
longed isovolumic relaxation time (84+13 vs 70+14 s, pcO.01 for all) compared to CTL. 
Systolic function assessed by fractional shortening was preserved in OBS (36~1 v.s 34tl 
%) YS CTL. Conclusions: Morbid obesity, in the absence of hypertension is associated 
with increased LV muscle mass, disturbances in diastolic function and increased LV cav- 
ity dimensions. Transoesophageal echocardiography is a useful technique for monitoring 
these adaptive changes especially if therapeutic maneuvers aimed at weight reduction 
are contemplated rn these patients. who are at high risk of cardrovascular complications. 
1267-67 Inter-Study Reproducibility of Left Ventricular Structure and 
Function in Heart Failure Patients With Cine MR Imaging 
Prasad M. Panse, Olaf Muehling, Andrey Zenovich, Neeta Panse, Ravi Seethamraju, 
Yimei Huang, Cory Swingen, Michael Jerosch-Herold, Norbert Wilke, lnder Anand. 
University of Minnesota, Minneapolis, MN 
Background: Serial measurement of ventricular mass, volume and function is important 
for assessing new drugs considered to attenuate ventricular remodeling. Although tine 
MRI provides highly reproducible data in normal hearts, in patrents with LV dysfunction. 
low cardiac output and distorted ventricles, the resolution between anatomic structures is 
often poor. Values for inter-study reproducibility in such patients are not available. These 
are required for calculating sample size in drug studies. We report reproducibility data of 
LV structure and function in patients with a wide range of LV dysfunction. 
Methods: Eight subjects underwent MRI of the heart, with a 1.5T Siemens scanner on 
two occasions, one week apart using the same breath-hold protocol. The entire heart 
was covered from base to apex in 8 mm slices with 2 mm inter-slice gap, and 15 to 20 
phases to include end-diastole (ED) and end-systole (ES). An experienced observer 
manually traced the RV and LV contours using MASS analysis software version 4.0 to 
determine the ED volume (EDV), ES volume (ESV), Stroke volume (SV), Ejection fraction 
(EF) and LV mass. 
Results: The siandard deviation, correlation coefficient and percent variabrtity for the LV 
mass, volumes, EF and SV are show in the table. Percent vanability was determined as 
the absolute value of the difference between the two measurements over the mean of the 
two measurements. The data are very similar to those described for subjects with normal 
hearts. 
Parameters %variabiilty Std.dev Coeficient corelatron 
LVEDV 3.79 3.1 0.99 
LVESV 8.79 4.72 0.98 
LVmass 3.33 2.76 0.99 
EF 7.46 3.9 0.94 
sv 7.97 3.31 0.84 
Conclusion: Assessment of LV remodeling by MRI in heart failure patients is highly 
reproducible. Therefore, MRI is capable of assessing a given change in LV structure and 
function with a much smaller sample size as compared with other non-invasive Imaging 
techniques such as echocardiography 
1267-68 NOGA Electra-Mechanical Characteristics of Non-lschemic 
Dilated Cardiomyopathy 
SChiu Wang, Barry Cohen, Stylianos Papakodos, Mark Blum, Mohsen Mabudian. Mark 
Reisman The New York Presbyterian Hospital-Cornell Campus, New York. NY; 
Morristown Memorial Hospifal, Morristown, NJ 
Background: Electro-mechanrcal (EM) data from Biosense NOGATM maps are useful for 
assessing myocardial viability Normal myocardium is represented by high unipolar volt- 
age (UV, 14+2.4mv) and linear local shortening (LS, 12.5+2.8%) values whereas non-via- 
ble myocardium is characterized by low UV and LS scores (<7-9 mV and ~4.8.6.8% 
respectively). Currently, the NOGATM EM findings in pts wrth non-ischmeic dilated cardi- 
omyopathy (NIDC) are unknown. 
Background: Invasive hemodynamic monrtoring in heart failure is widely used despite its 
known risks and costs. Impedance cardiography is a noninvasive method that determines 
stroke volume, cardiac output (CO), cardiac index (Cl), and thoracic fluid content by 
assessing the change in impedance of an alternating current applied across the thorax. It 
is not known if hemodynamic measurements obtained by impedance cardiography corre- 
late with those obtained via right heart catheterization in patients with heart failure. Meth- 
ods: Twenty-nine consecutive patients (72% male, NYHA class 3 i 0.8, mean LVEF 0.30 
i 0.17) underwent simultaneous right heart catheterization and impedance cardiography 
(BioZ.com@). Twenty-one of these patients also had CO measured by Fick. The invasive 
and impedance hemodynamic measurements were compared with correlation coeffi- 
cients and the Bland-Altman method (bias and limits of agreement). The positive and 
negative predictive values for detecting a low output state (thermodilution Cl < 2.3) by 
impedance cardiography were calculated. Results: There was no correlation between 
the thoracic fluid content and the pulmonary capillary wedge pressure (r = 0.09, p=O.65). 
Impedance cardiography correlated well with invasive measures of CO and Cl. 
Correlation and Agreement of Impedance and Invasive Hemodynamics 
Comparison Correlation P value Bias Lower limit of Upper limit of 
coefficient (r) agreement agreement 
Impedance vs. 0.83 <O.OOl -0.2 -2.2 1.8 
Thermodiiution CO 
Impedance vs. 
Thermodilution Cl 
Impedance vs. 
Frck CO 
Impedance vs. 
Fick Cl 
0.77 co.001 -05 -2.5 1.5 
0.73 <O.OOi -0.1 -1.2 0.9 
0.65 =O.OOl -0.3 -0.7 1.3 
Impedance cardiography detected a thermodilution Cl < 2.3 with a negative predictive 
value of 0.87 and a positive predictive value of 0.71. Conclusion: In patients wrth heart 
failure: 1) Thoracic fluid content does not correlate with pulmonary capillary wedge pres- 
sure; 2) The CO and Cl measured by impedance cardiography correlate with those 
obtained by invasive measures; 3) Impedance cardiography has a high negative predic- 
tive value in detecting a low output state. This technology may have clinical utility in heart 
failure management. 
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Conclusion: This finding underscores the profound genetic heterogeneity in HCM. Less 
than 1% of unrelated individuals seen at a tertiary referral center for HCM possessed a 
“malignan? mutation. These results suggest that routine cllnical testing for these specific 
mutations is of low yield. 
1268-72 A Common Variant of the AMPDl Gene Predicts Improved 
Survival in Patients With lschemic Cardiomyopathy, but not 
Non-lschemic Cardiomyopathy 
Yoshikazu Yazaki, Siavash Ghaffari, Joseph B. Muhlestein, Noal I. Hart, Tami L. Bair, 
Benjamin D. Home, Dale G. Renlund, Jeffrey L. Anderson, John F. Carlquist. LDS 
Hospital, Salt Lake City lJ1; University of Utah, Salt Lake Ci& UT 
Background: Reduced adenosine monophosphate deaminase (AMPD) activity may 
result in increased circulating levels of adenosine. A recent study has demonstrated a 
survival benefit associated with carriers of a nonsense AMPDl gene polymorphism 
(C34T) in patients with congestive heart failure (CHF). Since adenosine may have car- 
dioprotective actlons, leading to increased coronary blood flow and ischemic precondi- 
tioning, we hypothesized that this survival benefit may occur preferentially in patients with 
ischemic cardiomyopathy (IC). 
Methods: To test this hypothesis, blood samples were drawn from 390 consecutive 
patients with a left ventricular ejection fraction (LVEF) c 40% consisting of IC in 210 and 
non-ischemic cardiomyopathy (n-IC) in 180. Genotyping was performed by introduction 
of a restriction site in the T allele by PCR and subsequent digestion with Nspl restriction 
endonuclease. Patients were followed-up prospectively to assess survival (mean 3.0 
years, maximum 5.6 years). The survival of home- (TT) or heterozygous (CT) carriers 
were compared with that of non-carriers (CC) in each IC and n-IC group separately. 
Results: Of the IC patients, 153 (72.9%) were CC homozygotes, 54 (25.7%) were CT 
heterozygotes, and 3 (1.4%) were TT homozygotes. Of the n-IC patients 144 (80.0%) 
were CC, 31 (17.2%) were CT, and 5 (2.8%) were TT Overall, mortality was 9.7% for T 
allele carriers compared to 19.2% for non-carriers (log rank statistic, 4.4, p=O.O36). In IC 
patients, T allele carriers showed a significantly lower mortality compared with non-carri- 
ers (14.0% versus Z&l%, log-rank=4.4, p=O.O36), but this was not the case in n-IC 
patients (2.8% versus 9.6%, 1.6, p=O.21). In IC patients, multivariate Cox regression 
analysis (adjusting for age, sex, hypertension, hyperlipidemia, diabetes, history of CHF, 
LVEF) identified age (odds ratio [OR]= l.O3/year, p=O.O46) and AMPDl T carriage 
(OR=0.44, p=O.O4) as independent predictors of mortality. 
Conclusions: The AMPDl polymorphism predicts future mortality preferentially in 
patients with ischemic compared to non-ischemic cardiomyopathy. This may be related 
to the differing underlying pathophysiology of these two disease processes. 
1268-73 Prevalence of Carrier Status in Relatives of Naxos Disease 
Patients 
Nikos Protonotarios, Adalena Tsatsopoulou, Aris Anadasakis, Antigone Milieu, Elias 
Sevdalis, Angeles Rigopoulos, Artemisia Theopistou, Godfrina McCoy, Christodoulos 
Stefanadis, Pavlos Tot&was. Department of Cardiology, University of Athens, Athens, 
Greece, J. Protonotarios Medical Center, Naxos, Greece 
Background: Naxos disease is a syndrome of arrhythmogenic right ventricular cardi- 
omyopathy with autosomal recessive Inheritance. The responsible pathogenic gene is 
that of plakoglobin, a constituent of the cardiac cells desmosomes. The patients are 
homozygous for the mutated gene, whereas neither the carriers (heterozygous) nor the 
percentage of gene prevalence in the communities where the disease appears were 
known until today (isolated communities phenomenon). 
Methods: We assessed 58 subjects from 6 families with Naxos disease (4 from Naxos, 
2 from Milos). Mean age was 35 years (range 5-86) and the mean number of relatives 
assessed par family was 9.7 (range 8-12). The genetic screening consisted of: DNA 
extraction from venous blood, multiplication of a 2 Kb area around the Pk2157del2 site of 
the gene (where the mutation appears by the deletion of 2 bases) by using polymerase 
chain reaction (PCR) with specifically designed primers. Restriction enzyme analysis, 
using the restriction endonuclease BstOl, verifies the presence or not of the mutation, 
which is recognized in an agarose gel depending on the number and the molecular 
weight of the DNA bands that are produced by BstOl cleavage. 
Results: Of 58 Naxos disease family members, 14 subjects were affected and 44 had a 
normal phenotype. Of those 44,34 were gene carriers. The gene carrier prevalence is up 
to 77%. 
Conclusion: The prevalence of carriers for the Naxos disease gene comes to 7X from 
the study made in Naxos and Miles. Those members are not affected, but they pass the 
mutation on to the next generations. Screening for the Naxos disease gene (plakoglobin) 
could be initiated in selected populations in a similar strategy as that of P-thalassemia. 
1268-74 QT Dispersion in Gene-Affected Members Without 
Hypertrophy in Familial Hypertrophic Cardiomyopathy 
Caused by Myosin-Binding Protein C Gene Mutation 
Hiroaki Kitaoka, Tom Kubo, Makoto Okawa, Toshikazu Yabe, Takashi Furuno, Yoshinori 
Doi, Akinori Kimura. Kochi Medical School, Kochi, Japan 
Hypertmphic cardiomyopathy (HCM) is caused by several gene mutations of the cardiac 
sarcomere. However, it is unclear whether or not gene-affected members have electri- 
cally abnormal myocardium when they have not yet developed lefi ventricular hypertro- 
phy (LVH). QT dispersion (QTd) in surface ECG may reflect the abnormality of 
repolization and can be a useful marker for electrically abnormal myocardium. Methods: 
QTd and corrected QTd (QTcd) were studied in eleven patients with HCM and sixteen 
family members (8 family members with positive gene abnormality and negative pheno- 
type and 8 unaffected family members) from five families with HCM caused by myosin- 
binding protein C gene mutation (exonl8TCCeL3174;CC). Results: (1)QTd and QTcd in 
patients with HCM were greater than those in other family members. However, there 
1268 Cardiomyopathy: The Genetic Puzzle 
Unfolds II 
Tuesday, March 20, 2001, 3:00 p.m.-500 p.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 3:00 p.m.-4:OO p.m. 
1268-70 Association Between pi-Adrenergic Receptor Gene 
Polymorphism and Ventricular Tachycardia in Patients With 
Dilated Cardiomyopathy 
Chikao Iwai, Horuka Akita, Nobuyuki Shiga, Yasuaki Matsuda, Eiji Takai, Yoshitomo 
Miyamoto, Masakatsu Shimizu, Hiroya Kawai, Akira Takarada, Mitsuhiro Yokoyama. The 
1st Dept. of Internal Medicine, Kobe University School of Medicine, Kobe, Japan, Dept. of 
Cardiology, Himejf Cardiovascular Center, Himeji, Japan 
Background:P-Adrenergic receptor (AR) stimulation plays an important role in the 
arrhythmogenesis of dilated cardiomyopathy (DCM). p-Blockers can prevent sudden 
death due to ventricular arrhythmias in patients with heart failure. Recently, a common 
functional plAR gene polymorphism (Arg389Gly;C1165G) has been identified. In vitro 
functional assays revealed that adenylyl cyclase activities for the Arg389PlAR (CC) were 
much higher than those for the Gly389plAR (GG) with agonist stimulation. We hypothe- 
sized ihat this gene variant could be a genetic risk factor for ventricular tachycardia (VT). 
Methods: To elucidate whether this gene variant can be a genetic risk factor for DCM in 
Japanese, we conducted a case control study, and evaluated Arg389Gly polymorphism 
in human Pl AR gene in 163 DCM patients and 157 age- and sex- matched control sub- 
jects by using polymerase chain reaction and the restriction fragment length polymor- 
phism analysis. We further analyzed 133 DCM patients who underwent 24. Halter 
monitoring. VT was defined as 23 consecutive ventricular ectopic beats. Results: There 
was no statistical difference of allele distribution between DCM and controls (C allele fre- 
quencies ware 0.71 and 0.70, respectively). We also assessed the relations between the 
severity of the disease and the gene variant in the patient group and found that cardiac 
function parameters including the ejection fraction, the left ventricular end diastolic vol- 
ume index, and cardiac index were not different according to the genotype. In 133 DCM 
patients, C allele frequency of VT+ group was much higher than that of VT- group (0.76 
vs 0.54, p=O.OOl).The logistic regression analyses revealed ihat the odds ratio of 
Arg389plAR (CC) was 4.75 ( p<O.OOOl). 
\a+ h=94) vr- h=39) P 
&18389Gly mwtype, n&j 
pi 
c alleb frequency 
Conclusion: Our flndings suggest that Arg389Gly polymorphism in human Pl AR gene is 
associated with VT in patients with DCM. C allele could be a genetic risk factor for VT. 
1268-71 Malignant Mutations in Hypertrophic Cardiomyopathy: A 
Rare Find Indeed 
Michael J. Ackerman, Steve R. Ommen, Sara L. Van Driest, David J. Tester, Timothy M. 
Olson, Bernard J. Gersh, Rick A. Nishimura, A. Jamil Tajik. Mayo Clinic, Rochester, MN 
Background: Hypertrophic cardiomyopathy (HCM) is a genotypically and phenotypically 
diverse disease involving the cardiac sarcomere. Previous genotype-phenotype studies 
have identified three mutations (R403Q, R453C, and R719WiQ) as highly malignant 
defects within the most common HCM-predisposing gene, beta myosin heavy chain. 
Routine clinical screening for these malignant mutations has been suggested to identify 
high-risk families. 
Methods: We screened 249 near-consecutive. unrelated cases (t 10 female) of HCM 
seen at Mayo Medical Center’s HCM Clinic during a 3.year period from April 1997 to April 
2000. DNA was obtained following informed consent, PCR amplification of axons encod- 
ing R403Q (exon 13), R453C (14), and R719WiQ (19) was performed, and the mutations 
were detected using mutation-specific restriction enzyme assays and high performance 
liquid chromatography (WAVETM). 
Results: The mean age at diagnosis of HCM was 41 f 19 years with 53 subjects diag- 
nosed before age 25. 127 of 249 (51%) had evidence for obstruction with a mean peak 
resting gradient of 67 + 40 mm Hg. The mean maximal wall thickness was 22 i 5 mm. 
83 of 249 (33%) cases were familial. There was a family history of sudden death in 54 
(22%). Only 2 of the 249 (0.8%) had a malignant mutation. A lo-year-old male had the 
R453C mutation despite no family history of HCM or sudden death. He was diagnosed 
during infancy and had extreme hypertrophy (38 mm septum). He previously underwent 
a septal myecto?ny, and most recently he had an AICD implant following an episode of 
symptomatic VT and inducible VT during EP study. The second case involved a 16.year- 
old female with a R719Q defect. She was diagnosed at 9 years of age. There was a 
family history of sudden death but no suggestion of HCM. Her maximum wall thickness 
was 23 mm. She received an orthotopic heart transplant this summer due to refractory 
symptoms from severe restrictive hemodynamics. 
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were no significant difference in QTd and QTcd between members wiih positive gene 
abnormality and unaffected members(Table). (2) There was good correlation between 
maximal wall thickness and QTd(r=0.86,p<O.O01).Conclusion: Although QTd was pro- 
longed in patients with HCM, it was within normal limits in family members with positive 
gene abnormality and negative phenotype. QTd in patients with HCM caused by myosin- 
binding protein G gene mutation may relate to the degree of wail thickness. 
QTd(msec) vs. HCM pts QTcd (mm) vs. HCM pts 
HCM pts 
affected (No LVH) 
unaffected 
65t24 65+30 
27~~6 <0.005 28i7 co.005 
3&15 <0.05 39*15 <a.05 
ORAL CONTRIBUTIONS 
872 Gender and Ethnic Differences in Heart 
Failure 
Tuesday, March 20, 2001, 4:00 p.m.-%00 p.m. 
Orange County Convention Center, Room 231 A 
872-l 
4:oo p.m. 
Racial Differences in Heart Failure Presentation but Not 
Therapy: Report From the UNITE-HF Multicenter Heart 
Failure Database 
Hector 0. Ventura, Ron M. Oren, Jalai K. Ghali, Mandeep f?. Mehra, lleana Pina, Daniel 
J. Lenihan, Alan B. Miller, Grady Hendrix, Wendy A. Gattis, Sirisha Mallemala, 
Christopher M. O’Connor. Kirkwood E Adams, Jr., for the UNITE-HF Investigators. 
University of North Carolina, Chapel HI//, NC 
Background: Heart Failure is an important cause of morbidity and mortality in African- 
Americans but current clinical characteristics and treatment patterns of this group remain 
poorly defined 
Methods: To compare clinical aspects and medication use in African-American versus 
other races, data were analyzed on randomly selected patients seen in HF clinics at 11 
institutions participating in the UNITE-HF Database between 11116/99 8/17/00. 
Results: Among the 454 patients analyzed to date with respect to race, a significant 
number were African-American (38%) and female (40%) with a mean age of 56 t 14 and 
NYHA class of 2.6 + 0.7. Left ventricular systolic dysfunction predominated (LVEF 28 + 
14%). Medication usage was similar between African-American and other races: for 
ACEI (81 vs Sl%), diuretic (91 vs 86%), beta blocker (60 vs 55%) and digoxin (85 vs 
89%) but use of calcium blocker was higher (24 vs 12% p<.OO?) in African-Americans. 
Contrasts in other clinical characteristics are shown below: 
Race (N) NYHA LVEF Age F% HTN Etio BMI 
African-American (172) 2.7t0.7 27r16 52-if3 53% 71 28 30i8.6 
Non African-American (282) 2.6t0.7 28~14 59+14 32% 59 44 30i7.2 
P value NS NS co1 <.Ol .03 <.Ol NS 
BMI=body mass index. Etio=% ischemic etiology of HF, F=% female, HTN=% hyperten- 
sion history 
Conclusions: African-Americans with heart failure tend to be younger, more often 
female, more likely to have history of HTN and less likely to have IHD as origin of heart 
failure. in contrast to these differences, usage of ACEI and beta blockers was similar 
between African-Americans and Non African-Americans. 
872-2 
4:15 p.m. 
Differences in Clinical Characteristics and Outcomes 
Between African American and White Heart Failure Patients 
Mark Alexander, Maria N. Ansari, Ali Tutar, Barry Massie. KaiserPermanente, Division of 
Research, Oakland. CA, Center for Aging in Diverse Communities, University of 
California San Francisco, San Francisco, CA 
Background: Several studies have noted differences in the characteristics and out- 
comes of African Americans (AA) with CHF compared to whites, including higher rates of 
hospitalization and (more variably) mortality in AA. However, these data were mostly 
dewed from hospitalized patients or clinical trials with highly selecred subjects. Rela- 
tively little IS known about racial differences in unselected outpatients, particularly in pop- 
ulations where access to care is similar. 
Methods: We identified a cohort of Pts in the Northern California Kaiser Permanent-e 
Medical Care Program with new outpatient diagnoses of CHF between 7/l/96 and 81311 
97. Pts with prior CHF diagnosis or hospitalization or severe comorbidities (such as ter- 
minal cancer, ESRD, or dementia) were excluded. Hospitalization and mortality data 
were collected for up to 2 years (mean 21 months following the initial CHF diagnosis. 
Results: The cohort included 361 Pts (13.3% AA, 86 1% whites). There was no racial 
difference in the age of men (68 yrs), but AA women were significantly younger than 
white women (60 vs 73 yrs). hypertension and diabetes were more frequent in AA, 
whereas CAD and atrial fibrillation were more common in whites. Similar numbers of AA 
and whites were treated with ACE inhibitors (81.3% and 80.2% and beta-blockers (31.3% 
and 33.6%). lnvolvment of cardiologists was also similar. Proportional hazards models 
found that there were no significant ethnic differences in 2-yr cardiovascular hospitaliza- 
tions (AA 29.2%, whites 31%) or deaths (AA 12.5%, whites 12.1%. Risk of the composite 
endpoint of death or cardiovascular hospitalization was not different (HR~0.83, 95% 
Cl=0 46-l .42). 
Conclusions: Although previously described differences in comorbid conditions were 
present between AA and whites, there were no significant differences in adjusted hospi- 
talization or mortality rates. This may have reflected more similar access to care and ACE 
inhibitor and beta-blocker use in this HMO outpatient cohort. 
Clinical Characteristics of Outpatient CHF Patients by Ethnicity 
Factors African Americans (n=48) n Whites (n=313) n (%) 
(“4 
CAD 19 (39.6)* 177 (56.5) 
Atrial Fib 3 (6.3) 73 (23.3) 
HTN 39 (81.3)* 211 (67.4) 
Diabetes 18 (37.5)’ 70 (22.4) 
Cardiology Care 23 (47.9) 160 (51.1) 
‘p< 0.05 
4:30 p.m. 
872-3 Differences in Men and Women With Advanced Heart Failure 
JoAnn Lindenfeld, Yves D. Rosenberg, Heidi J. Krause-Steinrauf, Surai Thaneemit-Chen, 
Steven S. Kahn, Brian D. Lows, Rhonda L. Larsen, James B. Young, Jalal K. Ghali, For 
BEST Investigators. University of Colorado Health Sciences Center; Denvq CO 
Background: 
Limited data are available comparing demographic and clinical characteristics of men 
and women with advance heart failure. We examined the baseline characteristics of 
patients by gender in BEST (Beta-blocker Evaluation of Survival Trial), a trial of beta- 
blocker therapy in patients with advanced heart failure (NYHA Class III and IV and EFs 
35%). 
Results: 
Women Men p-value 
n 593 2115 
Age (Y@ 58213 62+12 <0.001 
Black/Non-Black 30% / 70% 21% / 79% <O.OOl 
NYHA III/IV 93% I 7% 9 1% I 9% 0.356 
CAD/ non-ischemic 38% I 62% 64% / 36% <O.OOl 
Heart rate (bpm) 84+13 81413 co.001 
BMI (kg/m*) 28.2?6.8 27.9i5.8 0.336 
Systolic BP (mmHg) 117*18 117~18 0.879 
LVEF (%) 25i7 2317 <O.OOi 
RVEF (%) 38114 34*13 <O.OOi 
BUN (mg/dL) 23.2k15.9 25.2515.2 <0.001 
PNE (pgiml) 487t321 523t350 0.007 
Conclusions: A number of differences in baselrie characteristics are influenced by gen- 
der in patients with advanced heart failure. In BEST women were younger, more often of 
black and non-Hispanic background, had less CAD, had a higher heart rate, LVEF, and 
RVEF, and lower PNE compared to men. These differences may be important in deter- 
mining whether gender effects prognosis in patients with advanced heart failure. Consid- 
ering these important differences future trials in heart failure should stratify 
randomization by gender. 
872-4 
4~45 p.m. 
Gender Differences in Heart Failure Clinical Characteristics 
and Therapy: Report From UNITE-HF Multicenter Heart 
Failure Database 
Stephanie H. Dunlap, Ron M. Oren, Hector 0. Ventura, lleana Pina, Mandeep R. Mehra, 
J&l K. Ghali, Grady H. Hendrix, Daniel J. Lenihan, Alan B. Miller, Carla A. Sueta, James 
H. Patterson, Sirisha Mallemala, Christopher M. O’Connor, Kirkwood F. Adams, Jr., for 
the UNITE-HF Investigators. University of North Carolina, Chapel Hit/, NC 
Background: Potential differences in the clinical characteristics and outcome of males 
(M) and females (F) with cardiovascular disease remain of significant interest. Heart fail- 
ure is an important cause of morbidity and mortality In F but current clinical trial data pro- 
vide limited information concerning the characteristics and treatment patterns of F versus 
M with heart failure. 
Methods: The UNITE-HF investigators randomly enrolled 454 patients from their heart 
failure specialty practices between 11/16/99 - 8/17/00. Demographic, clinical and medi- 
cation data were collected through a standard form set and analyzed through a comput- 
erized database. 
Results: A significant number of patients enrolled were F (40%) and African-American 
(38%) with a mean age of 56 ? 14 and NYHA class of 2.6 t 0.7. Left ventricular systolic 
dysfunction predominated (LVEF 28 i- 14%). Medication usage differed between F and 
M with ACEI (76 vs 84%, p=O.O56) and digoxin (83 vs 91%, ~~0.024) being less used, 
diuretic given more frequently (92 vs 86%, p=O.O63) and beta blocker (57 vs 56% p=NS) 
to a similar degree. Contrasts in other characteristics are shown below: 
Gender(N) NYHA LVEF Age African- HTN Etio IHD 
American 
F (181) 2.6kO.7 31+15 56~15 50 69 30 
M (273) 2.6r0.7 26*13 56+13 20 60 43 
P value NS <.OOl NS c.01 ,045 co1 
Etio=% ischemic etiology of heart failure HTN=% hypertension history 
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with suspected heart failure but preserved LV systolic function. As yet there are no reli- 
able indictors on which to base an echocardiographic diagnosis of “diastolic heart fail- 
ure”. 
Number of patients with indicators of diastolic function out-with recommended refer- 
ence range 
E/A IVRT AFF EIA:DT 
Mantero 40- 1/5;0/8;4/18;2/ 4/5;5/8;4/18;15/ 0/5;0/8;1/18:6/ 
49;50-59;60- 46 46 46 
69;70-80; 
Framingham 40. 0/5;1/8;1/18;1/ 3/5;7/8;8/18;7/ 
49;50-59;60-69 44 0194 44;47/94 
270;all ages 
European Work- NA agw30:1/ age&i/ 
ing Group 1:age30-50:1/ 6;age>50: 3188 
5;aae>50:45/88 
Conclusions: M and F with heart failure differ in baseline characteristics and treatment 
patterns. LVEF was significantly higher in F. Females were less likely to receive ACEI 
and digoxin, but more likely to be on diuretic than M. Beta blocker “se was similar. 
Potential impact of these differences on outcome will be explored. 
ORAL CONTRIBUTIONS 
877 Identification of Patients With Diastolic 
(or Nonsystolic) Heart Failure 
Wednesday, March 21, 2001, 8:30 a.m.-lo:00 a.m. 
Orange County Convention Center, Hall F4 
877-l 
8:30 a.m. 
Autopsy Findings in Patients With Diastolic Versus Systolic 
Heart Failure 
Shen-Li Tan, Horng H. Chen, William D. Edwards, Michele Senni, Margaret M. Redfield. 
Mayo Clinic and Mayo Foundation, Rochester, MN 
Background: Heart failure (HF) is associated with normal systolic function in ~40% of 
cases. This study compared autopsy findings in patients (pts) with a diagnosis (dx) of 
diastolic HF (DHF) to those of pts with HF and systolic dysfunction (SHF) to evaluate dif- 
ferences in structure or histology. Secondly, as pts with DHF are less likely to have a clin- 
ical dx of coronary artery disease (CAD), we sought to determine if clinically 
unrecognized CAD was common in DHF. 
Methods: Pts previously identified in two population-based studies of HF in Olmsted 
County, MN in 1991 (SHF and DHF) and 19961997 (DHF only) who had cardiac autop- 
sies were included in this study. Of the 78 pts with SHF, 11 had autopsies. Of the 164 pts 
with DHF, 17 had autopsies. 
Results: Patients with DHF were older at dx (median age =80 yrs, vs 72 yrs for SHF, 
~~0.05) and more likely to be female (90% vs 36% for SHF, p<O.Ol). Mean ejection frac- 
tion (EF) at dx was 62110% in DHF and 24+6% in SHF. Clinical dx of CAD was present in 
35% of DHF vs 45% of SHF. Hypertension was present in 75% of DHF vs 36% of SHF 
(p=.O3); Median time from dx to death was 16 months (DHF) and 17 months (SHF). Of 
the 17 subjects with DHF, 8 had repeat echo prior to death with EF>45% confirmed in 7. 
Immediate causes of death (CAD, HF, infection, pulmonary embolus, arrhythmia) were 
similar in DHF and SHF. Of the 8 pts with SHF and Grade III/IV CAD, 4 (50%) had no clin- 
ical dx of CAD. Of the 11 pts with DHF and Grade Ill/IV CAD, 5 (45%) had no clinical dx 
of CAD. 
Autopsy results 
SHF (n=i 1) DHF (n=17) 
Heart weight(g) 564k 242 477*130 
LVH 73% 82% 
LV dilation 73% 29%* 
Atrial dilation 55% 70% 
Diffuse fibrosis 45% 35% 
Amyloid 9% 0% 
Grade Ill/IV CAD, n(%) 8 (73%) 11 (65%) 
*p<O.O5 vs SHF; Left ventricular hypertrophy (LVH); Left ventricle (LV) 
Conclusion: At autopsy, pts with DHF have less LV dilation but similar prevalence of 
LVH, atrial enlargement, and CAD. DHF was not associated with a higher prevalence of 
diffuse fibrosis or amyloid deposition. Clinically unsuspected CAD was common in both 
groups. While other age related morphologic changes can not be excluded, concentric 
LVH and CAD are the primary structural abnormalities associated with DHF. 
877-2 
8:45 a.m. 
Can We Diagnose Diastolic Heart Failure by Transthoracic 
Echocarcliograhy? 
Mark C. Petrie, Lynne Caruana, John .I. V. McMurray. Western lnfimaryof Glasgow, 
Glasgow, United Kingdom 
Background: Though it is often assumed that a high proportion of patients with heart 
failure but preserved left ventricular (LV) systolic function have “diastolic heart failure” it is 
not clear how diastolic function should be measured. A variety of echocardiographic crite- 
ria have been proposed. Our aim was to determine the concordance of different “diag- 
nostic” criteria for diastolic dysfunction in patients with suspected heart failure but 
preserved LV systolic function. Methods: 159 consecutive patients referred by general 
practitioners with suspected heart failure to an outpatient-based direct access echocar- 
diography service were studied. Each participant had a transthoracic echocardiogram. All 
patients had assessment of LV systolic function (both qualitative and quantitative [Simp- 
son’s biplane and M-Mode]) and the following putative indicators of diastolic dysfunction 
measured: E/A ratio, IVRT, AFF and E/A:DT. Reference ranges for these diastolic indica- 
tors were taken from recently published studies (Mantero et al, Framingham and the 
European Working Group). The concordance of values out-with these recommended 
ranges was sought. Results: 109 of 159 participants had suspected heart failure in the 
absence of left ventricular systolic function, vaivular heart disease or AF. Concordance of 
abnormalities of putative indicators of diastolic function was poor (see Table). Conclu- 
sion: There is poor concordance of putative indicators of diastolic dysfunction in patients 
877-3 
9:00 a.m. 
Two-Dimensional and Doppler Echocardiographic Features 
in New Onset Diastolic Heart Failure: A Community Based 
Study 
Horng H. Chen, John G. Lainchbury, Michele Senni, Magaret M. Redfield. n/lay0 Clinic, 
Rochester, MN 
Background: While > 40% of pts with heart failure (HF) in the community have normal 
ejection fraction (EF) (diastolic HF; DHF), the echo features and Doppler diastolic profile 
at HF diagnosis (dx) are not well described. Our objective was to describe the Doppler 
echo features of pts with a new dx of DHF. Methods: Using the Rochester Epidemiology 
Project, we identified all pts with a new dx of HF (Framingham criteria) in Olmsted County 
MN during 1996 & 97 in whom EF >45% (n=l03). Pts with valve disease (n=20) were 
excluded, leaving 83 pts with pure DHF. Diastolic assessment included mitral early to late 
filling velocity ratio (E/A) and deceleration time (DT) and the pulmonary venous (PV) sys- 
tolic to diastolic flow velocity ratio (S/D). Diastolic function was not assessed in 15 pts. 
Diastolic function was classifted as: Abnormal relaxation (E/A<0.75) or Restrictive (Ei 
Azl.5 &/or DT<l60 ms &/or PV S/D <I). Pts with a normal vs psuedonormal pattern 
(0.75 < E/A c 1.5 & DT > 160 8 PV S/D>l) were classified as Indeterminate as few pts 
had PV atrial reversal duration, Valsalva or Doppler tissue imaging to discriminate 
between these. In the 18 pts in atrial fibrillation at echo, DT was used to classify diastolic 
function. Results: Age (mean isem) at dx was 79+ 1 yrs. Echo was done within 3 days 
of dx in 71% and 80% of pts had been treated between dx and echo. 
2-D Findings 1 Doppler Findings 
Ejection fraction (%, mean Asem) 61kl 
~ Regional wall motion abnormality 37% 
Mortality at 1, 2 and 3 years was 29%, 37% and 60 %. No 2D or Doppler features other 
than TR velocity (RR= 3.3, p=O.O007) correlated with mortality. Conclusion: In the com- 
munity, the 20 echo features in DHF are diverse and LV hypertrophy is not an invariant 
feature. A restrictive diastolic pattern is common. A third of pts have a normal vs psuedo- 
normal pattern and utilization of maneuvers to distinguish between these is needed. 
These data demonstrate that even basic diastolic assessment can confirm diastolic dys- 
function in the majority of pts with DHF. 
9:15 a.m. 
877-4 BNP Can Differentiate Normal LV Function From Diastolic 
Dysfunction in Patients With Clinical Congestive Heart 
Failure 
Padma B. Krishnaswamy, Emily Lubien, Radmila Kazanegra, Judy Hope, Alan S. Maisel. 
VA San Diego Health Care System, San Diego, CA 
Background: As many as 30% - 40% of patients who present with symptoms of conges- 
tive heart failure have normal LV systolic function. A definite diagnosis of CHF in the 
presence of preserved eystolic function is difficult, especially in an elderly population with 
coexisting lung and renal disease. We hypothesized that BNP can be used as a diagnos- 
tic aid in these patients who have signs and symptoms of heart failure, but have a normal 
ejection fraction. Methods: 400 patients with either known or unknown LV function were 
recruited over a period of one year. Patients were determined to have congestive heart 
failure based on Framingham’s criteria, hospitalization for CHF, and response to treat- 
ment. BNP levels were measured by a point-of-care immunoassay (Biosite Diagnostics, 
La Jolla, CA) and echocardiogram was performed. Results: 25% of the patients (n=98) 
had diastolic dysfunction by standard echocardiography criteria. 41% of the patients with 
diastolic dysfunction (n=40) had clinical congestive heart failure. The BNP levels in this 
group of patients was 475 + 65 pg/ml compared to BNP levels in patients who had clinical 
signs and symptoms but had a normal echocardiogram (45 i 8 pgiml). A ROC of BNP 
versus clinical CHF, showed that BNP was able to differentiate normal LV function from 
diastolic dysfunction, with the AUC of 0.994. A BNP cut point at EOpglml was 98% sensi- 
tive, 88% specific, and had a PPV of 98% for having diastolic dysfunction in patients who 
have clinical signs and symptoms, but a normal ejection fraction by echo. Conclusions: 
Thus BNP is able to reliably delineate patients with diastolic dysfunction in patients pre- 
senttng with clinical CHF. 
JACC February 2001 
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877-5 Diastolic Heart Failure or Misdiagnosis? 
Mark C. Petri% Lynne Caruana. John J V. McMurray. Western lnfirmaryof Glasgow, 
Glasgow, United Kingdom 
Background: Patients with suspected heart failure but preserved left ventricular systolic 
function are often thought to suffer from “diastolic heart failure”. We sought to character- 
ise the clinlcal features of this patient group to determine if they had other potential 
causes for their symptoms. Methods: 159 consecutive patients referred by general prac- 
titioners with suspected heart failure to an outpatient-based direct access echocardio- 
graphy service were studied. A full climcal history (including shortness of breath, ankle 
oedema, paroxysmal nocturnal dyspnoea, angina and chronic pulmonary disease) was 
taken. Each participant also had a transthoracic echocardiogram, an electrocardiogram 
and measurement of body mass index and pulmonary function tests. Results: 109 of 159 
participants had suspected heart failure in the absence of left ventricular systolic func- 
tion, valvular heart disease or AF. Of these 109, a third of patients were either obese or 
very obese. Half had a significant reduction in FEVl (70 per cent or less) and 89 per cent 
had a PEFR less than or equal to 70 per cent of normal. 30% patients either had a his- 
tory of angina, a myocardiai infarction or had undergone coronary artery bypass grafilng. 
Only 7% of the patients in this study with a diagnow of heart failure but preserved left 
ventricular systolic function lacked a recognised explanation for their symptoms. Conclu- 
sions: The ma]ority of patients with a diagnosis of heart failure but preserved left ventric- 
ular systolic function have sufficient alternative explanations for their symptoms eg 
obesity, lung disease and myocardial ischaemia. For that reason the diagnosis of “dias- 
tolic heart failure” need not be invoked and management should target these alternative 
conditions 
877-6 Screening for Diastolic Heart Failure Among Elderly 
Patients: Experience From a Randomised, Multicentre, 
Clinical Trial Comparing Perindopril and Placebo: The PEP- 
CHF Study, UK Centres 
Jackie Taylor, John G. F Cleland, Michael Lye, Christopher Gray, Tumpa Banerjee, Eve 
Shannon, Nick Wisniacki, John Baxter, Emma Owen, Anne Spensley, Anita Dunn. 
University of Hull. Kingston upon Hull, United Kingdom, Royal Infirmary, Glasgow, United 
Kingdom 
Several multicentre studies are investigating the effects of treatment on patients with 
heart failure thought to be secondary to diastolic dysfunction. Most of these studies 
define ‘diastolic’ heart failure as a clinical diagnosis of heart failure in the absence of left 
ventricular systolic dysfunction. Recent reports have suggested that many such patients 
may not have cardiac disease as the cause of their symptoms and signs. The Perindopril 
in Elderly People Chronic Heart Failure (PEP-CHF) trial aims to randomise 1,000 
patients aged >70 years who have had a recent cardiovascular hospitalisation, who 
exhibit at least 3 pre-specified clinical features of CHF and who fulfil at least two out of 
four echo criteria confirming the presence of cardiac disease, including a) mild systolic 
dysfunction, b) left atrial dilatation, c) left ventricular hypertrophy d) Doppler criteria, with 
atrial fibrillation being regarded as equivalent to a positive Doppler finding. Thus PEP- 
CHF in contrast to other studies of ‘diastolic’ heart failure requires evidence confirming 
cardiac dysfunction rather than merely the absence of systolic dysfunction. We screened 
a total of 1568 consecutive patients of which 773 had echocardiograms resulting in the 
randomisation of 68 patients by August 2000. 96% of patients were excluded. 256 
because heart failure was excluded on further evaluation, 253 because they were too frail 
to walk even with a walking aid, 353 patients were excluded because they had significant 
systolic dysfunction (WMlcl.4), 172 had valvular disease or uninterpretable echocardio- 
grams, serious co-morbid disease excluded 153 patients and 78 patients had major cag- 
mtive impairment. Some patients had >1 exclusion criterion. This report highlights the 
difficulties encountered in studying a frail elderly population with heart failure, Using “pos- 
itive” echo criteria for diastolic dysfunction rather than simply the absence of systolic dys- 
function greatly reduces the proportion of patients with diastolic heart failure compared to 
that reported in some series More studies in older, more representative patient popula- 
tions are required. 
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1308-45 Conduit Artery Stiffness Increases Post-Exercise in Patients 
With Chronic Heart Failure but Decreases in Normal 
Subjects 
Katerina K. Naka, Jonathan Goodfellow, Ann C. Tweddel, Chris J. H. Jones, Michael P 
Frenneaux. Cardiovascular Sciences Research Group, Cardifff. United Kingdom 
Background: Limited exercise capacity is a cardinal feature of chronic heart failure 
(CHF). Increased arterial stiffness affects cardiac function adversely and may contribute 
to exercise limitation. We have demonstrated that during increased blood flow, endothe- 
lial nitric oxide production leads to improved arterial distensibility (reduced stiffness) in 
normal subjects but not in CHF patients. Distensibility is inversely related to pulse wave 
velocity (PWV). Increased PWV will result in the earlier arrival in the aorta of peripherally 
reflected waves that increase systolic cardiac load, reduce coronary perfusion and thus 
adversely affect cardiovascular performance. We hypothesised that exercise-induced 
changes in PWV are disturbed in CHF. 
Methods: We measured PWV in the lower limb before and after maximal treadmill exer- 
cise in 40 normal subjects (~45 yrs, n=25; >45 yrs, n=15) and in 9 patients with treated 
CHF (NYHA II-III). We used a novel non-invasive method that measures the transit time 
between the upslopes of pressure waveforms recorded in two leg cuffs (inflated to 65 
mmHg) a known distance apart. 
Results: In normals, resting PWV was higher in the older group (8.8k1.3 v. 7.5~0 8 m/s, 
mean&D, ~~0.05) and increased linearly with age (r=O.24, p=O.OOl). PWV was initially 
unchanged post exercise but declined to a nadir at 10 min, recovering by 60 min. The 
post-exercise PWV decrease was greater in younger normals (-25% v. -12%, p<O.Ol at 
10 min). The pattern of PWV decline mirrored that of systolic blood pressure @BP); SBP 
increased by 41% at min 3 and decreased by 6% after 30 min (both ~~0.01 v. baseline). 
In CHF patients, resting PWV (8.2rl.9 m/s) was Similar to normal. However, PWV initially 
increased post exercise (+26%, p<O.Ol v. baseline and matched normals) and returned 
to baseline over 30 minutes (~~0.05 v normals). This PWV increase could not be anrib- 
uted to SBP increase, which was blunted in CHF (CHF +23% v. normals +41% at min 3, 
P<O.O5) 
Conclusion: Arterial stiffness is increased after exercise in patients with CHF, in contrast 
with a prolonged age-dependent decrease in stiffness in normals. Increased arterial stiff- 
ness may further depress cardiac function in exercising CHF patients. 
1308-46 Aortic Distensibility is Independently Correlated With 
Exercise Tolerance in Patients With Dilated Cardiomyopathy 
Stefano Eonapace, Mariantonietta Cicoira, Lorenzo Franceschini, Luisa Zanolla, Giorgio 
Golia, Piero Zardini, Andrea Fiossi. Universita’di Verona, Verona, /My 
Background: Peak exercise oxygen consumption (VOZ) is crucial for the prognostic 
assessment of patlents with congestive heart failure, but Its hemodynamic determinants 
are far from clearly understood. Aortic elastic properties play an essenttal role in deter- 
mining left ventricular (LV) function. An increased aortic stiffness rises LV afterload lead- 
ing to an increased LV work. Aim of this study was to assess the relationship between 
aortic distensibility measured by pulse wave velocity (PWV) and exercise tolerance 
expressed by peak V02 in patients with dilated cardiomiopathy. Methods: 34 patients 
with clinical diagnosis of dilated cardiomiopathy (age 61.3t14 years; 26% female; mean 
ejection fraction (EF) 34X!%) were selected. LV stroke volume (SV), LV volumes and EF, 
mitral E, E/A and E wave deceleration time (DTe) were measured by Doppler-echocardio- 
graphy. PWV was calculated as the time (t) taken by the pulse wave to travel from the 
descending thoracic aorta to the abdominal aorta by Doppler flow recordings and the dis- 
tance (d) travelled by the pulse wave was measured over the body surface as the dis- 
tance between the two recording sites: PWV=dit (misec). To rneawre peak V02 bicycle 
exercise testing with expiratory gas exchange monitoring was performed. Results: in 34 
patients the mean PWV was 6.Ok2.5 m/set (range 2.9-12.2) and V02 was 16.9k5.3 ml/ 
Kg/min (range 8.9-33.4). The hemodynamic variables correlated with V02 were PWV (r= 
-0.50, p&003) and SV (r= 0.45, p=O.O08). In a multiple regression analysis PWV 
(p=O.O3) and SV (p=O.O9) were independently correlated with peak VO2 (A2=0.32). Con- 
clusion: Aortic distensibility affects peak V02 in patients with dilated cardiomyopathy. The 
degree of aortic distensibility impairment might independently predict the exercise toler- 
ance in those patients. 
1308-47 A Short Course of I-Arginine Improves Exercise Capacity 
and Endothelial Function in Chronic Heart Failure: A 
Prospective, Randomised, Double Blind Trial 
Mohammed Yousufuddln, Marcus Flather, Waqar Shamim, Zaheer Yousef, Michael 
Marber, Mohammad Amranl, Nicholas Banner, Michael Kemp, James Hooper, Andrew J. 
S. Coats. National Heart and Lung Institute, London, United Kingdom, Kings Cokge, 
London, United Kingdom 
Background: L-arginine, a precursor of nitric oxide, has been shown to improve endot- 
helial function. The effects of I-arginine in patients with chronic heart failure (CHF) are 
not known. Methods and Results: In this prospective and double-blind study we ran- 
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domised 30 male patients with stable CHF to a short course of I-arginine (6grams per day 
for one week) as add on medication or matched placebo. The cardiopulmonary testing 
was performed using a modified Bruce treadmill protocol. The peak oxygen consumption 
(V02) was determined utilising a breath-by-breath analysis with mass spectrometer 
(AMIS 2000, Denmark) and endothelial function was measured as flow-mediated dilata- 
tion of the brachial artery by a high-resolution linear array ultrasound probe (7-l 1 MHz) 
connected to HP SON0 5500 (Agilant, USA). P&ants with peripheral vascular disease, 
diabetes, concomitant non-cardiovascular problem and inability to exercise were 
excluded. Patients, who were not familiar with treadmill testing, were offered a limited 
exercise testing before the maximal test was performed. Urea, electrolytes and liver 
function tests ware measured on each visit. Age (57+8, 6&9y; p=O.46), NYHA class 
(2i0.5, 2.1+0.5; p=O.6), medications, resting heart rate (71il1, 68+13; p=O.42), mean 
blood pressure (86i-16, 8Oi26) left ventricular ejection fraction (36i12, 37+13%; p=O.88), 
and baseline brachial artery diameters (5.37+0.68, 5.25+0.76mm; p=O.65) were similar in 
both I-arginine and placebo groups. A one-week treatment with I-arginine has resulted in 
a significant increase in exercise duration (523+138 to 598+154; p=O.O04 vs 4951205 to 
512+222;p=O.32), anaerobic threshold (12.3i-3.1 to 13.8+3.1; p=O.OZ vs 12.9f5.0 to 
13.8zb3.5; p=O.84), VO2 (21.7k5.0 to 24.36.9; p=O.O18 “s 21.9*7.0 to 22.1+6.7; p&24) 
and flow-mediated dilatation of the brachial artery (2.312.3 to 3.3+1.1%; p=O.O3 vs 
1.53k2.2 to 2.35?2.3; p=O.l) in I-arginlne group compared to placebo. Conclusion: 
Improved exercise function with I-arginine is associated with improved endothelial func- 
tion 
1308-48 Chronotropic Incompetence Is Related to Reduced Exercise 
Capacity and Increased Mortality in Congestive Heart 
Failure 
Hans P. Brunner-La Rocca, Christoph Scharf, Christoph Schalcher, Erwin Oechslin, 
Wolfgang Kiowski. Cardiology, University Hospifal, Zurich, Switzeriand 
Background: Heart rate response to exercise has been shown to be reduced in patients 
with congestive heart failure (CHF). However, results are controversial regarding its effect 
on exercise performance. In addition, no data are available whether chronotropic incom- 
petence is related to mortality in CHF. Methods: 147 patients with CHF (EF<40%, age 
52~1 years, 88% male) without previous pacemaker implantatton underwent ergospiro- 
metric exercise testing. Chronotropic response was defined as percentage of predicted 
maximal heart rate (220.age) achieved. Chronatroprc incompetence was defined as max- 
imal heart rate ~85% of predicted maximum. Patients were followed up prospectively for 
21+1 months. Results: Chronotropic incompetence was present in 87 patients (59%). 
There was no clear relation to medication including beta-blockade. Patients with chrono- 
tropic incompetence had lower peak 02.consumption (17.5r0.5 vs 20.81-0.8mllminfkg, 
p<O.Ol), lower exercise capacity (1.4+0.1 vs 1.7tO.l W/kg, p<O.Ol), higher ventilatory 
response to exercise (VWCOZ 39+1 vs 35*1, p<O.O5), lower systolic blood pressure at 
peak exercise (119&2 vs. 144+4mmHg, p<O.OOl), and were more symptomatic (NYHA 
2.4~0.1 vs 2.1i0.1, p<O.OS) despite lower pulmonary wedge pressure at rest (16+1 vs 
Ig-tlmmHg, p<O.O5). Maximal respiratory exchange ratio did not differ between the 
groups (1 07+0.01 vs 1.08+0.01, n.s.)lnterestingly, peak oxygen pulse as a non-invasive 
estimate of stroke volume was also reduced (0.13+0.01 vs 0.15+0.1ml/min*/kg, p<O.O5). 
24 patients (16%) died during follow-up. Patients with chronotropic incompetence had a 
2-year survival of 75% which was significantly worse compared to patients with normal 
heart rate response to exercise (89%, p<O.O5). These results were not influenced by the 
medication of the patients. Conclusions: Chronotropic incompetence seems to impor- 
tantly contribute to reduced exercise capacity in patients with CHF, independently of 
hemodynamics at rest. It may be considered as a measure of severity of CHF in that it is 
related to poor outcome and is associated with reduced contractile reserve in these 
patients. 
1308-49 Different Prognostic Value of the Oxygen-Uptake and the 
Ventilatory Efficacy in the Risk Stratification of Heart Failure 
Patients With and Without Chronic Betablocker Therapy 
Anselm K. Gttt, Caroline Bergmeier, Armin Schwarz, Andreas Kilkowski, Thomas 
Kleemann, Matthias Bangert, Jochen Senges. Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany 
Background: The maximal oxygen-uptake (peak VO2), the oxygen-uptake at the anaer- 
obic threshold (V02 AT) and the ventilatory efficacy (VE/VC02-Slope) are used in the 
risk stratification of patients (pts) with chronic heart failure (CHF). It is unknown if the 
prognostic value of these parameters is influenced by the beneficial effect of chronic 
beta-blocker (BB) therapy in CHF. Methods: During 1996 and 1998 we performed car- 
diopulmonary exercise tests with gas-exchange-measurements in 227 CHF-pts (age 
63+10 years, LV-EF 29t8%, NYHA 136, II 123, Ill 68; etiology: 112 CAD, 91 dilated cardi- 
omyopathy, 24 others) who consecutively had been included in a heart failure registry. 
We measured peak V02 breath-by-breath (mllkgimin), the anaerobic threshold (VO2AT, 
mllkgimin) and the ventilatory efficacy (VENC02Slope). We selected peak VO2<14 ml/ 
kg/min, VO2AT ~11 mlikgimin and VE/VCO2-Slope ~35 as threshold values for high risk. 
The median follow-up time was 651 days. We evaluated the prognostic value of these 
parameters in CHF-patients who did (961227, 42%) or did not (1311227, 48%) receive 
chronic BB therapy. Results: Cardiopulmonary exercise capacity was higher in CHF-pts 
with BB as compared to those without BB therapy (peakV02 = 16.955.4 vs 14.6+_5.2 ml/ 
kgimin, p=O.O02 and VO2AT = 12.1t3.6 vs 11.0~3.5 mllkgimin, p=O.Ol). In CHF-pts with- 
out BB therapy the oxygen uptake and the ventilatory efficacy discriminated patients with 
high risk for early death within 6 months, The combination of VO2AT and the VENCO2- 
Slope identified high risk CHF-pts without chronic BB therapy with a %-year mortality of 
32.4%. In CHF-pts with BB therapy these prognostic factors did not identify patients with 
increased ‘/2 year mortality 
l/2 year mortality in CHF 
Theraov BB BB 
JACC February 2001 
no BB no BB 
Prognostic Factor Pas “f?3 P Pas neg P 
peakV02<14mllkg/min 17.7% 4.8% 0.03 6.3% 4.8% 1 
VO2 AT<1 1 ml/kg/min 19.4% 2.3% 0.01 9.1% 3.8% 0.37 
VEiVC02-Slope>35 22.2% 1.5% 0.001 3.1% 6.4% 0.66 
VOZAT + VEIVCO2 32.4% 1.8% 0.001 5.6% 5.5% 1 
Conclusion: In tit+patmts on cnromc w therapy the known prognostrc parameters 
peakV02<14 mllkglmin, VO2ATcli mlikglmin and VEIVCOZ-Slope 235 could not iden- 
tify patients on high risk for early death. 
1308-50 Assessment of Erectile Dysfunction in a Multidisciplinary 
Heart Failure Program 
Kathy A. Hebert, Lee M. Arcement, Tom Ewing, Hector 0. Ventura. Leonard J. Chabert 
Medical Center, Houma, LA, Tulane University Medical Cenfeer, New Orleans, LA 
Background: The prevalence of erectile dysfunction (ED) and its impact on quality of life 
is not well documented in patients with heart failure. 
Methods: Of one hundred fifty patients enrolled in a multidisciplinary heart failure pro- 
gram (January to March 2000) eighty males were evaluated for erectile dysfunction and 
quality of life utilizing the InternatIonal index of Erectile Function (IIEF). This index is a 
questionnaire, which includes several aspects of sexual performance, such as: erectile 
function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfac- 
tion. Erectile dysfunction was defined as the inability to achieve or maintain an erection 
sufficient for satisfactory sexual performance. 
Results: The prevalence of erectlle dysfunction in the total population of patients with 
heart failure was 80%. The clinical characteristics of the patients are detailed in the table 
below. Medical reaimens for heart failure were similar in both oroulx. Patients with ED 
had a decrease in-quality of life. 
” 
ED present (n=64) ED absent (n=l6) 
Age (years) 525 10 48* 10 
NYHA 2.5 2.1 
Ejection Fraction(%) 1955 19-L6 
lschemic Etiology (%) 56 14 
Hypertension (%) 59 86 
Diabetes(%) 34 0 
Conclusions: Erectile dysfunction is a common finding in patients with heart failure and 
systolic dysfunction. 
1) Erectile dysfunction is associated with a decrease in quality of life. 
2) The presence of diabetes and ischemlc etiology is associated with a higher prevalence 
of erectrle dysfunction. 
3) Further studies focused on the treatment of erectile dysfunction in patients with heart 
failure may be beneficial to impact quality of life. 
1308-51 Cough is More Common in Women Than Men With Heart 
Failure Regardless of Medical Therapy 
Kimberly Schleman. Rick Realson, Alastair 0. Robertson, JoAnn Lindenfeld. University of 
Colorado Health Scknces Center, Denver, CO 
Background: Cough is a common reason for discontinuation of angiotensin converting 
enzyme inhibitor (ACE-l) therapy. Both hypertension and heart failure studies have noted 
a female preponderance of cough. We sought to determine if gender plays a significant 
role with respect to ACE-I cough in heart failure patients. 
Methods: We performed a retrospective analysis of the ELITE I and II databases which 
were studies comparing losartan to captopril in elderly patients with systolic dysfunction. 
Cough related adverse events (CRAE), although not primary endpoints, ware prospec- 
tively evaluated by questionnaire. We analyzed the data with a chi-square model, and a 
homogeneity test to assess the possible interaction of gender and ACE-I therapy. 
Results: Women have significantly greater CRAE compared to men in both the losartan 
and captopril arms. 
LOSARTAN CAPTOPRIL 
Male Female P- Male Female P- 
(n=1337) (n&93) value (n=1331) (n&13) value 
AE of cough(%) 6.6 11.5 0.001 14.8 19.6 
0.008 
Drug related AE cough (%) 2.7 4.9 0.014 10.1 15.3 0.001 
Withdrawn (%) Due to AE 0.1 0.7 0.017 2.0 4.1 0.009 
cough 
The homogeneity test showed that the odds ration for cough with captopril vs. losartan 
was not significantly greater in women that men in any of the three cough groups (p=O.Z, 
0.6, 0.2 respectively). 
Conclusions: Cough is more common in women than men with heart failure with both 
losartan and captopril. Both men and women have significantly increased CRAE with 
captopril compared to losartan, but the relative risk of cough in women compared to men 
is the same in both treatment groups. 
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1308-52 Hormone Replacement Therapy Predicts Outcome in 
Women With Advanced Heart Failure. 
JoAnn Lindenfeld, Jalal K. Ghali, Heidi J. Krause-Steinrauf, Surai Thaneemit-Chen, 
Rhonda i. Larsen, Brian D. Lowes, Yves D. Rosenberg, For BEST Investigators. 
Unwersity of Colorado Health Sciences Center, Denver, CO 
Background: The effect of hormone replacement therapy (HRT) on prognosis of heart 
disease in women IS unclear. We sought to determine if the use of HRT predicts an 
improved outcome rn women with advanced heart failure when other important risk fac- 
tors for mortality are included in the analysis. Results: 435 (73%) of the 593 woman were 
age 50 or older. Of these, 95 (22%) were using HRT at baseline. HRT was a predictor of 
survival when adjusted for known baseline risk factors: New York Heart Associatron 
(NYHA) functional class, coronary artery disease (CAD), left ventricular ejection fraction 
LVEF, history of diabetes; creatinine, and plasma norepinephrine (PNE). Age, race, and 
diabetes were not predictive of survival. 
C&variates Hazard Ratio 95% Cl P-Value 
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was no significant difference in the Age, use of angiotensin converting enzyme inhibitors 
or the use of digoxin between the Africa” American and Caucasian patients. Conclu- 
sions: Thus investigation suggests that African Americans treated with beta adrenergic 
blockade who suffer from symptomatic systolic heart failure benefit in a similar manner to 
Caucasians. Furthermore, this data calls into question previously held beliefs regarding 
the potential lack of efficacy of beta blockade in this distinct ethnic population. 
Equal Improvement In NYHA Class and Ejection Fraction Between Races 
Race Pre-NYHA Post-NYHA Pre-EF Post-EF 
African American (N=88) 2.5 2.1’ 24 30”’ 
Caucasian N=l43 2.3 1.8* 26 28** 
p value co.005 p<o.o05 
between Pre between Pre 
and post- and Post-EF 
NYHA 
1308-55 Evidence for intracellular Edema in Euvolemic Heart Failure 
Patients 
Jonathan Sackner-Bernstein, Catalin Toma, Pilar Haynes, Jack Wang, Chris Nunez, 
John Thornton, Donald Kotler, Richard N. Pierson, Steven 8. Heymsfield. St. Luke’s- 
Roosevelt Hospital Center, New York, NY 
Background. Volume overload is the hallmark of congestive heart failure (HF). Yet 
despite use of diuretics to rid patients of edema, symptoms persist. We hypothesized that 
patients treated with optimal diuretic doses remain affected by congestion. To test this 
hypothesis, we assessed body composition of euvolemic HF patients. Methods. In the 
fasting state, HF patients (n=19) underwent measurement of: 1) extracellular, intracellular 
and total body water via bromide and deuterium dilution techniques (ECW, ICW, and 
TBW, respectively), 2) total cell mass measured by total body potassium (TBK) using 
whole body 40K counting, and 3) fat-free “lass (FFM) by DXA scanning. Results were 
compared to normal values matched for age, gender, race, height, and weight by Mann- 
Whitney U test. Patrents treated (“=-I 1) and not treated (n=8) with digoxin were corn- 
pared. Results. Patients had left ventricular ejection fraction < 35%. NYHA Class I (n=l). 
II (n=13), Ill (“~4) or IV (“~1) symptoms, and were 66 f 14 years old. Compared to nor- 
mal values, patients ware euvolemic (normal TBW and TBW/FFM) and were not cachec- 
tic (normal weight, BMI and FFM). However, the ECW/ICW ratio was significantly lower 
than normal (14 % lower, p = ,006) which paralleled reduced intracellular potassium con- 
centration (Ki) (19 % lower, p < O.OOOl), indicating intracellular edema. Digox!” treatment 
was not associated with differences in ECWilCWbr Ki. 
NYHA (Ill vs. IV) 
CAD (Ischemic vs. 
Non-lschamic) 
Creatinine 
LVEF (per1 % 
increase) 
HRT 
“~435, deaths=134 
2.77 [1.40 - 4.291 .OOOl 
2.33 [I .75 - 4.371 .oooi 
2.14 Il.62 - 3.341 .OOOl 
0.96 [1.53 - 3.001 .0008 
0.60 [0.22 - 0.781 .0048 
Conclusions: HRT predicts improved survival in women with advanced heart failure 
even when accounting for other known Important predictors of prognosis. These data 
suggest the need for a prospective study of the use of HRT in women with heart failure. 
1308-53 Predictors of Survival in Women With Advanced Heart 
Failure 
Jalal K. Ghalr, Heidi Krause-Steinrauf, Yves Rosenberg, Rhonda Larsen, Brian D. Lowes, 
Joann Lindenfeld. Cardiac Centers of Louisiana, Shreveport, LA 
Background: Limited data are available on survival of women with advanced heart fail- 
“W. 
Methods: The Beta Blocker Evaluation of Survival Trial (BEST) enrolled 2708 patients 
including 593 (22%) wmnen wrth advanced heart failure (NYHA class Ill or IV with EF < 
35%) to bucindolol or placebo. Complete data were available on 580 women, mean age 
57, 30% black, 62% with CAD, 36% With diabetes, mean LVEF 24%. A multivariate anal- 
ysis, using Cox proportronal hazard regression, was performed to assess the predictive 
value of the followrng clinical and laboratory variables on prognosis: age, race, NYHA, 
CAD, diabetes, systolic blood pressure, BMI, Cardio-thoracic ratio (CTR), baseline LVEF, 
atrial fibrillation, BuniCreatinine, LBBB and QT interval. 
Results: At a mean follow up of 734 days, 158 patients died (26.6%). The following vari- 
ables found to be independent predictors of survival. 
Covariate Hazard Ratio 95% Cl 
NYHA (Ill/IV) 2.64 [1.72-4.051 * 
CAD 2.42 (1.76-3.331 * 
AFIB 2.01 [l .13-3.58]‘* 
CTR 1.04 [i .Oi-I.061 **’ 
BunlCreatinine 1.02 [l.Ol-I.041 *I* 
LVEF (per unit increase) 0.97 [0.94-0.991 ‘** 
SBP (per 1 mmHq) 0.99 10.98-1.001 ** 
*p 5 ,001 
**p < .05 
‘**p < .Ol 
Conclusio”:These data indrcate that severity of heart failure (as assessed by NYHA, 
LVEF, CTR, Bun/Creatinine and SBP) and rschemic etiology are predictors of survival in 
women Interestingly, age, race and the presence of diabetes do not appear to affect sur- 
vival. 
1308-54 Is Beta Adrenergic Blockade in African Americans and 
Caucasians Equally Effective ? 
Robert L. Scott, Aditya Samal, T&l Hamdan, Myung H. Park, Mandeep Mehra and 
Rochelle Howard. Ochsner Heart and Vascular Institute, New Orieans, LA 
Background: Neurohormonal attenuation has clearly demonstrated significant improve- 
ments in total mortality, ejection fraction, New York Heart Association class and sudden 
cardiac death when used in patients with mild to moderate systolic heart failure. Among 
the most effective agents in attenuating toxrc neurohormone production are beta-adren- 
ergic blocking agents and angiotensrn converting enzyme Inhibitors. The majority of the 
systolic heart failure trials using beta-adrenergic blocking agents have included very few 
African American patients forcing clinicians to extrapolate the data form non-African 
American patients. This is particularly concerning given the trend towards an adverse 
outcome noted in African Americans patients with systolic heart failure treated with 
Bucindolol in the BEST Trial. Methods: In our investigation we retrospectively analyzed 
patients with systolic heart failure treated with various beta-adrenergic blocking agents. 
Among the variables assessed were: Age, Race, Pre and Post beta-blocker ejection frac- 
tion, pre and post beta-blocker NYHA Class, concomitant use of angiotensin converting 
enzyme inhibitor and concomrtant use of digoxin. Results: Our investigation demon- 
strated a significant improvement rn both the ejection fraction and the New York Heart 
Association Class in patients maintained on beta-blocker therapy (p<.OO5). Furthermore 
the improvement was present in both African American and Caucasian patients. There 
Conclusions. HF patients without clinical evidence of edema, whose TBW is normal, 
can have “intracellular edema.” This intracellular volume expansion is not a function of 
Na-K ATPase inhibition by digoxin, and may represent an important mechanism in the 
functional abnormalities of heart failure and a new therapeutic target. These are the first 
data describing “intracellular edema” measured in viva in human disease. 
1308-56 Electromechanical Dysfunction of the Left Atrium Due to 
lnteratrial Block 
Sanjeev B. Goyal, David H. Spodick. University of MassachusettsNVorcester Medical 
Center, Worcester MA 
Background: lnteratrial block (IAB, P wave duration 2 120 ms) is associated with left 
atrial (LA) enlargement and predisposes to atrial fibrillation. LA dysfunction is associated 
with decreased left ventricular filling, propensity for LA appendage thrombus formation 
and reduced atrial natriuretic peptide levels. We measured LA function in patients with 
IAB and control patients. Methods: Echocardiograms with LA enlargement (LA diameter 
1 4 cm in the parasternal long axis view) were analyzed. Patients with poor endocardial 
edge detection, absence of sinus rhythm, significant mitral regurgitation, aortic valvular 
disease, prosthetic cardiac valves or pacemakers ware excluded. Twerity four patients 
had IA6 and 16 patients with LA enlargement without IAB formed the control group. 
Using the biplane area-length method, LA volumes at mitral opening (maximal LA vol- 
ume), onset of P wave on simultaneous electrocardiogram and mitral closure were 
obtained. Based on Simpson’s formula, LA stroke volume (Vs), ejection fraction (LAEF) 
and kinetic energy (LAKE) were calculated. A wave acceleration time and velocity were 
also determlned. Results: The control group and patients with IAB were comparable with 
respect to age, LA diameter and maximal LA volumes (p > 0.05). Patients with IAB had 
significantly smaller Vs (6 ml vs. 16 ml, p c O.OOl), LAEF (7% vs. 23%, p < 0 001) and 
LAKE (2 Kdynes/cm/s vs. 7 KdynesicrnIs, p < 0.001) and larger A wave acceleration 
times (107 ms vs. 80 ms, p = 0.003). LAKE varied inversely with the P wave duration (I = 
-0.47, p = 0.02). On multivariate regression analyses P wave duration and maximal LA 
volume were independent determinants of LAKE (p < 0.001 and = 0.03 respectively). 
Conclusions: Patients with IAB have reduced LA function as indicated by lower Vs, 
LAEF and LAKE than control patients with LA enlargement without IAB. These aspects of 
LA dysfunction are related to the degree of IAB. IAB should be considered a marker of a 
electromechanically dysfunctional LA and hence a risk factor for atrial fibrillation, congas- 
tive heart failure and cerebrovascular accidents. 
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Methods: 35 HCM patients with LV gradients ~30 mm Hg were ACE genotyped and 
were divided into 2 age- and gender-matched groups based on maximum oxygen con- 
sumption (MVO,) during symptom-limited upright bicycle exercise testing: group 1, MVO* 
< 20 mlO$kg/min (n=l8); and group 2, MVOp > 20 mlO,/kglmin (n=17). LV mass was 
measured by magnetic resonance imaging, LV function by radionuclide angiography, and 
myocardial perfusion by exercise thallium scintigraphy. 
Resulis: Exercise ejection fraction (EF) and peak filling rate (PFR) were significantly 
lower in group 1. Abnormal blood pressure (BP) response to exercise (systolic BP 
increase < 25 mm Hg) was present in 1 i/18 (61%) patients in group 1 and 4/17 (24%) 
patients in group 2, ~~0.05. LV mass-index (LVMI) was not significantly different in the 
two groups. Perfusion defects were present in 1111.5 (73%) patients in group 1 and 13115 
(87%) patients in group 2 (p>O.O5). mere was a significantly greater proportion of the DD 
genotype in group 1. Patients with DD genotype (n=9) had lower exercise ejection frac- 
tions (69ill% vs. 83+13%, p=O.O3), and lower MVOl (17*5 vs. 25F9, p-zO.05) compare 
to patients with II and ID genotypes. PFRs tended to be less (2.4kO.8 vs. 3.6ki.4, p=O.i). 
1309 Hypertrophic Cardiomyopathy: Genetic 
Aspects 
Wednesday, March 21, 2001, 9:00 a.m.-l I:00 a.m. 
Orange County Convention Center, Hall A4 
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1309-57 Prevalence and Clinical Characteristics of Hypertrophic 
Cardiomyopathy Caused by Actin Mutations 
Saidi A. Mohiddin, Judith Winkler, Elisha MClam, David A. Begley, Lameh Fananapazir. 
NHLBI, National lnstifufes of Healfh, Befhesda, MD 
Introduction: Hypertrophic cardiomyopathy (HCM)is caused by mutations in one of nine 
sarcomeric genes. Actin is a critical component of the thin filaments of the contractile 
apparatus of the heart: 80% are encoded by thecardiac actin gene (ACTC) and 20% by 
the ACTS gene (skeletal isoform which has 99% homology with cardiac actin). Mutations 
in cardiac actin (ACTC) may interfere with either generation or transmission of contractile 
force to result in HCM or dilated cardiomyopathy. We examihed the frequency with which 
mutations in ACTC and ACTS penes cause HCM. 
Methods: DNA from 200 unrelated HCM patients was screened for mutations in ACTC 
and ACTS by Single Stranded Conformation Polymorphism. Non-conformers.were 
sequenced. Following mutation detection, further family members were evaluated by 
echocardiography and magnetic resonance imaging. 
Results: Two novel missense mutations were detected in highly conserved regions of 
ACTC. Both mutations were absent from DNA in 200 unrelated normal subjects (400 
chromosomes). a ValSLeu substitution was sporadic (absent in both parents) and a 
Leu261 Phe mutation that was present in several affected family members. Both sporadic 
and familial cardiac actin mutations were associated with a an unusual and previously 
undescribed HCM morphology characterized by apical hypertrophy and trabeculation. 
This distinctive morphology resembles ventricular non-compaction that may result from 
interrupted ventricular development. Several nucleotide substitutions were detected in 
the 6 exons of ACTS; none, however, altered translation. 
Conclusions. (1) ACTC mutations cause spontaneous and familial HCM; (2) ACTC 
mutations are responsible for about 1% of HCM, but should be suspected in patients with 
apical HCM; (3) ACTC may be critical for normal myocardial compaction during develop- 
ment; and (4) ACTS mutations are not a common cause of HCM. 
1309-58 The Val606Met Mutation of the Cardiac B-Myosin Heavy 
Chain Gene in Patients With Hypertrophic Cardiomyopathy 
is Associated With a High Risk of Sudden Death at Young 
Age 
Ole Havndrup, Henning Bundgaard, Paal S. Andersen, Lars A. Larsen, Jens Vuust, 
Michael Christiansen, Keld Kjeldsen. National University Hospital, Copenhagen, 
Denmark, Statens Serum lnstitut, Copenhagen, Denmark 
Objectives: The purpose of this study was to identify families with hypertrophic cardi- 
omyopathy (FHC) associated with the cardiac beta-myosin heavy chain (MYH7) gene 
Val606Met mutation, and characterise the phenotype with specific focus on the prognosis 
associated with the mutation. Background: A cohort of FHC patients at a tertiary referral 
centre for hypertrophic cardiomyopathy patients. Materials and methods: A cohort of 70 
families with FHC was studied clinically, para-clinically with ECG and echocardiography 
and molecular genetically using single strand conformation polymorphism - heteroduplex 
formation (SSCP) analysis with subsequent sequencing of the MYH7 gene. Results: The 
Val606Met mutation was found in one family. SSCP and sequence analysis identified a 
nucleotide 10457 G to A missense mutation in the MYH7 gene, resulting in a substitution 
of a Val-codon for a Met-codon at position 606 in the affected family members of family 
JO. The mutation was associated with full penetrance before adulthood, high morbidity 
and a high mortality. The family history revealed three sudden deaths before the age of 
30 years. In three additional family members an ICD-unit was implanted based on the 
family history, NSVT on Halter monitoring and episodes of syncope’s. In the literature, 
five additional studies of FHC caused by the Val606Met mutation have been reported, i.e. 
a total of 49 known genetically affected persons and three clinically suspected in nine 
families. Based on pooled data, the cumulative incidence of sudden death (before 30 
years of age) in families with the Val606Met mutation is 18.23% (9/49 genetically veri- 
fied). Some of these early deaths occurred in previously asymptomatic individuals. Con- 
clusion: The cumulative incidence of sudden death at young age in FHC patients with 
the Val606Met mutation of the MYH7 gene is high, and management of these patients 
should take this potentially high risk into account. 
1309-59 Angiotensin-I Converting Enzyme Gene Deletion 
Polymorphism is Associated With Impaired Left Ventricular 
Systolic Function and Exercise Performance in Non- 
Obstructive Hypertrophic Cardiomyopathy 
David A. Begley, Saidi Mohiddin, Lameh Fananapazir. National lnstitufes of Health, 
Bethesda, MD 
Background: The insertion/deletion (I/D) angiotensin-I converting enzyme (ACE) gene 
polymorphism is associated with increased plasma ACE levels and increased left ventric- 
ular (LV) hypertrophy in hypertrophic cardiomyopathy (HCM). We sought to determine 
the influence of the l/D genotypes on LV mass, systolic and diastolic function, and myo- 
cardial perfusion. in non-obstructive HCM patients with and without exercise limitation. 
DD Genotvoe LVMI a/m’ Rest EF (%) Exercise EF I%) PFR ml/set 
Group 1 
Group 2 
*p<o.oz 
I. 
8/l 8 (44%) 96t.38 69k.14 74+13 2.5rl .O 
l/17 (6%) 108147 78+13 85~13” 4.1?1.2* 
Conclusions: ACE DD genotype is associated with impaired exercise systolic function 
and exercise performance. The etiology of the LV dysfunction is uncertain but does not 
appear to’be directly related to LV mass. Further studies are necessary to determine if 
the findings are due to ACE-induced increased myocardial fibrosis and fiber disarray, and 
whether ACE inhibition reverses the abnormalities. 
1309-60 Isoproterenol-Induced Sudden Deaths in Transgenic Mice 
Expressing a Troponin T Mutant Linked to Familial 
Hypertrophic Cardiomyopathy 
Bjoern C. Knollmann, Neil J. Weissman, Stephen A. Blatt, Kenneth Horton, Fatima de 
Freitas, James D. Potter. Georgetown University Medical Center, Washington, DC, 
Washington Hospital Center, Washington, DC 
Background: The cardiac troponin T (TnT) l79N mutation has been linked to familial 
hypertrophic cardiomyopathy and a high incidence of sudden death in humans, despite 
causing little or no cardiac hypertrophy. To study the mechanisms of sudden death 
caused by this mutation, we generated transgenic mice, in which mouse TnT was 
replaced with either human wild-type (WT) or mutant (179N) Tn% In vitro skinned fiber 
studies showed that the l79N mutation caused higher Ca2+ sensitivity of force. Here we 
examine the cardiac contractility and electrophysiology of this murine FHC model in viva 
Methods: WT (n=43) and l79N (1x37) mice underwent tail-cuff blood pressure measure- 
ments,.ECG, and 2-D and Doppler echocardiography at baseline and after high (1.5 mg/ 
kg IP) or low (0.1 mglkg IP) isoproterenol (ISO). Results: l79N mice had a lower heart 
rate (179N 522*7 vs. WT 606+10 blmin, p=8E-9) but similar blood pressure (112+2 vs. 
115+2 mmHQ, p=n.s.). Anesthetized 179N mice had a significantly longer PR interval on 
ECG, but no spontaneous arrhythmias. Echocardiography revealed increased fractional 
shortening (FS: l79N 43+3%, vs. WT 27~tl%, p=5E-10) without evidence of left ventricu- 
lar hypertrophy. High dose IS0 initially increased heart rate, but 6 of 8 (75%) 179N vs. 1 
of 8 (12.5%) WT mice (p=O.OlZ) died within 10 min after the IS0 challenge, with QRS 
widening, bradycardia and heart block on ECG. Low dose IS0 caused ECG changes 
(loss of R-wave, QRS widening, T-wave inversion) in 75% of l79N mice, but in none of the 
WT mice. Echocardiography revealed an impaired contractile response to low-dose IS0 
(%increase in FS: l79N 8r3.3%, n=12, vs. WT 27+2.7%, n=lO, p=O.O009) despite a sim- 
ilar heart rate response. Doppler studies ruled out aortic outflow obstruction and were 
consistent with impaired diastolic filling (E/A ratio: l79N 4.0+/-1.3 vs. WT l.l+/-.07, 
p=O.O06). Global left-ventricular hypokinesis developed in l79N mice with the most 
severe ECG changes. Conclusion: The increased myofilamental Ca2+ sensitivity due to 
the l79N mutation enhances baseline contractility in viva, but may lead to impaired dias- 
tolic ventricular filling and excess mortality under beta-adrenergic stimulation, even with- 
out cardiac hypertrophy. 
1309-61 Reversal of Myocardial Interstitial Fibrosis in the Cardiac 
Troponin T-Q92 Transgenic Mouse Model of Human 
Hypertrophic Cardiomyopathy With Angiotensin II Receptor 
1 Blockade 
Do-Sun Lim, Fiajnikant Pa&l, Silvia Lutucuta, Pavan Bachireddy, Keith Youker, A. Evans, 
Mark Entman, Robert Roberts, Ali J Marian. Baylor Co/fege of!&dicine, Housfon, TX 
Hypertrophic cardiomyopathy (HCM) is a genetic disease due to mutations in contractile 
sarcomeric proteins. It is characterized by cardiac hypertrophy, myocyte disarray, and 
interstitial fibrosis (IF). IF is a major cause of sudden cardiac death (SCD) in HCM. We 
and others have proposed that IF in HCM is a secondary phenotype due to activation of 
trophicimitotic factors in the heart. We tested whether blockade of angiotensin II receptor 
1 (ATRl), a major trophiclmitotic factor, can attenuate or reverse IF in a transgenic 
mouse model of human HCM. We randomized 24 adult mutant cardiac troponin T (cTnT- 
Q92) mice, which exhibit myocyte disarray and IF to therapy with losartan or placebo. 12 
non-transgenic (non-tg) mice were also included as. controls. The mean dose of losartan 
and the duration of therapy were 14.215.3 mg/kg/d 42e9.6 days. All mice tolerated lasa- 
ratn. Male/Female, Heart/Body weight (HT/BT) ratio, and the extent of mydcyte disarray, 
expressed as % of total myocardium, were similar in placebo and losartan groups 
(Table). However, % volume fraction of Collagen (CVF) was reduced by 49% in the losar- 
tan group (p=O.Ol) and was similar to that in the non-tg. Expression of transforming 
growth factor (GF) 61, a mediator of ATFil fibrotic effect, was reduced and normalized in 
the losartan group. There was a &strong correlation between % of disarray and CVF in the 
placebo group (p&001). Thus, TX with losartan reduced and normalized IF and TGFB1 
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in ihe mutant cTnT-QQ2 mouse model of human HCM, but had no effect on myocyte dis- 
array. These findings raise the possibility of reversal or attenuation of IF, major predictor 
of SCD, in human patients with HCM. 
Los&an and Reversal of interstitial Fibrosis 
Non-Transgenic cTnT-Q9P cTnT-Q92 
N=l2 Placebo N=lZ Losartan N=l2 
Age 447 +I- 69 409 +/- 53 403 +/- 49 
Heart/Body Weight (mgig) 4.1 J- 0.5 3.9 +/- 0.5 3.9 +/- 0.7 
Myocyte Disarray Volume 3.9 +/- 2.3 27.6 +/- 10.6 23.4 +/- 9.6 
Fraction (%) 
Collagen Volume Fraction 4.5 +/- 2.2 9.8 +I- 6.8 4.9 +I- 2.9 
(%I 
TGFBl Volume Fraction (“A) 0.66 +/- 0.3 l.lo+l-oo.4 0.5 +/- 0.5 
LVEDD (mm) 3.5~0.2 3.8+0.1 4.9~0.2* 5.4t0.1* 0.48 
LVESD (mm) 2.1+0.1 2.2iO.i 3.2+0.2* 3.3+0.1' 0.83 
IVS+PW (mm) l.liO.1 1.3+0.1 1.2*0.1 1.8+0.1*# 0.01 
VCFr @c-0.5) 2.7~0.2 2.920.2 2.2%0.2 2.5+0.1 0.82 
RIAWm?an arterial pressure, WH-WnOle heart weight, LV-lett VentrlCUlar weight, HV-rlgiit 
ventricular weight, LVEDD-LV end-diastolic dimension, LVESD-LV end-systolic dimen- 
sion, IVS+PW-septum + posterior wall thickness, VCFr-rate corrected velocity of circum- 
ferentlal shortening. *p<O.O5 compared to respective Sham groups, #pcO.O5 compared 
to respective 111 groups. AxG-p value, interaction between ACF x genotype by 2 way 
ANOVA. n=5-6. 
This findings support the hypothesis that ANP protects the heart from developing both LV 
and RV enlargement in response to volume overload. Echo data indicated that cardiac 
function did not differ between two genotypes in either sham or ACF mice. 
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1310-62 Two Distinct Chronic Heart Failure Phenotypes Following 
Myocarclial Infarction in Mice 
Svetlana A. Voitchikhina, Bryan C. Yacono, Edward G. Lakatta, Mark I. Talan. 
Gerontology Research Center, National Institute on Aging, NIH, Baltimore, MD 
Objectives: While advances in murine transgenic technology offer an opportunity for the 
development of novel therapies for prevention of post-infarct ventricular dysfunction and 
failure, practical applications require the development of experimental models to charac- 
terize diverse aspects of chronic post-infarct myocardial remodeling and its relation to 
function. We have established such a mouse model of chronic heart failure. Method: 
Eight weeks after ligation of the left coronary artery or sham operation (S), 3-mo old mice 
were subjected to Doppler echocardiography (15 mhz) and detailed closed chest charac- 
terization of ventricular function measured across a range of preloads effected by vena 
cava occlusion, via a left ventricle (LV) pressure/volume (PV) conductance catheter. 
Results: The total mortality at 8 weeks was 17%, of which the early post-operative mor- 
tality was 7%. Among surviving animals at 8 wks, two distinct LV remodeling phenotypes 
with distinctly different functions were identified: hypertrophic (H) and dilated (D) hearts. 
Compared to S: LV mass/chamber volume index was increased by 134% and decreased 
by 58% in H and D respectively; and LV volume was reduced by 42% and increased 
byiOO% in H and D respectnely. Stroke volume (SV) and ejection fraction (EF) were 
reduced in both H and D (Table). 
S 
SV (mkL) 14.2 + 1.6 
EF (“Io) 80.1 + 5.5 
Tau (msec) 13.2 + 3.6 
* - p<O.Ol, vs Sham; # - pcO.01, D vs H 
H D 
8.1 + 1.6* 5.0 + 1.3‘# 
51.6 + 5.9’ 32.6 + 5.5’# 
17.4 + 5.6 24.9 + 3.3* 
Whereas the slope of end-systolic pressure volume relationship (ESPVR) was decreased 
by 57% in D, in H the ESPVR was increased 3 fold vs S. Conclusion: Two distinct phe- 
notypes (H and D), both manifesting systolic failure (reduced EF and SV), evolve after 
experimental myocardial infarction in mice; however, in H, markedly exaggerated LV con- 
tractility, indexed by an increase in the slope of ESPVA, occurs in the context of reduced 
diastolic filling volume and limits the extent of systolic fallwe. Thus, H and D have fea- 
tures of clinical syndromes of “diastolic” and “systolic” heart failure. 
131 O-63 Cardiac Enlargement in Response to Volume Overload is 
Exaggerated in Mice With Homozygous Deletion of the 
Atrial Natriuretic Peptide Gene 
Tatsuhiko Mori, Gilbert J Perry, Ji An Feng, Suzanne Oparil, Yiu-Fai Chen. University of 
Alabama at Birmingham, Birmingham, AL 
AtrIal natriuretic peptide (ANP) ii overexpressed as part of the fetal gene program in the 
hypertrophied left ventricle (LV) and is thought to have an antihypertrophic effect in 
heart. The current study tested the hypothesis that ANP protects the volume overloaded 
heart from developw?g hypertrophy. Wild type mice (l/l) and mice with homozygous 
d&ton of the ANP gene (O/O) underwent placement of an aorto-caval fistula (ACF) or 
sham surgery (Sham) and were subjected to echo-cardiographic examination under tri- 
bromoethanol anesthesia at 2 wks. ACF shuntmg assessed by a microsphere technique 
was similar in l/i and O/O. Results (means&EM) were: 
Sham l/l Sham 010 ACF iii ACF O/O AxG 
1310-64 Effects of Xylazine/Ketamine Versus Avertin Anesthesia on 
Left Ventricular Structure and Function in Normal Mice 
Char1 Y. T. Hart, John C. Burnett, Jr., Margaret M. Redfield. iMayo C/if&, Rochester, MN 
Background: Assessment of cardiac function in murine models with altered genotype is 
crucial if the influence of genetic manipulation on cardiovascular physiology is to be fully 
appreciated. Evaluation of left ventricular (LV) function in the conscious state is not yet 
widely available and assessment of LV structure and function by echo or NMR spectros- 
copy requires anesthesia. Avertin (2,2.2-tribromo-ethanol; AV) or a combination of xyla- 
zinc with k&amine (XK) are the two most commonly utilized anesthetic regimens. While it 
is appreciated that XK results in bradycardia, the effects of these agents on LV function 
and structure has not been formally compared. While myocardial contractility is rate 
dependent (force frequency relationship), load-dependent measures of LV systolic func- 
tion (fractional shortening or ejection fraction) may be augmented by bradycardia if It 
results in increases in preload (Frank Starling mechanism). Thus, we compared the 
effects of XK and AV on LV structure and function assessed by echo I” the normal 
mouse. Methods: Male Swiss Webster mice (12.16 weeks old) weighing 35-49 grams 
were studied using XK (n=7) or AV (n=5) anesthesia. Xylazine 0.05mg + k&amine 
0.75mg IM or AV 2.5% O.O15ml/g body weight IP was administered and ‘/2 the initial dose 
was given after 40 minutes as needed. Transthoracic echo (GE SystemFive, lo-MHz 
probe) was performed in a semi-decubitus position on a standoff gelpad. Results: Level 
of anesthesia was similar between the two agents. ‘pcO.05 vs. XK. 
XK Avertin 
Weight (g) 4122 39+1 
Heart rate (bpm) 27lt21 452i35* 
LV end-diastolic dimension (cm) 0.42~0.01 0.37+0.01= 
LV end-systolic dimension (cm) 0.22*0.01 0.22t0.01 
Fractional shortening (%) 47t2 4oi1* 
Ejection fraction (46) 85t2 79*2* 
Conclusion: XK results in non-physiologic heart rates in the mouse. This bradycardia is 
associated with increases in preload (LV end-diastolic dimensiori) and increases in load- 
dependent indices of systolic function. As murine cardiovascular physologic assessment 
matures, increased attention to methodology is needed to insure that data are collected 
under (near) physiologic conditions. 
1310-65 Comparision of Two Methods to Determine Left Ventricular 
Pressure-Volume Relationships in Mice 
Marc D. Feldman, Rebecca Blackwood, Danny Escobedo, Gregory L. Freeman. 
Unwersity of Texas He&h Science Center, San Antonio, TX 
Background: The generation of left ventricular (LV) pressure-volume ,elationships in the 
in situ murine cardiovascular system is important to define functional phenotype. There 
are two methodologies to generate this information, dual frequency conductance (vol- 
ume) and 2.dimensional crystals. There have been no comparisons of these two meth- 
ods. 
Methods: Open-chest C57B mice (n=12) were mechanically ventilated. The LV was 
instrumented with epicardial 2.dimensional crystals and a dual frequency pressure-vol- 
ume (conductance) catheter. A flow probe was placed on the thoracic aorta. Baseline 
pressure-segment and volume relations were acquired at steady state and during tran- 
sient occlusion of the inferior vena cava. 
Results: Heart rate was 477 F 66 bpm, maximal LV pressure was 73 i 9 mmHg, and 
end-dlastollc pressure was 6 i- 2 mmHg. A comparison of the conductance and crystal 
derived data is shown on the table and includes Ved (end-diastolic volume, ,&I), V,, (end- 
systolic volume, PI), SV (stroke volume, pl), E,, (end-systolic etastance, mmHg/@), and 
V, (E,, extrapolated volume intercept, pl). 
Although the mean SV and E,, were similar, there were poor correlations of individual 
mice between the two methods (SV r=O.45, E,, r=0.26). 
Conclusion: Volumes detected with the P-dimensional crystals are greater than conduc- 
tance due to the volume offset of their epicardial location. Although the mea” E,, was 
similar between the techniques, individual values did not correlate. 
Ved VeS SV Ees VO 
Conductance 20 f 11 11 t8 ilk5 17+19 4k6 
Crystals 63+14' 55&i? * Qe4 14*7 50+10" 
MAP (mmHg) 93.9t4.6 126.2t9.5# 73.525.7 105.8&.0# 0.98 
WH hi) 101.3k7.2 174.0r9.4# 173.4~8.2 310.7*14.V# 0.01 
LV (vi 71.9+5.5 117.3k7.7# 111.7&2- 191.1+8.1*# 0.03 
RV hs) 22 Qrl.7 43.0+1.5# 43.6+3.0* 83.6t5.7*# 0.02 
* 0 < 0.01 
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1310-66 Which Contractile Index Is Most Sensitive in Examining 
Murine Cardiac Contractility ? 
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1311-69 Testosterone Deficiency as a Risk Factor of Coronary Artery 
Disease in Postmenopausal Women 
Shintaro Nemoto, Giberto DeFreitas, Douglas L. Mann, Blase A. Carabello. VA Medical Agnieszka D. Kaczmarek, Krzysztot Reczuch, Katarzyna Sosnik, Jacek Majda, 
Center, Houston, TX, Baylor Co//ege of Medicine, Houston, TX Waldemar Banasiak, Piotr Ponikowski. Military Haspita/, Wroclaw, Poland 
Background: Measurements of LV function in large mammal? are well described but 
these sophisticated techniques are often overlooked in m@ne studies which have been a 
mainstay of analyzing the effects of genetic manipulation on cardiac phenotype. The goal 
of this study was to address which indices of LV function ware most sensitive to change 
in cardiac contractility. Methods: LV function was assessed in viva in closed chest mice 
by echocardiograms and also by LV catheterization using 1.4F micro-tipped combined 
pressure-volume catheter under intrinsic sinus rhythm (SR:290+29 beatslmin) and during 
atrial-pacing at a HR (HRm:505+14 beatsimin) which we used to increase inotropy by 
augmentation of the force-frequency-relation. Preload independent parameters, such as 
&stance maximum (Emax) and slope of dP/dt-max.EDV relation (dP/dt-ED!/), were 
measured dunna w&ad reduction bv IVC occlusion as well as standard uarameters. 
Results: See the table. 
Background: Testosterone (T) is assumed to be a risk factor for coronary artery dwase 
(CAD). However, recent studies have demonstrated a beneficial effect of T on myocardial 
ischaemia in men with CAD. The potential role of T in CAD I” women has not been eluci- 
dated. We assessed whether abnormal T lev& are associated with CAD in postmeno- 
pausal women and whether there is any correlation between T and other CAD metabolic 
risk factors. 
Method:: We studied 97 consecutive postmenopausal women (mean age: 63yrs) who 
underwent coronary angiography. Exclusion criteria were previously documented CAD or 
endocrine disease. In all patients we measured: serum T levels and sex hormone-binding 
globulin (SHBG) Testosterone free index (TFI) was calculated as TxiOOiSHBG. We also 
evaluated: total cholesterol (T-chol), LDL-chol, HDL-chol, triglycerides (TG), apolipopro- 
teins A, and 6 (apa A,, apo B), lipoprotein a [Lp(a)], and fibrinogen level. 
Results: CAD was documented in 51 (53%) patients (CAD+). CAD+ group demonstrated 
decreased T level (1.0?0.4 vs 1.3i0.6nmol/L, CAD+ vs CAD-, p=O.O3) and a trend 
towards lower TFI (3.2kl.4 vs 3.8Al.9, p=O.12). No difference in SHBG was found 
between the 2 groups (31.9 vs 35 Snmol/L, p>O.2). Abnormal llpid parameters were 
found in CAD+ vs CAD- [increased T-chol(p=0.04), Lp(a)(p=0.007), apoB(p=0.02), 
decreased apo A,(p=O.O02)]. However, T level did not correlate with any CAD metabolic 
risk factors (rc0.2, p>O.2 for all correlations). In 15 (13%) women who used hormonal 
replacement therapy (HRT) we observed significantly elevated T levels (1.64+0.59 vs 
1.05+0.52nmol/L, HRT+ vs HRT- respectively, p&001) and higher TFI (5.122.3 vs 
3.2fl.4, p=O.O006). After exclusion of these women, still T levels were decreased in 
CAD+ group (p=O.O9). 
Conclusions: Decreased T levels are assoctated with CAD in postmenopausal women, 
independently of other CAD metabolic risk factors. HRT tends to increase T levels and 
this may support the beneficial role of HRT on postmenopausal women. 
FS(%) EF(%) VCf MNSER Emax dP/dt-EDV 
SR 27.9k2.0 40.0+1.1 4.7750.32 6.9i0.3 11.711.7 590.6zt82.1 
HRm 30.5e2.4 46.6i2.4 6.75r0.56 10.4+0.3 21.6k3.6 1456.5~231.7 
P 0.38 0.027 0.0037 0.001 0.0386 0.0078 
%Change 10.2k6.3 16.6k5.3 42.2&O 41.9k5.6 67.9i-12.2 162.8r95.9 
Vcf: circumferences per second, MNSER: mean normalized systolic ejection rate. Con- 
clusion: This study demonstrated that 1)preload independent parameters ware most 
sensitive to change in LV contractility in mice and 2)FS failed to show this significant 
change. Moreover, HR has a substantial effect on murine LV performance and must be 
considered in the evaluation of cardiac function 
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131 I-68 Incremental Prognostic Value of Clinical, Exercise 
Treadmill, and Scintigraphic Data in the Elderly 
Richard M. Steingart, Patty Hodnett, Joseph Musso, Florence M. Prigent, Martin 
Feuerman. Winthrop-University Hospital, Mineola, NL: Health Sciences Center, SUNY at 
StonyBrook, Ston);.Brook, NY 
To characterize the incremental prognostic information from treadmill exercise testing 
(TXT) and exercise SPECT myocardial petfusion imaging (MPI) in the elderly, we ana- 
lyzed clinical, TXT, MPI and follow up data for all outpts r65 yrs old who underwent symp- 
tom limited Bruce protocol TXT MPI at our institution between 1992 and 1996. The Duke 
treadmill exercise score (TES) was calculated from TXT time, ST segment depression 
and exercise angina. There were 400 men and 228 women, age 70.1+4.4 yrs 
(mean&D). Most had stable symptoms (93%). TI was used in 79% and Tc99m in 21%. 
Peak TXT heart rate was 135.2r18.8 bpm or 9li12% of MPHR. TXT time was 6.0~2.1 
min. Follow up was for 4.4kl.3 yrs and was 97% complete. Five yr survival without death 
(N=39) or Ml (N=21) was 89.3il.5%. Univariate predictors of death or Ml included male 
sex (12% vs 6%, ~~0.04) abnl rest ECG (12% vs 6%, p<O.Ol), MPI cardiomegaly (16% 
vs 8%, p<O.Ol), MPI ischemia (13% vs 6%,p<O.O4), TI lung uptake (21% vs 8%, 
p<O.OOl) and TES risk group (27% high vs 14% moderate vs 7% low, p=O.O05). Age, 
peak TXT heart rate, TXT time, TXT ST segment depression and number of ischemic 
MPI vascular territories also predicted death or MI, but risk factors, medications, exercise 
induced angina, isotope and MPI infarct did not. The Cox multiple regression analysis is 
shown below. Gender, age, and the resting ECG were independent clinical predictors of 
subsequent death or Ml. Incremental prognostic information was provided by TXT time 
(lower risk wth increasing TXT time). Once TXT time was known, the TES and its other 
components, angina and ST depression, did not aid in the prediction of subsequent 
death or Ml. Then, when MPI results were added to the Cox equation, TI lung uptake was 
the only other independent predictor of death or Ml. Conclusions: In this large series of 
elderly outpatients, age, sex, and the rest ECG best predicted death or Ml. Exercise tol- 
erance and TI lung uptake, a sign of left ventricular dysfunction, provided important incre- 
131 l-70 Characteristics and Blood Pressure Responses of 6,057 
Hispanic Hypertensive Patients With Coronary Artery 
Disease Enrolled in the INVEST 
Rhonda M. Cooper-DeHoff, Eileen M. Handberg, Heather A. Bristol, Henry R. Kolb, 
Efrain Gaxiola, Jose Cangiano. Carl J. Pepine, for the INVEST Investigators. Universityof 
Florida, Gainesville, FL 
Background: The INternattonal VErapam SRflrandolapril STudy (INVEST) is a ran- 
domized, multicenter, prospective trial designed to control elevated blood pressure in 
patients with CAD and to compare risks for adverse outcomes (death, non-fatal MI or 
non-fatal stroke). Methods: Patients are randomized to pharmacologic therapy with 
either a calcium antagonlst-based or a non-calcium antagonist-based strategy. Physi- 
cians, primarily in the community, utilize a unique, Internet data capture system to input 
patient data and generate electronic prescriptions from the assigned strategy. Medica- 
tions are mailed to the patient’s home from a mail order pharmacy. Results: Enrollment 
in the INVEST is 83% complete (18,257 out of 22.000 planned enrollments) and is 
scheduled to end by Dec. 2000. To date, 6,057 Hispanic patients have been enrolled 
(33%). Analyw of this cohort of patients reveals 70%>60 years old and 61% female. 
Cardiac risk factors include diabetes (28%, 27% in non-l-lisp), BMl>25 (78%, 78% in non- 
Hisp), dyslipidemia (43%, 60% in non-Hisp), and smoking history (43%, 67% in non- 
Hisp). Following 6 months of antihypertensive therapy, systolic and diastolic control 
(according to JNC VI guidelines) was achieved in 68% and 87% of the Hispanic patients, 
respectively, compared to 54% and 86% in the non-Hispanics patients. 43% of diabetic 
Hispanics and 64% of overweight Hispanics have systolic and diastolic pressures con- 
trolled, compared to 31% and 50% in non-Hispanics. 46% and 26% of the Hispanic 
patients required 2 and 3 drugs, respectively, to achieve blood pressure control, com- 
pared to 41% and 29% in non-Hispanic patients. Daily doses of medications ranged 
from: verapamil, SR 240.480mg, trandolapril 2.8mg, atenolol 50-IOOmg and hydrochlo- 
rothiazide 25.50mg. Conclusions: Achieving blood pressure control in an elderly, over- 
weight population of Hispanic patients with CAD, dyslipidemia and diabetes can be 
accomplished with an internet based data collection system, and an electronic prescrip- 
tion system. In order to achieve this degree of blood pressure control, physicians have 
needed to prescribe combination drug therapy and doses that are higher than those com- 
monly prescribed. 
1311-71 Pulse Pressure and Risk of Cardiovascular Events Among 
Persons With Isolated Systolic Hypertension 
Viola Vaccarino, Alan K. Berger, Jerome Abramson, Henry R. Black, John F. Setaro, 
Janice A. Davey, Harlan M. Krumholz. Yale University School of Medicine, New Haven, 
CT Rush-Presbyterian-St Luke’s Medical Center, Chcago, IL - 
Background: Pulse pressure has been related to increased risk of cardiovascular events 
in older persons. The purpose of this study was to determine the role of r&e pressure 
as a predictor of cardiovascular outcomes in elderly persons with isolated systolic hyper- 
tension, and what influence the lowering of blood pressure has on the pulse pressure 
effect. 
Methods: We assessed the relationship between pulse pressure, measured throughout 
the follow-up period, and the incidence of coronary heart disease, heart failure and 
stroke in 4,632 participants in the Systolic Hypertension in the Elderly Program (SHEP), 
a &year randomized, placebo-controlled clinlcal trial of treatment of isolated systolic 
hypertension in older adults. 
Results: In the treatment group, a IO-mm Hg increase in pulse pressure was associated 
with a statistically significant 32% increase in risk of heart failure and a 24% increase in 
risk of stroke after controlling for systolic blood pressure and other known risk factors, as 
mental prognostic information. 
Variable p value 
male sex 0.015 
Odds ratio 
2.29 
95% Cl 
1.18-4.47 
TI lung uptake 0.018 
rest ECG abnormal 0.042 
we Wsl 0.002 
TXT time (min) 0.005 
2.08 1 .I 3-3.83 
2.06 1.03-4.14 
1.10 1.03-1.16 
0.81 0.70-0.94 
JACC February 2001 ABSTRACTS - Cardiac Function and Heart Failure 217A 
wel! as with a 23% increase in risk of heart failure and a 19% increase in risk of stroke 
after controlling for diastolic blood pressure and other risk factors. pulse pressure was not 
significantly associated with heart iallure or stroke in the placebo group, nor it was with 
coronary heart disease incidence in either the placebo or treatment group. 
Conclusion: These results indicate that pulse pressure is a useful marker of risk for 
heart failure and stroke among older adults being treated for isolated systolic hyperten- 
sion. In these patlents, monitoring of pulse pressure during anti-hypertensive treatment 
should be a useful tool for risk stratification, and utilizing therapies that lower both pulse 
pressure and sys!olic blood pressure may be partwiarly beneficial. 
Lateral (cm/s) 2.6+1.4 2.3tl.4 11+1.3* 
IVS (cm/s) 2.0%0.9 1.0~1.0 O.lrl.l* 
Inferior (cm/s) 2.4eO.S 2.0+0.9 1.7io.9 
’ p&O5 versus normal, No CHF 
IO:45 a.m. 
1311-72 Is Aortic Valve Sclerosis a Manifestation of 
Atherosclerosis? 
886-2 3-D Mitral Annular Dynamics in Tachycardia Induced 
Cardiomyopathy 
Jignesh S. Shah, Michael J. Wade, Abld Hussain, Agha J. Ahmed, Paul Shanahan, Paul 
Kelly, Prabhakara S. Heggunje. Veterans Affairs Medical Cenfer, Syracuse, NI: SUNY 
Upstate Medicai University, Syracuse 
Tomasz A. Timek, Paul Dagum, David T. Lai, David Liang, George T. Daughters, Neil B. 
lngels Jr., D C. Miller. Stanford Universi~ Stanford, CA, Research Institute of the Palo 
Alto Medical Foundaton, Palo Alto, CA 
Background: Prior studies have shown that aortic valve sclerosis (AVS) is associated 
with increased cardiovascular events. It alas been suggested that AVS is a manifestation 
of atherosclerosis. However, its association with atherosclerotic diseases such as periph- 
eral vascular disease (PVD) or carotid artery stenosis (CAS) has not been studied. Meth- 
ods: We assessed 2411 consecutive echocardiograms performed at our institution 
between January 1994 and December 1995 for the presence of AVS without outflow 
obstruction Of the 805 patients with AVS for whom information on piedefined variables 
was available, 280 had known coronary artery disease (+AVS/+CAD) and 525 did not 
(+AVS/-CAD) We compared the prevalence of PVD and CAS between the above two 
groups and also 244 age matched controls with neither AVS nor CAD (-AVS/-CAD) 
Results: There was no difference in the prevalence of symptomatic PVD among the . 
AVS/-CAD and +AVS/-CAD groups (11.9% vs. 11.8%. p=O.98). Similarly, the CAS rates 
between the two groups was not significantly different (-AVSI-CAD=8.2%, +AVS/- 
CAD=7.4%; p=O.71). Patients with AVS without CAD had a lower prevalence of CAS 
compared io those with AVS and CAD (7.4% vs. 11 8%, p=O.O39) and a trend towards 
lower PVD (11.8% vs. 15.7%, p&l IS). Adjusting for risk factors such as age, smoking, 
diabetes, renal failure did not change the results. Conclusion: We did not find a signifi- 
cant independent association between aortic valve sclerosis and other atherosclerotic 
diseases such as peripheral vascular disease and carotid disease. Our findings do not 
support the belief that AVS is a manlfestatlon of atherosclerosis. 
Purpose: Annular dilatation accompanied by mitral regurgitation (MR) often occurs in 
dilated cardiomyopathy (DCM), but the 3-D mitral annular (MA) geometric perturbations 
associated with MR have not been well characterized. 
Methods: Eight radiopaque markers were afflxed to the MA creating 8 distinct annular 
segments, (segments: 1-4~ anterior MA, 5.8= posterior MA) in 9 sheep. Simultaneous 
biplane videofluoroscopy and TEE were performed before and after rapid pacing (180. 
230 min.’ for 15i6 days) sufficient to develop tachycardia induced cardiomyopathy (TIC) 
and MR. MA segmental coniraction was defined as percent difference between max and 
min length. MA area (MAA) and MA septal-lateral (S-L) and commissure-commissure 
(C-C) diameters were computed from 3-D marker coordinates at end-diastole (ED). 
Results: With TIC, MAA, S-L, and C-C at ED increased by 36i 1456, 25+ 12%. and 9+ 
5%. resoectivelv lot .Oli. MR increased from 0.3i 0.2 to 2.2f 0.9 (w.0001). (Table 
“pc.05, “pc.01, “;b< .oo; “s. Control) 
Segment# ED Length (cm) 
,. ,. 
Contraction (%) 
Control TIC Control TIC 
1 13.323.6 15.0*4.3** 9.6i3.2 7.3r2 1 
2 11.4i-2.2 12.2*2.2” 9 7~2.6 8.8~3.4 
3 15.6i3.1 15.9L3.5 6.523.1 6.8k3.1 
4 13.2rl.E 14.7~2.2” 10.7+3.0 9.3k4.3 
5 11 .O-t2.7 13.oi3.1’** 13.31;2.6 8.4+3.5* 
6 13.2i-3.2 15.5*3.5*** 13.0&l 9.241“ 
7 16.4~3.2 19.6t3.5”* 14.026 9 8.Oi3.0’ 
8 14.855.4 18.5*5.9”* 13.8~5.7 7.4r1.4’* 
Conclusion: MA area increase in TIC was primarily due to S-L diameter augmentation; 
additionally, greater segmental dilatation and decreased segmental contraction occurred 
in the posterior annular segments. These experimental findings have direct Implications 
relevant to clinical surgical approaches for patients with DCM and MR. 
ORAL CONTRIBUTIONS 
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886-l 
IO:30 a.m. 
Reduced Longitudinal Myocardial Contraction and 
Relaxation Are Related to the Onset of Congestive Heart 
Failure in Patients With Primary Cardiac Amyloidosis 
Jun Koyama, Patricia A. Ray. Ravin Davidoff. Rodney H. Falk. Bosfoon Medical Center, 
Boston, MA 
Backgrcund: Cardiac amyloidosis is an infiltrative cardiomyopathy characterized by 
heart failure (CHF) with normal or near normal fractional shortening. It is generally 
thought that CHF is due to diastolic dysfunction, but it is possible that systolic dysfunction 
is underestimaied by standard echocardiographic measurements. 
Methods: Twenty-seven consecutive biopsy-proven patients with primary amyloidosis 
were examined by pulsed Doppler tlssue imaging (DTI). Eighteen had evidence of heart 
involvement, of whom 8 had clinical CHF. Nine patients had non-cardiac amyloidosis. 
Sample volumes were placed on basal and mid-posterior walls in parasternal long-axis 
view, and were placed on basal and mid ventricle ai lnterventricular septum, lateral, Infee- 
rior and anterior walls in apical two or four chamber views. Peak systolic wall motion 
velocities (S-vel), peak early and late diastolic wall motion velocities (E-w and A-vel) 
were measured at each site. Longitudinal myocardial velocity gradients (L-MVG) were 
calculated for septum, inferior and lateral walls by calculating the difference on basal and 
mid-LV velocities. 
Results: Despite a normal fractional shortening in each group, the L-MVG of S-w was 
significantly Impaired at the lateral wall and interventricular septum in the patients with 
CHF compared both to normal and cardiac amyloidosis wthout CHF. In contrast to the S- 
vel, the L-MVG of E-vel differed significantly among all 3 groups of patients (PcO.05 by 
ANOVA) but L-MVG of A-w did not differ, although the absolute values were decreased 
in CHF patrents. 
Conclusion: In amyloidosis, decreased tissue Doppler E-vel is an early sign of cardiac 
involvement. The onset of CHF is associated wilh a significant wnpamnent of iongitudlnal 
myocardial contraction despite normal fractional shortening indicating that traditional 
measures of systolic function underestimate the co-existence of systolic and diastolic 
dysfunction in amyloidosis with heart failure. 
I-MVG S-w 
Fractonal Shortening (%) 
Normal No CHF CHF 
4028 3957 34*9 
886-3 
1 I:00 a.m. 
Mechanisms Whereby Rapid Ventricular Pacing Causes LV 
Dysfunction 
Lazaros A. Nikolaidis, Youtang Shen, Aaron Doverspike, Teresa Hentosz, Rhonda 
Huerbin, Richard P. Shannon. Allegheny General Hospital, Pittsburgh, PA 
Background: Rapid ventricular pacing (RVP) induces dilated cardiomyopathy in expert- 
mental models, yet the mechanisms are not well understood. We hypothesized that 
excessive chronotropic demands require compensatory reductions in contractility in 
order to balance energy requirements. 
Methods: We studied 18 conscious, chronically instrumented dogs during RVP (240 
bpm) over 4 weeks. Dogs were instrumented with LV pressure transducers (LV dP/dt), 
flow probes to measure cardiac output (CO) and coronary blood flow (CBF), aortic and 
coronary sinus catheters to calculate MVO,. We measured the transmyocardiai produc- 
tion (Ao-Cs) of nitric oxide (NOx) and the cardiac respiratory quotient (RQ). 
Results: Initiation of RVP (10 min) was associated with significant decreases in CBFi 
beat and MVO$beat and comparable decreases in LVdP/dt (p<O.OOl), consistent with 
hibernating myocardium (flow-function matching). The matched decline in flow and func- 
tion persisted over the first 72 hours and was associated with increased cardiac NO pro- 
duction (+4.7 pM from -0.9 PM). Thereafter, CBWbeat and MVO,/beat increased to 
levels greater (~~0.05) than those seen during acute pacing (10 min), yet LV dP/dt contin- 
ued to decline (p<O.OOl), consistent with flow-function mismatch or stunning. Cardiac NO 
production was lower (+2.9 VM from +4.7 PM) over 21 days, while RQ progreswely 
increased (0.61~0.06~0.79~0.06, p<O.O03). 
Control 1Omin id 7d 14d > 21d 
LVdPidt 2,552i95 1,944i134 1,644+77 1.348+98 1,097?67 867~95 
CBFlbeat 0.33iO.02 0.21r0.01 0.16+0.01 0.17iO.01 0.2OkO.01 0.24~0.02 
ml/beat 
MVOdbeat 3.16t0.22 1.96kO.18 1.4OiO.10 1.74+0.10 1.74i0.16 2.05~0.18 
ml/beat 
Conclusion: In the early stage of RVP, contractile dysfunciion is due to hibernation, 
while later there IS stunning with flow-function mismatch. These changes are associated 
with alterations in cardiac NO oroduction. 
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II:15 a.m. 
Improved Cardioprotection With the Oral Iron-Chelator Ll, 
Over Standard Therapy With Subcutaneous Deferoxamine 
in Iron Overload Cardiomyopathy 
Lisa Anderson, Beatrix Wonke, Emma Prescott Sally Holden, J Malcolm Walker, Dudley 
Pennell. Cardiac Magnetic Resonance Unit, Royal Brompton Hospital, London, United 
Kingdom, The Whittington Hospital, London, United Kingdom 
Background: Iron-induced cardiomyopathy is the major cause of death in patients with 
thalassemia major. The only widely available iron-chelation therapy is deferoxamine, 
given daily via 12. or 24.hour infusions. Despite this life-long, arduous therapy, more than 
50% have excess myocardial iron deposition and 50% still die before 35 years in the UK. 
Early results with the new oral chelator Ll, appeared promising, but iis long-term effec- 
tiveness has recently been questioned due to high levels of liver iron in some patients. 
Methods: We compared myocardial iron, liver iron and cardiac function in patients 
receiving Ll with age-, sex- and ferritin-matched controls receiving subcutaneous defer- 
oxamine. We included all UK thalassemia major patients taking Ll alone for more than 3 
years (n=l5, mean duration 5.7 +/-1.8years) and have matched each Ll patient to 2 
thalassemia major, standard therapy controls. All patients were assessed by cardiac 
magnetic resonance (CMR) and myocardial iron was measured using T2’ values, which 
are inversely proportional to tissue iron concentration. Results: The Ll patients had sig- 
nificantly less myocardial iron with higher T2* values (p=O.OlZ, mean difference 16ms, 
95% Cl 4.1 to 27.8ms). This corresponded with significantly higher ejection fractions 
(p=O.O04, mean difference 7.5%, 95% Cl 2.8 to 12.2%) and significantly lower end sys- 
tolic volumes (p=O.OOOE, mean difference -19.6ml, 95% Cl -29.6 to -9.7ml) in the Ll 
group. There was no significant difference in liver iron between the two groups (p=O.78, 
mean difference -0.4ms, 95% Cl-3.9 to 3.0ms) and the groups were well matched for 
mean serum ferritin levels (p=O.83, mean difference 15.7ng/l, 95% Cl -140 to 17lngil). 
, Conclusion: The oral chelator Ll appears to be more effective in preveniing iron- 
induced cardiomyopathy than standard therapy with deferoxam!ne. A prospective trial in 
a larger group of patients is needed to confirm these findings. As the primary role of iron- 
chelating therapies is to prevent heart failure, direct measurement of cardiac iron and 
function must be included in the assessments of new therapies, with less emphasis 
placed on indirect measures such as serum ferritin levels and liver iron. 
of submaximal exercise (Ex) on cardiac function in Sgcd-null mice at an age prior to 
development of overt cardiomyopathy. Methods: 8 unsedated Sgcd-null mice, age 4-5 
mo., and 6 wild-type controls (WT) were studied with high-speed 2D [1X2 MHz, 162 
frames/sec]and Doppler echocardiography at rest and after staged treadmill Ex [5’ 
incline, 6 metersiministage]. Ex was terminated when the mouse preferred a noxious 
stimulus [tail shock] to Ex. Left ventricular (LV) mass and volumes were measured using 
the area-length method, previously validated [R=.95, slope=1 .l vs true LV mass]. Heart 
rate (HR) was measured by frame count and Doppler. Results: HR, LV mass, ejection 
fraction (EF), LV end-diastolic volume (EDV) and cardiac output (CO) were normal at rest 
I” Sgcd-null mice (p=NS vs WT), but Ex time was diminished (5+2 min vs 12+3 min in 
WT; x&D: *=p<.O5). Immediately post-Ex (first image ~15 set) Sgcd-null mice had no 
change in ‘HR (598+23 vs 606+19 min.’ @rest) or EF(.94+.02 I/S .92t.03) but EDV fell 
(33+2 w 48i6 ml*) causing 32% fall in CO*. Diastolic filling period did not change (23i4 
vs 24k2 sec/min) but LV inflow deceleration time (DT) rose (35% v.s 26i4 msec*) indi- 
cating LV diastolic dysfunction -which explains the fall in EDV and CO. At 3 min post-E& 
Sgcd-null mice developed LV dilatation (EDV 67210 ml, p <I101 vs immediate) and 
decreased EF (.62?.17*). One Sgcd-null mouse died with LV contracture (ED&O) and 2 
more developed regional akinesis. LV mass did not change throughout the study (mean 
absolute difference=6%) indicating consistant imaging and analysis. HR, blood pres- 
sure (n=3), EDV, EF, DT, and CO didn’t change after Ex in WT mice (D<lO%, p=NS). 
Conclusion: young adult Sgcd-null mice develop profound LV dysfunction with exercise, 
in a pattern suggesting low-flow ischemia. These findings support a role for ischemia in 
the development of overt cardiomyopathy in these mice and, possibly, in similarly affllcted 
humans. 
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11:30a.m. 
GLP-1 Improves Myocardial Performance in Conscious 
Dogs With Pacing Induced Heart Failure 
Lazaros A. Nikolaidis, Josephine M. Egan, Dariush Elahi, Richard P. Shannon. Allegheny 
General Hospital, Pittsburgh, PA, Massachusetts General Hospital, Boston, MA 
888-I 
IO:30 a.m. 
Medicare Costs for Heart Failure in 1995: The True Burden 
of Heart Failure 
Background: Glucose-insulin- potassium (GIK) has been used as an effective metabolic 
adjuvant in cardiogenic shock, yet the volume requirements are a significant limitation. 
GLP-1 is a glucose dependent, insulinotropic peptide wiih loss of insulinotropic activity at 
glucose levels s 4 mmolll. 
Methods: To determine the effects of GLP-1 on left ventricular (LV) function in heart fail- 
ure (CHF), we studied 11 conscious dogs, that were chronically instrumented with LV 
pressure transducers to measure LV dP/dt, aortic and coronary sinus catheters and flow 
probes to measure cardiac output (CO) and coronary flow (CBF). CHF was induced by 3. 
4 weeks of rapid pacing (240 min.‘). During moderate CHF, 7 dogs received a 48 hour 
infusion of GLP (5 ngikgimin) and 4 served as sham controls. We measured LV, coronary 
and systemic hemodynamics, endothelial dependent vasodilatation, MVO,, the respira- 
tory quotient (RQ), free fatty acids utilization (cFFA) and plasma +echolamines (NE) 
before and after GLP-1 infusion. 
Results: 
David J. Whellan, Neela Pania, Kevin A. Schulman. Duke University Medical Center, 
Durham, NC 
Background: CHF is the highest volume Medicare Diagnosis Related Group (DRG); and 
ihe burden on HCFA is expected to grow as the number of heart failure patients older 
than 65 years grows. We undertook the present study to describe the 1995 Medicare 
population with CHF and identify what costs were for the primary care of CHF. Methods: 
We used the 1995 Standard Analytic File (SAF) that represents a 5% sample of all Medi- 
care patients. Medicare patients were identified as having CHF if they had 3 or more 
claims with diagnosis of ICD-g-CM 428.~~ (congestive heart failure) in Part B file or with 
at least one inpatient hospital claim in Part A with primary diagnosis of congestive heart 
failure. All patients with end stage renal disease (ESRD), disabled and under the age of 
65 were excluded from this analysis. Admissions and hospital costs are summarized for 
all hospitalizations and CHF related hospitalizations. Results: After excluding 178,183 
patients for ESRD, disability, or age less than 65, a total of 91,693 CHF patients were 
found in part A and part B of the 1995 SAF There were a total of 20,167 deaths (22%) in 
1995 and 1996 out of the overall cohort of 91,693 CHF patients. 62,084 patients were 
hospitalized; 39% had at least one hospitalization for CHF. The total costs for CHF 
patients (extrapolated to the entire Medicare) was $22,804,754,800. Hospital costs with a 
primary diagnosis of CHF represented 17% of the Part A costs and 10% of Part 6 costs. 
Medicare Costs for CHF Patients 
GLP-1 Sham 
BEFORE AFTER BEFORE AFTER 
LVP(mmHg) 99+2 105+1* 109*4 104t2 
LVEDP(mmHg) 26rl l&l* 25r2 21+2 
dP/dt(mmHg/s) 1,158*51 2,1521t75 1,650rlOO 1,736&L-112 
CO (I/min) 1.33?0.12 1.86t0.10* 1.60+0.10 1.42kO.14 
CEF (ml/min) 25kl 33&Z' 3313 33+1 
MV02 (ml/min) 233i13 264~16 28Ok39 287523 
NE (nmollml) 2.30+0.15 1.62r0.09* 1.55+0.37 1.87+0.14 
GLP-1 significantly (* p<O.O5) improved LV pressures and function and CO while sup 
pressing plasma NE levels in moderate CHF compared to sham controls. GLP-1 also 
caused increased myocardial utilization of FFA (w: 53r78mEq/l; AFTER: 
237i47mEqil) and decreased the RCI (BEFORE: 0.80*0.12; &?lXZ 0.66+0.12), sug- 
gesting a shift toward FFA oxidation. GLP-1 was associated with increased endothelial 
dependent vasodilatation as determined by increased CBF responses to ACH (0.5mgi 
kg). 
Conclusion: Thus, GLP-1 infusion causes a significant improvement in LV performance 
in moderate CHF, in association with increased FFA oxidation and improved endothelial 
function. 
886-6 
II:45 a.m. 
Exercise-Induced Left Ventricular Dysfunction Precedes 
Overt Cardiomyopathy in Delta-Sarcoglycan Deficient Mice 
Robert M. Weiss, Ronald C. Cohn, Robin L. Davisson, Richard E. Kerber, Kevin P 
Campbell. Unversity of Iowa, fowa City IA, VA Medical Center, low Cit)! /A 
Background: Mutation of the gene encoding delia-sarcoglycan, a cytoskeletal protein, 
causes adult-onset cardiomyopathy in mice (Sgcd-null) and humans - putatively via a 
process involving coronary microvascular dysfunciion. Purpose: to evaluate the effects 
5% Samole Total 
Total Pari A Cost ,n 1995 $872,939,149 $17,458,782,980 
Total Part B Cost in 1995 
Total CHF related Cost: Part A 
Total CHF related Cost: Part 6 
5267,298,591 $5,345,971,820 
$147,031,472 $2,940,629,440 
$27.582.190 $551.643.800 
Conclusion: Health care costs for Medicare patients with CHF have increased to over 
22.5 billion dollars. The cost for hospitalizations or outpatient visits with a primary diagno- 
sis of heart failure was a small percentage of the total costs suggesting that other cotnor- 
bidities contribute to the cost of care. This has implications for clinical interventions 
designed for heart failure patients in Medicare. 
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Persistent High Mortality in a Population Based Cohort of 
39,710 Newly Diagnosed Heart Failure Patients in Ontario, 
Canada 
Erika Vowinckel, Phlip Jong, Peter Liu, Jack Tu. Heart & Stroke/Richard Lewar Centre of 
Excellence, Toronto, ON. Canada, Institute for Clinical Evaluative Sciences, Toronto, ON, 
Canada 
Contemporary heart failure trials suggest that mortality from heart failure has dramati- 
cally decreased in the past decade. To determine if this observation reflected heart fail- 
ure patients outside research centers in the community, we sought to determine the 
short-term (30-day) and long-term (one-year) mortality from all heart failure patients 
requiring hospitalization in Ontario, Canada. This cohort includes the entire population in 
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the province of Ontario and reflects a single health payer system. All patients admitled 
with a primary diagnosis of heart failure (ICD-O-CM code 428) exclusive of previous his- 
tory of heart failure between 1994.1997 were linked to the Ontario Registered Persons 
Database for deaths. 
Overall, 39,710 new paiients were diagnosed with heari failure during this period. Of this 
group, 51.1% were women, 84.8% were 65 years of age or older (including 58.0% who 
were 75 years old or more). lschemic etiology was attributed in 73.7% of the cases. The 
age/gender-stratified 30.day (30d) and one-year (lyr) mortality rates foilowing hospltal- 
ization for heart failure were: 
Age Male-3Od Female-30d Male-lyr Female-yr 
20-49 4.4% 4.2% 14.6% 10.6% 
50-64 5.4% 5.3% 20.3% 19.2% 
65-74 8.4% 6.7% 28.8% 22.9% 
75t 15.4% 14.5% 42.9% 37.8% 
Total 11 .2% 11.7% 33.9% 32.2% 
Even for a relatively young age group of 50-64 years, the annual mortality following new 
onset of heart failure was approxlmateiy 20%, much higher than the published annual 
mortality III contemporary heart failure trials. 
We conclude that the heart failure mortality in the community on a population basis is 
extremely high, and is noi reflected in the highly selected populations who are entered 
Into clinical trials. 
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Outcomes Following Discharge From an Urban County 
Hospital Emergency Room With a Primary Diagnosis of 
Heart Failure 
.I. Eduardo Rame, Michael A. Sheffield, Dan@ L. Dries, Elizabeth B. Gardner, Kathleen 
H. Toto. Clyde W. Yancy, Mark H. Drazner. Unwersityof Texas Southwestern Medical 
Center. Da//as, TX, Parkland Memorial Hospital, Dallas, TX 
Background: Patients with heart failure (HF) are frequently discharged from the emer- 
gency room (ER) Of Parkland Memorial Hospital, a facility serving predominantly indigent 
Dallas County residents. In performing a review of the medical literature, we were struck 
that the outcomes of HF patients discharged from the ER are not well known. Methods: 
In order to define the outcomes of this patient population and Identify risk factors for 
adverse events, all patients discharged from the Parkland Memorial Hospital ER between 
10198 and 12198 with a primary diagnosis of HF were identified by computerized search. 
Patients on dialysis (n = 14) and those with no clinical follow-up after the index ER visit (n 
= 16) or unretnevable medical records (n = 8) ware excluded. A prespecified composite 
endpoint (failure of outpatient therapy) included recurrent ER HF visit, hospitalization for 
HF. or death at 3 months. The diagnosis of HF was verified by data abstraction in all 
cases. Results: The demographics of the study population (n = 112) included age: 56 i 
14 years; gender: 56% women; ethnic distribution: 78% African American, 12% Cauca- 
sian, and 10% Hispanic. 48% of patients were Medicare or Medicaid recipients. Within 3 
months of the index ER visit, 61% of subjects met the composite endpoint. The median 
time to endpoint was 30 days (25% percentile: 10 days, 75% percentile: 60 days). 
Univarlate analysis of 24 clinical and demographic variables yielded only initial respira- 
tory rate during the index visit as a predictor of failure of outpatient therapy (p < 0.03). In 
a multivariate model incorporating 8 prespecified variables, respiratory rate remained as 
the only predictor of the endpoini (odds ratio 1.6 for each increase of 5 breaths/minute, p 
< 0.03). Conclusion: Patients discharged with HF from an urban county hospital ER 
have an alarmingly high rate (61%) of failure of outpatIent therapy within 3 months. Simi- 
lar dais need to be acquired in other patlent populations to determine the extent of this 
problem. Respiratory rate on presentation to the ER is associated with an adverse out- 
come following ER discharge for HF. 
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Restoration and Maintenance of Sinus Rhythm in Patients 
With Left Ventricular Dysfunction and Atrial Fibrillation/ 
Flutter is Associated With Improved Survival. A DIAMOND 
Substudy 
Oie D. Pedersen. department of Cardfology E Gent&e University Hospital, Hellerup, 
Denmark 
Purpose: Patients with leff ventricular (LV) dysfunction commonly exhibits atrial fibrilla- 
tion (AF) and flutter (AFI) which is associated with Increased morbidltyimortallty. Dofetil- 
ide, a new class Ill antiarrhythmic agent, is effective in resioring and maintaining sinus 
rhythm (SR). The effect of restoring SR on morbidity and mortality is unknown. This sub- 
study was designed to answer this question. Methods:The Danrsh Investigations of 
Arrhythmia and Mortality ON Dofetilide (DIAMOND) studies on congestive heart failure 
and myocardial infarction included 3028 patients with LV wall motion indices of f1.2 ran- 
domlsed to treatment with either dofetilide or placebo. Results: Five hundred and six 
patients were in AFiAFl at baseline. Ai 1 month, SR was restored pharmacologically in 
12% (31/249) of dofetilide-treated patients and 2% (5R57)of placebo-treated patients 
(P<O.OOl). Over the course of the study, spontaneous, pharmacologic, or direct-current 
(DC) cardioversion occurred in 148 (59%) dofetillde- and 86 (34%) placebo-treated 
patients. In these patients, the probability of maintaining SK for 1 year was 79% for 
dofetlilde compared with 42% for placebo (P<O.OOl). Dofetilide had an overall neutral 
effect on mortality but a Cox multivariate analysis including restoration and mamtenance 
of SR as a time dependent variable, revealed that being in SR was associated with a sig- 
nificant reduction of mortality (Hazard Ratlo (HR) = 0.44 (0.30-0.64); P<O.OOl). This 
effect was most pronounced in patients who received DC-cardioversion. In addition, 
relapse of AF/AFL was associated with a significant increase in mortality (HR = 2.71 
(1 67-4.41); P<O.OOl). Conclusions This study demonstrates that restoration and main- 
tenance of SR in patients with LV dysfunction is associated with an improved survival and 
relapse of AFiAFL with an increased risk of death. Further studies to assess the benefit 
of pharmacological/electrical cardioversion are needed. 
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Subjects in Heart Failure Trials Are Not the Same as Your 
Patients 
Maria N. Ansari, Ali Tutar, Mark Alexander, John R. Teerlink, Barry M. Massie. San 
Francisco VAMUUCSF; San Francisco, CA, Kaiser Division of Research, Oakland, CA 
Background: CHF guidelines and practices are based primarily on large clinical trials 
However, this “evidence-based’ approach assumes trial patrants (Pts) are representative 
of the general CHF population. Objective: To evaluate to what extent this assumption is 
accurate, we compared CHF Pts in two clinic populations--a large staff-model HMO and 
an academic VA medical center--with Pts enrolled in several major CHF trials. Methods: 
Outpatients with a CHF diagnosis from 7/96 to 8/97 (HMO sample) or 7/Q&12/98 (VA 
sample) were evaluated, of whom a total of 778 Pts were included in this analysis after 
excluding individuals without Framingham CHF criteria, those lacking continuous follow- 
up, and Pts wiih terminal comorbidities. The cohorts were compared with the partici- 
pants of landmark trials that have defined CHF practices. Results: Compared to study 
participants, our Pts ware older (by 3-13 yrs), included nearly twice as many women 
(HMO cohort only), and had a higher mean EF Preserved LV function (EF >45%) was 
present 1-1 43% of the HMO sample and 29% of the VA cohort. The table below gives the 
proportion of the two cohorts who met the entry criteria for specific trials. The largest 
exclusions ware for EF>45%; however, even when only low EF (~45%) patients were 
analyzed, the percentage of Pts meeting entry criteria was low except for the DIG trial, 
which had the most liberal entry criteria. Other trial specific exclusions in order of 
fequency ware EF >45% but still above entry criteria, low HR, low or high BP, COPD, 
absence of required background medication or use of excluded medcations, age, and 
significant valve disease. Conclusions: Clinical trial populations are poorly representa- 
tlve of CHF outpalients. In addition to the large number of exclusions, trial patients are 
also younger, more often male and have fewer comorbidities. Care must be taken in 
extrapolating results from highly selected study participants to the general population. 
Patients Meeting Entry Criteria for Major Clinical Trials 
Trial HMO Cohort HMO low EF VA Cohort VA low EF only 
(n=403) only (n=191) (n=375) (n=248) 
SOLVD 19.8% 35% 33.5% 47.2% 
US Carvediiol 9.6% 14.1% 24.3% 34.3% 
DIG 45.6% 80.6% 42.4% 59.7% 
CIBIS II 20.5% 33.5% 23.4% 33% 
MERIT 16.7% 27.2% 19.8% 27.8% 
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Randomized, Controlled Evaluation of Short- and Long- 
Term Benefits of Heart Failure Disease Management Within 
a Diverse Provider Network: The SPAN-CHF Trial 
Carey D Kimmelstiel, Daniel Levine, Kathleen Perry, Ayan Pa&l, Ara Sadaniantz, Noreen 
Gorham, Peggy Cunnie, Lynn Duggan, Linda Cotter, Kenneth LaBresh, David Brtli, Will- 
iam Rand, James Udelson, Beverly Lorell, Marvin A. Konstam. New England Medical 
Center, Boston, MA 
Background: Most prior studies of disease management (DM) in heart failure (HF) have 
been uncontrolled; performed in an academic medical center (AMC); and/or provided 
only short-term follow-up. We performed a long-term, prospective, controlled trial of 
SPAN-CHF, a nurse-driven, home and telephonic DM program 
Methods: We randomized 200 recently-hospitalized HF pts, across 6 community prac- 
tice and AMC sites, to intervention (INT; 1 home education visit; 90 day intensive trans- 
l&phonic monitoring; active IN1 continued for 1 yr in overtly unstable pts) or control 
(usual care). with 1 yr follow-up and blinded event adjudication. HF nurses received 24 
hdd support and weekly management teleconferences with HF physician specialists with 
frequent communication with PCP’s. 
Results: Over 90 days, INT pis showed reduced HF hospitalizaiions (0.13 vs. 0.27/pt; 
~~0.05) and trends toward reduced cardiac and all-cause hospitakzations. However, at 
one year, hospitalization rates ware equivalent within the 2 groups (p=ns). 
Conclusions: These data support the short-term benefit of HF DM, delivered across a 
diverse provider network, in reducing recurrent HF hospitalizations. Longer-term beneftt 
likely requires more active chronic intervention, even among pts who appear clinically 
stable 
